0000950170-24-09401010-Q 4D Molecular Therapeutics, Inc. 20240808202408081615561615571615571 0 0000950170-24-094010 10-Q 90 20240630 20240808 20240808 4D Molecular Therapeutics, Inc. 0001650648 2836 473506994 DE 1231 10-Q 34 001-39782 241188590 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680 5858 HORTON STREET #455 EMERYVILLE CA 94608 4D Molecular Therapeutics Inc. 20200506 4D Molecular Therapeutics Inc 20150811 10-Q 1 fdmt-20240630.htm 10-Q 10-Q false0001650648Q2--12-31http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpenseone year0001650648us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2020-12-012020-12-310001650648srt:MaximumMember2024-01-012024-06-300001650648fdmt:FiveNineEightZeroHortonStreetMember2023-12-310001650648fdmt:PublicOfferingMember2024-01-012024-06-300001650648fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2024-01-012024-06-300001650648us-gaap:CommonStockMemberfdmt:TwoThousandTwentyFourFollowOnPublicOfferingMember2024-02-290001650648us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-01-012024-06-300001650648fdmt:FebrurayAndMarchTwoThousandAndTwentyFourPublicOfferingSaleMember2024-01-012024-03-310001650648us-gaap:CommonStockMember2023-01-012023-03-310001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001650648us-gaap:CommonStockMemberfdmt:CysticFibrosisFoundationMemberfdmt:FundingAgreementMember2021-10-012021-10-310001650648us-gaap:WarrantMember2023-12-310001650648fdmt:CorporateBondMemberfdmt:ShortTermMarketableSecuritiesMember2023-12-310001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001650648fdmt:ShortTermMarketableSecuritiesMember2023-12-310001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMemberus-gaap:SubsequentEventMember2024-07-310001650648us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember2023-04-012023-06-300001650648country:US2024-04-012024-06-300001650648fdmt:AevitasTherapeuticsIncAgreementMember2023-04-212023-04-210001650648us-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembersrt:MaximumMemberfdmt:CustomerBMember2024-01-012024-06-300001650648country:US2023-01-012023-06-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMemberus-gaap:SubsequentEventMember2024-07-310001650648us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001650648us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648us-gaap:MachineryAndEquipmentMember2023-12-310001650648us-gaap:CommonStockMember2023-03-310001650648country:US2023-04-012023-06-300001650648us-gaap:CommonStockMemberfdmt:TwoThousandTwentyFourFollowOnPublicOfferingMember2024-02-012024-02-290001650648us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648country:NL2024-01-012024-06-300001650648fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember2024-01-012024-06-300001650648fdmt:AtmOfferingProgramMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001650648us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001650648us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001650648fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-12-310001650648us-gaap:AdditionalPaidInCapitalMember2022-12-310001650648fdmt:WarehouseLeaseAgreementMember2024-01-012024-01-010001650648us-gaap:AdditionalPaidInCapitalMember2023-06-300001650648us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648fdmt:UniQureBiopharmaBVMember2024-06-300001650648us-gaap:AdditionalPaidInCapitalMember2023-03-310001650648fdmt:TwoThousandFifteenEquityIncentivePlanMember2024-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CysticFibrosisFoundationAgreementMember2023-01-012023-12-310001650648us-gaap:LeaseholdImprovementsMember2023-12-310001650648us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember2024-04-012024-06-300001650648us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001650648us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001650648us-gaap:CommonStockMember2022-12-310001650648us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648srt:MaximumMemberfdmt:LicenseAgreementWithUniversityOfPennsylvaniaMember2023-04-210001650648srt:MinimumMember2024-01-012024-06-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember2018-10-310001650648us-gaap:CommonStockMember2024-03-3100016506482023-04-012023-06-300001650648us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001650648fdmt:ArborAgreementMemberfdmt:ArborBiotechnologiesIncMember2024-01-012024-06-300001650648us-gaap:RetainedEarningsMember2024-03-310001650648us-gaap:WarrantMember2024-01-012024-06-300001650648fdmt:ShortTermMarketableSecuritiesMemberus-gaap:USTreasurySecuritiesMember2024-06-3000016506482020-12-310001650648fdmt:TwoThousandFourteenPlanMember2024-01-012024-06-300001650648fdmt:SeriesCRedeemableConvertiblePreferredStockMemberfdmt:CysticFibrosisFoundationMemberfdmt:FundingAgreementMember2020-04-012020-04-300001650648us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001650648us-gaap:LeaseholdImprovementsMember2024-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CysticFibrosisFoundationAgreementMembersrt:MaximumMember2016-09-012016-09-300001650648us-gaap:RetainedEarningsMember2023-04-012023-06-300001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001650648fdmt:AtmOfferingProgramMember2024-04-012024-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CollaborationAndLicenseRevenueMember2023-04-012023-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CollaborationAndLicenseRevenueMember2024-01-012024-06-300001650648us-gaap:CommonStockMember2023-04-012023-06-300001650648fdmt:FiveNineEightZeroHortonStreetMember2016-01-012016-01-310001650648fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember2023-01-012023-06-300001650648fdmt:AtmOfferingProgramMember2024-01-012024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:UniQureAgreementMember2019-08-310001650648srt:MaximumMember2023-04-012023-06-300001650648us-gaap:AdditionalPaidInCapitalMember2024-06-300001650648fdmt:ReigniteAgreementMembersrt:MaximumMember2024-03-3100016506482024-06-300001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001650648us-gaap:CommonStockMemberus-gaap:IPOMember2020-12-310001650648fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMembersrt:MaximumMember2021-07-012021-07-310001650648srt:MaximumMemberfdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2024-06-300001650648fdmt:TwoThousandFourteenPlanMember2023-01-012023-03-310001650648us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001650648fdmt:AevitasTherapeuticsIncAgreementMember2024-06-300001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001650648fdmt:EmployeeOptionsIssuedAndOutstandingAndFutureVestingOfRestrictedStockUnitsMember2024-06-300001650648fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2024-01-012024-06-300001650648fdmt:CysticFibrosisFoundationMember2023-12-310001650648fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2024-01-012024-06-300001650648fdmt:LongTermMarketableSecuritiesMemberus-gaap:CommercialPaperMember2023-12-310001650648us-gaap:OfficeEquipmentMember2024-06-300001650648fdmt:AstellasGeneTherapiesIncMember2024-06-300001650648fdmt:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001650648us-gaap:FurnitureAndFixturesMember2023-12-310001650648fdmt:UniQureBiopharmaBVMembersrt:MaximumMemberfdmt:AmendedUniQureAgreementMember2019-08-310001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember2023-01-012023-12-310001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001650648fdmt:CorporateBondMemberfdmt:ShortTermMarketableSecuritiesMember2024-06-300001650648fdmt:TwoThousandFourteenPlanMember2023-01-012023-06-300001650648fdmt:AtmOfferingProgramMemberus-gaap:CommonStockMember2024-04-012024-06-300001650648fdmt:WarehouseLeaseAgreementMember2024-06-300001650648fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2024-02-290001650648us-gaap:RetainedEarningsMember2024-06-300001650648us-gaap:CommonStockMemberfdmt:TwoThousandTwentyThreeFollowOnPublicOfferingMember2023-05-012023-05-310001650648us-gaap:CommonStockMember2024-01-012024-03-310001650648srt:MinimumMember2023-01-012023-06-300001650648fdmt:ReigniteAgreementMembersrt:MaximumMember2024-03-012024-03-310001650648fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2020-12-310001650648us-gaap:FurnitureAndFixturesMember2024-06-300001650648us-gaap:RetainedEarningsMember2024-01-012024-03-3100016506482020-12-012020-12-310001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001650648fdmt:FiveNineEightZeroHortonStreetMember2018-10-012018-10-310001650648fdmt:UCAgreementsMember2016-01-012016-01-310001650648fdmt:TwoThousandFifteenEquityIncentivePlanMember2024-01-012024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember2024-01-012024-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CysticFibrosisFoundationAgreementMember2023-08-012023-08-310001650648fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember2021-07-310001650648us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001650648srt:MaximumMemberfdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2024-01-012024-06-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember2024-06-300001650648fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2023-12-310001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001650648fdmt:FiveNineEightZeroHortonStreetMember2015-05-310001650648fdmt:CollaborationAndLicenseRevenueMember2024-01-012024-06-300001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001650648us-gaap:CommonStockMemberfdmt:TwoThousandTwentyOneFollowOnPublicOfferingMember2021-11-012021-11-300001650648srt:MaximumMember2024-04-012024-06-3000016506482023-01-012023-03-310001650648fdmt:UniQureBiopharmaBVMemberfdmt:UniQureAgreementMember2014-01-310001650648us-gaap:CommonStockMember2024-04-012024-06-300001650648us-gaap:OfficeEquipmentMember2023-12-310001650648us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-3100016506482023-03-310001650648us-gaap:AdditionalPaidInCapitalMember2024-03-310001650648srt:MaximumMember2023-01-012023-12-310001650648fdmt:FiveNineEightZeroHortonStreetMember2024-06-300001650648us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberfdmt:CustomerBMember2024-04-012024-06-300001650648us-gaap:CommonStockMemberfdmt:TwoThousandTwentyThreeFollowOnPublicOfferingMember2023-05-310001650648us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648fdmt:TwoThousandTwentyOneFollowOnPublicOfferingMemberus-gaap:CommonStockMember2021-11-3000016506482021-01-010001650648fdmt:UCAgreementsMember2018-12-310001650648us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CysticFibrosisFoundationAgreementMember2023-12-310001650648us-gaap:CommonStockMember2023-12-310001650648fdmt:CollaborationAndLicenseRevenueMember2023-01-012023-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:CollaborationAndLicenseRevenueMember2024-01-012024-06-300001650648us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001650648fdmt:UniQureBiopharmaBVMember2023-12-310001650648us-gaap:CommonStockMemberfdmt:FebrurayAndMarchTwoThousandAndTwentyFourPublicOfferingSaleMember2024-01-012024-03-310001650648fdmt:ReigniteAgreementMember2024-01-012024-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CysticFibrosisFoundationAgreementMember2024-06-300001650648fdmt:LongTermMarketableSecuritiesMember2024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:CollaborationAndLicenseRevenueMember2024-04-012024-06-3000016506482024-03-310001650648srt:MaximumMemberfdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2024-06-3000016506482024-01-012024-06-300001650648fdmt:EmployeeOptionsIssuedAndOutstandingAndFutureVestingOfRestrictedStockUnitsMember2023-12-310001650648us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001650648country:NL2023-04-012023-06-300001650648us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001650648fdmt:UCAgreementsMember2019-01-310001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMember2024-06-300001650648fdmt:ShortTermMarketableSecuritiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001650648us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001650648fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMembersrt:MinimumMember2021-07-012021-07-310001650648us-gaap:RetainedEarningsMember2023-01-012023-03-310001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001650648fdmt:FiveNineEightZeroHortonStreetMember2018-11-012018-11-300001650648us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-12-310001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMemberus-gaap:SubsequentEventMember2024-07-012024-07-310001650648fdmt:CysticFibrosisFoundationMemberfdmt:CollaborationAndLicenseRevenueMember2024-04-012024-06-300001650648us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000016506482018-05-012018-05-310001650648fdmt:WarehouseLeaseAgreementMember2024-01-010001650648fdmt:CollaborationAndLicenseAgreementMember2024-06-300001650648country:NL2024-04-012024-06-300001650648fdmt:AstellasGeneTherapiesIncMembersrt:MaximumMember2023-07-050001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember2024-01-012024-06-3000016506482024-04-012024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember2023-01-012023-06-300001650648us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001650648us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2024-03-012024-03-310001650648fdmt:AstellasGeneTherapiesIncMember2023-07-052023-07-050001650648fdmt:ShortTermMarketableSecuritiesMemberus-gaap:CertificatesOfDepositMember2024-06-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember2018-10-012018-10-310001650648us-gaap:CommonStockMember2023-06-300001650648us-gaap:RestrictedStockUnitsRSUMember2023-12-310001650648us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001650648us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648us-gaap:RestrictedStockUnitsRSUMember2024-06-300001650648us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648us-gaap:CommonStockMemberfdmt:PublicOfferingMember2023-04-012023-06-300001650648us-

gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-310001650648us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648us-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648us-gaap:CommonStockMember2024-08-020001650648us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-310001650648fdmt:UCAgreementsMembersrt:MaximumMember2019-01-012019-01-310001650648fdmt:PublicOfferingMember2023-01-012023-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CysticFibrosisFoundationAgreementMember2016-09-012016-09-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember2023-12-310001650648us-gaap:CommonStockMember2024-06-300001650648us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberfdmt:CustomerBMember2024-01-012024-06-300001650648country:NL2023-01-012023-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:FundingAgreementMember2021-10-310001650648us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648srt:MinimumMember2023-01-012023-12-310001650648fdmt:LongTermMarketableSecuritiesMemberus-gaap:CommercialPaperMember2024-06-300001650648us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMembersrt:MaximumMember2024-02-012024-02-290001650648fdmt:TwoThousandFourteenPlanMember2024-01-012024-03-310001650648fdmt:CollaborationAndLicenseRevenueMember2023-04-012023-06-300001650648us-gaap:CommercialPaperMemberfdmt:ShortTermMarketableSecuritiesMember2023-12-310001650648srt:MinimumMemberfdmt:UCAgreementsMember2019-01-012019-01-310001650648fdmt:PublicOfferingMember2023-04-012023-06-300001650648us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001650648us-gaap:CommonStockMemberfdmt:TwoThousandTwentyFourFollowOnPublicOfferingMemberfdmt:PreFundedWarrantsMember2024-01-012024-06-300001650648us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember2024-06-300001650648fdmt:FiveNineEightZeroHortonStreetMember2016-01-310001650648fdmt:AtmOfferingProgramMember2023-04-012023-06-300001650648fdmt:LongTermMarketableSecuritiesMemberfdmt:CorporateBondMember2024-06-300001650648us-gaap:RetainedEarningsMember2023-12-310001650648fdmt:LongTermMarketableSecuritiesMemberfdmt:CorporateBondMember2023-12-310001650648fdmt:CysticFibrosisFoundationMemberfdmt:FundingAgreementMember2020-04-300001650648srt:MaximumMember2024-06-300001650648fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2024-06-300001650648us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-06-300001650648us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648fdmt:CysticFibrosisFoundationMember2024-07-01srt:MaximumMember2024-06-300001650648fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember2023-04-012023-06-300001650648us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648us-gaap:CommonStockMemberfdmt:TwoThousandTwentyFourFollowOnPublicOfferingMemberfdmt:PreFundedWarrantsMember2024-02-290001650648fdmt:ArborAgreementMemberfdmt:ArborBiotechnologiesIncMember2024-04-012024-06-300001650648fdmt:LongTermMarketableSecuritiesMember2023-12-310001650648srt:MaximumMember2023-01-012023-06-300001650648srt:MinimumMember2023-04-012023-06-300001650648us-gaap:CommonStockMemberus-gaap:IPOMember2020-12-012020-12-310001650648248 2022-12-310001650648fdmt:CollaborationAndLicenseRevenueMember2024-04-012024-06-300001650648fdmt:UniQureBiopharmaBVMembersrt:MaximumMemberfdmt:UniQureAgreementMember2014-01-310001650648fdmt:CysticFibrosisFoundationMember2024-06-300001650648us-gaap:MachineryAndEquipmentMember2024-06-300001650648country:US2024-01-012024-06-300001650648us-gaap:WarrantMember2023-01-012023-06-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember2019-12-012019-12-310001650648fdmt:CysticFibrosisFoundationMember2024-07-01srt:MinimumMember2024-06-300001650648us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648us-gaap:RetainedEarningsMember2023-06-300001650648fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2023-01-012023-06-300001650648fdmt:ReigniteAgreementMember2024-06-300001650648fdmt:FebrurayAndMarchTwoThousandAndTwentyFourPublicOfferingSaleMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001650648us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2023-12-310001650648fdmt:ReigniteAgreementMember2024-04-012024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:CollaborationAndLicenseRevenueMember2023-01-012023-06-300001650648us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001650648fdmt:AtmOfferingProgramMemberus-gaap:CommonStockMember2023-01-012023-03-3100016506482023-01-012023-12-310001650648us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001650648us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-06-300001650648us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-01-012023-06-300001650648fdmt:CollaborationAndLicenseAgreementMember2023-12-310001650648fdmt:UniQureBiopharmaBVMemberfdmt:CollaborationAndLicenseRevenueMember2023-04-012023-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CollaborationAndLicenseRevenueMember2023-01-012023-06-300001650648us-gaap:CommercialPaperMemberfdmt:ShortTermMarketableSecuritiesMember2024-06-300001650648us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648us-gaap:WarrantMember2024-06-300001650648us-gaap:ComputerEquipmentMember2024-06-300001650648fdmt:AtmOfferingProgramMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001650648us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001650648fdmt:CysticFibrosisFoundationMemberfdmt:CysticFibrosisFoundationAgreementMember2024-01-012024-06-300001650648us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMemberus-gaap:SubsequentEventMember2024-07-012024-07-310001650648fdmt:AevitasTherapeuticsIncAgreementMembersrt:MaximumMember2023-04-210001650648us-gaap:RestrictedStockUnitsRSUMemberfdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2024-01-012024-06-300001650648fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember2021-02-012021-02-280001650648fdmt:UniQureBiopharmaBVMemberfdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember2023-12-3100016506482018-05-310001650648srt:MinimumMember2024-04-012024-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember2024-04-012024-06-300001650648us-gaap:ComputerEquipmentMember2023-12-310001650648fdmt:AtmOfferingProgramMember2023-01-012023-03-310001650648fdmt:ShortTermMarketableSecuritiesMember2024-06-3000016506482023-01-012023-06-300001650648us-gaap:RetainedEarningsMember2022-12-310001650648fdmt:PreFundedWarrantsMember2024-08-020001650648us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001650648fdmt:ReigniteAgreementMember2024-03-012024-03-310001650648us-gaap:ConstructionInProgressMember2023-12-310001650648fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember2024-02-290001650648us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-06-300001650648us-gaap:AdditionalPaidInCapitalMember2023-12-310001650648us-gaap:RetainedEarningsMember2023-03-310001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001650648fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember2024-06-300001650648fdmt:AtmOfferingProgramMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001650648fdmt:AtmOfferingProgramMember2023-01-012023-06-300001650648fdmt:UniQureBiopharmaBVMemberfdmt:UniQureAgreementMember2014-01-012014-01-310001650648fdmt:ArborAgreementMemberfdmt:ArborBiotechnologiesIncMember2024-06-300001650648us-gaap:RetainedEarningsMember2024-04-012024-06-300001650648us-gaap:SalesRevenueNetMemberfdmt:CustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001650648us-gaap:ConstructionInProgressMember2024-06-30xbrli:purefdmt:Periodutr:sqftxbrli:sharesfdmt:Segmentfdmt:Installmentiso4217:USDfdmt:Productiso4217:USDxbrli:shares

Â Â Â Â Â  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 47-3506994 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 5858 Horton Street #455Emeryville, CA 94608 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (510) 505-2680 Securities registered pursuant to Section 12(b) of the Act: Â  Title of each class Â  TradingSymbol(s) Â  Name of each exchange on which registered Common Stock, par value $0.0001 per share Â  FDMT Â  The Nasdaq Global Select Market Â  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â  Large accelerated filer â˜ Accelerated filer â˜ Â Â Â Â Â  Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Â Â Â Â Â Â  Emerging growth company Â â˜’ Â Â Â Â Â  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of August 2, 2024, there were 51,969,590 shares of 4D Molecular Therapeutics, Inc.'s common stock outstanding. This number does not include 3,583,476 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of August 2, 2024 (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations) sold in the registrantâ€™s public offering in February 2024. See Note 13, Common Stock Warrants, to the Registrantâ€™s unaudited condensed financial statements. Â Â Â Â Â  Table of Contents Â Â  Page PART I. FINANCIAL INFORMATION 3 Item 1. Condensed Unaudited Financial Statements 3 Â  Condensed Balance Sheets as of June 30, 2024 and December 31, 2023 3 Â  Condensed Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 4 Â  Condensed Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 5 Â  Condensed Statements of Stockholdersâ€™ Equity for the Three and Six Months Ended June 30, 2024 and 2023 6 Â  Condensed Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 8 Â  Notes to Unaudited Condensed Financial Statements 9 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3. Quantitative and Qualitative Disclosures About Market Risk 39 Item 4. Controls and Procedures 40 Â Â Â Â  PART II. OTHER INFORMATION 41 Item 1. Legal Proceedings 41 Item 1A. Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 105 Item 3. Default Upon Senior Securities 105 Item 4. Mine Safety Disclosures 105 Item 5. Other Information 105 Item 6. Exhibits 106 Signatures Â  107 Â Â Â Â 1 Â  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Â  This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as â€œaim,â€ â€œanticipate,â€ â€œassume,â€ â€œbelieve,â€ â€œcontemplate,â€ â€œcontinue,â€ â€œcould,â€ â€œdue,â€ â€œestimate,â€ â€œexpect,â€ â€œgoal,â€ â€œintend,â€ â€œmay,â€ â€œobjective,â€ â€œplan,â€ â€œpredict,â€ â€œpotential,â€ â€œpositioned,â€ â€œseek,â€ â€œshould,â€ â€œtarget,â€ â€œwill,â€ â€œwouldâ€ and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: â€¢the success, cost and timing of our development activities, preclinical studies and clinical trials, including our clinical trials for 4D-150, 4D-175, 4D-710, 4D-725, 4D-310, 4D-125 and 4D-110; â€¢the number, size and design of our planned clinical trials, and what regulatory authorities may require to obtain marketing approval; â€¢the timing of Investigational New Drug Application (â€œINDâ€) enabling studies and results from such studies; â€¢the timing and success of lead optimization for our product candidates in lead optimization; â€¢the translation of our preclinical results and data into future clinical trials in humans; â€¢the timing of any manufacturing runs for materials to be used in patient trials; â€¢the timing or likelihood of regulatory filings and approvals; â€¢our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate; â€¢our ability to obtain funding for our operations, including funding necessary to develop and commercialize our product candidates; â€¢the rate and degree of market acceptance of our product candidates, if approved; â€¢the success of competing products or platform technologies that are or may become available; â€¢our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval; â€¢future agreements with third parties in connection with the commercialization of our product candidates; â€¢the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets; â€¢existing regulations and regulatory developments in the United States and foreign countries; â€¢the expected potential benefits of strategic collaboration agreements, including our relationships with Arbor Biotechnologies, Inc., Astellas Gene Therapies, Inc., uniQure biopharma B.V. and Cystic Fibrosis Foundation (CFF), and our ability to attract collaborators with development, regulatory and commercialization expertise; â€¢the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; â€¢potential claims relating to our intellectual property and third-party intellectual property; â€¢our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; â€¢the pricing and reimbursement of our product candidates, if approved; 1 Â  â€¢the potential effects of public health emergencies, including the COVID-19 pandemic, to our preclinical and clinical programs and our business; â€¢our ability to attract and retain key managerial, scientific and medical personnel; â€¢the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; â€¢our financial performance; and â€¢our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act. These forward-looking statements are based on managementâ€™s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and managementâ€™s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled â€œRisk Factorsâ€ and elsewhere in this Quarterly Report on Form 10-Q. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this Quarterly Report on Form 10-Q. Â Â Â Â Â 2 Â  PART I. FINANCIAL INFORMATION Item 1. Condensed Unaudited Financial Statements 4D Molecular Therapeutics, Inc. Condensed Balance Sheets (Unaudited) (In thousands, except share and per share amounts) Â Â Â Â Â Â Â Â

securities Â Â 352,885 Â Â Â 39,124 Â Prepaid expenses and other current assets Â Â 10,687 Â Â Â 8,356 Â Total current assets Â Â 552,633 Â Â Â 296,588 Â Marketable securities, long-term Â Â 35,715 Â Â Â 10,954 Â Property and equipment, net Â Â 18,761 Â Â Â 20,126 Â Operating lease right-of-use assets, net Â Â 10,688 Â Â Â 11,539 Â Other assets Â Â 2,320 Â Â Â 684 Â Total assets Â $ 620,117 Â Â $ 339,891 Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Â Current liabilities Â Â Â Â Â Â Accounts payable Â $ 3,431 Â Â $ 3,515 Â Accrued and other current liabilities Â Â 12,776 Â Â Â 12,014 Â Deferred revenue Â Â â€” Â Â Â 273 Â Operating lease liabilities, current portion Â Â 3,196 Â Â Â 3,149 Â Total current liabilities Â Â 19,403 Â Â Â 18,951 Â Deferred revenue, net of current portion Â Â 1,318 Â Â Â 972 Â Derivative liability Â Â 382 Â Â Â 369 Â Operating lease liabilities, long-term portion Â Â 10,460 Â Â Â 11,522 Â Other liabilities Â Â 214 Â Â Â 248 Â Total liabilities Â Â 31,777 Â Â Â 32,062 Â Commitments and contingencies (Note 9) Â Â Â Â Â Â Stockholdersâ€™ equity Â Â Â Â Â Â Preferred stock, $0.0001Â par value, 10,000,000Â shares authorized at June 30, 2024 and December 31, 2023; noÂ shares issued and outstanding at June 30, 2024 and December 31, 2023 Â Â â€” Â Â Â â€” Â Common stock, $0.0001Â par value, 300,000,000Â shares authorized at June 30, 2024 and December 31, 2023; 51,914,275Â and 43,075,218Â shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Â Â 5 Â Â Â 4 Â Additional paid-in-capital Â Â 1,071,309 Â Â Â 723,136 Â Accumulated other comprehensive gain (loss) Â Â (293 ) Â Â 16 Â Accumulated deficit Â Â (482,681 ) Â Â (415,327 ) Total stockholdersâ€™ equity Â Â 588,340 Â Â Â 307,829 Â Total liabilities and stockholdersâ€™ equity Â $ 620,117 Â Â $ 339,891 Â The accompanying notes are an integral part of these unaudited condensed financial statements. 3 Â 4D Molecular Therapeutics, Inc. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share amounts) Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Collaboration and license revenue Â $ 5 Â Â $ 239 Â Â $ 33 Â Â $ 538 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 31,860 Â Â Â 23,584 Â Â Â 59,727 Â Â Â 46,002 Â General and administrative Â Â 10,601 Â Â Â 8,791 Â Â Â 20,898 Â Â Â 16,777 Â Total operating expenses Â Â 42,461 Â Â Â 32,375 Â Â Â 80,625 Â Â Â 62,779 Â Loss from operations Â Â (42,456 ) Â Â (32,136 ) Â Â (80,592 ) Â Â (62,241 ) Other income (expense): Â Â Â Â Â Â Â Â Â Â Â Interest income Â Â 7,548 Â Â Â 2,512 Â Â Â 13,293 Â Â Â 3,955 Â Other income (expense), net Â Â (45 ) Â Â 8 Â Â Â (55 ) Â Â (12 ) Total other income, net Â Â 7,503 Â Â Â 2,520 Â Â Â 13,238 Â Â Â 3,943 Â Net loss Â $ (34,953 ) Â $ (29,616 ) Â $ (67,354 ) Â $ (58,298 ) Net loss per share, basic and diluted Â $ (0.63 ) Â $ (0.77 ) Â $ (1.29 ) Â $ (1.63 ) Weighted-average shares outstanding used in computing net loss per share, basic and diluted Â Â 55,282,754 Â Â Â 38,335,219 Â Â Â 52,277,369 Â Â Â 35,661,995 Â The accompanying notes are an integral part of these unaudited condensed financial statements. Â 4 Â 4D Molecular Therapeutics, Inc. Condensed Statements of Comprehensive Loss (Unaudited) (In thousands) Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (34,953 ) Â $ (29,616 ) Â $ (67,354 ) Â $ (58,298 ) Other comprehensive loss: Â Â Â Â Â Â Â Â Â Â Â Net unrealized gain (loss) on marketable securities Â Â (184 ) Â Â 615 Â Â Â (309 ) Â Â 1,541 Â Total comprehensive loss Â $ (35,137 ) Â $ (29,001 ) Â $ (67,663 ) Â $ (56,757 ) Â The accompanying notes are an integral part of these unaudited condensed financial statements. 5 Â Â 4D Molecular Therapeutics, Inc. Condensed Statements of Stockholders' Equity (Unaudited) (In thousands, except share amounts) Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Other Comprehensive Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Loss Â Â Deficit Â Â Equity Â Balances at December 31, 2023 Â Â 43,075,218 Â Â $ 4 Â Â $ 723,136 Â Â $ 16 Â Â $ (415,327 ) Â $ 307,829 Â Issuance of common stock upon exercise of stock options and vesting of RSUs Â Â 236,856 Â Â Â â€” Â Â Â 3,113 Â Â Â â€” Â Â Â â€” Â Â Â 3,113 Â Issuance of common stock upon public offering, net of issuance costs - February / March 2024 Public Offering Sale Â Â 7,845,314 Â Â Â 1 Â Â Â 316,148 Â Â Â â€” Â Â Â â€” Â Â Â 316,149 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 5,974 Â Â Â â€” Â Â Â 5,974 Â Vesting of common stock warrants issued for services Â Â â€” Â Â Â â€” Â Â Â 22 Â Â Â â€” Â Â Â â€” Â Â Â 22 Â Net unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (125 ) Â Â â€” Â Â Â (125 ) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (32,401 ) Â Â (32,401 ) Balances at March 31, 2024 Â Â 51,157,388 Â Â $ 5 Â Â $ 1,048,393 Â Â $ (109 ) Â $ (447,728 ) Â $ 600,561 Â Issuance of common stock upon exercise of stock options and vesting of RSUs Â Â 81,290 Â Â Â â€” Â Â Â 850 Â Â Â â€” Â Â Â 850 Â Issuance of common stock upon ATM offering, net of issuance costs Â Â 585,938 Â Â Â â€” Â Â Â 15,263 Â Â Â â€” Â Â Â â€” Â Â Â 15,263 Â Issuance of common stock - 2020 ESPP Â Â 89,659 Â Â Â â€” Â Â Â 707 Â Â Â â€” Â Â Â â€” Â Â Â 707 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 6,074 Â Â Â â€” Â Â Â â€” Â Â Â 6,074 Â Vesting of common stock warrants issued for services Â Â â€” Â Â Â â€” Â Â Â 22 Â Â Â â€” Â Â Â â€” Â Â Â 22 Â Net unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (184 ) Â Â â€” Â Â Â (184 ) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (34,953 ) Â Â (34,953 ) Balances at June 30, 2024 Â Â 51,914,275 Â Â $ 5 Â Â $ 1,071,309 Â Â $ (293 ) Â $ (482,681 ) Â $ 588,340 Â Â Continued on next page. Â The accompanying notes are an integral part of these unaudited condensed financial statements. 6 Â Â 4D Molecular Therapeutics, Inc. Condensed Statements of Stockholders' Equity (Unaudited) (In thousands, except share amounts) Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Other Comprehensive Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Loss Â Â Deficit Â Â Equity Â Balances at December 31, 2022 Â Â 32,626,627 Â Â $ 3 Â Â $ 547,020 Â Â $ (1,196 ) Â $ (314,490 ) Â $ 231,337 Â Issuance of common stock upon exercise of stock options Â Â 122,207 Â Â Â â€” Â Â Â 1,135 Â Â Â â€” Â Â Â â€” Â Â Â 1,135 Â Issuance of common stock for the ATM offering program, net of issuance costs Â Â 487,934 Â Â Â â€” Â Â Â 9,647 Â Â Â â€” Â Â Â â€” Â Â Â 9,647 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 4,221 Â Â Â â€” Â Â Â â€” Â Â Â 4,221 Â Vesting of common stock warrants issued for services Â Â â€” Â Â Â â€” Â Â Â 22 Â Â Â â€” Â Â Â â€” Â Â Â 22 Â Net unrealized gain on marketable securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 926 Â Â Â â€” Â Â Â 926 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (28,682 ) Â Â (28,682 ) Balances at March 31, 2023 Â Â 33,236,768 Â Â $ 3 Â Â $ 562,045 Â Â $ (270 ) Â $ (343,172 ) Â $ 218,606 Â Issuance of common stock upon exercise of stock options Â Â 72,217 Â Â Â â€” Â Â Â 894 Â Â Â â€” Â Â Â â€” Â Â Â 894 Â Issuance of common stock upon public offering, net of issuance costs Â Â 8,625,000 Â Â Â 1 Â Â Â 129,207 Â Â Â â€” Â Â Â â€” Â Â Â 129,208 Â Issuance of common stock - 2020 ESPP Â Â 82,637 Â Â Â â€” Â Â Â 658 Â Â Â â€” Â Â Â â€” Â Â Â 658 Â ATM offering costs Â Â â€” Â Â Â â€” Â Â Â (212 ) Â Â â€” Â Â Â â€” Â Â Â (212 ) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 4,969 Â Â Â â€” Â Â Â 4,969 Â Vesting of common stock warrants issued for services Â Â â€” Â Â Â â€” Â Â Â 22 Â Â Â â€” Â Â Â â€” Â Â Â 22 Â Net unrealized gain on marketable securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 615 Â Â Â â€” Â Â Â 615 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (29,616 ) Â Â (29,616 ) Balances at June 30, 2023 Â Â 42,016,622 Â Â $ 4 Â Â $ 697,583 Â Â $ 345 Â Â $ (372,788 ) Â $ 325,144 Â Â The accompanying notes are an integral part of these unaudited condensed financial statements. 7 Â 4D Molecular Therapeutics, Inc. Condensed Statements of Cash Flows (Unaudited) (In thousands) Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities Â Â Â Â Â Â Net loss Â $ (67,354 ) Â $ (58,298 ) Adjustments to reconcile net loss to net cash used in operating Â Â Â activities Â Â Â Â Â Â Stock-based compensation expense Â Â 12,048 Â Â Â 9,190 Â Vesting of common stock warrants in return for services Â Â 44 Â Â Â 44 Â Change in fair value of derivative liability Â Â 13 Â Â Â â€” Â Depreciation and amortization Â Â 2,367 Â Â Â 2,108 Â Amortization of right-of-use assets Â Â 851 Â Â Â 732 Â Net amortization (accretion) of premium (discount) on marketable securities Â Â (3,092 ) Â Â (615 ) Changes in operating assets and liabilities Â Â Â Â Â Â Prepaid expenses and other current assets Â Â (2,330 ) Â Â (475 ) Other assets Â Â (1,636 ) Â Â â€” Â Accounts payable Â Â (83 ) Â Â 614 Â Accrued and other liabilities Â Â 785 Â Â Â (2,239 ) Deferred revenue Â Â 72 Â Â Â (538 ) Operating lease liabilities Â Â (1,016 ) Â Â (494 ) Net cash used in operating activities Â Â (59,331 ) Â Â (49,971 ) Cash flows from investing activities Â Â Â Â Â Â Purchases of marketable securities Â Â (374,084 ) Â Â (20,156 ) Maturities of marketable securities Â Â 38,346 Â Â Â 114,391 Â Acquisition of property and equipment Â Â (1,059 ) Â Â (1,817 ) Net cash provided by (used in) investing activities Â Â (336,797 ) Â Â 92,418 Â Cash flows from financing activities Â Â Â Â Â Â Issuance of common stock upon the exercise of stock options and warrants Â Â 3,963 Â Â Â 2,029 Â Issuance of common stock upon public offering, net of issuance costs Â Â 316,148 Â Â Â 129,720 Â Issuance of common stock for the ATM offering program, net of issuance costs Â Â 15,263 Â Â Â 9,647 Â Issuance of common stock - 2020 ESPP Â Â 707 Â Â Â 658 Â Payment of offering costs Â Â â€” Â Â Â (329 ) Payment of ATM costs Â Â â€” Â Â Â (212 ) Net cash provided by financing activities Â Â 336,081 Â Â Â 141,513 Â Net increase (decrease) in cash and cash equivalents Â Â (60,047 ) Â Â 183,960 Â Cash and cash equivalents, beginning of period Â Â 249,108 Â Â Â 52,351 Â Cash and cash equivalents, end of period Â $ 189,061 Â Â $ 236,311 Â Supplemental disclosures of noncash investing and financingÂ Â Â information Â Â Â Â Â Â Unpaid offering costs Â $ â€” Â Â $ 183 Â Purchases of property and equipment in accounts payable Â Â Â and accrued and other liabilities Â $ 177 Â Â $ 312 Â Â The accompanying notes are an integral part of these unaudited condensed financial statements. 8 Â 4D Molecular Therapeutics, Inc. Notes to Unaudited Condensed Financial Statements 1. The Company 4D Molecular Therapeutics, Inc. (the â€œCompanyâ€) was formed as a limited liability company in September 2013 under the name 4D Molecular Therapeutics, LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware in March 2015. The Company is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. Initial Public OfferingIn December 2020, the Company sold and issued 9,660,000 shares of common stock at a price to the public of $23.00 per share, which included shares sold upon the underwritersâ€™ exercise of their overallotment option to purchase 1,260,000 additional shares. The Company received an aggregate of $204.7 million in net proceeds, after deducting underwriting discounts and commissions and offering costs.Upon the closing of the Company's initial public offering in December 2020 (the "IPO"), all outstanding shares of redeemable convertible preferred stock automatically converted into 11,575,984 shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.2021 Follow On Public OfferingIn November 2021, the Company completed an underwritten public offering ("2021 Offering") in which 4,750,000 shares of the Company's common stock were sold at an offering price of $25.00 per share pursuant to an effective Registration Statement on Form S-1. The net proceeds from the 2021 Offering were $111.1 million, after deducting underwriting discounts and commissions and offering expenses. 2023 Follow On Public Offering In May 2023, the Company completed its third underwritten public offering (the â€œ2023 Offeringâ€) in which 8,625,000 shares of the Companyâ€™s common stock were sold at an offering price of $16.00 per share pursuant to an effective Registration Statement on Form S-3. The net proceeds from the 2023 Offering were $129.2 million, after deducting underwriting discounts and commissions and offering expenses. 2024 Follow On Public Offering In February 2024, the Company completed an underwritten public offering (the â€œ2024 Offeringâ€) in which 6,586,015 shares of the Companyâ€™s common stock were sold at an offering price of $29.50 per share, as well as pre-funded warrants to purchase 3,583,476 shares of the Companyâ€™s common stock at an offering price of $29.4999 per underlying share pursuant to an effective Registration Statement on Form S-3. The net proceeds from the 2024 Offering were $281.2 million, after deducting underwriting discounts and commissions and other offering expenses. The Company also granted the underwriters the option to purchase up to 1,525,423 additional shares of common stock in connection with the offering.In March 2024, the underwriters exercised their option to purchase 1,259,299 additional shares of common stock resulting in net proceeds of $34.9 million, after deducting commissions.LiquidityThe Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $482.7 million as of June 30, 2024. The Company believes that its cash and cash equivalents and marketable securities as of June 30, 2024 are sufficient for the Company to fund planned operations for at least one year from the issuance date of these unaudited condensed financial statements. The Company has historically financed its operations primarily through the sale of equity securities, and to 9 Â a lesser extent, from cash received pursuant to its collaboration and license agreements. To date, none of the Companyâ€™s product candidates have been approved for sale, and therefore, the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows from operations to continue for the foreseeable future. The Company plans to raise additional funding as required based on the status of its clinical trials and projected cash flows. There can be no assurance that, in the event the Company requires additional financing, such financing will be available on terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Companyâ€™s ability to achieve its business objectives. 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (â€œU.S. GAAPâ€) and the rules and regulations of the United States Securities and Exchange Commission (â€œSECâ€) for interim reporting.Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC.The accompanying financial information for the three and six months ended June 30, 2024 and 2023 is unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Companyâ€™s financial position as of June 30, 2024 and December 31, 2023 and its results of operations and cash flows for the six months ended June 30, 2024 and 2023. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods.Use of Estimates and JudgmentsThe preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and the derivative instrument and income tax uncertainties. Actual results could differ from those estimates. Due to the war in Ukraine, conflicts in the Middle East, rising interest rates and inflation, and the lingering impacts of the coronavirus (â€œCOVID-19â€) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2024. While there was not a material impact to the Companyâ€™s unaudited condensed financial statements as of June 30, 2024, these estimates may change, as new events occur and additional information is obtained, as well as other factors that could result in material impacts to the unaudited condensed financial statements in future reporting periods. Segment Information The Company operates and manages its business as one reportable and operating segment. The Companyâ€™s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance. 10 Â Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Companyâ€™s cash is held at two financial institutions in the United States of America. The Companyâ€™s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, U.S. government sponsored agencies, commercial paper, corporate bonds and certificates of deposit. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits. The Companyâ€™s partners in collaboration and license agreements who represent 10% or more of the Companyâ€™s total revenue are as follows: Â Â Â Three Months Ended June 30, Â Six Months Ended June 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Â Customer A Â 0% Â 96% Â 0% Â 98% Â Customer B Â 100% Â * Â 100% Â * Total Â 100% Â 96% Â 100% Â 98% Â * Less than 10% The Company did not have accounts receivable from its partners in collaboration and license agreements as of June 30, 2024 and December 31, 2023. Â The Companyâ€™s total revenue by geographic region, based on the location of the customer, are as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2024 Â Netherlands Â $ â€” Â Â $ 230 Â Â $ â€” Â Â $ 525 Â United States Â Â 5 Â Â Â 9 Â Â Â 33 Â Â Â 13 Â Total revenue Â $ 5 Â Â $ 239 Â Â $ 33 Â Â $ 538 Â Other Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (â€œCMOsâ€) and contract research organizations (â€œCROsâ€), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting. There can be no assurance that the Companyâ€™s research and development will be successfully completed, that adequate protection for the Companyâ€™s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Companyâ€™s product development efforts are successful, it is uncertain when, if ever, the Company

will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing). 11 Â Recently Issued Accounting Pronouncements Not Yet AdoptedOn December 14, 2023, the Financial Accounting Standards Board issued Accounting Standards Update (â€œASUâ€) No. 2023-09, Improvements to Income Tax Disclosures. The final guidance adds clarifications related to the presentation of rate reconciliation for public business entities and definitions of specific categories in rate reconciliation. These amendments are effective for public business entities for annual periods beginning after December 15, 2024. For other entities, amendments are effective for annual periods beginning after December 15, 2025. The Company is not early adopting ASU 2023-09. The Company expects to make additional disclosures for income taxes upon adoption of this ASU. Â 3. Fair Value Measurements The following tables represent the Companyâ€™s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Â Â Â Basis for Fair Value Measurements Â Â Fair Value as of Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â June 30, 2024 Â Assets Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 146,308 Â Â $ â€” Â Â $ â€” Â Â $ 146,308 Â Certificates of deposit Â Â â€” Â Â Â 69,677 Â Â Â â€” Â Â Â 69,677 Â Commercial paper Â Â Â â€” Â Â Â 96,220 Â Â Â â€” Â Â Â 96,220 Â Corporate bonds Â Â â€” Â Â Â 203,733 Â Â Â â€” Â Â Â 203,733 Â U.S. Treasuries Â Â â€” Â Â Â 18,970 Â Â Â â€” Â Â Â 18,970 Â Total Â $ 146,308 Â Â $ 388,600 Â Â $ â€” Â Â $ 534,908 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Derivative liability Â $ â€” Â Â $ â€” Â Â $ 382 Â Â $ 382 Â Total Â $ â€” Â Â $ â€” Â Â $ 382 Â Â $ 382 Â Â Â Basis for Fair Value Measurements Â Â Fair Value as of Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 217,644 Â Â $ â€” Â Â $ â€” Â Â $ 217,644 Â Commercial paper Â Â â€” Â Â Â 18,243 Â Â Â â€” Â Â Â 18,243 Â Corporate bonds Â Â â€” Â Â Â 28,939 Â Â Â â€” Â Â Â 28,939 Â U.S. government sponsored agencies Â Â â€” Â Â Â 2,896 Â Â Â â€” Â Â Â 2,896 Â Total Â $ 217,644 Â Â $ 50,078 Â Â $ â€” Â Â $ 267,722 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Derivative liability Â $ â€” Â Â $ â€” Â Â $ 369 Â Â $ 369 Â Total Â $ â€” Â Â $ â€” Â Â $ 369 Â Â $ 369 Â Level 3 Inputs The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability was determined using a present value analysis with multiple scenarios. In determining the fair value of the derivative liability, the inputs impacting fair value include the change of control payment to Cystic Fibrosis Foundation (CFF), the probability of a change of control event, the product status at time of a change of control event and the discount rate. See Note 15 for further discussion on the embedded derivative. There were no transfers between Level 1, 2 and 3 during the periods presented. 12 Â The following tables set forth a summary of the changes in the fair value of the Companyâ€™s Level 3 financial instrument during the six months ended June 30, 2024 and 2023 (in thousands): Â Â Â DerivativeLiability Â Balance as of December 31, 2023 Â $ 369 Â Change in fair value includedÂ in other income (expense), net Â Â Â 13 Â Balance as of June 30, 2024 Â $ 382 Â Â Â Â DerivativeLiability Â Balance as of December 31, 2022 Â $ 212 Â Change in fair value includedÂ in other income (expense), net Â Â â€” Â Balance as of June 30, 2023 Â $ 212 Â Â 4. Marketable Securities Marketable securities, which are classified as available-for-sale, consisted of the following as of June 30, 2024 and December 31, 2023 (in thousands):Â Â Â Amortized Cost Basis Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value as of June 30, 2024 Â Short-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â Â Certificates of deposit Â $ 69,674 Â Â $ 21 Â Â $ (18 ) Â $ 69,677 Â Commercial paper Â Â 95,009 Â Â Â 8 Â Â Â (68 ) Â Â 94,949 Â Corporate bonds Â Â 169,491 Â Â Â 10 Â Â Â (212 ) Â Â 169,289 Â U.S. Treasuries Â Â 18,977 Â Â Â â€” Â Â Â (7 ) Â Â 18,970 Â Total short-term marketable securities Â $ 353,151 Â Â $ 39 Â Â $ (305 ) Â $ 352,885 Â Long-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 1,275 Â Â $ â€” Â Â $ (4 ) Â $ 1,271 Â Corporate bonds Â Â 34,466 Â Â Â 20 Â Â Â (42 ) Â Â 34,444 Â Total long-term marketable securities Â $ 35,741 Â Â Â $ 20 Â Â $ (46 ) Â $ 35,715 Â Â Â Â Â Amortized Cost Basis Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value as of December 31, 2023 Â Short-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 17,603 Â Â $ 1 Â Â $ (26 ) Â $ 17,578 Â Corporate bonds Â Â 18,641 Â Â Â 12 Â Â Â (3 ) Â Â 18,650 Â U.S. government sponsored agencies Â Â 2,900 Â Â Â â€” Â Â Â (4 ) Â Â 2,896 Â Total short-term marketable securities Â $ 39,144 Â Â $ 13 Â Â $ (33 ) Â $ 39,124 Â Long-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 661 Â Â $ 4 Â Â $ â€” Â Â $ 665 Â Corporate bonds Â Â 10,257 Â Â Â 32 Â Â Â â€” Â Â Â 10,289 Â Total long-term marketable securities Â $ 10,918 Â Â $ 36 Â Â $ â€” Â Â $ 10,954 Â Â All marketable securities held as of June 30, 2024 had contractual maturities of less than two years. There have been no material realized gains or losses on marketable securities for the periods presented. 13 Â Aggregate fair values of marketable securities with unrealized losses and gains were as follows as of June 30, 2024 and December 31, 2023 (in thousands):Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Aggregate fair value of marketable securities in a continuous loss position for less than twelve months Â $ 304,777 Â Â $ 20,494 Â Aggregate fair value of marketable securities in a continuous loss position for more than twelve months Â Â â€” Â Â Â 4,986 Â Aggregate fair value of marketable securities in unrealized gain position Â Â 83,823 Â Â Â 24,598 Â Total marketable securities Â $ 388,600 Â Â $ 50,078 Â The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for any period presented. The Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company further considered the maximum unrealized loss amounts both at the individual instrument level, $13 thousand, as well as in aggregate, $350 thousand, as of June 30, 2024, as immaterial. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company anticipates that it will recover the entire amortized cost basis of such securities, and therefore, no credit loss existed as of June 30, 2024. 5. Property and Equipment, Net Property and equipment, net, consisted of the following (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â Machinery and equipment Â $ 13,766 Â Â $ 12,996 Â Leasehold improvements Â Â 17,325 Â Â Â 16,902 Â Furniture and fixtures Â Â 566 Â Â Â 566 Â Office equipment Â Â 239 Â Â Â 239 Â Computer equipment and software Â Â 866 Â Â Â 805 Â Construction in progress Â Â 299 Â Â Â 550 Â Total property and equipment Â Â 33,061 Â Â Â 32,058 Â Less: Accumulated depreciation and amortization Â Â (14,300 ) Â Â (11,932 ) Property and equipment, net Â $ 18,761 Â Â $ 20,126 Â Â All property and equipment are maintained in the United States. Depreciation expense was $1.2 million and $1.1 million for the three months ended June 30, 2024 and 2023, respectively, and $2.4 million and $2.1 million for the six months ended June 30, 2024 and 2023, respectively. 6. Accrued and Other Current LiabilitiesAccrued and other current liabilities consisted of the following (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â Payroll and related expenses Â $ 5,494 Â Â $ 8,149 Â Accrued clinical and preclinical study costs Â Â 5,165 Â Â Â 2,180 Â Consulting and professional Â Â 2,021 Â Â Â 1,581 Â Other accrued expenses Â Â 96 Â Â Â 104 Â Total accrued and other current liabilities Â $ 12,776 Â Â $ 12,014 Â Â 14 Â 7. Research and Collaboration Arrangements Collaboration and license revenue for each period was as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â uniQure Â $ â€” Â Â $ 230 Â Â $ â€” Â Â $ 525 Â CFF Â Â 5 Â Â Â 9 Â Â Â 33 Â Â Â 13 Â Total revenue Â $ 5 Â Â $ 239 Â Â $ 33 Â Â $ 538 Â Â Deferred revenue is summarized as follows (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â CFF Â $ 1,318 Â Â $ 1,245 Â Total deferred revenue Â $ 1,318 Â Â $ 1,245 Â Â The total amount of revenue in the six months ended June 30, 2024 which was included in deferred revenue at January 1, 2024 was zero. The total amount of revenue in the six months ended June 30, 2023 which was included in deferred revenue at January 1, 2023 was $0.5 million. uniQure In January 2014, the Company and uniQure biopharma B.V. (â€œuniQureâ€) entered into a Collaboration and License Agreement (the â€œuniQure Agreementâ€) to collaborate on the discovery and non-clinical research activities related to the Companyâ€™s Therapeutic Vector Evolution platform in order to generate and validate vectors for gene delivery to treat diseases within the central nervous system and liver (together, the â€œuniQure Fieldâ€). The uniQure Agreement provided uniQure with a research license as well as an exclusive development and commercialization license for each project variant selected for further development. The initial research term is three years with an option for uniQure to extend the research term one time for an additional year. Once the Companyâ€™s research plan has concluded, uniQure is solely responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. In October 2016, uniQure exercised its option to extend the research term for an additional year to January 2018. The Company was also required to work exclusively with uniQure in the uniQure Field (the â€œuniQure Exclusivity Clauseâ€). Pursuant to the uniQure Agreement, the Company received upfront payments of $0.2 million, and was entitled to receive (i) contingent payments for the achievement of research and development milestones of up to $5.0 million for each licensed product selected under the arrangement, and (ii) royalties in the single digit range on future sales of the potential product candidates and sublicense consideration in the low teens to low thirties range on any future sublicensing arrangements. The Company also received capped research and development service fees based on contractual full-time employee rates per year. In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of 609,744 of uniQure ordinary shares that vested over the initial three-year term of the agreement. The upfront payment of $0.2 million was recorded as deferred revenue and was recognized on a ratable basis over the estimated performance period of four years. Payments and reimbursements for research costs were recognized on an as-incurred basis. The options to purchase uniQure shares were deemed to be a noncash component of the arrangement consideration, as the vesting of options is linked to the uniQure Agreement and there is a requirement for the holders of the options to provide services under the agreement. The fair value of the uniQure options, which was estimated to be $10.6 million, was recognized ratably as revenue over the estimated performance period of four years and the associated compensation expense related to the stock options was recorded as research and development expense. In August 2019, the Company and uniQure entered into an Amended and Restated Collaboration and License Agreement (the â€œAmended uniQure Agreementâ€), which amended and restated the uniQure 15 Â Agreement, and a separate Collaboration and License Agreement (the â€œSecond uniQure Agreementâ€). Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the uniQure Exclusivity Clause and transferring other rights back to the Company. Under the Amended uniQure Agreement, uniQure continues to have an exclusive license to select AAV capsid variants (the â€œSelected Variantsâ€) in the uniQure Field. uniQure continues to be solely responsible, at its cost, to develop and commercialize the compounds and products containing the Selected Variants. The amended uniQure Agreement eliminated the uniQure Exclusivity Clause in the uniQure Agreement. Furthermore, the contingent payments that the Company was entitled to from uniQure for the achievement of research and development milestones of up to $5.0 million for each licensed product selected under the uniQure Agreement were eliminated and sublicense consideration on any future sublicensing arrangements was reduced from the low teens to low thirties percentages to mid-single digit to mid-twenties percentages. Under the Second uniQure Agreement, the parties agreed to research and develop new AAV capsid variants (the â€œNew Variantsâ€) that are not Selected Variants that affect certain targets selected by uniQure (the â€œuniQure Targetsâ€) in the uniQure Field. The Company is solely responsible, at its cost, for the research of the New Variants. The Company granted uniQure an exclusive license to a certain number of the New Variants (the â€œuniQure New Variantsâ€) that affect the uniQure Targets. uniQure is solely responsible, at its cost, to develop and commercialize the compounds and products containing the uniQure New Variants that affect the uniQure Targets (the â€œLicensed Productsâ€). The Company retains all rights to New Variants in the uniQure Field that affect targets other than the uniQure Targets. Under both the Amended uniQure Agreement and the Second uniQure Agreement, uniQure will be required to pay the Company royalties on worldwide annual net sales of Licensed Products at a mid-single digit percentage rate, subject to certain specified reductions. uniQure will also be required to pay the Company sublicensing consideration for sublicensing the Companyâ€™s intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties at a rate between the mid-single digit to mid-twenties. The Company has reciprocal obligations, at the same percentage rates as uniQure, to pay uniQure royalties and sublicensing consideration for sublicensing certain intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties. The Company concluded that the Amended uniQure Agreement and the Second uniQure Agreement should be accounted for as one combined contract that should be accounted for as a separate contract from the uniQure Agreement given that the incremental licensed intellectual property rights and research and development services are distinct from the rights and services previously transferred to uniQure under the uniQure Agreement and the transaction price increased by an amount that equals the standalone selling price of the incremental rights and services to be transferred to uniQure under the Amended uniQure Agreement and Second uniQure Agreement. Neither party was required to pay monetary consideration in connection with the execution of the Amended uniQure Agreement or the Second uniQure Agreement or for subsequent performance by the parties under those agreements, notwithstanding the potential future royalty and sublicense consideration described above. The fair value of the non-monetary consideration given by uniQure to the Company, for the intellectual property right is $5.1 million. This intellectual property right is considered to be an in-process research and development asset with no alternative future use and, accordingly, was written off as acquired in-process research and development expense in the year ended December 31, 2019. The incremental transaction price described in the paragraph above was recorded as deferred revenue given that the Company identified one single combined performance obligation under ASC 606, which includes the licenses to the New Variants, research services and participation in the joint steering committee (â€œJSCâ€). Revenue is being recognized using the input method based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligation. The Company completed its performance obligation during the third quarter of 2023 and the deferred revenue was recognized as revenue in the same period.16 Â The Company determined the transaction price using the risk adjusted net present value analysis (â€œrNPVâ€) methodology to value the elimination of the uniQure exclusivity clause and other material rights received by the Company, including the potential royalties the Company would receive from uniQure. The rNPVs incorporate estimates and assumptions including the number of products the Company and uniQure would develop, the risk-adjusted probability of successfully developing a biopharmaceutical product, the probability that uniQure will develop a product, the research and development costs, the potential worldwide sales and associated commercialization costs, corporate tax rate, and discount rate. During each of the three and six months ended June 30, 2024, the Company recognized no revenue under both of the Amended uniQure Agreement and the Second uniQure Agreement. The Company recognized $0.2 million and $0.5 million during the three and six months ended June 30, 2023, respectively, under both of the Amended uniQure Agreement and the Second uniQure Agreement. There were no amounts due from uniQure under the uniQure Agreement, Amended uniQure Agreement or Second uniQure Agreement as of June 30, 2024 and December 31, 2023. As of June 30, 2024 and December 31, 2023, deferred revenue relating to uniQure was zero and the aggregate amount of the transaction price allocated to the remaining performance obligation was zero.Cystic Fibrosis Foundation (CFF)In September 2016, the Company entered into an award agreement for the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program with CFF, a non-profit organization dedicated to finding a cure for cystic fibrosis, an inherited disorder that causes disease in the pulmonary airways leading to morbidity and mortality. Under this agreement, CFF contributes funding to help advance the Companyâ€™s CF research program. The September 2016 grant award agreement was incorporated into a new grant award agreement with the CFF in September 2017 with the same objectives, which was subsequently amended in August 2018 and February 2021. In August 2023, the Company executed a third amendment to the agreement (the â€œAugust 2023 Amendmentâ€), which modified the research plan, increased the aggregate milestone payments from $3.5 million to $6.3 million and extended the estimated project completion date. The aforementioned September 2017 agreement and three amendments are collectively referred to as the â€œCFF Agreementâ€. The August 2023 Amendment represents a contract modification to an existing contract under Topic 606, given the amendment did not include any additional goods or services, and the remaining research activities are not distinct from those previously provided. The August 2023 Amendment did not impact the transaction price, given the increased award amount relates to variable consideration for future milestones that are fully constrained. Accordingly, the contract modification did not result in a revenue adjustment. As of June 30, 2024 and December 31, 2023, the Company had achieved milestones totaling $1.8 million and $1.7 million, respectively, under the CFF Agreement. The remaining award amount will be paid by CFF based on achievement of certain development milestones by the Company. The Company expects to make payments to CFF equal to six times the actual award received by the Company in three installments within the first four years of the first commercial sale of a product developed under this agreement. The Company also has agreed to make future sales-based milestone payments to CFF of up to three times the actual award received upon achieving specified commercialization milestones with respect to the first of any product developed utilizing any compound covered under the CFF Agreement. The CFF Agreement also requires the Company to pay to CFF royalties of a mid-single digit percentage, up to six times the actual award received, on any amounts received by the Company from the sale, license or transfer to a third-party of rights in the technology developed as a result of this collaboration. Any such royalty payments shall be credited against the payments owed by the

Company upon first commercial sale. In the event of a change of control of the Company, CFF will receive certain payments, depending on the timing of the change of control and the size of the transaction. To date, the Company has not developed a commercial product in connection with the CFF Agreement, and it has not licensed, sold or otherwise transferred to another party the product developed under the CFF Agreement or the underlying technology. If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of 180 consecutive days and fails to present a 17 Â reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Companyâ€™s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license. The Company identified one performance obligation within the CFF grant agreement for research activities. The Companyâ€™s contract with CFF does not include a significant financing component. The Company concluded that the transaction price should not include the variable consideration related to future research milestones as they were considered to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company re-evaluates the transaction price and estimated period of performance at each reporting period. Revenue recognized during each of the three and six months ended June 30, 2024 and 2023 was immaterial. As of June 30, 2024 and December 31, 2023, deferred revenue relating to the CFF Agreement was $1.3 million and $1.2 million, respectively. There were no accounts receivable from CFF under the CFF Agreement as of June 30, 2024 and December 31, 2023. As of June 30, 2024 and December 31, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligation was $1.3 million and $1.2 million, respectively. Based on current timelines, the deferred revenue is expected to be recognized as revenue over the next one to three years as the Company performs research services through the completion of IND-enabling studies. The obligation to make payments to CFF upon a change of control meets the definition of an embedded derivative that is required to be bifurcated and separately accounted for as a derivative liability. See Note 15 for further discussion of the embedded derivative. Arbor Biotechnologies, Inc.On December 20, 2023 (the â€œEffective Dateâ€), the Company entered into a co-development and co-commercialization agreement (the â€œArbor Agreementâ€) with Arbor Biotechnologies, Inc. (â€œArborâ€), pursuant to which the Company and Arbor agreed to co-develop and co-commercialize on a fifty-fifty cost-and-profit-sharing basis up to six genetic medicine products to treat central nervous system (â€œCNSâ€) indications, based on combining the Companyâ€™s CNS-targeting vectors and Arbor's Cas enzymes and Guide RNAs. The first product candidate under the Arbor Agreement will address a molecular target implicated in amyotrophic lateral sclerosis (ALS). The Company will account for its costs related to the co-development and co-commercialization of product candidates under the Arbor Agreement as research and development expenses in the periods in which they are incurred. As of June 30, 2024, no Shared Product has been designated by the JSC (each as defined in the Arbor Agreement) under the Arbor Agreement, and no research and development expenses were incurred related to the Arbor Agreement during the three and six months ended June 30, 2024. 8. License Arrangements Astellas Gene Therapies, Inc.On July 5, 2023, the Company entered into a licensing agreement (the â€œLicense Agreementâ€) with Astellas Gene Therapies, Inc. (â€œAGTâ€), pursuant to which the Company granted to AGT a license to utilize its intravitreal R100 vector (â€œ4D Vectorâ€) to develop and commercialize licensed compounds and licensed products for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees. Under the terms of the License Agreement, the Company has provided its 4D vector technology to AGT to deliver AGT's genetic payloads for the treatment of rare monogenic diseases. AGT will conduct all subsequent research, development, manufacturing, and commercialization activities. As partial consideration for the rights and licenses granted to AGT by the Company under this Agreement, AGT paid the Company an upfront amount of $20 million, which was received in July 2023. The Company 18 Â may receive potential future option fees and milestones of up to $942.5 million. In addition, the Company is entitled to receive mid-single digit to double-digit, sub-teen royalties on net sales of all licensed products. Under the License Agreement, the Companyâ€™s performance obligation is to grant and make available to AGT the Licensed IP and Licensed Know-How (each as defined in the License Agreement) with respect to the 4D Vector. In connection with the grant of the license, in July 2023, the Company delivered to AGT the Transferred Material (as defined in the License Agreement). As of June 30, 2024, there was no deferred revenue and no accounts receivable relating to the License Agreement.Aevitas Therapeutics, Inc. and The Trustees of the University of PennsylvaniaOn April 21, 2023, the Company entered into an agreement (the â€œAgreementâ€) with Aevitas Therapeutics, Inc. (â€œAevitasâ€), pursuant to which the Company acquired all of Aevitasâ€™ worldwide rights to short-form human complement factor H ("sCFH"), which the Company plans to use for its 4D-175 product candidate research program. The asset purchase was accounted for as an asset acquisition. As consideration for the Agreement, the Company shall pay Aevitas up to approximately $144 million in cash upon certain late-stage development, regulatory and sales milestones being achieved plus royalties in the low single digits range on sales of 4D-175. In addition, as part of the Agreement, the Company was assigned a License Agreement for sCFH with the Trustees of the University of Pennsylvania, under which the Company shall pay the University of Pennsylvania up to approximately $42 million in cash upon certain late-stage development, regulatory and sales milestones being achieved plus royalties in the low single digits range on sales of 4D-175. No upfront consideration was paid under the Agreement.As of June 30, 2024, the Company has not recorded a liability related to contingent consideration for future milestone and royalty payments to either Aevitas or the University of Pennsylvania, as the achievement of such milestones has not occurred and was not deemed probable and product sales have not commenced.Regents of the University of California The Company has exclusive, worldwide license agreements (the â€œUC Agreementsâ€) with the Regents of the University of California (the â€œUC Regentsâ€) relating to the use of certain patents and intellectual property surrounding its core technologies, including Therapeutic Vector Evolution. Pursuant to each of the UC Agreements executed prior to January 2019, the Company was obligated to pay a (i) non-refundable license fee of $5,000 upon execution, (ii) a non-refundable license fee of $5,000 each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents, (iii) reimbursement of domestic and foreign patent filing, prosecution and maintenance fees, and (iv) either $50,000 or issuance of a 3% equity interest in the Company upon the closing of the first qualified financing at the option of the UC Regents. The Companyâ€™s first qualified financing occurred in 2015 and at the election of the UC Regents, the Company issued the UC Regents in January 2016 an amount of common stock equal to 6% of the equity interests in the Company pursuant to the applicable clause in each of the UC Agreements.Pursuant to an agreement with the UC Regents executed in January 2019 the Company paid a non-refundable license fee of $50,000 to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license fee of $5,000 on the one-year anniversary of the contract effective date and each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $3.1 million, (ii) low single digit royalties on the net sales of its developed products that consists of a minimum annual royalty of up to $0.1 million per year for the term of the agreement beginning in the first calendar year after the year in which net sales first occurred, and (iii) sublicense consideration in the mid-teens to the mid-twenties-range on any future sublicensing arrangements the Company may enter into with third-party licensees. 19 Â Regents of the University of California and The Trustees of the University of Pennsylvania In July 2021, the Company entered into an exclusive license agreement with the UC Regents and the Trustees of the University Pennsylvania to license intellectual property related to certain vectors. In July 2021, the Company paid a non-refundable license fee of $100,000 to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license maintenance fee of $10,000 on the one-year anniversary of the contract effective date and each year thereafter, except years for which the Company has paid royalties on the net sales of a licensed product. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $3.9 million, (ii) low single digit percentage rate royalties on the net sales of its licensed products that consists of a minimum annual royalty of up to $0.1 million per year for the term of the agreement beginning in the first calendar year after the year in which net sales first occurred and (iii) sublicense consideration in the mid-single digits to the low twenties percentage rate range on any future sublicensing arrangements the Company may enter into with third-party licensees. On February 22, 2023, the Company provided 90 days written notice to the UC Regents and the Trustees of the University Pennsylvania to terminate said agreement in its entirety at-will. Accordingly, the effective termination date of this agreement is May 23, 2023.The Company did not incur any expense under the provisions of the outstanding license agreements during each of the three and six months ended June 30, 2024 and 2023. 9. Commitments and Contingencies Operating Lease Commitments 5980 Horton Street Building LeaseIn May 2015, the Company executed a lease agreement for office and laboratory space in Emeryville, California. In January 2016, the Company executed the first amendment to the lease agreement for additional rentable office and laboratory space which extended the lease term to March 31, 2023 and updated the option to renew the lease at market rent from the prior additional term of three years to five years. In October 2018, the Company executed a second amendment to extend the lease to September 2026. Additionally, the second amendment provided a tenant improvement allowance of $0.2 million, which was paid to the Company in November 2018. The 5980 Horton Street Building Lease is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of June 30, 2024, the operating lease right-of-use asset and operating lease liability were $1.0 million and $1.2 million, respectively. As of December 31, 2023, the operating lease right-of-use asset and operating lease liability were $1.2 million and $1.4 million, respectively. The discount rate used to determine the lease liability was 7.5%. 5858 Horton Street Building Lease and ExpansionIn October 2018, the Company executed a second lease agreement for additional office and laboratory space in Emeryville, California. The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years at market rent. The Company did not have to pay rent until October 2019. This lease agreement also provided for a tenant improvement allowance of $0.4 million, which was paid to the Company in December 2019. The Company amortizes the tenant improvement allowance on a straight-line basis over the remaining term of the lease as a reduction of rent expense. In May 2019, the Company amended the second lease agreement executed in October 2018 to add additional office, manufacturing and laboratory space (the â€œ2019 Expansionâ€). The amendment extended the term of the lease to December 31, 2029. The Company did not have to pay rent until December 2019. The lease agreement also included a tenant improvement allowance, which was increased to $2.3 million in February 2021 pursuant to a second amendment to the second lease agreement. The Company fully received the $2.3 million tenant improvement allowance in 2023. The tenant improvement allowance funds improvements to the additional office, manufacturing and laboratory space, which the Company has determined to be lessee owned. The allowance is treated as a reduction of lease payments used to measure the lease liability. 20 Â The 5858 Horton Street Building Lease and 2019 Expansion are considered operating leases under ASC 842 as they do not meet the criteria of a finance lease. As of June 30, 2024, the operating lease right-of-use asset and operating lease liability was $9.7 million and $12.5 million, respectively. As of December 31, 2023, the operating lease right-of-use asset and operating lease liability was $10.3 million and $13.2 million, respectively. The discount rate used to determine the lease liability was 7.8%.In July 2024, the lease term for the 5858 Horton Street Building Lease and 2019 Expansion was extended for a period of 12 months and will expire on December 31, 2030. Neither of the leases include a general option for the Company to terminate the leases.In July 2024, the Company entered into a lease for additional office and laboratory space in Emeryville, California (the "2024 Expansion") with a projected lease commencement date of September 1, 2024. The lease consists of approximately 32,038 square feet of office and laboratory space and has a lease term through December 31, 2030. Future minimum lease payments under the 2024 Expansion from its projected commencement date through lease expiration are approximately $13.2 million. As of June 30, 2024, the Company has not recorded a right-of-use asset or lease liability on its condensed balance sheets as the Company has not yet obtained control of the additional office and laboratory space.Emeryville, California Warehouse Lease In January 2024, the Company entered into a new lease for warehouse space in Emeryville, California (the â€œWarehouse Lease Agreementâ€), with a projected lease commencement date of August 31, 2024. The lease consists of approximately 7,800 square feet of warehouse space and has a lease term of five years and four months. Future minimum lease payments under the Warehouse Lease Agreement from its projected commencement date through lease expiration in the fourth quarter of 2029 are approximately $1.5 million. As of June 30, 2024, the Company has not recorded a right-of-use asset or lease liability on its condensed balance sheets as the Company has not yet obtained control of the warehouse space.The following table summarizes the components of lease expense for the three and six months ended June 30, 2024 and 2023, which are included in operating expenses in the Companyâ€™s condensed statements of operations (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 698 Â Â $ 698 Â Â $ 1,397 Â Â $ 1,397 Â Variable lease cost Â Â 354 Â Â Â 311 Â Â Â 707 Â Â Â 622 Â Total Â $ 1,052 Â Â $ 1,009 Â Â $ 2,104 Â Â $ 2,019 Â Variable lease payments include amounts relating to common area maintenance and are recognized in the condensed statements of operations as incurred. The following table summarizes supplemental information related to operating leases:Â Â Â June 30,2024 Â Â December 31,2023 Â Weighted-average remaining lease term (in years): Â Â 5.2 Â Â Â 5.7 Â Weighted-average discount rate: Â Â 7.8 % Â Â 7.8 % Â 21 Â The following table summarizes the maturities of lease liabilities as of June 30, 2024 (in thousands):Â 2024 (remaining six months) Â $ 1,588 Â 2025 Â Â 3,244 Â 2026 Â Â 3,135 Â 2027 Â Â 2,810 Â 2028 Â Â 2,894 Â Thereafter Â Â 2,982 Â Total future minimum lease payments Â Â 16,653 Â Less: Amount representing interest Â Â (2,997 ) Present value of future minimum lease payments Â Â 13,656 Â Less: Current portion of operating lease liabilities Â Â 3,196 Â Long-term portion of operating lease liabilities Â $ 10,460 Â Indemnification Agreements In the ordinary course of business, the Company enters into agreements that may include indemnification provisions, such as with vendors and other parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently maintains directorsâ€™ and officersâ€™ liability insurance that would generally enable it to recover a portion of any future amounts paid. The Company believes the estimated fair value of its indemnification agreements in excess of applicable insurance coverage is not material.Legal Proceedings From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. There are no material legal proceedings outstanding at June 30, 2024. 10. Income TaxesÂ For the three and six months ended June 30, 2024 and 2023, the Company did not record a federal or state income tax provision due to its recurring net losses. In addition, the Company has taken a full valuation allowance against its net deferred tax assets as the Company believes it is not more likely than not that the benefit will be realized. Â 11. Common Stock As of June 30, 2024 and December 31, 2023, the Companyâ€™s certificate of incorporation authorized the Company to issue 300,000,000 shares of common stock, at the par value of $0.0001 per share. The holder of each share of common stock is entitled to one vote per share. Common stockholders are entitled to dividends, if and when declared by the board of directors. To date, no dividends on common stock have been declared by the board of directors. 22 Â As of June 30, 2024 and December 31, 2023, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: Â Â Â June 30,2024 Â Â December 31,2023 Â Issuance of common stock under the 2020 Equity Incentive Award Plan Â Â 2,332,657 Â Â Â 524,078 Â Issuance of common stock under the 2020 Employee Stock Purchase Plan Â Â 273,375 Â Â Â 313,034 Â Exercise of options issued and outstanding and future vesting of restricted stock units Â Â 8,450,290 Â Â Â 8,423,481 Â Exercise of common stock warrants Â Â 3,637,145 Â Â Â 53,669 Â Total common stock reserved for future issuance Â Â 14,693,467 Â Â Â 9,314,262 Â Funding Agreement with CFF â€” In April 2020, CFF made a $10.0 million investment in the Company's Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of Series C redeemable convertible preferred stock, and the Company and CFF entered into a Funding Agreement (the â€œFunding Agreementâ€). Pursuant to the terms of the Funding Agreement, except in the event of a technical failure, the $10.0 million received from CFF will be used to advance the development program for 4D-710, the Companyâ€™s lead product in cystic fibrosis, or any other therapeutic approved by the Program Advisory Group (â€œPAGâ€) to alleviate pulmonary complications of cystic fibrosis (the â€œFunding Agreement Productâ€). CFF committed to provide an additional $4.0 million of funding upon acceptance of an Investigational New Drug (â€œINDâ€) application or its equivalent to allow for human testing of the Funding Agreement Product (â€œAcceptanceâ€). In October 2021, the IND was cleared by the U.S. Food and Drug Administration and CFF made the additional investment of $4.0 million in cash for the issuance of 125,715 shares of the Company's common stock to CFF. The Company was committed to providing an amount equal to the funding provided by CFF to be used solely to advance the Funding Agreement Product. As of June 30, 2024, the funding commitment has been fulfilled. Under

the terms of the Funding Agreement, neither the $10.0 million investment in the Series C redeemable convertible preferred stock, which converted to common stock as of December 31, 2020, nor the $4.0 million of funding upon Acceptance are restricted as to withdrawal or usage. 12. Stock-based Compensation 2020 Equity Incentive Award Plan In December 2020, the Company adopted the 2020 Incentive Award Plan (â€œ2020 Planâ€), which became effective on December 10, 2020. The 2020 Plan initially reserved 2,606,546 shares of common stock for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance bonus awards, performance stock units, dividend equivalents or other stock or cash based award granted to employees, directors and consultants of the Company. The number of shares reserved for future issuance under the 2020 Plan will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) 5% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than 18,000,000 shares of the Company's common stock may be issued upon the exercise of incentive stock options. On February 29, 2024, an additional 2,153,533 shares of common stock became available for issuance under the 2020 Plan, as a result of the operation of the automatic annual increase provision. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options were issued. As of June 30, 2024 there were 1,997,052 shares available for grant under the 2020 Plan.23 Â Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the â€œ2015 Planâ€). However, the 2015 Plan continues to govern the terms of options that remain outstanding under the 2015 Plan. As of June 30, 2024, there were 335,605 shares available for grant under the 2015 Plan.2015 Equity Incentive PlanThe 2015 Plan provided for grants of stock options, stock appreciation rights, restricted stock and restricted stock unit awards to employees, directors and consultants of the Company. As of June 30, 2024, options to purchase 1,545,023 shares of common stock were outstanding under the 2015 Plan. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options were issued and are granted at prices not less than the estimated fair market value of the Companyâ€™s common stock on the grant date as determined by the board of directors. No additional grants will be made under the 2015 Plan, and all outstanding grants under the 2015 Plan that are repurchased, forfeited, expire or are cancelled are returned to the 2015 Plan and are not available for grant under the 2020 Plan. Employee Stock Purchase PlanIn December 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the â€œ2020 ESPPâ€). Under the 2020 ESPP, 252,337 shares of the Company's common stock were initially reserved for employee purchases of the Company's common stock under terms and provisions established by the Company's board of directors and approved by the Company's stockholders. The number of shares reserved for future issuance under the 2020 ESPP will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) 1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than 15,000,000 shares the Company's common stock may be issued under the 2020 ESPP. On February 29, 2024, an additional 50,000 shares of common stock became available for future issuance under the 2020 ESPP, as a result of the operation of this automatic annual increase provision. Under the 2020 ESPP the Company's employees may purchase common stock through payroll deductions at a price equal to 85% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2020 ESPP provides for a series of overlapping 24-month offering periods comprising four six-month purchase periods. The initial offering period under the 2020 ESPP is longer than 24 months, commencing February 15, 2021 and ending on May 14, 2023. Contributions under the 2020 ESPP are limited to a maximum of 15% of an employee's eligible compensation. Restricted Stock Units The Company has granted restricted stock unit (RSU) awards under the 2020 Equity Incentive Award Plan that vest over a period of four years. The following table summarizes the RSU activity for the six months ended June 30, 2024:Â Â Â Number ofShares Â Unvested balance at December 31, 2023 Â Â 181,181 Â Issued Â Â 129,650 Â Vested Â Â (21,963 ) Canceled/Forfeited Â Â (30,751 ) Unvested balance at June 30, 2024 Â Â 258,117 Â Â 24 Â Stock Options The following table summarizes the stock options activity for the six months ended June 30, 2024:Â Â Â Number ofSharesUnderlyingOutstandingOptions Â Balances at December 31, 2023 Â Â 8,240,154 Â Options granted Â Â 434,500 Â Options exercised Â Â (296,183 ) Options expired Â Â (8,837 ) Options forfeited Â Â (177,461 ) Balances at June 30, 2024 Â Â 8,192,173 Â Options exercisable at June 30, 2024 Â Â 3,726,662 Â Options vested and expected to vest at June 30, 2024 Â Â 8,192,173 Â The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Companyâ€™s stock options was estimated using the following assumptions for the three and six months ended June 30, 2024 and 2023:Â Â Â Three Months Ended June 30, Â Six Months Ended June 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Expected term Â 6.0Â - 6.1Â years Â 6.0Â - 6.1Â years Â 6.0Â - 6.1Â years Â 6.0Â - 6.1Â years Expected volatility Â 84.9% - 85.4% Â 81.1% - 82.2% Â 81.4% - 85.4% Â 80.9% - 84.4% Risk-free interest rate Â 4.4% - 4.5% Â 3.5% - 4.0% Â 3.9% - 4.5% Â 3.5% - 4.0% Expected dividend yield Â â€”% Â â€”% Â â€”% Â â€”% Â Expected Term. The expected term for employee options is calculated using the simplified method as the Company does not have sufficient historical information to provide a basis for this estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee options is the contractual term of the options.Expected Volatility. The expected volatility is based on a mix of the Company's historical volatility and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. For each grant, the Company measured historical volatility over a period equivalent to the expected term. Risk-free Interest Rate. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues whose term is similar in duration to the expected term of the respective stock option. Expected Dividend Yield. The Company has not paid and does not anticipate paying any dividends on its common stock in the future. Accordingly, the Company has estimated the dividend yield to be zero. 25 Â Stock-Based Compensation Expense The following table is a summary of stock-based compensation expense incurred for employees and nonemployees by function (in thousands): Â Â Â Three Months EndedJune 30, Â Â Six Months EndedJune 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 3,196 Â Â $ 2,678 Â Â $ 6,231 Â Â $ 5,148 Â General and administrative Â Â 2,877 Â Â Â 2,291 Â Â Â 5,817 Â Â Â 4,042 Â Total stock-based compensation expense Â $ 6,073 Â Â $ 4,969 Â Â $ 12,048 Â Â $ 9,190 Â Â 13. Common Stock Warrants In May 2018, the Company issued a warrant for 23,669 shares of the Companyâ€™s common stock to a service provider with an exercise price of $3.19 per share. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model, expires in 2025 and upon issuance was fully vested.In December 2020, the Company issued a warrant for 30,000 shares of the Companyâ€™s common stock to a service provider with an exercise price of $18.00 per share. This warrant vests over a period of four years and expires in 2027. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model. In February 2024, the Company completed an underwritten public follow-on offering which included the sale of pre-funded warrants (the â€œPre-funded Warrantsâ€) to purchase 3,583,476 shares of the Companyâ€™s common stock at an offering price of $29.4999. The exercise price of each Pre-funded Warrant is $0.0001 per share, and each Pre-funded Warrant is exercisable from the date of issuance. The Pre-funded Warrants are classified as a component of stockholdersâ€™ equity within additional paid-in-capital. The Company valued the Pre-funded Warrants at issuance and recorded net proceeds of $99.4 million after deducting underwriters fees during the six months ended June 30, 2024 related to the sale of the Pre-funded Warrants.There was no material expense related to the above warrant shares during each of the three and six months ended June 30, 2024 and 2023. 14. Net Loss Per Share, Basic and DilutedThe following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (34,953 ) Â $ (29,616 ) Â $ (67,354 ) Â $ (58,298 ) Denominator Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares outstanding used in computing net loss per share, basic and diluted Â Â 55,282,754 Â Â Â 38,335,219 Â Â Â 52,277,369 Â Â Â 35,661,995 Â Net loss per share, basic and diluted Â $ (0.63 ) Â $ (0.77 ) Â $ (1.29 ) Â $ (1.63 ) Â In February 2024, the Company issued and sold Pre-funded Warrants to purchase 3,583,476 shares of common stock at a nominal exercise price of $0.0001 (see Note 13). The shares of common stock into which the Pre-funded Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and the Pre-funded Warrants are immediately exercisable upon their issuance date.26 Â Â The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Options issued and outstanding Â Â 8,192,173 Â Â Â 6,422,876 Â Restricted stock units subject to future vesting Â Â 258,117 Â Â Â â€” Â 2020 ESPP Â Â 244,622 Â Â Â 269,102 Â Common stock warrants Â Â 53,669 Â Â Â 53,669 Â Total Â Â 8,748,581 Â Â Â 6,745,647 Â Â 15. Derivative Liability The Company identified an embedded derivative resulting from the change of control provision in the CFF Agreement. Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as separate financial instruments. At the inception of the derivative in 2017, the Company recognized this derivative as a liability and revenue was reduced by the initial fair value of the derivative liability. The Company remeasures the derivative liability to fair value at each reporting period and records the change in fair value of the derivative liability as other income (expense), net. The Company uses a present value analysis with multiple scenarios, which incorporates assumptions and estimates to value the derivative instrument. The Company assesses these assumptions and estimates on a periodic basis as additional information impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the change of control payment to CFF (range of zero to $18.9 million at June 30, 2024 and December 31, 2023), the probability of a change of control event, the probability of the product achieving development or commercial status at time of change of control (range of 4.8% to 17.2% at June 30, 2024 and December 31, 2023) and the discount rate (15% at June 30, 2024 and December 31, 2023). The Company determined the estimated fair value of this liability as of the inception date of the CFF Agreement and concluded that the amount was immaterial. The Company determined the fair value of this derivative liability was $0.4 million as of June 30, 2024 and December 31, 2023. 16. Related Party Transactions In March 2024, the Company entered into a research and option agreement (the â€œReignite Agreementâ€) with Reignite Therapeutics Inc. (â€œReigniteâ€), which was founded by David Kirn, M.D., Chief Executive Officer of the Company. Reignite has the expertise to develop high-capacity, helper-dependent adenovirus capsids which the Company plans to utilize as they expand their therapeutic capsid evolution platform. Reignite and the Company plan to collaborate on a one-to-two year program to develop these high capacity, helper-dependent adenovirus capsids. Under the Reignite Agreement, the Company shall have the final authority to amend and make updates to the plan and budget of the program. Further, the Company is responsible for the funding of the related research which includes the budgeted full-time employees and CRO costs, equipment costs not to exceed $60 thousand and all other costs, in total not to exceed $1.5 million in any year of the program. The Company will have an option to acquire up to three capsids resulting from the program. The Company shall pay to Reignite an option exercise fee of $1.0 million per selected capsid for which the Company has exercised its option. The maximum total amount payable is $3.0 million.During the three and six months ended June 30, 2024, the Company paid Reignite $0.4 million for research and development expenses. No option exercise fees were incurred during the three and six months ended June 30, 2024. As of June 30, 2024, no other amounts were due to Reignite under the Reignite Agreement. 27 Â 17. 401(k) PlanIn 2014, the Company adopted a 401(k) plan for all employees who have met certain eligibility requirements. The 401(k) plan allows employees to make pre-tax and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company made contributions to the 401(k) plan for all eligible participants and recorded contribution expenses of $0.4 million and $0.2 million for the three months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and 2023, the Company recorded contribution expenses of $0.8 million and $0.7 million, respectively. 28 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q (this â€œreportâ€). This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled â€œRisk Factorsâ€ and elsewhere in this report. Overview We are a leading clinical-stage biopharma company focused on unlocking the full potential of genetic medicines through proprietary customized vectors that are designed for the specific diseases we seek to treat. Our proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. We believe key features of our targeted and evolved vectors will help us to potentially create targeted genetic medicine product candidates with improved therapeutic profiles. These profiles will allow us to treat a broad range of large market diseases, unlike most current genetic medicines that generally focus on rare or small market diseases. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. â€¯We have built a deep portfolio of genetic medicine product candidates, with three novel, highly targeted next generation AAV vectors currently in the clinic. This portfolio includes six product candidates in clinical trials: 4D-150 for the treatment of wet age-related macular degeneration (â€œwet AMDâ€) and diabetic macular edema (â€œDMEâ€),â€¯4D-175 for geographic atrophy (â€œGAâ€), 4D-710 for the treatment of cystic fibrosis lung disease, 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (â€œXLRPâ€) and 4D-110 for the treatment of choroideremia. In addition, we have one product candidate in preclinical development: 4D-725 for alpha-1 antitrypsin deficiency lung disease. In July 2024, the U.S. Food and Drug Administration removed the clinical hold on the Phase 1/2 INGLAXA clinical trial in the United States for 4D-310 for the treatment of Fabry disease cardiomyopathy. We have funded our operations primarily through the sale and issuance of equity securities and to a lesser extent from cash received pursuant to our collaboration and license agreements. In February 2024, we completed an underwritten public offering (the â€œ2024 Offeringâ€ and, together with the 2023 Offering and the 2021 Offering (as defined below), the â€œFollow-on Offeringsâ€) in which 6,586,015 shares of our common stock were sold at an offering price of $29.50 per share, as well as pre-funded warrants to purchase 3,583,476 shares of our common stock at an offering price of $29.4999 per underlying share pursuant to our effective registration statement on Form S-3. The net proceeds from the 2024 Offering were $281.2 million, after deducting underwriting discounts and commissions and other offering expenses. We also granted the underwriters the option to purchase up to 1,525,423 additional shares of common stock in connection with the offering. In March 2024, the underwriters exercised their option to purchase 1,259,299 additional shares of common stock resulting in net proceeds of $34.9 million, after deducting underwriting discounts and commissions. We have incurred significant operating losses and expect that our operating losses will increase significantly as we, among other things, continue to advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for, and, if approved, proceed to commercialization; broaden and improve our platform; acquire, discover, validate and develop additional product candidates; maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. 29 Â Our net losses were $35.0 million and $29.6 million for the three months ended June 30, 2024 and 2023, respectively, and $67.4 million and $58.3 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, we had an accumulated deficit of $482.7 million. We do not expect positive cash flows from operations in the foreseeable future. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We do not have any products approved for sale and have not generated any revenue from product sales since our inception. Our ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates, if approved. We will require substantial additional funding to support our continuing operations and further the development of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include income from collaborations, strategic partnerships, or other strategic arrangements, for the foreseeable future. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from conflicts in the Middle East, the lingering impact of the COVID-19 pandemic, the war in Ukraine, rising interest rates, inflation and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. Components of Results of

Operations Revenue Our revenue to date has been generated through payments from our collaboration and license agreements, primarily from upfront and milestone payments and expense reimbursement. We have not generated any revenue from the sale of approved products and do not expect to do so for the foreseeable future. In July 2023, we entered into the License Agreement with AGT where we provided our 4D vector technology to AGT to deliver AGTâ€™s genetic payloads for the treatment of rare monogenic diseases. As partial consideration for the rights and licenses granted to AGT under License Agreement, we received an upfront payment of $20.0 million which we recognized as revenue during the third quarter of 2023. In August 2019, we amended our agreement with uniQure and entered into a separate new collaboration and license agreement with uniQure. Neither party was required to pay monetary consideration in connection with the amendment or new agreement. We determined the incremental transaction price of the amendment and new agreement to be $5.1 million and recorded the amount as deferred revenue in August 2019. We began recognizing revenue related to uniQure in 2020 and recognized the remaining revenue under the agreement during the third quarter of 2023. We recognized revenue of $0.2 million and $0.5 million during the three and six months ended June 30, 2023, respectively, related to this agreement. See Note 7, Research and Collaboration Agreements, to our financial statements included elsewhere in this report for further discussion regarding the accounting treatment of this agreement. Future collaboration and license revenue is highly dependent on the successful development and commercialization of products by our collaboration partners, which is uncertain, and revenue may fluctuate significantly from period to period. Additionally, we may never receive the consideration from our license agreements that is contemplated for option fees, development and sales-based milestone payments or royalties on sales of licensed products, given the contingent nature of these payments. 30 Â  Operating Expenses Research and Development Our research and development expenses primarily consist of costs incurred for the discovery and preclinical and clinical development of our product candidates. These expenses include salaries and personnel-related costs, including stock-based compensation of our scientific personnel performing research and development activities; laboratory supplies; research materials; fees paid to CROs to execute preclinical studies and clinical trials; fees paid to CMOs to manufacture materials for preclinical studies and clinical trials; fees related to obtaining technology licenses; consulting costs; costs related to seeking regulatory approval of our product candidates; and allocated facility-related costs, information technology costs, depreciation expense, and other overhead. We expense all research and development costs in the periods in which they are incurred. We have entered into various agreements with CROs and CMOs. Costs of certain activities are recognized based on an evaluation of the progress to completion of specific tasks. Payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses and other current assets on our balance sheet. The capitalized amounts are recognized as expense as the goods are delivered or the related services are performed. We do not allocate our costs by product candidate, as a significant amount of research and development expenses includes internal costs, such as salary and other personnel-related expenses, laboratory supplies and allocated overhead, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, none of which are tracked by product candidate. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs and, therefore, the costs cannot be allocated to a particular product candidate or development program. At this time, we cannot reasonably estimate or know the nature, timing or estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect our research and development expenses to increase for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, and incur expenses associated with hiring additional personnel to support our research and development efforts. We have strengthened ophthalmology senior leadership team and announced formation of Ophthalmology Advisory Board, ahead of first Phase 3 clinical trial initiation for 4D-150 in wet AMD. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. See the section titled â€œRisk Factorsâ€ for additional risks regarding regulatory development and approval. General and Administrative Our general and administrative expenses consist primarily of personnel-related expenses, including salaries, employee benefit costs and stock-based compensation expense for our personnel in executive, finance and accounting, legal, human resources, business development, and other administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, accounting and tax services, allocated overhead, including rent, equipment, depreciation, information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses. We expect our general and administrative expenses to increase as a result of increased personnel-related costs, patent costs for our product candidates, consulting, legal and accounting services associated with maintaining compliance with stock exchange listing and requirements of the SEC, investor relations costs, director and officer insurance premiums, and other costs associated with being a public company. 31 Â  Other Income (Expense), Net Our other income (expense), net primarily consists of interest income earned on our cash equivalents and marketable securities and adjustments for the change in the fair value of our derivative liability which must be remeasured at each reporting date. Results of Operations Comparison of the Three and Six Months Ended June 30, 2024 and 2023 The following tables summarize our results of operations for the periods indicated (dollars in thousands): Â Â Â Three Months Ended June 30, Â Â Â Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Revenue Â Â Â Â Â Â Â Â Â Â Â Â Collaboration and license revenue Â $ 5 Â Â $ 239 Â Â $ (234 ) Â Â (98 )% Operating Expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 31,860 Â Â Â 23,584 Â Â Â 8,276 Â Â Â 35 % General and administrative Â Â 10,601 Â Â Â 8,791 Â Â Â 1,810 Â Â Â 21 % Total operating expenses Â Â 42,461 Â Â Â 32,375 Â Â Â 10,086 Â Â Â 31 % Loss from operations Â Â (42,456 ) Â Â (32,136 ) Â Â (10,320 ) Â Â 32 % Other Income, Net Â Â 7,503 Â Â Â 2,520 Â Â Â 4,983 Â Â Â 198 % Net loss Â $ (34,953 ) Â $ (29,616 ) Â $ (5,337 ) Â Â 18 % Â Â Â Six Months Ended June 30, Â Â Â Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Revenue Â Â Â Â Â Â Â Â Â Â Â Â Collaboration and license revenue Â $ 33 Â Â $ 538 Â Â $ (505 ) Â Â (94 )% Operating Expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 59,727 Â Â Â 46,002 Â Â Â 13,725 Â Â Â 30 % General and administrative Â Â 20,898 Â Â Â 16,777 Â Â Â 4,121 Â Â Â 25 % Total operating expenses Â Â 80,625 Â Â Â 62,779 Â Â Â 17,846 Â Â Â 28 % Loss from operations Â Â (80,592 ) Â Â (62,241 ) Â Â (18,351 ) Â Â 29 % Other Income Â Â 13,238 Â Â Â 3,943 Â Â Â 9,295 Â Â Â 236 % Net loss Â $ (67,354 ) Â $ (58,298 ) Â $ (9,056 ) Â Â 16 % Revenue Revenue decreased by $0.2 million, or 98%, from the three months ended June 30, 2023 to the three months ended June 30, 2024, while revenue decreased by $0.5 million, or 94%, from the six months ended June 30, 2023 to the six months ended June 30, 2024. The decrease in revenue is due to revenue from uniQure that was fully earned in 2023 when the Company completed its performance obligation. Research and Development Expenses The following table provides a breakout of research and development expenses for the periods indicated (dollars in thousands): Â Â Â Three Months Ended June 30, Â Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Research and development trials and consumables expenses Â $ 14,162 Â Â $ 9,237 Â Â $ 4,925 Â Â Â 53 % Payroll and personnel expenses Â Â 13,158 Â Â Â 10,790 Â Â Â 2,368 Â Â Â 22 % Facilities and other research and development expenses Â Â 4,540 Â Â Â 3,557 Â Â Â 983 Â Â Â 28 % Total research and development expenses Â $ 31,860 Â Â $ 23,584 Â Â $ 8,276 Â Â Â 35 % Â 32 Â Â Â Â Six Months Ended June 30, Â Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â $ Change Â Â % Change Â Research and development trials and consumables expenses Â $ 25,781 Â Â $ 16,984 Â Â Â 8,797 Â Â Â 52 % Payroll and personnel expenses Â Â 25,591 Â Â Â 21,887 Â Â Â 3,704 Â Â Â 17 % Other research and development expenses Â Â 8,355 Â Â Â 7,131 Â Â Â 1,224 Â Â Â 17 % Total research and development expenses Â $ 59,727 Â Â $ 46,002 Â Â $ 13,725 Â Â Â 30 % Research and development expenses increased by $8.3 million, or 35%, from the three months ended June 30, 2023 to the three months ended June 30, 2024. The increase was primarily due to the following: â€¢a $4.9 million increase in clinical trial costs mainly due to increased clinical trial activity for our product candidates, primarily 4D-150; â€¢a $2.4 million increase in payroll and personnel expenses, including a $0.5 million increase in employee stock-based compensation, due to increased headcount of research and development personnel; and â€¢a $1.0 million increase in facilities and other research and development expenses mainly due to higher consulting services and fixed assets depreciation. Â  Research and development expenses increased by $13.7 million, or 30%, from the six months ended June 30, 2023 to the six months ended June 30, 2024. The increase was primarily due to the following: â€¢a $8.8 million increase in clinical trial costs mainly due to increased clinical trial activity for our product candidates, primarily 4D-150; â€¢a $3.7 million increase in payroll and personnel expenses, including a $1.1 million increase in employee stock-based compensation, due to increased headcount of research and development personnel; and â€¢a $1.2 million increase in facilities and other research and development expenses mainly due to higher consulting services and fixed assets depreciation. General and Administrative Expenses General and administrative expenses increased by $1.8 million, or 21%, from the three months ended June 30, 2023 to the three months ended June 30, 2024. The increase was primarily due to: â€¢a $1.2 million increase in payroll and personnel expenses due to increased headcount of general and administrative personnel; â€¢a $1.1 million increase in facilities and other expenses mainly due to higher non-employee stock compensation expense, consulting services, software expenses and business taxes, which was partially offset by lower business insurance; and â€¢a $0.5 million decrease in outside services. General and administrative expenses increased by $4.1 million, or 25%, from the six months ended June 30, 2023 to the six months ended June 30, 2024. The increase was primarily due to: â€¢a $2.9 million increase in payroll and personnel expenses, including a $1.2 million increase in employee stock-based compensation, due to increased headcount of general and administrative personnel; â€¢a $1.9 million increase in facilities and other expenses mainly due to higher non-employee stock compensation expense, consulting services, software expenses, audit and tax fees and business taxes, which was partially offset by lower business insurance; and â€¢a $0.7 million decrease in outside services. 33 Â  Other Income, Net Other income, net increased by $5.0 million, or 198%, from the three months ended June 30, 2023 to the three months ended June 30, 2024. It increased by $9.3 million, or 236%, from the six months ended June 30, 2023 to the six months ended June 30, 2024. The increase is attributable to higher balances of cash equivalents and marketable securities, and higher market yields on our cash equivalents and marketable securities. Liquidity and Capital Resources Sources of Liquidity We have funded our operations primarily through the sale and issuance of our equity securities, including from the sale of our common stock in our IPO and Follow-on Offerings and the sale of our Series A, Series A-1, Series B and Series C redeemable preferred stock, and to a lesser extent from cash received pursuant to our collaboration and license agreements. In December 2020, we completed our IPO. We issued and sold 9,660,000 shares of common stock at a price to the public of $23.00 per share. The aggregate net proceeds from our IPO were $204.7 million after deducting underwriting discounts and commissions and other offering costs. In November 2021, we completed an underwritten public offering ("2021 Offering") in which 4,750,000 shares of our common stock were sold at an offering price of $25.00 per share. The net proceeds from the 2021 Offering were $111.1 million after deducting underwriting discounts and commissions and offering expenses. In March 2022, we filed a Registration Statement on Form S-3 covering the offering of up to $300.0 million of common stock, preferred stock, debt securities, warrants and units, which was declared effective by the SEC in April 2022 (the â€œS-3 Registration Statementâ€). In March 2022, we also entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC as sales agent to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $100.0 million pursuant to the S-3 Registration Statement as an â€œeat-the-marketâ€ offering under the Securities Act (the "2022 ATM Offering Program"). For the three and six months ended June 30, 2024, 585,938 shares of the Company's common stock had been sold pursuant to the Sales Agreement for net proceeds to the Company of $15.3 million, after deducting issuance costs. In May 2023, we completed the 2023 Offering in which 8,625,000 shares of our common stock were sold at an offering price of $16.00 per share. The net proceeds from the 2023 Offering were $129.2 million after deducting underwriting discounts and commissions and offering expenses. In July 2023, we entered into the License Agreement with AGT where we provided our 4D vector technology to AGT to deliver AGTâ€™s genetic payloads for the treatment of rare monogenic diseases. As partial consideration for the rights and licenses granted to AGT under the License Agreement, we received an upfront payment of $20.0 million. In February 2024, we completed the 2024 Offering in which 6,586,015 shares of our common stock were sold at an offering price of $29.50 per share, as well as pre-funded warrants to purchase 3,583,476 shares of our common stock at an offering price of $29.4999 per underlying share. The net proceeds from the 2024 Offering were $281.2 million, after deducting underwriting discounts and commissions and other offering expenses. We also granted the underwriters the option to purchase up to 1,525,423 additional shares of common stock in connection with the offering. In March 2024, the underwriters exercised their option and purchased 1,259,299 additional shares of common stock resulting in net proceeds of $34.9 million, after deducting underwriting discounts and commissions. On May 31, 2024, we terminated the Sales Agreement and the 2022 ATM Offering Program pursuant to the terms of the Sales Agreement. In June 2024, we entered into a Sales Agreement (the â€œLeerink Sales 34 Â  Agreementâ€) with Leerink Partners LLC (â€œLeerinkâ€) as sales agent to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $250.0 million pursuant to a Registration Statement on Form S-3 that we filed with the SEC in February 2024 as an â€œeat-the-marketâ€ offering under the Securities Act (the "2024 ATM Offering Program"). For the three and six months ended June 30, 2024, no shares had been sold pursuant to the Leerink Sales Agreement. As of June 30, 2024, we had cash, cash equivalents and marketable securities of $577.7 million. Future Funding Requirements We have experienced recurring net losses and had an accumulated deficit of $482.7 million as of June 30, 2024. Our transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and those of our collaboration partners and achieving a level of revenue adequate to support our cost structure. We expect to continue to incur losses for the foreseeable future. We expect that our research and development and general and administrative expenses will continue to increase for the foreseeable future. Additionally, we expect our capital expenditures will increase significantly in the future for costs associated with building commercial manufacturing capacity. As a result, we will need significant additional capital to fund our operations, which we may obtain through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements. Because of the numerous risks and uncertainties associated with the development and commercialization of gene therapy product candidates, we are unable to estimate the amount of increased capital we will need to raise to support our operations and the outlays and operating expenditures necessary to complete the development of our product candidates and build additional manufacturing capacity, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: â€¢the progress of our current and future product candidates through preclinical and clinical development; â€¢potential delays in our preclinical studies and clinical trials, whether current or planned; â€¢expanding our manufacturing facilities and working with our contract manufacturers to scale up the manufacturing processes for our product candidates; â€¢continuing our research and discovery activities; â€¢continuing the development of our Therapeutic Vector Evolution platform; â€¢initiating and conducting additional preclinical, clinical or other studies for our product candidates; â€¢changing or adding additional contract manufacturers or suppliers; â€¢seeking regulatory approvals and marketing authorizations for our product candidates; â€¢establishing sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval; â€¢acquiring or in-licensing product candidates, intellectual property and technologies; â€¢making milestone, royalty or other payments due under any current or future collaboration or license agreements; â€¢obtaining, maintaining, expanding, protecting and enforcing our intellectual property portfolio; â€¢attracting, hiring and retaining qualified personnel; â€¢potential delays or other issues related to our operations; â€¢meeting the requirements and demands of being a public company; 35 Â  â€¢defending against any product liability claims or other lawsuits related to our products; and â€¢the impact of the COVID-19 pandemic and adverse macroeconomic conditions such as, but not limited to, higher inflation and increased interest rates, each of which may exacerbate the magnitude of the factors discussed above. We believe that our existing cash and cash equivalents will allow us to fund our planned operations for at least one year from the date of the issuance of this report. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing sooner than currently projected, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. See the section titled â€œRisk Factorsâ€ for additional risks associated with our substantial capital requirements. We do not have any committed external sources of funds. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources to complete the clinical development for the product candidates for treatment of wet AMD, DME, GA, cystic fibrosis lung disease, alpha-1 antitrypsin deficiency lung disease, Fabry disease cardiomyopathy, XLRP, choroideremia or any other indication we may pursue. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter would result in fixed payment obligations and may involve agreements that include grants of security interests on our assets and restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, granting liens over our assets, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. Any debt financing or additional equity that we raise may contain terms that could

adversely affect our common stockholders. Further, additional funds may not be available when we need them, on terms that are acceptable to us, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic, the war in Ukraine, rising interest rates and inflation. If we are unable to obtain additional funding, we expect to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or investment in internal manufacturing capabilities, which could adversely affect our business. If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. Summary Statement of Cash Flows The following is a summary of cash flows for the periods indicated below (in thousands): Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (59,331 ) Â $ (49,971 ) Net cash provided by (used in) investing activities Â Â (336,797 ) Â Â 92,418 Â Net cash provided by financing activities Â Â 336,081 Â Â Â 141,513 Â Net increase (decrease) in cash and cash equivalents Â $ (60,047 ) Â $ 183,960 Â Net Cash Used in Operating Activities Net cash used in operating activities was $59.3 million for the six months ended June 30, 2024. This was primarily due to the net loss of $67.4 million, adjusted for noncash charges of $12.2 million and net changes in operating assets and liabilities of $4.2 million. Noncash charges included $12.0 million of stock-based compensation expense, $2.4 million of depreciation and amortization and $0.9 million for the 36 Â amortization of operating lease right-of-use assets, offset by $3.1 million net amortization/accretion of premium/discount on marketable securities. Net changes in operating assets and liabilities included a $1.0 million decrease in operating lease liabilities, a $0.1 million decrease in accounts payables, a $2.3 million increase in prepaid expenses and other current assets and a $1.6 million increase in other assets, offset by a $0.8 million increase in accrued and other liabilities and a $0.1 million increase in deferred revenue. Net cash used in operating activities was $50.0 million for the six months ended June 30, 2023. This was primarily due to the net loss of $58.3 million, adjusted for noncash charges of $11.4 million and net changes in operating assets and liabilities of $3.1 million. Noncash charges included $9.2 million of stock-based compensation expense, $2.1 million of depreciation and amortization and $0.7 million for the amortization of operating lease right-of-use assets, offset by $0.6 million net amortization/accretion of premium/discount on marketable securities. Net changes in operating assets and liabilities included a $2.2 million decrease in accrued and other liabilities, $0.5 million decrease in operating lease liabilities, $0.5 million decrease in deferred revenue and a $0.5 million increase in prepaid expenses and other current assets which were offset by a $0.6 million increase in accounts payable. Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities was $336.8 million for the six months ended June 30, 2024. This was due to purchases of marketable securities of $374.1 million and purchases of property and equipment of $1.0 million, offset by $38.3 million in maturities of marketable securities. Net cash provided by investing activities was $92.4 million for the six months ended June 30, 2023. This was due to $114.4 million in maturities of marketable securities, offset by purchases of marketable securities of $20.2 million and purchases of property and equipment of $1.8 million. Net Cash Provided by Financing Activities Net cash provided by financing activities was $336.1 million for the six months ended June 30, 2024. This was primarily due to proceeds from the issuance of common stock upon public offering, net of issuance costs, of $316.1 million, proceeds from the issuance of common stock from the 2022 ATM Offering Program of $15.3 million, proceeds from the issuance of common stock from the exercise of stock options and warrants of $4.0 million and proceeds from the issuance of common stock from ESPP purchases of $0.7 million. Net cash provided by financing activities was $141.5 million for the six months ended June 30, 2023. This was primarily due to proceeds from the issuance of common stock upon public offering of $129.7 million, proceeds from the issuance of common stock from the 2022 ATM Offering Program of $9.6 million, proceeds from the issuance of common stock from the exercise of stock options of $2.0 million, and proceeds from the issuance of common stock from ESPP purchases of $0.7 million, offset by payments of public offering costs of $0.3 million and ATM costs of $0.2 million. Contractual Obligations, Commitments and Contingencies Our commitments include obligations under vendor contracts to provide research services and other purchase commitments with our vendors. In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided. These amounts are not fixed and determinable. As of June 30, 2024, our principal commitments consisted of obligations under our operating leases for our headquarters. Please see Note 9, Commitments and Contingencies, to our unaudited condensed financial statements included elsewhere in this report for further details. 37 Â Critical Accounting Policies and Significant Judgments and Estimates Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenue and expenses during the reported periods. We evaluate these estimates and assumptions on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. During the three and six months ended June 30, 2024, there were no changes to our critical accounting policies and significant judgments and estimates as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023. Recent Accounting Pronouncements See Note 2, Summary of Significant Accounting Policies, to our unaudited condensed financial statements included elsewhere in this report for information. Off-Balance Sheet Arrangements Since our inception, we have not engaged in any off-balance sheet arrangements as defined in the rules and regulations of the SEC. JOBS Act We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€). Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, while we are an emerging growth company, we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. We will remain an emerging growth company until the earlier of (i) December 31, 2025, (ii) the last day of the year in which we have total annual gross revenue of at least $1.235 billion, (iii) the last day of the year in which we are deemed to be a â€œlarge accelerated filerâ€ as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: â€¢we will present only two years of audited financial statements for any interim period, and related managementâ€™s discussion and analysis of financial condition and results of operations; â€¢we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (the â€œSarbanes-Oxley Actâ€); â€¢we will provide less extensive disclosure about our executive compensation arrangements; â€¢we will not require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements; and 38 Â â€¢we will take advantage of extended transition periods to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. As a result, the information in this report in the future may be different from what you might receive from other public reporting companies. Item 3. Quantitative and Qualitative Disclosures About Market Risk. Interest Rate Sensitivity and Effects of Inflation The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of June 30, 2024, we had cash and cash equivalents and marketable securities of $577.7 million, consisting of bank deposits, interest-bearing money market funds, and marketable securities, for which the fair value would be affected by changes in the general level of U.S. interest rates. However, due to the short to medium-term maturities of our cash equivalents and marketable securities, an immediate 10% change in interest rates would not have a material effect on the fair value of our cash equivalents or marketable securities. We do not believe that inflation or interest rate changes have had a significant impact on our results of operations for any periods presented herein. 39 Â Item 4. Controls and Procedures. Evaluation of our Disclosure Controls and Procedures We maintain â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissionâ€™s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial and accounting officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives. Our management, with the participation of our principal executive officer and principal financial and accounting officer, evaluated the effectiveness of our disclosure controls and procedures at the end of the period covered by this report. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date. Changes in Internal Control over Financial Reporting There has been no change in our internal control over financial reporting during the quarter ended June 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 40 Â PART II. OTHER INFORMATION Item 1. Legal Proceedings. The legal proceedings information set forth in Note 9 Commitments and Contingencies of the notes to our unaudited condensed financial statements in Part I, Item I of this report is incorporated by reference. Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this report, including our financial statements and the related notes and the section of this report â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ before deciding whether to invest in our common stock. If any of the following risks actually occur, our business, reputation, financial condition, results of operations, revenue and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in these risk factors and elsewhere will include harm to our business, reputation, financial condition, results of operations, future prospects and stock price. If our business is seriously harmed, the market price of our common stock could decline, and you could lose part or all of your investment. Risk Factor Summary Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. The following is a summary of the principal risks that could seriously harm our business, all of which are more fully described below. This summary should be read in conjunction with the other risk factors included in this â€œRisk Factorsâ€ section and should not be relied upon as an exhaustive summary of the material risks facing our business. â€¢We are in the early stages of drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. â€¢We have had recurring net losses, and we expect to continue to incur significant net losses for the foreseeable future. â€¢We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. â€¢All of our product candidates are based on a novel AAV genetic medicine technology with which there is limited regulatory and clinical experience to date, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Further, the regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities. â€¢Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise seriously harm our business. â€¢Adverse public perception or regulatory scrutiny of genetic medicine technology may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators. â€¢Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization. 41 Â â€¢The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, expensive, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. â€¢Our employees, independent contractors, consultants, research or commercial partners or collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. â€¢Our success depends on our ability to protect our intellectual property and our proprietary technologies. â€¢Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors. Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements We are in the early stages of drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. We are a clinical-stage genetic medicine company pioneering the development of product candidates using our targeted and evolved AAV vectors. We commenced operations in September 2013, have no products approved for commercial sale and have not generated any product revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. If our product candidates are not successfully developed and approved, we may never generate any product revenue. To date, we have not completed any clinical trials (including any pivotal clinical trial), obtained marketing approval for any product candidates, manufactured commercial scale quantities of any of our product candidates or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company and early stage of drug development make any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will be seriously harmed. We have had recurring net losses, and we expect to continue to incur significant net losses for the foreseeable future. We have incurred recurring net losses, including net losses of $35.0 million and $29.6 million for the three months ended June 30, 2024 and 2023, respectively, and $67.4 million and $58.3 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, we had an accumulated deficit of $482.7 million. We have devoted substantially all of our financial resources and efforts on research and development activities, including for our product candidates and our Therapeutic Vector Evolution platform. We do not expect to generate revenue from product sales for several years, if at all. We continue to incur significant research and development and other expenses related to our ongoing operations. The amount of our future net losses will depend, in part, on the level of our future expenditures and our ability to generate revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: â€¢progress our current and any future product candidates through preclinical and clinical development; 42 Â â€¢expand our manufacturing facilities and work with our contract manufacturers to scale up the manufacturing processes for our product candidates; â€¢continue our research and discovery activities; â€¢continue the development of our Therapeutic Vector Evolution platform; â€¢initiate and conduct additional preclinical, clinical or other studies for our product candidates; â€¢change or add additional contract manufacturers or suppliers; â€¢seek regulatory approvals and marketing authorizations for our product candidates; â€¢establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval; â€¢acquire or in-license product candidates, intellectual property and technologies; â€¢make milestone, royalty or other payments due under any current or future collaboration or license agreements; â€¢obtain, maintain, expand, protect and enforce our intellectual property portfolio; â€¢attract, hire and retain qualified personnel; â€¢experience any delays or encounter other issues related to our operations; â€¢meet the requirements and demands of being a public company; â€¢are adversely impacted by general economic conditions, such as rising inflation and increased interest rates; â€¢defend against any product liability claims or other lawsuits related to our products; and â€¢experience delays in our preclinical studies

and clinical trials, whether current or planned, due to pandemics or public health emergencies (including, for example, the novel coronavirus (â€œCOVID-19â€) pandemic). Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholdersâ€™ deficit and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time consuming, expensive and uncertain process that takes years to complete. Our operations have required substantial amounts of cash since inception. To date, we have financed our operations primarily through the sale of equity securities and to a lesser extent from cash received pursuant to our collaboration and license agreements. We have initiated clinical trials, which are ongoing, and have additional product candidates in preclinical development that may enter clinical development. Developing our product candidates is expensive, and we expect to continue to spend substantial amounts as we fund our early stage research projects, continue preclinical and clinical development of our product candidates and, in particular, advance our product candidates through clinical trials. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial funding. As of June 30, 2024, we had $577.7 million in cash and cash equivalents and marketable securities. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will allow us to fund our planned operations for at least one year from the date of the issuance of the financial statements included in this Quarterly Report on Form 10-Q. 43 Â Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. Our ability to raise additional capital may be adversely impacted if global economic conditions continue to worsen as a result of volatility in credit and financial markets (including due to increased interest rates and high inflation rates) and to product supply chains. If adequate funds are not available to us on a timely basis, we may be required to: â€¢delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities or eliminate one or more of our development programs altogether; or â€¢delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates, or reduce our flexibility in developing or maintaining our sales and marketing strategy. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to, or jointly own some aspects of, our product candidates or technologies that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until a product candidate is clinically tested, approved for commercialization and successfully marketed. We will be required to seek additional funding in the future and currently intend to do so through collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution, and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could seriously harm our business and cause the price of our common stock to decline. Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on product candidates that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. Due to the significant resources required for the development of our product candidates, in particular our product candidates in IND-enabling studies and those in clinical trials, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain product candidates may subsequently also prove to be less than optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the biopharmaceutical industry, in particular for ophthalmology, cardiology and pulmonology, and cardiology diseases, our business could be seriously harmed. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. 44 Â The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including: â€¢the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or collaboration partners; â€¢the timing and cost of, and level of investment in research, development and commercialization activities, which may change from time to time; â€¢the timing of receipt of approvals from regulatory authorities in the United States and internationally; â€¢the timing and status of enrollment and safety and efficacy readouts for our clinical trials; â€¢the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity of production, the cost of continuing to establish and scale up our internal manufacturing capabilities, and the terms of any agreements we enter into with third-party suppliers; â€¢timing and amount of any option, milestone, royalty or other payments due under any current or future collaboration or license agreement; â€¢coverage and reimbursement policies with respect to our genetic medicine product candidates and potential future drugs that compete with our products, if approved; â€¢expenditures that we may incur to acquire, develop or commercialize additional products and technologies; â€¢the level of demand for our genetic medicine products, if approved, which may vary significantly over time; â€¢future accounting pronouncements or changes in our accounting policies; and â€¢the impact from general macroeconomic trends, such as higher inflation and increased interest rates. For example, most of our collaboration and license revenue for the year ended December 31, 2021 was from Roche. However, Roche terminated its collaboration and license agreement with us effective September 16, 2021. Furthermore, most of our collaboration and license revenue for the year ended December 31, 2023 was from AGT. The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of financial analysts or investors for any period. If our revenue or operating results fall below or if operating expenses or other costs are higher than the expectations of analysts or investors or below or above, as the case may be, any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. 45 Â Risks Related to the Research, Discovery, Development and Commercialization of Our Product Candidates All of our product candidates are based on a novel AAV genetic medicine technology with which there is limited regulatory and clinical experience to date, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Further, the regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities. All of our product candidates are based on genetic medicine technology, and our future success depends on the successful development of this novel therapeutic approach. We cannot assure you that any development problems we or other genetic medicine companies experience in the future related to genetic medicine technology will not cause significant delays or unanticipated costs in the development of our product candidates, or that such development problems can be solved. In addition, the clinical study requirements of the FDA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities. Further, as we are developing novel treatments for diseases in which there is limited clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, European Medicines Agency (â€œEMAâ€) or comparable foreign regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. To date, few genetic medicine products have been approved by the FDA or comparable foreign regulatory authorities, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the European Union ("EU") or other jurisdictions. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval. Regulatory requirements governing genetic medicine products have evolved and may continue to change in the future. For example, the FDA has established the Office of Therapeutic Products within its Center for Biologics Evaluation and Research (â€œCBERâ€) to consolidate the review of genetic medicine and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and other regulatory review agencies, committees and advisory groups and the requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval limitations or restrictions. The National Institutes of Health (â€œNIHâ€) Guidelines for Research Involving Recombinant DNA Molecules (â€œNIH Guidelinesâ€) require supervision of human gene transfer trials, including evaluation and assessment by an Institutional Biosafety Committee (â€œIBCâ€), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. We are subject to significant regulatory oversight by the FDA, and, in addition, the applicable IBC and Institutional Review Board (â€œIRBâ€), of each institution at which we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, need to review and approve the proposed clinical trial. Similar requirements apply in the EU. The EMA has a Committee for Advanced Therapies (â€œCATâ€) that is responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products, or ATMP(s). ATMPs include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing 46 Â authorization for ATMP candidate that is submitted to the EMA. In the EU, the development and evaluation of an ATMP must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Similarly complex regulatory environments exist in other jurisdictions. Changes in applicable regulatory guidelines may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all and could seriously harm our business. Adverse public perception or regulatory scrutiny of genetic medicine technology may negatively impact the developmental progress or commercial success of product candidates that we develop alone or with collaborators. The developmental and commercial success of our current product candidates, or any that we develop alone or with collaborators in the future, will depend in part on public acceptance of the use of genetic medicine technology, including the use of AAVs, for the prevention or treatment of human diseases. Adverse public perception of gene therapies may negatively impact our ability to raise capital or enter into strategic agreements for the development of product candidates. Genetic medicine remains a novel technology. The commercial success of our genetic medicine product candidates, if successfully developed and approved, may be adversely affected by claims that genetic medicine is unsafe, unethical or immoral. This may lead to unfavorable public perception and the inability of any of our product candidates to gain the acceptance of the public or the medical community. Unfavorable public perceptions may also adversely impact our or our collaboratorsâ€™ ability to enroll clinical trials for our product candidates. Moreover, success in commercializing any product candidates that receive regulatory approval will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of such product candidates in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. Publicity of any adverse events in, or unfavorable results of, preclinical studies or clinical trials for any current or future product candidates, or with respect to the studies or trials of our competitors or of academic researchers utilizing similar technologies, even if not ultimately attributable to our technology or product candidates, could negatively influence public opinion. Negative public perception about the use of AAV technology in human therapeutics, whether related to our technology or a competitorâ€™s technology, could result in increased governmental regulation, delays in the development and commercialization of product candidates or decreased demand for the resulting products, any of which may seriously harm our business. Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. 47 Â During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Less common adverse effects may not become evident until investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If any serious adverse events occur, clinical trials or commercial distribution of any product candidates or products we develop alone or with collaborators could be suspended or terminated, and our business could be seriously harmed. Treatment-related side effects could also affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us or our collaborators to cease further development of, deny approval of, or require us to cease selling any product candidates or products for any or all targeted indications. If we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenue from them or other product candidates that we develop may be delayed or eliminated. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to: â€¢regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution; â€¢regulatory authorities may require additional warnings on the label including â€œboxedâ€ warnings, or issue safety alerts, Dear Healthcare Provider letters,

press releases or other communications containing warnings or other safety information about the product; â€¢we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies; â€¢we may be required to create a Risk Evaluation and Mitigation Strategy (â€œREMSâ€), which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; â€¢the product may become less competitive; â€¢we may be subject to fines, injunctions or the imposition of criminal penalties; â€¢we could be sued and held liable for harm caused to patients; and â€¢our reputation may suffer. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm our business. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have no products approved for commercial sale, and we have never generated any revenue from product sales, and we may never generate product revenue or be profitable. We have no products approved for commercial sale and have not generated any revenue from product sales. We do not anticipate generating any revenue from product sales until after we have successfully completed clinical development and received regulatory approval for the commercial sale of a product candidate, which will not occur for several years, if ever. Our ability to generate revenue and achieve profitability depends significantly on many factors, including: â€¢successfully completing research and preclinical and clinical development of our product candidates; 48 Â  â€¢obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials; â€¢developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and any commercial demand for our product candidates; â€¢identifying, assessing, acquiring and/or developing new product candidates; â€¢negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; â€¢the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any; â€¢launching and successfully commercializing product candidates for which we obtain marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; â€¢obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our product candidates are commercialized; â€¢obtaining adequate reimbursement for our product candidates or procedures using our product candidates from payors; â€¢the convenience and durability of our treatment or dosing regimen; â€¢acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates, or any future product candidates, if approved, including relative to alternative and competing treatments; â€¢patient demand for any of our product candidates that may be approved; â€¢addressing any competing technological and market developments; â€¢the effects of any public health emergencies, including the COVID-19 pandemic, which may result in delays to patient enrollment, patients discontinuing their treatment or follow up visits or changes to trial protocols; â€¢maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade secrets and know-how; and â€¢attracting, hiring and retaining qualified personnel. Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our collaboratorsâ€™ clinical trials or the development of any of our product candidates. Even if one or more of our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable, and we will need to obtain additional funding through one or more equity or debt financings in order to continue operations. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as large as we anticipate, the indication approved by regulatory authorities is narrower than we expect, the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines or the price and available third-party reimbursement are lower than anticipated, we may not 49 Â  generate significant revenue from sales of such product candidate, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock, all or any of which may seriously harm our business. We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all. Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. We also cannot be sure that submission of an IND or a clinical trial application (â€œCTAâ€) will result in the FDA or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could delay, suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include: â€¢inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials; â€¢delays in reaching a consensus with regulatory agencies on study design or implementation of the clinical trials; â€¢delays or failure in obtaining regulatory authorization to commence a trial; â€¢delays in reaching agreement on acceptable terms with prospective contract research organizations (â€œCROsâ€) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; â€¢refusal of the FDA to accept data from clinical trials in geographies outside the United States; â€¢delays in identifying, recruiting and training suitable clinical investigators; â€¢delays in identifying, recruiting, and enrolling patients who meet the requirements of our clinical trials; â€¢delays in obtaining required IRB approval or ethics committee opinion at each clinical trial site; â€¢delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; â€¢insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; â€¢imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, CTA or amendment, or equivalent foreign application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; or a negative finding from an inspection of our clinical trial operations or study sites; â€¢developments on trials conducted by competitors for related technology that raise FDA or foreign regulatory authority concerns about risk to patients of the technology broadly; or if the FDA or a foreign regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; â€¢delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up; â€¢difficulty collaborating with patient groups and investigators; â€¢failure by our CROs, other third parties, or us to adhere to clinical trial protocols; 50 Â  â€¢failure to perform in accordance with the FDAâ€™s or any other regulatory authorityâ€™s good clinical practice (â€œGCPâ€) requirements or applicable regulatory guidelines in other countries; â€¢occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; â€¢changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; â€¢changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; â€¢the cost of clinical trials of our product candidates being greater than we anticipate; â€¢clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates; â€¢transfer of manufacturing processes to larger-scale facilities operated by a CMO or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; â€¢third parties being unwilling or unable to satisfy their contractual obligations to us; and â€¢adverse public perception or regulatory scrutiny of genetic medicine technology may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators. Patient enrollment, a determinative factor in the timing of clinical trials, is affected by many factors including the severity of and difficulty of diagnosing the disease under investigation, knowledge of the disease in the medical community and availability of effective diagnostic methods, size and distribution of the patient population and process for identifying subjects, access of patients to medical professionals experienced in their disease, our ability to effectively disseminate information about our clinical trials to the patient population and access of patients to such information, eligibility and exclusion criteria for the trial in question, design of the trial protocol, availability, efficacy of, and our ability to compete with approved and standard of care therapies or other clinical trials for the disease or condition under investigation, perceived risks and benefits of the product candidate under trial or testing, availability of genetic testing for potential patients, efforts to facilitate timely enrollment in clinical trials, patient referral practices of physicians, ability to obtain and maintain subject consent, the risk that enrolled subjects will drop out before completion of the trial, the ability to monitor patients adequately during and after treatment, the time and financial commitments required of patients to enroll in our trials beyond the costs covered by the company, and the proximity and availability of and access to clinical trial sites for prospective patients. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required, or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may seriously harm our business. We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse 51 Â  side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates and could seriously harm our business. The limited number of patients who have the diseases for which many of our product candidates are being studied may make it more difficult for us to enroll or complete clinical trials or may result in findings in our clinical trials that do not reach levels of statistical significance sufficient for marketing approval. Many of the conditions for which we plan to evaluate our current product candidates in clinical trials are rare genetic diseases. Accordingly, there are limited patient pools from which to draw for clinical trials. In addition to the rarity of these diseases, the eligibility criteria of our clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their disease is either severe enough or not too advanced to include them in a trial. We or our collaborators may not be able to initiate or continue clinical trials on a timely basis or at all for any of our product candidates if we or our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. Similarly, because many of the conditions we intend to treat are rare in nature, we plan to design and conduct clinical trials utilizing a small number of patients in order to evaluate the safety and therapeutic activity of our product candidates. Conducting trials in smaller subject populations increases the risk that any safety or efficacy issues observed in only a few patients could prevent such trials from reaching statistical significance or otherwise meeting their specified endpoints, which could require us to conduct additional clinical trials, or delay or prevent our product candidates from receiving regulatory approval, which would seriously harm our business. Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized or if they will ever be successfully commercialized. We are at an early stage of development of our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: â€¢our product candidates may not successfully complete preclinical studies or clinical trials; â€¢a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria; â€¢our competitors may develop therapeutics that render our product candidates obsolete or less attractive; â€¢our competitors may develop platform technologies that render our Therapeutic Vector Evolution platform technology obsolete or less attractive; â€¢the product candidates and Therapeutic Vector Evolution platform technology that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights or may be covered by third-party patents or other intellectual property or exclusive rights; â€¢the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; â€¢a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; â€¢if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; 52 Â  â€¢delays in our clinical development plans due to public health emergencies, such as the COVID-19 pandemic; and â€¢a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors. If any of these events occur, we or our collaborators may be forced to abandon our development efforts for a product candidate or candidates, which would seriously harm our business. Failure of a product candidate may occur at any stage of preclinical or clinical development, and, because our product candidates and our Therapeutic Vector Evolution platform technology are in an early stage of development, there is a relatively higher risk of failure, and we may never succeed in developing marketable products or generating product revenue. We may not be successful in our efforts to further develop our Therapeutic Vector Evolution platform technology and current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates or if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates. If any of our product candidates successfully completes clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the EU, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would seriously harm our business. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, purity, potency, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on our collaborators or collaboration partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be sure that our collaborators or collaboration partners will conduct these activities successfully or do so within the timeframe we desire. Even if we (or our collaborators or collaboration partners) are successful in obtaining approval in one jurisdiction, we cannot assure you that we will obtain approval in any other jurisdictions. Failure to obtain approval for our product candidates in multiple jurisdictions will seriously harm our business. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety

warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would seriously harm our business. Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot assure you that we will be able to successfully 53 Â  advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates. Public health crises such as pandemics or similar outbreaks have affected and could continue to seriously and adversely affect our preclinical and clinical trials, business, financial condition and results of operations. Public health crises, such as pandemics or similar outbreaks, could result in public health guidance measures, including in the locations of our offices, clinical trial sites, key vendors and partners. We expect that our clinical development program timelines could be negatively affected by such pandemics, any public health orders or measures implemented in response to such pandemics, or residual effects thereof, which could seriously harm our business. Further, in response to COVID-19 health guidance measures, we implemented a work-from-home policy for all staff members excluding those working in certain laboratory and manufacturing functions and those necessary to maintain minimum basic operations. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise seriously harm our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories will be delayed. Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could seriously harm our business. The ability of the FDA and foreign regulatory authorities to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDAâ€™s and foreign regulatory authorities' ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDAâ€™s or foreign regulatory authoritiesâ€™ ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Separately, in response to the COVID-19, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations, any resurgence of the virus or emergence of new variants may lead to inspectional or administrative delays. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could seriously harm our business. Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization, which could seriously harm our business. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we or our collaborators must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Further, because our product candidates are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of 54 Â  our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our ongoing and planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business. Further, even if such clinical trials are successfully completed, we cannot assure you that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. In addition, the FDAâ€™s and other regulatory authoritiesâ€™ policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (â€œCTRâ€), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate CTA to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member stateâ€™s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the EU Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans in the EU. Interim, â€œtop-lineâ€ and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we publicly disclose top-line or preliminary data from preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related 55 Â  to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or â€œtop-lineâ€ data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available. From time to time, we also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, top-line or interim data and final data could seriously harm our business. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what we determine to be material information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line or interim data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could seriously harm our business. We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited, â€¯which could seriously harm our business. One of our strategies is to identify and pursue preclinical and clinical development and commercialization of additional product candidates through our Therapeutic Vector Evolution platform technology. Our Therapeutic Vector Evolution platform technology may not produce a pipeline of viable product candidates, or our competitors may develop platform technologies that render our Therapeutic Vector Evolution platform technology obsolete or less attractive. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make them unmarketable or unlikely to receive marketing approval. Identifying, developing and obtaining regulatory approval and commercializing additional product candidates will require substantial funding and is prone to the risks of failure inherent in drug development. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunity may be limited, which could seriously harm our business. We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the indications for which we have product candidates, including wet AMD, DME, GA, cystic fibrosis lung disease, Fabry disease, X-linked retinitis 56 Â  pigmentosa ("XLRP"), and choroideremia. Certain of our competitors have commercially approved products for the treatment of the diseases that we are pursuing or may pursue in the future, including Regeneron, Roche, Sanofi, Takeda and Vertex. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to convince these parties to switch to our product candidates. Companies that we are aware are developing therapeutics in the ophthalmology, cardiology and pulmonology disease areas include large companies with significant financial resources, such as Abbvie, Astellas, Novartis, Opthea, Outlook, Pfizer, Roche, Sanofi, Takeda and Vertex, and biopharmaceutical companies such as Adverum, Amicus, Apellis, Eyepoint Pharmaceuticals, Kodiak Sciences, Krystal, Ocular Therapeutix, REGENXBIO, Sangamo, and Spirovant. In addition to competition from other companies targeting ophthalmology, pulmonology, and cardiology any products we may develop may also face competition from other types of therapies, such as gene-editing therapies and drug delivery devices. Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of ophthalmology, cardiology and pulmonology indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing against competitors any product candidates we may develop. If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for some of our product candidates if and when they are approved. There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel. Factors that may inhibit our efforts to commercialize any approved product on our own include: â€¢our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, compliance, customer service, medical affairs and other support personnel; â€¢our inability to recruit and build a commercial infrastructure; 57 Â  â€¢the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; â€¢the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; â€¢the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; â€¢restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; â€¢the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and â€¢unforeseen costs and expenses associated with creating an independent commercialization organization. If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved and our business would be seriously harmed. Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success. The commercial success of any of our product candidates will

depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: â€¢the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals; â€¢the potential and perceived advantages compared to alternative treatments; â€¢the ability to offer our products for sale at competitive prices; â€¢the ability to offer appropriate patient access programs, such as co-pay assistance; â€¢sufficient third-party coverage or reimbursement; â€¢the extent to which physicians recommend our products to their patients; â€¢convenience and ease of dosing and administration compared to alternative treatments; â€¢the clinical indications for which the product candidate is approved by FDA, EMA or other regulatory agencies; â€¢product labeling or product insert requirements of the FDA, EMA or other comparable foreign regulatory authorities, including any limitations, contraindications or warnings contained in a productâ€™s approved labeling; â€¢restrictions on how the product is distributed; â€¢the timing of market introduction of competitive products; 58 Â  â€¢publicity concerning our products or competing products and treatments; â€¢the strength of marketing and distribution support; and â€¢the prevalence and severity of any side effects. If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable and our business could be seriously harmed. Risks Related to Manufacturing Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise seriously harm our business. We currently manufacture and test clinical trial material for all of our products internally at our cGMP facility, and we have standing relationships with several contract manufacturing organizations. Our product candidates require processing steps that are more complex than those required for most chemical and protein pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ multiple steps to control our manufacturing process to assure that the process works and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory, which could delay or prevent the initiation of clinical trials or receipt of regulatory approvals. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. In addition, FDA and other comparable foreign regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other comparable foreign regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches which could be costly to us and otherwise seriously harm our business. We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing process which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies, which could limit our access to additional attractive development programs. Problems in manufacturing processes or facilities also could restrict our ability to meet market demand for our products. Additionally, should our supply needs exceed our internal capabilities and supply agreements with other parties with whom we have manufacturing agreements be terminated for any reason, there are a limited number of manufacturers who would be suitable replacements, and it would take a significant amount of time to transition the manufacturing to an alternative manufacturing organization. Delays in obtaining regulatory approval of our manufacturing process or disruptions in our manufacturing process may delay or disrupt our commercialization efforts. Before we can begin to commercially manufacture our product candidates in third-party or our own facilities, we must obtain regulatory approval from the FDA to market our product using the manufacturing process and facility we proposed in our marketing application. In addition, we must successfully complete a pre-approval inspection of our manufacturing facility by the FDA before any of our product candidates 59 Â  can obtain marketing approval, if ever. In order to obtain approval of a BLA for our product candidates, we will need to ensure that all of our manufacturing processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any products that we may develop. Similar risks may exist in foreign jurisdictions. Delays in developing our manufacturing capabilities or failure to achieve operating efficiencies from it may require us to devote additional resources and management time to manufacturing operations and may delay our product development timelines. We have recently completed the build out of approximately 17,000 square feet of laboratory and manufacturing space at our headquarters in Emeryville, California, a large portion of which we plan to devote to manufacturing activities for our clinical trials under cGMP. We may face delays in the production of clinical supply at our manufacturing facility and cannot guarantee when our facility will be able to produce sufficient quantities of product candidates needed to support our planned clinical trials. Any delays in developing our internal manufacturing capabilities may disrupt or delay the supply of our product candidates if we have not maintained a sufficient back-up supply of such product candidates through third-party manufacturers. Moreover, changing manufacturing facilities during the clinical development process may also require that we or our collaborators conduct additional studies, make notifications to regulatory authorities, make additional filings to regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. We will further need to comply with the FDAâ€™s and applicable foreign regulatory authoritiesâ€™ cGMP requirements for the production of product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspection. These requirements include the qualification and validation of our manufacturing equipment and processes. We may not be able to develop or acquire the internal expertise and resources necessary for compliance with these requirements. In order to develop internal manufacturing expertise, we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations, quality, regulatory, facilities and information technology. We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing processes. If we experience unanticipated employee shortage or turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from developing these capabilities, which may negatively affect our product development timeline or result in difficulties in maintaining compliance with applicable regulatory requirements. Any such problems could result in the delay, prevention or impairment of clinical development and commercialization of our product candidates and would seriously harm our business. We currently rely and expect to continue to rely on third parties to conduct product manufacturing for certain of our product candidates, and these third parties may not perform satisfactorily. Although we are in process of expanding internal manufacturing capabilities, we currently rely, and expect to continue to rely, on third parties for the production of some of our planned clinical trial drugs and commercial drug materials and, therefore, we can control only certain aspects of their activities. The facilities used by us and our contract manufacturers to manufacture certain of our product candidates must be reviewed by the FDA pursuant to inspections that will be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the cGMP or similar foreign requirements for manufacture of our products. If we or our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to obtain and/or maintain regulatory approval for our products as manufactured at their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality 60 Â  control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. In addition, we rely on additional third parties to manufacture plasmids used in the manufacture of our product candidates and to perform quality testing, and reliance on these third parties entails risks to which we would not be subject if we manufactured the plasmids ourselves, including: â€¢reduced control for certain aspects of manufacturing activities; â€¢termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and â€¢disruptions to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider. Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future product candidates. Some of these events could be the basis for FDA or EU member state competent authority action, including injunction, recall, seizure or total or partial suspension of product manufacture. Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our research studies, preclinical, and clinical development or marketing schedules. Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials required in our manufacturing process, such as plasmids, are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could seriously harm our business. We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could seriously harm our business. We rely on third-party suppliers for the raw materials required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors who are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any interruption in supply of raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supplier in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would seriously harm our business. Risks Related to Regulatory Approval and Other Legal Compliance Matters The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, expensive, time consuming, and inherently unpredictable. If we are ultimately unable 61 Â  to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be seriously harmed. We and any collaborators are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidateâ€™s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. We have not submitted for or obtained regulatory approval for any product candidate. We and any collaborators must complete additional preclinical or nonclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the regulatory authorities before we will be able to obtain these approvals, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: â€¢the FDA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our or our collaboratorsâ€™ clinical trials; â€¢the FDA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use of our products; â€¢the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; â€¢we or our collaborators may be unable to demonstrate to the FDA, or comparable foreign regulatory authorities that a product candidateâ€™s clinical and other benefits outweigh its safety risks; â€¢the FDA or comparable foreign regulatory authorities may disagree with our or our collaboratorsâ€™ interpretation of data from preclinical studies or clinical trials; â€¢the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere; â€¢the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and â€¢the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our or our collaboratorsâ€™ clinical data insufficient for approval. This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would seriously harm our business. In addition, even if we or our collaborators were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a REMS. Regulatory authorities or other authorities responsible for pricing negotiations may not approve the price we or our collaborators intend to charge for products we may develop, may grant approval contingent on the performance of costly 62 Â  post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business. We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval. We may in the future seek an accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsorâ€™s agreement to conduct, in a diligent manner, confirmatory studies to verify and describe the drugâ€™s clinical benefit. If such confirmatory studies fail to confirm the drugâ€™s clinical benefit, or if the sponsor fails to conduct required

confirmatory studies in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. In addition, in December 2022, President Biden signed an omnibus appropriations bill to fund the U.S. government through fiscal year 2023. Included in the omnibus bill is the Food and Drug Omnibus Reform Act of 2022, which among other things, provided FDA new statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted. Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval for any of our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. Even if we or our collaborators obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. If one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post- market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. 63 Â  Manufacturers and manufacturersâ€™ facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations or similar foreign requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP or similar foreign requirements and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the productâ€™s approved label. As such, we may not promote our products â€œoff-labelâ€ for indications or uses for which they do not have approval, though we may share truthful and not misleading information that is otherwise consistent with our productâ€™s approved labeling. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval or label restrictions. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: â€¢issue warning letters; â€¢impose civil or criminal penalties; â€¢suspend or withdraw regulatory approval; â€¢suspend any of our clinical trials; â€¢refuse to approve pending applications or supplements to approved applications submitted by us; â€¢impose restrictions on our operations, including closing our manufacturing facility or our contract manufacturersâ€™ facilities; or â€¢seize or detain products, or require a product recall. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, our business will be seriously harmed. Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability. We have received Fast Track designation for 4D-310 for the treatment of Fabry disease, and for 4D-125 for the treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including XLRP, and we may seek Fast Track designation for certain future product candidates. 64 Â  However, we may not be able to obtain such designations, and there is no guarantee that 4D-310 or 4D-125 will experience a faster regulatory review or obtain regulatory approval. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this disease condition, the product sponsor may apply for Fast Track designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the application may be eligible for priority review. A BLA for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. We have received Fast Track designation for 4D-310 for the treatment of Fabry disease, and for 4D-125 for the treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including XLRP and we may receive Fast Track designation for other product candidates in the future; however, we may not experience a faster development, review or approval process, and receipt of the designation does not increase the likelihood that the FDA will approve 4D-310 or 4D-125 for any indication. In addition, the FDA may rescind the Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. We have received orphan drug designation for 4D-710 for cystic fibrosis, 4D-110 for the treatment of choroideremia as well as 4D-125 for the treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including XLRP, and for 4D-310 for the treatment of Fabry disease, and we may seek orphan drug designation for certain future product candidates. However, we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced. We have received orphan drug designation in the United States for 4D-710 for the treatment of cystic fibrosis, 4D-110 for the treatment of choroideremia and for 4D-310 for the treatment of Fabry disease. In the EU, we have received orphan designation for 4D-125 for the treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including XLRP, and for 4D-310 for the treatment of Fabry disease. Although we may seek orphan product designation for some or all of our other product candidates, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan drug designation must be requested before submitting a BLA. Orphan drug designation is granted by the European Commission (â€œECâ€) based on a scientific opinion of the EMAâ€™s Committee for Orphan Medicinal Products (â€œCOMPâ€). A medicinal product may be designated as orphan if its sponsor can establish that (i) the product is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. The application for orphan designation must be submitted before the application for marketing authorization. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. In addition, if a product receives the first FDA approval for the disease or condition for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of 65 Â  seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for a disease or condition broader than the orphan designated disease or condition and may be lost if the FDA later determines that the request for designation was materially defective. In the EU, orphan designation entitles a party to financial incentives such as reduction of fees, fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Moreover, upon grant of a marketing authorization and assuming the requirement for orphan designation are also met at the time the marketing authorization is granted, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed Pediatric Investigation Plan (â€œPIPâ€). The European exclusivity period can be reduced to six years, if, at the end of the fifth year a medicine no longer meets the criteria for orphan designation (i.e. the prevalence of the condition has increased above the orphan designation threshold or it is judged that the product is sufficiently profitable so as not to justify maintenance of market exclusivity). Even if we obtain orphan drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA and foreign regulatory authorities can subsequently approve the same drug with for the same condition if the FDA or foreign regulatory authorities concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process. We have received Regenerative Medicine Advanced Therapy ("RMAT") and PRIME designation for 4D-150 for the treatment of wet AMD. We may seek RMAT and PRIME designations for certain future product candidates, however we may not be able to obtain such designations, and there is no guarantee that 4D-150 will experience a faster regulatory review or obtain regulatory approval. The FDA has granted RMAT designation for 4D-150 for the treatment of neovascular (wet) age-related macular degeneration, and may seek additional RMAT designations for 4D-150 or for our other product candidates. An biological product candidate is eligible for RMAT designation if: (1) it meets the definition of a regenerative medicine therapy, which the FDA defines as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) the candidate is intended to treat, modify, reverse, or cure a serious disease or condition; and (3) preliminary clinical evidence indicates that the candidate has the potential to address unmet medical needs for such disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review of BLAs. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or through reliance upon data obtained from a meaningful number of sites, including through expansion of clinical trials to a sufficient number sites, as appropriate. RMAT-designated product candidates that receive accelerated approval may, as appropriate, be able to fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence (such as electronic health records), through the collection of larger confirmatory data sets, or via post-approval monitoring of patients treated with the therapy prior to approval. RMAT designation is within the sole discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for RMAT designation, the FDA may disagree and instead determine not to make such designation. RMAT designation does not change the standards for product approval, and there is no assurance that such designation or eligibility for such designation will result in expedited review or approval, or that the approved indication will not be narrower than the indication covered by the RMAT designation. 66 Â  In the EU, 4D-150 was accepted into the PRIority MEdicine (â€œPRIMEâ€) scheme by the EMAâ€™s Committee for Medicinal Products for Human Use (â€œCHMPâ€) for the treatment of wet AMD. In the EU, innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which was launched by the EMA in 2016 and provides incentives similar to the Breakthrough Therapy designation in the United States. PRIME is a voluntary scheme aimed at enhancing the EMAâ€™s support for the development of medicines that target an unmet medical need. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. The benefits of a PRIME designation include the appointment of a rapporteur before submission of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process. Product developers that benefit from PRIME designation may be eligible for accelerated assessment (in 150 days instead of 210 days), which may be granted for medicinal products of major interest from a public health perspective or that target an unmet medical need, but this is not guaranteed. Receipt of these designations does not increase the likelihood that FDA or EC will approve 4D-150 for any indication. In addition, the FDA or foreign competent authorities may rescind the designations if they believe that the designation is no longer supported by data from our clinical development program. We have obtained a rare pediatric disease designation for 4D-710, however, there is no guarantee that FDA approval of 4D-710 will result in issuance of a priority review voucher. In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a â€œrare pediatric diseaseâ€ that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. We have obtained a rare pediatric disease designation for 4D-710 for the treatment of cystic fibrosis, however, there is no guarantee that we will be able to obtain a priority review voucher, even if 4D-710 is approved by the FDA for this indication. For example, the FDA may determine that a BLA, even if ultimately approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons: â€¢the product no longer meets the definition of a rare pediatric disease; â€¢the product contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in another marketing application; â€¢the application does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population; â€¢the application is approved for a different adult indication than the rare pediatric disease for which the product is designated Moreover, Congress included a sunset provision in the statute authorizing the rare pediatric disease priority review voucher program. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the product candidate, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any rare pediatric disease priority review vouchers, regardless of any rare pediatric disease designation, unless the program is reauthorized by Congress. 67 Â  If the product candidates that we or our collaborators may develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for such product candidates and seriously harm our business. Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or our collaboratorsâ€™ ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from

being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the EU and many other jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or our collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and seriously harm our business. Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and to commercialize our product candidates and may affect the prices we may set. In the United States, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the â€œACAâ€) was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: â€¢an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; â€¢new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting â€œtransfers of valueâ€ made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; â€¢an increase to the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and an extension the rebate program to individuals enrolled in Medicaid managed care organizations; â€¢a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; â€¢expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturerâ€™s Medicaid rebate liability; â€¢a licensure framework for follow-on biologic products; 68 Â  â€¢a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and â€¢establishment of a Center for Medicare & Medicaid Innovation (â€œCMMIâ€) at the Centers for Medicare & Medicaid Services (â€œCMSâ€) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Since its enactment, there have been judicial, U.S. Congressional and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024. The rebate was previously capped at 100% of a drugâ€™s average manufacturer price. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient assistance programs. Most recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). On August 29, 2023, CMS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. We also expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures and could seriously harm our business. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could seriously harm our business. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. Prescription drugs and biological products that are in violation of these requirements will be included on a public list. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing and could seriously harm our business. In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in 69 Â  the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or judicial action in the United States, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such products at competitive prices which would seriously harm our business. The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs (â€œVAâ€) hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, other third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. For genetic medicine and other products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, that the level of reimbursement will be sufficient. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly 70 Â  from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could seriously harm our business. Even if we obtain FDA approval for any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential. In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell any products effectively, if approved, or generate product revenue. We currently do not have a marketing or sales organization. In order to commercialize any product, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In advance of any of our product candidates receiving regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time-consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our 71 Â  own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses and our business would be seriously harmed. Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties and seriously harm our business. Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: â€¢the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; â€¢the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and

services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; â€¢the federal Health Insurance Portability and Accountability Act of 1996 (â€œHIPAAâ€), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation; â€¢the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; â€¢the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; â€¢the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Childrenâ€™s Health Insurance Program, with specific 72 Â  exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (as defined by statute), certain other non-physician practitioners (including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants, and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; â€¢analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and â€¢similar healthcare laws in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. We may also be subject to additional federal laws, such as the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof, and federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain of our advisory board arrangements with physicians, some of whom are compensated in the form of stock or stock options, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. We use and generate materials that may expose us to material liability. Our research programs involve the use of hazardous materials and chemicals. We are subject to foreign, federal, state and local environmental and health and safety laws and regulations governing, among other matters, the use, manufacture, handling, storage and disposal of hazardous materials and waste products such as human tissue samples that may have the potential to transmit diseases. We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. In addition, we cannot completely eliminate the risk of contamination or injury from hazardous materials and may incur material liability as a result of such contamination or injury. In the event of an accident, an injured party may seek to hold us liable for any damages that result. Any liability could exceed 73 Â  the limits or fall outside the coverage of our workersâ€™ compensation, property and business interruption insurance and we may not be able to maintain insurance on acceptable terms, if at all. We currently carry no insurance specifically covering environmental claims. Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products. The Animal Welfare Act (â€œAWAâ€) is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. Risks Related to Our Reliance on Third Parties We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. We currently rely and expect to continue to rely on third parties, such as CROs, CMOs, clinical data management organizations, clinical data assessments and analysis organizations, medical institutions and clinical investigators, to conduct some aspects of our manufacturing, research, preclinical testing and clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities reduces our control over these activities, but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and to post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Similar risks may exist in foreign jurisdictions. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. We also expect to rely on other third parties to manufacture, store and distribute drug supplies for our clinical trials. Any performance failure on the part of our manufacturers or distributors could delay clinical development, marketing approval or commercialization of any product candidates, producing additional losses and depriving us of potential product revenue. We rely on various CROs to obtain NHPs for use in vector discovery and preclinical development work. In February 2023, we were informed that Charles River Laboratories ("Charles River"), one of our primary suppliers of NHPs, received a subpoena from the United States Department of Justice with respect to its importation of NHPs from Cambodia. Charles River reported that it has voluntarily suspended NHP shipments from Cambodia at this time. If we are unable to secure adequate supply of NHPs from Charles 74 Â  River or other CROs, or the shortage of NHPs causes the price of NHPs to rise substantially, certain of our vector discovery projects and preclinical development efforts will be delayed, and the cost of conducting discovery projects and preclinical development activities may substantially increase. Such delays or cost increases could materially adversely affect our discovery and preclinical development activities and our business. We may depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates. We have sought, and may in the future seek, third-party collaborators for the research, development and commercialization of certain product candidates we may develop. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional, national and international pharmaceutical companies, biotechnology companies and academic institutions. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaboratorsâ€™ abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into. Collaborations involving our product candidates we may develop, pose the following risks to us: â€¢collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations; â€¢collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property; â€¢collaborators may own or co-own intellectual property covering our product candidates that result from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates; â€¢disputes may arise with respect to the ownership of intellectual property developed pursuant to collaborations; â€¢we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; â€¢collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; â€¢disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; â€¢collaborators may decide not to pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaboratorâ€™s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; â€¢collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; â€¢collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that 75 Â  competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; â€¢collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates; â€¢we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; â€¢collaborators may undergo a change of control and the new owners may decide to take the collaboration in a direction which is not in our best interest; â€¢collaborators may become party to a business combination transaction and the continued pursuit and emphasis on our development or commercialization program by the resulting entity under our existing collaboration could be delayed, diminished or terminated; â€¢collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, devices, materials, know-how or intellectual property of the collaborator relating to our products and product candidates; â€¢key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators; â€¢collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business; â€¢collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or our Therapeutic Vector Evolution platform technology; and â€¢collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate or delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue which could seriously harm our business. If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elect not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaboratorâ€™s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Any collaborator may also be subject to many of the risks relating to product development, regulatory approval, and commercialization described in this â€œRisk Factorsâ€ section, and any negative impact on our collaborators may adversely affect us. 76 Â  Risks Related to Our Intellectual Property Our success depends on our ability to protect our intellectual property and our proprietary technologies. Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. Further, we have three granted patents (U.S. patent nos. 11,136,557, 11,634,691 and 10,988,519) and five pending patent applications (U.S. patent application nos. 18/167,598, 17,468,290, 18/167,598, 18/494,883 and 18/184,184), that were made with government support, that may be subject, under certain circumstances, to march-in-rights under 35 U.S.C. 203, which is a right that allows the government, in certain limited circumstances, to force a party with a license to intellectual property funded, at least in part, by the government, to grant a license to such property to another entity. U.S. patent nos. 11,136,557 and 11,634,691 were made with the support of U.C. Berkeley and relate to our A101 vector of our 4D-710 and 4D-725 product candidates. U.S. patent no. 10,988,519 was made with the support of University of Pennsylvania and relates to our short-form human complement factor H (sCFH) payload of our 4D-175 product candidate. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could seriously harm our business. We and our licensors have applied, and we intend to continue applying, for patents covering aspects of our product candidates, proprietary technologies and their uses that we deem appropriate. However, we may not be able to apply for patents on certain aspects of our current or future product

candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent coverage we obtain may not be sufficient to prevent substantial competition. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators or licensors will be successful in protecting our product candidates, proprietary technologies and their uses by obtaining and defending patents. These risks and uncertainties include the following: â€¢the U.S. Patent and Trademark Office (â€œUSPTOâ€) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; â€¢patent applications may not result in any patents being issued; â€¢patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; â€¢our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates; 77 Â  â€¢other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; â€¢any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; â€¢because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; â€¢an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our licensors' patent applications for any patent application with an effective filing date before March 16, 2013; â€¢there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and â€¢countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates. The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Moreover, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents, if issued, patents obtained by our collaborators or the patent rights that we license from others, may be challenged in the courts or patent offices in the United States and abroad. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical products or product candidates, or limit the duration of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitorâ€™s or potential competitorâ€™s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. 78 Â  In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our product candidates are invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights. If we initiate lawsuits to protect or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel. The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that: â€¢any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; â€¢any of our pending patent applications or those of our licensors may issue as patents; â€¢others will not or may not be able to make, use, offer to sell, or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license; â€¢we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire; â€¢we or our licensors were the first to make the inventions covered by each of the patents and pending patent applications that we own or license; â€¢we or our licensors were the first to file patent applications for these inventions; â€¢others will not develop similar or alternative technologies that do not infringe the patents we own or license; â€¢any of the patents we own or license will be found to ultimately be valid and enforceable; â€¢any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable products or will provide us with any competitive advantages; â€¢a third party may not challenge the patents we own or license and, if challenged, a court would hold that such patents are valid, enforceable and infringed; â€¢we may develop or in-license additional proprietary technologies that are patentable; â€¢the patents of others will not have an adverse effect on our business; â€¢our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; â€¢we will develop additional proprietary technologies or product candidates that are separately patentable; or â€¢our commercial activities or products will not infringe upon the patents of others. Where we obtain licenses from or collaborate with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could seriously harm our business. 79 Â  Furthermore, our owned and in-licensed intellectual property rights may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could seriously harm our business. The lives of our patents may not be sufficient to effectively protect our product candidates and business. Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date. Although various extensions may be available, the life of a patent, and the protection it affords, are limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent life has expired, we may be open to competition. In addition, although upon issuance in the United States a patentâ€™s life can be extended based on certain delays caused by the USPTO and clinical development, this extension can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we do not have sufficient patent life to protect our product candidates, proprietary technologies and their uses, our business would be seriously harmed. If we are unable to protect the confidentiality of our trade secrets, our business would be seriously harmed. We rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. We have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees and consultants. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant or third party with authorized access. Our security measures may not prevent an employee, consultant, collaborator or third party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our product candidates that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the industry through 80 Â  independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our employees, collaborators, licensors, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because from time to time we have relied on, and in future expect to rely on third parties in the development, manufacture, and distribution of our product candidates and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors. We currently are reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology, including technology related to our product candidates. For example, we rely on our exclusive license agreements with i) U.C. Berkeley for certain rights with respect to the intellectual property covering certain compositions of matter and methods of use of certain AAV variants related to our 4D-710 and 4D-725 product candidates, and ii) University of Pennsylvania for certain rights with respect to the intellectual property covering certain compositions of matter and methods of use of the short-form human complement factor H (sCFH) payload related to our 4D-175 product candidate. These and other licenses we may enter into in the future may not provide adequate rights to use such intellectual property and technology in all relevant fields of use or in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to develop and commercialize our technology and product candidates in fields of use and territories for which we are not granted rights pursuant to such licenses. Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, which could seriously harm our business. In some circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or collaborators will prosecute, maintain, enforce and defend such intellectual property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade secrets, or by paying all applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted the patents and patent applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products. Our current licenses, and our future licenses, likely will impose various royalty payments, milestones, and other obligations on us. If we fail to comply with any of these obligations, we may be required to pay 81 Â  damages and the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could prevent us from developing and commercializing our product candidates and proprietary technologies. Our business would be seriously harmed if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any current or future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensorâ€™s rights. In addition, while we cannot currently determine the amount of royalty obligations we would be required to pay on the sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in product candidates that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize any product candidates, we may be unable to achieve or maintain profitability. If our trademarks and trade names, whether registered in the future or unregistered now, are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Any trademarks we may register in the future or any current registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these

trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names, to the extent any are registered, to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could seriously harm our business. Intellectual property rights do not necessarily address all potential threats to our competitive advantage. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: â€¢others may be able to make genetic medicine products that are similar to our product candidates or utilize similar genetic medicine technology but that are not covered by the claims of the patents that we own or have exclusively licensed; â€¢we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed; â€¢we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; â€¢others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; 82 Â  â€¢it is possible that our pending patent applications will not lead to issued patents; â€¢issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; â€¢our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; â€¢we may not develop additional proprietary technologies that are patentable; and â€¢the patents of others may have an adverse effect on our business. Should any of these events occur, they could seriously harm our business. Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products. Any future collaborations that we enter into may not be successful, such as our collaboration agreement with Pfizer that was terminated in 2018, with AstraZeneca that concluded in 2020 without AstraZeneca exercising its option and with Roche that was terminated without cause effective September 2021. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: â€¢collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations; â€¢collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; â€¢collaborators could independently develop, or develop with third parties, products and product candidates that compete directly or indirectly with our product candidates; â€¢a collaborator with marketing, manufacturing and distribution rights to one or more products and product candidates may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; â€¢we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; â€¢collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; â€¢disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; â€¢collaborations may be terminated, and, if terminated, may adversely affect the price of our common stock and may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates; â€¢collaborators may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and â€¢a collaboratorâ€™s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. 83 Â  Risks Related to Our Operations We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business. We conduct our operations at our facilities in Emeryville, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region, and doing so may be costly and difficult. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option grants. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. In addition, our employees are employed at-will, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract, incentivize and retain quality personnel on acceptable terms, or at all, it could seriously harm our business. We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. As of June 30, 2024, we had 201 full-time employees. As our development plans and strategies develop, we must add a significant number of additional managerial, operational, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including: â€¢identifying, recruiting, integrating, retaining and motivating additional employees; â€¢managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties; â€¢expanding our operational, financial and management controls, reporting systems and procedures; and â€¢managing increasing operational and managerial complexity. Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities. We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. 84 Â  If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development and commercialization goals. Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, a severe or prolonged economic downturn, including a recession or depression resulting from factors such as increased inflation or closure of or liquidity issues at financial institutions (including, for example, Silicon Valley Bank) or other macro factors such as a pandemic or geopolitical tensions could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption, including any international trade disputes, could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could seriously harm our business, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could seriously harm our business. If we engage in acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: â€¢increased operating expenses and cash requirements; â€¢the assumption of indebtedness or contingent liabilities; â€¢the issuance of our equity securities which would result in dilution to our stockholders; â€¢assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel; â€¢the diversion of our managementâ€™s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership; â€¢retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; â€¢risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and â€¢our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. In addition, if we undertake such a transaction, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. 85 Â  Our information technology systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches and other disruptions. We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, clinical trial data, proprietary business information and personal information of our employees and contractors (collectively, â€œConfidential Informationâ€). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. Despite the implementation of security measures, our internal information technology systems and those of our collaborators, future CROs and other contractors and consultants may be vulnerable to attack, damage and interruption from computer viruses and malware (e.g. ransomware), malicious code, misconfigurations, â€œbugsâ€ or other vulnerabilities, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, denial or degradation of service attacks, and sophisticated nation-state and nation-state supported actors. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We and our third party service providers and partners may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. Our third party service providers and partners are also subject to these heightened risks. The costs to us to investigate and mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. There can also be no assurance that our and our collaboratorsâ€™, future CROsâ€™ and other contractorsâ€™ and consultantsâ€™ cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information. We and certain of our service providers have experienced certain cyberattacks and security incidents from time to time. Although to our knowledge we have not experienced any significant system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss, corruption or unauthorized disclosure of our Confidential Information or other similar disruptions. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of clinical trial data or personal data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media, and other parties pursuant to privacy and security laws. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their information technology systems could also seriously harm our business. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of Confidential Information, we 86 Â  could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed. Any losses, costs or liabilities may not be covered by, or may exceed the coverage limits of, any applicable insurance policies. Business disruptions could seriously harm our business. Our operations, and those of our CROs, CMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our business. All of our operations including our corporate headquarters are located in multiple facilities in Emeryville, California. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, earthquake and other natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business could be seriously harmed by such delays and interruption. Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition. The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the United States and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could seriously harm our business. As our operations and business grow,

we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder (collectively, â€œHIPAAâ€), imposes, among other things, certain standards on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities, and their covered subcontractors. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. Certain states have also adopted comparable privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act 87 Â  (collectively, the â€œCCPAâ€) requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the businessâ€™s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the businessâ€™s behalf. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (â€œEEAâ€). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to â‚¬20 million or 4% of the annual global revenue of the noncompliant undertaking, whichever is greater. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease or change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/or civil claims (including class actions). Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (â€œCJEUâ€) states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the Data Privacy Framework (DPF), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames. Further, from January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of â‚¬20 million (Â£17.5 million) or 4% of global turnover. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. Additionally, the Securities and Exchange Commission (the â€œSECâ€) recently adopted a rule that enhances and standardizes disclosures regarding cybersecurity risk management and governance, as well as material cybersecurity incidents. Under this new rule, we will be required to make annual disclosures describing our processes for identifying and managing material cybersecurity risks, management's role in assessing and managing such risks and our board of directorsâ€™ oversight of cybersecurity risks. We will also be required to disclose, in a Current Report on Form 8-K, the nature, scope and timing of any material cybersecurity incidents identified and the material impact or reasonably likely material impact on the company. We expect to face increased costs to comply with this new SEC cybersecurity rule, including increased costs for cybersecurity training and management. Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply 88 Â  with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and seriously harm our business Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. Under Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended (the â€œCodeâ€), if a corporation undergoes an â€œownership changeâ€ (generally defined as a greater than 50-percentage-point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporationâ€™s ability to use its pre-change net operating loss carryforwards (â€œNOLsâ€) and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or other pre-change tax attributes if we undergo a future ownership change. We have experienced ownership changes in the past. We may also experience ownership changes as a result of any future shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation. We will be unable to use our NOLs or other tax attributes if we do not attain profitability sufficient to offset our available NOLs or other tax attributes prior to their expiration, to the extent subject to expiration. Changes in tax laws or regulations that are applied adversely to us or our customers may seriously harm our business. New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. Risks Related to Ownership of Our Common Stock The market price of our common stock may be volatile, which could result in substantial losses for investors. Some of the factors that may cause the market price of our common stock to fluctuate include: â€¢results from, and any delays in, our clinical trials for our clinical-stage product candidates or any other future clinical development programs; â€¢the success of existing or new competitive products or technologies; â€¢commencement or termination of collaborations for our product candidates; â€¢failure or discontinuation of any of our product candidates; â€¢failure to develop our Therapeutic Vector Evolution platform technology; â€¢results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; â€¢regulatory or legal developments in the United States and other countries, including sanctions imposed by either the U.S. or foreign governments; â€¢developments or disputes concerning patent applications, issued patents or other proprietary rights; â€¢the recruitment or departure of key personnel; â€¢the commencement of litigation; â€¢the level of expenses related to any of the research programs or product candidates that we may develop; 89 Â  â€¢the results of our efforts to develop additional product candidates or products; â€¢actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; â€¢announcement or expectation of additional financing efforts; â€¢sales of our common stock by us, our insiders, or other stockholders; â€¢variations in our financial results or those of companies that are perceived to be similar to us; â€ ¢changes in estimates or recommendations by securities analysts, if any, that cover our stock; â€¢changes in the structure of healthcare payment systems; â€¢the impact of political instability, natural disasters, war and/or events of terrorism, such as the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other countries such as China; â€¢market conditions in the pharmaceutical and biotechnology sectors; â€¢general economic, industry, and market conditions; and â€¢the other factors described in this â€œRisk Factorsâ€ section. In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Further, the stock market in general has been highly volatile due to macroeconomic factors such as higher inflation and increased interest rates and political uncertainty in the United States. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Since the completion of our initial public offering in December 2020, the price of our common stock has been volatile, and we expect such volatility to continue. Following periods of such volatility in the market price of a companyâ€™s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert managementâ€™s attention and resources from our business. If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of these analysts should drop research coverage of us or if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. Sales of a substantial number of shares of our common stock in the public market could occur at any time, which could cause the market price of our common stock to decline significantly, even if our business is doing well. Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market price of our common stock. Further, shares issued upon the exercise of stock options outstanding under our equity incentive plans, or pursuant to future awards granted under those plans, will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended (the â€œSecurities Actâ€). 90 Â  Moreover, holders of an aggregate of approximately 1.9 million shares of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. We will seek additional capital through one or a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. Insiders have substantial influence over us, which could limit your ability to affect the outcome of key transactions, including a change of control. Our directors, executive officers, holders of more than 5% of our outstanding stock and their respective affiliates beneficially own shares representing approximately 55% of our outstanding common stock as of June 30, 2024. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock. We are an â€œemerging growth companyâ€ and a â€œsmaller reporting companyâ€ and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors. We are an â€œemerging growth company,â€ as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an â€œemerging growth companyâ€ the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) December 31, 2025, (2) the last day of the year in which we have total annual gross revenue of at least $1.235 billion, (3) the last day of the year in which 91 Â  we are deemed to be a â€œlarge accelerated filerâ€ as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. Even after we no longer qualify as an â€œemerging growth company,â€ we may still qualify as a â€œsmaller reporting company,â€ which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including, among other things, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, presenting only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and reduced disclosure obligations. We incur significant costs as a result of operating as a public company, and our management devotes substantial time to public company compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would seriously harm our business. We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Select Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations have and will likely continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directorsâ€™ and officersâ€™ insurance, on acceptable terms. We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (â€œSection 404â€) and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the

effectiveness of our internal control over financial reporting. Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal controls over financial reporting. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or, when required to do so, our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs to provide timely and accurate notice of their costs to us. 92 Â  Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our Company may deem advantageous. These provisions, among other things: â€¢provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; â€¢eliminate cumulative voting in the election of directors; â€¢authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval; â€¢provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship; â€¢provide that our directors may be removed only for cause; â€¢permit stockholders to only take actions at a duly called annual or special meeting and not by written consent; â€¢prohibit stockholders from calling a special meeting of stockholders; â€¢provide for a staggered board, which will result in only a few directors being up for re-election in each calendar year; â€¢require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings; â€ ¢authorize our board of directors, by a majority vote, to amend the bylaws; â€¢require the affirmative vote of at least 66 2/3% or more of the outstanding shares of our common stock to amend many of the provisions described above; and â€¢limit the liability of, and provide indemnification to, our directors and officers. In addition, Section 203 of the General Corporation Law of the State of Delaware (â€œDGCLâ€) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Any provision of our certificate of incorporation, bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. 93 Â  In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that: â€¢We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such personâ€™s conduct was unlawful. â€¢We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. â€¢We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. â€¢We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. â€¢The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. â€¢We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Our amended and restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, by the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law. This choice of forum provision may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companiesâ€™ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types 94 Â  of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could seriously harm our business. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock. We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. Unfavorable conditions in the global economy caused by global political unrest or conflicts, including the ongoing conflict between Russia and Ukraine and in Israel and Gaza, may exacerbate certain risks we face. Political unrest, international conflict, terrorism or war, such as Russiaâ€™s invasion of Ukraine and the armed conflict in Israel and Gaza, and the global response to these conflicts, including the imposition of sanctions by the United States and other countries, could create or exacerbate risks facing our business. We have evaluated our operations and partner contracts, and we currently do not expect existing conflicts to directly have a significant effect on our financial condition or results of operations. However, if hostilities persist, escalate or expand, risks that we have identified in this Quarterly Report on Form 10-Q may be materially increased. For example, if our supply arrangements or clinical operations are disrupted due to expanded sanctions or involvement of countries where we have operations or relationships, our business could be materially disrupted. Further, the use of cyberattacks could expand as part of the ongoing conflicts, which could adversely affect our ability to maintain or enhance our cyber security measures. These and other risks are described more fully in this â€œRisk Factorsâ€ section. General Risk Factors Any legal proceedings or claims against us could be costly and time-consuming to defend and could harm our reputation regardless of the outcome. We may in the future become subject to legal proceedings and claims that arise in the ordinary course of business, such as disputes or employment claims made by our current or former employees. Any litigation, whether meritorious or not, could harm our reputation, will increase our costs and may divert managementâ€™s attention, time and resources, which may in turn seriously harm our business. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims, and might not continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs and could seriously harm our business. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise 95 Â  unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to cease commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: â€¢decreased or interrupted demand for our products; â€¢substantial monetary awards to trial participants or patients; â€¢product recalls, withdrawals or labeling, marketing or promotional restrictions; â€¢injury to our reputation; â€¢withdrawal of clinical trial participants and inability to continue clinical trials; â€¢initiation of investigations by regulators; â€¢costs to defend the related litigation; â€¢a diversion of managementâ€™s time and our resources; â€¢loss of revenue; â€¢exhaustion of any available insurance and our capital resources; â€¢the inability to commercialize any product candidate; and â€¢a decline in our share price. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. Our employees, independent contractors, consultants, research or commercial partners or collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, research or commercial partners or other collaborators, including the foundations we work with, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA, EMA and other comparable foreign regulatory authorities; provide true, complete and accurate information to the FDA, EMA and other comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and 96 Â  the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could seriously harm our business, including the imposition of significant fines or other sanctions. If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business. We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workersâ€™ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could seriously harm our business. Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. Reliance on third parties to conduct clinical trials, assist in research and development and to manufacture our product candidates, will at times require us to share trade secrets with them. We seek to protect our proprietary technology by in part entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties

to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitorâ€™s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may seriously harm our business. 97 Â  We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business. We are party to various agreements that we depend on to operate our business. Our rights to use currently licensed intellectual property, or intellectual property to be licensed in the future, are or will be subject to the continuation of and our compliance with the terms of these agreements. These agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations which could lead to disputes, including but not limited to those regarding: â€¢the scope of rights granted under the license agreement and other interpretation-related issues; â€¢the extent to which our proprietary technology and product candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement; â€¢the sublicensing of patent and other rights; â€¢diligence obligations under the license agreement and what activities satisfy those diligence obligations; â€¢the ownership of inventions and know-how resulting from the creation or use of intellectual property by us or our counterparties, alone or jointly; â€¢the scope and duration of our payment obligations; â€¢rights upon termination of such agreement; and â€¢the scope and duration of exclusivity obligations of each party to the agreement. The resolution of any contractual interpretation dispute that may arise, if unfavorable to us, could seriously harm our business. Such resolution could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement, or decrease the third partyâ€™s financial or other obligations under the relevant agreement. If disputes over intellectual property rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future license agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements. Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products. Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents or other proprietary rights of third parties. Third parties may have or obtain patents or other proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products, if any, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, inter partes review proceedings and post-grant review proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent 98 Â  applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patentâ€™s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies or product candidates are not covered by a third-party patent or may incorrectly predict whether a third partyâ€™s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. patent applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our product candidates. As a result, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates, and cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and could: â€¢result in costly litigation; â€¢divert the time and attention of our technical personnel and management; â€¢cause development delays; â€¢prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; â€¢require us to develop non-infringing technology, which may not be possible on a cost-effective basis; â€¢require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; â€¢require us to pay the attorneyâ€™s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or â€¢require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. 99 Â  Although no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent our product candidates or any future products from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or proprietary technologies could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our product candidates or any future products. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be time-consuming and a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Even if such licenses are available, we could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins, and the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. In addition, we cannot be certain that we could redesign our product candidates or proprietary technologies to avoid infringement, if necessary, or on a cost-effective basis. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates or any future products which could seriously harm our business. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology. If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. Also, we may be obligated under our agreements with our collaborators, licensors, suppliers and others to indemnify and hold them harmless for damages arising from intellectual property infringement by us. We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged. Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court or administrative tribunal may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and may result in the revocation, cancellation, or amendment of any foreign patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on an affected product candidate. Such a loss of patent protection would seriously harm our business. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO, or equivalent actions brought in foreign jurisdictions, may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be seriously harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain 100 Â  access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market. Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace and seriously harm our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and licenses. We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, license or use these proprietary rights. We may be unable to acquire or license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. We have collaborated with a U.S. academic institution and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institutionâ€™s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business could be seriously harmed. 101 Â  We may be subject to claims that we have wrongfully hired an employee from a competitor or that we, our employees or consultants have wrongfully used or disclosed alleged confidential information or trade secrets of their former or concurrent employers or former or current clients. As is common in the biotechnology and biopharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees or consultants, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer or former or current client. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could seriously harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management and other employees. We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. Our agreements with employees and consultants provide that any inventions conceived by an individual in the course of rendering services to us shall be our exclusive property. Although our policy is to have all such individuals complete these agreements, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. The assignment of intellectual property may not be self-executing and despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. We may also be subject to claims that former employees, consultants, or other third parties have an ownership interest in our patents or other intellectual property. In addition, we may face claims by third parties that our agreements with employees or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership

disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could seriously harm our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to our management and other employees. If we do not obtain patent term extension for our product candidates, our business may be seriously harmed. Depending upon the timing, duration and specifics of FDA marketing approval of any of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period 102 Â or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration of the applicable product, and our business may be seriously harmed. Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. Our patent rights may be affected by developments or uncertainty in the U.S. or foreign patent statutes, patent case laws, USPTO rules and regulations or in the rules and regulations of foreign patent offices. There are a number of recent changes to the U.S. patent laws that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, on September 16, 2011, the Leahy-Smith America Invents Act (â€œLeahy-Smith Actâ€) was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a â€œfirst to fileâ€ system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. This could have a negative impact on some of our intellectual property and could increase uncertainties surrounding obtaining and enforcement or defense of our issued patents. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. Similarly, statutory or judicial changes to the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. We may not be able to protect our intellectual property rights throughout the world. Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and 103 Â attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our business may be seriously harmed. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own, and if we license intellectual property we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with respect to any patents and patent applications that we license. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. Our business could be negatively impacted by corporate citizenship and ESG matters and/or our reporting of such matters. Institutional, individual, and other investors, proxy advisory services, regulatory authorities, consumers and other stakeholders are increasingly focused on environmental, social and governance (â€œESGâ€) practices of companies. As we look to respond to evolving standards for identifying, measuring, and reporting ESG metrics, our efforts may result in a significant increase in costs and may nevertheless not meet investor or other stakeholder expectations and evolving standards or regulatory requirements, which may negatively impact our financial results, our reputation, our ability to attract or retain employees, our attractiveness as an investment or business partner, or expose us to government enforcement actions, private litigation, and actions by stockholders or stakeholders. Â 104 Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Recent Sales of Unregistered Securities None. Use of Proceeds Not applicable. Item 3. Default Upon Senior Securities None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. During the fiscal quarter ended June 30, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any â€œnon-Rule 10b5-1 trading arrangement,â€ as defined in Item 408(a) of Regulation S-K. 105 Â Item 6. Exhibits Â Â Â Â Â Incorporated by Reference Â Â ExhibitNumber Â Exhibit Description Â Form Â Date Â Number Â FiledHerewith Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1.1 Â Sales Agreement, dated June 7, 2024, by and between the Company and Leerink Partners LLC Â 8-K Â 6/7/24 Â 1.1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.1 Â Amended and Restated Certificate of Incorporation, as currently in effect. Â 8-K Â 12/15/20 Â 3.1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.2 Â Amended and Restated Bylaws, as currently in effect. Â 8-K Â 11/22/23 Â 3.1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.1 Â Description of Securities of the Registrant. Â 10-K Â 3/15/23 Â 4.1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.2 Â Form of Common Stock Certificate. Â S-1/A Â 12/7/20 Â 4.2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.3 Â Form of Pre-Funded Warrant Â 8-K Â 2/9/2024 Â 4.1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 31.1 Â Certification of the Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â 31.2 Â Certification of the Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â 32.1* Â Certifications of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â 101.INS Â Inline XBRL Instance Document Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â 104 Â The cover page from the Companyâ€™s Quarterly Report on Form 10-Q for the three months ended June 30, 2024, has been formatted in Inline XBRL. Â Â Â Â Â Â Â XÂ * The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of 4D Molecular Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. 106 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. Â 4D Molecular Therapeutics, Inc. Date: August 8, 2024 By: /s/ David Kirn David Kirn, M.D. Chief Executive Officer and DirectorPrincipal Executive Officer Â Â Â Â Date: August 8, 2024Â By: /s/ Uneek Mehra Â Â Â Uneek Mehra Â Â Â Chief Financial and Business OfficerPrincipal Financial and Accounting Officer Â 107 EX-31.1 2 fdmt-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 Â CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, David Kirn, certify that: Â 1.I have reviewed this Quarterly Report on Form 10-Q of 4D Molecular Therapeutics, Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Â Dated: August 8, 2024 By: Â /s/ David Kirn Â Â David Kirn Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â EX-31.2 3 fdmt-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 Â CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Uneek Mehra, certify that: Â 1.I have reviewed this Quarterly Report on Form 10-Q of 4D Molecular Therapeutics, Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Â Dated: August 8, 2024 By: Â /s/ Uneek Mehra Â Â Uneek Mehra Â Â Chief Financial and Business Officer Â Â (Principal Financial and Accounting Officer) Â Â EX-32.1 4 fdmt-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 Â CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q (the â€œReportâ€) of 4D Molecular Therapeutics, Inc. (the â€œCompanyâ€) for the period ended June 30, 2024, David Kirn, as Chief Executive Officer of the Company, and Uneek Mehra, as Chief Financial Officer of the Company, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge: Â a)the Companyâ€™s Report for the period ended June 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â b)the

information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â  Dated: August 8, 2024 Â  By: /s/ David Kirn Â  David Kirn Â  Chief Executive Officer Â  (Principal Executive Officer) Â  Dated: August 8, 2024 Â  By: /s/ Uneek Mehra Â  Uneek Mehra Â  Chief Financial and Business Officer Â  (Principal Financial and Accounting Officer) Â  Â  EX-101.SCH 5 fdmt-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Accrued and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Research and Collaboration Arrangements link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - License Arrangements link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Net Loss Per Share, Basic and Diluted link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - 401(K) Plan link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Accrued and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Research and Collaboration Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Net Loss Per Share, Basic and Diluted (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - The Company - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Marketable Securities - Summary of Aggregate fair values of marketable securities with unrealized losses and gains (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Research and Collaboration Arrangements - Summary of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details 1) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details 1) [Default] link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1) [Default] link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - License Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Commitments and Contingencies- Summary of Components of Lease Expense - (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Commitments and Contingencies - Summary of Supplemental Information Related to Leases - (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Common Stock - Schedule of Common Share Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Stock-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Units (RSU) (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Common Stock Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - Net Loss Per Share, Basic and Diluted - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - Derivative Liability - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - 401(K) Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] uniQure Uni Qure Biopharma B V [Member] uniQure biopharma B.V. Plan Name Plan Name [Domain] Contingent payments development milestones. Contingent payments development milestones Contingent payments development milestones Issuance of common stock upon exercise of stock options and warrants. Issuance of Common Stock upon Exercise of Stock Options and Warrants Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Research and Development, Contract to Perform for Others [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue, Remaining Performance Obligation, Amount Aggregate amount of transaction price allocated to remaining performance obligation Remaining performance obligations Office Equipment Office Equipment [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: License Arrangements License Arrangements [Text Block] License arrangements. Other impairment charges related to marketable securities Other Impairment Charge Related To Marketable Securities Other impairment charge related to marketable securities. Revenue: Revenues [Abstract] Additional funding upon acceptance of investigational New Drug application Additional funding committed. Additional Funding Committed Number of Operating Segments Number of operating segments Percentage of maximum contributions of employee's eligible compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Shares, Outstanding Stockholders' Equity, beginning balances (in shares) Stockholders' Equity, ending balances (in shares) Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Area of office and warehouse space Area of Real Estate Property Number of installments to pay actual award Number Of Installments To Pay Actual Award Number of installments to pay actual award. Lease commencement date. Lease Commencement Date Lease commencement date UC Regents and the Trustees of the University of Pennsylvania U C Regents and the Trustees of the University of Pennsylvania [Member] U C Regents and the Trustees of the University of Pennsylvania [Member] Collaborative arrangement receive future option fees and milestones Collaborative Arrangement Receive Future Option Fees and Milestones Future option fees and milestones 2024 (remaining six months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Change in fair value of derivative liability Increase (Decrease) in Derivative Liabilities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Estimated fair value of derivative liability Derivative Liability, Subject to Master Netting Arrangement, before Offset Derivative Liability, Fair Value, Gross Liability, Total Amount paid non-refundable license fee Amounts Paid Non Refundable License Fees Amount paid non-refundable license fees. Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Summary of Changes in Fair Value of Level 3 Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Amended uniQure Agreement and Second uniQure Agreement Amended UniQure Agreement and Second UniQure Agreement [Member] Amended uniQure agreement and second uniQure agreement. Product and Service Product and Service [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Summary of Supplemental Information Related to Operating Leases Summary Of Supplemental Information Related to Operating Leases [Table Text Block] Summary of supplemental information related to operating leases Related Party Transaction [Line Items] Related Party Transaction [Line Items] Document Information [Table] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Common Stock Equity [Text Block] 5858 Horton Street Building Lease and 2024 Expansion Five Eight Five Eight Horton Street Building Lease and Two Thousand Twenty-Four Expansion [Member] Five eight five eight horton street building lease and two thousand twenty-four expansion. Class of Warrant or Right Class of Warrant or Right [Axis] Sale of Stock Sale of Stock [Domain] Summary of Aggregate Fair Values of Marketable Securities with Unrealized Losses and Gains Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Option exercise fees payable to releted party. Option Exercise Fees Payable to Releted Party Option exercise fee Entity Central Index Key Entity Central Index Key Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Common Stock Warrants Warrant [Member] Non-refundable license fee payable upon execution Non Refundable License Fee Payable Upon Execution Non-refundable license fee payable upon execution. Number of additional shares available for grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Available For Grant Share based compensation arrangement by share based payment award number of additional shares available for grant. Number of Shares Underlying Outstanding Options, forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Aggregate fair value of marketable securities in unrealized gain position Aggregate fair value of marketable securities in unrealized gain position Aggregate fair value of marketable securities in unrealized gain position. Changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Concentration Risk [Table] Concentration Risk [Table] Common Stock, Shares, Issued, Total Common stock, shares, issued Common Stock, Shares, Issued Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Lesae term extended period Lessee, Operating Lease, Remaining Lease Term Shared product designated by JSC. Shared Product Designated by JSC Shared product designated by JSC Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Issuance of common stock - 2020 ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock - 2020 ESPP Proceeds From Issuance of Employee Stock Plans Proceeds from issuance of employee stock plans. Class Of Warrant Or Right [Table] Class of Warrant or Right [Table] Percentage of equity interests issued as common stock Percentage Of Equity Interests Issued As Common Stock Percentage of equity interests issued as common stock. Concentration Risk Type Concentration Risk Type [Domain] Marketable Securities Total marketable securities Revenue included in deferred revenue at the beginning of the current year Contract with Customer, Liability, Revenue Recognized Revenue recognized Customer Customer [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Accrued clinical and preclinical study costs Accrued Clinical And Preclinical Study Costs Accrued clinical and preclinical study costs. Unpaid offering costs. Unpaid Offering Costs Unpaid offering costs Retirement Plan Name Retirement Plan Name [Domain] Liability Class Liability Class [Axis] Summary of Accrued and Other Current Liabilities Schedule Of Accrued And Other Current Liabilities [Table Text Block] Schedule of accrued and other current liabilities. Cover [Abstract] Net loss per share, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies line items. UC Agreements U C Agreements [Member] UC Agreements. Lease option to renew term description Lessee, Operating Lease, Option to Extend Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Februray two thousand and twenty four public offering sale. Februray Two Thousand and Twenty Four Public Offering Sale [Member] Februray 2024 Public Offering Sale Operating expenses: Operating Expenses [Abstract] Non-refundable license fee payable annually Amount Obligated To Pay Non Refundable License Fee Annually Amount obligated to pay a non-refundable license fee annually. Deferred revenue Contract with Customer, Liability, Current Amount due to related party Other Liabilities Other Liabilities, Total Option exercise fees per selected capsid payable to releted party. Option Exercise Fees Per Selected Capsid Payable To Releted Party Option exercise fees per selected capsid Investments, Debt and Equity Securities [Abstract] Derivative Liability Derivative Instruments and Hedging Activities Disclosure [Text Block] Expected payments multiples to equal actual award received Future Sales Based Milestone Payment Expected Payments Multiples of Actual Award Received Future sales based milestone payment expected payments multiples of actual award received. Share-Based Payment Arrangement, Expense Total stock-based compensation expense Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance

Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Contingent payments eliminated Contingent Payments Eliminated Contingent payments eliminated. Plan Name Plan Name [Axis] Number of Shares Underlying Outstanding Options, Balances at June 30, 2024 Number of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Shares Underlying Outstanding Options, Balances at December 31, 2023 Warrant expiration year Warrant Expires Year Warrant expires year. Current assets: Assets, Current [Abstract] Number of shares reserved for issuance Common stock reserved Common Stock, Capital Shares Reserved for Future Issuance UNITED STATES US United States Corporate bond. Corporate Bond [Member] Corporate Bonds Investment Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Arbor biotechnologies, inc. Arbor Biotechnologies, Inc. [Member] Arbor Biotechnologies Inc Product and Service Product and Service [Domain] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive gain (loss) Lease initial term Lessee, Operating Lease, Term of Contract Concentration Risk [Line Items] Concentration Risk [Line Items] Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Reignite Reignite Therapeutics Inc. [Member] Reignite Therapeutics Inc. [Member] Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value on Recurring Basis Fair Value, Recurring [Member] Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Upfront consideration payment. Upfront Consideration Payment Upfront consideration payment Common stock, par value Common Stock, Par or Stated Value Per Share Options Issued and Outstanding Net unrealized gain (loss) on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Contract with Customer, Liability, Total Deferred revenue Contract with Customer, Liability Total deferred revenue Statement of Cash Flows [Abstract] Counterparty Name Counterparty Name [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Astellas gene therapies inc Astellas Gene Therapies INC [Member] Astellas GeneTherapies Inc Warrant shares become exercisable Warrants shares exercised Warrants to purchase shares of common stock 5858 Horton Street Building Lease and 2019 Expansion Five Eight Five Eight Horton Street Building Lease and Two Thousand Nineteen Expansion [Member] Five eight five eight horton street building lease and two thousand nineteen expansion. Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Collaborative arrangement, initial research term Collaborative Arrangement Initial Research Term Collaborative arrangement, initial research term. Ordinary shares vesting period Vesting Period Of Share Awards Vesting period of share awards. Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Payroll and related expenses Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Issued Schedule of Concentration of Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Februray and March two thousand and twenty four public offering sale. Februray And March Two Thousand And Twenty Four Public Offering Sale [Member] February / March 2024 Public Offering Sale Computer Equipment and Software Computer Equipment [Member] Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Subsequent Event Type [Axis] Nonoperating Income (Expense) Total other income, net Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Additional investment in cash Additional investment in cash. Additional Investment in Cash Reignite agreement. Reignite Agreement [Member] Reignite Agreement Long-term marketable securities. Long-term Marketable Securities [Member] Long-term Marketable Securities Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] 2015 Equity Incentive Plan Two Thousand Fifteen Equity Incentive Plan [Member] Two thousand fifteen equity incentive plan. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Shares, Unvested Beginning Balance Number of Shares, Unvested Ending Balance Amendment Flag Amendment Flag Increase (Decrease) in Operating Lease Liability Operating lease liabilities Operating lease liabilities, long-term portion Operating Lease, Liability, Noncurrent Long-term portion of operating lease liabilities Corporate Debt Securities [Member] Corporate Bonds Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid-in-capital Additional Paid in Capital, Common Stock Incurred expenses Incurred Expenses Incurred expenses Sale of Stock, Price Per Share Common stock offering price Net loss Net loss Number of Shares Underlying Outstanding Options, exercised Issuance of common stock upon exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Related party expenses Operating Costs and Expenses Operating Costs and Expenses, Total Number of Shares Underlying Outstanding Options, Options exercisable at June 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Research and Development Research and Development Expense [Member] Customer Customer [Domain] Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] Organization And Nature Of Business [Table] Organization And Nature Of Business [Table] Organization and nature of business. General and Administrative Expense, Total General and administrative General and Administrative Expense Other income (expense), net Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Options exercisable period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Furniture and Fixtures Furniture and Fixtures [Member] Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Preferred stock, shares issued Preferred Stock, Shares Issued uniQure Agreement Uni Qure Agreement [Member] uniQure Agreement. Lessee, Operating Lease, Discount Rate Weighted-average discount rate Operating lease, discount rate Astellas Astellas [Member] Astellas. Payables and Accruals [Abstract] Issuance of common stock - 2020 ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Contract with Customer, Receivable, after Allowance for Credit Loss, Total Accounts receivable Contract with Customer, Receivable, after Allowance for Credit Loss Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock [Domain] Increase in shares available for issuance percentage Increase in Shares Available for Issuance Percentage Increase in shares available for issuance percentage. Research and Collaboration Arrangements Collaborative Arrangement Disclosure [Text Block] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares, outstanding Common Stock, Shares, Outstanding Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Percentage of common stock outstanding increased annually for future issuance Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Increased Annually For Future Issuance Share based compensation arrangement by share based payment award percentage of outstanding stock increased annually for future issuance. Collaborative arrangements special term Collaborative Arrangements Special Term Collaborative arrangements special term. Revenue Revenue Benchmark [Member] Antidilutive Securities Antidilutive Securities [Axis] Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of Restricted Stock Units (RSU) Entity Interactive Data Current Entity Interactive Data Current Liabilities, Level 1 and Level 2 transfers Fair Value Liabilities Level One And Level Two Transfers Amount Fair value liabilities level one and level two transfers amount. Lease extended term date Lease Expiration Date Derivative [Table] Derivative [Table] Document Quarterly Report Document Quarterly Report Related Party Transaction Related Party Transaction [Domain] Related Party Transactions Related Party Transactions Disclosure [Text Block] Statistical Measurement Statistical Measurement [Axis] Fair value of non monetary consideration of intellectual property right Fair Value Of Non Monetary Consideration Of Intellectual Property Right Fair value of non monetary consideration of intellectual property right. Operating Lease, Cost Operating Lease, Cost Operating lease cost Assets, Fair Value Disclosure, Total Assets Assets, Fair Value Disclosure Related Party Related and Nonrelated Parties [Domain] Lease, Cost Total Total Derivative Liability Derivative Financial Instruments, Liabilities [Member] Disaggregation of Revenue [Table Text Block] Summary of Collaboration and License Revenue Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Summary of Maturities of Lease Liabilities Commercial Paper [Member] Commercial Paper Number of Shares Available for Grant, Balances at December 31, 2022 Number of shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of Shares Available for Grant, Balances at June 30, 2023 Derivative [Line Items] Derivative [Line Items] Machinery and Equipment Machinery and Equipment [Member] Stock issued during period shares stock options exercised and vesting of restricted stock units. Stock Issued During Period Shares Stock Options Exercised And Vesting of Restricted Stock Units Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares) Contingent payments development milestones for initial target. Contingent Payments Development Milestones for Initial Target Contingent payments development milestones initial target Employer contribution Defined Benefit Plan, Plan Assets, Contributions by Employer Income Statement Location Statement of Income Location, Balance [Axis] Cystic Fibrosis Foundation Cystic Fibrosis Foundation [Member] Cystic Fibrosis Foundation [Member] Total assets Assets Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Vested Upfront payments received Collaboration Arrangements Upfront Payment Received Collaboration arrangements upfront payment received. New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Equity [Abstract] Payments Of Stock Issuance Costs Payment of ATM costs Payments of Stock Issuance Costs March two thousand and twenty four additiional public offering sale. March Two Thousand and Twenty Four Additiional Public Offering Sale [Member] March 2024 Additiional Public Offering Sale Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Canceled/Forfeited Canceled/Forfeited Derivative liability Derivative Liability, Noncurrent Depreciation, Total Depreciation expense Depreciation Warrant vesting period Warrant Vesting Period Warrant vesting period. Stock-based Compensation Share-Based Payment Arrangement [Text Block] License agreement with university of Pennsylvania. License Agreement With University Of Pennsylvania [Member] License Agreement for sCFH with University of Pennsylvania Construction in Progress Construction in Progress [Member] Number of shares authorized Number of shares authorized and reserved for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Contingent payments entitled to receive for achievement of research and development milestones Collaborative Arrangement Research And Development Milestones Entitled To Receive For Each Licensed Product Collaborative arrangement research and development milestones entitled to receive for each licensed product. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Number of Shares Underlying Outstanding Options, expired Number of Shares Underlying Outstanding Options, expired Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Fair Value Disclosures [Abstract] Option exercise fees payable to related party. Option Exercise Fees Payable to Related Party Option exercise fee Stock Issued During Period, Value, New Issues Issuance of common stock, net of issuance costs Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Current liabilities Liabilities, Current [Abstract] Lease Contractual Term [Axis] Accounts Receivable Accounts Receivable [Member] Document Type Document Type U.S. Government Sponsored Agencies US Government Agencies Debt Securities [Member] Number of warrant shares issued Number Of Warrant Shares Issued Number of warrant shares issued. Title of 12(b) Security Title of 12(b) Security Aggregate unrealized loss Aggregate Unrealized Loss Aggregate unrealized loss. Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Lease, Cost [Table Text Block] Summary of Components of Lease Expense Statement of Stockholders' Equity [Abstract] Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and Development Expense Research and development expenses Number of Shares Underlying Outstanding Options, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Asset Class Asset Class [Domain] Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Total property and equipment Property, Plant and Equipment, Gross Termination Date Subsequent Event Type [Domain] Warrant expense. Warrant Expense Warrant expense Two thousand twenty four follow on public offering. Two Thousand Twenty Four Follow On Public Offering [Member] 2024 Follow On Public Offering Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options Arbor agreement. Arbor Agreement [Member] Arbor Agreement Organization And Nature Of Business [Line Items] Organization And Nature Of Business [Line Items] Organization and nature of business. Percentage of equity interest upon closing of first qualified financing at option. Percentage of equity interest upon closing of first qualified financing at option Percentage of equity interest upon closing of first qualified financing at option of UC Regents Customer A Customer A [Member] Customer A. Aggregate fair value of marketable securities in a continuous loss position for more than twelve months Individual securities held in an unrealized loss position for 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Exercise price Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Deferred revenue, estimated performance period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Deferred revenue expected to be recognized over period Class Of Warrant Or Right [Line Items] Class of Warrant or Right [Line Items] Sale of Stock Sale of Stock [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Two Thousand Fourteen Plan [Member] Two thousand fourteen plan. 2014 401(k) Plan Investments [Domain] Marketable Securities, Current, Total Marketable Securities, Current Marketable securities Revenue from Contract with Customer, Excluding Assessed Tax, Total Collaboration and license revenue Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Retirement Plan Name Retirement Plan Name [Axis] Income Taxes Income Tax Disclosure [Text Block] Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Common stock overlapping offering period Share Based Compensation Arrangement By Share Based Payment Award Stock Overlapping Offering Period Share based compensation arrangement by share based payment award stock overlapping offering period. 2024 Expansion Two Thousand and Twenty Four Expansion [Member] 2024 Expansion Collaboration and License Agreements Collaboration and License Agreement [Member] Collaboration and License Agreement Expiration Date Debt Securities, Available-for-Sale [Table] Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Other accrued expenses Other Accrued Liabilities, Current Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Liabilities and Stockholdersâ€™ Equity Liabilities and Equity [Abstract] Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Other Risks and Uncertainties Other Risks And Uncertainties Policy Policy [Text Block] Other risks and uncertainties. Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share based compensation arrangement by share based payment award number of duration purchase period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Duration Purchase Period Number of duration purchase period APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Investment in redeemable convertible preferred stock financing Sale of Stock, Consideration Received on Transaction Accrued Liabilities, Current Accrued and other current liabilities Total accrued and other current liabilities Deferred Revenue, Total Deferred revenue Deferred Revenue 2020 Equity Incentive Award Plan Two Thousand Twenty Equity Incentive Award Plan [Member] Two thousand twenty equity incentive award plan. Provision for income tax Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Debt Securities, Available-for-Sale [Abstract] Maturity period of marketable securities Debt Securities, Available-for-Sale, Term Customer C Customer C [Member] Customer C Vesting of common stock warrant in return for services Vesting Of Common Stock Warrant In Return For Services Vesting of common stock warrant in return for services. Trading Symbol Trading Symbol Total stockholdersâ€™ equity Equity, Attributable to Parent Stockholders' Equity, beginning balances Stockholders' Equity, ending balances Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Pre-funded warrants. Pre-funded Warrants [Member] Pre-funded Warrants Total other liabilities, noncurrent Other

liabilities Other Liabilities, Noncurrent Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSU) Restricted Stock Units Subject to Future Vesting Related Party Transactions [Abstract] Continuous period where the Company ceases to develop or commercialize any product Continuous Period Where Company Ceases To Develop Or Commercialize Any Product Continuous period where the Company ceases to develop or commercialize any product. Variable Lease, Cost Variable Lease, Cost Variable lease cost Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Vesting of common stock warrants Adjustments To Additional Paid In Capital Vesting Of Stock Warrant Issued For Services Adjustments to additional paid in capital vesting of stock warrant issued for services. Vesting of common stock warrants issued for services Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function Change in fair value included in other income (expense), net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Equipment costs. Equipment Costs Equipment costs Geographical Geographical [Axis] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Use of Estimates and Judgements Use of Estimates, Policy [Policy Text Block] Number of capsids. Number of Capsids Number of capsids Summary of Deferred Revenue Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Common Stock Warrants Common Stock Warrants [Text Block] Common stock warrants. Concentration risk, percentage Concentration Risk, Percentage Class Of Stock [Line Items] Class of Stock [Line Items] Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Security Exchange Name Security Exchange Name Counterparty Name Counterparty Name [Domain] Dividends, Common Stock, Total Common stock dividend Dividends, Common Stock Fair Value by Liability Class Fair Value by Liability Class [Domain] Total operating expenses Operating Expenses Schedule of Revenues by Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Exercise of options issued and outstanding and future vesting of restricted stock units. Employee Options Issued and Outstanding and Future Vesting of Restricted Stock Units [Member] Exercise of Options Issued and Outstanding and Future Vesting of Restricted Stock Units Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Class of Stock [Axis] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Fair Value Measurements Fair Value Disclosures [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Assets, Level 1 and Level 2 transfers Fair Value Assets Level One And Level Two Transfers Amount Fair value assets level one and level two transfers amount. Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Subsequent Event Subsequent Event [Member] Maximum Maximum [Member] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Operating lease, right-of-use assets Operating lease right-of-use assets, net Operating lease right-of-use ("ROU") assets Financial Liabilities Fair Value Disclosure, Total Liabilities Financial Liabilities Fair Value Disclosure Retirement Benefits [Abstract] Net loss per share, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Leasehold Improvements Leasehold Improvements [Member] Entity Ex Transition Period Entity Ex Transition Period Warehouse lease agreement. Warehouse Lease Agreement [Member] Warehouse Lease Agreement Fair value of options Fair Value Of Options Fair value of options. Total liabilities Liabilities Common stock voting rights Common Stock, Voting Rights Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Collaboration and License Revenue Collaboration And License Revenue [Member] Collaboration and License Revenue. Future sales-based milestone payments multiples Collaborative Arrangements Future Sales Based Milestone Payment Multiples Collaborative arrangements future sales based milestone payment multiples. Issuance of common stock for the ATM offering program, net of issuance costs (in shares) Number of shares sold and issued Issuance of common stock, net of issuance costs (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Lease existence of option to renew term Lessee, Operating Lease, Existence of Option to Extend [true false] Entity Filer Category Entity Filer Category Property, Plant and Equipment [Abstract] Collaborative arrangement achieved milestones Collaborative Arrangement Achieved Milestones Collaborative arrangement achieved milestones. The Company Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Payments to Acquire Marketable Securities Payments to Acquire Marketable Securities, Total Purchase of marketable securities Purchase of marketable securities Other income (expense): Nonoperating Income (Expense) [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Amount representing interest Less: Amount representing interest Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Related Party Transaction Related Party Transaction [Axis] 2021 Follow On Public Offering Two thousand Twenty One Follow On Public Offering [Member] Two thousand twenty one follow on public offering Related Party Related and Nonrelated Parties [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Entity Registrant Name Entity Registrant Name CFF Agreement Cystic Fibrosis Foundation Agreement [Member] Cystic Fibrosis Foundation Agreement. Number of Reportable Segments Number of reportable segments Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Loss Per Share, Basic and Diluted Earnings Per Share [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Money Market Funds Money Market Funds [Member] Weighted-average shares outstanding used in computing net loss per share, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Schedule of common shares reserved for future issuance [Table Text Block] Schedule Of Common Shares Reserved For Future Issuance [Table Text Block] Schedule of Common Shares Reserved for Future Issuance Research And Collaboration Arrangements [Abstract] Research and Collaboration Arrangements. Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Common stock, shares authorized Common Stock, Shares Authorized Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs Proceeds from Issuance of Common Stock Issuance of common stock upon public offering, net of issuance costs Issuance of common stock for the offering program, net of issuance costs Proceeds from Sale and Maturity of Marketable Securities, Total Proceeds from Sale and Maturity of Marketable Securities Maturities of marketable securities 2023 Follow On Public Offering Two Thousand Twenty Three Follow On Public Offering [Member] Two thousand twenty three follow on public offering. Concentration Risk Type Concentration Risk Type [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Financial Instrument [Axis] Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones. Potential Cash Payment Upon Achievement Of Certain Late Stage Development Regulatory And Sales Milestones Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones Change in control event percentage Fair Value Assumptions Probability Of Change In Control Event Percentage Fair value assumptions probability of change in control event percentage. General and Administrative General and Administrative Expense [Member] Share-Based Payment Arrangement [Abstract] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Proceeds from Issuance of Warrants Issuance of pre-funded warrants Debt Securities, Available-for-Sale Debt Securities, Available-for-sale, Total Fair Value Accounting Policies [Abstract] Summary of Stock Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Amount obligated to pay upon closing first qualified financing at option of UC Regents Amount Obligated To Pay Upon Closing First Qualified Financing At Option Amount obligated to pay upon closing first qualified financing at option. 5980 Horton Street Building Lease Five Nine Eight Zero Horton Street [Member] 5980 Horton Street. Income Tax Disclosure [Abstract] Marketable Securities, Noncurrent, Total Marketable Securities, Noncurrent Marketable securities, long-term Stockholdersâ€™ equity Equity, Attributable to Parent [Abstract] Class of warrants expense. Class Of Warrants Expense Warrant expense recognized Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosures of noncash investing and financing information Maximum unrealized loss at individual instrument level Maximum Unrealized Loss at Individual Instrument Level Maximum unrealized loss at individual instrument level. Aevitas therapeutics, Inc. agreement. Aevitas Therapeutics Inc Agreement [Member] Aevitas Therapeutics, Inc. Agreement Statement [Table] Statement [Table] Segment Information Segment Reporting, Policy [Policy Text Block] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment and contingencies. Series C Redeemable Convertible Preferred Stock. Series C Redeemable Convertible Preferred Stock [Member] Series C Redeemable Convertible Preferred Stock Preferred stock, shares authorized Preferred Stock, Shares Authorized Entity File Number Securities Act File Number Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Earnings Per Share [Abstract] Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Initial Public Offering IPO [Member] Loss from operations Operating Income (Loss) Amended uniQure Agreement Amended Uni Qure Agreement [Member] Amended uniQure agreement. Stock sold and issued price per share Shares Issued, Price Per Share Stock issued price per share Entity Shell Company Entity Shell Company Change of control payment Fair Value Assumptions Change Of Control Payment Fair value assumptions change of control payment. Consulting and professional Accrued Professional Fees, Current Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Class of Warrant or Right Class of Warrant or Right [Domain] Entity Current Reporting Status Entity Current Reporting Status Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic, Total Net loss Research And Development Arrangement Contract To Perform For Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Realized gains or losses on marketable securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Debt Securities, Available-for-Sale, Realized Gain (Loss), Total Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Accrued and Other Current Liabilities Accrued And Other Current Liabilities [Text Block] Accrued and other current liabilities. Geographical Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Certificates of Deposit [Member] Certificates of Deposit Asset Acquisition, Contingent Consideration, Liability, Total Asset Acquisition, Contingent Consideration, Liability Liability related to contingent consideration Preferred stock, $0.0001 par value, 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Change in control discount rate Fair Value Assumptions Probability Of Change In Control Discount Rate Fair value assumptions probability of change in control discount rate. Purchases of property and equipment in accounts payable and accrued and other liabilities Capital Expenditures Incurred but Not yet Paid Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations City Area Code City Area Code Total current liabilities Liabilities, Current 4D Molecular Therapeutics. 4D Molecular Therapeutics [Member] 4DMT Public Offering. Public Offering [Member] Public offering Actual award payment period upon first commercial sale of product Actual Award Payment Period Upon First Commercial Sale Of Product Actual award payment period upon first commercial sale of product. 401(K) Plan Defined Contribution Plan [Text Block] Tenant improvement allowance Proceeds From Tenant Improvement Allowance Proceeds from tenant improvement allowance. Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number License Arrangements [Abstract] License arrangements. Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stock issued during period value stock options exercised and vesting of restricted stock units. Stock Issued During Period Value Stock Options Exercised And Vesting of Restricted Stock Units Issuance of common stock upon exercise of stock options and vesting of RSUs Commitments and Contingencies Disclosure [Abstract] Number of shares priced under public offering Shares, Issued Shares, Issued, Beginning Balance Shares, Issued, Ending Balance Debt Securities, Available-for-sale, Amortized Cost Amortized Cost Basis Operating lease liabilities, current portion Operating Lease, Liability, Current Less: Current portion of operating lease liabilities Document Information [Line Items] Number shares issued upon conversion of redeemable convertible preferred shares Convertible Preferred Stock, Shares Issued upon Conversion Accumulated Deficit Retained Earnings [Member] Defined Contribution Plan [Table] Defined Contribution Plan [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. Over-Allotment Option [Member] Exercise of Overallotment Option Payments to Acquire Property, Plant, and Equipment, Total Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Document Transition Report Document Transition Report Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Employee purchase price of common stock as percentage of fair market value Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Building lease. Building Lease [Member] 5980 Horton Street Building Lease Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Minimum Minimum [Member] Minimum [Member] Numerator Earnings Per Share Reconciliation [Abstract] Common Stock Common Stock [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Other assets Other assets Increase (Decrease) in Other Noncurrent Assets Operating Lease, Right-of-Use Asset, Periodic Reduction Amortization of right-of-use assets Additional Paid-in Capital Additional Paid-in Capital [Member] Short-term marketable securities. Short-term Marketable Securities [Member] Short-term Marketable Securities Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment and contingencies. Other Assets, Noncurrent, Total Other assets Other Assets, Noncurrent ATM offering program. ATM Offering Program Atm offering program ATM Offering Program [Member] Customer B Customer B [Member] Customer B. Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties Non Refundable License Fee Payable Every Year After Execution Non-refundable license fee payable every year after execution until sales of a licensed product are made and royalties paid. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Aggregate fair value of securities held in a continuous unrealized loss position for less than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Basis of Presentation Basis of Accounting, Policy [Policy Text Block] ATM offering costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total Common stock, $0.0001 par value, 300,000,000 shares authorized at June 30, 2024 and December 31, 2023; 51,914,275 and 43,075,218 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Investment Income, Interest Interest income Option exercise fees per selected capsid payable to related party. Option Exercise Fees Per Selected Capsid Payable To Related Party Option exercise fees per selected capsid Royalties multiples on actual award received Collaborative Arrangement Royalties Multiples On Actual Award Received Collaborative arrangement royalties multiples on actual award received. Operating Lease, Liability Present value of future minimum lease payments Operating lease liability Present value of future minimum lease payments Debt Securities, Available-for-Sale [Table Text Block] Summary of Available for Sale Securities Measurement Frequency Measurement Frequency [Axis] Commitments and Contingencies Commitments and contingencies (Note 9) Weighted-average shares outstanding used in computing net loss per share, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Research and Development Expense (Excluding Acquired in Process Cost) Research and development Accounts Receivable, after

Allowance for Credit Loss, Current, Total Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Lease renewal term Lessee, Operating Lease, Renewal Term Number of Shares Underlying Outstanding Options, Options vested and expected to vest at June 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Lessee, Operating Lease, Liability, to be Paid Total future minimum lease payments Future minimum lease payments 5858 Horton Street Building Lease and Expansion Five Eight Five Eight Horton Street Building Lease and Expansion [Member] Five eight five eight horton street building lease and expansion. Denominator Weighted Average Number of Shares Outstanding, Diluted [Abstract] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Entity Small Business Entity Small Business Total revenue Revenues Total revenue Revenues US Treasury Securities [Member] U.S. Treasuries Total amount of award under agreement. Total Amount Of Award Under Agreement Collaborative arrangement total amount of award Annual royalty Annual Royalty Annual royalty. Funding Agreement Funding Agreement [Member] Funding agreement. Options to purchase ordinary shares Options To Purchase Ordinary Shares Options to purchase ordinary shares. Accretion (Amortization) of Discounts and Premiums, Investments Net amortization (accretion) of premium (discount) on marketable securities Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Thereafter Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Asset Class Asset Class [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] 2020 Employee Stock Purchase Plan 2020 ESPP Two Thousand Twenty Employee Stock Purchase Plan [Member] Two thousand twenty employee stock purchase plan. Lease extended term period Operating Lease Term Extended Expiration Period Operating lease term extended expiration period. Measurement Frequency Measurement Frequency [Domain] Credit Concentration Risk Credit Concentration Risk [Member] Temporary Equity, Shares Outstanding Outstanding shares of redeemable convertible preferred stock Redeemable Convertible Preferred Stock, beginning balances (in shares) Redeemable Convertible Preferred Stock, ending balances (in shares) Level 3 Fair Value, Inputs, Level 3 [Member] Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Due to/from customer Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Customer Member Customer. Customer Netherlands NETHERLANDS Increase (Decrease) in Accrued Liabilities, Total Accrued and other liabilities Increase (Decrease) in Accrued Liabilities XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 02, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Document Quarterly Report true Â Document Transition Report false Â Entity Registrant Name 4D Molecular Therapeutics, Inc. Â Entity Central Index Key 0001650648 Â Entity Current Reporting Status Yes Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Shell Company false Â Entity Interactive Data Current Yes Â Entity File Number 001-39782 Â Entity Tax Identification Number 47-3506994 Â Entity Address, Address Line One 5858 Horton Street #455 Â Entity Address, City or Town Emeryville Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94608 Â City Area Code (510) Â Local Phone Number 505-2680 Â Entity Incorporation, State or Country Code DE Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol FDMT Â Security Exchange Name NASDAQ Â Pre-funded Warrants [Member] Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 3,583,476 Common Stock [Member] Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 51,969,590 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=fdmt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 189,061 $ 249,108 Marketable securities 352,885 39,124 Prepaid expenses and other current assets 10,687 8,356 Total current assets 552,633 296,588 Marketable securities, long-term 35,715 10,954 Property and equipment, net 18,761 20,126 Operating lease right-of-use assets, net 10,688 11,539 Other assets 2,320 684 Total assets 620,117 339,891 Current liabilities Â Â Accounts payable 3,431 3,515 Accrued and other current liabilities 12,776 12,014 Deferred revenue 0 273 Operating lease liabilities, current portion 3,196 3,149 Total current liabilities 19,403 18,951 Deferred revenue, net of current portion 1,318 972 Derivative liability 382 369 Operating lease liabilities, long-term portion 10,460 11,522 Other liabilities 214 248 Total liabilities 31,777 32,062 Commitments and contingencies (Note 9) Stockholdersâ€™ equity Â Â Preferred stock, $0.0001 par value, 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 0 0 Common stock, $0.0001 par value, 300,000,000 shares authorized at June 30, 2024 and December 31, 2023; 51,914,275 and 43,075,218 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 5 4 Additional paid-in-capital 1,071,309 723,136 Accumulated other comprehensive gain (loss) (293) 16 Accumulated deficit (482,681) (415,327) Total stockholdersâ€™ equity 588,340 307,829 Total liabilities and stockholdersâ€™ equity $ 620,117 $ 339,891 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-

gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name

Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â  Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares, issued 51,914,275 43,075,218 Common stock, shares, outstanding 51,914,275 43,075,218 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue: Â Â Â Â Collaboration and license revenue $ 5 $ 239 $ 33 $ 538 Operating expenses: Â Â Â Â Research and development 31,860 23,584 59,727 46,002 General and administrative 10,601 8,791 20,898 16,777 Total operating expenses 42,461 32,375 80,625 62,779 Loss from operations (42,456) (32,136) (80,592) (62,241) Other income (expense): Â Â Â Â Interest income 7,548 2,512 13,293 3,955 Other income (expense), net (45) 8 (55) (12) Total other income, net 7,503 2,520 13,238 3,943 Net loss $ (34,953) $ (29,616) $ (67,354) $ (58,298) Net loss per share, basic $ (0.63) $ (0.77) $ (1.29) $ (1.63) Net loss per share, diluted $ (0.63) $ (0.77) $ (1.29) $ (1.63) Weighted-average shares outstanding used in computing net loss per share, basic 55,282,754 38,335,219 52,277,369 35,661,995 Weighted-average shares outstanding used in computing net loss per share, diluted 55,282,754 38,335,219 52,277,369 35,661,995 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to

nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Â Net loss $ (34,953) $ (29,616) $ (67,354) $ (58,298) Other comprehensive loss: Â Â Â Â Â Net unrealized gain (loss) on marketable securities (184) 615 (309) 1,541 Total comprehensive loss $ (35,137) $ (29,001) $ (67,663) $ (56,757) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total ATM Offering Program Public offering February / March 2024 Public Offering Sale Common Stock Common Stock ATM Offering Program Common Stock Public offering Common Stock February / March 2024 Public Offering Sale Additional Paid-in Capital Additional Paid-in Capital ATM Offering Program Additional Paid-in Capital Public offering Additional Paid-

in Capital February / March 2024 Public Offering Sale Accumulated Other Comprehensive Loss Accumulated Deficit Stockholders' Equity, beginning balances at Dec. 31, 2022 $ 231,337 Â Â Â $ 3 Â Â Â $ 547,020 Â Â Â $ (1,196) $ (314,490) Stockholders' Equity, beginning balances (in shares) at Dec. 31, 2022 Â Â Â Â 32,626,627 Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of stock options 1,135 Â Â Â Â Â Â Â 1,135 Â Â Â Â Â Â Issuance of common stock upon exercise of stock options (in shares) Â Â Â Â 122,207 Â Â Â Â Â Â Â Â Â Issuance of common stock, net of issuance costs Â $ 9,647 Â Â Â Â Â Â Â $ 9,647 Â Â Â Â Issuance of common stock, net of issuance costs (in shares) Â Â Â Â Â 487,934 Â Â Â Â Â Â Â Â Stock-based compensation expense 4,221 Â Â Â Â Â Â Â 4,221 Â Â Â Â Â Vesting of common stock warrants issued for services 22 Â Â Â Â Â Â Â 22 Â Â Â Â Â Net unrealized gain (loss) on marketable securities 926 Â Â Â Â Â Â Â Â Â Â 926 Â Net loss (28,682) Â Â Â Â Â Â Â Â Â Â (28,682) Stockholders' Equity, ending balances at Mar. 31, 2023 218,606 Â Â Â $ 3 Â Â Â 562,045 Â Â Â (270) (343,172) Stockholders' Equity, ending balances (in shares) at Mar. 31, 2023 Â Â Â Â 33,236,768 Â Â Â Â Â Â Â Â Stockholders' Equity, beginning balances at Dec. 31, 2022 231,337 Â Â Â $ 3 Â Â Â 547,020 Â Â Â (1,196) (314,490) Stockholders' Equity, beginning balances (in shares) at Dec. 31, 2022 Â Â Â Â 32,626,627 Â Â Â Â Â Â Â Â Net unrealized gain (loss) on marketable securities 1,541 Â Â Â Â Â Â Â Â Â Â 1,541 Â Net loss (58,298) Â Â Â Â Â Â Â Â Â Â (58,298) Stockholders' Equity, ending balances at Jun. 30, 2023 325,144 Â Â Â $ 4 Â Â Â 345 (372,788) Stockholders' Equity, ending balances (in shares) at Jun. 30, 2023 Â Â Â Â 42,016,622 Â Â Â Â Â Â Â Â Stockholders' Equity, beginning balances at Mar. 31, 2023 218,606 Â Â Â $ 3 Â Â Â 562,045 Â Â Â (270) (343,172) Stockholders' Equity, beginning balances (in shares) at Mar. 31, 2023 Â Â Â Â 33,236,768 Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of stock options 894 Â Â Â Â Â Â Â 894 Â Â Â Â Â Issuance of common stock upon exercise of stock options (in shares) Â Â Â Â 72,217 Â Â Â Â Â Â Â Â Issuance of common stock, net of issuance costs Â Â $ 129,208 Â Â Â $ 1 Â Â Â $ 129,207 Â Â Â Issuance of common stock, net of issuance costs (in shares) Â Â Â Â Â 8,625,000 Â Â Â Â Â Â Issuance of common stock - 2020 ESPP 658 Â Â Â Â Â Â Â 658 Â Â Â Â Â Issuance of common stock - 2020 ESPP (in shares) Â Â Â Â 82,637 Â Â Â Â Â Â Â Â ATM offering costs Â (212) Â Â Â Â Â Â Â (212) Â Â Â Â Stock-based compensation expense 4,969 Â Â Â Â Â Â Â 4,969 Â Â Â Â Â Vesting of common stock warrants issued for services 22 Â Â Â Â Â Â Â 22 Â Â Â Â Â Net unrealized gain (loss) on marketable securities 615 Â Â Â Â Â Â Â Â Â Â 615 Â Net loss (29,616) Â Â Â Â Â Â Â Â Â Â (29,616) Stockholders' Equity, ending balances at Jun. 30, 2023 325,144 Â Â Â $ 4 Â Â Â 697,583 Â Â Â 345 (372,788) Stockholders' Equity, ending balances (in shares) at Jun. 30, 2023 Â Â Â Â 42,016,622 Â Â Â Â Â Â Â Â Stockholders' Equity, beginning balances at Dec. 31, 2023 307,829 Â Â Â $ 4 Â Â Â 723,136 Â Â Â 16 (415,327) Stockholders' Equity, beginning balances (in shares) at Dec. 31, 2023 Â Â Â Â 43,075,218 Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of stock options and vesting of RSUs 3,113 Â Â Â Â Â Â Â 3,113 Â Â Â Â Â Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares) Â Â Â Â 236,856 Â Â Â Â Â Â Â Â Issuance of common stock, net of issuance costs Â Â Â $ 316,149 Â Â Â $ 1 Â Â Â $ 316,148 Â Â Â Issuance of common stock, net of issuance costs (in shares) Â Â Â Â Â Â Â 7,845,314 Â Â Â Â Â Â Â Stock-based compensation expense 5,974 Â Â Â Â Â Â Â 5,974 Â Â Â Â Â Vesting of common stock warrants issued for services 22 Â Â Â Â Â Â Â 22 Â Â Â Â Â Net unrealized gain (loss) on marketable securities (125) Â Â Â Â Â Â Â Â Â Â (125) Â Net loss (32,401) Â Â Â Â Â Â Â Â Â Â (32,401) Stockholders' Equity, ending balances at Mar. 31, 2024 600,561 Â Â Â $ 5 Â Â Â 1,048,393 Â Â Â (109) (447,728) Stockholders' Equity, ending balances (in shares) at Mar. 31, 2024 Â Â Â Â 51,157,388 Â Â Â Â Â Â Â Â Stockholders' Equity, beginning balances at Dec. 31, 2023 $ 307,829 Â Â Â $ 4 Â Â Â 723,136 Â Â Â 16 (415,327) Stockholders' Equity, beginning balances (in shares) at Dec. 31, 2023 Â Â Â Â 43,075,218 Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of stock options (in shares) 296,183 Â Â Â Â Â Â Â Â Net unrealized gain (loss) on marketable securities $ (309) Â Â Â Â Â Â Â Â Â Â Net loss (67,354) Â Â Â Â Â Â Â Â Â Â Stockholders' Equity, ending balances at Jun. 30, 2024 588,340 Â Â Â $ 5 Â Â Â 1,071,309 Â Â Â (293) (482,681) Stockholders' Equity, ending balances (in shares) at Jun. 30, 2024 Â Â Â Â 51,914,275 Â Â Â Â Â Â Â Â Stockholders' Equity, beginning balances at Mar. 31, 2024 600,561 Â Â Â $ 5 Â Â Â 1,048,393 Â Â Â (109) (447,728) Stockholders' Equity, beginning balances (in shares) at Mar. 31, 2024 Â Â Â Â 51,157,388 Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of stock options and vesting of RSUs 850 Â Â Â Â Â Â Â 850 Â Â Â Â Â Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares) Â Â Â Â 81,290 Â Â Â Â Â Â Â Â Issuance of common stock, net of issuance costs Â $ 15,263 Â Â Â Â Â Â $ 15,263 Â Â Â Â Issuance of common stock, net of issuance costs (in shares) Â Â Â Â 585,938 Â Â Â Â Â Â Â Â Issuance of common stock - 2020 ESPP 707 Â Â Â Â Â Â Â 707 Â Â Â Â Â Issuance of common stock - 2020 ESPP (in shares) Â Â Â Â 89,659 Â Â Â Â Â Â Â Â Stock-based compensation expense 6,074 Â Â Â Â Â Â Â 6,074 Â Â Â Â Â Vesting of common stock warrants issued for services 22 Â Â Â Â Â Â Â 22 Â Â Â Â Â Net unrealized gain (loss) on marketable securities (184) Â Â Â Â Â Â Â Â Â Â (184) Â Net loss (34,953) Â Â Â Â Â Â Â Â Â Â (34,953) Stockholders' Equity, ending balances at Jun. 30, 2024 $ 588,340 Â Â Â $ 5 Â Â Â $ 1,071,309 Â Â Â $ (293) $ (482,681) Stockholders' Equity, ending balances (in shares) at Jun. 30, 2024 Â Â Â Â 51,914,275 Â Â Â Â Â Â Â Â X - DefinitionAdjustments to additional paid in capital vesting of stock warrant issued for services. + ReferencesNo definition available. + Details Name: fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period shares stock options exercised and vesting of restricted stock units. + ReferencesNo definition available. + Details Name: fdmt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfRestrictedStockUnits Namespace Prefix: fdmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value stock options exercised and vesting of restricted stock units. + ReferencesNo definition available. + Details Name: fdmt_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStockUnits Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 +

Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities Â Â  Net loss $ (67,354) $ (58,298) Adjustments to reconcile net loss to net cash used in operating activities Â Â  Stock-based compensation expense 12,048 9,190 Vesting of common stock warrant in return for services 44 44 Change in fair value of derivative liability 13 0 Depreciation and amortization 2,367 2,108 Amortization of right-of-use assets 851 732 Net amortization (accretion) of premium (discount) on marketable securities (3,092) (615) Changes in operating assets and liabilities Â Â  Prepaid expenses and other current assets (2,330) (475) Other assets (1,636) 0 Accounts payable (83) 614 Accrued and other liabilities 785 (2,239) Deferred revenue 72 (538) Operating lease liabilities (1,016) (494) Net cash used in operating activities (59,331) (49,971) Cash flows from investing activities Â Â  Purchase of marketable securities (374,084) (20,156) Maturities of marketable securities 38,346 114,391 Acquisition of property and equipment (1,059) (1,817) Net cash provided by (used in) investing activities (336,797) 92,418 Cash flows from financing activities Â Â  Issuance of Common Stock upon Exercise of Stock Options and Warrants 3,963 2,029 Issuance of common stock - 2020 ESPP 707 658 Net cash provided by financing activities 336,081 141,513 Net increase (decrease) in cash and cash equivalents (60,047) 183,960 Cash and cash equivalents, beginning of period 249,108 52,351 Cash and cash equivalents, end of period 189,061 236,311 Supplemental disclosures of noncash investing and financing information Â Â  Unpaid offering costs 0 183 Purchases of property and equipment in accounts payable and accrued and other liabilities 177 312 Public offering Â Â  Cash flows from financing activities Â Â  Issuance of common stock for the offering program, net of issuance costs 316,148 129,720 Payments Of Stock Issuance Costs 0 (329) ATM Offering Program Â Â  Cash flows from financing activities Â Â  Issuance of common stock for the offering program, net of issuance costs 15,263 9,647 Payments Of Stock Issuance Costs $ 0 $ (212) X - DefinitionIssuance of common stock upon exercise of stock options and warrants. + ReferencesNo definition available. + Details Name: fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of employee stock plans. + ReferencesNo definition available. + Details Name: fdmt_ProceedsFromIssuanceOfEmployeeStockPlans Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnpaid offering costs. + ReferencesNo definition available. + Details Name: fdmt_UnpaidOfferingCosts Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionVesting of common stock warrant in return for services. + ReferencesNo definition available. + Details Name: fdmt_VestingOfCommonStockWarrantInReturnForServices Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards

Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-

gaap_SubsidiarySaleOfStockAxis=fdmt_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fdmt_AtmOfferingProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Net Income (Loss) $ (34,953) $ (32,401) $ (29,616) $ (28,682) $ (67,354) $ (58,298) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef - Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 The Company 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â The Company 1. The Company 4D Molecular Therapeutics, Inc. (the â€œCompanyâ€) was formed as a limited liability company in September 2013 under the name 4D Molecular Therapeutics, LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware in March 2015. The Company is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. Initial Public OfferingIn December 2020, the Company sold and issued 9,660,000 shares of common stock at a price to the public of $23.00 per share, which included shares sold upon the underwritersâ€™ exercise of their overallotment option to purchase 1,260,000 additional shares. The Company received an aggregate of $204.7 million in net proceeds, after deducting underwriting discounts and commissions and offering costs.Upon the closing of the Company's initial public offering in December 2020 (the "IPO"), all outstanding shares of redeemable convertible preferred stock automatically converted into 11,575,984 shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.2021 Follow On Public OfferingIn November 2021, the Company completed an underwritten public offering ("2021 Offering") in which 4,750,000 shares of the Company's common stock were sold at an offering price of $25.00 per share pursuant to an effective Registration Statement on Form S-1. The net proceeds from the 2021 Offering were $111.1 million, after deducting underwriting discounts and commissions and offering expenses. 2023 Follow On Public Offering In May 2023, the Company completed its third underwritten public offering (the â€œ2023 Offeringâ€) in which 8,625,000 shares of the Companyâ€™s common stock were sold at an offering price of $16.00 per share pursuant to an effective Registration Statement on Form S-3. The net proceeds from the 2023 Offering were $129.2 million, after deducting underwriting discounts and commissions and offering expenses. 2024 Follow On Public Offering In February 2024, the Company completed an underwritten public offering (the â€œ2024 Offeringâ€) in which 6,586,015 shares of the Companyâ€™s common stock were sold at an offering price of $29.50 per share, as well as pre-funded warrants to purchase 3,583,476 shares of the Companyâ€™s common stock at an offering price of $29.4999 per underlying share pursuant to an effective Registration Statement on Form S-3. The net proceeds from the 2024 Offering were $281.2 million, after deducting underwriting discounts and commissions and other offering expenses. The Company also granted the underwriters the option to purchase up to 1,525,423 additional shares of common stock in connection with the offering.In March 2024, the underwriters exercised their option to purchase 1,259,299 additional shares of common stock resulting in net proceeds of $34.9 million, after deducting commissions.LiquidityThe Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $482.7 million as of June 30, 2024. The Company believes that its cash and cash equivalents and marketable securities as of June 30, 2024 are sufficient for the Company to fund planned operations for at least one year from the issuance date of these unaudited condensed financial statements. The Company has historically financed its operations primarily through the sale of equity securities, and to a lesser extent, from cash received pursuant to its collaboration and license agreements. To date, none of the Companyâ€™s product candidates have been approved for sale, and therefore, the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows from operations to continue for the foreseeable future. The Company plans to raise additional funding as required based on the status of its clinical trials and projected cash flows. There can be no assurance that, in the event the Company requires additional financing, such financing will be available on terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Companyâ€™s ability to achieve its business objectives. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (â€œU.S. GAAPâ€) and the rules and regulations of the United States Securities and Exchange Commission (â€œSECâ€) for interim reporting.Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC.The accompanying financial information for the three and six months ended June 30, 2024 and 2023 is unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Companyâ€™s financial position as of June 30, 2024 and December 31, 2023 and its results of operations and cash flows for the six months ended June 30, 2024 and 2023. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods.Use of Estimates and JudgmentsThe preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and the derivative instrument and income tax uncertainties. Actual results could differ from those estimates. Due to the war in Ukraine, conflicts in the Middle East, rising interest rates and inflation, and the lingering impacts of the coronavirus (â€œCOVID-19â€) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2024. While there was not a material impact to the Companyâ€™s unaudited condensed financial statements as of June 30, 2024, these estimates may change, as new events occur and additional information is obtained, as well as other factors that could result in material impacts to the unaudited condensed financial statements in future reporting periods. Segment Information The Company operates and manages its business as one reportable and operating segment. The Companyâ€™s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and

accounts receivable. The Companyâ€™s cash is held at two financial institutions in the United States of America. The Companyâ€™s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, U.S. government sponsored agencies, commercial paper, corporate bonds and certificates of deposit. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits. The Companyâ€™s partners in collaboration and license agreements who represent 10% or more of the Companyâ€™s total revenue are as follows: Â Â Â Three Months Ended June 30, Â Six Months Ended June 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Â Customer A Â 0% Â 96% Â 0% Â 98% Â Customer B Â 100% Â * Â 100% Â * Total Â 100% Â 96% Â 100% Â 98% Â * Less than 10% The Company did not have accounts receivable from its partners in collaboration and license agreements as of June 30, 2024 and December 31, 2023. Â The Companyâ€™s total revenue by geographic region, based on the location of the customer, are as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2024 Â Â 2024 Â Â 2024 Â Netherlands Â $ â€” Â Â $ 230 Â Â $ â€” Â Â $ 525 Â United States Â Â Â 5 Â Â Â 9 Â Â Â 33 Â Â Â 13 Â Total revenue Â $ 5 Â Â $ 239 Â Â $ 33 Â Â $ 538 Â Other Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (â€œCMOsâ€) and contract research organizations (â€œCROsâ€), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting. There can be no assurance that the Companyâ€™s research and development will be successfully completed, that adequate protection for the Companyâ€™s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Companyâ€™s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing). Recently Issued Accounting Pronouncements Not Yet AdoptedOn December 14, 2023, the Financial Accounting Standards Board issued Accounting Standards Update (â€œASUâ€) No. 2023-09, Improvements to Income Tax Disclosures. The final guidance adds clarifications related to the presentation of rate reconciliation for public business entities and definitions of specific categories in rate reconciliation. These amendments are effective for public business entities for annual periods beginning after December 15, 2024. For other entities, amendments are effective for annual periods beginning after December 15, 2025. The Company is not early adopting ASU 2023-09. The Company expects to make additional disclosures for income taxes upon adoption of this ASU. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 3. Fair Value Measurements The following tables represent the Companyâ€™s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Â Â Â Basis for Fair Value Measurements Â Â Fair Value as of Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â June 30, 2024 Â Assets Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 146,308 Â Â $ â€” Â Â $ â€” Â Â $ 146,308 Â Certificates of deposit Â Â â€” Â Â Â 69,677 Â Â Â â€” Â Â Â 69,677 Â Commercial paper Â Â â€” Â Â Â 96,220 Â Â Â â€” Â Â Â 96,220 Â Corporate bonds Â Â â€” Â Â Â 203,733 Â Â Â â€” Â Â Â 203,733 Â U.S. Treasuries Â Â â€” Â Â Â 18,970 Â Â Â â€” Â Â Â 18,970 Â Total Â $ 146,308 Â Â $ 388,600 Â Â $ â€” Â Â $ 534,908 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Derivative liability Â $ â€” Â Â $ â€” Â Â $ 382 Â Â $ 382 Â Total Â $ â€” Â Â $ â€” Â Â $ 382 Â Â $ 382 Â Â Â Â Basis for Fair Value Measurements Â Â Fair Value as of Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 217,644 Â Â $ â€” Â Â $ â€” Â Â $ 217,644 Â Commercial paper Â Â â€” Â Â Â 18,243 Â Â Â â€” Â Â Â 18,243 Â Corporate bonds Â Â â€” Â Â Â 28,939 Â Â Â â€” Â Â Â 28,939 Â U.S. government sponsored agencies Â Â â€” Â Â Â 2,896 Â Â Â â€” Â Â Â 2,896 Â Total Â $ 217,644 Â Â $ 50,078 Â Â $ â€” Â Â $ 267,722 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Derivative liability Â $ â€” Â Â $ â€” Â Â $ 369 Â Â $ 369 Â Total Â $ â€” Â Â $ â€” Â Â $ 369 Â Â $ 369 Â Level 3 Inputs The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability was determined using a present value analysis with multiple scenarios. In determining the fair value of the derivative liability, the inputs impacting fair value include the change of control payment to Cystic Fibrosis Foundation (CFF), the probability of a change of control event, the product status at time of a change of control event and the discount rate. See Note 15 for further discussion on the embedded derivative. There were no transfers between Level 1, 2 and 3 during the periods presented. The following tables set forth a summary of the changes in the fair value of the Companyâ€™s Level 3 financial instrument during the six months ended June 30, 2024 and 2023 (in thousands): Â Â Â DerivativeLiability Â Balance as of December 31, 2023 Â $ 369 Â Change in fair value includedÂ in other income (expense), net Â Â 13 Â Balance as of June 30, 2024 Â $ 382 Â Â Â Â DerivativeLiability Â Balance as of December 31, 2022 Â $ 212 Â Change in fair value includedÂ in other income (expense), net Â Â â€” Â Balance as of June 30, 2023 Â $ 212 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Marketable Securities 4. Marketable Securities Marketable securities, which are classified as available-for-sale, consisted of the following as of June 30, 2024 and December 31, 2023 (in thousands):Â Â Â Amortized Cost Basis Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value as of June 30, 2024 Â Short-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Certificates of deposit Â $ 69,674 Â Â $ 21 Â Â $ (18 ) Â $ 69,677 Â Commercial paper Â Â 95,009 Â Â Â 8 Â Â Â (68 ) Â Â 94,949 Â Corporate bonds Â Â 169,491 Â Â Â 10 Â Â Â (212 ) Â Â 169,289 Â U.S. Treasuries Â Â 18,977 Â Â Â â€” Â Â Â (7 ) Â Â 18,970 Â Total short-term marketable securities Â $ 353,151 Â Â $ 39 Â Â $ (305 ) Â $ 352,885 Â Long-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 1,275 Â Â $ â€” Â Â $ (4 ) Â $ 1,271 Â Corporate bonds Â Â 34,466 Â Â Â 20 Â Â Â (42 ) Â Â 34,444 Â Total long-term marketable securities Â $ 35,741 Â Â $ 20 Â Â $ (46 ) Â $ 35,715 Â Â Â Â Â Amortized Cost Basis Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value as of December 31, 2023 Â Short-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 17,603 Â Â $ 1 Â Â $ (26 ) Â $ 17,578 Â Corporate bonds Â Â 18,641 Â Â Â 12 Â Â Â (3 ) Â Â 18,650 Â U.S. government sponsored agencies Â Â 2,900 Â Â Â â€” Â Â Â (4 ) Â Â 2,896 Â Total short-term marketable securities Â $ 39,144 Â Â $ 13 Â Â $ (33 ) Â $ 39,124 Â Long-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 661 Â Â $ 4 Â Â $ â€” Â Â $ 665 Â Corporate bonds Â Â 10,257 Â Â Â 32 Â Â Â â€” Â Â Â 10,289 Â Total long-term marketable securities Â $ 10,918 Â Â $ 36 Â Â $ â€” Â Â $ 10,954 Â Â All marketable securities held as of June 30, 2024 had contractual maturities of less than two years. There have been no material realized gains or losses on marketable securities for the periods presented. Aggregate fair values of marketable securities with unrealized losses and gains were as follows as of June 30, 2024 and December 31, 2023 (in thousands):Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Aggregate fair value of marketable securities in a continuous loss position for less than twelve months Â $ 304,777 Â Â $ 20,494 Â Aggregate fair value of marketable securities in a continuous loss position for more than twelve months Â Â â€” Â Â Â 4,986 Â Aggregate fair value of marketable securities in unrealized gain position Â Â 83,823 Â Â Â 24,598 Â Total marketable securities Â $ 388,600 Â Â $ 50,078 Â The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for any period presented. The Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company further considered the maximum unrealized loss amounts both at the individual instrument level, $13 thousand, as well as in aggregate, $350 thousand, as of June 30, 2024, as immaterial. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company anticipates that it will recover the entire amortized cost basis of such securities, and therefore, no credit loss existed as of June 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] Â Property and Equipment, Net 5. Property and Equipment, Net Property and equipment, net, consisted of the following (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â Machinery and equipment Â $ 13,766 Â Â $ 12,996 Â Leasehold improvements Â Â 17,325 Â Â Â 16,902 Â Furniture and fixtures Â Â 566 Â Â Â 566 Â Office equipment Â Â 239 Â Â Â 239 Â Computer equipment and software Â Â 866 Â Â Â 805 Â Construction in progress Â Â 299 Â Â Â 550 Â Total property and equipment Â Â 33,061 Â Â Â 32,058 Â Less: Accumulated depreciation and amortization Â Â (14,300 ) Â Â (11,932 ) Property and equipment, net Â $ 18,761 Â Â $ 20,126 Â Â All property and equipment are maintained in the United States. Depreciation expense was $1.2 million and $1.1 million for the three months ended June 30, 2024 and 2023, respectively, and $2.4 million and $2.1 million for the six months ended June 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued and Other Current Liabilities 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Accrued and Other Current Liabilities 6. Accrued and Other Current LiabilitiesAccrued and other current liabilities consisted of the following (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â Payroll and related expenses Â $ 5,494 Â Â $ 8,149 Â Accrued clinical and preclinical study costs Â Â 5,165 Â Â Â 2,180 Â Consulting and

professional Â Â 2,021 Â Â Â 1,581 Â Other accrued expenses Â Â 96 Â Â Â 104 Â Total accrued and other current liabilities Â $ 12,776 Â Â $ 12,014 Â X - DefinitionAccrued and other current liabilities. + ReferencesNo definition available. + Details Name: fdmt_AccruedAndOtherCurrentLiabilitiesTextBlock Namespace Prefix: fdmt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements 6 Months Ended Jun. 30, 2024 Research And Collaboration Arrangements [Abstract] Â Research and Collaboration Arrangements 7. Research and Collaboration Arrangements Collaboration and license revenue for each period was as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â uniQure Â $ â€" Â Â $ 230 Â Â $ â€" Â Â $ 525 Â CFF Â Â 5 Â Â Â 9 Â Â Â 33 Â Â Â 13 Â Total revenue Â $ 5 Â Â $ 239 Â Â $ 33 Â Â Â $ 538 Â Â Deferred revenue is summarized as follows (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â CFF Â $ 1,318 Â Â $ 1,245 Â Total deferred revenue Â $ 1,318 Â Â $ 1,245 Â Â The total amount of revenue in the six months ended June 30, 2024 which was included in deferred revenue at January 1, 2024 was zero. The total amount of revenue in the six months ended June 30, 2023 which was included in deferred revenue at January 1, 2023 was $0.5 million. uniQure In January 2014, the Company and uniQure biopharma B.V. (â€œuniQureâ€) entered into a Collaboration and License Agreement (the â€œuniQure Agreementâ€) to collaborate on the discovery and non-clinical research activities related to the Companyâ€™s Therapeutic Vector Evolution platform in order to generate and validate vectors for gene delivery to treat diseases within the central nervous system and liver (together, the â€œuniQure Fieldâ€). The uniQure Agreement provided uniQure with a research license as well as an exclusive development and commercialization license for each project variant selected for further development. The initial research term is three years with an option for uniQure to extend the research term one time for an additional year. Once the Companyâ€™s research plan has concluded, uniQure is solely responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. In October 2016, uniQure exercised its option to extend the research term for an additional year to January 2018. The Company was also required to work exclusively with uniQure in the uniQure Field (the â€œuniQure Exclusivity Clauseâ€). Pursuant to the uniQure Agreement, the Company received upfront payments of $0.2 million, and was entitled to receive (i) contingent payments for the achievement of research and development milestones of up to $5.0 million for each licensed product selected under the arrangement, and (ii) royalties in the single digit range on future sales of the potential product candidates and sublicense consideration in the low teens to low thirties range on any future sublicensing arrangements. The Company also received capped research and development service fees based on contractual full-time employee rates per year. In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of 609,744 of uniQure ordinary shares that vested over the initial three-year term of the agreement. The upfront payment of $0.2 million was recorded as deferred revenue and was recognized on a ratable basis over the estimated performance period of four years. Payments and reimbursements for research costs were recognized on an as-incurred basis. The options to purchase uniQure shares were deemed to be a noncash component of the arrangement consideration, as the vesting of options is linked to the uniQure Agreement and there is a requirement for the holders of the options to provide services under the agreement. The fair value of the uniQure options, which was estimated to be $10.6 million, was recognized ratably as revenue over the estimated performance period of four years and the associated compensation expense related to the stock options was recorded as research and development expense. In August 2019, the Company and uniQure entered into an Amended and Restated Collaboration and License Agreement (the â€œAmended uniQure Agreementâ€), which amended and restated the uniQure Agreement, and a separate Collaboration and License Agreement (the â€œSecond uniQure Agreementâ€). Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the uniQure Exclusivity Clause and transferring other rights back to the Company. Under the Amended uniQure Agreement, uniQure continues to have an exclusive license to select AAV capsid variants (the â€œSelected Variantsâ€) in the uniQure Field. uniQure continues to be solely responsible, at its cost, to develop and commercialize the compounds and products containing the Selected Variants. The amended uniQure Agreement eliminated the uniQure Exclusivity Clause in the uniQure Agreement. Furthermore, the contingent payments that the Company was entitled to from uniQure for the achievement of research and development milestones of up to $5.0 million for each licensed product selected under the uniQure Agreement were eliminated and sublicense consideration on any future sublicensing arrangements was reduced from the low teens to low thirties percentages to mid-single digit to mid-twenties percentages. Under the Second uniQure Agreement, the parties agreed to research and develop new AAV capsid variants (the â€œNew Variantsâ€) that are not Selected Variants that affect certain targets selected by uniQure (the â€œuniQure Targetsâ€) in the uniQure Field. The Company is solely responsible, at its cost, for the research of the New Variants. The Company granted uniQure an exclusive license to a certain number of the New Variants (the â€œuniQure New Variantsâ€) that affect the uniQure Targets. uniQure is solely responsible, at its cost, to develop and commercialize the compounds and products containing the uniQure New Variants that affect the uniQure Targets (the â€œLicensed Productsâ€). The Company retains all rights to New Variants in the uniQure Field that affect targets other than the uniQure Targets. Under both the Amended uniQure Agreement and the Second uniQure Agreement, uniQure will be required to pay the Company royalties on worldwide annual net sales of Licensed Products at a mid-single digit percentage rate, subject to certain specified reductions. uniQure will also be required to pay the Company sublicensing consideration for sublicensing the Companyâ€™s intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties at a rate between the mid-single digit to mid-twenties. The Company has reciprocal obligations, at the same percentage rates as uniQure, to pay uniQure royalties and sublicensing consideration for sublicensing certain intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties. The Company concluded that the Amended uniQure Agreement and the Second uniQure Agreement should be accounted for as one combined contract that should be accounted for as a separate contract from the uniQure Agreement given that the incremental licensed intellectual property rights and research and development services are distinct from the rights and services previously transferred to uniQure under the uniQure Agreement and the transaction price increased by an amount that equals the standalone selling price of the incremental rights and services to be transferred to uniQure under the Amended uniQure Agreement and Second uniQure Agreement. Neither party was required to pay monetary consideration in connection with the execution of the Amended uniQure Agreement or the Second uniQure Agreement or for subsequent performance by the parties under those agreements, notwithstanding the potential future royalty and sublicense consideration described above. The fair value of the non-monetary consideration given by uniQure to the Company, for the intellectual property right is $5.1 million. This intellectual property right is considered to be an in-process research and development asset with no alternative future use and, accordingly, was written off as acquired in-process research and development expense in the year ended December 31, 2019. The incremental transaction price described in the paragraph above was recorded as deferred revenue given that the Company identified one single combined performance obligation under ASC 606, which includes the licenses to the New Variants, research services and participation in the joint steering committee (â€œJSCâ€). Revenue is being recognized using the input method based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligation. The Company completed its performance obligation during the third quarter of 2023 and the deferred revenue was recognized as revenue in the same period.The Company determined the transaction price using the risk adjusted net present value analysis (â€œrNPVâ€) methodology to value the elimination of the uniQure exclusivity clause and other material rights received by the Company, including the potential royalties the Company would receive from uniQure. The rNPVs incorporate estimates and assumptions including the number of products the Company and uniQure would develop, the risk-adjusted probability of successfully developing a biopharmaceutical product, the probability that uniQure will develop a product, the research and development costs, the potential worldwide sales and associated commercialization costs, corporate tax rate, and discount rate. During each of the three and six months ended June 30, 2024, the Company recognized no revenue under both of the Amended uniQure Agreement and the Second uniQure Agreement. The Company recognized $0.2 million and $0.5 million during the three and six months ended June 30, 2023, respectively, under both of the Amended uniQure Agreement and the Second uniQure Agreement. There were no amounts due from uniQure under the uniQure Agreement, Amended uniQure Agreement or Second uniQure Agreement as of June 30, 2024 and December 31, 2023. As of June 30, 2024 and December 31, 2023, deferred revenue relating to uniQure was zero and the aggregate amount of the transaction price allocated to the remaining performance obligation was zero.Cystic Fibrosis Foundation (CFF)In September 2016, the Company entered into an award agreement for the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program with CFF, a non-profit organization dedicated to finding a cure for cystic fibrosis, an inherited disorder that causes disease in the pulmonary airways leading to morbidity and mortality. Under this agreement, CFF contributes funding to help advance the Companyâ€™s CF research program. The September 2016 grant award agreement was incorporated into a new grant award agreement with the CFF in September 2017 with the same objectives, which was subsequently amended in August 2018 and February 2021. In August 2023, the Company executed a third amendment to the agreement (the â€œAugust 2023 Amendmentâ€), which modified the research plan, increased the aggregate milestone payments from $3.5 million to $6.3 million and extended the estimated project completion date. The aforementioned September 2017 agreement and three amendments are collectively referred to as the â€œCFF Agreementâ€. The August 2023 Amendment represents a contract modification to an existing contract under Topic 606, given the amendment did not include any additional goods or services, and the remaining research activities are not distinct from those previously provided. The August 2023 Amendment did not impact the transaction price, given the increased award amount relates to variable consideration for future milestones that are fully constrained. Accordingly, the contract modification did not result in a revenue adjustment. As of June 30, 2024 and December 31, 2023, the Company had achieved milestones totaling $1.8 million and $1.7 million, respectively, under the CFF Agreement. The remaining award amount will be paid by CFF based on achievement of certain development milestones by the Company. The Company expects to make payments to CFF equal to six times the actual award received by the Company in three installments within the first four years of the first commercial sale of a product developed under this agreement. The Company also has agreed to make future sales-based milestone payments to CFF of up to three times the actual award received upon achieving specified commercialization milestones with respect to the first of any product developed utilizing any compound covered under the CFF Agreement. The CFF Agreement also requires the Company to pay to CFF royalties of a mid-single digit percentage, up to six times the actual award received, on any amounts received by the Company from the sale, license or transfer to a third-party of rights in the technology developed as a result of this collaboration. Any such royalty payments shall be credited against the payments owed by the Company upon first commercial sale. In the event of a change of control of the Company, CFF will receive certain payments, depending on the timing of the change of control and the size of the transaction. To date, the Company has not developed a commercial product in connection with the CFF Agreement, and it has not licensed, sold or otherwise transferred to another party the product developed under the CFF Agreement or the underlying technology. If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of 180 consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Companyâ€™s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license. The Company identified one performance obligation within the CFF grant agreement for research activities. The Companyâ€™s contract with CFF does not include a significant financing component. The Company concluded that the transaction price should not include the variable consideration related to future research milestones as they were considered to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company re-evaluates the transaction price and estimated period of performance at each reporting period. Revenue recognized during each of the three and six months ended June 30, 2024 and 2023 was immaterial. As of June 30, 2024 and December 31, 2023, deferred revenue relating to the CFF Agreement was $1.3 million and $1.2 million, respectively. There were no accounts receivable from CFF under the CFF Agreement as of June 30, 2024 and December 31, 2023. As of June 30, 2024 and December 31, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligation was $1.3 million and $1.2 million, respectively. Based on current timelines, the deferred revenue is expected to be recognized as revenue over the next one to three years as the Company performs research services through the completion of IND-enabling studies. The obligation to make payments to CFF upon a change of control meets the definition of an embedded derivative that is required to be bifurcated and separately accounted for as a derivative liability. See Note 15 for further discussion of the embedded derivative. Arbor Biotechnologies, Inc.On December 20, 2023 (the â€œEffective Dateâ€), the Company entered into a co-development and co-commercialization agreement (the â€œArbor Agreementâ€) with Arbor Biotechnologies, Inc. (â€œArborâ€), pursuant to which the Company and Arbor agreed to co-develop and co-commercialize on a fifty-fifty cost-and-profit-sharing basis up to six genetic medicine products to treat central nervous system (â€œCNSâ€) indications, based on combining the Companyâ€™s CNS-targeting vectors and Arbor's Cas enzymes and Guide RNAs. The first product candidate under the Arbor Agreement will address a molecular target implicated in amyotrophic lateral sclerosis (ALS). The Company will account for its costs related to the co-development and co-commercialization of product candidates under the Arbor Agreement as research and development expenses in the periods in which they are incurred. As of June 30, 2024, no Shared Product has been designated by the JSC (each as defined in the Arbor Agreement) under the Arbor Agreement, and no research and development expenses were incurred related to the Arbor Agreement during the three and six months ended June 30, 2024. X - DefinitionResearch and Collaboration Arrangements. + ReferencesNo definition available. + Details Name: fdmt_ResearchAndCollaborationArrangementsAbstract Namespace Prefix: fdmt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Arrangements 6 Months Ended Jun. 30, 2024 License Arrangements [Abstract] Â License Arrangements 8. License Arrangements Astellas Gene Therapies, Inc.On July 5, 2023, the Company entered into a licensing agreement (the â€œLicense Agreementâ€) with Astellas Gene Therapies, Inc. (â€œAGTâ€), pursuant to which the Company granted to AGT a license to utilize its intravitreal R100 vector (â€œ4D Vectorâ€) to develop and commercialize licensed compounds and licensed products for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees. Under the terms of the License Agreement, the Company has provided its 4D vector technology to AGT to deliver AGT's genetic payloads for the treatment of rare monogenic diseases. AGT will conduct all subsequent research, development, manufacturing, and commercialization activities. As partial consideration for the rights and licenses granted to AGT by the Company under this Agreement, AGT paid the Company an upfront amount of $20 million, which was received in July 2023. The Company may receive potential future option fees and milestones of up to $942.5 million. In addition, the Company is entitled to receive mid-single digit to double-digit, sub-teen royalties on net sales of all licensed products. Under the License Agreement, the Companyâ€™s performance obligation is to grant and make available to AGT the Licensed IP and Licensed Know-How (each as defined in the License Agreement) with respect to the 4D Vector. In connection with the grant of the license, in July 2023, the Company delivered to AGT the Transferred Material (as defined in the License Agreement). As of June 30, 2024, there was no deferred revenue and no accounts receivable relating to the License Agreement.Aevitas Therapeutics, Inc. and The Trustees of the University of PennsylvaniaOn April 21, 2023, the Company entered into an agreement (the â€œAgreementâ€) with Aevitas Therapeutics, Inc. (â€œAevitasâ€), pursuant to which the Company acquired all of Aevitasâ€™ worldwide rights to short-form human complement factor H ("sCFH"), which the Company plans to use for its 4D-175 product candidate research program. The asset purchase was accounted for as an asset acquisition. As consideration for the Agreement, the Company shall pay Aevitas up to approximately $144 million in cash upon certain late-stage development, regulatory and sales milestones being achieved plus royalties in the low single digits range on sales of 4D-175. In addition, as part of the Agreement, the Company was assigned a License Agreement for sCFH with the Trustees of the University of Pennsylvania, under which the Company shall pay the University of Pennsylvania up to approximately $42 million in cash upon certain

late-stage development, regulatory and sales milestones being achieved plus royalties in the low single digits range on sales of 4D-175. No upfront consideration was paid under the Agreement.As of June 30, 2024, the Company has not recorded a liability related to contingent consideration for future milestone and royalty payments to either Aevitas or the University of Pennsylvania, as the achievement of such milestones has not occurred and was not deemed probable and product sales have not commenced.Regents of the University of California The Company has exclusive, worldwide license agreements (the â€œUC Agreementsâ€) with the Regents of the University of California (the â€œUC Regentsâ€) relating to the use of certain patents and intellectual property surrounding its core technologies, including Therapeutic Vector Evolution. Pursuant to each of the UC Agreements executed prior to January 2019, the Company was obligated to pay a (i) non-refundable license fee of $5,000 upon execution, (ii) a non-refundable license fee of $5,000 each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents, (iii) reimbursement of domestic and foreign patent filing, prosecution and maintenance fees, and (iv) either $50,000 or issuance of a 3% equity interest in the Company upon the closing of the first qualified financing at the option of the UC Regents. The Companyâ€™s first qualified financing occurred in 2015 and at the election of the UC Regents, the Company issued the UC Regents in January 2016 an amount of common stock equal to 6% of the equity interests in the Company pursuant to the applicable clause in each of the UC Agreements.Pursuant to an agreement with the UC Regents executed in January 2019 the Company paid a non-refundable license fee of $50,000 to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license fee of $5,000 on the one-year anniversary of the contract effective date and each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $3.1 million, (ii) low single digit royalties on the net sales of its developed products that consists of a minimum annual royalty of up to $0.1 million per year for the term of the agreement beginning in the first calendar year after the year in which net sales first occurred, and (iii) sublicense consideration in the mid-teens to the mid-twenties-range on any future sublicensing arrangements the Company may enter into with third-party licensees. Regents of the University of California and The Trustees of the University of Pennsylvania In July 2021, the Company entered into an exclusive license agreement with the UC Regents and the Trustees of the University Pennsylvania to license intellectual property related to certain vectors. In July 2021, the Company paid a non-refundable license fee of $100,000 to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license maintenance fee of $10,000 on the one-year anniversary of the contract effective date and each year thereafter, except years for which the Company has paid royalties on the net sales of a licensed product. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $3.9 million, (ii) low single digit percentage rate royalties on the net sales of its licensed products that consists of a minimum annual royalty of up to $0.1 million per year for the term of the agreement beginning in the first calendar year after the year in which net sales first occurred and (iii) sublicense consideration in the mid-single digits to the low twenties percentage rate range on any future sublicensing arrangements the Company may enter into with third-party licensees. On February 22, 2023, the Company provided 90 days written notice to the UC Regents and the Trustees of the University Pennsylvania to terminate said agreement in its entirety at-will. Accordingly, the effective termination date of this agreement is May 23, 2023.The Company did not incur any expense under the provisions of the outstanding license agreements during each of the three and six months ended June 30, 2024 and 2023. X - DefinitionLicense arrangements. + ReferencesNo definition available. + Details Name: fdmt_LicenseArrangementsAbstract Namespace Prefix: fdmt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLicense arrangements. + ReferencesNo definition available. + Details Name: fdmt_LicenseArrangementsTextBlock Namespace Prefix: fdmt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â  Commitments and Contingencies 9. Commitments and Contingencies Operating Lease Commitments 5980 Horton Street Building LeaseIn May 2015, the Company executed a lease agreement for office and laboratory space in Emeryville, California. In January 2016, the Company executed the first amendment to the lease agreement for additional rentable office and laboratory space which extended the lease term to March 31, 2023 and updated the option to renew the lease at market rent from the prior additional term of three years to five years. In October 2018, the Company executed a second amendment to extend the lease to September 2026. Additionally, the second amendment provided a tenant improvement allowance of $0.2 million, which was paid to the Company in November 2018. The 5980 Horton Street Building Lease is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of June 30, 2024, the operating lease right-of-use asset and operating lease liability were $1.0 million and $1.2 million, respectively. As of December 31, 2023, the operating lease right-of-use asset and operating lease liability were $1.2 million and $1.4 million, respectively. The discount rate used to determine the lease liability was 7.5%. 5858 Horton Street Building Lease and ExpansionIn October 2018, the Company executed a second lease agreement for additional office and laboratory space in Emeryville, California. The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years at market rent. The Company did not have to pay rent until October 2019. This lease agreement also provided for a tenant improvement allowance of $0.4 million, which was paid to the Company in December 2019. The Company amortizes the tenant improvement allowance on a straight-line basis over the remaining term of the lease as a reduction of rent expense. In May 2019, the Company amended the second lease agreement executed in October 2018 to add additional office, manufacturing and laboratory space (the â€œ2019 Expansionâ€). The amendment extended the term of the lease to December 31, 2029. The Company did not have to pay rent until December 2019. The lease agreement also included a tenant improvement allowance, which was increased to $2.3 million in February 2021 pursuant to a second amendment to the second lease agreement. The Company fully received the $2.3 million tenant improvement allowance in 2023. The tenant improvement allowance funds improvements to the additional office, manufacturing and laboratory space, which the Company has determined to be lessee owned. The allowance is treated as a reduction of lease payments used to measure the lease liability. The 5858 Horton Street Building Lease and 2019 Expansion are considered operating leases under ASC 842 as they do not meet the criteria of a finance lease. As of June 30, 2024, the operating lease right-of-use asset and operating lease liability was $9.7 million and $12.5 million, respectively. As of December 31, 2023, the operating lease right-of-use asset and operating lease liability was $10.3 million and $13.2 million, respectively. The discount rate used to determine the lease liability was 7.8%.In July 2024, the lease term for the 5858 Horton Street Building Lease and 2019 Expansion was extended for a period of 12 months and will expire on December 31, 2030. Neither of the leases include a general option for the Company to terminate the leases.In July 2024, the Company entered into a lease for additional office and laboratory space in Emeryville, California (the "2024 Expansion") with a projected lease commencement date of September 1, 2024. The lease consists of approximately 32,038 square feet of office and laboratory space and has a lease term through December 31, 2030. Future minimum lease payments under the 2024 Expansion from its projected commencement date through lease expiration are approximately $13.2 million. As of June 30, 2024, the Company has not recorded a right-of-use asset or lease liability on its condensed balance sheets as the Company has not yet obtained control of the additional office and laboratory space.Emeryville, California Warehouse Lease In January 2024, the Company entered into a new lease for warehouse space in Emeryville, California (the â€œWarehouse Lease Agreementâ€), with a projected lease commencement date of August 31, 2024. The lease consists of approximately 7,800 square feet of warehouse space and has a lease term of five years and four months. Future minimum lease payments under the Warehouse Lease Agreement from its projected commencement date through lease expiration in the fourth quarter of 2029 are approximately $1.5 million. As of June 30, 2024, the Company has not recorded a right-of-use asset or lease liability on its condensed balance sheets as the Company has not yet obtained control of the warehouse space.The following table summarizes the components of lease expense for the three and six months ended June 30, 2024 and 2023, which are included in operating expenses in the Companyâ€™s condensed statements of operations (in thousands): Â  Â  Â  Three Months Ended June 30, Â  Â  Six Months Ended June 30, Â  Â  Â  2024 Â  Â  2023 Â  Â  2024 Â  Â  2023 Â  Operating lease cost Â  $ 698 Â  Â  $ 698 Â  Â  $ 1,397 Â  Â  $ 1,397 Â  Variable lease cost Â  Â  354 Â  Â  Â  311 Â  Â  Â  707 Â  Â  Â  622 Â  Total Â  $ 1,052 Â  Â  $ 1,009 Â  Â  $ 2,104 Â  Â  $ 2,019 Â  Variable lease payments include amounts relating to common area maintenance and are recognized in the condensed statements of operations as incurred. The following table summarizes supplemental information related to operating leases:Â  Â  Â  June 30,2024 Â  Â  December 31,2023 Â  Weighted-average remaining lease term (in years): Â  Â  5.2 Â  Â  Â  5.7 Â  Weighted-average discount rate: Â  Â  7.8 % Â  Â  7.8 % Â  The following table summarizes the maturities of lease liabilities as of June 30, 2024 (in thousands):Â  2024 (remaining six months) Â  $ 1,588 Â  2025 Â  Â  3,244 Â  2026 Â  Â  3,135 Â  2027 Â  Â  2,810 Â  2028 Â  Â  2,894 Â  Thereafter Â  Â  2,982 Â  Total future minimum lease payments Â  Â  16,653 Â  Less: Amount representing interest Â  Â  (2,997 ) Present value of future minimum lease payments Â  Â  13,656 Â  Less: Current portion of operating lease liabilities Â  Â  3,196 Â  Long-term portion of operating lease liabilities Â  $ 10,460 Â  Indemnification Agreements In the ordinary course of business, the Company enters into agreements that may include indemnification provisions, such as with vendors and other parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently maintains directorsâ€™ and officersâ€™ liability insurance that would generally enable it to recover a portion of any future amounts paid. The Company believes the estimated fair value of its indemnification agreements in excess of applicable insurance coverage is not material.Legal Proceedings From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. There are no material legal proceedings outstanding at June 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Â  Income Taxes 10. Income TaxesÂ For the three and six months ended June 30, 2024 and 2023, the Company did not record a federal or state income tax provision due to its recurring net losses. In addition, the Company has taken a full valuation allowance against its net deferred tax assets as the Company believes it is not more likely than not that the benefit will be realized. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â  Common Stock 11. Common Stock As of June 30, 2024 and December 31, 2023, the Companyâ€™s certificate of incorporation authorized the Company to issue 300,000,000 shares of common stock, at the par value of $0.0001 per share. The holder of each share of common stock is entitled to one vote per share. Common stockholders are entitled to dividends, if and when declared by the board of directors. To date, no dividends on common stock have been declared by the board of directors. As of June 30, 2024 and December 31, 2023, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: Â  Â  Â  June 30,2024 Â  Â  December 31,2023 Â  Issuance of common stock under the 2020 Equity Incentive Award Plan Â  Â  2,332,657 Â  Â  Â  524,078 Â  Issuance of common stock under the 2020 Employee Stock Purchase Plan Â  Â  273,375 Â  Â  Â  313,034 Â  Exercise of options issued and outstanding and future vesting of restricted stock units Â  Â  8,450,290 Â  Â  Â  8,423,481 Â  Exercise of common stock warrants Â  Â  3,637,145 Â  Â  Â  53,669 Â  Total common stock reserved for future issuance Â  Â  14,693,467 Â  Â  Â  9,314,262 Â  Funding Agreement with CFF â€” In April 2020, CFF made a $10.0 million investment in the Company's Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of Series C redeemable convertible preferred stock, and the Company and CFF entered into a Funding Agreement (the â€œFunding Agreementâ€). Pursuant to the terms of the Funding Agreement, except in the event of a technical failure, the $10.0 million received from CFF will be used to advance the development program for 4D-710, the Companyâ€™s lead product in cystic fibrosis, or any other therapeutic approved by the Program Advisory Group (â€œPAGâ€) to alleviate pulmonary complications of cystic fibrosis (the â€œFunding Agreement Productâ€). CFF committed to provide an additional $4.0 million of funding upon acceptance of an Investigational New Drug (â€œINDâ€) application or its equivalent to allow for human testing of the Funding Agreement Product (â€œAcceptanceâ€). In October 2021, the IND was cleared by the U.S. Food and Drug Administration and CFF made the additional investment of $4.0 million in cash for the issuance of 125,715 shares of the Company's common stock to CFF. The Company was committed to providing an amount equal to the funding provided by CFF to be used solely to advance the Funding Agreement Product. As of June 30, 2024, the funding commitment has been fulfilled. Under the terms of the Funding Agreement, neither the $10.0 million investment in the Series C redeemable convertible preferred stock, which converted to common stock as of December 31, 2020,

nor the $4.0 million of funding upon Acceptance are restricted as to withdrawal or usage. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â  Stock-based Compensation 12. Stock-based Compensation 2020 Equity Incentive Award Plan In December 2020, the Company adopted the 2020 Incentive Award Plan (â€œ2020 Planâ€), which became effective on December 10, 2020. The 2020 Plan initially reserved 2,606,546 shares of common stock for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance bonus awards, performance stock units, dividend equivalents or other stock or cash based award granted to employees, directors and consultants of the Company. The number of shares reserved for future issuance under the 2020 Plan will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) 5% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than 18,000,000 shares of the Company's common stock may be issued upon the exercise of incentive stock options. On February 29, 2024, an additional 2,153,533 shares of common stock became available for issuance under the 2020 Plan, as a result of the operation of the automatic annual increase provision. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options were issued. As of June 30, 2024 there were 1,997,052 shares available for grant under the 2020 Plan.Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the â€œ2015 Planâ€). However, the 2015 Plan continues to govern the terms of options that remain outstanding under the 2015 Plan. As of June 30, 2024, there were 335,605 shares available for grant under the 2015 Plan.2015 Equity Incentive PlanThe 2015 Plan provided for grants of stock options, stock appreciation rights, restricted stock and restricted stock unit awards to employees, directors and consultants of the Company. As of June 30, 2024, options to purchase 1,545,023 shares of common stock were outstanding under the 2015 Plan. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options were issued and are granted at prices not less than the estimated fair market value of the Companyâ€™s common stock on the grant date as determined by the board of directors. No additional grants will be made under the 2015 Plan, and all outstanding grants under the 2015 Plan that are repurchased, forfeited, expire or are cancelled are returned to the 2015 Plan and are not available for grant under the 2020 Plan. Employee Stock Purchase PlanIn December 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the â€œ2020 ESPPâ€). Under the 2020 ESPP, 252,337 shares of the Company's common stock were initially reserved for employee purchases of the Company's common stock under terms and provisions established by the Company's board of directors and approved by the Company's stockholders. The number of shares reserved for future issuance under the 2020 ESPP will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) 1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than 15,000,000 shares the Company's common stock may be issued under the 2020 ESPP. On February 29, 2024, an additional 50,000 shares of common stock became available for future issuance under the 2020 ESPP, as a result of the operation of this automatic annual increase provision. Under the 2020 ESPP the Company's employees may purchase common stock through payroll deductions at a price equal to 85% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2020 ESPP provides for a series of overlapping 24-month offering periods comprising four six-month purchase periods. The initial offering period under the 2020 ESPP is longer than 24 months, commencing February 15, 2021 and ending on May 14, 2023. Contributions under the 2020 ESPP are limited to a maximum of 15% of an employee's eligible compensation. Restricted Stock Units The Company has granted restricted stock unit (RSU) awards under the 2020 Equity Incentive Award Plan that vest over a period of four years. The following table summarizes the RSU activity for the six months ended June 30, 2024:Â Â Â  Number ofShares Â  Unvested balance at December 31, 2023 Â Â  181,181 Â  Issued Â Â  129,650 Â  Vested Â Â  (21,963 ) Canceled/Forfeited Â Â  (30,751 ) Unvested balance at June 30, 2024 Â Â  258,117 Â Â Stock Options The following table summarizes the stock options activity for the six months ended June 30, 2024:Â Â Â  Number ofSharesUnderlyingOutstandingOptions Â  Balances at December 31, 2023 Â Â  8,240,154 Â  Options granted Â Â  434,500 Â  Options exercised Â Â  (296,183 ) Options expired Â Â  (8,837 ) Options forfeited Â Â  (177,461 ) Balances at June 30, 2024 Â Â  8,192,173 Â  Options exercisable at June 30, 2024 Â Â  3,726,662 Â  Options vested and expected to vest at June 30, 2024 Â Â  8,192,173 Â  The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Companyâ€™s stock options was estimated using the following assumptions for the three and six months ended June 30, 2024 and 2023:Â Â Â  Three Months Ended June 30, Â  Six Months Ended June 30, Â Â  2024 Â  2023 Â  2024 Â  2023 Expected term Â  6.0Â - 6.1Â years Â  6.0Â - 6.1Â years Â  6.0Â - 6.1Â years Â  6.0Â - 6.1Â years Expected volatility Â  84.9% - 85.4% Â  81.1% - 82.2% Â  81.4% - 85.4% Â  80.9% - 84.4% Risk-free interest rate Â  4.4% - 4.5% Â  3.5% - 4.0% Â  3.9% - 4.5% Â  3.5% - 4.0% Expected dividend yield Â â€”% Â â€”% Â â€”% Â â€”% Expected Term. The expected term for employee options is calculated using the simplified method as the Company does not have sufficient historical information to provide a basis for this estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee options is the contractual term of the options.Expected Volatility. The expected volatility is based on a mix of the Company's historical volatility and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. For each grant, the Company measured historical volatility over a period equivalent to the expected term. Risk-free Interest Rate. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues whose term is similar in duration to the expected term of the respective stock option. Expected Dividend Yield. The Company has not paid and does not anticipate paying any dividends on its common stock in the future. Accordingly, the Company has estimated the dividend yield to be zero. Stock-Based Compensation Expense The following table is a summary of stock-based compensation expense incurred for employees and nonemployees by function (in thousands): Â Â Â  Three Months EndedJune 30, Â Â Â  Six Months EndedJune 30, Â Â Â  2024 Â Â  2023 Â Â  2024 Â Â  2023 Â Research and development Â  $ 3,196 Â Â  $ 2,678 Â Â  $ 6,231 Â Â  $ 5,148 Â General and administrative Â Â  2,877 Â Â Â  2,291 Â Â Â  5,817 Â Â Â  4,042 Â Total stock-based compensation expense Â  $ 6,073 Â Â  $ 4,969 Â Â  $ 12,048 Â Â  $ 9,190 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock Warrants 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â  Common Stock Warrants 13. Common Stock Warrants In May 2018, the Company issued a warrant for 23,669 shares of the Companyâ€™s common stock to a service provider with an exercise price of $3.19 per share. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model, expires in 2025 and upon issuance was fully vested.In December 2020, the Company issued a warrant for 30,000 shares of the Companyâ€™s common stock to a service provider with an exercise price of $18.00 per share. This warrant vests over a period of four years and expires in 2027. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model. In February 2024, the Company completed an underwritten public follow-on offering which included the sale of pre-funded warrants (the â€œPre-funded Warrantsâ€) to purchase 3,583,476 shares of the Companyâ€™s common stock at an offering price of $29.4999. The exercise price of each Pre-funded Warrant is $0.0001 per share, and each Pre-funded Warrant is exercisable from the date of issuance. The Pre-funded Warrants are classified as a component of stockholdersâ€™ equity within additional paid-in-capital. The Company valued the Pre-funded Warrants at issuance and recorded net proceeds of $99.4 million after deducting underwriters fees during the six months ended June 30, 2024 related to the sale of the Pre-funded Warrants.There was no material expense related to the above warrant shares during each of the three and six months ended June 30, 2024 and 2023. X - DefinitionCommon stock warrants. + ReferencesNo definition available. + Details Name: fdmt_CommonStockWarrantsTextBlock Namespace Prefix: fdmt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share, Basic and Diluted 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â  Net Loss Per Share, Basic and Diluted 14. Net Loss Per Share, Basic and DilutedThe following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): Â Â Â  Three Months Ended June 30, Â Â  Six Months Ended June 30, Â Â Â  2024 Â Â  2023 Â Â  2024 Â Â  2023 Â Numerator Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â  $ (34,953 ) Â  $ (29,616 ) Â  $ (67,354 ) Â  $ (58,298 ) Denominator Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares outstanding used in computing net loss per share, basic and diluted Â Â  55,282,754 Â Â Â  38,335,219 Â Â Â  52,277,369 Â Â Â  35,661,995 Â  Net loss per share, basic and diluted Â  $ (0.63 ) Â  $ (0.77 ) Â  $ (1.29 ) Â  $ (1.63 ) Â In February 2024, the Company issued and sold Pre-funded Warrants to purchase 3,583,476 shares of common stock at a nominal exercise price of $0.0001 (see Note 13). The shares of common stock into which the Pre-funded Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and the Pre-funded Warrants are immediately exercisable upon their issuance date.Â The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Â Â Â  June 30, Â Â Â  2024 Â Â  2023 Â Options issued and outstanding Â Â  8,192,173 Â Â Â  6,422,876 Â  Restricted stock units subject to future vesting Â Â  258,117 Â Â Â Â â€” Â  2020 ESPP Â Â  244,622 Â Â Â  269,102 Â  Common stock warrants Â Â  53,669 Â Â Â  53,669 Â  Total Â Â  8,748,581 Â Â Â  6,745,647 Â  X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Derivative Liability 6 Months Ended Jun. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â  Derivative Liability 15. Derivative Liability The Company identified an embedded derivative resulting from the change of control provision in the CFF Agreement. Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as separate financial instruments. At the inception of the derivative in 2017, the Company recognized this derivative as a liability and revenue was reduced by the initial fair value of the derivative liability. The Company remeasures the derivative liability to fair value at each reporting period and records the change in fair value of the derivative liability as other income (expense), net. The Company uses a present value analysis with multiple scenarios, which incorporates assumptions and estimates to value the derivative instrument. The Company assesses these assumptions and estimates on a periodic basis as additional information impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the change of control payment to CFF (range of zero to $18.9 million at June 30, 2024 and December 31, 2023), the probability of a change of control event, the probability of the product achieving development or commercial status at time of change of control (range of 4.8% to 17.2% at June 30, 2024 and December 31, 2023) and the discount rate (15% at June 30, 2024 and December 31, 2023). The Company determined the estimated fair value of this liability as of the

inception date of the CFF Agreement and concluded that the amount was immaterial. The Company determined the fair value of this derivative liability was $0.4 million as of June 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â  Related Party Transactions 16. Related Party Transactions In March 2024, the Company entered into a research and option agreement (the â€œReignite Agreementâ€) with Reignite Therapeutics Inc. (â€œReigniteâ€), which was founded by David Kirn, M.D., Chief Executive Officer of the Company. Reignite has the expertise to develop high-capacity, helper-dependent adenovirus capsids which the Company plans to utilize as they expand their therapeutic capsid evolution platform. Reignite and the Company plan to collaborate on a one-to-two year program to develop these high capacity, helper-dependent adenovirus capsids. Under the Reignite Agreement, the Company shall have the final authority to amend and make updates to the plan and budget of the program. Further, the Company is responsible for the funding of the related research which includes the budgeted full-time employees and CRO costs, equipment costs not to exceed $60 thousand and all other costs, in total not to exceed $1.5 million in any year of the program. The Company will have an option to acquire up to three capsids resulting from the program. The Company shall pay to Reignite an option exercise fee of $1.0 million per selected capsid for which the Company has exercised its option. The maximum total amount payable is $3.0 million.During the three and six months ended June 30, 2024, the Company paid Reignite $0.4 million for research and development expenses. No option exercise fees were incurred during the three and six months ended June 30, 2024. As of June 30, 2024, no other amounts were due to Reignite under the Reignite Agreement. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 401(K) Plan 6 Months Ended Jun. 30, 2024 Retirement Benefits [Abstract] Â  401(K) Plan 17. 401(k) PlanIn 2014, the Company adopted a 401(k) plan for all employees who have met certain eligibility requirements. The 401(k) plan allows employees to make pre-tax and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company made contributions to the 401(k) plan for all eligible participants and recorded contribution expenses of $0.4 million and $0.2 million for the three months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and 2023, the Company recorded contribution expenses of $0.8 million and $0.7 million, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for defined contribution plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715-70/tableOfContent + Details Name: us-gaap_DefinedContributionPlanTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â  Basis of Presentation Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (â€œU.S. GAAPâ€) and the rules and regulations of the United States Securities and Exchange Commission (â€œSECâ€) for interim reporting.Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC.The accompanying financial information for the three and six months ended June 30, 2024 and 2023 is unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Companyâ€™s financial position as of June 30, 2024 and December 31, 2023 and its results of operations and cash flows for the six months ended June 30, 2024 and 2023. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods. Use of Estimates and Judgements Use of Estimates and JudgmentsThe preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and the derivative instrument and income tax uncertainties. Actual results could differ from those estimates. Due to the war in Ukraine, conflicts in the Middle East, rising interest rates and inflation, and the lingering impacts of the coronavirus (â€œCOVID-19â€) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2024. While there was not a material impact to the Companyâ€™s unaudited condensed financial statements as of June 30, 2024, these estimates may change, as new events occur and additional information is obtained, as well as other factors that could result in material impacts to the unaudited condensed financial statements in future reporting periods. Segment Information Segment Information The Company operates and manages its business as one reportable and operating segment. The Companyâ€™s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance. Concentration of Credit Risk Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Companyâ€™s cash is held at two financial institutions in the United States of America. The Companyâ€™s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, U.S. government sponsored agencies, commercial paper, corporate bonds and certificates of deposit. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits. The Companyâ€™s partners in collaboration and license agreements who represent 10% or more of the Companyâ€™s total revenue are as follows: Â  Â  Â  Three Months Ended June 30, Â  Six Months Ended June 30, Â  Â  2024 Â  2023 Â  2024 Â  2023 Â Customer A Â  0% Â  96% Â  0% Â  98% Â Customer B Â  100% Â  * Â  100% Â  * Total Â  100% Â  96% Â  100% Â  98% Â * Less than 10% The Company did not have accounts receivable from its partners in collaboration and license agreements as of June 30, 2024 and December 31, 2023. Â The Companyâ€™s total revenue by geographic region, based on the location of the customer, are as follows (in thousands): Â  Â  Â  Three Months Ended June 30, Â  Â  Six Months Ended June 30, Â  Â  Â  2024 Â  Â  2023 Â  Â  2024 Â  Â  2024 Â  Â  Netherlands Â  $ â€” Â  Â  $ 230 Â  Â  $ â€” Â  Â  $ 525 Â  United States Â  Â  5 Â  Â  Â  9 Â  Â  Â  33 Â  Â  Â  13 Â  Total revenue Â  $ 5 Â  Â  $ 239 Â  Â  $ 33 Â  Â  $ 538 Â  Other Risks and Uncertainties Other Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (â€œCMOsâ€) and contract research organizations (â€œCROsâ€), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting. There can be no assurance that the Companyâ€™s research and development will be successfully completed, that adequate protection for the Companyâ€™s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Companyâ€™s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing). Recently Issued Accounting Pronouncements Not Yet Adopted Recently Issued Accounting Pronouncements Not Yet AdoptedOn December 14, 2023, the Financial Accounting Standards Board issued Accounting Standards Update (â€œASUâ€) No. 2023-09, Improvements to Income Tax Disclosures. The final guidance adds clarifications related to the presentation of rate reconciliation for public business entities and definitions of specific categories in rate reconciliation. These amendments are effective for public business entities for annual periods beginning after December 15, 2024. For other entities, amendments are effective for annual periods beginning after December 15, 2025. The Company is not early adopting ASU 2023-09. The Company expects to make additional disclosures for income taxes upon adoption of this ASU. X - DefinitionOther risks and uncertainties. + ReferencesNo definition available. + Details Name: fdmt_OtherRisksAndUncertainties Namespace Prefix: fdmt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -

SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Schedule of Concentration of Risk The Companyâ€™s partners in collaboration and license agreements who represent 10% or more of the Companyâ€™s total revenue are as follows: Â Â Â Three Months Ended June 30, Â Six Months Ended June 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Â Customer A Â 0% Â 96% Â 0% Â 98% Â Customer B Â 100% Â * Â 100% Â * Total Â 100% Â 96% Â 100% Â 98% Â * Less than 10% The Company did not have accounts receivable from its partners in collaboration and license agreements as of June 30, 2024 and December 31, 2023. Schedule of Revenues by Geographic Region The Companyâ€™s total revenue by geographic region, based on the location of the customer, are as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2024 Â Netherlands Â $ â€” Â Â $ 230 Â Â $ â€” Â Â $ 525 Â United States Â Â 5 Â Â Â 9 Â Â Â 33 Â Â Â 13 Â Total revenue Â $ 5 Â Â $ 239 Â Â $ 33 Â Â $ 538 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis The following tables represent the Companyâ€™s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Â Â Â Basis for Fair Value Measurements Â Â Fair Value as of Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â June 30, 2024 Â Assets Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 146,308 Â Â $ â€” Â Â $ â€” Â Â $ 146,308 Â Certificates of deposit Â Â â€” Â Â Â 69,677 Â Â Â â€” Â Â Â 69,677 Â Commercial paper Â Â â€” Â Â Â 96,220 Â Â Â â€” Â Â Â 96,220 Â Corporate bonds Â Â â€” Â Â Â 203,733 Â Â Â â€” Â Â Â 203,733 Â U.S. Treasuries Â Â â€” Â Â Â 18,970 Â Â Â â€” Â Â Â 18,970 Â Total Â $ 146,308 Â Â $ 388,600 Â Â $ â€” Â Â $ 534,908 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Derivative liability Â $ â€” Â Â $ â€” Â Â $ 382 Â Â $ 382 Â Total Â $ â€” Â Â $ â€” Â Â $ 382 Â Â $ 382 Â Â Â Â Basis for Fair Value Measurements Â Â Fair Value as of Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 217,644 Â Â $ â€” Â Â $ â€” Â Â $ 217,644 Â Commercial paper Â Â â€” Â Â Â 18,243 Â Â Â â€” Â Â Â 18,243 Â Corporate bonds Â Â â€” Â Â Â 28,939 Â Â Â â€” Â Â Â 28,939 Â U.S. government sponsored agencies Â Â â€” Â Â Â 2,896 Â Â Â â€” Â Â Â 2,896 Â Total Â $ 217,644 Â Â $ 50,078 Â Â $ â€” Â Â $ 267,722 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Derivative liability Â $ â€” Â Â $ â€” Â Â $ 369 Â Â $ 369 Â Total Â $ â€” Â Â $ â€” Â Â $ 369 Â Â $ 369 Â Summary of Changes in Fair Value of Level 3 Financial Instruments The following tables set forth a summary of the changes in the fair value of the Companyâ€™s Level 3 financial instrument during the six months ended June 30, 2024 and 2023 (in thousands): Â Â Â DerivativeLiability Â Balance as of December 31, 2023 Â $ 369 Â Change in fair value includedÂ in other income (expense), net Â Â 13 Â Balance as of June 30, 2024 Â $ 382 Â Â Â Â DerivativeLiability Â Balance as of December 31, 2022 Â $ 212 Â Change in fair value includedÂ in other income (expense), net Â Â â€” Â Balance as of June 30, 2023 Â $ 212 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities (Tables) 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Summary of Available for Sale Securities Marketable securities, which are classified as available-for-sale, consisted of the following as of June 30, 2024 and December 31, 2023 (in thousands):Â Â Â Amortized Cost Basis Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value as of June 30, 2024 Â Short-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Certificates of deposit Â $ 69,674 Â Â $ 21 Â Â $ (18 ) Â $ 69,677 Â Commercial paper Â Â 95,009 Â Â Â 8 Â Â Â (68 ) Â Â 94,949 Â Corporate bonds Â Â 169,491 Â Â Â 10 Â Â Â (212 ) Â Â 169,289 Â U.S. Treasuries Â Â 18,977 Â Â Â â€” Â Â Â (7 ) Â Â 18,970 Â Total short-term marketable securities Â $ 353,151 Â Â $ 39 Â Â $ (305 ) Â $ 352,885 Â Long-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 1,275 Â Â $ â€” Â Â $ (4 ) Â $ 1,271 Â Corporate bonds Â Â 34,466 Â Â Â 20 Â Â Â (42 ) Â Â 34,444 Â Total long-term marketable securities Â $ 35,741 Â Â $ 20 Â Â $ (46 ) Â $ 35,715 Â Â Â Â Amortized Cost Basis Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value as of December 31, 2023 Â Short-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 17,603 Â Â $ 1 Â Â $ (26 ) Â $ 17,578 Â Corporate bonds Â Â 18,641 Â Â Â 12 Â Â Â (3 ) Â Â 18,650 Â U.S. government sponsored agencies Â Â 2,900 Â Â Â â€” Â Â Â (4 ) Â Â 2,896 Â Total short-term marketable securities Â $ 39,144 Â Â $ 13 Â Â $ (33 ) Â $ 39,124 Â Long-term marketable securities: Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â $ 661 Â Â $ 4 Â Â $ â€” Â Â $ 665 Â Corporate bonds Â Â 10,257 Â Â Â 32 Â Â Â â€” Â Â Â 10,289 Â Total long-term marketable securities Â $ 10,918 Â Â $ 36 Â Â $ â€” Â Â $ 10,954 Â Summary of Aggregate Fair Values of Marketable Securities with Unrealized Losses and Gains Aggregate fair values of marketable securities with unrealized losses and gains were as follows as of June 30, 2024 and December 31, 2023 (in thousands):Â Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Aggregate fair value of marketable securities in a continuous loss position for less than twelve months Â $ 304,777 Â Â $ 20,494 Â Aggregate fair value of marketable securities in a continuous loss position for more than twelve months Â Â â€” Â Â Â 4,986 Â Aggregate fair value of marketable securities in unrealized gain position Â Â 83,823 Â Â Â 24,598 Â Total marketable securities Â $ 388,600 Â Â $ 50,078 Â X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net (Tables) 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] Â Schedule of Property and Equipment, Net Property and equipment, net, consisted of the following (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â Machinery and equipment Â $ 13,766 Â Â $ 12,996 Â Leasehold improvements Â Â 17,325 Â Â Â 16,902 Â Furniture and fixtures Â Â 566 Â Â Â 566 Â Office equipment Â Â 239 Â Â Â 239 Â Computer equipment and software Â Â 866 Â Â Â 805 Â Construction in progress Â Â 299 Â Â Â 550 Â Total property and equipment Â Â 33,061 Â Â Â 32,058 Â Less: Accumulated depreciation and amortization Â Â (14,300 ) Â Â (11,932 ) Property and equipment, net Â $ 18,761 Â Â $ 20,126 Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued and Other Current Liabilities (Tables) 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Summary of Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â Payroll and related expenses Â $ 5,494 Â Â $ 8,149 Â Accrued clinical and preclinical study costs Â Â 5,165 Â Â Â 2,180 Â Consulting and professional Â Â 2,021 Â Â Â 1,581 Â Other accrued expenses Â Â 96 Â Â Â 104 Â Total accrued and other current liabilities Â $ 12,776 Â Â $ 12,014 Â X - DefinitionSchedule of accrued and other current liabilities. + ReferencesNo definition available. + Details Name: fdmt_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock Namespace Prefix: fdmt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements (Tables) 6 Months Ended Jun. 30, 2024 Research And Collaboration Arrangements [Abstract] Â Summary of Collaboration and License Revenue Collaboration and license revenue for each period was as follows (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â uniQure Â $ â€” Â Â Â $ 230 Â Â Â $ â€” Â Â Â $ 525 Â CFF Â Â 5 Â Â Â 9 Â Â Â 33 Â Â Â 13 Â Total revenue Â $ 5 Â Â $ 239 Â Â $ 33 Â Â $ 538 Â Â Summary of Deferred Revenue Deferred revenue is summarized as follows (in thousands): Â Â Â June 30,2024 Â Â December 31,2023 Â CFF Â $ 1,318 Â Â $ 1,245 Â Total deferred revenue Â $ 1,318 Â Â $

1,245 Â  X - DefinitionResearch and Collaboration Arrangements. + ReferencesNo definition available. + Details Name: fdmt_ResearchAndCollaborationArrangementsAbstract Namespace Prefix: fdmt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueByArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â  Summary of Components of Lease Expense The following table summarizes the components of lease expense for the three and six months ended June 30, 2024 and 2023, which are included in operating expenses in the Companyâ€™s condensed statements of operations (in thousands): Â Â Â  Three Months Ended June 30, Â Â  Six Months Ended June 30, Â Â Â  2024 Â Â  2023 Â Â  2024 Â Â  2023 Â  Operating lease cost Â  $ 698 Â Â  $ 698 Â Â  $ 1,397 Â Â  $ 1,397 Â  Variable lease cost Â Â  354 Â Â Â  311 Â Â Â  707 Â Â Â  622 Â  Total Â  $ 1,052 Â Â  $ 1,009 Â Â  $ 2,104 Â Â  $ 2,019 Â  Summary of Supplemental Information Related to Operating Leases The following table summarizes supplemental information related to operating leases:Â Â Â  June 30,2024 Â Â  December 31,2023 Â  Weighted-average remaining lease term (in years): Â Â  5.2 Â Â Â  5.7 Â  Weighted-average discount rate: Â Â  7.8 % Â Â  7.8 % Â  Summary of Maturities of Lease Liabilities The following table summarizes the maturities of lease liabilities as of June 30, 2024 (in thousands):Â  2024 (remaining six months) Â  $ 1,588 Â  2025 Â Â  3,244 Â  2026 Â Â  3,135 Â  2027 Â Â  2,810 Â  2028 Â Â  2,894 Â  Thereafter Â Â  2,982 Â  Total future minimum lease payments Â Â  16,653 Â  Less: Amount representing interest Â Â  (2,997 ) Present value of future minimum lease payments Â Â  13,656 Â  Less: Current portion of operating lease liabilities Â Â  3,196 Â  Long-term portion of operating lease liabilities Â  $ 10,460 Â  X - DefinitionSummary of supplemental information related to operating leases + ReferencesNo definition available. + Details Name: fdmt_SummaryOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock Namespace Prefix: fdmt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock (Tables) 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â  Schedule of Common Shares Reserved for Future Issuance As of June 30, 2024 and December 31, 2023, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: Â Â Â  June 30,2024 Â Â  December 31,2023 Â  Issuance of common stock under the 2020 Equity Incentive Award Plan Â Â  2,332,657 Â Â Â  524,078 Â  Issuance of common stock under the 2020 Employee Stock Purchase Plan Â Â  273,375 Â Â Â  313,034 Â  Exercise of options issued and outstanding and future vesting of restricted stock units Â Â  8,450,290 Â Â Â  8,423,481 Â  Exercise of common stock warrants Â Â  3,637,145 Â Â Â  53,669 Â  Total common stock reserved for future issuance Â Â  14,693,467 Â Â Â  9,314,262 Â  X - DefinitionSchedule of common shares reserved for future issuance [Table Text Block] + ReferencesNo definition available. + Details Name: fdmt_ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock Namespace Prefix: fdmt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â  Summary of Restricted Stock Units (RSU) The Company has granted restricted stock unit (RSU) awards under the 2020 Equity Incentive Award Plan that vest over a period of four years. The following table summarizes the RSU activity for the six months ended June 30, 2024:Â Â Â  Number ofShares Â  Unvested balance at December 31, 2023 Â Â  181,181 Â  Issued Â Â  129,650 Â  Vested Â Â  (21,963 ) Canceled/Forfeited Â Â  (30,751 ) Unvested balance at June 30, 2024 Â Â  258,117 Â Â  Summary of Stock Options Activity The following table summarizes the stock options activity for the six months ended June 30, 2024:Â Â Â  Number ofSharesUnderlyingOutstandingOptions Â  Balances at December 31, 2023 Â Â  8,240,154 Â  Options granted Â Â  434,500 Â  Options exercised Â Â  (296,183 ) Options expired Â Â  (8,837 ) Options forfeited Â Â  (177,461 ) Balances at June 30, 2024 Â Â  8,192,173 Â  Options exercisable at June 30, 2024 Â Â  3,726,662 Â  Options vested and expected to vest at June 30, 2024 Â Â  8,192,173 Â  Summary of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Companyâ€™s stock options was estimated using the following assumptions for the three and six months ended June 30, 2024 and 2023:Â Â Â  Three Months Ended June 30, Â Â  Six Months Ended June 30, Â Â  2024 Â Â  2023 Â Â  2024 Â Â  2023 Expected term Â  6.0Â - 6.1Â years Â  6.0Â - 6.1Â years Â  6.0Â - 6.1Â years Â  6.0Â - 6.1Â years Expected volatility Â  84.9% - 85.4% Â  81.1% - 82.2% Â  81.4% - 85.4% Â  80.9% - 84.4% Risk-free interest rate Â  4.4% - 4.5% Â  3.5% - 4.0% Â  3.9% - 4.5% Â  3.5% - 4.0% Expected dividend yield Â  â€”% Â  â€”% Â  â€”% Â  â€”% Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function The following table is a summary of stock-based compensation expense incurred for employees and nonemployees by function (in thousands): Â Â Â  Three Months EndedJune 30, Â Â Â  Six Months EndedJune 30, Â Â Â  2024 Â Â  2023 Â Â  2024 Â Â  2023 Â  Research and development Â  $ 3,196 Â Â  $ 2,678 Â Â  $ 6,231 Â Â  $ 5,148 Â  General and administrative Â Â  2,877 Â Â Â  2,291 Â Â Â  5,817 Â Â Â  4,042 Â  Total stock-based compensation expense Â  $ 6,073 Â Â  $ 4,969 Â Â  $ 12,048 Â Â  $ 9,190 Â  X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share, Basic and Diluted (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â  Computation of Basic and Diluted Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): Â Â Â  Three Months Ended June 30, Â Â  Six Months Ended June 30, Â Â Â  2024 Â Â  2023 Â Â  2024 Â Â  2023 Â  Numerator Â Â Â

Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fdmt_TwoThousandTwentyOneFollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fdmt_TwoThousandTwentyThreeFollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fdmt_TwoThousandTwentyFourFollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fdmt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Segment Dec. 31, 2023 USD ($) Summary Of Significant Accounting Policies [Line Items] Â Â Number of reportable segments 1 Â Number of operating segments 1 Â Collaboration and License Agreements Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Accounts receivable | $ $ 0 $ 0 X - DefinitionSummary of significant accounting policies line items. + ReferencesNo definition available. + Details Name: fdmt_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: fdmt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) - Revenue - Customer Concentration Risk 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Customer A Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 0.00% 96.00% 0.00% 98.00% Customer B Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 100.00% Â 100.00% Â Customer Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 100.00% 96.00% 100.00% 98.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=fdmt_CustomerAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=fdmt_CustomerBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=fdmt_CustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical) - Revenue - Customer Concentration Risk 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Customer A Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 0.00% 96.00% 0.00% 98.00% Customer B Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage Â Â 10.00% Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=fdmt_CustomerAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=fdmt_CustomerBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Disaggregation Of Revenue [Line Items] Â Â Â Â Total revenue $ 5 $ 239 $ 33 $ 538 Netherlands Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Total revenue 0 230 0 525 United States Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Total revenue $ 5 $ 9 $ 33 $ 13 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -

Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_NL Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value on Recurring Basis - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets $ 534,908 $ 267,722 Liabilities 382 369 Derivative Liability Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Liabilities 382 369 Commercial Paper Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 96,220 18,243 Corporate Bonds Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 203,733 28,939 U.S. Treasuries Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 18,970 Â U.S. Government Sponsored Agencies Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets Â 2,896 Money Market Funds Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 146,308 217,644 Certificates of Deposit Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 69,677 Â Level 1 Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 146,308 217,644 Level 1 | Money Market Funds Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 146,308 217,644 Level 2 Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 388,600 50,078 Level 2 | Commercial Paper Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 96,220 18,243 Level 2 | Corporate Bonds Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 203,733 28,939 Level 2 | U.S. Treasuries Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 18,970 Â Level 2 | U.S. Government Sponsored Agencies Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets Â 2,896 Level 2 | Certificates of Deposit Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Assets 69,677 Â Level 3 Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Liabilities 382 369 Level 3 | Derivative Liability Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Liabilities $ 382 $ 369 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Additional Information (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Fair Value Disclosures [Abstract] Â Â Assets, Level 1 and Level 2 transfers $ 0 $ 0 Liabilities, Level 1 and Level 2 transfers $ 0 $ 0 X - DefinitionFair value assets level one and level two transfers amount. + ReferencesNo definition available. + Details Name: fdmt_FairValueAssetsLevelOneAndLevelTwoTransfersAmount Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value liabilities level one and level two transfers amount. + ReferencesNo definition available. + Details Name: fdmt_FairValueLiabilitiesLevelOneAndLevelTwoTransfersAmount Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) - Derivative Liability - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Â Beginning Balance $ 369 $ 212 Change in fair value included in other income (expense), net $ 13 $ 0 Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List] Other income (expense), net Ending Balance $ 382 $ 212 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities - Summary of Available for Sale Securities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Short-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis $ 353,151 $ 39,144 Gross Unrealized Gains 39 13 Gross Unrealized Losses (305) (33) Fair Value 352,885 39,124 Long-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis 35,741 10,918 Gross Unrealized Gains 20 36 Gross Unrealized Losses (46) 0 Fair Value 35,715 10,954 Commercial Paper | Short-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis 95,009 17,603 Gross Unrealized Gains 8 1 Gross Unrealized Losses (68) (26) Fair Value 94,949 17,578 Commercial Paper | Long-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis 1,275 661 Gross Unrealized Gains 0 4 Gross Unrealized Losses (4) 0 Fair Value 1,271 665 Corporate Bonds | Short-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis 169,491 18,641 Gross Unrealized Gains 10 12 Gross Unrealized Losses (212) (3) Fair Value 169,289 18,650 Corporate Bonds | Long-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis 34,466 10,257 Gross Unrealized Gains 20 32 Gross Unrealized Losses (42) 0 Fair Value 34,444 10,289 U.S. Treasuries | Short-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis 18,977 Â Gross Unrealized Gains 0 Â Gross Unrealized Losses (7) Â Fair Value 18,970 Â U.S. Government Sponsored Agencies | Short-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis Â 2,900 Gross Unrealized Gains Â 0 Gross Unrealized Losses Â (4) Fair Value Â $ 2,896 Certificates of Deposit | Short-term Marketable Securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Amortized Cost Basis 69,674 Â Gross Unrealized Gains 21 Â Gross Unrealized Losses (18) Â Fair Value $ 69,677 Â X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=fdmt_ShortTermMarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=fdmt_LongTermMarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=fdmt_CorporateBondMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities - Summary of Aggregate fair values of marketable securities with unrealized losses and gains (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-Sale [Line Items] Â Â Aggregate fair value of securities held in a continuous unrealized loss position for less than twelve months $ 304,777 $ 20,494 Aggregate fair value of marketable securities in a continuous loss position for more than twelve months 0 4,986 Aggregate fair value of marketable securities in unrealized gain position 83,823 24,598 Total marketable securities $ 388,600 $ 50,078 X - DefinitionAggregate fair value of marketable securities in unrealized gain position. + ReferencesNo definition available. + Details Name: fdmt_AggregateFairValueOfMarketableSecuritiesInUnrealizedGainPosition Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities - Additional Information (Details) - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-Sale [Line Items] Â Â Realized gains or losses on marketable securities $ 0 $ 0 Maximum unrealized loss at individual instrument level 13,000 Â Aggregate unrealized loss 350,000 Â Allowance for credit loss 0 0 Other impairment charges related to marketable securities $ 0 $ 0 Maximum Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Maturity period of marketable securities 2 years Â X - DefinitionAggregate unrealized loss. + ReferencesNo definition available. + Details Name: fdmt_AggregateUnrealizedLoss Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum unrealized loss at individual instrument level. + ReferencesNo definition available. + Details Name: fdmt_MaximumUnrealizedLossAtIndividualInstrumentLevel Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOther impairment charge related to marketable securities. + ReferencesNo definition available. + Details Name: fdmt_OtherImpairmentChargeRelatedToMarketableSecurities Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Property Plant And Equipment [Line Items] Â Â  Total property and equipment $ 33,061 $ 32,058 Less: Accumulated depreciation and amortization (14,300) (11,932) Property and equipment, net 18,761 20,126 Machinery and Equipment Â Â  Property Plant And Equipment [Line Items] Â Â  Total property and equipment 13,766 12,996 Leasehold Improvements Â Â  Property Plant And Equipment [Line Items] Â Â  Total property and equipment 17,325 16,902 Furniture and Fixtures Â Â  Property Plant And Equipment [Line Items] Â Â  Total property and equipment 566 566 Office Equipment Â Â  Property Plant And Equipment [Line Items] Â Â  Total property and equipment 239 239 Computer Equipment and Software Â Â  Property Plant And Equipment [Line Items] Â Â  Total property and equipment 866 805 Construction in Progress Â Â  Property Plant And Equipment [Line Items] Â Â  Total property and equipment $ 299 $ 550 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Property, Plant and Equipment [Abstract] Â Â Â Â  Depreciation expense $ 1.2 $ 1.1 $ 2.4 $ 2.1 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â  Payroll and related expenses $ 5,494 $ 8,149 Accrued clinical and preclinical study costs 5,165 2,180 Consulting and professional 2,021 1,581 Other accrued expenses 96 104 Total accrued and other current liabilities $ 12,776 $ 12,014 X - DefinitionAccrued clinical and preclinical study costs. + ReferencesNo definition available. + Details Name: fdmt_AccruedClinicalAndPreclinicalStudyCosts Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 58 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â  Total revenue $ 5 $ 239 $ 33 $ 538 Collaboration and License Revenue Â Â Â Â  Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â  Total revenue 5 239 33 538 Collaboration and License Revenue | uniQure Â Â Â Â  Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â  Total revenue 0 230 0 525 Collaboration and License Revenue | Cystic Fibrosis Foundation Â Â Â Â  Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â  Total revenue $ 5 $ 9 $ 33 $ 13 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=fdmt_CollaborationAndLicenseRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Total deferred revenue $ 1,318 $ 1,245 Cystic Fibrosis Foundation Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Total deferred revenue $ 1,318 $ 1,245 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Jul. 05, 2023 Jan. 31, 2014 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Aug. 31, 2019 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â $ 0 $ 500,000 Â Â Deferred revenue Â Â $ 1,318,000 Â 1,318,000 Â $ 1,245,000 Â Astellas GeneTherapies Inc Â Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Upfront payments received $ 20,000,000 Â Â Â Â Â Â Â Â uniQure Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Accounts receivable Â Â 0 Â 0 Â 0 Â uniQure | uniQure Agreement Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Collaborative arrangement, initial research term Â 3 years Â Â Â Â Â Â Â Â Upfront payments received Â $ 200,000 Â Â Â Â Â Â Options to purchase ordinary shares Â 609,744 Â Â Â Â Â Â Ordinary shares vesting period Â 3 years Â Â Â Â Â Â Fair value of options Â $ 10,600,000 Â Â Â Â Â Â Fair value of non monetary consideration of intellectual property right Â Â Â Â Â Â Â $ 5,100,000 uniQure | uniQure Agreement | Maximum Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Contingent payments entitled to receive for achievement of research and development milestones Â $ 5,000,000 Â Â Â Â Â Â uniQure | Amended uniQure Agreement | Maximum Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Contingent payments eliminated Â Â Â Â Â Â Â $ 5,000,000 uniQure | Amended uniQure Agreement and Second uniQure Agreement Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Revenue recognized Â Â 0 $ 200,000 0 $ 500,000 Â Â Deferred revenue Â Â 0 Â 0 Â 0 Â Remaining performance obligations Â Â 0 Â 0 Â $ 0 Â Arbor Biotechnologies Inc | Arbor Agreement Â Â Â Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Shared product designated by JSC Â Â 0 Â 0 Â Â Â Research and development expenses Â Â $ 0 Â $ 0 Â Â Â X - DefinitionCollaboration arrangements upfront payment received. + ReferencesNo definition available. + Details Name: fdmt_CollaborationArrangementsUpfrontPaymentReceived Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaborative arrangement, initial research term. + ReferencesNo definition available. + Details Name: fdmt_CollaborativeArrangementInitialResearchTerm Namespace Prefix: fdmt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCollaborative arrangement research and development milestones entitled to receive for each licensed product. + ReferencesNo definition available. + Details Name: fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionContingent payments eliminated. + ReferencesNo definition available. + Details Name: fdmt_ContingentPaymentsEliminated Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of non monetary consideration of intellectual property right. + ReferencesNo definition available. + Details Name: fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of options. + ReferencesNo definition available. + Details Name: fdmt_FairValueOfOptions Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOptions to purchase ordinary shares. + ReferencesNo definition available. + Details Name: fdmt_OptionsToPurchaseOrdinaryShares Namespace Prefix: fdmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShared product designated by JSC. + ReferencesNo definition available. + Details Name: fdmt_SharedProductDesignatedByJsc Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionVesting period of share awards. + ReferencesNo definition available. + Details Name: fdmt_VestingPeriodOfShareAwards Namespace Prefix: fdmt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=fdmt_AstellasGeneTherapiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_UniQureAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_AmendedUniQureAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_AmendedUniqureAgreementAndSecondUniqureAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fdmt_ArborBiotechnologiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_ArborAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements - Additional Information (Details 1) Jan. 31, 2014 uniQure | uniQure Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-07-01 Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Deferred revenue, estimated performance period 4 years X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_UniQureAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-07-01 Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements - CFF - Additional Information (Details) - CFF Agreement - Cystic Fibrosis Foundation 1 Months Ended

6 Months Ended 12 Months Ended Aug. 31, 2023 USD ($) Sep. 30, 2016 USD ($) Installment Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Collaborative arrangement total amount of award $ 6,300,000 $ 3,500,000 Â Â Collaborative arrangement achieved milestones Â Â $ 1,800,000 $ 1,700,000 Expected payments multiples to equal actual award received Â 6 Â Â Number of installments to pay actual award | Installment Â 3 Â Â Actual award payment period upon first commercial sale of product Â 4 years Â Â Continuous period where the Company ceases to develop or commercialize any product Â 180 days Â Â Collaborative arrangements special term Â If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of 180 consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Companyâ€™s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license. Â Â Deferred revenue Â Â 1,300,000 1,200,000 Accounts receivable Â Â 0 0 Aggregate amount of transaction price allocated to remaining performance obligation Â Â $ 1,300,000 $ 1,200,000 Maximum Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Future sales-based milestone payments multiples Â 3 Â Â Royalties multiples on actual award received Â 6 Â Â X - DefinitionActual award payment period upon first commercial sale of product. + ReferencesNo definition available. + Details Name: fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct Namespace Prefix: fdmt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCollaborative arrangement achieved milestones. + ReferencesNo definition available. + Details Name: fdmt_CollaborativeArrangementAchievedMilestones Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaborative arrangement royalties multiples on actual award received. + ReferencesNo definition available. + Details Name: fdmt_CollaborativeArrangementRoyaltiesMultiplesOnActualAwardReceived Namespace Prefix: fdmt_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionCollaborative arrangements future sales based milestone payment multiples. + ReferencesNo definition available. + Details Name: fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentMultiples Namespace Prefix: fdmt_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionCollaborative arrangements special term. + ReferencesNo definition available. + Details Name: fdmt_CollaborativeArrangementsSpecialTerm Namespace Prefix: fdmt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContinuous period where the Company ceases to develop or commercialize any product. + ReferencesNo definition available. + Details Name: fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct Namespace Prefix: fdmt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFuture sales based milestone payment expected payments multiples of actual award received. + ReferencesNo definition available. + Details Name: fdmt_FutureSalesBasedMilestonePaymentExpectedPaymentsMultiplesOfActualAwardReceived Namespace Prefix: fdmt_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionNumber of installments to pay actual award. + ReferencesNo definition available. + Details Name: fdmt_NumberOfInstallmentsToPayActualAward Namespace Prefix: fdmt_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionTotal amount of award under agreement. + ReferencesNo definition available. + Details Name: fdmt_TotalAmountOfAwardUnderAgreement Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Research and Collaboration Arrangements - CFF - Additional Information (Details 1) - Cystic Fibrosis Foundation - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-07-01 Jun. 30, 2024 Minimum Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Deferred revenue, estimated performance period 1 year Maximum Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Deferred revenue, estimated performance period 3 years X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-07-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Arrangements - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Jul. 05, 2023 Apr. 21, 2023 Jul. 31, 2021 Jan. 31, 2019 Jan. 31, 2016 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2018 Astellas GeneTherapies Inc Â Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Â Upfront payments received $ 20,000,000 Â Â Â Â Â Â Â Â Deferred revenue Â Â Â Â Â $ 0 Â $ 0 Â Â Accounts receivable Â Â Â Â Â 0 Â 0 Â Â Astellas GeneTherapies Inc | Maximum Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Future option fees and milestones $ 942,500,000 Â Â Â Â Â Â Â Â Â Aevitas Therapeutics, Inc. Agreement Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Upfront consideration payment Â $ 0 Â Â Â Â Â Â Â Â Liability related to contingent consideration Â Â Â Â Â 0 Â 0 Â Â Aevitas Therapeutics, Inc. Agreement | Maximum Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones Â 144,000,000 Â Â Â Â Â Â Â Â License Agreement for sCFH with University of Pennsylvania | Maximum Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones Â $ 42,000,000 Â Â Â Â Â Â Â Â UC Regents and the Trustees of the University of Pennsylvania Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Amount paid non-refundable license fee Â Â $ 100,000 Â Â Â Â Â Â Â Â Non-refundable license fee payable annually Â Â 10,000 Â Â Â Â Â Â Â Â Incurred expenses Â Â Â Â Â $ 0 $ 0 $ 0 Â UC Regents and the Trustees of the University of Pennsylvania | Maximum Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Contingent payments development milestones Â Â 3,900,000 Â Â Â Â Â Â Â Â UC Regents and the Trustees of the University of Pennsylvania | Minimum Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Annual royalty Â Â $ 100,000 Â Â Â Â Â Â Â UC Agreements Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Non-refundable license fee payable upon execution Â Â Â Â Â Â Â Â $ 5,000 Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties Â Â Â Â Â Â Â Â 5,000 Amount obligated to pay upon closing first qualified financing at option of UC Regents Â Â Â Â Â Â Â Â $ 50,000 Percentage of equity interest upon closing of first qualified financing at option of UC Regents Â Â Â Â Â Â Â Â 3.00% Percentage of equity interests issued as common stock Â Â Â 6.00% Â Â Â Â Â Amount paid non-refundable license fee Â Â $ 50,000 Â Â Â Â Â Non-refundable license fee payable annually Â Â 5,000 Â Â Â Â Â Â Â UC Agreements | Maximum Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Contingent payments development milestones Â Â 3,100,000 Â Â Â Â Â Â UC Agreements | Minimum Â Â Â Â Â Â Â Â Â Research And Development Arrangement Contract To Perform For Others [Line Items] Â Â Â Â Â Â Â Â Â Annual royalty Â Â $ 100,000 Â Â Â Â Â X - DefinitionAmount obligated to pay a non-refundable license fee annually. + ReferencesNo definition available. + Details Name: fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount obligated to pay upon closing first qualified financing at option. + ReferencesNo definition available. + Details Name: fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount paid non-refundable license fees. + ReferencesNo definition available. + Details Name: fdmt_AmountsPaidNonRefundableLicenseFees Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAnnual royalty. + ReferencesNo definition available. + Details Name: fdmt_AnnualRoyalty Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaboration arrangements upfront payment received. + ReferencesNo definition available. + Details Name: fdmt_CollaborationArrangementsUpfrontPaymentReceived Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaborative arrangement receive future option fees and milestones + ReferencesNo definition available. + Details Name: fdmt_CollaborativeArrangementReceiveFutureOptionFeesAndMilestones Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionContingent payments development milestones. + ReferencesNo definition available. + Details Name: fdmt_ContingentPaymentsDevelopmentMilestones Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncurred expenses + ReferencesNo definition available. + Details Name: fdmt_IncurredExpenses Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon-refundable license fee payable every year after execution until sales of a licensed product are made and royalties paid. + ReferencesNo definition available. + Details Name: fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNon-refundable license fee payable upon execution. + ReferencesNo definition available. + Details Name: fdmt_NonRefundableLicenseFeePayableUponExecution Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of equity interest upon closing of first qualified financing at option. + ReferencesNo definition available. + Details Name: fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption Namespace Prefix: fdmt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of equity interests issued as common stock. + ReferencesNo definition available. + Details Name: fdmt_PercentageOfEquityInterestsIssuedAsCommonStock Namespace Prefix: fdmt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPotential cash payment upon achievement of certain late-stage development, regulatory and sales milestones. + ReferencesNo definition available. + Details Name: fdmt_PotentialCashPaymentUponAchievementOfCertainLateStageDevelopmentRegulatoryAndSalesMilestones Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUpfront consideration payment. + ReferencesNo definition available. + Details Name: fdmt_UpfrontConsiderationPayment Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details Name:

us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=fdmt_AstellasGeneTherapiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_AevitasTherapeuticsIncAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_LicenseAgreementWithUniversityOfPennsylvaniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_UCAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Additional Information (Details) $ in Thousands 1 Months Ended 6 Months Ended 12 Months Ended Jan. 01, 2024 USD ($) ftÂ² Jul. 31, 2024 USD ($) ftÂ² Feb. 28, 2021 USD ($) Dec. 31, 2019 USD ($) Nov. 30, 2018 USD ($) Oct. 31, 2018 Jan. 31, 2016 Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) May 31, 2015 Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Operating lease right-of-use ("ROU") assets Â Â Â Â Â Â Â Â $ 10,688 $ 11,539 Â Operating lease liability Â Â Â Â Â Â Â Â 13,656 Â Â Future minimum lease payments Â Â Â Â Â Â Â Â 16,653 Â Â 5980 Horton Street Building Lease Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Lease extended term date Â Â Â Â Â Â Mar. 31, 2023 Â Â Â Operating lease right-of-use ("ROU") assets Â Â Â Â Â Â Â 1,000 1,200 Â Operating lease liability Â Â Â Â Â Â Â Â $ 1,200 1,400 Â Operating lease, discount rate Â Â Â Â Â Â Â Â 7.50% Â Â Lease extended term period Â Â Â Â Â 2026-09 Â Â Â Â Â Tenant improvement allowance Â Â Â Â Â $ 200 Â Â Â Â Â Â Lease renewal term Â Â Â Â Â Â 5 years Â Â 3 years 5858 Horton Street Building Lease and Expansion Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Tenant improvement allowance Â Â Â $ 400 Â Â Â Â Â Â Lease initial term Â Â Â Â Â 87 months Â Â Â Â Lease option to renew term description Â Â Â Â Â Â Â The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years at market rent. Â Â Lease existence of option to renew term Â Â Â Â true Â Â Â Â Lease renewal term Â Â Â Â Â 5 years Â Â Â Â 5858 Horton Street Building Lease and 2019 Expansion Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Operating lease right-of-use ("ROU") assets Â Â Â Â Â Â Â $ 9,700 10,300 Â Operating lease liability Â Â Â Â Â Â Â Â $ 12,500 13,200 Â Operating lease, discount rate Â Â Â Â Â Â Â Â 7.80% Â Â Tenant improvement allowance Â Â $ 2,300 Â Â Â Â Â $ 2,300 Â 5858 Horton Street Building Lease and 2019 Expansion | Subsequent Event Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Lease extended term date Â Dec. 31, 2030 Â Â Â Â Â Â Â Â Lease renewal term Â 12 months Â Â Â Â Â Â Â Â 5858 Horton Street Building Lease and 2024 Expansion Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Operating lease right-of-use ("ROU") assets Â Â Â Â Â Â Â Â $ 0 Â Â Operating lease liability Â Â Â Â Â Â Â Â 0 Â Â 5858 Horton Street Building Lease and 2024 Expansion | Subsequent Event Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Lease extended term date Â Dec. 31, 2030 Â Â Â Â Â Â Â Â Lease commencement date Â Sep. 01, 2024 Â Â Â Â Â Â Â Â Area of office and warehouse space | ftÂ² Â 32,038 Â Â Â Â Â Â Â Â Future minimum lease payments Â $ 13,200 Â Â Â Â Â Â Â Â Â Warehouse Lease Agreement Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Operating lease right-of-use ("ROU") assets Â Â Â Â Â Â Â Â 0 Â Â Operating lease liability Â Â Â Â Â Â Â Â $ 0 Â Â Lease initial term 5 years 4 months Â Â Â Â Â Â Â Â Â Lease commencement date Aug. 31, 2024 Â Â Â Â Â Â Â Â Area of office and warehouse space | ftÂ² 7,800 Â Â Â Â Â Â Â Â Future minimum lease payments $ 1,500 Â Â Â Â Â Â Â Â X - DefinitionCommitment and contingencies. + ReferencesNo definition available. + Details Name: fdmt_CommitmentAndContingenciesLineItems Namespace Prefix: fdmt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLease commencement date. + ReferencesNo definition available. + Details Name: fdmt_LeaseCommencementDate Namespace Prefix: fdmt_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionOperating lease term extended expiration period. + ReferencesNo definition available. + Details Name: fdmt_OperatingLeaseTermExtendedExpirationPeriod Namespace Prefix: fdmt_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionProceeds from tenant improvement allowance. + ReferencesNo definition available. + Details Name: fdmt_ProceedsFromTenantImprovementAllowance Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_LeaseContractualTermAxis=fdmt_FiveNineEightZeroHortonStreetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=fdmt_FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=fdmt_FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=fdmt_FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=fdmt_WarehouseLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies- Summary of Components of Lease Expense - (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Operating lease cost $ 698 $ 698 $ 1,397 $ 1,397 Variable lease cost 354 311 707 622 Total $ 1,052 $ 1,009 $ 2,104 $ 2,019 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 67 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Summary of Supplemental Information Related to Leases - (Details) Jun. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Weighted-average remaining lease term (in years) 5 years 2 months 12 days 5 years 8 months 12 days Weighted-average discount rate 7.80% 7.80% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 68 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â 2024 (remaining six months) $ 1,588 Â 2025 3,244 Â 2026 3,135 Â 2027 2,810 Â 2028 2,894 Â Thereafter 2,982 Â Total future minimum lease payments 16,653 Â Less: Amount representing interest (2,997) Â Present value of future minimum lease payments 13,656 Â Less: Current portion of operating lease liabilities 3,196 $ 3,149 Long-term portion of operating lease liabilities $ 10,460 $ 11,522 X - DefinitionLessee operating lease liability payments due after year four. + ReferencesNo definition available. + Details Name: fdmt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-

gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 69 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes - Additional Information (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Provision for income tax $ 0 $ 0 $ 0 $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 70 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock - Additional Information (Details) - USD ($) 1 Months Ended 6 Months Ended 12 Months Ended Oct. 31, 2021 Apr. 30, 2020 Jun. 30, 2024 Dec. 31, 2023 Class of Stock [Line Items] Â Â Â Â Common stock, shares authorized Â Â 300,000,000 300,000,000 Common stock, par value Â Â $ 0.0001 $ 0.0001 Common stock voting rights Â Â one vote per share Â Common stock dividend Â Â $ 0 $ 0 Funding Agreement | Cystic Fibrosis Foundation Â Â Â Â Class of Stock [Line Items] Â Â Â Â Additional funding upon acceptance of investigational New Drug application $ 4,000,000 $ 4,000,000 Â Â Additional investment in cash $ 4,000,000 Â Â Â Funding Agreement | Cystic Fibrosis Foundation | Common Stock Â Â Â Â Class of Stock [Line Items] Â Â Â Â Number of shares sold and issued 125,715 Â Â Â Funding Agreement | Cystic Fibrosis Foundation | Series C Redeemable Convertible Preferred Stock Â Â Â Â Class of Stock [Line Items] Â Â Â Â Investment in redeemable convertible preferred stock financing Â $ 10,000,000 Â Â X - DefinitionAdditional funding committed. + ReferencesNo definition available. + Details Name: fdmt_AdditionalFundingCommitted Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAdditional investment in cash. + ReferencesNo definition available. + Details Name: fdmt_AdditionalInvestmentInCash Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=fdmt_FundingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=fdmt_SeriesCRedeemableConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock - Schedule of Common Share Reserved for Future Issuance (Details) - shares Jun. 30, 2024 Dec. 31, 2023 Dec. 31, 2020 Class Of Stock [Line Items] Â Â Â Common stock reserved 14,693,467 9,314,262 Â 2020 Equity Incentive Award Plan Â Â Â Class Of Stock [Line Items] Â Â Â Common stock reserved 2,332,657 524,078 2,606,546 2020 Employee Stock Purchase Plan Â Â Â Class Of Stock [Line Items] Â Â Â Common stock reserved 273,375 313,034 252,337 Exercise of Options Issued and Outstanding and Future Vesting of Restricted Stock Units Â Â Â Class Of Stock [Line Items] Â Â Â Common stock reserved 8,450,290 8,423,481 Â Common Stock Warrants Â Â Â Class Of Stock [Line Items] Â Â Â Common stock reserved 3,637,145 53,669 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEquityIncentiveAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=fdmt_EmployeeOptionsIssuedAndOutstandingAndFutureVestingOfRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Additional Information (Details) 6 Months Ended Jun. 30, 2024 Period shares Feb. 29, 2024 shares Dec. 31, 2023 shares Dec. 31, 2020 shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Number of shares reserved for issuance 14,693,467 Â 9,314,262 Â Number of options outstanding 8,192,173 Â 8,240,154 Â Expected dividend yield 0.00% Â Â Â 2020 Equity Incentive Award Plan Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Number of shares reserved for issuance 2,332,657 Â 524,078 2,606,546 Percentage of common stock outstanding increased annually for future issuance 5.00% Â Â Â Number of shares available for grant 1,997,052 2,153,533 Â Â 2020 Equity Incentive Award Plan | Restricted Stock Units (RSU) Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Vesting period 4 years Â Â Â 2020 Equity Incentive Award Plan | Maximum Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Number of shares authorized 18,000,000 Â Â Â Options exercisable period 10 years Â Â Â 2015 Equity Incentive Plan Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Number of shares available for grant 335,605 Â Â Â Options exercisable period 10 years Â Â Â Number of options outstanding 1,545,023 Â Â Â Number of additional shares available for grant 0 Â Â Â 2020 ESPP Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Number of shares reserved for issuance 273,375 Â 313,034 252,337 Number of shares available for grant Â 50,000 Â Â Increase in shares available for issuance percentage 1.00% Â Â Â Employee purchase price of common stock as percentage of fair market value 85.00% Â Â Â Common stock overlapping offering period 24 months Â Â Â Number of duration purchase period | Period 4 Â Â Â Percentage of maximum contributions of employee's eligible compensation 15.00% Â Â Â 2020 ESPP | Maximum Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Number of shares authorized 15,000,000 Â Â Â X - DefinitionIncrease in shares available for issuance percentage. + ReferencesNo definition available. + Details Name: fdmt_IncreaseInSharesAvailableForIssuancePercentage Namespace Prefix: fdmt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award number of additional shares available for grant. + ReferencesNo definition available. + Details Name: fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant Namespace Prefix: fdmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionShare based compensation arrangement by share based payment award number of duration purchase period. + ReferencesNo definition available. + Details Name: fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDurationPurchasePeriod Namespace Prefix: fdmt_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award percentage of outstanding stock increased annually for future issuance. + ReferencesNo definition available. + Details Name: fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance Namespace Prefix: fdmt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award stock overlapping offering period. + ReferencesNo definition available. + Details Name: fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod Namespace Prefix: fdmt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe highest percentage of annual salary that an employee is permitted to utilize with respect to the plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEquityIncentiveAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=fdmt_TwoThousandFifteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Summary of Restricted Stock Units (RSU) (Details) - Restricted Stock Units (RSU) 6 Months Ended Jun. 30, 2024 shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â  Number of Shares, Unvested Beginning Balance 181,181 Issued 129,650 Vested (21,963) Canceled/Forfeited (30,751) Number of Shares, Unvested Ending Balance 258,117 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R68.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Summary of Stock Options Activity (Details) 6 Months Ended Jun. 30, 2024 shares Share-Based Payment Arrangement [Abstract] Â  Number of Shares Underlying Outstanding Options, Balances at December 31, 2023 8,240,154 Number of Shares Underlying Outstanding Options, granted 434,500 Number of Shares Underlying Outstanding Options, exercised (296,183) Number of Shares Underlying Outstanding Options, expired (8,837) Number of Shares Underlying Outstanding Options, forfeited (177,461) Number of Shares Underlying Outstanding Options, Balances at June 30, 2024 8,192,173 Number of Shares Underlying Outstanding Options, Options exercisable at June 30, 2024 3,726,662 Number of Shares Underlying Outstanding Options, Options vested and expected to vest at June 30, 2024 8,192,173 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 75 R69.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â  Â  Â  Â  Expected volatility, minimum 84.90% 81.10% 81.40% 80.90% Expected volatility, maximum 85.40% 82.20% 85.40% 84.40% Risk-free interest rate, minimum 4.40% 3.50% 3.90% 3.50% Risk-free interest rate, maximum 4.50% 4.00% 4.50% 4.00% Expected dividend yield Â  Â  0.00% Â  Minimum Â  Â  Â  Â  Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â  Â  Â  Â  Expected term 6 years 6 years 6 years 6 years Maximum Â  Â  Â  Â  Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â  Â  Â  Â  Expected term 6 years 1 month 6 days 6 years 1 month 6 days 6 years 1 month 6 days 6 years 1 month 6 days X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-

types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R70.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense $ 6,073 $ 4,969 $ 12,048 $ 9,190 Research and Development Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense 3,196 2,678 6,231 5,148 General and Administrative Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Total stock-based compensation expense $ 2,877 $ 2,291 $ 5,817 $ 4,042 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R71.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock Warrants - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Dec. 31, 2020 May 31, 2018 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Feb. 29, 2024 Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Number of warrant shares issued 30,000 23,669 Â Â Â Â Â Exercise price $ 18 $ 3.19 Â Â Â Â Â Warrant expiration year 2027 2025 Â Â Â Â Â Warrant vesting period 4 years Â Â Â Â Â Warrant expense Â Â $ 0 $ 0 $ 0 $ 0 Â 2024 Follow On Public Offering | Common Stock Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Warrant shares become exercisable Â Â Â Â Â Â 3,583,476 2024 Follow On Public Offering | Common Stock | Pre-funded Warrants Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Exercise price Â Â Â Â Â Â $ 0.0001 Warrant shares become exercisable Â Â Â Â Â Â 3,583,476 Common stock offering price Â Â Â Â Â Â $ 29.4999 Issuance of pre-funded warrants Â Â Â Â $ 99,400,000 Â Â X - DefinitionNumber of warrant shares issued. + ReferencesNo definition available. + Details Name: fdmt_NumberOfWarrantSharesIssued Namespace Prefix: fdmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWarrant expense. + ReferencesNo definition available. + Details Name: fdmt_WarrantExpense Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWarrant expires year. + ReferencesNo definition available. + Details Name: fdmt_WarrantExpiresYear Namespace Prefix: fdmt_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionWarrant vesting period. + ReferencesNo definition available. + Details Name: fdmt_WarrantVestingPeriod Namespace Prefix: fdmt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fdmt_TwoThousandTwentyFourFollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fdmt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R72.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Numerator Â Â Â Â Net loss $ (34,953) $ (29,616) $ (67,354) $ (58,298) Denominator Â Â Â Â Weighted-average shares outstanding used in computing net loss per share, basic 55,282,754 38,335,219 52,277,369 35,661,995 Weighted-average shares outstanding used in computing net loss per share, diluted 55,282,754 38,335,219 52,277,369 35,661,995 Net loss per share, basic $ (0.63) $ (0.77) $ (1.29) $ (1.63) Net loss per share, diluted $ (0.63) $ (0.77) $ (1.29) $ (1.63) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19:

http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 79 R73.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share, Basic and Diluted - Additional Information (Details) - $ / shares Feb. 29, 2024 Dec. 31, 2020 May 31, 2018 Class of Warrant or Right [Line Items] Â Â Â Exercise price Â $ 18 $ 3.19 Common Stock | 2024 Follow On Public Offering Â Â Â Class of Warrant or Right [Line Items] Â Â Â Warrants to purchase shares of common stock 3,583,476 Â Â Common Stock | Pre-funded Warrants | 2024 Follow On Public Offering Â Â Â Class of Warrant or Right [Line Items] Â Â Â Warrants to purchase shares of common stock 3,583,476 Â Â Exercise price $ 0.0001 Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fdmt_TwoThousandTwentyFourFollowOnPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fdmt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R74.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities 8,748,581 6,745,647 Options Issued and Outstanding Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities 8,192,173 6,422,876 Restricted Stock Units Subject to Future Vesting Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities 258,117 0 2020 ESPP Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities 244,622 269,102 Common Stock Warrants Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Antidilutive securities 53,669 53,669 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R75.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Derivative Liability - Additional Information (Details) - USD ($) $ in Millions 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Derivative [Line Items] Â Â Change in control discount rate 15.00% 15.00% Estimated fair value of derivative liability $ 0.4 $ 0.4 Minimum Â Â Derivative [Line Items] Â Â Change of control payment $ 0.0 $ 0.0 Change in control event percentage 4.80% 4.80% Maximum Â Â Derivative [Line Items] Â Â Change of control payment $ 18.9 $ 18.9 Change in control event percentage 17.20% 17.20% X - DefinitionFair value assumptions change of control payment. + ReferencesNo definition available. + Details Name: fdmt_FairValueAssumptionsChangeOfControlPayment Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value assumptions probability of change in control discount rate. + ReferencesNo definition available. + Details Name: fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate Namespace Prefix: fdmt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value assumptions probability of change in control event percentage. + ReferencesNo definition available. + Details Name: fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage Namespace Prefix: fdmt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R76.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions - Additional Information (Details) - Reignite Agreement $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Mar. 31, 2024 USD ($) Product Jun. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Related Party Transaction [Line Items] Â Â Â Research and development expenses Â $ 400 $ 400 Option exercise fee Â 0 0 Option exercise fees per selected capsid $ 1,000 Â Â Amount due to related party Â $ 0 $ 0 Maximum Â Â Â Related Party Transaction [Line Items] Â Â Â Related party expenses 1,500 Â Â Equipment costs $ 60 Â Â Number of capsids |

Product 3 Â Â  Option exercise fee $ 3,000 Â Â  X - DefinitionEquipment costs. + ReferencesNo definition available. + Details Name: fdmt_EquipmentCosts Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of capsids. + ReferencesNo definition available. + Details Name: fdmt_NumberOfCapsids Namespace Prefix: fdmt_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionOption exercise fees payable to related party. + ReferencesNo definition available. + Details Name: fdmt_OptionExerciseFeesPayableToRelatedParty Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOption exercise fees per selected capsid payable to related party. + ReferencesNo definition available. + Details Name: fdmt_OptionExerciseFeesPerSelectedCapsidPayableToRelatedParty Namespace Prefix: fdmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionAxis=fdmt_ReigniteAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R77.htm IDEA: XBRL DOCUMENT v3.24.2.u1 401(K) Plan - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Mar. 31, 2024 Mar. 31, 2023 Jun. 30, 2023 Jun. 30, 2024 401(k) Plan Â Â Â Â Defined Contribution Plan Disclosure [Line Items] Â Â Â Â Employer contribution $ 0.4 $ 0.2 $ 0.8 $ 0.7 X - DefinitionAmount of contribution received by defined benefit plan from employer which increases plan assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_DefinedBenefitPlanContributionsByEmployer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1 + Details Name: us-gaap_DefinedContributionPlanDisclosureLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RetirementPlanNameAxis=fdmt_TwoThousandFourteenPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT Begin 644 Financial_Report.xlsx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Ð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}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§HR3NX1Y*)22,W+"C%G;DA?U#:%H<@3 :/#L, M<41(#^)0#*=1F(PD0-R"C%^? %-0B.INIIDL78!C1R[$])*0RD$TW D%9(6 M;G(@%0RK2OW74'"F:X#TA+Q7,'I M+2]&=U/TIE3W5M;V?>[(#OG9[G.6B=J0&UC39[N1.!TFPX 'I%^(+JEP9V/9 M!]AQ/'*3G $H:]-V#6GCT#(-Z0SA.([ZL%UB$(UE>T=[R,][5VS)#,[<]/ / MK*K=@1TRUZ 4AR(X)B/@.G)#?G;K[V\[H9RV\5T+:2<(_ AGQ&4#D+KD@&K M]KB.])"?]?:I^5 6.)@L#6"? GUUB21J.;2D=XR$_Y?6SH&$-()9'!=E!@ 3U MB<0AE<9X!'?'\A/@%=,FK;73HYM@)^=&(<\1A+DN\ M,_-YJ6=;9X?P84>-QW&?LUUB&$9C,>SH"Q\8UD19T[WU$C#KS]RHT6V?U*%#F3ZL. [!*/X4]-6 MNTL5>WGVU1/Z&UG=[UC5WQPJMQNK,H&80K>PU,((3)MC 1F7K<[+8)3\Y7] M VI%I1T]:[T2DO]KVPD-OM85:\]8FNRY8ADK;TU1OAR=? *5>%'F2K5]2*V5 M-A=V\SG.D'- !#K. 5V0_=!WW8S_WVY(1E2=N!+Y%X$(T35$PQ7'82 1D"N-P MBE'R)O&<&D)5:]:<;1;N='=,YOWH#D5&VC[<-2?8WYQ\SG-N^<;LG/;88\:K M64;7W.RD3I"N.3M&!*9]]$/!&!-$1N9\HK\!) (91R[Z+#[F.&TWYWY9!"8\B[%@7[6Y1=Y#E;\HP[QW$\;#YF M08*CI#^_. 7-3(YC-U+2=2K$WZELB%2]:K?*/RCE?*-(!+HPA/8Q,& MN7D?L;G18MT"M@/E]*4R#L+VQ;PG:MT*+_P!02P,$% M @ ]X$(668LDN?Q @ \ D !@ !X;"]W;W)KN*^,4*DRRF ND"SSG(C?UY#Q MS=3QG*>'6[I*E1EPHTE!5K =5?,A>ZYC4M"R)AQK/O-%'IU!DY*($E*3-URS>?H$XH-'XQSZ3]1ILJ=C!P4%Q*Q?-: MK ERRJI?\E@OQ); Z^\1^+7 /U40U(+ )EJ1V;1NB"+11/ -$B9:NYF&71NK MUME09E[C0@G]E&J=BF:<)?JE0(*N2498#&AAO"0ZNV.D3*B"Y!R=S8D IE)0 M-";9.7J/WB(7R52/RHFK-(8Q<^- ZRNMJ2G /E%]*UD,!OD ^]OL=\MEA^0W$ M6NY9>="6NSKY9@7\9@5\ZQ?L\5LHHD 7ID)\B3Y2IA>!D@S-N:2VT'YYL]>"D+$L/4T9M,@EB#$[U[XPWPAZ[$_Y-9:QF"9AF"0^[1 M7&\? $$(7@JZY^.$"%42@-C2L MQ3EJ.$WU_W@WL M!W@8^MZH&]C#_TXR_ KD(X5;>YX WA&YA]S=.H[-7>@K$2O*),I@J:6X-]0> MHKI>5!W%"WM"WW.ESWO;3/65# (0)T,^7G*NGCCGTFTM>]!=02P,$% @ MJX$(66_GV: A!0 W18 !@ !X;"]W;W)KRARP"4227VFCH&+[;97]-H@N?2>&8NVA9-$5Z2<]-^7E!39 MIE9JVOHEL>39(6=W28XY?1;E- [GE7*&7/"ODS62KU.[:<>1JRW,FK\2.%_J; MM2ASIO1CN7'DKN0LJ8/RS"&N&S@Y2XO);%]_NRMG4U&I+"WX78EDE>>L_.N6 M9^+Y9H(GKR_NT\U6F1?.;+IC&_[ U>/NKM1/3L>2I#DO9"H*5/+US>0COE[B MR 34B#]2_BR//B,CY4F(;^;A4W(S<,97RE P_6_/YSS+#).>QY\MZ:0; MTP0>?WYE_[$6K\4\,&^"]=02_ M#:BE.XWV.G$+IMAL6HIG5!JT9C,? ZNS7T3I?:6$:Y4&5^MM4QZ97!2)+CM/ MT(-BBNL64!*)-?I]QTMF2BG1Q6/!JB15/'F/+M'CPP)=O'N/WJ&T0%^VHI*L M2.344THRAM)9M0/?-@.3@8$I^BP*M95HJ2>0 /&+\?A@)- (12>@R05XS<4M& M"7^IBBM$W0^(N,0#YC-_>SB%Y/R_T9?_>?239-"N+6C-1P?X[OF>%Q6_ANK: M1'IPI-G8KN6.K?C-1.]2:RDTH$ M726"T=:[UXRL7&WKKDMTMV5B9TX%J!P- DW_<*S@*7*OK^BA"_X+H$;KZPDQR.2OZ)%[K[LEHQ2_0AFTIENG$/+K.P-P7L!BZV1/=1 M41A;H$4?1-PHCBS-P(!!&(:PJC3'(UJ_B*45BQZRPY2'/633KS 5MQ'44)# M:PM:]%&1&Q +M>RC A*&,2PY[B3'HY)_%5*B=2GR5]G:W$!RX][@EUJO'UAZ M 1@EF%JP!0*+7#\FEF( %A#B85@R=@_VSAW?6-66E]JJK43.T45;Y??@YMHR MG6EW/2O;XJQLRW.QG=;DR'+CT4;\5"BN>55;%K 6N-]9.\,<0!$?6ZVU M %"8DM@^U0$8C7U_H ')02P9%0LWX =4'Q[FX% M>. PP0?KC$>MX>O6>J1[6"T%RNQ26VX?17SBVHK[*%UF:I\F (S&'AT0?3"L M>-RQ_L85RO0&"ZKL&\9+ZL5^3R> (W& [2T5P@4A]3U;*H#S(Q(/>%5*MX MU(%U8I$^1Y#VT? M-KS1+Y&HE%3:.QH;59F;E+1 >M7OJMI8%?^J5_I>S_=)$*[M^< DD:4^@3; M/^@@3J+=% UZB0,X_2# <3QT"AS<)AZWF^? +W5BW]6WC4/8 LSJ0/8!S('L M)YP]Y^BZ+N?EIKXGE5IW5:CFBJ9[V]W%?JQO(*WWM_AZCH'W"W-W6U\/'NB; MB]_/K-RDA4097^NA]!K3TRV;N]3F08E=?5GX))02>?UQRUG"2P/0WZ^%4*\/ M9H#N1GOV-U!+ P04 " #W@0A9Z'!)CD8# !R"P & 'AL+W=OJ9')J MY4IMQK8MTQPJ*B_X!AA^67%1485+L;;E1@#-&E!5VI[C1'9%"V8EDV;O1B03 M7JNR8' CB*RKBHK_KJ'DNZGE6@\;'XIUKO2&G4PV= VWH.XV-P)7=L^2%14P M67!&!*RFUI4[7L3:OC'X5,!.[KT3G)U-+4<!"6D2C-0?&QA!F6I MB3",?SM.JW>I@?OO#^Q_ -;EC+DLJ8<;+ST6F\JEU:9$,5K0NU0>^>P5=/J'F M2WDIFU^RZVP=BZ2U5+SJP!A!5;#V2;]V==@#((\9X'4 ;P@(G@#X'@ M P3/]1!V@"9UN\V]*=R<*II,!-\1H:V13;\TU6_06*^":9W<*H%?"\2I9,99 MAEV'C-PJ@ 5H"3A*S+C%>HNUX+8 OF;2TG.[ABMLT]!=DY>DKO;.3E[<4Y> MD(*1CSFO)669G-@*@]+4=MH%<-T&X#T1@$_>.Y8:F,+606(+8@I7_IL;.7^: M"G]*LODIR18G(CMH4="W*#C&GKS#RZ3$\VDJ?XN,&]2^,;;)2S\8A:B,[7YA M#6;>*"C0[.YP2R*_3 X-%L8S,)+;W39FQVD&?9IAD>5^%[E($AZ($&=]MB4 M=WA*V9V2;'Y*LL6)R [Z$? 7]B'XHNYKA:%(6_^/ML<:1A)SIAIP3O/]QYK@' M19_[_3M-/J6BG7! M)"EAA:Z%MI!/V8GWP!0 M2P,$% @ ]X$(64OL83I;$P $RP! !@ !X;"]W;W)K=[H87EAC$;. MQ4.Q6)U=?GC^L^O-Y8?U4[5G@H-O_^M5RNOWT\T\]>_^"WQ=U] MU?S!Q>6'Q^*N_%16?SQ>;^KO+MZ4F\5#N=HNUBMM4]Y^//N'_DONC)L-GE_Q MST7Y;?ON:ZWY43ZOUU^:;*;CV>C9H_*93FO&J*H__>UO"J7RT:]]^-?._3L MK6:SX?NO7W7O^8>0?YC/Q;:\6B__=W%3W7\\FYQI-^5M\;2L?EM_"\K=#V0W MWGRJW#[_5_NV>^WH3)L_;:OUPV[C>@\>%JN7_Q=_[@[$NPUT<\\&QFX#0]C MT/=L8.XV,,4*SIX-K-T&EK"!M6^7[-T&]K$_@[/;P!$V,*T]&XQW&XS%'WJZ M9X/);H.)L(&][X>>[C:8BA7&^]ZXT>L[-Q*/TV3?)F]OMOAN[SVT^NO;K8OO M]WCO&?7ZANOB.V[N_5E>WW)=?,^- O55>W_27$_[BY8Q_OEQF155W;A]W55+"6;7:DW^\?OJ9;? MWI:,Q>I.N]ZL[S;%@T29J97KI_+Q;S^B5\@">"J :_\O'FJ&ZMVH:7%9GZO M&2/#TG;LV_Y]*I:EQ/;4]M7ZX:%NH<_OA61K__BMM2./5C" /'SHP@':7SJ. MT8%3Y:8^:>M_C(JE=ETL;L[K_6]>%S(3[OX5.O88YR<7.#P$4]/MO_2\<\. ME)W/GQZ>EG5_N='RZK[<:/5;7X]F[IMAQM=22]9;6=_(CU=GY>UBOJBZR$7= M"]\:HO'6$(UGU=]CRAK?3]KG\FZQ6C5'X'.Q+%;S] ZE[OY=KF;S.7^0]TKM_=%_?/\>-2EKRP[\!!= MD=B,Q%P2\UXP^WV#,!S#<0RA8?IDU8#$0A*+2"PFL83$4A++2"R'L$YGLMXZ MDZ7L3.%V^]2TGN;3V/QEI+Q]'BD_/=9?EG^6F_EB^_RW+W^\?FQ&=M+/7U;O MNM)UTQ8& (B8\R#X1DO499=.BXA\1F).:2F&?WKR_#,$;BJ(>L&9!82&(1B<4DEI!8 M2F(9B>40UNE*SEM7EM)1SO* D,[D-/[V#EU+.'" MG)$571+S2,PGL8#$0A*+2"P^YOQ)R(HIB64DED- 8IZ^,W_K*F,PKAT8YRF)# M>PR)S4C,)3&/Q/QQ;\AD3<93T^I>60%9,R2QB,1B$DM(+"6QC,1R".MTH\E; M-YHS$OI9^9IKV3HWFJU6DMRAT9VEI(S"4QC\1\$@M( M+"2QZ/#9$Y/U$A)+22PCL1S".HU%'[UUEB9)J6@M6?VYZ&FU*8OEXO_J#G)7 MU)^(?EBNM]L?M;K-/!2;+V55?%Z6=5^9/VT6U4+>6795WI\<4T-XN'^EWI6A MS0757%3S4,U'M0#50E2+4"U&M0354E3+CKG\KN=M$ MC+:)G)+;+5VBFHMJGGXXN8L6#% M M1+5(-^EWT9X]5,RO.%E M+P1X# [2(R*89R5ZFFF>DMW%;79VW_6XSC=1U!P]4T,PMJKFHYNG] MV.V>Z49HW0#50E2+4"U&M0354E3+4"VGM&ZG:B.XNCJ#2SWY<7K7EVY;8F)% MO2^#^PT:Q44U#]5\5

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}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{O?#?]JTYUT63&-2YG]SF.37O=G?8@Q865F/LO-+UCK6E0@?QW2N(,?'(6W"7.J"17C=IXS0]ZPOWC] M:C3QWYTA/&X)C\^A_XAKS@(=IQD.X(0 >$P1$IE1OG*Q!L-6&=E)H3LK#!A: M7LJ\8&+[^M4L&$W?:4&LU).#2CDJIJ)T2Q@*$BZ8B#C+@&F-!,Y$W)G,.%OQ MC!M.$O**0PS,=/%LZI+TJ%3*TJ$4Y(2B029 (8)MB#CD.XPP7Z&"<.1F0WC# M!3&6I:9E_?:R=^O.6VJGU._,.S&]#_B$&8R@^@_J_W!??. &Z=>C+, M9:CZ M1A4U*4DH_ 2C\<0+_1E].8L%[ :^ZM7>$I7A"8^80:=>C(74W+0[)W-O,IT> M#'ODBAR5LV;!"E*]69]/O"#P#X:T7152D0A824NN60[\T)N&X>&X]V7P,(!' MY0QDO=2LCV;>?.H?#'N/TA"/KL+A;.9-?'|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

QG@0(7X&/)#N+ M;S\&(*Q.]FA"9.R&YPX8O@RZXX4ZET*Q<1 MD$\Q'@7.6!F'(!&"8N5W_P\CPC&?*"Y%S-J+XNX)SZQC!"(PYC=75?
KU>HW'FLD7=SCK10G9O@J!6.T_]5.;SB9^_PU1C:#R9EPXL MU*FD9X>-V?$MTUTW(.HNLKHY7R3\3>N>"GL3.T]>= ^#F8/QM2U7@H^ZSZ7_M(+,]H,]
(2WGA$053\6/H>;M+I2<@.Z53*H!X$#37-RGI9@IZ+8L;A%MBKKNJ4+6A51T MQ#24K1C[C> G*(%;H,>B,@J6%JUFFD;F:JTH"<&]$-@M4\(IO[R#^L07IDX3
M[2OY>JK*!$!/EN@%>DZN@72(4%;4WK/W=V.&3.]WAHQ#5%L$A]AQA@7IE007 M*UDM[G+"J7YN%0DKH!PKL5'N2W9S"T!EB]5 B5,>R)"X<6QW02&2F'0/!CO9
M_N>8FG+'%PP#6/A^JX*$4O=@VIA!YCDV%FQ=51BJU9% M\-VO\5%[?/X&O'P=;A(#;<_3O9RW:<7>\HRA4%HHS')CHH;U_M$MSF.*$'>2# +:2-I."\:ZA36JC*OF2W M'JT6TN2M6B$(7ND;.5?
+P)[3#,O8-"(4ER9] 6OML0^$+XCP3T+K[M-6[8T0 MN,01$LI+*,%#=,C2["E-"&,@M))T:T!L92=;3'D!R%G6V?1V07X#BX:;H^Q[KZBD4M5%ID-8J[P%0E<'@=>S0/H A6)\ $9.$=$[V.G"[Y65R^N+
[.GQT]=5<7V<-EI6 TT M3D-B*+<(; O>L+:Q!6)L4E' 32OTFI!8M1P9JPJE(GV_]I?KRX I/X;F $KB M\U%EK??@1-5-#ZFG!&,KOHG<5L>Y/.JKH!0_HK".1D)-[U5? )ZD.&2X8=4E M(;%]2HD( #'Y-
!N'0917%'M69 7WTLB?4SP&-]UVG'E08]QY^Y'\!V7&J+SH MNB06OR@]R+$*B35Q4H?I.!(8VRKS)1/%;SV5V1'3T@1,W5D/(V1[K#$[837 MOO_PV2= +!!=Z@VUE7D)N617J I..73[0KTC#
[4JS@&P5MJ]$)9\:V&U2]T6 MJ^[8NP:(EA1 "&FXWEA<_F#&X:5(@W3;<& ?%6Y9S\$E]94K:B?^H>><^[+ 2*U52#V4-42%'CX6]GYU;1G6-, >14QLF-+\6KC7K M]R'WD>0./LE,%\WZ13*6Q8#-
(1OB%,@R*2I<#[K&=I? X$Y\M2D0'8@S% AE M*-E]H:-AHI(5GVXXT[1%&TH0DAKP_!ZH(Y(*1A9:0ECJ4X/9WSG@'#H= M>$)Z!X'W]&R97=SWT<78H5+GA'@>T*R?
CO+M%]^E##-2TTY4E"6DEE$K!M" M+<3,Q(]H%.MR9W#"YTJM6HWN]0HK. S4H\NKJ\?8E[F63<>7XGF)6+&'[1AQ M*R"V>!3J8=VOX+4JTL<+P WZ\"(8Z6?5]MQH?-
<#S3\WB,I+);*_X+C0&S/6O%4%ADN:LYX\R!M>7 M@N$AZ*#">-> 0[( 3.K 4?4EV IB7D#$MV('&;04A15PI=N5*1!% MV/ ;( #X+51GE0GL6N!E.-54JQZ]_KJOW4[ %/"6Q8V8F\>YO(I&HAVMPSQM
M(RVG>$6-'U!JNAU\+(NA4,3 $9/#=[?ET@*.%CK?CH/T/O.V0-7R"X4^;$HR M!9.X&%9<,-N.ZBMNF' ?"SR)H*FV CYR MY_'E@D99T^-(P)UWPT@74.JJ'.;K/$Q(26K4)O-J&(9RN 2.1W@.\2Q.85U#
M;RPA=P-@5%\BKVE6PHZH$'[D&/X[PF-LNUM1N/Y?D5".>1,*Z&%VLGP^ #,G MRV=A)F(*F#@7-P)=UU%OA&*X#ZNC#*]I#GIRJDS?-JL-Q )L8\,">.@LTEWC ;I#YNV$D[2,\,U=
MOM)=K.@;+R84;6ABC'.!2%(4JZSNN##!S,#+U[NIZW>0V7SC^=2=;XIE-(*= MU,XG5" Y*!D'3=,VUTYA3D1]H/7^IL["IAN>NK-PK6L'M.>4RA>:46P+W\Q$ M?.'C@I>.**/ HI(A7MHFD9\"?42 +'
M[,J57DO,5K*]@JLL"+*)#38$.UOL16F5&I7M0Z M*K#;DL",%QD:A7:Y'7Q=[@@">]T!\:RI.8 N9M5"-W1Q!0$@: !L9BN8;XRP[,%3DPST@:Z;%/F6,!-:'<7!&^!!'F M]4Z>'U/\IH8#OHF
60<*:BU4:6<2N7PF8LIH4)_G._KJS@ND=R?-YD3 ^B-, ME$#4-Y!]TAA!F'0(91FLS;=MWR1O0_"%T6Y3$TIZOCA>Y]Q&^J9!Y$1H.K\I M->@GN0?
+4G88L2=R1[L!C8$K\%XDZH/3AE/T#P9)TCKX7,H=@B^RSB94B:@G MP&=RDN>.AV8N_6P3G>=H[V[#C.H/MD\;'X(,S M$#0:#W6=)G>_*.YR2K'C:L^H41,A5'Q243N'JXJE3/JLJ'=7(E_6*[R]-
TB/^93A5N6+W'U?5&OLR?NWN9)#?XB>G MT^!]5 ?DWKS#)R1=@B1XSIP'_?<4]/X_RG._DU>O_=L:V'M"%PUA$=_3M4Y\ M)"TP),Y O+%-MWC\!'DMOW;\KIA#XG9M[C=;FUWZR@4P M[NW[-
X<20P\A]JXOO.N+N#*7*#'@GX!.E92V"P*WI_Z[[-PP"HG0?!.,=%<'-,%VAF"S@X>ZVTCWL*Q?JVSO'=O*"@I^[EV+BJ]3--N"%!;X#] M4,Z:K^$"_P['+S8>CM.GF3(:43M^9Y5BU;ZK/(HW"
(0VT7MK7(,;]K5XTY!B M!OJG:.D*\"@*M'Q_B>RFHB?Q.3Y5UIG75MW=+M)?1RJA:VJ >BMZVP?SXW"P?K#WE8$9]PK]9ZJ)OP7/$$C MUM]VE6V& :5'%/;Q_84U* ;'HW?
4XFF:5(!VT*\H6IQ:@*S3OX#%A& QJ[0% M=@RIU4Z#]34@J0P! #+#Y*7D[L*CBW?7@_E-WIY-B:S#3:*.WE"^KUZ&'FC\ M#M[\!> Q>HK/7SD@TZ]>&7=44W-M_\E(@K,XV36^[N0G,RF?
6N%,82$1A8@( ME?YR?9D]HLC.\Q@$@"P% ^H?SU]L8=\#O\?M*,CZP84!WX?\^OT-P_/EU)^O M.(K^# F(<$-_; 5E#YK ?Y'$?^K_GLL%_QF3\#C_,9B_@2KB$' IU[#T>/GL
MR0$7'MPOG6[HCYJL=-?IBG[<2@&,PP?@^[4&EV1_P0/\7[EY7]02P,$% M @ )X$(63;X=\B2"@ ]R !D !X;"]W;W)K&ULU5IM<]NX$?XK&%UZ=68D69+MO-J><7R72]*FY\DYUP^=?H!(2,2$)!@
MM*S^^CZ[ "E2DE]R,TWGOB0B'.S[/KL+^G1E[!>7*>7%;9&7[FR0>5^].CQT M2:8*Z<:F4B7>+(PMI,>C71ZZRBJ9[J$B/YQ-)L\."ZG+P?DIKUW9\U-3^UR7
MZLH*5Q>%M.LW*C>KL\%TT"Q\TLO,T\+A^6DEE^HWY3]75Q9/ARV55!>J=-J4 MPJK%V>!B^NK-,>WG#;]KM7*=WX(TF1OSA1[>IV>#"0FDHG)'?\K5F'OT6P@DMIY4\3#D*#09?A?WD8[=
Z\F-QQ8!8/S%CNP(BE_$EZ M>7YJS4I8V@UJ](-5Y=,03I?DE-^\Q5N-<_[\$WA\FD;9$V5:62P5S>W=ZZ$&9 MWA\FD;$SV6JTO[Y0TC4BC5KQ'HSNY?@A[HYWK_RBA80&(;>6-
]H"Q7'R:3B;B!BAA;,OS^"?Q.Z^T M H-"JFX 8I6092H24Q3*)EHRSUR94U:)V ,%!4&NBZAL->) M\-(N@;RZJ+!7>K:LL-(J49C28!?VF"KSF-9S.$*,+54;_<9,KYTY]K>DL);:T239L M7! D+V19+P
;M85AACOA(#?E!A9C/M!16H^WQ,E!5QLV->):JAV]F";L3Q? M]^Q61VMKU[4L;:RD3GM;98FX6%@ M) %@I-M\@3)C7J2YQ!C&#-I!5]8E2@8 MF$.$88 P8$RYV=
(KY+K9)BKCP9@46]2PAVDB@T*"U0$+A2)6*@Z($]/Q,OC MV?BD83]&NK?AU8\.:$?D?1[LT' M=#HBU,D5G+G4# :IJ>>Y&O'SD)PX\DHA MS,U:YN0%I)U L @G\R
+^7HG0;MA?'_D$C!,G[^&9Y7EWJA,H/T\U\O@6LU) MR4X,AI!?E) W4N<2&3BO=7O+-]_EMI5J-WJ!P'2L(|\ [:#6 \.V>O MA!%7$;<5;>D;84,6QY;)67RM=8D#Z4 5.D< M1T13&YVGZ$);6
(1EQGK1Q3G(JL1ZUSH\J #02%P()TX&+C+M^\&3X=[>%:Y M#&6JIH*![0'K1/]G)TWRB026URDBIP5>>H78+ ( 2>>0P- M0=4(@1&]#UV( M)BV4<1LKZ1A3.+SV ^\=5I5]AW&
('MZYQ>4N[*W21B(Y+'-SCR M^)09Q@JV&RDVS^O=/M=L.1.QU5,!% MZEX28U/V7:[E'-VO7P=H#+@-K@22:D< \FLLYZT!V"A!WS4Y)TP2H*(TP72; M)S&O[G,\=M&6:.]F27,UXJ!C[Z &7B5)S;A/
JSB8DK6X*H]9\"G=PV*!$-G M$GT";>7.#+4Y'8M/:LE2[PW.2[1N4)P"ZWK+FNHV@;>Q>=C!QF:R:+'<]<#\ M\^7&::X/Z+3KL:)LD8S'6GK;A8[ %02:6*^D9RYD'M0>S%HH_#6J,FR%M@7<
M'&Q+\PK1H'!%Q*A-X\VSF"ZA/6_H5*#84(B?;TQ>!XR]ZM0<[E<:W;J6H*$A MJ3W[3E.L&/$!W;2TU&5,7^X"4.RH0L02*, F^BD\6XZL6D!RJG_C+#2=H;D] M&4XPU'!BIXZ,>P<:1^4C#[,.:Y2AT(?
P,$2HA3&RTT3NM)"'APV9=C.&$(*6 M0VMN&K-$;[)ZIPM4JWMG"WNPG%9]Q)M.,2H0B!N#?)%[(1C=5&/(!{J\M NEMPW4[,D:_BH=QBK\DEY2W.'!GVO2SJ]=!MI#24:5-LKY.+_L243 ^(AE"
ML.Q$[59R-6++3:6Z[IE\7R8_+A%CQ*$JC#@=91G0DK2*7*F4T46>4(N%XGM> MP7TD!<=WR^/[Y]B>^CP,-BC=J<-M8=V +J%=IU'IELAFFCX:3S>C/&/<=A_2 M'X-)LMXH3,@?
>70OJWPF8VO@?+12H4M=U 7Y@'*@:0@ZH_UD(PR-QL'R[;6, MP@"Q'2EHK98:/J425';0)(%XB(Q((EQ&T5M^Q,[0.FX4":<:@&B C\SAZGD3 M6_U.) *C^P2Z+7-4WEA15MVNBGAX2],?C%5
MM4U'U'ZOFYBC*Z+'-@1_8#A]OQGCI_?/I6VCL]O=[,49$N:!MK\G";@TA/>W M()WN-&9'N P,R76'&H]$LNGD^7U5CEN!/Q?X1I[L6_1XP M^&LIWJJY#1W+;-]=6ONQX.4$N;!V8F6U1XK1L [+
[#Z 4^0TM)[1VC"VM MZV!!LA>9R"H3<8VQ,@#G+W,'QG3(>O$1QB)=-V] M;T]U&@9ZY$QMV?SJMF+W;FX(V"R.OP5%]4SMG9=AM-LSK*;\]:+7H\['R,+I1=\B=WFBS1!"%G\%=HIQ@L *LD 9
>&PO=V]R M:W-H965T'&>2IWU;E[PLW?VYH4I?*(S]:TR815RY>]V]'UJRFMYP6 ;[5QK=>"%D8\Y'> M_!B_[ W()(6HR),$B3_WZDXE"0F"&7^5,GNU2MK8?EU)^\.JPY>%=.K.)'_H
MV*]?]N8]$:NE+!+_F]G\H$I_9B0O,HGC\4FK)V>R(JG#=IN1D6I#H+?^5# M&8?6AOGPR(9QN6',=@=%;.5KZ>7-"VLVPM)J2*,7["KOAG$ZHZ1]Q:?:NSS M-W0L#:B>^S
M6,7=_>_FVV]&%\/G)UR8UBY, M3TG__)2=%'?8V*N!.!VI7W-E);T7/RL416?U[&H^%#\8ZU%UT$34\JK02=RL M_C$3;^46.1W-^L*O>7LNLZU0#RHJO[J%% FOE"OL)[$"!"3,8DBLM%DQ&C/4)
M"RGR6%:FF9QI# NA#FS7LLN#$>Q'A-FR<=:D_&EN====.UF26^!".B*V2UI&\ M)7BQ?,>Q^C7R9J$LQ6I^-#U.1086=D(5G&N[9L1[E7N5!G'C*RBSK\)MD'Z MGJCN[HL]9EG9OFLH-0[
M!^$$E=UEB98+G6B %1M8C3B-!L,J3KR!GK0BA]+/%;?(9%M9U1VS(5@5*/_3 M%HWW+)H>LX@R%8.>30$(0"Z[A1G.%:$:[!:"W@M7Q"RWY'&;[^9C\?#YV16 M4S?\=14GQZ>
[21@ZV6!+%\'DB MQH-)35P(ZANUL.5P,1Z)O+"ND*$A'FZ3QW/5]7=9H$7"PTBAW$+8NKI/ A*& M$64'D2=7+M&^7/LS5UGY1=*H M>&*?
?%6S=,6&\9.C"=#C,>_*'1F93O55H5'ATAJZW\BQ:IBP?TA!3%HC@\!AE/19G:N2^<9L#*'P >=8B/:4W"&7$2%^Q4=?3;N6<(),V%V> "7468T,C/%#& ,!N.5&[\WP6
MBFDLB3'A),QC?/ D2O+;4>0Q*$+:PDNF?FSVUB05OA^'L<$QA/V!>*P-&5U? M+#0G_4\ O9F]"># R;6M*C4%U./KOZ;ZM.7@U! _<]"^VVQ*IRO*/>Q6+_LSX?# M7:CO^G,0WCNC?$;\5=B*L1X/\:-
A^$JTZW"&(:,01'+0!VJDX?!P+31][?^M M%'8R%G*_-#02\:&!;YC"Y7E])$$LI0J7)6@TDT"_>CR>3LLSB,S:65@#0%(%M_Q5K@+ MK>[I]=D'MK)]>]Q8]QYV'_SDC.WFZ[+ZU=FO.[-
'9%!23\3%U;S^?]2?7%U6 M?\]^1T YN*WUD]D403@2E\-+<3$>GWTP'A1%.X:S-Q%>U'1#><60IK MJ\GZ!(Y<)2X&'.@M?](3O7))P^VCVIM[KLSHY[=9X]@=_"Z+B9SBB6;EJ
M'WI;M$.Y9\IY>BUFZ%VSP>7^SLZ\=QW&N/+_1Q0&7, )Q=-5=5T85?720[E/ M#7N0# \;#YKR>7@,1\-*2753ZB80,5%J>*.0$-WL'3S$8Y;QX9YBB\O<)6DZV><6H? MN8U. /WIQ1 -.U9IIM'Y
^;JSN&HE_.)PV+\IH8.-%C'[BP*!P)U[D![=V5W M\\3X-5]1;>LBU#LJ^7J)1C/(M M*ULLMJQK;^- O#>IJOI*XU\X?R0ZU;Z2RP=]0YW.8@UR57Y[H&W\+!@A^=@= M3A".Q$9$ /VNYC*4+#_B+XH
O #UZK:'CB0E,GCPZ]YYI/*!H9D;3[A&602N M;*&WQFL[O@ %(KH@HOFKT+:\") ?53.=N$X(=&C$U;F1N*-[Z*M6M&E71UG MFBXLV42MP85C)VKZFZDRKN[M;
M^&:HD@TQW(]\#5B>IFV)_S(Z[=#U*<)T3\S(1L:S%66UT<7@2J$*] =Z@3": M6SIE7-<6H4<1'NF:K$ZRMMRABC(^]I[G^[:E]7=ZMKYSHELOHC,^4GLZ2@.N M/J#]-
:*Z"1BF9'RCL)Q0.A&JGC7#';84EILP.[AA MC)4'[X2(ACN.]N'6/.(;7MFFOG![QZBM6CY=/G<-7:A$ VP748JKFV:AD:5%6F-(@( M1C%X"%#XEYF&D_;#;PJ/LLOXU@I^=X:<@3CT"%3$O](<.A=\
<]D:(R'WO!; MDOII_4N^3;OX-4$L#!!0 ( />!"%E%=\+>M@( /(% 9 M >&PO=V]R:W-H965T1D8]W* M5X@$VUH;/TTJHN8J37U982W\9P#9H>&=A72V(EVZ9^L:AD!%4ZS3/LHNT%LHD
MLTGT/;C9Q+:DE<$'![ZM:^%V<]1V,TV&R<'QJ)85!4!P,4VNAU?S<8B/ 3\4;OR1#:&2PMI56-S):9(%0:BQI, @^+/& M&]0Z$+&,/WO.I$\9@,?V@?USK)UK*83'&ZM_*DG5-+E,0.)"M)H>[>8+[NLY
M#WREU3[^PZ:+'8T2*%M/MMZ#64&M3/<5V_TY' %NLU< ^1Z01]U=HJCR5I*8 M39S=@ O1S!:,6&I$LSAEPJ4\D>-=Q3B:W9G2U@C?Q!,])"5F#/ZTW*/G'3I_ M!7'T!]90Y>&3D2B?XU-
6TLO)#W+F^4G"KZT9P"@[@SS+QR?X1GUYH\@W>K,\ MN%6^U-:W#N'7=>')\8/X_5+)'>/X9<;0)%>^$25.$^X"CVZ-R>S]N^%%]O&$ MWG&O=WR*_9@,X9@!^N$ 5\L\A@C 2O-
I"W=T9ACL#/G'L3SR&L#$Z MB[ ;6S?"[$ J"<8"<1>6UDD0L$")3FA@?D^"$%27EOB@&V?7*C:M;-EC09$/ MR-8Y999@>-+P/7CT02P(*57HS^<9*^&9:X4FY&JUAK70K>CZ6/,@$:;D>I8\
M=#Q%_L#*S8C.<4U!A> ,[ \\1[P%:H5K/AG%,$99XM/@%Z'5"O6.0X6)3C8H M @#C6(1!7(=0JN_* &ULG5=;;]LV%'[/KR#YEQY M/!C8)!,YMWU=B@(K"VUR[C TRX$MC>"!!^5]$/?A9)!S6?
3.3_WWW&_Z48FT[WXPLF6O]A08WZ5DO)$)"B<21!(Y_*W$IE"!! MH/&UD=EK51*P^[V1?NUMARUS;L6E5G_)U&5GO<,>2\6"5\I]U.O?1&//F.0E M6EG_EZWKO1$V)Y5U.F_ 8)#+HO[/[QL_=
"'X1. N '$GG>MR+.\XHZ?GQ] M9H9V0QI]>%,]&N1D04&YUND(MW%#\"DI1-OZ%S$SPK\O2KZ;!@&+ [CT3/RAJUY0R]O^(2\
MMU\KZ1[8W[.Y=089,\^&VL1H_TBJ"J.;F)9(HR3'YEP)TB.+!)M2FUX7565R[21_XJTBV5.,VEM10K# M(*Q_F=(E:::1B^TF#?RF*MASR@%FH9K72!J5S)5!2I#9A<>)>M
M,U&@Z!.%K2F;/WCB<\U-2B12:=!LM+'@"C0<%K"B(P9,=HEF? 6X^$&9_R^. M4&)9DQSI(\]3 /%CWR2Z6"',I)];"7O1[MFB'[0L MNLH/;C9;'T>D*BAJQ K\0M:4Y0VV%M25V6Q-YMXJL(F#X3
.)N,I&\>C()P> M_KC4O%3Z08@F[6\KD\!VT8B=#H/A= R:PR W@N32.N%ZI)RV=8IFWJ? MXORR#A^R6/IQXXN5L(ZF ()+G9$)^6S#1CK++#H/1. SBHY"^$(K18;2C:\< M6&UX =0PF
RG030:LS$^)T<'G[3C:G=S&\-]L8E&P>0(VB93=A0,,8HG,;NN M:@-F2R,$3E*'P\5E[+ZFOGJCD\0 C8KC53>@X%?RGF*6*,"(Y0@SAREJ-!E M0;9[(;+HYM*Q&X5U720_D*2V=OV\9/Z
A_!;DG0F&1#B:!MLD"U\SW^>DTH\E4CDU_[E&H4!T=-@Q"0FGNF-/@&%$!QGXBR=:18D2KLY@ F68%6]]B"2X4( MUZ7*!:M2Q9&Y]Z0-5;02%AEZ\[%TY5/"P*GD*]TZ>TIC5X:GGMGCZ[>3*-P
M?\]7N-_1YK1*/,WD 7F?(!'SHWU_)X2$50*CI^?(U2">V2>3Y( M1("LV :+_$6%)9VKG46$)>>4\6F&:2M*# +QDHX[+H7;1B*Y*?YND"&ZZ$I W M/FWEDC?P#[B07IEJV5IZ\^&JM11.VEA$GJ2^(=
2E-I8V6J;M?RVAJ/6_L!10LT:U1[5D01L(3;,%OOG>X>Q>-@&HT[I;[ M:';Z(=P$_?6U8%/8WI)O8UMW<<9S78$27 V.3:ENHMHD@7< F87E33U9K81Z M>%Q63\9@[T$=["BK*7H0<[^!K"HU
(N$FF??6[/M>\UDD+(305'OV'_=-M< M9Q)WK.W= ![8B0#WU!Y?/T*Z]&PH/5=#VQSU-Z_.@0K!T$6'56KX&L&"O,KB MD=AG^^[<@\[]Q=FZ5]YE B(=OT4:F?;A^2L?C]MM]>OT/?<+&5!#7 !:-
B? MCGO,U"^[>N!TZ5]3<^WP-O.?&9JE,+0!ZPN-FV8S( 7M_K\/U!+ P04 M" #W@0A9NN)7"H$+ "X(@ &0 'AL+W=O1+G+D$2.;2G0*[&TQFMBB*/C 2;1.11"\I M)?'^^G[G4)
(E1\YD=PNT#P5F8DDD#_YSIW2ZWMC;]U*J5(\Y%GAWARNRG+1 M\N3$)2N52S?-++54D/3LY?K^527:ORK*XNZDI9+J M7!5.FT)8M7AS>!&O)SO?)[PBU;WKG,M2();8V[IYF/ZYC
DAE2FDI(H2/S< MJ;HG)'\5]W[N9'PHDLJ5)J\7@X-<% Y7/M0X=!;,PST+XGI!S'S[ MC9C+=[*4YZ^MN1>69H,:7;"HO!K,Z8*4J M&(EQ&(@XC"=/T!NWHHZ9WGB?]"MIU?$EBWHE-
["L4EQ8*XNEXNM_7MRXTL), M_C4DO*<]&:9-KO/2K66BWAS"-YRR=^KP_/MOHEGXZ@G.)RWGDZ>H_RXE/4EI MF,\H'HE]6Q#XH7C_:Z7+C?A8) *7B0N[J4%BIDL\%"\4XG*;Y3ER8$H5XII MR&
(C9&K6)6C2,R8U2./H^V_F<1R^XAGTA.^C5R\"<;_2R4K)$N^CR%0+*U.2.!Z%LDX-%"!-SQ? M*\N!E7:Z,47EVA7=D=Z25- I5!6I4%#*GZ>J5!81GS;?=%7Q%P=3(8UB4:L^&
(PU9!AI(%;F7H'M0!1&Y 8:*5<0 M)YH'81C2_\ZF?;(]%G*(=^.U"1;J=2VZ>E VT8X=0[>^W'.1D?BY$!_4C:V0 MYD5\YB-XP)BFJ:8Y@"4.HNDXF([^S"H?5[>29W)FTRQ3UE7 !)LDF8<.- M="A?K'?
2^H&LD%/Q)*FM;VN-C'!5&R-Q 2NMI1%@KI&:V3# %MN KC8I,"[9 MI1X258T;M ?B1\:"V[)\"T"5A<5! 7B M2]*#MTE"F?EN0(3!E[ #*DI[GKW#F\=B .2@B_)X/$?6F#X7XY;N$^)_[HG5
M>.Z6H/NS:0?19C#EU.GE#R>]0:Q:U(U85S99D2)%2++3((SW>C=#^N7"_X M(:-"NS9X"1^,ETXVMM2.ROB..Y3-40QH&7CG#N*&/8E]E:V;<(
M#:L:;2/GP'072I=TJ1[6FG1K>59"T3K+5%JO08E0^"JD3[;!F!!]=AA[7]NP M+U_%56-]?Z0P?9)6/U[1[.NKJVV\^M)GC@;A'-,X&()/GY=MO;D]+E@)@,93 M6^_Z&K$:*XZ*A&NV!R9)X#5:!B?
559XM:R)P- "WFYE,FSG_@,5(N\7ZH0 MH_]7B"*:[E(SR\'ROR>57@=+DXEJ-WS2L$!W][!I"HV4,=&BO>'*0=6H)/1-Y?4UM"E
MKDSGNFZP)1W1Z;SBFB.J=0EF&DLAH\GT4A/22>>T920^;:LVGX>^4-?//(#29 M"_"TE_-0$O8,O!;'!435C)P=C;3(?1UXQ M:&FC /\//OH@%"'(S*;AP2]^Z9&(T2#-QN+%P5LN0E1ZU]$!4S"*?
4^G$4:' M-NOW7/%T'D31::V2G^L2\1DP]&O*/P'(I6?-#0,Q#^))B'YZJX3=\F&MDMJSV#KW[]9SE*84=]O(V8;,OF(J MU[3"EYE,;H^O$Q0U%-!XG(,S3O-
L1&Y8.]QSPIM!Z1ZEAZXI\B,&^/<3*4(.QT]E( MU^E2MJ)O35G"G_*MXGV/O;*U?$\,+4\AHWQY\)F7=-*;*=>@\C@R(%W.++]_ M]NK@?6L!U,?-1J$XQM^H#DB_\WY+[>1\,CI#F#Y&YAU-
<#&/1I&_MCT>QOY_TQL-F_H3N#SYI=WN\('DU_([LK#4O$WJ99,198$Q_Z6[D._]HUM M>6R/>S=:92GW(%\ZKNG+MJUGPDM;R2JAV"OJ^C8*(K1I,IV[,IS-0+C8>Y M*EDHL%HLX"
[T1@4U%BI/G7!EY5\@DCO1.8&O'^ &WO"] ME>FM87JN'V^-*?Y0NZZSL:.5R];R*3PPWPA_R4KY_F7W, 455OS<*# M5]Y[NK!2VS/05@N_;*UL9Y^._77E0O4 [WC4XG70["QL!!P>]07U6EK9E!JR
MH$KM7J/6 KHHJZD2]-6/U?K;!!00SQ5=?>45@A9&S][J@%G')--DBD\1&!C M7A:Z /14K&7*ZX9.&VT'[Y3QJ>KBCG[!&@5XAL7WDTG/9TAO*I=<./C1M^ M:JW)[O'179ORGK9M.O#XR^@:-
"SSNA&_*6N.$\-GXMP =*5FMHKJ?'.@JO+4MC##2JS7T7CJ/OP66X+SQ]& MZV4EMGB(_K?JSM+;J$?)9(G:2:/!8KZ*KL>7U.V#P:_2]R[HV?@3#;&//#+ MIVP5Q4P(%::>$03][? =*L5 1.-
KBQGU(=GQ^+E#_QARIUPVPN$[H[[(S!>K M:!Y!AKFHE?]LJC]CF\\YXZ5&N? +^\8V22)(:^=-V3H3@U+JYE\\MCH<.5[X<5Z:+%L3&C^$5(,WD9.:BW+O+:U*\O/K=Z8L29Q[ M;]
(^'"*L%=][Y<@3-!N,TA;FIH%)7H"9P:W1OG#P06>8/?5]+QNDE> M!?REUD.8Q -(XF3Z"MZDSW,2\8OX'WX6DM_@#^N-\Y;:H4_3^780$Q/0_#V MN'252'$54?\[M#N,UF_?C&?
QU2L$ISW!Z6OHWU^(5V%.DQQ/4D2 2'SIN14! M$GD\X OD,TJH0\@G:LQ P'QA1H_T,R&TJ72\PNL$^ -,AN,%5&04H@SA5PJ1 M"VEA)U2-7=".U5XXVH,>+67-INO#*I,7FA SX1%J) 4V?
+]1(GTXNT\+HYA_M%,X_F^E',^'%.*9EM+U+)@\1=[1LF C:3)VRTUMX8#"NI#ZBTL258KB92Q"38>/W5OI/1),O5$RI7P473QGA&OR MG+(DX"TATX(R2E5-AU6 [:&P,K[Z MB0M4U38MZ(Z
R>!\/AE,+Y;_IL(DECBB>53)9#&<+A:+5OUO:XV"$OJ6&^E. MSC%U03Q^ZH-!4]B775I\L2%-J"=M5/[1@ M4\&33/Q3YW'.%E-CV4+3M$-;*%?7*/P@A2F^U6I,"KDU,#4QEE-,P-5HN\K
M(@PY4CFSVG8][.0CM6JX_#"$IZL+^ZN+8BK![4G=<=QH+U .Z=GFC-&&+GH* M*4D%VH8T"._'?T<2&]F^_]]I6:[F% K>1?&GD> ?V+()/=!]<>I*&QW-&27:
M;9BFN(EK[9N1H__:#VS7S9SR9-Y,>[?";J5VH# GUWAX<1Z!;2:HYL6;*DPM M&^-I!@J/!0V=:-F UG-C?/?" ?HQ=OT74$L#!!0 ( />!"%D(8-:)L00 M )$* 9 >&PO=V]R:W-H965TG6ZQ4_K>%
(@6'JM2FLMA86U],1Z;K,"*FY&J4=+-1NF*6]KJ[=C4 M&GGNE:IRS,(P'5=KE0C2V%Q)4&TU05UT]76*K=Y3 :[@^^B&UA MW<%XN:CRV%N_0 E:O-.W&/4HN*I1&* D:-Y?#]]'%5>+DO<#O G?F8
W.D[52 M]V[S*;\S(>2XX4UIOZC=3]CY,W%XF2J-_X5=*QN3<-88JZL.F1A40K;__+&+ MPX'"+'Q!@74*S/-N#7F6'[CERX56.]!.FM#$/[\8?"TTXK_R#2A; MT&?+G7@\?C-P>>22*89^-
;AM*8C<*CVXW?-Z#6<0)\%\$L.YW[!YD$9IMTFG M03Q)NLUD%K#Y#,X''U J*E4/],VW!"WF)+W0#U1V/)'1>ZQA Q\KJ- MECOY,2S!D>!-)@&;L6!*#.)9$,>TC>8P80&;$]JT#G22IE$PGT^>'3J)Z-
P( M1^G>UW TG7;+.,3F_=(+?)+P$=>ZH5;N0QCX%[\F'[A\ F%,0X .W*@RAY7& MMYO&/\$WKC67E"=0=WHK*F"G$PF<5!,DW[ &U(K,W58PPK_@1K M[,V1/]HE-7V2:W4<.X-=]!QD
M*:REP]*55+UI7U$^X$^>TJ8IRR=X0&.[F+_DD!,6586YX!9)I?/,UVY3*U=Y M*+2WSV7F2PQ'WU7ZH=//H:TIY-(*[HCX=**/+;6#K-'""A+94-([31
MJCK6(4[TA3Z^J(7*Z<:U+.F$]W$4TJ'[9D2C"XT##25>085'$D@# -';,[L8 M_-@(!K_6CH8YS-U#7V=!-&=!-(TA#1+&@MDT'7RAD%,*.A9M4C524)A-L_Z+ MQ@Z7X9O&-
L3>O8T#8=0EHF@*;U[-6,3>.LAW-RM5L"2)$@9 Y;.@RAD@^O# M7-WM'W 24TG/N[_!5V6I&F!-)E1_41$;)I0S2=3,/;5&1^,"=3HMGX8,O0$ MC;3MQ-
"?]O/6^W;,>!9OA[7/7&\%A:K$#:E2GY@,0;<#4+NQJO9#QUI9&F\ MLJ"9$;43H/N-HGSI-LY /X4N_P%02P,$% @ ]X$(63]:U!2'! 6 L M !D !X;"]W;W)K&ULC59M]LV$/XK!ZT;6B"0
M_):79;8!)VG0#BL0M'OY,.P#39XLHA*IDI0=]]?OCI(5>W&\ $%,D7?/?=& MWG1CW5=?( 9XK$KC9TD10OEI[5>W66 F?VAH-G>3652+0IUMEOG8H5%2JRFPT M%^QDE=
FF4_CWH.;3VT32FWPP8%QJDJX[0V6=C-+ALENX[->%8$WLOFT%BO\ M@N&/^L'15]:C*%VA\=H:<)C/DL7P^F;"\E'@3XT;O[<&]F1I[5?^^*AFR8 ) M88DR,(*@GS7>8EDR$-
'XUF$FO4E6W%_OT.^C[^3+4GB\M>5?6H5BEEPEH# 7 M31D^V\T'[/PY9SQI2Q__PZ:5O2!AV?A@JTZ9&%3:M+_BL8O#GL+5X 6%4:2TX:1\"8Y.->F%^1TZO18<&?A-BZ4N M==A.LT#(?)
[)#N6F11F]@'(!GZP)A82W1J$ZU,^(44]KM*-U,SH)^&MC4A@/ MSF T&$U.X(U[-\<1; S_;GXT/KB&ZBIX$$;!!U0K;5:FX)K00:.'.^UE:7WC M$/Y>+$F<:N>?
8U%IC4Z.&^5^NO:UD#A+J&$\NC4F\]^&%X,?CGATJ1W:7(* M_=69.XTR\@$_A&!+\7B#%BN'R-E(X?US8$]R(H!P;.); MHQV=!@M+A*7.&R=%H(W>9$/5Y\HMTRBL#V1FE^J((*2TC8D:UL7 M/-
;"$1KDV@@CM2CWM'T*BQ M:".QCM<)^<4;>S$@IT:#X>59ZUH7.H?2KHS^ MSKP+[??ER:J L@\X\W&X1M,@;.B,7&TDJ2VWG66J36*5"^U:WD] 4AM!7" M6WRD!\;CNS,P& YY-QXY1K%Y*
(<=-2/*K:=0;G0HH.*RJTL$+]$(HNC/8%-H MHL[XCMA34@G$TZL3$]XS[*YR_XAJT)"_F-YCR> ^#9V('8 L)>,+O6Q M"R@F9:/PI?X4VRA%(>'.?.MV M_16=Y]\.K]&=ZALHROJ@!Z)[&_IZ.G.Y0
M\@7A8#R,N^-W;4-0\RJW-4"0XHA]+OYP5+K;HH:@3I%QC4[]DBAM'7D3 U- MY52ABZWK@PB-9V(4KM;&,VM/[DW2* B1_1M>IB-:O=*ON!VKAIX+OE@@7B!O
M87C^>I##XE(8T%62]<2/@5X4F/O9/9WK1#"5_%FE)_%VYOPD'+W]%$O,27607IXGX-HYKOT(MHZST|&FL3B MLJ#1%QT+T'EN;=A]L(%^F)[_"U!+ P04 " #W@0A9<=KR.9@$ #O"@ M&0
'AL+W=OSJ>F]DIJO+?@ZK(4=GN-RJQGO5&O_? @EX7G#X/YM!)+ M_(K^6W5OZ6W0H62R1.VDT6 QG_6N1A?7$]X?-OPE<>UVGH&9+(SYSB^ZLUEO MR &APM0S@J"_%=Z@4@Q$8?
QH,'N=2S;>T.:T=MZ4C3%%4$H=_\6FT6'X'SXBL$X M,1B'N*.C$.6M\&(^M68-EG<3&C\$JL&:@I.:D_+56UJ59.?G#ZB$QPSNA?5; M>+1".Q'T-4@;K\0N-(7X%ZPSNC/;%@X\ZPVS??D!Q=<&-
V^"NQPF"GAQ"?V.&#F.-SA(X(,)G#7?"ID70NP^^0+@Q M927T%E![M&0EM3<@@&F&G4)G8*K88$N+2/WJX0-;OG]W/AX/+Q^H+[3T"%?M MX+Z-8?"[2BPMK+E"-)$_CP#*
(U[,.ZD.1[+1SDIN9B@\46;L5* M9O"'M+H/=\EMTH>;0F(.'S>8UMS[\"7/98H63+[++7F*H2!$7L%-A=9+AT!L M,US1[*]@H 8_3

729KZVY]A4BPT MNE7J:X>BC""MTCS+CE,MI$EFDVB[)L-D9[B6 MJXJ"(9U-:K'"&Z0O]97C7=JSE%*C\=(:<+B<)N?#L_DX^$>'KQ+7?F\-(9.% MM;=ANWQ>!;["*A^?
L&Y]1QRQ:#Q9W8%YKZ5IWV+3G<,> MX#1[!)!W@#SJ;@-%E6\$B=G$V36XX,UL81%3C6@6)TVXE!MR_%4RCF;C;/C\ MXPNX4L),4F+"8$Z+#CQOP?DCX&/X9 U5'MZ:$LO[^)2%]&KRG9IY?
I#P0V,& M,,J.(,_R\0&^49_=*/*-'N&[1I(.N88(YFAP*A:UV$:?2T/HC%!PC7=H&H0; MOA-98*MIE[86)?X1IHOQX#'$/#E<+1S)0C(%ETV0[+"PCBO]'A?@AB>DYRSM M$IY"-
AASGRH51PYC@B7O+2%&B$N50\ZP[1X,W0-<^]C7?H3R8G3$07V-<7:I M[0#>=01>;OX/OG_]Z? ]"_])SO+'VH>JOET;Q9I=*LX<3U'Y)MKQU)O[8?Z M>3O+?KNW?X1/PJTDWY7")4-
9QJL$7#MEVPW9.DZVA26>DW%9\8\)77#@[TMK M:;<) ?I?W>P74$L#!!0 ( />!"%EK\"8[. T &HD 9 >&PO=V]R M:W-H965TS;L[O0][5U M-WZI5!"W=67\ZYUE",V+W5U?+%4M_=0VRN#-
W+I:!GQUBUW?."5+WE17NP=[ M>\]V:ZG-SNDK?G;A3E_9-E3;J LG?%O7TMV]495=O][9W^D>?-*+9: 'NZ>O M&KE0ERI<-Q<.WW8SE5+7RGAMC7!J_GKG;/_%FQ-:SPM^T6KM!Y\%G61F[0U]
M>5^^WMDC@52EBD 4)/ZMU+FJ*B($,7Y+-'N=X1Y1J+MLJ?++KOZATGB.B5]C*\U^QCFN/L+AH?;!UV@P):FWB?WF; M]##8<+SWP(:#M.& Y8Z,6,JW,LC35\ZNA:/5H$8?^*B\&\)I0T:Y# YO-
?:% MT\MH#&'GXE(OC)[K0IH@SHK"MB9HLQ 7MM*%5EY\WWUZ_&HW@#41V"T2FS>1 MS<$#;)Z)#]:$I1?O3*G*S?V[$#G+?=#) >9@*\&?6C,5AWL3<;!W\'0+O<.L MAT.F=_@ O;$#_^-
LYH.#W_QS[,"1WM-Q>A1++WPC"_5Z!\'BE5NIG=/OOME_ MMO=RB[1/L[1/MU$_?2.]]F2S"Z)M@B0/'Q/R/R CKI8*P5+8NI'FCA32&MF6 M.JA2%!;F,QZ?YMI(4VA9*8]M"F$:O%C*E1(SI8S
F1OIL$X;IN5*K%;P[; 4 MUX9I7=(^+WY41CE957?DR^OIY=3\>/9V05_ MWW_Y6$A3B@"A74OKZ)M3B[;BT_#QZ.4FUTM5M$X'G=:_NRV6TBR4.+=UK3UG MG[(?Y;OSS E)$"
<*RND:/!KK2,BI.%0)#4UCK@S%-6]"LA:G4W865\M47] MTK95"=J",CY)@0V?6Q-3*HM!]#IJHS2R>11,HJ)6/#UQ*M@-3="]\^AWI/+] MYR^].
(O:^<3:%F!*R5CL[SWY*M+MPIZ82BQ*+>JD+5,^*Z$4GZAD.(5.%Y MEA36G'[IX;W<0Q-V],/2*<7\'I6U#&117Y(0RJG[5["3!%56<61*W7\30S9J MQLM:$0*!N/11[5$WOZ?]2:=;VVA#!T-(U-(
.M$ MK)>Z6'86@AAPW.C!V(+X<:2ZC0T&ZO>>\ 26;6)2$7.I'7:.&;>7N+%>Q[CA MB/U2KU]:EIYJG!!L ,&\#;6*2V%/;POIEV*.NL-G6WZE!:/1.LK#L <';4O0 M=XH\.1]9%$@[^R^>0S/"4EQT3*9;
MH.(H0\71UAQ_[5F8=S[HFE,?'?&GMHS&JV.@L97@.+(]R"4Z(2DSNG.,+"S] MG3"(F89B48>[^_G.J=]:3?FT]V)RN%K>**$V1/B<10A+"0^?S\G1HV4HH8"] MK
ELV'VD]XK;."}Z(4S*ILO8[(@=5*15]M' 4"],8R0U=- M#'3:36)232.("!XY:;R,Z;QQNHCG+*R/&D%Y6+%2E9M4DR-B,/I;'$CO@<3"@'+"]]??'P\26]LTP=N/*;3JQA,VJ .
M:]G,'/0&)*$+>8NT6D3L)043T(66LU.,NH+!J]2PNA-S9VL0MG[@(U/Q%C(F M8=:2HEQ?_VR?Y)KCJ0,DM5ZV(201,0X2-" M]*>_ZQS2M:S&3N1%96=0B,)9;!T7]?Z&PO]&D;-=]:F9H(O2FES+Z-
;TS"-Y M46<@*!0"I:I"NZ*MX;!4C7!HK5G7*3*Q2[0->SE!?-CP$3>(2LIZ%&':)U]F MI4CG&):S"Q&%%%38\65,;23QJ?AU"=!/REK+=*"!![!UC/-N@,_M]3/IJI!Y# M*C;1T,/ ]4[$XI)CQJ!/92UB(D;,<0;K
M4F(KDO;)[\GV]\[JN\-^]>% 8]X&2FVYSLVH)+; TK,,2\-VPM*E8@\0[_OS MCD'15B+C4#1">S*N;$5%M #SYRV(B; M[#[%4JLY@ (%4BH$$#C*43%ER+LX+RF)U@BO#@ ",$<0PY-
'QXH2RD1BU2\ M/EGKLBL*.?.W#I54S,0HYVP1&4 YMG5%.C1%DO>;=2]D80Z(YZWV?9[M^WRK M?<\M*!'2="!UCDI6! _%)^YQU0V^E-F[H;2S$##P/5=>"18J5!_P&\X#[,[M// M7470.0A"A?
1[CW@1B3LBCI=0>.#'5&+F6I.R'Y)61,B87ME__&:[*6.#2Z5K MH; !2QYP)B(*TRX5HANBA[7=< IDF=!&V$P)?[/-A8!G-:*VD%OH#X3FJE8; MU!$A=F0
;G673H*$8,I[:"$K;],&%H%KM"OTBJB*N'KB!PN[4LYP5/H&PEKJ M:A!WIN U5" H%]U0-A0 @,6&B@ZX-M)4*N8!=3R>2@MOJM!DPU6%Z+1#YA&^B:A%:WA:+DJ]]2_A76Y>KQ_L<@@U< *6:
ME:"8,D-%3=":+1U?GC,;_Z&Z5?!*G!8SP86K;4-#D0(3;( M(Q$4"SRRU!_6\E?WG.-6W=3Y[$XLE%TXV:!IDD45X(T.XYJVWI(XQ__[^SW]-'/BHJ(BNB*/PD^RL%+?#HXW-OX?G1P]&@SIQR)
M$W%X*/8/DRV["N2?.1JAY)ZS /7PY)_#$JV MDAN'DJT\[I?'&3,LHT'H+!:J(396N5D/=. HF)I;&47 M/#V '[B[2>KV -#PFS9P0N.L B,$.T%*6JG*,7<6QR(1ZPY!N1+"8.D7DR< CFRP*L6AH/$+5/1;>
.03[TU1E7THU]JF MJ30%&)4<]-+)=2ŸX.:&G'A/U1$MU:LN]CW4+'/]?:4"3VYT/'_W&*#?O)O-( MAQS\P,9/_48&$0C53T<'F#.,I-V3P)88SL(M+*P;V!OP1EZ0O00 >>Y-^.<51!Q.9
MCPL_&)GTYADHPM,1ER7V$'AGG^GZ8B>I%BNXKXCSE.XX_-%H?-P_8K;,/"E M*300 -5KZ_J^TM@ACUTZ-EWWQJ!-N2'U6A/P=(E MFO$A*&7BG3B]K7'JE8YEYSMD;Z''BXE$8]UDH\!F>19\
[Q,V':O#$H;RCKM'/7:O[,P]'%^?"&56VMFH'O@DH!?%0KK1 MH53;YU@>XK]I."9I9A-#=",:AFDCT)3"+!YO;?A.,DR?;(7I3ZJ(2? ]XO/~)9XUECPC M5EL_ \[^CG;BK+1TW3<&X?
\G5N*CZ6NZ_:>QIHM&Z_O% 354/*:4#B72&XM_ML.A]?OV*ZSCNZ4#[I/(Z@]K/=LJ'-YO/?Q^79B )?#>^%XP=1-M?& TT4DW[4)X PVHU="NX/??R##+_A7 M+CS^-
B'^%"0_S3^D.8N_'^F7QU_A?) .^O"B4G-LW9L^/]I!EE F0Z6H#W#!]%3;=*WYL2T<)#):29!:6U]648FK3$BIDS5:.DE5SIBEF:
MZB(TM4:6^:!*A'$4G8<5XS*83[WM1L^GJK&"[2S18)JJ8OIQB4)M9\$PV!EN M>5%:9PCGTYH5N$+[I;[1- M[E(Q7* U7$C3FLV QO%R.G;]W^,IQ: _;&X"I9 M*W7O)A^R61 Y0B@PM0Z!T6N#URB$
R(:WSK,H$_I O?'._3??>U4RYH9O%;B M;Y[9(*I$L8_8=OZCN, TL98577!Q*#BLGVSAZX/ M>P&3Z(6 N N(/>\VD6?YGEDVGZVU!>V\",K1P)L[MA9HWDY#2XE=>)AV299MDOB% M).?P64E;&OA-
9I@JCP^)<,\ZWK%>QD0'O M4+G_+-;&:E+-OX<*;O%&A_'<2;HT-4MQ%M!1,:@LGVSAX,Q?OQJ>1U=*V(YZMJ-C MZ/,5G@V[5K)%"7QJ!HGPRTW]X<('X4\3/BN1,*O:B8??[^:Q,-W5P9J MIJU$;8!+
(.T)ME9=;B8SH-;1>45@A4:DHVL-;$M%A]>#DJZ&T0DH#972GKT] MD,$JRP2%;% VA$2.S$!.J=367 [N2D)^)B<@,: 7PXH_'%X9.)DXK230CP;7 M_G"AA@5$< (7Y_3P@PFHTA3YQATMR+6J@-
O_T65]$;6S[6X2OTKF^)_!J374D M0V]-SN"( ,> ] ,< _+,#;=]_,K! A#U2%9G7)4S(71/>0${]" [@0G\N$DA=/ MR;5/?NH_UQE0UYS.A$K[0^+F:;?%I__1&+SA+D UAAIHWOX\R8T&?R$EUL+A
MPB_@2XFO:!0GT;/Y.!X/ODAN"6]EF:7FCN$"D@2&22> _7=WDZ^,OZ$GK-$TF M!WWE MUTZLJOV&LU:6.NR')?TOH'8.M)XK97<3EZ#_YE_!U!+ P04 " #W@0A9 MK53MA6($ !G# &0
'AL+W=O',-D*^J@Q D>"V"SK9%;S$JZ@F?0W\I'B9+76DE8 5PQP8F$=.Y<#R]O+HR^5?C.8*,Z M[\0P60KQ:H0OR=SQ#2#((=;& L7'&EXASXTAA/%'8]-I79J#W?>M]7O+';DL MJ8);D?_*$IW-
G8E##$DAIE>LGL?D,#1\+,!:YLK]DT^CZ#HDKI471'$8$!>/U MD]XU 7D JBH)&'&MR*<7NLQ!G!+T&?ZGX.0E]EP1^,,JQ%[:40VLO_'O*=TS%N3"L%?GM
M>JFTQ"KY_1CGVN3HN$G3.9>JI#','6P-!7(-SN+CAV'D7_4 'K6 1WW6NX_ M,Y!4QMD[P7XD]XQ3'C..:DVNE +-&>=)9_,KHDN5,,V37)#R+)X@K M*1E?D1NJF#I&OA?>6-
:VF+")K0+7I./VK2A*RM\ ,?I@$P_&5 M(JF!M;:PLCV::FMW!+4C-4A93#99> J50 M3+>:T=2-QN,#<8"I*$#::):T1.K;_6GD!H% (**Z+(5$%V01#+CM=N"'[C@, M#^7!M /,G<_(B;8!,EK;[PXD['?
L'XN!%:,31)1Q.)F[D^WN$+*1.T7"G2(? MW(%D:VK&?%L4[R?B%4Z"^K=UUZ_U/Z;\+ _75FW;L#3<:C4X ;'9/)Q!C&HS" M _%T C$#X?1 K-.W$FN0W% EJA1<"=ME*\ >[&0T<"?3:%][
[QC,5E@7"D61$%D$_PAC=8!6T_#"FP=1W\-TA-@?;@ M"FLW1\O6ZUS^< :L[!57D5A47-?WP':UO45?UY?'G7I]!7^@-0_ M'V,YROI:6PM:E/8JN10:+Z;V-<-_B"- NZG0NBM8!RT_RT6?P)02P,$% M
@ ]X$(62I?6=K ! \0P !D !X;"]W;W)K&ULM5=9;]LX$'[WKQBX1=$ 2JS[2&T#.7HM6B"HD[#8A]H>2P3D427I.UV M?_T.*5MV-HHWW>/%%H=S?!_G$#7<"'FO%H@:OE=EK4;]A=;+\\%
Y0NLF#H3 M2ZQI9RYDQ30M93%02XELH9VJ++01#,;#)2MP@OIN>2-I-6B]S'B%M>*B!HGS4?_".[^, MC+Y5^,IQHPZ>P3"9"G%O%A]GH[YK &&)N38>&/VM\0K+TC@B&-^V/OMM2&-X
M^+SS_LYR)RY3IO!*E+_RF5Z,^FD?9CAGJU)_$9L/N.5C >:B5/87-EM=MP_Y M2FE1;8T)0<7KYI]]WY[#!+,IKIMEX*,4&I-$F;^,!4K76!([7 M)BD3+6F7DYT>?
V;R'C6;E@@3S%>2:XX*7M\:B3H9#C3%,)J#?.OOLO'G/^$O MAL^BU@L%;^L9SA[:#PA;"]#? ;STCSK\956?0> ZX+M^>,1?T!(.K+_@"7\? MZS4J366EE0/7-7 ZAF_;;B^L?A&?
QV,55:4M'W4GD(38RP.X9IˈU9#F. M^M0I"N4:^^-7+[S8?7.$0=@R"(]Y'T^:_@$QAXLUXZ5-'K4G3-B#+';A/NJY M&_=!A:C6MP.;!<\7P"1"7C*E^)SC#)@"MH-T2I!.%4%R(!?4Q$J3 F'6"X.V MI&G
Z\)8D(R2C&V2;4*N,<=JBA("STH#>,UKLA4K1=OJY+QW40FI^1_D]$HH M#9>,0L![*92"NYKF4VGWWM-]*U%5*'/.2EBR M)=',(L=U,TA),S::6>AD849Z8>I(-K@D7V8>>"YI.A[/FD:D9]FO;NS
MR1G<$D-%Z B-ESI9DL"K%RGIO2'UQ"@;=H=N[%9HBJ[^A1W"#*'"\R# (,DLC M<"/+(XA\)TVCWB=1%\=/Z*],7X+G^$E$_SMHQF]HO9H=[Q'I('3".*:4&#U# MV0C"<,NB/([ 8G62T'
@#S96O*7@)%[T_]31H_)]3BUUG%3BQ&Y@'BQPOP%. MTBA)']=&ZL1$DX]"TM3D.H[U I M)AF4WBS^B4+)'"\TY>X%39T$S1F3F!KIGU1)'!O2X8,ZB>/H,6W7\:,$ K_5 M,Q)JB.>6!ZEGU)T$-
GX0S,BC$(Y,[*B=V-&S)W912"P,^GW-V(KI?A%ON%YT MU)N9D+8BNV;\42S=,WZ/:FY0K5M4W6=F4:WVJ,H]JL+VR0:E[81FSJM_,>5; MFT/5GG5@VZH+^=/ R3DS;R/-
ZQ7%L,#!3FQS0S3O4+KU* + ",4&RS5"U5QG MJ#K;.^4AHEKQF?D.FZ2=G;%X. :2MU),&]XJ-85\XKHL6XN\0?>Y61I:13N40M2HK- *#);S MX"*97@Z]?6?P1>#&
[LG@,UEI_<,OWA3S(/:$4&+N/ *GSRU>H90>B&C\W&(& MNY#>=5^^1W_5Y4ZYK+C%*RV_BL)5\V <0($E;Z7[J#>O<9O/R./E6MKN#9O> M=D@1\]8Z76^=:5T+U7_YW;8.>P[C^!\,;.O
.MY]H([E"^[X8F;T!HRW)C0O M=*EVWD1.*-^4&V=H5Y"?6RP-]=>X7\!5 2]_MJ*ABKL0WM-Y./G$5Q+MZ2QR M%,G;1_D6];)'9?] S>!:*U=9>*D*+![[1\1P1Y/=T[QD1P'?MNH,TC@$%K/A
M$;QTEW;:X:7_23N$I>3*/OEVLK#-T8+X?2KU"AY&]I=H:AN>XSR@6V+1 MW&*P>/8DR>+G1W@/=[R'Q] 7-W0IBU8BZ!*.M.X0[:/ AVD_BH /$132*]=T M,ZW#PG-
Q%4*I)5UQH=9P(A1I=&O)SYY.!]0][+KW G.L5V@@3><+!-<\K8F'^ M@H>GD*3A>99Y@863239XAW3O*BT+$'5C]"UZ.PO)>9BR$219.(G9X%5KE'"M MP0ZN%'=>MC
B('H&'\I2Y+@7AJ43_PRN=-VTCC@];'D JTNWX80V)H!Q/"([ M18>B[8<))4A$UA3 IM,8#2*!Y^TX]*K#]0,TC2,LP12%L:C,25D[10N\KRM M6\E]#0NDLN>"]Z.*7'FMC1._>\4)),,PC6,X]6(23E(&IX,C[?
&U&U,1$0)8 M"'8L@T.G+]H;'#6:=3<>+;6V5:Z?(3OM;@)?]/GP;P?W]?@~$)[=[_P 7; I<4?4$L#!!0 ( M />!"%D@BMD_QP( #(& 9 >&PO=V]R:W-H965T%-( M55&#IMH$>JN Y@Y4\2
.PV%042:\=.K.5BJ=RMIP)F"EB*ZKBJJ7!7"YFWF1 MMS^X8YO2V(,@G6[I!N[!?-^N%%I!QY*S"H1F4A %Q7+)-?NE^P:WV3LD:S61E8M&!543#0K M?6[K< 8A:\ XA80.]U-(*?
RFAJ:3I7<$66]D*8L(]R;Q3>,L29 M=)YEJH:<4)&3;Z8$19:U4B ,^,R7%&VT830:49S#SL$PWJ";ST_;MH M&'XXH3?I]":GV-/IGN(+,B;WNZ8_I,1CNL_C"5=K*R-Q0^^DTQBMVJ#?B@/
MO4@A.;8]$QMRS@2>R%HC@[Z8]/ =P;WC-610K9&P'_D]? V%$!=& :>6"IYQ M FED/R,#/QDGN([*!GW]IHRS(!EM$&AY,[6ILY?4)0V&]'1<$!B/QJ%O27* MQ*ZULAJ(+$#;,8.8V
_CB$3^8!3UFJ+2-DRG8SPD49CT'J2Q,=]4F#,2Q?[5 MU;#9A%%"CGT*P4$?5Z V;EK9JM;"-"W=G78#<=[,@7_NS32]I6K#A"8<"H2& MEU<#CZAF0C6&D5LW%=;2X(QQVQ*'.BCK@/>%E&9OV
#=WT3Z%U!+ P04 M" #W@0A9; 9A?ML" 5!P &0 'AL+W=OLY.&KK1!:0H]MGWW',O]GF\D>[]SA$-/):%T!,O-V8]\GV=YE@R2K7*&AG M*57)#(EJY>NU0I8Y4%QX$<^<27CPDO&;NU.)6-
9F8(+O%.@J[)DZN\427YK)>,E"LVE (7+B3<-1Y<#J^\4/G/< MZ)TYV$@64GZWPKMLX@76(2PP-=8"H^$!K[ HK"%RXT=CTVLI+7!WOK5^XV*G M6!9,XY4LOO#,Y!-OZ$&&2U859B8W;
[&)QSF8RD*[/VQJW0$QII4VLFS ))=< MU"-[;/*P Q@&+P"B!A YOVLBY^4U,RP9*[D!9;7)FIVX4!V:G./"%F5N%.UR MPIEDAAJ92G-@(@,*K6 +J9A+V%0I)E9(%3 :7MVS18'Z>.P;8K58/VT8+FN&
MZ 6&,[B5PN0:WH@,LZ=XG[QM78ZV+E]&G0;?5^(4XN $HB#J=]B+VQ3$SE[\ MKQ1,NU/P=;K01M$Q^K8O"35'S^'O5HCO68I3CRZ.QK5 WK)T4%X%EQT1-!O
M(^AW64_F]8T"N7SFORWJ!Y[2'4*8X0.*"O?YWFE]O^]_\Q0-CZIY@!H&(*.T MKE%QF<&&:::!O24"YH0/%!9A<5IJP^GC4N\\5XI.C E1H=(6>\\?].SU[!.PY MB*&=]2K!/U8*X1".#H91&%W0+
(J#)_(@&O2N;FY@ .<0QQ#&O7MI6-$Z3QH. M=4Y_VBD0PI,X'+HQZ@^:7&7/F9ZI[EKRI:JFW M&+EVC6\A#;51-\WIW4)E M%6A_*:79"I:@?0F3WU!+ P04 " #W@0A9T#K,7C($ "M"@ &0 'AL
M+W=OO6#!M$ .*>8HZ(@GP MD:();,2PW>2AZ,.*$F+[,'L+BV[O[ZS2X]26T4U_"#M-<Z4?][60-8 M\BBX-+-@;6TU"4-3K$%0]"DVE@9:>2? PB:(%)3)8#[U
M=S=Z/E6UY4S"C2:F%H+JIW/@:C,+XF![<_N*FA:, E+"DM;;AC;/ E+4QBK1,B,"P62STL?6#WL,H^@G#$G+D'CFX$QZO+RIW5^,J0S\XOE!#,HI>M(526Y$))R^0*9,' MD'?
W=,'!G$Q#B[H<1UBT(L0.:;(&>)T<% M?][E*4FC/DFB)#LB+^T,3[V\]%6&7S)3<&5J#>3/LX6Q&K/GKT->:)1DAY6X MBIJ8BA8P"[!D#.@'".9OW\1Y].&("5EG0G9,^ORN*22BEHA>5$IZ8_!T!9BG
MY.,C5JZ!0ZB/RCV,^GX-9*DX%C%ZB5B7%VTEL[_181:?BV<@N Q+YG M\ [='>(^^-+SN!UFTNUZ7SJ8C3*92SYA>3C4?(Q.9A)R#!B_-L+NZJKAW
M'JK^))O/@>NKM\#1JR6QBNR,]1EH#]7>486O2CVSCXSM(=,[9.IY&,RDU\7S M%@H0"]#HX7[OF^_B4+ZG#\BP I3AOFR[^%G0PJ?+$U"-J4(&IPG^AO_E++&%
MJ%I:@HIA0H:G(_)K^W\D,GD7F?RED;FFMM:,,NK;5U?X5YA#C_O)0$([*?G7] MBV= &G_Q'1!"_?WS,O]WY367.Z_ONL2)3_3!:.1H!B3M)UGFMCENXW3@MD/, M_%$W(;
<<95C+@K++$L.'%>+2MG65M76_'#RH3M6BQ5O2I:0YQW)\':>* MC)F0,]%$$;PO_$<'LPP% E;F.R<5J_>D=]\D@?*:W!V_H^*%%7DK8J+6FO' M6RGM$W?7G+J\V_
M3!/=;3>+G34CR(Z\&>2NJ5XQ;*H&ULC55M;]LV$/Z>7W'0@&(#M$C6 MFYW4-N"D*9H!!8RD:S\,^T!+9XL(1:HD%2?_?D=*UIS!,088%N]T]]SS',G3 M?
*_TDZD1+;PT0II%4%O;7D>1*6MLF+E4+4IZLU6Z899,O8M,JY%5/JD141+' M1=0P+H/EW/O6>CE7G15%*@L;M(EA-KF\R%^\#OG/9:?F&7+N59[T"Z:T-S"2_791(Y+MRF/5M-
;3GEV>:N:AIKS:%7Y!+]^8QN! MYK=Y9 G:!43E '/3PR3OP!3P54E;&[B3%59O\R.B-/)*#KQNDK. ?W3R$M(X MA"1.LC-XZ:@S]7CI.WAW/SMN7^&OU<9834?A[U,:>XCL-(2['M>F924N CK_
M!O4S!LL/OTR*^..,9@ME(,#N'OGRDZU9U D%MX; I-:,Z\-#7JH"N('SN;*<1 M[HWIF"SQE(JS=4ZK6!E7EGJ.8\^!R0H^88G-!C6D$^]-0[ U.GXMDZ)0,P/Z MP*[L21MWDD)P%XY^YO=2R6?
4E@+H\G 3>A7;7@4?5% "C@Z<]JR(7PS#/M]3J'3W59[IBM8"V*3A&F:A$4^A3S)PG@Z^ _^H M32O4*^)P3]:=+DD[#K#3-$RG.=%,PSC-+NY>4)?<>%#5NMECO%)J@>LI349C M:
<'ESMM#+Y[16.>B)&JIU;QT/3NPX=; +,SR.$RN8K>BKUW@@@U9I) MRDK#(IV&DRR'G);%U<4W99EX&2S]4ZR_]V:2A<4552NF"64N/+*4U/W< _7WK"J M3-MHRQ-2+^LZ9.$V@70^ZU2]F"X
N-';OD/4$L#!!0 ( />!"%F:@T4) MG 4 ,P. 9 >&PO=V]R:W-H965TGT!N5J==8/N MYL.UF"\L?>A/3I=\#C=@[Y97&D?]QDHF"I!&*,DTS,ZZY\')14+R3N";@)79
M>6<4R52I>QI\SLZZ/@&"%)+%C@^'N #Y#D90AC?:YO=QB4I[KYOK']RL6,L M4V[@@\K_$IE=G'5'79;!C)>YO5:KWZ&.9TCV4I4;]\)6M:S?96EIK"IJ9410
M"%D]^6.]#B]1"&N%T.&N'#F4'[GEDU.M5DR3-%JC%Q>JTT9P0E)2;JS&68%Z M=G)C57I_3'%E[(,J,->&N^4ZNN73',R[T[Y%-R3<3VN3%Y7)\!F3,?NBI%T8
M=BDSR/;U^PBOP1AN,%Z$!PW^4& @>" TP.F!OT,0_SZ?&JN1+_^T!5_9CMIM4PV=F"5/X:R+16) /T!W\O95 M$/OO#R"/&N31(>N3FZITF)JQ:T",(K48@\LANY/"&G9T?7/7FK.#AMMAWR[
M<8++-5MPP^:X1.1/;UT;Y[I$UY5GQE=<9P:_9*"910.8,Y]=?B^%7;//,L7U MQ2IDYR3&KG(N48A;]H FF7I 'K&]1BAF:DXDP4") M*4=@*3 $]A%2^5:I'+ R\<3Q@[SH? MR$8.61_;QPQ$-8M^DV&
LVW.]I"Q<#CR@B!A!W@S;'@S?"EO*K+\N:0B-^R\ M7JTVQAPT^3QC?I*CBC&J]O_LG51K9MIS]+("R/?"X919Q/JAKW1(/*&OM]\ MAT?
0J3!5[L8QYI:2MYU=*NWF1MYHD.S,S':R&B2)%\64UEU4^^G$9(Y#+T@& M3SV[5?!!?. E8>S%<=B(UWSA,B-4X.K/JJITGO=VB#YQ0Y_XI?0Y1]87-: [ M6C0AV47.<0^Y21<*-
PSVC>=EM85\41GD!/'26($;*+!/7&@G #]0L8V!AU'M MMB>H/50=/6M0+'.U!G!YD$HV MXXT#8;!!IFHND?+8Q?#@P6@WH=/!,85 APB4<B-
VBD=:93M3DJU^:M<]E0&W3!XI[/CO$_J+>!7QQOK3VH'5F9 M4ZL91;TQ>X-BH/$OPI=1@.)N'/;":ASMS?L;*8C&G6MA[H]G%*_AD*;(=-$ M[JA6BWI#? [TL2 BE 4>0RYKOQF7_Z[8
#)NNV:=2NM-V6S4?Q/'R_01KAV_N$$UYUZC3 M7=10HQ8R+37U<(((>_#E$_BS&CX[$G0P4:5!*?.NE=]/:=W*9CRE(0_3A?.6 MP0->@I;NC/D:&WPPCO$9>G$RPF?LA8,
GT,OB$:=WT"'YKG3XQD>_ 4U$7=V M"KU1DN! _.Y0>(0GA,CSH[!SJRPJ_'0YR).^\)K5!O'8WP&(>H3A#%"\ELW MC/[.#:, /??W*(,.2FFKRT;SM;FJG5! M"%F4\(!2#P0 '0) 9 >&PO=V]R:W-H965T,
(EML\%'U8D2-Q:Y++[^XMŸ^\[ M2U*T7"M"^R+M9>;PS,P9#F<[J1YUCFC@N2PJ/7=R8^I+S]-ICB77%[+&BFXV M4I7_W$*[FHG,6L/5NJQ4PVIA 5+A7HIBRY^G:-A=S-
MG<#9']R+;6[L@;>8U7R++*S2_UTM%.V] R42)E1:R H6;N7,57%[ˈUKXU^$/@ M3A^LP4:REO+1;G[)YHYO"6&!J;$(G/Z>\ :+P@(1C:\]IC,\TCH>KO?H/[6Q
M4RQKKO%&%"E]9O*Y,W$@PPUO"G,O=S]C'T]+,)6%;G]AU]OZ#]2--K+LG8E! M*:KNGS_W>?@O#]QW8"WO[D$MRX_<\,5,R1TH:TUH=M&&VGH3.5'9HJR,HEM! M?F9Q1W7_36H-
2U2PRKE"%ZZY%BGP*H./HF@,9G#VP-<%ZO.99^B9UM-+>_SX M#]]!S^!3[(RN8;,*KL/LM;]'7 ?";$_XFIT$_+6I+B#T76 ^BT[@A4,"PA8O M_[>+5>5J+8'"8 _K];-*-++7\?B[>"BXW"VARYUS5.
<.]0D&M43.HOW[X+$ M_W"":#20C4ZA+VYD63>&MWJ6FR.%>EO.8R&-?'0;5;/1$6^LM%DIUW YQ1KT]]9UQ?+C(1\ M?CEZR!7B*_D %1_;XJ_$_&;D96%U48(PVITUYZHN)%]=+?G]0.
<01BYTSB$ M\W;#IFX2)/TF&;MA'6;>.*RZ03.1Q^QDM2"+="7MMTQ^Y$_%2C0.^H:Z+VG M#85C4]=(D91=]FR)V_3XAY)7AR(;,+<,3$()VX8TC:80LQ<-B9>R13H)$D" M=$J-
7P(ZB6C#\"^2?:S^Q7C<+X,+-AV6UN"$2N-!I?%) 7T^R,&J3\L&EM@) M900OBF^=7.EM#"M,&R6,()/;Y[1H;"DW2I;P+Z7_/WV?I'>\15^+_K"*>HB@ M/H@@VT>@7R+8(8D77X5QI%E.M
@U6.M!)T)F=&/I5=9XC2DG.9&:+'K;ES2= M:>(U108Y:9 LD&8ZX4L1?0QR2NJ?]W^A!&EX0 ML7$T<>-)0,3&$TTE:"K3#<7A=/BDN.HFZ8MYJSWR MB:NMH%05N"%7:AE2E>IF?
+&ULS9UK;]O(%8;_RD!=%+M UA))7;.V =N\3='$QF:S^Z'H M!YH<241X4+&I$>B)F7[7QAXBD>XSM%X/S\P;#2^?T^Q3OF6, MD\]QE.17HRWGN[?C<>YO6>SE%^F.)>*==9K%'A>[V6:
<[S+F!550'(WUR60^ MCKTP&5U?5L<>LNO+M.!1F+"'C.1%'O9EUL6I<]7(VWT7. MV[ /C'_\B>\X-M4E[*8YI^ M*G=H<#6:E"UB$?-YB?#$RQ.[8U%4DD0[_M5 1_N<9>#A]@O=KBY>7,RCE[.[
M-/HC#/CV:K0Y=7V;I,\G*LP6MW*@45$6+SSQ, M2K% X)EX-Q1Q_/JW+2-W:;SSDB_D9W(3!&&I02\B-*G_DDI%_F@R[H51_I,X MY>,'D_SXPT_D!S(F=+;+6$["A'Q,0IZ_$0?
%]F_;M,B]),@OQURTL,PS]IO6 MW-:MT5]IC4;>I0G?YL1* A;(\6-Q9?O+TU\N[U97 MJŸV04QM#=$G^C3GO;< MJ<-M]GA!]-6KX>;7LGJŸ26[T1%OJZ/?IDVC[I K7>L)M=;C)_/VE3WK"'77X
MWXIDG[WOTMW3L_==._U*=D]DGVA]UR[IP-C+W*AXQBN\^VSC)>&_:SG?) %Y M[_$B8^1^36Z+7)ROA'(6Y_LDVZ=8=J?H;PIOVU.U-J]\;WB[B(/"X$*2K4T ]Y
MGR25D*&2],,Q"PFPDS*EA\X,/?KK4YTMM_^G78NLY39L9^D(^C8*:)BEN MOE?<7*7DX4>O&H@3X4/9^Y#^BRA7UKJAV'XK'*/1%.2!Z1]&1]HE0R1TJ0B3, M1,(L),Q&PAPDS$7"*
@F"7JQ%_3B()7M BEM),Q$PBPDS$;"'"3,1<(H""9) M>[F7]E+95[\OXD>6E=5L4]?F:1004>J2,,^+X_F!6LI*XE I(V$F$F8A8?:R
M4]:MYO.)^)'OVPXRJ8N$41!,4NEJKJ*54J5U*7$D33'0"GTQW!+RK;3;)U4E M=JA4D3 3";.0,'O5J3#+V25)IB=J,=:FTW&-F*H11+& MA3Y3G[$@?T.\-1A;Y%I5'O MITVY+-
[(>?]TK{)-0T4.I9E0F@6EV0U-$OIDNNATR="L+I1&4319[P?&AG9* M]?+B4=3=0;Z)TZ]V"]0BTX*,WN_97T36- MT[I0&D719"FV=ISV%3_N_S)&$-[I-&QG1U_+'=]9L^6,E0YPY*LZ$T!TISH32*
MHLER;[U ;9 96/Y?(V*GHG!^)O?)*9Z@FC^XMH"Z@E":!:794)H!E;0&D71 M9(6WYJ!V?G=0@]J#4)H)I5E0F@VE:"Z51%$T6>6L3:@-]PLI\">HJA>SJ M;CQ5>=-0UQ!*,Z$T2^MZ?
=/%K%LDV]"T#I3F0FD419/%V[J'VIGL0S5WL&BA M!B*49FD]KM_L6*_(C Z4YD)I%$63OT_1VHCZ=V@CJMLT5.M0F@FE67K7^-/$
M3Z=_AF9UH#072],HFJSWUD;4U39B=XQH#!LCJOF#M0LU":$T"TJSH30'2G.A M-(JBR0IOC41=/_L848UP5+>>LCZF?V$=7\P0KO>G7S MV7(^T8Z\#Q.:UH+2;"C-@=)<*
(VB:+)X6Q]1/Y./J.8.%FU-6QUZ=:N+CF*A M_B"49D-I#I3F0FD419-7Y&J=1.,[=!+5;1JJ=J/G:WI+K3.N,Z%9+2C-AM(< M*,V%TBB*)NN]=1(-M9/XAY=E7JEF#E=O] M"IXQ6QK3Q?
Q8NE"+$$JSH30'2G.A-(JBR=)M+4)CT'<-U1_J4*M0@;VD*>ZIBNCK^#:T+36E":#:4Y4)H+ MI5$4399JZQ$:@SS"=][G,"[B;URX0YUKL)"A?B&49D%I-I3F0&DNE$91-%GM MK5]HG-\O-
*!^(91F0FD6E&9#:0Z4YD)I%$631=[ZA09^25(U%W_%U!+ P04 " #W@0A994H" M "1"0 &0 'AL+W=OW< M\]P]=^>7X9J+>YD@*GC(4BY3'J)4?N&Z,DPP(_*XU0ID3#.W:3
1#7JB4,IP)D$66$?'S$E.^'CDM9[-P2^-$F04W M&.8DQCFJNWPF],RM62*:(9.4,Q"X'#GCUL5D8.RMP1>*:[DU!J-DP?F]F5Q% M(\?J612D;.MP($(EZ1(U2U?O\=*3]?PA3R5]A?
6E.WG0%A(Q,,*K"/(*"O_R4.5ARU_^Q# MKP#^(X#O'P"T*T#;*BTCL[*F1)%@*/@:A+'6;&9@-WC**(F^22%*U9VD"G%Z105
MH:D\@Q.@##XGO)*$17+H*AVA\>.&5327933^@6AZ<,.92B2\91%&NWA7*ZOE M^1MYEWXCX8>"G4/;>P6^YW?@;CZ%TY,SF&.L&U'MB6_23#?%4 .U+%U[0]<0
M9KNN0MORMI^HPJ>GJ_#M6F/A2F$FO^]+<.FHL]^1.1,N9$Y"'#EZTTL4*W2" MERJ;/>_OFPU=.;P M6@6MH,O:EM/H\)ERNK6<[E_*T2>P(+:H36JZ3ZII]/=,,;U:3.]1C3XU4[+@ MHCP
]&:':QKJLQUA' O$@ZH:6?^U.X]$MI. ?IV_O_:L?UCYN1(9#LY&=0Y M&30V125>Z@T;(EW9#?L

I2WZ06*Y'3M]!,2SQ-I%S-MMO\,>4 =S1>Q1)A?M,]M/0=%6R%9FH/5#%)"LW_\F":?B"*!XJ@'-' \!;3/ M %HYH'6IAW8.:%_JH9,#3.AN%KM)7( E'@\YVR.NK16,;ICL&[3*%Z%ZH2PD M5T^)PLGQ(EL@B"W1@JPH69((4XENHHAMJ21TA68L(1$!@3Z@A5JF\38!,3UE M-{J.39ZJX$Y$0_H70-2DT2\5]9SV-'=@FI-31S-3T :,72EBD+/Q8WR&4^R-M&3?/S+B%[AB5.X%"&D-<@0_J\=T:O*NR5Z2P>4CAI%E+^&5+&ZCE7:&FUVQ7 MS&=Z.;Q5%<[ >0 _V7LI&:UB/;4,7_L,7R'U396RM5A=$P=B@R,8..KH"> [ M<,9OW_A=[V-56FV2!3;)0DMD)0':A0!MP]XZ)\"S+89^?E4VZ%9"*GY5]=*V MJ8I-LL F66B)K*1*IU"E4{\M2JIPI)PFJB?F%5"KE;A-R]K!),JL*KQ,YVS=DD"VR2A9,(2@+T M"@%ZMBM!SZ8J-LD"FV2A),*2*OU"E;[E2M! _OCO]DTI0Z_*UJ7[97VC)7RF! MUT4"KR^J*U6IJD6^=OW:) MLDH66R$K]|VG$X-GNZ[DC):$LJFPJOC0NH_K/4)U^:[A')UJUUU?F*D$@+QF3AXYV4%SZC\"4$L#!!0 ( />!"%E?^CRG M;@, )82 9 >&PO=V]R:W-H965T6 M*ZD'W/%PC9.JYY:4F*1 !6$4<5B,G&M_$/K&P,SX1F K]MI(AW+/ MV(/NW,0CQ],K@@0BJ1%8?6U@"DFB26H=OPJH4_K4AOOM?VC"5X%Q!)A/M&VF.LY*,J$9&EAK%:0$IH_X\,**C9%G$]**
**M6]%TPV3?6*M\$:HWREQRJ90H.SF>YQL$L06:DR4E"Q)A*M%U%+&,2D*7:,82 M$A$0Z#V:JVT:9PGHV5-&(Z*28Z.W&K@CX@&=!2**
**Q2<0Y.IMAKIZO0"IB^]0RVMU:M8S/=Z\71?._WD/_]E{)1GM]#*75IMP@*;L- 2K") MIQ2@8^CMEP1X]HJA'U_4"0C(14_ZU3IV%3%)BRP"0LMP2JJ=$M5NLVO1445 MKE1YA];**
**]9CZ>.X3)>?YG@'JG__-V!NZF_U4UTVYN.I59P6O@\)Z4+^<50FY M5X;<.ZX23.K":[0]=<_9A 4V8:$E6$6 RU* 2]N5X-*F*C9A@4U8: E64:5? MJM*W7 GZS]]._Z 2-+H\-**
**=6O^PLM^:LD*I_X%5C F_Q(TFS%/U!S16FD7+J M7K8)"US"0DNPBA2^]W2:\&S7F()H21BKM, J+,1%JVJS=]+S+5>:9N#)TMBD M!07MX$,*86&RY3-/N;MWSE9U9FDN.**
**0R1^7\2%2.EI+QB3NXYV4%Y%C?\"4$L#!!0 ( />!"%F=@*D-9P, /D/ 9 M>&PO=V]R:W-H965TN*Y(<2BP.V JH>K-DO,12#7GFBA4'G!I26;B^YTW=$A/J**
**MA#,S=\'#&:MD02A<<<"2JLL3\YQD4,#-W1L[-Q"7)NL8!S5GPFJ<;1#7:*6F'TST#5O%BU"]41:2 MJ[=$\62XJ#*<{8DNT(!DE2Y)@*M%IDK"*2D(S=,$*DA 0Z!E:J&V:5@5H]"6L**
**M@59J^OHG>@DLXWB5DT1-9SK_CR.0F!3BB6)=+2+T^.$3]! 1BC[FK!*8IF+F M2F6^-L)-&E//:EJ/]6TP-T*M&92Y03%-(>_C1,\'ZP'=5V-K8^3>Q._;!=J4 M]**
**%WE/D>_ZXQY[SN].#/G?NMWK\SZMW@A&T&RDP>L$M>A$1.,LX9-@< !_: M'8*^O%50]%"*;[V9;W6'??KZH/R1*QP G-'G80"^!J<\-&#T=1[WA=RFV*1 M3;'8DE@G.>,V.>,A]?**
**CD[A0Y[I)2%\,:OK4T/7=L@XG,W>]'=AJA!\<=S'1 M/B8(NI"X9Z'@J,5TG)NTSDT&G7L/,@=>W':H#)+_=GO9%(MLBL66Q#H9F+89 MF/ZGVI_:3(Y-LK_9H^V2I);Z?**
**V]Q%^L(.)_J@2[R,F M_J2_I{):WXX&?;NB1$***%A)+Z"W^0?K?[B^-IL=B26"<'QVT.CO]3\1_; M3(Y-LR>_7W0;/N_A[,*@Y -RM5J8$ MGID>4B#30<=0:**
**H^ULVZ>>FNYL9_YL=\(^ZIF/=%]K6J??\G53_ [SC%"!"EBJ MI;R#0W54\;K/K >2K4PC='!@ R#8 !D !X,"]W;W)K&ULS5MMC]HX$/XK%E>=6NFZ)+83H,Q].]\$+9HD:**
**M8FH;MBO=CS\G9.,8C"&4_EE<\$>40TI6.9 M0Q#UL*)7-$US)!7'!Q*T4WUF[EA__H)^4R2ODGD@@EZQ]*]D(F?GG7X'3.B4**
**M+%/YB3V]IV5"18!CEHKB+W@J;8,.&"^%9//2644P3[+U(_E1%J+F$.(=#K!T M@(6RNT_$E1F\);99-D^3++>2Z[>392?'-V0 MA(.O)%U2<$N)6'*JUD@*\!;4WGF?4${X>/8,%&_**
**39*1;)R0%%P(094MR2.U M%S\YY"%)$YE0\0(Y 436\=3R?:+(>)=+]@@N0A@$>'U-)4E2\<,\9(OE6_#E M_AJ\'O4&O ))!C[/V%*H",2P*U4+]JRZXS+WRW7N<$?NOR^S,X"'"7P ,(+:X**
**M7[G=K^E8N8>%.S+=NVH5]J6 U5+ @_M7XJRL!>]L-9R_EDO2V[U!\OX1HW^ M_JCPP0=)Y^(?6VW6P6![,/GN\4XLR)B>=]3V("A?T<[HYY_"./C55BE/8$;= M4%4WY$(?**
**K8ME2W'M%Q=^^7ZV&D4(#X+^L+NJ![]M!N->#\\+*S @+5V%A9UBU MA;/%MG:..:A^*^G C,(M-/+!"%5511RS;I[ C+KUJKKU_@]]>P?0UV*SB[[]*JJ^,ZHK-I]37GS/W)$% MY;;0G A-**
**E\ 3F)'LH$IVT":J#GS6S1.84;[A+U\P3B0%EVR79G$B-%'T7VAFOEK2A*W2-*%74>,+S:R= MEC7AL;JF=*RS$P:HA] FBRUV_0':L0>'6MF$;FGSY>S^#'SFQ**
**M"4]H9KY:,X51JUCL57SY0C-KI^57Z%0I+A,'ECUVT-O:BD^A@D(M@T*W#BJX M_AM;49[EOXS!_8)E@N5+??%(U2_>'?1W@C9>0D]H9@FTY@K[K:*_5P'G"\VL**
**MG99PH5/IN.CO56^5.!M;?6S?Z.$64M MI&Y91I_!+>'?J 0WRQV2Q0W2N)?@ M"-!W.MMLOD4V@MJ[07=VNLC7=$4A-8$O#:J?*&9>6J-!GNM MXKA7<><+S:R=%G?**
**0W5%S<+Q_X);>?%4O-'.F MH947"MK$;>15POE",VNG)1QR=]D<$Z'P,$Y,[%R<1EHA(;=*6G,:6F/SVKSR MA6;F69O)H5;1UZMD\X5FUDY+-N1NKSGH:YL:]N-@LV=BL8N"H-??**
**P5XMB)!; M$)7L53OR(8,8-UCC13F%ED):2Z%6S1&15WTW"\VLG=9GR-U#T9H&\=8 MS!SC&*3%##W*+GSJ?]PYFW%B-E^04?2FDM15JU6P1>95FOM#,VQH'PZV: M5&*OBM**
**7FED[K0CQL9-*O#U;M#6[W?A'QA]I51:Y5=F:_EK"1>U:DH9>55\OM#,VM5.].]IRNTA]=H[=I/:8K1%ZF[M M-J\']J];PA^33("43I57<-93('QJV]3Z0K)%<>?1 Y.2S8NG,THFE.<&ZOTI**
**M8_+E(K^9J;IY;?0?4$L#!!0 ( />!"%G5FNO>3 >&PO M=V]R:W-H965TKIQT_WZ2)@$TG2,O5A?]Q8=A5@I8$5'E2*( K#05 R+FF6^KV9**
**MSE)5&\$ES#3!NBR9_GT%0FU'M$]W&P]\M39N(\C2BJU@#N:QFFF"CJ6@I<@ MD2M)-"Q'=-P?3A(7[P.>.&QQ;TZHU%E"[8*2BZ;D;VT>=@#])-7 %$+B/X6$+> V!MME'E;4V98**
**MEFJU)=I%6S8W\;GQ:.N&2_<7YT;,4VYQ)KMF7),G)FH@]\"PUF!_D4'RD8R+ M@KM,,T%N9?-<7-[/IF 8%WAN0Q[G4W+V_CP-C%7B^(*\O?6JN35ZY=9OM>R1 M.+P@41@E1^"3T_**
**IY!;>]_#X$!Y8_UT2HBX)D>++WT[":E&,NE,L#DA_C!1IM M'|K/8PX;RN0XI2N^(58LAQ4UU86@-T"S#^_Z@_#K,;__B>S ?=RWU*C2*Q9V-$ M,'A!{F**
**#@O0)DT4[CXBU+W$)&H]EH*$=>%K7+399F :,?5NG(@ZT)IW6Y*36 M.\X67-AW"?\B.'E3*F(1G"P5VNNS]TSO>(2B8"EQ82]3Y>4Z*9W- NC*E]^ M"V5L,?OIVK9,T"[**
**GB^5,KN%J^BN@6=__%!+ P04 " #W@0A9TX?VC$0# M #W" &0 'AL+W=OHF!)5VW#BE6--?=PW /BLW$PF0ID^2D_?>C9,=-FRS= 7NQ M)8K\Q(^D20_62G\S!:*%AU)**
**(,PP*:Y<786BR DMF3M02)9W,E2Z9I:U>A&:I MD>7>J!1A'$6]L&1->]&/>=OE?XPG%MMM;@F,R4^N8V MU_DPB)Q#*#"S#H'1:X5C%,(!D1O?&\R@O=(9;J\WZ%>>.W&9,8-C)?**
**[EN2V& MP7D .R=6G_$AL^9P\N4,/&,)ZT8W"B"KC%5E8TP>E%S6;_;0@+(#[_MB4'<&,2_:I TH!HDG6GOF:5TRR]*!5FO03IO0W,+'QEL3&RY=%J=6TRDG.YM> M,:**
**[A"Q,5P@TR4VFD%%D#;V%:YQ74',8%DPLTP"5LZ=/!!%T2-5\QES*8<#;C@MM'$M]/+^'HS3&\<=C_%*HR3.9F**
**M$%gJBYAP,LX;&J*81_X1&#VZ4M(6!]S+'_+E]2"%IXQ)OXC**#P)^JN0))%$' MXB@^W>//^-?-DP/N)&V.$H^7O)ZF3?@X):1)60Z?)=QA5FG-Y0)&S' #]U+-**
**M#.H5FPFDM"PKZU04I4EPYC^AKQ.Z!.XMEN:_?2&O73K=[Y)K+Q=FR3(U%^^+UV\">Q:]TS9ZIX?0TQ$MO>5*NYC6T/T/(3K?:LT MZ?TU"%?,?)'9UXF[R@;_6WY=IX[0**
**M@0\T>.!HHHPABE/+K.]'KM=]C=S_\KHN/?!/8L MLOTVLOV#Z-3.7BG;_F[9GLK_S M0^N%?$13O1{"3S#U+\$-T_0=&A X)\CHI$^%.J-LQ6V^L6OI)-5.6YIY?%O1G**
**M@MHIT/E<*;O9N O:?YWT!U!+ P04 " #W@0A9?BO5.\$& !Q+P &0 M 'AL+W=O/DE51$E\:.?10H+'LN^/=D7KN MT9UFCRS_6FPIY>!;FF3%Q6C+^>[-%%RLMC2-BG.VHYGX9EC**
**MT?H,RE#N&/M:7GQ87XR\TB..T!4O343BSP=-T"0I+0D_JJ-CIHU2\7VY^_6 MWU;!BV#NHH(N6/)[O.;;B]%D!-9T$^T3_HD]OJ=U0)6#*Y84U?_@L9;U1T'U**
**M+SA+:V7A01IGA[_1MSH1+05(# JH5D!/5<"U JX"/7A6A74=\6@^R]DCR$MI M8:W\4.6FTA;1Q%FYC4N>BU]CHI)Y>H[ >9:+P]V_[R/0]5$8CU[@6->\$P]SZ***
**M:_T]%"B+GV'/[WFH$S*XNAE87WT9Q#KY$R9[JO K5K/EH,NG[I1&;0F38 MVTGCV<3JV4>6W0\${JO!H?>>(V.=V*=-[-.3 ]'493(<&>LD WJR;GM.H*@V**
**MTSVO(>E#D48,>E,XT9]7V*(7T!$:U8;:'B"0[Z4J@P.#M[*X6W MY'X(M:4. MVI"@[Z0JY!E\E$486LO:#R"I5N[M,>Q#DD9,[+%OP"0HBR*T5\4%2U:..K^(H M 3?1CN;@7W**
**,9;*O,O3N=&6MFQ-9A*%_%?>ZLD0H"W^"9+)C(7C 7+-^Q/.(47+%L71Q)JNR+#+XI'5GKID06 M9Q2>']6L]7]P0AQ92ZR9$D@%D)P-/1BFUR,- %%SE)&OD)@$Q(96D \A.!P8@**
**ME:,I*U"ED4%Z%[$D!=A."@9@%5:?E<]0RX.Z3ZF1,M!3+.LTMC].V^$*JX_'M8IO1I$^L="*3P#> *99%$]N+I@I91_ J^QJ#N\4GZ9VWFN?_0_?<;?O\%/US M+"D!=M-**
**!QVJMQX0$_5Z+1@QZR \,)UG2 NRJB8[5XJ^TK30RV 18DA]@9XUT MK&F2$P6O*$3(,B"C9_32<>:'CDAI$_[-6)BCUN@UG5.%DI+YZWY\MS\%FD MKQ!W)SV68-**
**D7&7QWGJ+#CF6=QJ?OL6.G3797UKKC/LD*B)LN.]&TSR?3,.P= M9?MJQT8CV0-QU8PG*D/H@YI]K6-CD5R#..O:$TW77MF94_ $(GD'>4Y_GV@:**
**M}^)T*3MRDM%X:S9N+^T5GKYC#S3/4IH)'-FQK&"YV)K++>Y]MCH=8^[I#$<65 MM6Z6)+,@IQ\,$*>#_5?6N@F1/(:X&0S8S0P.6F4[:.H9" ^1A(>X&A_8#0T.**
**M1^5(IE@D/R+.)@UV2X.#T8PD#+U({JD-??MO7&!K#N/4^=/DRNL#$>W%>0$(W MPKQW!HX5\L/[W8^3<SG;5*]}WC'.65A^W-%K3O!00OV\8X]\ORK>NF[?LY_\! M4$L#!!0 ( />!"%FT-7)!] ( #\( 9 >&PO=V]R:W-H965TC[XD9BS^Z\Q"R#7#&1$PGKN74Q M.E\$QKXV^,;@4KTV,20K(1Y,YSJ>6XX)"#A$VGB@^-G C@WCC",7ZU/JUO2**
**M"/OM)^\?:W9D65$%"\&_LUBG"U ]\&;2*KL:ZHIN%,BHI(8XW> M3*/.3:U&&I:;75QJB;,,=3K\2N4#:+KB0)80E9)!HJX MS/WRBAP>')$##PG)REXI2H9V:V1K13(!VU&)<-ACN"QB?**
**R_R4>,XQ<1W7'Y O M7I=?083R42WWMN4V)K3+JMMEU:W]>2_Z6^E>/H_)Q0:)3:9.\."=+"FF[,<7 M%)%K#9GZ.03OX9WYGM<7N=^S^/[$/'YW=#.QC M9T+"&[&;P,8]'F>'>-**
**_"/YL&P\#C#GC\?X%[NVRNAPYW"&F\%_#4FYH#NX6u M,^7ZX[/L,%?0<06O!L[#^V9CQYGLAFKWKG?SM.*= MG9B+E,,;=<[I!%EE\UPU'2V*<>F!U9?*8WO1]U,$4':0QP?BV$?**
**NJ81Z3[SQ#^ M!5!+ P04 " #W@0A9&/LP%V(# (# &0 'AL+W=O&K1@+-+:CB?A0$B5]15GOIQ#Z{ENE$M}JS M&JXE46U547E_#EQLIE[HI1{-3%6ED+]4=R6-**
**&6ZQNQ^0VVAD:&+Q-R5FE1;<&HH&)U]T_OMH78 R#/,"#: J+'@.090+P%Q-9HI\S:NJ": MIA,I-D2::&0S%[8V%HUN6&W:N- 2WS+$Z?2*REO0=,F!+"!K)=,,%#DBLSQG**
**MILZ4D\NZ6RVFZN\O,>AQ]0%#OBPNR/N?/TQ\C3H,FY]M!C ?HJ1+LJG$=.QM_;^IC$P4<2!=')D" W_(RA(<6 M'CODQ'U38LL7/\NWU'OM^$AF:RRZ:=(1MN)H0;%;__R!('*IH5)?**
**AUK093@9 MSF .AS/5T RF'NY^!7(-7OKNIS )/@_9?R.R@V*<|,4X<;&G-T Y^Q=R4N^A M(B0A NE<}'B5J_JRS54C2Y%8E.8DVV=!A-_O6_1%7&@>]3K'CEU7]$[ M5K45:6NYM#**
**.@L<&G&I^ ML$=)[S5Q>IT5A82":GCL=LA.\L1./ J>^G%F_$$_X]{/V.V'X^>-UAD0W&\D MDX"'X;-^QD_\/+;BBCC0=]KK.W7J^U.7( FK&LJD73M9266!>T("QR[D1(O7**
**M[XW3%_>&*^) _Z=>_Z?7{TA-4[@]YY;;T1VX#%,'CZMP?]^C&]3O%$]WHKM ML"!LT;X0MNU[<4]:4 RD1.Q>OTJ?8$Z(O= Y1!R[D9^KVE_;]: J #>=&4$5 MR41;ZV[LZI_V8^[,#G?**
**^0W@W(^/L59A/&H<50H/C,9X0LAL[NQLM&CNY+87& M.=!>ECBJ@S0!^'XEA-[=F 3]\)_^!U!+ P04 " #W@0A9%[233C,$ "W M%@ &0 'AL+W=O*K%__(1^6Q4OB[G'**
**MG"QH]G>:B,WX$R?F_NDIKZ)$>6CVI5WR+8S)WY*/("=L1)_KU%QAZO^GJM@0V4,%O5?!- MZ-$7*G &MOU6($\JZ JOT<(*3>THN\CWO1#.W%V_(DT4\H))&S6@.FJICHQ4**
**M/Q#.K\!U')=%!$OET2T7B%-?[AZ2.<\I$^E]U0<>^OD\0X,46CGS/.Z"O M"X-3'GY!RW_P,A_J17Y A1$JW1P1 ).QD=*'TU@:=-I2G;ZP'$=41RUKR4CSJFK8PEL4#+TNI>[=[XN**
**M;; M"6$+;:A$S^9 JYW:P V:<.RCX*!5=6'AU'MFZX>=V8#&MWAT6[(B%24C M%=/;]%$=ZTV456]A"VU8=NMBEYJ AUDNEZ*[H6NPQ(JV1L23E\H2 MVK#^SO[**
**Z1F;UJHGLH4V_!_?F2)DM!HG-VT#U^_'R='6]@OR GW3HLZU(+-K M6="""U;6$Z^T4#.8!RF)U@B8H4X>,EA"&Q;>&[:<<]HB=]QR#DN$.DN$[$Y< MT/$P1?YY.NS6XZ @\ ZZU>U-**
**%=5(R-F#VG!04;6,LN[',MF9_64M#X1=%L- M&N^I$#2O#C<$)X2I-/G[FE+Q=*)FE^VL.OH)4$L#!!0 ( />!"%G/]JZ MH@( ,4' 9 >&PO=V]R:W-H965T:NOY]5B\!#+DON- #;VE,V?-**
**]G2VAH+HC2Q#X92Y500U>U<+7!0*: M.U#!_3 (SOV",N$E?2>;]JOO5X8S 5-%]*HHJ'H8 9>;@=?UMH(KME@:*_"3 M?DD7< WFIHPJO/D-2\X*$)I)013,!]ZPVYO$5M\I?**
**&>PT3MG8B.927EK+Q?Y MP NL0\A,Y:!XFL-8^#<$J$;=S6GUYBTP-WSEOVSBQUCF5$-8\E_L-PL!]X' MC^0PIRMNKN3F"]3QG%F^3'+MGF13ZP8>R5;.R*(&HP<%$]6;WM=YV**
**$@3SL@ MK 'A4T#\#"""J =%++<0U('ZIA;,:X$+WJ]A=XE)J:-)7W#9=VC, M%Q.V3ZZ-PJ\,<2:9*FPY91X(%3F9W*U8B4U@3LDW;-%W9)CGS-:3U'Z/*C_ 9/R)R*859**
**M:C(1.>0M^/0P_OP WL><-(D)MXD9A0<)OZY$ATA'0F#,&[G0)QR>-06SO[9 MG_RS];UD1$V71(XO^DN7G)(I\+L-POY.9QHI_"7_]56]XHY;F>V8[*G2YK!**
**MP,,YIT&MP4O>ONF>!Y_:DOZ:9.EKDDU>B6RO/*%3GO0@0>Y("DF:L^CGA'G> ( MAK925"P?'8M=(.NDVPG[_GHWPVTZW7V=]$^=L!/OZTS:=!YYJC#]G;E5@%JX**
**MA:%))E2"5,W92)N=-'2C^(E\U.V-NRWR%'=8M7(>Z:L%>$G5@@E-.,S15-!Y MCV-554NENAA9NJDYDP9GL#LN<0^#L@KX?2ZEV5ZL@6:S)[\!4$L#!!0 ( M />!"%D61W1WX ( D( 9**
**>&PO=V]R:W-H965TT _]<[ M=D)&(46]V W8\7E/GO?8.1YNA'Q4.8 FVX*7:N3D6J^N75>E.11478H5E+BR M$!*+@&J=RZ.J5!)I94<'=P/-BMZ"L=)*A?3:5R1 4FK,2I#*HJBBH?**
**+H%+C8C MQW=V#^[8,M?F@9L,5W0),] /JZG$F=MFR5@!I6*B)!{6(^?&OQ[W3;P-^,%@ MH_;&Q#B9"_%H)I^SD>,9(."0:I.!XM\QL"Y2808?YJ<3OM*{]P?[{)_M-[1 MRYPJ&**
**O^DV4Z'SD#AV2PH!77=V+S"1H_D9WD M? *:,JXN4/PPFY#SLPMR1EA){G-1*=2JH:O1@,%PTP,VMH8-7H#]4I67I.>] M(X$7A!WR\6GY!%*4^U;>>RYWL6QM[8*V=H'-**
**UWLAWY0^T3E'KZ82MBJ4*_+K M9JZTQ./YN\\M@G3'LSF@^V6NUHBF,'/PF%<@U,,G;-WL?>BR^Y'2/3/?:\WH**
**M3F4WYJ7@W'J7P*G&$P%;;"X*.G>VSA;;;*:UK),HO,)-7.\;.@X:^.%5&_0, M-&Q!PY.@N^.:X@)++:4V,!6GG2E?9$TF%TIW@=?9H']R/HP/PXZ# 'WC=X%$+ M'I'$'XM283-**
**BY,)!%@M0IGM2WL49'2-X@7_ >1SD1P._FS-N.>.3G'4/H$V9 M3YV!^.CM5_$!X'&{[X7=?/V6KW^2[UYHL^M[74M8XK3I6OQ?U^J"[A^=23_H M]P^YNZ(_Y#V?_ 502P,$% @**
**]X$(62$CDU[ P *A4 !D M !X;"]W;W)K&ULS5A;;]LV&/TKA%8,+;!%- ]NY MS!:06 K6N2VR)-T>ACW0TF=;J$2Z)&6WP'\)24H1+)M6D0IF/>;%)ZCN'WTW' M)L<;RK[P)8! W\]"**
**(FS%&)UX;H\74*)^0E= 9%/YI256,@I6[A\Q0!G&E06 M;N!Y{[?$.7&BL5Z[8=&85J+("=PPQ*NRQ.S[%11T,W%\YV'A-E\LA5IPH_$* M+^ .Q.?5#9,SMV7)\A((MLS<:RSEI!#.83Y]*_2/Q0**
**;3%7SEL^-88J5!FE'Y1D_?9 MQ/&41U! *A0%EE]KF$)1*";IQ]>&U&GW5,#M\0/[M0Y>!C/#'*:T^#O/Q'+B MG#DH@SFN"G%+-[]#$]!0\:6TX/H3;1I;ST%IQ04M&[#TH,Q)_8V_-8G8**
**D@> M,R!H .$N8' .\+D[#!K X+D[#!N #MVM8]>$]D! T9C1#6+*6K*I@QB!P7O!W$OCY+D9OW[Q#;U!.T/V25EPB^-@5 MTGWEA)LVKE[5K@8'7 W11TK$DJ.$9) 9\'$_?**
**M2#=V7:VMP%#[F["GH)_ZC( M"0J]7U#@!0.#/]/GPT-3.,?MGOSOW3O)"-M&"C5?>(!OJR?6T.V=2]D@GRA) M#UF@>SGD6'L'1_]\D,SHO8"2_VMJDMJ-@=D-I:L7?(53F#A2.#FP-**
**3C1SS_Y M(^\W4X5LDL4VR1)+9)U:#MI:#OK8HWLJ<"%_!O2[;*I!#1]IN/HI6D?#L;O> M3NR^11">=VWB?9LP{)HDAHW"L];F$]RP#6[8&]R3XF4*N)?RI4UGDRRV2998**
**M(NO49=369?0Z!&1DLY8VR6*;9(DELDXM3]M:GAXG(#5\V",@^Q;[ K)OLR<@ MAHT."4+SCQ*3!;[_DWHZ:&$R"<,IE =1G][;U?9B{U)?9^VL7_D74]^P'JN+0'W7]$A?WR)^**
**MQ&R1R]8M8"ZW\DY.I2RR^F*NG@BZTC=/,RH$+?5P"3@#I@SD\SFEXF&B-FBO M1Z,?4$L#!!0 ( />!"%F!8W(%( ( #8( 9 >&PO=V]R:W-H965T M:I*KB9.H75]**
**MZ;HJ+:"BZES4P'$F%[*B&KMRY:I: LTLJ"K=P/,BMZ*,.TELQ^YD$HM&EXS# MG22JJ2HJGZ^A%)N)XSLO W.V*K09<).XIBM8@'ZH[R3VW)XE8Q5PQ00G$O*) M<^5?**
**3B,3;P.^,]BHK38QF2R%>#2=VVSB>$80E)!JPT#QM88IE*4A0AF_.TZG M_Z0!;K=?V&]L[IC+DBJ8BO('RW0Q<2X83=/F,#5\J2F6?9-/% M>@Y)&Z5%U8%10<5X^Z9/G0];**
**\^T!Q!T@.."U@+ #A#;15IE-:T8U36(I-D2: M:&0S#>N-16,VC)M57&B)LPQQ.IF# BK3@E">$?2BI$LAJ77X2DK*5X!+IA5Y M3Q;M.A.1DQGD("5D9 YKX**
**V0TQEHRDIUAG$/BQDY/3DC)X1Q[HL@]]A4U-:M(C^_(#.YU5"I7T.NM#)&PS+,IKY4 M-4UAXN"N52#7X"1OW_B1]W'(HR.1[3@6]HZ%A]B3>Z%I:,946RNRK96AE%N>**
**MR/*88V>=^*%_$;OK[50&@H+1N _:D3CJ)8X.2IP^*\U2&:K M?TCF0:Y_79DCD>VD/>[3'O\?M3P^IF-'(MMQ+.H=BXY4R]%K:GD@Z.]:=K=. M=7.C?**
**j5RQ=#*T$G*$>>!"%FM].A+LP@ -%> 9 >&PO=V]R:W-H965T]*K!2+0MK"2ZE.Q,BO[X4KB0FE0#6]CW(G.1\26=YU#R2^I(K\2,)R%_M*]>**
**<5^1[GA7E[6!=59OKX;",USQGY2>6S.LQ0R9Y7Z*E?#E*DHB.3+V\'"N:;C21W0;/&/E#^51Y})O2N/ M0OQ67?Z')[6!4MXAG/*YJ!%/_[?@]S[*:I-KQGQ8Z..2L X_O]"#9N?5SCRR**
**MDM^+{)]I4JUO!Y<#DO EVV;55_$4\7:'IC4O%EG9_"5/[;.C 8FW927R-EBU M(S^+_?_L>WL@C@*Q22-3I<2,F*%?*KDKR9[)(DK1> MSC)"BWTOJ[?**
**ZP>,52[/R1{7)MP>/_/#"!V^2&6I9S1_&;2ONJZUPWVF%OSZ+ MHEJ7Q"\2GACB/7O\^%\8(^?6>*ZH@>#JO['^^>&FQ@>_+WOX^!)^G"/QR^'SAA. M[>&+[>IPY*\L0A@?**
**^M>XX8W?X1UUJ1W7N]1"];B_B2)^;PORJ_I8LN:D4))_ M_561":UX7O[L%MWC^V9,S,VH3YG7Y8,%_':@SHDEESL^F/_I#\YL]!>3.I$P M#PGSD; "0N1L @)HR"8IO_)0?**
**\3&UV=7W:\V')5%\5B5:3_-8[.=U9&7_$B M81X2YB-AP1XV:V!U2;N;CVZ&NV-%OMUB.JK_Z9M%R%91$$S3VO2@M:E5:QY? M$^4A8 M@(2%2%B$A%$03!/QQ4'$%Q^C^+Q ZA\))\Y**
**P'PD+D+ 0*8UU^#*TCPHS8?2 B@MA-(B*(VV-.UI3$PMV;E_10FD>E.9:#:0&4%D)1$9I&431=V9W#YCH?XU:R"_7HH#0/ M2O.AM !*"Z&f*JC*)K>$SJ3T+6;A/>BJ*\'^?'--**
**_4GK3*>U+#O$;H0CU- M*,V#TGPH+8#20B@M@(HBJ;WA,[G=.T^YWFS6=@AO64,?=^PI=F>^'??>Q-2 MWRXXC0H-*.,4%-!J!"B:+I+.9G3M-N,YTU#8$;TE O4+6Y1{E**
**3\'3"$)HP M.IV0HA+JDT9UGM[8[NE]Y?5$A>T30,UD:T7,B7C,TA5[]^$*.[.OJ* TKZ79 M1 5-&)Q.&$(31BW-,B$/12741=79:>,3+ZQ)5:*1NU14/%X7(A.K=DJ3^G*F**
**M66>]3K'3>\L+:I)!.3Z4%D!(90606D41=/UW9ED8_=C7*>,H=X8E.9!:3Z4 M%D!(90606D41=-[PM&DDW8#[:%^BCBIGUM+MG%%$EZFJ^9^*GE\)C_W!M%**
**MC9U!$CN%Y/AT]8"=&?)DPA":.(+2*(JFRZ]SM\96ST"?5/CXD0/^?<.+TOS M@9W96W]0IZJE66H[YHP.)TPA":,H#2*HNWU-SR:WCKG__Y"I5%4'&ERK5Z-.%&A'D M?**
**O[T_9=*;)K)M1]%58F\^;CF+.&RWD"M7PI5;;=?Z@2'6>SG_P=02P,$%% M @ ]X${6> RZG1\ @ J 4 !D !X,"]W;W)K&ULM53;;MLP#/T5P@.CK2]QVR!**
**(#:;MA&7;)DFY[&/;@<Y+0M5)8\24E: M8!_2DZ,%$CRMA>;HLBC0K8U6S328 ?= MGSUNZI"7$*=']M0N)Y=P=YEG?,LFRDU0.TBR8T9WBI/IO(<>F:LK":=CGE MV6R.!IG.:V"R )**
**(FV%)IY@LVT9K)"JD#UL Y3{P.S\3,)7=;7!1K^[0,BX,MQ*]'H25&#C?,MZ??=*DI!>3=*K23Q>>@1O)?FW ME4;X"SMK4FGT$LQWQS7*%9Z1X:XKEQ7,4'LI,D?XNA2\\J+.X-UC2]**
**<&"[CG MC8M3)2QHRY0L[P(6EFD+5'(<$ODD/8^NSZ/X4 5.,G8S-S0MRW$S)-)]? KT^$#%.+ MC?E]2.3@/XA,>Y'IR:,?88E.4Z_TKK]H+*?K2.YVK[]D!"%GH1^IN7@8 "$? 9**
**>&PO=V]R M:W-H965T#$"I9A M+8IDW1Z&/=#2V>8JB2I)V?&P/WY'21:E6*,C@@_+0RR)O.^.]QW)X_%JS<4W MN010Y"F)4WG=62J577:**
**[,EQ"0N49SR#%ECD7"57X*A9=F0F@D1%*XJ[?ZXVZ M"65I9WQEOGT1XRN>JYBE\$40F2<)%9L;B/GZNN-UMA\>V&*I](?N^"JC"W@$ M]37[{O"M6Z%$+(%4,IX2**
**?/KSL2[#+QS+6!Z_,Y@+6O/1 ]EQODW_7(?77=Z MVB*((50:@N+/"FXACC42VO&]!.U4.K5@_7F+?F<&CX.940FW//Z#16IYW;GH MD CF-(_5 U__#.6 AAHOY+$T_\FZ[-**

OKD#"7BB>E,%J0L+3XI4^E(VH"OG]-MP"\%_&<"!S7T2X'^2S4,2H'!2P6&I8 9>K<8NW'.^#V_3[X^3LF;G]ZV&'9KAWF$##&%Z&L8;;6&0(JEH'&LB MVGQEA_PE3[>0_L!B66"'F4)X;(-Q_6KR.T;W/X!W%JPKJ 9K!.,Y<\\#0_U M(+_AHZ1FJ9+DSU\1F=PK2.1?;1%9F#%H-T,OY)A_;6'0)-G4)%C@":W YJ+@_KOJKNH${/?K#UOZ3:T&G^I;1V -
WPXKWPY_T+B&ROSHN,7,*@1DH36 K;I.=7,!-JS/AF?Q[5)= MX BLP<)YQ<*YE87/>3(#H=<&MMOM# %(2]/]_Q[9$&^LFD[EX'R/@_XS#ERJ M"QR!-3BXJ#BXL'(PJ7NYG TD \%X1/(,\\,Y$U*1D"<)B)!A5TECT)QE@D=Y MV$J&\>6I9-O%*= MH2J8XUE5O3BR"9V>6<4_94T1D!8T+]Z82VJG#$1LDA+EA2H>F.57/]<'8{$?:
MR3KOJEN6Q335C7K R=$!-,>~9G%,%A@0.D\VEB(6$P)6/-12[P@\A7$NM3EK M+N)HS2+ ,;1+C1>29.;C'+ 2TN1PP:JU<7NAX_>K"]\X_RD(*LT1\,.UB6S@H
M!@#A,N4Q7VQ,YO.4Q9PI(G/=7KCT#$]EV+AD(GJ?4:$VE6HS .1]MFD,3BZU M-3- E-G?F&=I8 /89O]9:RG 9?@'KM":RT"M3N-9I]<4YCAJT#GD"M(<6N>[
M%>+D^>X2;5JBU=,AK^V %K1U]"W9NN?O7.@?R%?]8R491JN9TBK%ZTH)WO1 M)=JT1*L[9\]_MBY-S^U*+9[U]#^>+'%7% %M9.XVM50]&(?@EX]<-W14]FL M9[I,S=*%7B)-
H3#%+GP6L\7AVI_34HM3M&F)-CH>ORT=K?&[*Y)X]BK))_K$ MDKQ]HW=9KKAUBC9UBA:X0FMRL"NF>,/_1]71EA+9.>5*Z>U&V^_>/.\<.!48> *K4G KG[CV0LX
M#WQ#T;E0+Y\55X@O*YS9X4_V_G[9YGGIS*G"P!5:X?UN[2H0#Q(+T.IK@_D3%@N$*%L,<(7MGY^@K4=S'%B^* M9^,"<<:5XHEY7 +%\X7N@.USSM7V12NH;L7'_P%02P,$% @
]X$(65(# MB:BS @ W < !D !X;"]W;W)K&ULS551;]HP M$/XKITR:-JDT(5"8&"#1=FBMU@U!MSU,>S#)!:PZ=F8[0/_]S@Y$5((\3*]T ME^1LWWWYOKMS;KA5^LFL$2WL MW.
(N'061(X0"$^L0&+TV>(-"."B\6>/&=2?=(''}@%]ZK63EB4S>*/$3Y[. M]2CX$)@%:GM9]SKN7)XB1+&/V&[}XT"2$!C5,V<J)@8YE]6;[?9Y. IH M=\\$Q/N
V/.N/N19WC++QD.MMJ"=-Z$YPTOUT42.2U>4A=5TRBG.CN=HD.ED M#4RF0-($6RK-?,(F6C.Y0JJ -="'F^F4GI,TY>Z4';B354\XWW>W:!D7!MKO
MG>NSL3R!*5]J9;B!J2IE6CFV8(X;E"5>D.&:ALL5S%![*)D@?%L*OO*^^_!I M5U#Q,(5'GCL_E<&"CDS&DLIA89FV0,)Q '$4=UM1OQ6UAZ&ES#A]8;+/PG65 MA?
A,%NY+>0F=Z,*#O P/*:%U5N,ZJ["ZY{!>R!=>9F?(M(8Z*[@P!0LP5% M=\R@WF P?ONFW8L'-M#JU+0Z'KUSAM91?3?XLKX3*O]7)9-S'O!(IJGR;N#7 M%T*&.XNY^7U*9.
<51'9KD=W&W-]BAEI3T^A#HR%U(_4I;15'C48V5^DI]LWX M;7BF&]-_]*HF>M7<)&QWKDD: _\Q?[V:5N__):+>*XCLUR+[K]PDS?@=WR3F M%-/PZ&?MYMX#TRM.Z1*8$51V:?
BZVJ65 NK"O__7BI+T\";.QJ_J)T#G6=* MV0+ &GP &0 'AL+W=O M]OFT@>Q_%_9>0[G7:EW=I@)VUR2:0T M_&;WKNIN[QZ<[@&UQS8J!A=PTDC[Q]^ B0D-'L>;]RG[8!O_F-
=@AT]F@"]P M<9?E7XJEE*7XMDK2XG*P+,OU^7!83)=R%15OLK5,U2OS+%]%I7J8+X,%.I?1 MK&ZT2H;F:'0Z7$5Q.KBZ])_[D%]=9)LRB5/Y(1?%9K6*\OOW,LGN+@?&X.&)
MC_%B659/#*\NUM%"_B;+3^L/N7HTW"FS>"73(LY2D#;. \GIU6#^AW_
MBN5=\>AG47V4SUGVI7K@SRX'HVJ}9"*G945$ZI];>2.3I)+49,E_XYGY?)R\&X@9G(>;9+R8W;GR>8#G53>-$N*^O_B MKGGO:""FFZ+,5DUCM02K.-
W^&WUKOHA'#8S)G@9FT\\;H-QTV#\?8.3/0TF M38/)SN%KEHT3XZ3:X50!^L&09Q4GQHWK+I]\L M\<-??[P8EFHQ*FPX;,]TMEV:>[HTQ*]96BX+8:MH[^K;CP^U]_7M3S7M
MA^KKVWV'YL-W^-[4@L$F>2-&)S\)Y;G1M_\>IV_$::QM[GUC-['V^9& M3W/[0/,H?6ANG/4T=Y{?_+3O=WEHX:OFHWKA)SW-O>9-]Z5)1J9(H*X;2.9:'R.^U9MO=:JQK( MSXMU-)67
S52%S*_E8.KO_W%.!WJO6\%)S&+Q&P2$UJ?;PG7A^5&.73I;A.9*2MVHVNJZ&R\=#I[A1(TNNIHGB]TQ\D'DU M<@HU]1/_+%4>"_&?7Q0J_%*NBO_VA7)"AI+$+!*S2J0W/^K^+
MX>WCY&C[/#8Y)&:3F$-B+HEY)..36$!B{81UDG.Z2\ZI-CF6G,L\ES.5F%N9 M;F1?8+3"L<,1B5DD9I.80V+NZ9._6-_]?+({OR#W05B=R&$=5;_MO5_ZU^
M8VDZS3;M@!%]3GH3H$6.30")621FDYA#8NX6.]$D@.S./]A=0'870E@G>]V M"7CW)W<7B#_$K]&W>+59]45"JQX."1*S2,PF,8?$7!+S2,PGL8#$0@CK!.UL M%
[2S5]HQ<$:&DL0L$K-)S"$QE\0\$O-)+'""Q$,(ZH31&[8&OD7,\K>M.&UF4TFF:/ MKH5V:*.:@VHNJGFHYJ-:@&HAI74CU)9=&-H#R%>_Q-'G.(G+>Y'+)"KE3)19
ME:,X[9ZQ=17K{SN;%:_<,=&UWQ:5#,Q>R>S:+\VJCFHYJ*:AVH^J@6H%E): M-Y9M%8RIKX+Y=",^RD5])EJ5)340BM_S35%6U64JBM7C_?/9WJ2AY3&H9J&:
MC6H.JKFHYJ&:CVH!JH64UDUC6QYCOGYYC(F6QZ":A6HVJCFHYJ*:AVH^J@6H M%E):-Z!M>8QYX)(EJ^HD/#5[C6V:R-]NJ@FHMJ'KYJ!:@6DAIW4"UQ3*FOECF'WM#5&TBUL]%
M:;])DN2^-U5HJ0RJ6>;3>@ZC+U1H#0RJN:CFH9J/:@&JA936#55;66/J*VO\ M=+JI+Y4@OZVK./7O$D&+9U#-0C4;U1Q4<\VGUWCYOLKL%O\PV\)#K\EI#Y9
M=ZUM"U),_04^7K0K0G]H3=_ST>LZ6H>":C:J.:CFHJ':CZJ!:@64EHWEVT= MBOGV]7=*H-4FJ&:AFHUJ#JJYJ.:AFH]J :J%E-8-:%N08NH+4F[:
[P)-3]KW3.!5I2@FHMJ'JKYJ!:@6DAIW52U%26FI]H#X MRZ>C<;IW.IH6QJ*:AVH^J@6H%E):]YKA,2')>/3JT]$Q6BZ"M:A:JV:CFH)J+:AZJ^:@6H%I(:=V
MB4EXP,75JGWUXL\NX^2LG>OO1XX.EYH MC4BC'3P6AO;JH)J+:AZJ^:@6H%I(:=W@M-4?8^W!ZVK&N3NGH'=33=_^Z-R@ M1!NH9J:.@VHNJGFHYJ-
:@&HAI773]>AF,^/7GS>R-ZEA[U+#WJ:&O4\->Z,:. M]DXU[*UJV'O5L#>K^7^4@HS;4I#QBTM!ZK,%Y#R[=HJ^CZ,3B!:.$H))J-
M:@ZJN:CFH9J/:@&]A8WV>./CY/&F1S=9;3W(6%\/WMQKP,;.D=G M+J-Y*7.Q28B>!F8IUGLXT:-JL]!0^G]JAW;+]OFH%J!.V&@GSXMJ6P0SUA?!- 7&V>^*$U,:AFH9J-
M:@ZJN:CFH9J/:@&]A>.GM_XY&>W/7UOL,CYPT169JR&M/N=4)4A^W50']^)4 MC7ZR*+LI5*\S041K7U#-0C4;U1Q4OW84*&:A6IVH^W=;MYF"NW3134/ MU7Q4"U
MI+1NMI"DLG!:Y.TQ\/U)_CHI:/S@U:4H]J-:@ZJN:CFH9J/:@&J MA936S5E;=S)Y_:N.3-#2%52S4,U&-0?57%3S4,U'M0#50DKK!K0M79GHKSKR MLA-\]/C1T4.+4E#-
;K3.Z4)]Q9L.VJV+:AZJ^:@6H%I(:=U4M?4F$WVJR9/I MY?3=O32T1%"]TJ!O$48U!]5<5/-0S4>U -5"2NOFK*T^F9R_O02K25!-0O5 M;%1S4,U%-0_5?%0+4"VDM&Y
VYJ3R8&:DX,G[.B!H^.%UHJ@FCUY6E?0/X-$ MJT!0S4,U']4"5 LI;1N<8;&4LK2B,KJZ6,E\(6]DDE0'F#=I677RZ%F1RWEU M4X+S:W,P?/*\99P[1L_SKG'N]3WO&^=!_?
RP[?,J8ATMY*]1OHC30B1RKA9A M].:M^DN1QXOE[D&9K2\'QD!\SLHR6]4_+F4TDWGU!O7Z/,O*AP=5!W=9_J7^ MF%?_ U!+ P04 " #W@0A9@;+D?UT, !KJ0 &0 'AL+W=O[-
LVS]\?P\G9(MH0)7]}1+I9+L/DVYU,*VXX MO[E:AX_RL\Q+7^2Y+^=[Y1M)2K-(I7(I&SZ]ZM]C$8]HL!Y3W^%/-UN*P&7}]Z&+3^ZRO#-MW3\IXZTANQ=
[N]!MEY)R$3/#++RY2N)GD13WS[WBAW(Y+G5>9;/5$&?3ZH9N-_.@/[&#&CB4S{>2JL MU51.6\9[ZO&C8^/](J7%A]?2!^_VR* M[[_[0>]N*U,):-:,>7D9;.T
M2P5CJYE_QD\YTR^9L8)QU,S/DVPW-^.6X>X)KUDU?-2V$!Y[B58O#Z)^B=J6 MQ9.?4MU0,(&:^11^>WDL0\7R;.S>(HR2,XZ^18C;@W>(?_^4WUMXF5RF_VF9
MT[LM/6BGB\\+']-U.)'TO?P#02J3)]F[R9?K4;\U)R1FDIA%8C:).23FDIA' M8CZ)!1#62-M@E[:!2K_Y>2V3L B86,C\HZ)(BL^$'^+9ATW^R_>]7W_^O?>#^ M"-
-49FTKVSLEWC5O)&:2F$5B-HD);.2F+?%1B56;&D]W66CJT3A?63Z]#E++ MO;2A<=F$P#-6",APUU"AIT2LHC"AV@19=_:\]"DNN:!Q$P2LTC,)C&'Q%P2 M\[;8\/62;HR&H[T\D),,
(*P1F]$N-B-E,.Q-MDEDL149+3?+*COK\%NY[=<6 M'277-3HD9I*816(VB3DDYI*8-SJ,SF@T-/-B0TXR@+!&="YVT,E01F=X.>X+ M-TZR>"7RVXL]G7>;;#$MUD$_%3EJBX^2[!H?
$C-)S"(QF\0<$G-)S",QG\0" M"&ND;+Q+V?C]]C.,R;21F$EB%HG9)..0F$MB'HGY)!9 6"-ME[NT72K7:>5Z M2\BOF2QV>XM,)DLQ#;/659E2ZAHN$C-)S"(QF\0<$G/5R\6G,-
GN@RYW0K?E MB9P9Q6\0""&OD2>O71]+Z[[GG3JUW31FJF:AFH9J-:@ZJN:CF55ICLZO?[^]M M=;7=2]^_5T#-63,KKXXZ:]P^/+75.LFD?]Z&+3^ZRO#-MW3\IXZTANQ=:5VDCY3+O5_=J M)&-PF
QHSIK)T.MDZ%V2\:.81NDDWN0;1$G&I .5A.[46.<0H4T% M5+-0S48U\A+FF^1C#[T+UL#@U834,U!M8#2FK&JZPF:NI_PFUR%^^O"Q2)^#E>3]K43VDA
-1/5+%2SM<,#\0>?:!QTDBZJ>:CFHUI .V3!&(IO,DS:=@]Y MZ'SXJ!8<>51&VZ-J1JE/I8+>NC4[20347U3Q4\U$MH+1F
MANK.@W9*Z2%.15FDVO!^PZH9J*:A6HVJCE'7LKQA5B6W]ML#10=QZJ^:@6 M4%KSFZYUYT%?=QZV@8K7Y9>"LWB[3Z,J$\ETDD3E7]I"IH:[A@S53%2S4,U& M-0?
57%3SCBQZ0\VE*!:V;8%@'A;?7V^\M8MX)G;O$N)!/D:K5;&;H%A2Y^7N MMTQ,LV9?.-E^W&J]+^)YRB;EW_6*CSV[;3FL5)CD@1UM^-?YG>+'J2V[T=
M(LS$,DR^R*RCX,16UWCE[:#D%U2Q4LU'-0347U;Q*>WU4 MYO+BH).OMYR%HV\OJZBMSM% ^R6H9J&:C6H.JKFH MYE5:\^LJP\-
LM)QFPSC*A*BYSC%"'Q[Z825#/UBK6^@'T;5I M4,U%-0_5-)->JX":9C,<=7-#5Q_N_RM[Z\1_Q>?-0RK_W!19LI[R?UMSA-8] M4,U$-0O5;%1S4,U%-0_5?%0+**UY:NBZ
&+TWV\'GH%V0%#-1#4+U6Q4:CFHUI .:O: (>T41]I(B[#5%V(N*L%<582\KPEY7 MY#W*%D9=MC#>L6QAH&4+5#-1S4(U&]4<5'-1S4,U']4"2FLFKRY;&.]:ME#K
MG;.'EBU0S4(U&]4<5'-1S3,.RQ;[1Y/1"0:4U@Q47<@PP$*&VNH<'[20@6H6 MJMFHYJ":BVJ>-<=BT.(@/>A8/2FO&I^YL&$JOFH%E!:\X+&=4=D M<,D)0@Y.M= 6+;74-
5I'YNNS7)\)T:^N=3-HRQ8Z/Q:JV:CFH)J+:AZJ^:@64%HS5G4!9*!N6W2^6++: MZQPC_6!W;LLW?TQTHA:JV:CFH)J+:AZJ^:@64%HS1G7M8Z"N??RQ6Q5M/P/> M/B:R_
#8&B&TVX%)]J9J&:CFH-J+JIYJ..C6D!IS:35W8[!.W8[!FBW )5, M5+-0S48U!]5<5/-0S4>U@-*:R:N['8-W[7:H]<[90[L=J&:AFHUJ#JJYJ.8- M#D^1L7]P&IU@0&G-0-
7=C@'8[5!;G>.#=CM0S4(U&]4<5'-1S1LDYNAS%4DWNV\?=(=W6PT[W:J!SM-#R!:K9J..@FHMJ'JKY MJ!906C-:=?EBH.XX_/\'L2X//B)?C/=WE]^KYZ)SJM#:!:K9J..@FHMJ'JKY
MJ!906B-5P[IV,537&SH?PZJ\QE&G@[/2W:NGVC5%J&:AFHUJ#JJYJ..AFH]J M :5M4W2>SJ7,S# +,ZZ6,GF4]W*Q2$5YPL+K7G%\>'>K2.2LN*38QUN]=WYP
M^[WVT=6*V\]KYN9J'3[*3V'R&*W2/'"SG.R?7>2KI7*GX,LO6;R^[FD]\1!G M6;PL?YS+<"]3X@[YWV=QG+W\4DS@.4Z^E+-]\SJ02P,$% @ ]X$(683H MR,+_ @ R D !D
!X;"]W;W)K&ULK59M;]HP M$/XK5E9-K0VKZ?%0:06F+9IU:K2=A^F?3") :N)G=D.=/]^9R=D$%**NGXA M?KGGN7ONC'W]%1>/T,4V9%?;-V(Z(^+U1*&;D12!99AL6?
*Y+RU951!X95$F'5HR)FB;$Y83(D\19/R^" ^@YTL MY\P8PNP,@>]@\1.<5_B>HN,149BF\@3&]Y,1.CXZ04>(,G2WX(4$9MFW%<2K
MO=IQ%=M5&9OW3&P^NH9H%A*-64*2%OQH/S[<@[O]KZ5#+\^-,[A\U]SW40CM[A3Y@0?$T)2_H+$DZ&Z[]3M#0V6+CN@V=NS;G3E/FKDWH M>>TJPUIEN%?E'5A;-?
(=J/=$.ZN8M^@M02P,$ M% @ ]X$(621KQ5-[ @ 5 8 !D !X;"]W;W)K&ULK55M:]LP$/XKAP>C@S5V[*0MG6-H$\8Z-B@M6S^,?5#L2RRJ%T]2 MDO;?
[R2[)@4WZ\:^Q#KIGD=WS^DN^4Z;>ULC.GB00ME95#O7G,>Q+6N4S(YT M@XI.5MI(V@TZ]@V!ED50%+$9*SZ&)\I]X_^#P MG>/.[JW!9[+4^MX;5]4L2GQ *+!TGH'19XMS%,
(341B_LZHO[(#]]=/[!]# M[I3+DEF<:W"'U?/HK,(*ERQC7 W>O<)NWRFGJ_4PH9?V'6^203EQCHM.S!% M(+EJO^RATV$/D$Y? *0=('TM(L 64BTC2RDM6".%;G1.S#>F]C\
(F@3T)0- M5[Z*M\[0*2><*^9:2NZH+,X"4Q7,M7)#+_DFA!;>ET'9C$'Y<+*TS]"Y_ M#N7<7C(9OL3WZKEM6(FSB)K1HMEB5+Q],SY)/@PI\),(GNF1]7IDA]B+N] 9
M6!VS+1IJ=.IE/RU($A"^^N#02#CB"AZ1F>$'J,<&&J&H:1;OG';B7ZZ;HMDE)R>Y?%V/Z,_MNK7AQGL]^?M5V;67%FJP8IPR>B4YH=I9UAK.-V$,,#4CH9*6-8T]M%X!SI?
M:>V>##]9^C^2XC=02P,$% @ ]X$(65.+JP&1 P 0PT !D !X;"]W M;W)K&ULK9=M;]LV$,>_"J$510(LT;-L9;: U,:P M#2D0-.WVHM@+6CY;1"51)2D[_?
8[4HKBR*JR:GMCBQ3O[O<_2KS3XLC%%YD! M*/)8Y*5<6IE2U8UMRS2#@LIK7D&)=W9<%%3A4.QM60F@6V-4Y+,G.)%=4%9:
MR<+,W8MDP6N5LQ+N!9%U45#Q[1WD_+BT7.MIX@-/9TI/V,PBTFMGX/6INA!2SH1)6/^+;56VM.86V<*.UKGZ
MP(^_02LHU/Y2GDOS2X[M6L:2O"&L)\!S7DMT+A>V0F0=V$Y,O'<-GO<=O#_J\IKXSL_$<[Q@ MP'PU;KZ&%,U=8^Z_-+( 5O+V)S=R?AG*P/_D[$4^_"X?_ICW1.*N1"@ MSPO,
Y'LD128DTQ>#NENG$7&F3Y?#HD;SN<+^W"J9S3B1#U!IR=X34\X!-Y8 MA2?@OA<$/?!1UQ/!PPX\? T\&@(/S\%=/^R!C[J>"!YUX-%KX+,A\.@,W)N[ M3@]\U/5$\%D'/GL-?#X$/AL
C_N/RJCKB>#S#GP^O%2Q ZSW.P5B"']^CA_/ MO1{^:(^'&"X_C4A7?*;+C:+0[PD; M#3U1F.L\EV)G5-H=2'E#;@>M>EPI;)!/#U!@9C,;J?ESY3HW!8Z M^0V!!5!2*%W#!._^V=0?
=&X*51L0D+*MBHA.FOWW8^\.J?J;MM6WY.R8Z? MH\,/T05^YH2C+4D*Z//1"+K41YNPH()-6NYX5\H9?&3BF\4Z#HX;!\=G.XBV M3-)LC,C^E(L^$XVL2TVT"0O,O61]X5.=
Y0#KZ9=W\I@J4&=.$R:.$S.CT-, MMS2&K'<],&(N#8%-6%#!QNT!>C2$324ZKETWKET;77LHLEB/V+LU!U";98G^ M0XMO0M((/= E9X(*],!4H7+3U&>GD7^IG39A@4U8: G6"=)-
$Z0;F]N0&YL1 ML0D+;,)"2[!.1+!WR#$\X\1I916K>$>9DE1!+DD6@ T:S+:C)M"9UT<\J MRPQXL48DSQ.:G9Q4=>7MB3[LVQ@LSBT8F+MSJ?>V/%WS6PD>/M?\RN%RY:(9
MBHC8]/}S_736/&EX]TJ+;1%ZYKN'TSW+7XJ],M6'MX;%&-]ERY45FF!55IH MB]:-W"&+Q5;36&PUC[5*'ZS20ENT;EP.N2PV)[.?BW2IMM,J,'4B*U@2(Y+% MB
I1]&>S^/M4$/NC"1X=+V16,U6KM- 6K6O{(>7%YISWXH7L!3A5T5F@9XB5 M@BP34(N;^O!P2?7U$X<5< ZQ8.VSFCU;I056::$M6C>XAVPO[8V:?
QPT2*6A,I;R92E<:O.*9VTFJN]H:..B*/OT^M M<>__X@*K]8:V.%58W-:I20\?1Y7">5QDZ@N8 !"%G5+-NHV0, #L4 9 >&PO=V]R M:W-H965T\KFU$:*ZMFV>;* @_(I64,J5%64%$7+
(UC:O&)4>GX6]APGM-N2E=9B MIN>6;#&CM M;O^$MB"=8$)SKG_1MHUU+)347-"B!^# GB%%=X_@#\9AP>0R+AKH;C M 7A\.=SIPVVI:">KU\GJ:3Y\3M:
<<([N5JVP__XMU]&M@(+_-R1-0^8/DRGK M7_.*)#"WI+?U<[ 6O{US0^>/(:%,DL6&R'HBXDY$/,:^VYM<2]C2IT/R-32! MIE$ONN>%ZX=3[(?1S'X^E.8T<(I=WPN]?EP\FM[
M2G7V7+>)LG$D98KN:L&%O,C*M1ZWC>1WX$)-29#L,P7+\B$!S;,Z5F9BN)T< MS>2M&\HH6VR*K?\4#GIZUZ0S6S932HDBTVQ]97:1"T$)?;"H"DP%2
M7%]1*G8#=1S4G1&ULQ9M=;]LV%(;_"N$!6P>LL41*_N@2 M TFD8AG6S4C0[F+8!6/1-A%]N!3EQ$-__$A9L4Q)8:WM%.E%{JOBJC6 WSC6 T M*@LE\1 [SFB84)X.9N?
E=W,Q.*&?.4S07*BR2A8G?%XNSQ8N .GK^XY:NU MU%\9^<;NF)W3'[D"Y1F?.'O,CXZ1 MOI3[+'O0'VZBBX&C:\1BMI :0=6?+,MF<:Q}JAZ?*^C@$%,7/#Y^IK\O+UY= MS#W-
V746 \DCN;X83 8H8DM:Q(V>_R^51?D:]XBB_/R?_2X/4<\':!%D!7!H:(\Q/"#O;0G F>12A?4\'RCMI= MV'OY?T9PM,*]B(EL%,"ME!59D2GDYQ.BF&7N20;5)BR4O9UB!TU<[V M1I
T73'5 DATM4/Y\WIKOSZ\I&*"/WUFT*B&\F2_.^N&V ?W^.N3EL=_F& M+MC%0#5K.1-;-IA]_YT[(8F>C3[[O4CNF4#9LKHO
M4!4B0NHA13S/"YHN6%=R]ER_Y.H>9#MSO=&4>*/Q^7![++RU GV%,T>=$M?# M(VP&*&IKZ!TW]$S7--OJ!R)'J5'-)TXBGJRXI_=9%3=PI=L>DH:0U;%\E
M:X)BSW%]KZ$D4%!#R=%!R9%5R?!HH$ ZF:,^)9'+(W0CK,XZM)P#W*=H^MQ M&O)98_65#Q(6 L$,C<<'C<=6C-)HT?HJ-O(&?G>Z"">(9;KU/;!4DNV MR))$W>^Y-
A7'/2CBZ4+96'W#TS0M:!SO2CF7A2S4HV!3M8IO[A)GCM0U5[- MOJ]"TD(HFIFB(X?G]KNCZ5,Y-WH?LS('*]4VR4[EW?9P<3H=.SYN:M\^$;L^ M\4EC,!38*]I;5B":*2NN9<7_JQ-
&7] MRZ7@Y6BH]-GH8\IECM[L9T#[,I M)W\Z4V$'>&C'J.B<+[*7["T[)"V$HIFRUW[9M1OF$UI_#_2))T72F1)(6WP- M2@M :2$4S4Q3;
<;=T6LW=)"N^AJ4%H#20BB:FQA5RG0G^3W,F MO6WH7:O5G/U130:R)V5S>%Z.F2T=C1WF M.I:>!M2,@\}"*)J9@]J/NW9#CAW7;_@M "4%D+1S%36$P3XVTP0X+;O)\0?
M>9F[.%[2P\ZB0!%,Z6O M)Q&P^1*A7P?S%9BM@[$7[9T#'I_D *)J9@WHR %L=:O^UOXIG#*U\SW=P<_'/ M'KBWZ*"V'8IBE[;=GSJ{C:MMYGT,'[:"\O-H:V]$KT3 &K@H6AF
FH#CT\Q M\'?S>:>TH/XL732Q+Y^'R2;.=DP)78C%%GJ=D(_BBO99.\Z-4Z%^7E N44/' M)-K2N.C,#^E<.Y\TVQ5['7OOLP2UQE T,S^U-29V:WQM;&C8,A'3S48O-V7+
MI;)IUG6GKZ"QAY)R-W3GSE=0RPQ*"Z%H9DIJRTSL+K?N-J)"[ =+]<.SWP'^ MI=H*WID5W&KOO>;S .J506DA%,T4_VC_N-TKF]M]DOT*GVJJ4BGX?5&YYR5B M5;/V0XY8S%=
<]RN+H^M9V)(5V/EMAHKV$WAL+O"OX6G)K6G9/?;!T]L57 M.Z7W'GU0BPU*'Z%H9CYJBTW\5S9W!-2G@}("4%H(13-36?MT8M_5WG/QM:*9
M,X2=BZ_VN+TU!S744+2]YL.CE]02)E;EVX&YZA:*5.[?5SM\>W@#\;)\[VY8 MG[Y_??$#%2NN>IJ8+551YVRLA!;[-P+W'V2V*5]YN\^DS)+R<,UHQ(0^0?V^ MS#++Y_$$'.+R7.?
L74$L#!!0 ( />!"%D9ZYT(R ( !X' 9 >&PO M=V]R:W-H965TM[7N@6E'$GCNS: M3,.1*'7.,,PD46514/DZ@5SL1D[7.2S,V3K39L&-HPU=PP+TXV8F<>,6*"DK
M@"LF.)&P&CGC[NUD:.RMP1.#G3H:$Q/)4HAG,[E/1XYG!$5.B38(%#]:F$*> M&R"4\6N/Z=24QO%X?$#_9&/'6)94P53DWUFJLY$S=$@**UKF>BYVGV$?3V#P
M#I$K^T]V>UO/(4FIM'CVSJB@8+SZTI=']HX<_.X9!W_OX%O=%9%>4'++HZ$;$B M)RJ@$U0+;JY/8L[*] ML8V[PR{^(G?;H"IH5O6MJNZ5*M^>B8HO M..7S;\+ :^8+:
[ZPE>_)1MS$%Y[P=?SN3=AKYAO4?(-6OJE)9PZIB\UG!>P, M]^"4N^<-@C.Y'=;"+)#[#>@S>2W*.>58!-JHL7&=L"ET-A/[3##!PRD M,<#]E1#Z,#$$]9,8_P902P,$% @
]X$(6>"H>Z$9 P X@D !D !X M;"]W;W)K&ULM99=;]HP%(;_BI5)TR:-YI,D=! ) MVDW;I*ZHJ-O%M N3'(+5Q,YL!\]_G^V$E(U0]8+>@+_..<]{CAU[O&7\0:P!
M)'HL"RHFUEK*ZM*V1;J&$HL+5@%5,RO&2RQ5E^>VJ#C@S!B5A>TY3FB7F% K M&9NQ4_&K)8%H3#G2-1EB?EN!@7;3BS7V@_,RK5 MGV@&V;_VMM+0"?'V0F;>LPZ_U?
0"^@,0:-[Z#?MSYPEZ+"*4PL=:($\ U8 MR=LW;NA\?(8\Z,B#Y[PGW^MR"=Q4SR0#W:M,\V)':(YN:RDDHEI-U7]@&:X MP#15"[%$UY"",?==DU&_3UT3?VCBZ]._26(O<-

QA,+8W/>###GQX7O!?IJ^Z<%WO_;6]W*EX6\"(%+<>A!#_RPC#T3D@XN)CDNKVU!U)#/#+Y/DOK_J]L&U6P+/S>-"H)355#8W<#?:/6"FS;7]
MM+QY_=Q@GA/%7L!*F3H7D8K.FP=%TY&L,I?XDDGU)##-M7J$ =<+U/R*,;GO MZ #=LR[Y"U!+ P04 " #W@0A9&"!"81P$ >%@ &0 'AL+W=O<">C-5["$\BOZP>N1F[-
MDI(,HOS]@HOM&NLO4<--\(R,(*K':0D;S\Q:^5$$> (&P!!!4@.!<05H#P M7$!4 .)S ;T*4+CNEKX7PL58XLF(LQWBVEJQZ8M"_0*M]"*Y3I0GR=5=HG!R
M\B39_.5*2YVB&0[54+E"<")7D*J0$?=^/[!7A7Z5B+<,)7Z-Y-R3Y'6M*KJ*S)91%3U*Y/Z3+D,DVV2F MD)1L?
EEM]$MJ._&N!]%PY&Z/Q3:,;^,YW]/&;F+@%$PZ//TU,8L9X0_/Z#85Z MM4*]"Q3"KVT*]8Q;ZD4G"IG-@N!$E//8$K-9%)E=[}>N]SM=?R3BY6K! =3; M0()*/HFX*O>="=
(W[<2+!3MTWFX6]$_=;S$[3X%VVAOLWM?LW%[K?'OT;L_LG M?LTJ,^_$[,3[\\B2]\@:S@.]JYP?GI7U*MB2%/$5[ M3T$IYV$GVT3-LDBP<& M94[$L[1>0^-AK?
&P4^/[!L>H$-A136V2Q3;)$MD#?5][_#7V/O._V"J#5B* MHU6VV"!,8HNM6VVRQ5;9$EMLS1@<3E+^]SY*^5;/4E;98JMLB2VV9B@/YRG_ MS -5:R'JQE>/-O)1GL7J{]2O#?
7)4M$L2VBQ )1J;I[U._*@^^+1J- <[;) M9=F@J&?K9N9=T<([F9_ZMS/?,!_KYF?17SO0EYW3>\R7)!>(PD(MY5W?J*,5 M+YN1Y4"R==%M>V92LJRX7 %.@6L#=7_!F'P;Z
7JEO#D7U!+ P04 " #W M@0A9SPAIV;P# U$0 &0 'AL+W=O869>*&'OZ$6M!$\44TX^4O.M180T/1C@N: MU\9R!WE*JBN^KP/1,I
\PP96;6#U#9Q'#.S:P'ZJ!Z/6.ORX@V8;6.85U:9PG_VI$+9!N_(W32%X3S M3\OI*LMH5 W_WJ ;B.B6I)\EZAI8 M2A68"X[^?2,=H-<"82J+0PEI^)U2U[U%-O[KC&5
M5;9O!_T4Y'BNUP4%IR#3,IQ9%Q6>HCS3,QI01_VD43\Yj_Y&QA.S*"D;70![ M^;@MY,-3#.D]R_2MQ03@F63 F63@262<=;I,.]Z?]+^Z8*1V3+!B3+!R)K)/2
M:9/2Z0_J+Q7OI/5_MTW/[?674Y#E3GN=(S@%N99M]MK!+%ABMGI01_RL$3\[ M*_X/(,"D?-5=KF+YTI=RP;!ZH1X2?);K6ZMQ3++)3++)P)++).0KPF(=Y/U6"\
M,5,Z)EDP)EDX$EDGI:,Q}>!C_* 64Q.WWRFLV73:ZS%#*,OK]8]@ #69F3VN M< #E&({5:S-ZZQB8 ]N6YV\N9>V(J-[6F]7FC']5GFQ[ZTOS(O9-B4<9,"1KHR+J>R(K#JC5Q-
!B_(0>DN%/-*6PP1P#$P!Y/T- MI>(X4OZ:-+R7^%U!+ P04 " #W@0A9FSJ5"5,% !+*@ &0 'AL+W=O MN MMMMJJMGYL-H/)I@2-8N2%RM>S"*,V\^R"8_#:2.C&;TR21%GH0 M-'Q"7S%C.!4-$$_(\
M,IH6EC&OBYCFD9@&NJ6I6'/DIDNR,-$[:GWOE-Y3ZVV%7I/WK[J)YOXF7IM* MH$/"+NH9OR)3-_66\YFKY;?XM50;P[:[H5;_ODUE<#T/;K7(W?/EO;9[^7W1
M_>^+'JCE'EETD3EJB][HR%[U-/1R7N_8TQ!CSM'=:O\DH#N&\N$<_?V';(IN M!$GX/VV.+[A6.S=+0&.^P2&9=F2&X80]D\[LEY\,6_^MS2Z0, <2YD+"/$B8 M#PD+@& -
#UJ5!RT5??;G-ED0AN@*[4H3\C6685#$^;9UN+LN@/TZJ]ZW,GNV/6JV),R'A 5 L(9=^I5=^DJ[N"^$A1$G M:,.BD+2YH]#;M7[/TDS#&D638=U 7>.M,Y3G<:DS(&$>),R'A 5
L(8S[,H9 MMM(9^QQ&7C81*Z9OKP2S-HNH03*Y#MK2U$E5ORT?*567V@@2YD'"?$A8 1K MV&A0V6APEHV>"1=1^H@VA$6T-0VI.5;N/MYF)*7PTOD.),R%A'F0,!\2%@#!
M&OX:5OX:GCM,D92W9C EX-+)-23,&;[+K6]F7>[)%M[)%O[)%@'0134Z<%1U MX.C40&\AC\:QE-VEZ'Z[B*-0OD2MY$ AQXM_4;W&T-.]2OREW0L)4+_(*$-"$RT>5O;'@1MR8[-?-
B'T+2'%":"TKS0&D^*"TH:8T*37_8LP9V ME<>,%C,/%C/ADJ_-(UGX4(W$7X_S?1@ZPTST%I#BC-!:5Y MH#0?E!:4M/,G>H=BOJ$NIY?S.)[/X^A^?G=\^(*L\]!:0XHS06E>: T'Y06
ME+3Z\&6.NM9H-#IBKD.)WU#7YF\XW^(T)-FOSIO#&\).]88 68">@]{<4)H+ M2O-*6KV8.QI9^OO?ZWW0N $4K7"85EMQEA#VF\\'Y"BDVU042QVJH]4*QZM\ M7=^;X]?
&>&ZT''>,L=MVW#/&?K&N\1"V6&9YB]ECE'(4DY4\!,T[D(,P*U8N M%CN";O)U< LJ!$WRS37!2*R!O+[%:5BOY,%J-:/SOX#4$L#!!0 (/>! M"%G;D139C0, -T- 9 >&PO=V]R:W-
H965T$P9,E%Q56 M<"M6KJP%P;DA5:7K#P:Q6V'*G,G(M#V(R8@WJJ2,/ @DFZK"XM\I*?EF['C. MMN$+715*-[B348U7Y)&HI_I!P)W;J^2T(DQ2SI @R['SUKN?IQIO 'I3LI$[
MUT@[>>;\F[YYGX^=@7XA4I*%T@H8_M9D1II2*%K--I.GV7FKA[O55_9[R# MEV^^9-T?B*MM^^E-+]RTI$#EHT4O&K)(\,, M5)2UU__A[E\,. 73L!+\C^(>$\ 0AZ
C!I3V$'2&\M(>H(QCK;NO=!)=AA2BRP(#=HBB5=(,QR ME-&R421'MVC&J[I1V PN7UH@QT+H5484IJ5\#?RGQPR]>O$:O4 NDOJI1)2A
M)T:5O(%&N/ZKX(T$13ER%1C3K^YA9^=Y\=G M^"X$VJ?J;U.=^F<%/S3L#@6#&^0/_-#R/K/+Z8'-SN_U/O_EWO?""/H2"XQ> M<*K$FHH(K+BP#6Q+#>U4/4G>RQHOR-B!65
2L2,.X.4:?CQ4B?OUFF+9-<7F M5Q+;RS_L\P_/J9M/O(0OTQ9_RXP-4R\IEM$*81#/MZ-U@+S$]C+]Z'9198 MG 11N
^;6V#1T$^'/6S/9M3;C,Z66488APGR5*%%URRT:XIEUQ2;7?EL;P3B M?@3BLX7VU:S*)+_%:_C@5V0[T6):E@X M9+L"/>OEQ3:*[0M$.Z431?[03PYK;'8,#(9!$/E>>E"S%D7?
3Y(@/@#.+8I1 M'MI&MGK-NE32_ZGU/)V*;,EEER:VS'P1&X617MN%L6SN0W[W(8736L7U4TK M-=R=<@9W\>$T9T4ER8%S"\J[\P]M6U$[/>YY3GO/Z7_V?&;4TXM<6U%'KBTH
MBVLKZLBOL[-?A;W!RAP4)%1WPU2[K^A;^[/(6[,%/VB?>OP=FE/6K\ ME&\/!^P6%$F44F6T!7XA,(4[6&BO5&\-KOE9ZY@[VTN"SA_$:$!\'S)N=K> MZ [Z$]WD!U!+ P04 "
#W@0A9,5D.K4<# ##P &0 'AL+W=OM-2<.MKL.B1^/G62AF=J(0G;3QLEYWYSSQ,>)ISLN;N4&4<%]RC(Y MLS9*Y>>V+:,-ID3V>
(Z9OI)PD1*EAV)MRUP@B0M1RFS/<89V2FAF!=/BW$($ M4[Y5C&:X$""W:4K$SPMD?#>S7.OAQ U=;Y0Y80?3G*QQB>ISOA!Z9-.P92RXOS6#*[BF>68C)!AI(P%T7]W.$?&
MC)/.XT=E:M7W-,+]XP?WRZ)X7$?2N,15#[S):_ 0=6D6=F36X.G7//TV]^#= M/8J(2H1W<*OHA'@DC.],,.U!HOMBNFFO$X2%#1;'X+0:G\JA'[-PH[,M&E@'~
=;!$S7CH$N>79J%'9DU> YKGL/6:5IAE* XY%L1;?1+MUKV#>6HG,72 MS.)#4$OSP7[G#,9^?S1L=MB\-8E3>75DUN UJGF-3FGKA<"S9)O%^J5:D_R7
M9F^]Z:F3LTNSL".S!NQQ#7O\1,T^[)GEV9A1V8-GI.:Y^0IFWWRE\W>FL2I MO#HR:_!RG3^?T\Y_?JM4!J,]*D[/<1SW$93V&YU*I2NW$HN]M^$PV\./1*QI M)H%AHNV=WD@_%&
[U)1F !+]%]P:_ M 5!+ P04 " #W@0A9AI-.:L\# "F$0 &0 'AL+W=OV4[M_O.$E# B$;4BYZ-[%SSN/G/.=@CCW>>).[K>*#UA3LE8\"T2VAK0$.N3>X-T5"TF[A4 MY2\%/3SU
I'[F4:$$$6FZP(._0 M#$L:(LPB=$GC3)$(O4>WF9(*IBA,HP57A"F*X_AW80&)0$L29H(J2B2Z>@KC M+ *W:\$3-.=)FBF<)XVO*LC#A=&;2Z(PC>5;6$_J&3DV%<2HF9IA&
<^LB,#CEOE MR\WQW"-X%R!\=)+FMRMTA06#Q-6U_OX1@-&-(HG\T:9RP<)K9Z'WEG.9XI!, M#-@\)!&/Q)B^?F7[UHA-P60E6%O,!= @!]+,W^-T&'C# MP= >FX_U< [M_,
;^%Y0V368#BJF@TZFMZG.ET0W4F:02/W[J_WJV@AWXIV: M)[ &]'[5>C^BZAJOT_!>@)K"!94@@5]575P6-7VR+$#=Z^J#^U\SW&&@=]> MU<.*Z;"3Z1V12M!0;_E+Q<,']
(51)=$RN_\)_^1(<72=J0QR]Q4,C]1YYPJG MIJTGL(88HTJ,78NH!\U&?O4$UA#,MG;]B=57I9=(]1)V8/>V@[U*,[&SVHO< MKK51=B=-^'NWT-
5RL6@EUNE[:C[Z0FM&ZNPB=5Y$#9[L M<4ZJ8O>PBCW/=YS]*FZQ\T>VY1PIY5W#9'=W3)"Z!+)6[-,?L!"8J7:FG3@G
M9Z@GM&;4N^;+'KR,LNZU:>L+K2G:KFVS.YNO[H_VJ_IM9P=2L MG73@4;Y18!$(<^8*LYVU6QUV7"1'[WYF?Z$B(_2>]@BAN,3UBL*;3C,5D! MI'46 "=17 H4
\73_%Q]SQ6&ULK5==;],P%/TK5D!H2-!\M&N[T4;;6A!#3)J8@ ?$@Y?A?A^2SL M6X"+^,%@_J_?NB;5R) 6]'5RE4R^PBH!#8BP%Q UJ U[\ MYE4X##XTN>R(K.9Y4'D>M+''LQ452[
+*\&Y55@5*=.)7 M#%#70Y+T@# /' M:#>O31STPM.)O]DW=2RJIO:T4GO:JO:C-@P+!%*RH$R1#>5K('*!NTDU5QU%7Q3/J MTG-'9#7/X\KS^%^*!Q?@KGAR^H@GKVER75 -]]?
5P^=.5TQ5;W MN=<.A%T53,G4E>^.V.J^HR??47=%4W+M[\;AN'=VL!2/1=65/K4#8>O)^Y_E M4Y(>%$8XB@Y%'XTK9/M[+6<&:NDZ<4W<&5UTG]73JMN_<#VN_Q1>?"I<4[5D
M0A,."X0&O1&>=:KHOHN!D;EK8.^DP7;8W:[BPF64#<#W"RG-;F#_H/H&BO\" M4$L#!!0 (/>!"%D*-,^KQ@, ,%\1 9 >&PO=V]R:W-H965TQCVP$C7 M-
E%)5$G*3H']^%Y2BB+9"EMAVHLM2CR'/$>7]Y*:'KCX)'< BRCF229GSDZI M_,IU9;2#E,HSGD.&3S9V.Z5ON/-I3K=P#^ICOA;87RN2)UZ3
UL7C^QOS/B4@Z)"JEX6H%Q!BG+RG_Z6!G1 (0O 8(*$!P!@N %0%@!PN\%C"K MR#A32C$^K*BB\ZG@!R)T;V33%\9,@T,Y+-/O_5X)?,H0I^9WD% %,5E3H;Z0
M#X)FDIHW(LG/]B9!"3%_3A-QD98SI=_5Z!8JR1+[!+G=H;,84D,56 &! */** ML(Q\V/%"TBR64U?A-/5@;E1-:5E.*7AA2CZYY9G:2?(VBR'NP%_\>&W\"L[ M?
F+!NVAO[7'PY/$RL!+>4G%&0O\G$GC!B'R\7Y'7K]Z0M>!Q$:DN?7:ZWXH, MZ;PV79?,_TS34AO6$14:WK!O1)&_WV-7-8J*U'2^:DECGI*U.2'+ VF^*(*RFBN61=B6PY.7'= M]XY?
S;5U^+XK82"REE/GM5/G5J<6*2\P[N,"B.*XZ2CS3*[S3)U'(OK')OZ2-+B[1+FA785I]09*N!R%J&7=:&?7Y/E>=R2#^' M)%L-1-,RT_>>-X?>-VI/8XU9"TY%U,R+_O@D%=F'Z^O-
4&QMCLSZ!7;9Q( M4Q!;<[*7N%"P@)>'T_IN_?5@8<[,G/W\M,#GIZV#(^C"6P0ZIV=8[2(C1? M-A3/S?GV@2L\+9O+'= 8A.Z SS>&'J#^IC+_"E!+ P04 " #W@0A9 MKN]@^L<"
!F"0 &0 'AL+W=ONCXSF;A@2V6 MVBRX\:"D"W@$_51.)<[<5B5C.12*B8)(F ^=6[_Z1F\!?QDL%9;8V(BF0GQ M;"9WV=#QC$/ (=5&@>+?"L, N1%"-
_XVFDYKTA"WQQOU+S9VC&5&%8P%_\4R MO1PZ-P[)8$XKKA_$^BLT\5@'4\&5_27K&GN-%M-*:9$W9)SGK*C_Z4N3ART" MZG03@H8OO"5$>PAA0PB/M1 UA.A8"[V&8$-
WZ]AMXA*J:3R08DVD0:..&<=CL M6S,FBQ5FSGQB5V$9\G0<>?[Y]PLRV;0@\'EMEC%3/\K)75%O0E/-\P0T95Q= M(.3I,2'G9Q?DC+'"W#/.$: &KD?C**;-
G9'M=U@C]V0W(M"+Q69%!ED'?SD M,/_J-_%'+2)"#:)& 4'!>^IO"2A_X$$7A!U^#,^GAYVA7.8_JTJD.[MM3XY MGAX>2$;8[HK0ZD5[] +/CXC9&L_UUNBJ[T$%<[WU54E3&#IX?
RF0*W#B]^_\ M*^]S5W)/*9:<4FQR(K&=,D1M&2*K'NXI0P)S7,G(&+>Z9+/*'D9[5!.F4BY4 M)8_H$8^&9]Y/?'?L=Z@H^(NN?_EZ]?('AA+EBA"{ 0<-TU P 2A, T
!X;"]S='EL97,N>&ULW5A=3]LP%/TKD1D32!-I MFQ&:T5;:*B%-VB8D>-@;38F>.R=K]^OG::?N"+.AXVNE0T]CT^YQ[; M-\0PJ,U*L+LY8R9:ED+60S(WIOH0Q_5TSDI:7ZB*28L42I?
4V*Z>Q76E&C]^YH!S@=%+P\0O>C8"U5V*:?'B;_G#@F?760 M]#/*F'!_5]B-/K4ZGG>*T,( S=K?,*'CR'&SWZ-!H>1FVQ/B U:=EBQZI&)( MQE3PB>;*FC)QQ"8*J%Y8&RJV71=B-
2_/-SU/2C%1J?D4FF7VV?PWY-F M^!ZP[H%!+D1KL$=\8#2HJ#%,RQO;<8-=\ D4->W[564=SC1==?N79$-P-YMD MHG3.=)NF2]:AT4"P NQH/IO#W:@]!M 85=I&SNE,2>H\K!E-
P\I.F1!W\)Q^ M+W:TE\76OG5@UV3;M(::II?Q'=#?5O/:V[*]%^E&%7]4YM/"3D>Z/M0GN]6L MX$O77Q:M 4R]BZO3JA*KCX+/9,G\Y ]..!K0-2^:*\U_V6Q0*E,;8)I$CTP,
M/MV. -2TNF=+LRZG98%[[AVAY[^[SC,FF:9BV[2M-=>\RB]VG%S]*\ONM\[^ MX:#'YN?[VDU>'H/)]A,'D5-]H_!9/8J3<;-"WSKE+!S1FBC$9S%AN0;G.S$
M)FDT67!AN&QZ^D&DCW+Z*,>S0LC8?; \84YFK_!,LRQ)TA1; MT?$XZ&",K5N:PD]8#?,&#"P/9/JSM<9W&Z^0Y^L V]/G*@2;*5Z)V$SQM08D MO&[ R++P;F-Y@('M E8[D#^*NQS
$P( L !?3T\$MP>:4#M.*2V MBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YV MX$G1H2)8%H%R=.B':5_:_;(% >,P #P 'AL+W=OV,?
YHLNJZ]:OIU%>_WX\OQ:WV>J$;W=T?38,?S41K3:ZU=]4?329381?V;L_ MK-/?K.ED^XDPLE5'D\%=K& M;QH^^JS>?.LNX)(^=*]TN.:Z@&
<#_+$FEH9KVKQJVRDJ908>M:+@S^-[&L" MF0+(=(^07U(".0>0\Z>"O(P$L;47=BD^KI4+K0ED!B"S_4">V#:L#BL"F0/( M?#^0EYVM;E:60!8 LMA33TJ_$F\; ED"R)
(7\D+>BULO+I0;WAYGSJGV56-] M[Q1!? $07_ BGAFO:^7$E9-U6*G%L7/27&_ZDQ"^'(OO>0FO5FJ8']+)H-HCJO*]F:TUB30+2NU$Y]ETROQ7LDX MYG[\LR;(*@FS5MY++=Z-"<-
$$GZBJ=[K3:@2';)(PZR2$7T5*$<(608HH>_>[V. M;W@N/JB.D^]C&L M,@'25#_&"22A-TDE6V5N))?QTQ('OTS.V+'A7$V1"XTED;R2+GE$6$.%S+&
M+M%K8=3]F)"DR!HI>TKRO<_$7S).A]%,2&$FPNR,L/R*<^N'F"ID(=*IYR$I M\;H:YL4IQ43V2)GM<:JT[(%\,F?V"8A4(RO%!9,VL%1JOC M(A(2S)Q9,#!:'6/"8A=[M0M$A.*
8B+7S-GK7226V#9QD&;FS)K9%8@]@%), M1)XYLWI@R#,>D4@]"%DH9[803BU& MF,A"^5XS(!HAYT.%,@"Q7[JLAM>I9BPJ-GW)M!NS%C.D0QD84*[LT@A#E> MD)'"%"NZ*',
,CZ>8R$(%=T4.]B9=-TMDH?(+/33[OW6!+A$%BJ9+82+VJ/> M1!8]W6<8)0+EC!0M.AL7_SNE9+;53](7R$#]NU.;58" "- M+0 &@ 'AL+U]R96QS+W=O24'XIM$-!*LONVG(%]4
]Z$G%&J$!<_M$G5/#X4@[- MN&]/PV[?#8O/X^$TK*K=.':_ZGI8![QQ&>[:KIS.5S9M?VS&\[+?UEVS?F^V MI9,E,NK^=D;U]'@[<_'ZU97_F=AN-OMU^=VN_QS+:?
S'X/JC[=^'?2ECM7AM M^FT95U7]>;B>'NK+(=V=)U>++Y[=5U3^_I:J>.T@@2.8/4@C2^8,,@FS^((<@ MGS\H("CF#\H0E.@^_F#'B#H8?Z@M$09EP1)$ZP)M$[(=2+P.B'8B4#L
MA&0G K,3HIT(U${(=B)P.R'@N!WH)Z"X'>@GH+@=Z">@N!WH)Z"X'>@GH+@=Z">@N!WHIZ*X'>BGHK
M@=Z*>BN!WCK9+"'06U%O)=!;46\ET%M1;R70VU!O M(}#;)IO=!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ
M;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>OOD8R6!WHYZ.X'>CGH[@=Z. M>CN!WHYZ.X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>,?G9A$#O M0+V#0.] O8-
[T"]@T#OC'IG KTSZIT)],ZH=R;0.Z/>F4#OC'IG KTSZIT) M],ZH=R;0.T]^%OQ)O8?QZU"&:_W&I__DU2/YWO+]?&7Y??)"3L7G.O;BN'I M+U!+ P04 " #W@0A95:BY9Q(" !S+ $P
%M#;VYT96YT7U1Y<&5S M72YX;6S-VM].VS 4!O!7J7*+&M?_-T2Y 6XW+O8"7G+:1DUBRS:LO/V<%) V ML0I4!TWC5K,YSOQD7Y7O?
KQ%"@M#D,_IG6URSE<,I::'0TNU3[06%8V@XN MEZJQRX)K]FY+3*Q6AC5^S#3F99YJ5-=7M[1Q#WU>W!W*SZGSX[]*U*=]<7/< M.&6M*Q="WS4NEW7V.+9_I2R?$^IRE7?
$TLI<]^/YJF MW5+[SNQRO;]\W,_S2&Q^G'_'?\[XM?X'^Q @?4B0/A1('QJD#P/2AP7IXPM( M'U]!^N KE$901.4HI'(44SD*JAQ%58["*D=QE:/ RE%D%2BR"A19!8JL D56
M@2*K0)%5H,@J4&05*+(*%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*K!)% M5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5H%BJ4635*+)]%%DUBJP: M15:-
(JM&D56CR*I19#4HLAH460V*K 9%5H,BJT&1U:#(:E!D-2BR&A19+8JL M%D56BR*K19'5HLAJ462U*++:_RGK3^_WGQP_/^O!=>-+/IO_:WS]&U!+ 0(4 M Q0 (/>!"%D'04UB@0 +$
0 "_0 !D;V-0 M&UL4$L! A0#% @ ]X$(62U]KCO *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ ]X$( M69E&PO=V]R:W-H965T&UL4$L! A0#% @ ]X$( M6=YC=94G!@ (1H
!@ ("!M X 'AL+W=O!"%EF+)+G\0( / ) 8 M " @1$5 !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ ]X$(6>AP28Y& P <@L !@ M ("!CQT 'AL+W=O!"%E+[&$Z6Q, !,L 0 8 "
@0LA !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ ]X$(690L(\F[ @ BPD !@ ("!DCP M 'AL+W=O!"%D0PNQ M1 ( (H& 8 " @8,_!X;"]W;W)K&PO=V]R:W-H965T!
M"%G&W("MR P &(A 9 " @5Y* !X;"]W;W)K&UL4$L! A0#% @ ]X$(62^H)?Q#!0 .@X !D M ("!75< 'AL+W=O&PO=V]R M:W-H965T!"%E!&UL M4$L! A0#% @ ]X$(6;,K2C2\ @ 1P8
!D ("!96< M 'AL+W=O&PO=V]R:W-H965T!"%DV^'?D@H /<@ 9 M " @?%_ !X;"]W;W)K&UL4$L! A0#% @ M]X$(627P5VBG&"P JR0 !D ("!NHH 'AL+W=O&PO=V]R:W-H965T!"%D(
M8-:)L00 )$* 9 " @6>P !X;"]W;W)K&UL4$L! A0#% @ ]X$(63]:U!2!" 6 L !D M ("!3[4 'AL+W=O&PO=V]R:W-H M965T!"%F(C#[9!@, /8& 9 M " @=R^ !X;"]W;W)K&UL4$L! M
A0#% @ ]X$(66OP)CLX#0 :B0 !D ("!&<( 'AL M+W=O&PO=V]R:W-H965T!"%FM5.V%8@0 &<, 9 " M@3S3 !X;"]W;W)K&UL4$L! A0#% @ ]X$( M62I?6=K ! \0P !D ("!U=<
'AL+W=O&PO=V]R:W-H965T!"%D@BMD_QP( #(& 9 " @1;@ !X;"]W;W)K M&UL4$L! A0#% @ ]X$(66P&87[; @ %0< M !D ("!%., 'AL+W=O&PO=V]R:W-H965T!"%D:(;62 M*@, / &
9 " @8_J !X;"]W;W)K&UL4$L! A0#% @ ]X$(69J#10F&PO=V]R:W-H965T M!"%E26X ,0D -!K 9 M " @0GX !X;"]W;W)K&UL4$L! A0# M% @ ]X$(665'.LWJ @ D0D !D ("!<0$!
'AL+W=O M&PO=V]R:W-H965T!"%E?^CRG;@, )82 9 " @2$( M 0!X;"]W;W)K&UL4$L! A0#% @ ]X$(69V MJ0UG P ^0\ !D ("!Q@L! 'AL+W=O&PO=V]R:W-H965T!"%G5FNO>3 (
,P% 9 " @2(6 0!X;"]W;W)K&UL4$L! A0#% @ ]X$(6=.']HQ$ P ]P> !D M ("!I1@! 'AL+W=O&PO M=V]R:W-H965T!"%FT-7)!] ( M #\( 9 " @1@C 0!X;"]W;W)K&UL4$L! A0#% @
]X$(61C[,!=B P " P !D ("!M0R8! 'AL+W=O&PO=V]R:W-H965T!"%G/]JZH@( .4 9 M " @48N 0!X;"]W;W)K&UL4$L! A0#% M @ ]X$(619'=']@ @ "0@ !D ("!'S$!
'AL+W=O&PO=V]R:W-H965T! M"%GH1^IN7@8 "$? 9 " @:-& 0!X;"]W;W)K&UL4$L! A0#% @ ]X$(65(#B:BS @ W < !D M ("!.$T! 'AL+W=O0+ &GP &0 @(B4 $ >&PO=V]R M:W-
H965T!"%F!LN1_70P &NI M 9 " @3U< 0!X;"]W;W)K&UL M4$L! A0#% @ ]X$(683HR,+_ @ R D !D ("!T6@! M 'AL+W=O&PO=V]R:W-H965T!"%E3BZL!D0, $,- 9 M " @;EN
0!X;"]W;W)K&UL4$L! A0#% @ M]X$(6;,%/#"# @ O < !D ("!@7(! 'AL+W=O&PO=V]R:W-H965T!"%G5+-NHV0, #L4 9 " @21Z 0!X;"]W M;W)K&UL4$L! A0#% @ ]X$(6=LV"U]6!P
MHSD !D ("!-'X! 'AL+W=ON=",@" >!P &0 @(! MA0$ >&PO=V]R:W-H965T!"%G@ M]'NA&0, .() 9 " @<"( 0!X;"]W;W)K&UL4$L! A0#% @ ]X$(61@@0F$&PO=V]R:W-H
M965T!"%F;.I4)4P4 $LJ 9 M " @5:4 0!X;"]W;W)K&UL4$L! M A0#% @ ]X$(6=N1%-F- P W0T !D ("!X)D! 'AL M+W=O&PO=V]R:W-H965T!"%F&DUHZSP, *81 9 " M@2*A
0!X;"]W;W)K&UL4$L! A0#% @ ]X$( M6:KX&^E1 P #PT !D ("!**4! 'AL+W=O&PO=V]R:W-H965T!"%FN[V#ZQP( &8) 9 " @:VL 0!X;"]W;W)K M&UL4$L! A0#% @ ]X$(6> 0<-TU P
2A, M T ( !JZ\! 'AL+W-T>6QE_;(% >,P #P @ 'TLP$ M>&PO=V]R:V)O;VLN>&UL4$L! A0#% @ ]X$(67KM3FU6 @ CBT !H M ( !T[D! 'AL+U]R96QS+W=O XML 85 Show.js IDEA:
XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the
scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:

150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .reu table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 321 322 1 false 86 0 false 9 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 100030 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 100050 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited Condensed Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 100060 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited Condensed Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 100070 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995455 - Disclosure - The Company Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompany The Company Notes 10 false false R11.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995475 - Disclosure - Fair Value Measurements Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 995485 - Disclosure - Marketable Securities Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecurities Marketable Securities Notes 13 false false R14.htm 995495 - Disclosure - Property and Equipment, Net Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 14 false false R15.htm 995505 - Disclosure - Accrued and Other Current Liabilities Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities Accrued and Other Current Liabilities Notes 15 false false R16.htm 995515 - Disclosure - Research and Collaboration Arrangements Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements Research and Collaboration Arrangements Notes 16 false false R17.htm 995525 - Disclosure - License Arrangements Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangements License Arrangements Notes 17 false false R18.htm 995535 - Disclosure - Commitments and Contingencies Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 995545 - Disclosure - Income Taxes Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 995555 - Disclosure - Common Stock Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStock Common Stock Notes 20 false false R21.htm 995565 - Disclosure - Stock-based Compensation Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-based Compensation Notes 21 false false R22.htm 995575 - Disclosure - Common Stock Warrants Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrants Common Stock Warrants Notes 22 false false R23.htm 995585 - Disclosure - Net Loss Per Share, Basic and Diluted Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted Net Loss Per Share, Basic and Diluted Notes 23 false false R24.htm 995595 - Disclosure - Derivative Liability Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiability Derivative Liability Notes 24 false false R25.htm 995605 - Disclosure - Related Party Transactions Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 25 false false R26.htm 995615 - Disclosure - 401(K) Plan Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlan 401(K) Plan Notes 26 false false R27.htm 995625 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 27 false false R28.htm 995635 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 28 false false R29.htm 995645 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements 29 false false R30.htm 995655 - Disclosure - Marketable Securities (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecurities 30 false false R31.htm 995665 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet 31 false false R32.htm 995675 - Disclosure - Accrued and Other Current Liabilities (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables Accrued and Other Current Liabilities (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities 32 false false R33.htm 995685 - Disclosure - Research and Collaboration Arrangements (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables Research and Collaboration Arrangements (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements 33 false false R34.htm 995695 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 34 false false R35.htm 995705 - Disclosure - Common Stock (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockTables Common Stock (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStock 35 false false R36.htm 995715 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation 36 false false R37.htm 995725 - Disclosure - Net Loss Per Share, Basic and Diluted (Tables) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables Net Loss Per Share, Basic and Diluted (Tables) Tables http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted 37 false false R38.htm 995735 - Disclosure - The Company - Additional Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails The Company - Additional Information (Details) Details 38 false false R39.htm 995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 39 false false R40.htm 995755 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) Details 40 false false R41.htm 995765 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParentheticа Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical) Details 41 false false R42.htm 995775 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details) Details 42 false false R43.htm 995785 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasur Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details) Details 43 false false R44.htm 995795 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 44 false false R45.htm 995805 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetails Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) Details 45 false false R46.htm 995815 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails Marketable Securities - Summary of Available for Sale Securities (Details) Details 46 false false R47.htm 995825 - Disclosure - Marketable Securities - Summary of Aggregate fair values of marketable securities with unrealized losses and gains (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAggregateFairValuesOfMarketableSecuritiesWithUnrealizedLosse Marketable Securities - Summary of Aggregate fair values of marketable securities with unrealized losses and gains (Details) Details 47 false false R48.htm 995835 - Disclosure - Marketable Securities - Additional Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails Marketable Securities - Additional Information (Details) Details 48 false false R49.htm 995845 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Details 49 false false R50.htm 995855 - Disclosure - Property and Equipment, Net - Additional

Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 50 false false R51.htm 995865 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) Details 51 false false R52.htm 995875 - Disclosure - Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details) Details 52 false false R53.htm 995885 - Disclosure - Research and Collaboration Arrangements - Summary of Deferred Revenue (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails Research and Collaboration Arrangements - Summary of Deferred Revenue (Details) Details 53 false false R54.htm 995895 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails Research and Collaboration Arrangements - Additional Information (Details) Details 54 false false R55.htm 995905 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details 1) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1 Research and Collaboration Arrangements - Additional Information (Details 1) Details 55 false false R56.htm 995915 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails Research and Collaboration Arrangements - CFF - Additional Information (Details) Details 56 false false R57.htm 995925 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1 Research and Collaboration Arrangements - CFF - Additional Information (Details 1) Details 57 false false R58.htm 995935 - Disclosure - License Arrangements - Additional Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails License Arrangements - Additional Information (Details) Details 58 false false R59.htm 995945 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 59 false false R60.htm 995955 - Disclosure - Commitments and Contingencies- Summary of Components of Lease Expense - (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails Commitments and Contingencies- Summary of Components of Lease Expense - (Details) Details 60 false false R61.htm 995965 - Disclosure - Commitments and Contingencies - Summary of Supplemental Information Related to Leases - (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails Commitments and Contingencies - Summary of Supplemental Information Related to Leases - (Details) Details 61 false false R62.htm 995975 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) Details 62 false false R63.htm 995985 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 63 false false R64.htm 995995 - Disclosure - Common Stock - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails Common Stock - Additional Information (Details) Details 64 false false R65.htm 996005 - Disclosure - Common Stock - Schedule of Common Share Reserved for Future Issuance (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails Common Stock - Schedule of Common Share Reserved for Future Issuance (Details) Details 65 false false R66.htm 996015 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 66 false false R67.htm 996025 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Units (RSU) (Details) Sheet http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails Stock-based Compensation - Summary of Restricted Stock Units (RSU) (Details) Details 67 false false R68.htm 996035 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails Stock-based Compensation - Summary of Stock Options Activity (Details) Details 68 false false R69.htm 996045 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateF Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details) Details 69 false false R70.htm 996055 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl Stock-based Compensation - Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function (Details) Details 70 false false R71.htm 996065 - Disclosure - Common Stock Warrants - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails Common Stock Warrants - Additional Information (Details) Details 71 false false R72.htm 996075 - Disclosure - Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details) Details 72 false false R73.htm 996085 - Disclosure - Net Loss Per Share, Basic and Diluted - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails Net Loss Per Share, Basic and Diluted - Additional Information (Details) Details 73 false false R74.htm 996095 - Disclosure - Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputat Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) Details 74 false false R75.htm 996105 - Disclosure - Derivative Liability - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails Derivative Liability - Additional Information (Details) Details 75 false false R76.htm 996115 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 76 false false R77.htm 996125 - Disclosure - 401(K) Plan - Additional Information (Details) Sheet
http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails 401(K) Plan - Additional Information (Details) Details 77 false false All Reports Book All Reports fdmt-20240630.htm fdmt-20240630.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "fdmt-20240630.htm": { "nsprefix": "fdmt", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "dts": { "inline": { "local": [ "fdmt-20240630.htm" ] }, "schema": { "local": [ "fdmt-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 248, "keyCustom": 74, "axisStandard": 28, "axisCustom": 0, "memberStandard": 36, "memberCustom": 41, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 5 }, "contextCount": 321, "entityCount": 1, "segmentCount": 86, "elementCount": 655, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 735, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical", "longName": "100030 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited", "longName": "100040 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R5": { "role":

"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited", "longName": "100050 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R6": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited", "longName": "100060 - Statement - Condensed Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_46b3a6e6-32ba-4519-820b-e29f64294d96", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f19e1397-1ec1-481a-a1d7-a23068207507", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R7": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited", "longName": "100070 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompany", "longName": "995455 - Disclosure - The Company", "shortName": "The Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995475 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureMarketableSecurities", "longName": "995485 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "longName": "995495 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities", "longName": "995505 - Disclosure - Accrued and Other Current Liabilities", "shortName": "Accrued and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:AccruedAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:AccruedAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements", "longName": "995515 - Disclosure - Research and Collaboration Arrangements", "shortName": "Research and Collaboration Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangements", "longName": "995525 - Disclosure - License Arrangements", "shortName": "License Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:LicenseArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:LicenseArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995535 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureIncomeTaxes", "longName": "995545 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStock", "longName": "995555 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation", "longName": "995565 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrants", "longName": "995575 - Disclosure - Common Stock Warrants", "shortName": "Common Stock Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:CommonStockWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:CommonStockWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted", "longName": "995585 - Disclosure - Net Loss Per Share, Basic and Diluted", "shortName": "Net Loss Per Share, Basic and Diluted", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":

"C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiability", "longName": "995595 - Disclosure - Derivative Liability", "shortName": "Derivative Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "longName": "995605 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLeaseCostTableTextBlock", "longName": "995615 - Disclosure - Lease Cost (Tables)", "shortName": "Lease Cost (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DefinedContributionPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DefinedContributionPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "995645 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesTables", "longName": "995655 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "longName": "995665 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables", "longName": "995675 - Disclosure - Accrued and Other Current Liabilities (Tables)", "shortName": "Accrued and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "fdmt:AccruedAndOtherCurrentLiabilitiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "fdmt:AccruedAndOtherCurrentLiabilitiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables", "longName": "995685 - Disclosure - Research and Collaboration Arrangements (Tables)", "shortName": "Research and Collaboration Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995695 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockTables", "longName": "995705 - Disclosure - Common Stock (Tables)", "shortName": "Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "longName": "995715 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables", "longName": "995725 - Disclosure - Net Loss Per Share, Basic and Diluted (Tables)", "shortName": "Net Loss Per Share, Basic and Diluted (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails", "longName": "995735 - Disclosure - The Company - Additional Information (Details)", "shortName": "The Company - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_f99f7a2a-37f0-4716-b9fe-3dc764af5983", "name": "us-gaap:TemporaryEquitySharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f99f7a2a-37f0-4716-b9fe-3dc764af5983", "name": "us-gaap:TemporaryEquitySharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef":

"C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "longName": "995755 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_77c56259-b637-4e33-b4d6-aad8b80736c2", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dc343c04-5d28-4565-af3b-57c308b12ab4", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R41": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic "longName": "995765 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)", "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_77c56259-b637-4e33-b4d6-aad8b80736c2", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_910a1d2c-50d3-494c-ae09-b20af7f0667d", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R42": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails", "longName": "995775 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_10e22855-6e96-44ee-aa63-f51d0bd9a6e5", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R43": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu "longName": "995785 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_90abbca6-3218-4a6f-b634-5b5432def95a", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_90abbca6-3218-4a6f-b634-5b5432def95a", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "995795 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "fdmt:FairValueAssetsLevelOneAndLevelTwoTransfersAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors":[ "fdmt:FairValueLiabilitiesLevelOneAndLevelTwoTransfersAmount", "fdmt:FairValueLiabilitiesLevelOneAndLevelTwoTransfersAmount", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "fdmt:FairValueAssetsLevelOneAndLevelTwoTransfersAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "fdmt:FairValueLiabilitiesLevelOneAndLevelTwoTransfersAmount", "fdmt:FairValueLiabilitiesLevelOneAndLevelTwoTransfersAmount", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail "longName": "995805 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)", "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_22ba116b-04cd-41f8-b5e2-f0fd879196a3", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_22ba116b-04cd-41f8-b5e2-f0fd879196a3", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "longName": "995815 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details)", "shortName": "Marketable Securities - Summary of Available for Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_6d711107-2794-43cd-a300-fd7af103b8b9", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6d711107-2794-43cd-a300-fd7af103b8b9", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAggregateFairValuesOfMarketableSecuritiesWithUnrealizedLoss "longName": "995825 - Disclosure - Marketable Securities - Summary of Aggregate fair values of marketable securities with unrealized losses and gains (Details)", "shortName": "Marketable Securities - Summary of Aggregate fair values of marketable securities with unrealized losses and gains (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "longName": "995835 - Disclosure - Marketable Securities - Additional Information (Details)", "shortName": "Marketable Securities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "longName": "995845 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "longName": "995855 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "shortName": "Property and Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails", "longName": "995865 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)", "shortName": "Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef":

"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "fdmt:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "div", "fdmt:AccruedAndOtherCurrentLiabilitiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "fdmt:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "div", "fdmt:AccruedAndOtherCurrentLiabilitiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails", "longName": "995875 - Disclosure - Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details)", "shortName": "Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4789744c-dc1f-48b3-87a2-44933dc55eb8", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R53": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails", "longName": "995885 - Disclosure - Research and Collaboration Arrangements - Summary of Deferred Revenue (Details)", "shortName": "Research and Collaboration Arrangements - Summary of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_48a89ac0-ddf5-4237-b7d9-074fa7da72ba", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R54": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails", "longName": "995895 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details)", "shortName": "Research and Collaboration Arrangements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1", "longName": "995905 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details 1)", "shortName": "Research and Collaboration Arrangements - Additional Information (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_0308f33f-5008-43a0-96a7-3fbef6c62da7", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0308f33f-5008-43a0-96a7-3fbef6c62da7", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails", "longName": "995915 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details)", "shortName": "Research and Collaboration Arrangements - CFF - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_e392bd2b-b28d-4e05-b9a0-ec0cc30aec18", "name": "fdmt:TotalAmountOfAwardUnderAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e392bd2b-b28d-4e05-b9a0-ec0cc30aec18", "name": "fdmt:TotalAmountOfAwardUnderAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1", "longName": "995925 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1)", "shortName": "Research and Collaboration Arrangements - CFF - Additional Information (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_41282611-dcff-40ae-9697-8be87342b315", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_41282611-dcff-40ae-9697-8be87342b315", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails", "longName": "995935 - Disclosure - License Arrangements - Additional Information (Details)", "shortName": "License Arrangements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_18acba55-5bfb-4824-ad05-a7135f3c64a5", "name": "fdmt:CollaborationArrangementsUpfrontPaymentReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "fdmt:LicenseArrangementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1110403d-dc24-4442-9410-e7b930982983", "name": "fdmt:CollaborativeArrangementReceiveFutureOptionFeesAndMilestones", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "fdmt:LicenseArrangementsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R59": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995945 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b9a81d3e-4812-412a-a46e-a93db7a5d534", "name": "us-gaap:LeaseExpirationDate1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R60": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails", "longName": "995955 - Disclosure - Commitments and Contingencies- Summary of Components of Lease Expense - (Details)", "shortName": "Commitments and Contingencies- Summary of Components of Lease Expense - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails", "longName": "995965 - Disclosure - Commitments and Contingencies - Summary of Supplemental Information Related to Leases - (Details)", "shortName": "Commitments and Contingencies - Summary of Supplemental Information Related to Leases - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "fdmt:SummaryOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "fdmt:SummaryOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails", "longName": "995975 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)", "shortName": "Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "995985 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "longName": "995995 - Disclosure - Common Stock - Additional Information (Details)", "shortName": "Common Stock - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:CommonStockVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-

gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R65": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "longName": "996005 - Disclosure - Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)", "shortName": "Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "fdmt:ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cc7c966c-e9ed-4910-9e6b-5651b448f404", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "fdmt:ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R66": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "996015 - Disclosure - Stock-based Compensation - Additional Information (Details)", "shortName": "Stock-based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_c2cfdddb-3216-4152-a61c-0740d993d0e5", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "fdmt:ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_867036fa-8b99-4e10-859b-ec2957cce468", "name": "fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R67": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails", "longName": "996025 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Units (RSU) (Details)", "shortName": "Stock-based Compensation - Summary of Restricted Stock Units (RSU) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_1ad89300-06ee-4873-8022-2ac9cbc68943", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1ad89300-06ee-4873-8022-2ac9cbc68943", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails", "longName": "996035 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)", "shortName": "Stock-based Compensation - Summary of Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_a1c93b55-6d8f-418a-8dde-f7f389f4ad21", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "unique": true } }, "R69": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateF "longName": "996045 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)", "shortName": "Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl "longName": "996055 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function (Details)", "shortName": "Stock-based Compensation - Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "longName": "996065 - Disclosure - Common Stock Warrants - Additional Information (Details)", "shortName": "Common Stock Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_db97c936-6f3f-4f65-9c53-4620b6a982f0", "name": "fdmt:NumberOfWarrantSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "fdmt:CommonStockWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_db97c936-6f3f-4f65-9c53-4620b6a982f0", "name": "fdmt:NumberOfWarrantSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "fdmt:CommonStockWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails", "longName": "996075 - Disclosure - Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_13c7d508-4a1b-4301-9346-8e7cf3cafbee", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "longName": "996085 - Disclosure - Net Loss Per Share, Basic and Diluted - Additional Information (Details)", "shortName": "Net Loss Per Share, Basic and Diluted - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_aec51244-fb0b-4c49-819d-71dec4d608cc", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "fdmt:CommonStockWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true }, "uniqueAnchor": null }, "R74": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa "longName": "996095 - Disclosure - Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails", "longName": "996105 - Disclosure - Derivative Liability - Additional Information (Details)", "shortName": "Derivative Liability - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_02b20369-2512-4329-88c3-86f414067b16", "name": "fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "996115 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_584fd9fb-0b22-4216-89bc-4216d4de85a5", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true },

"uniqueAnchor": { "contextRef": "C_584fd9fb-0b22-4216-89bc-4216d4de85a5", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails", "longName": "996125 - Disclosure - 401(K) Plan - Additional Information (Details)", "shortName": "401(K) Plan - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_2f50b1c7-5d37-4aa1-872b-dcd286d4185e", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2f50b1c7-5d37-4aa1-872b-dcd286d4185e", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "fdmt-20240630.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Due to/from customer", "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r60", "r779" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r713" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r932" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Net amortization (accretion) of premium (discount) on marketable securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r85" ] }, "fdmt_AccruedAndOtherCurrentLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "AccruedAndOtherCurrentLiabilitiesTextBlock", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and Other Current Liabilities", "label": "Accrued And Other Current Liabilities [Text Block]", "documentation": "Accrued and other current liabilities." } } }, "auth_ref": [] }, "fdmt_AccruedClinicalAndPreclinicalStudyCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "AccruedClinicalAndPreclinicalStudyCosts", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued clinical and preclinical study costs", "label": "Accrued Clinical And Preclinical Study Costs", "documentation": "Accrued clinical and preclinical study costs." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Total accrued and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r62" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting and professional", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r62" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Less: Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r33", "r143", "r566" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive gain (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r77", "r149", "r562", "r591", "r592" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r17", "r418", "r421", "r474", "r587", "r588", "r912", "r913", "r914", "r920", "r921", "r922", "r923" ] }, "fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct": { "xbrltype": "durationItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual award payment period upon first commercial sale of product", "label": "Actual Award Payment Period Upon First Commercial Sale Of Product", "documentation": "Actual award payment period upon first commercial sale of product." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r845" ] }, "fdmt_AdditionalFundingCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "AdditionalFundingCommitted", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional funding upon acceptance of investigational New Drug application", "documentation": "Additional funding committed.", "label": "Additional Funding Committed" } } }, "auth_ref": [] }, "fdmt_AdditionalInvestmentInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "AdditionalInvestmentInCash", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional investment in cash", "documentation": "Additional investment in cash.", "label": "Additional Investment in Cash" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in-capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r71" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r608", "r920", "r921", "r922", "r923", "r1050", "r1110" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r858" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r858" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r858" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r858" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r43", "r44", "r349" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit",

"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "ATM offering costs", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r9", "r99" ] },
"fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of common stock warrants", "label": "Adjustments To Additional Paid In Capital Vesting Of Stock Warrant Issued For Services", "documentation": "Adjustments to additional paid in capital vesting of stock warrant issued for services.", "verboseLabel": "Vesting of common stock warrants issued for services" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "fdmt_AevitasTherapeuticsIncAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AevitasTherapeuticsIncAgreementMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Aevitas therapeutics, Inc. agreement.", "label": "Aevitas Therapeutics Inc Agreement [Member]", "terseLabel": "Aevitas Therapeutics, Inc. Agreement" } } }, "auth_ref": [] }, "fdmt_AggregateFairValueOfMarketableSecuritiesInUnrealizedGainPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AggregateFairValueOfMarketableSecuritiesInUnrealizedGainPosition", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAggregateFairValuesOfMarketableSecuritiesWithUnrealizedLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of marketable securities in unrealized gain position", "label": "Aggregate fair value of marketable securities in unrealized gain position", "documentation": "Aggregate fair value of marketable securities in unrealized gain position." } } }, "auth_ref": [] },
"fdmt_AggregateUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AggregateUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate unrealized loss", "label": "Aggregate Unrealized Loss", "documentation": "Aggregate unrealized loss." } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r891" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r817", "r827", "r837", "r869" ] },
"ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r820", "r830", "r840", "r872" ] },
"ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r892" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r858" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r865" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r821", "r831", "r841", "r865", "r873", "r877", "r885" ] },
"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r883" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl
], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r378", "r382" ] }, "fdmt_AmendedUniQureAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AmendedUniQureAgreementMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended uniQure Agreement", "label": "Amended Uni Qure Agreement [Member]", "documentation": "Amended uniQure agreement." } } }, "auth_ref": [] }, "fdmt_AmendedUniqureAgreementAndSecondUniqureAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AmendedUniqureAgreementAndSecondUniqureAgreementMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended uniQure Agreement and Second uniQure Agreement", "label": "Amended UniQure Agreement and Second UniQure Agreement [Member]", "documentation": "Amended uniQure agreement and second uniQure agreement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] },
"fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AmountObligatedToPayNonRefundableLicenseFeeAnnually", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable license fee payable annually", "label": "Amount Obligated To Pay Non Refundable License Fee Annually", "documentation": "Amount obligated to pay a non-refundable license fee annually." } } }, "auth_ref": [] }, "fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount obligated to pay upon closing first qualified financing at option of UC Regents", "label": "Amount Obligated To Pay Upon Closing First Qualified Financing At Option", "documentation": "Amount obligated to pay upon closing first qualified financing at option." } } }, "auth_ref": [] },
"fdmt_AmountsPaidNonRefundableLicenseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AmountsPaidNonRefundableLicenseFees", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount paid non-refundable license fee", "label": "Amounts Paid Non Refundable License Fees", "documentation": "Amount paid non-refundable license fees." } } }, "auth_ref": [] }, "fdmt_AnnualRoyalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AnnualRoyalty", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual royalty", "label": "Annual Royalty", "documentation": "Annual royalty." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa
], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r200" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa
], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa
], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa
], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r24" ] }, "fdmt_ArborAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ArborAgreementMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Arbor agreement.", "label": "Arbor Agreement [Member]", "terseLabel": "Arbor Agreement" } } }, "auth_ref": [] },
"fdmt_ArborBiotechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ArborBiotechnologiesIncMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Arbor biotechnologies, inc.", "label": "Arbor Biotechnologies, Inc. [Member]", "terseLabel": "Arbor Biotechnologies Inc" } } }, "auth_ref": [] },
"us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area of office and warehouse space", "label": "Area of Real Estate Property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",

```
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than
Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } }
} }, "auth_ref": [ "r408" ] }, "us-gaap_AssetAcquisitionContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetAcquisitionContingentConsiderationLiability", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"totalLabel": "Asset Acquisition, Contingent Consideration, Liability, Total", "label": "Asset Acquisition, Contingent Consideration, Liability", "terseLabel": "Liability related to
contingent consideration", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition." } } }, "auth_ref": [ "r1049" ] }, "us-
gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets",
"label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r107", "r117", "r145", "r171", "r204", "r208",
"r221", "r222", "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r410", "r414", "r453", "r556", "r650", "r740", "r741", "r779", "r808", "r957",
"r958", "r1065" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets",
"label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang":
{ "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit,
classified as current." } } }, "auth_ref": [ "r139", "r150", "r171", "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r410", "r414", "r453", "r779",
"r957", "r958", "r1065" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "totalLabel": "Assets, Fair Value Disclosure, Total", "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value
portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r429", "r430", "r767" ] }, "fdmt_AstellasGeneTherapiesIncMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AstellasGeneTherapiesIncMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "documentation": "Astellas gene therapies inc", "label": "Astellas Gene Therapies INC [Member]", "terseLabel": "Astellas GeneTherapies Inc" } } }, "auth_ref": [] },
"fdmt_AstellasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AstellasMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetail
], "lang": { "en-us": { "role": { "terseLabel": "Astellas", "label": "Astellas [Member]", "documentation": "Astellas." } } }, "auth_ref": [] }, "fdmt_AtmOfferingProgramMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "AtmOfferingProgramMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"documentation": "ATM offering program.", "verboseLabel": "ATM Offering Program", "terseLabel": "Atm offering program", "label": "ATM Offering Program [Member]" } } },
"auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role":
{ "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains", "documentation": "Amount, before tax,
of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other
comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r235" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": {
"en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses", "documentation":
"Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r236" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role":
{ "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost Basis", "documentation": "Amortized cost of investment in debt security
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r232", "r270", "r555" ] }, "us-
gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "lang": {
"en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role":
{ "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-sale, Total", "terseLabel": "Fair Value", "documentation": "Amount of investment in
debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r233", "r270", "r429",
"r549", "r767", "r770", "r933", "r1054", "r1055", "r1056" ] }, "ecd_AwardExcrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardExcrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise
Price" } } }, "auth_ref": [ "r880" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value",
"terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r881" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } },
"auth_ref": [ "r876" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How
MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } },
"auth_ref": [ "r876" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award
Timing MNPI Considered" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing
MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r876" ] }, "us-gaap_AwardTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by
type of award under share-based payment arrangement." } } }, "auth_ref": [ "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363",
"r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype":
"decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r879" ] },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
"terseLabel": "Name" } } }, "auth_ref": [ "r878" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI
Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r877" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel":
"Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r877" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or
basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
} } }, "auth_ref": [] }, "fdmt_BuildingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"BuildingLeaseMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Building lease.", "label": "Building Lease [Member]", "terseLabel": "5980 Horton Street Building Lease" } } }, "auth_ref": [] }, "us-
gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Purchases of property and equipment in accounts payable and accrued and other liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation":
"Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r21", "r22", "r23" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and
Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and Cash
Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of
currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.
```

Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r141", "r729" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r83", "r168" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in interest rates." } } }, "auth_ref": [ "r0", "r83" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of noncash investing and financing information" } } }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r7", "r802", "r803", "r804", "r805" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r856" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r853" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r851" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r135", "r146", "r147", "r148", "r171", "r193", "r194", "r197", "r199", "r206", "r207", "r262", "r288", "r290", "r291", "r292", "r295", "r296", "r301", "r302", "r305", "r308", "r316", "r453", "r598", "r599", "r600", "r601", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r638", "r659", "r681", "r705", "r706", "r707", "r708", "r709", "r896", "r918", "r924" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r146", "r147", "r148", "r206", "r301", "r302", "r303", "r305", "r308", "r314", "r316", "r598", "r599", "r600", "r601", "r748", "r896", "r918" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant shares become exercisable", "terseLabel": "Warrants shares exercised", "label": "Warrants to purchase shares of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r40" ] }, "fdmt_ClassOfWarrantsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "ClassOfWarrantsExpense", "crdr": "debit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrants expense.", "label": "Class Of Warrants Expense", "terseLabel": "Warrant expense recognized" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r857" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r857" ] }, "fdmt_CollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "CollaborationAndLicenseAgreementMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collaboration and License Agreements", "label": "Collaboration and License Agreement [Member]", "documentation": "Collaboration and License Agreement" } } }, "auth_ref": [] }, "fdmt_CollaborationAndLicenseRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "CollaborationAndLicenseRevenueMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetail ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and License Revenue", "label": "Collaboration And License Revenue [Member]", "documentation": "Collaboration and License Revenue." } } }, "auth_ref": [] }, "fdmt_CollaborationArrangementsUpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "CollaborationArrangementsUpfrontPaymentReceived", "crdr": "credit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us":

{ "role": { "terseLabel": "Upfront payments received", "label": "Collaboration Arrangements Upfront Payment Received", "documentation": "Collaboration arrangements upfront payment received." } } }, "auth_ref": [] }, "fdmt_CollaborativeArrangementAchievedMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CollaborativeArrangementAchievedMilestones", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement achieved milestones", "label": "Collaborative Arrangement Achieved Milestones", "documentation": "Collaborative arrangement achieved milestones." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Collaboration Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r121", "r123", "r134" ] }, "fdmt_CollaborativeArrangementInitialResearchTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CollaborativeArrangementInitialResearchTerm", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, initial research term", "label": "Collaborative Arrangement Initial Research Term", "documentation": "Collaborative arrangement, initial research term." } } }, "auth_ref": [] }, "fdmt_CollaborativeArrangementReceiveFutureOptionFeesAndMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CollaborativeArrangementReceiveFutureOptionFeesAndMilestones", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement receive future option fees and milestones", "label": "Collaborative Arrangement Receive Future Option Fees and Milestones", "terseLabel": "Future option fees and milestones" } } }, "auth_ref": [] }, "fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments entitled to receive for achievement of research and development milestones", "label": "Collaborative Arrangement Research And Development Milestones Entitled To Receive For Each Licensed Product", "documentation": "Collaborative arrangement research and development milestones entitled to receive for each licensed product." } } }, "auth_ref": [] }, "fdmt_CollaborativeArrangementRoyaltiesMultiplesOnActualAwardReceived": { "xbrltype": "pureItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CollaborativeArrangementRoyaltiesMultiplesOnActualAwardReceived", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties multiples on actual award received", "label": "Collaborative Arrangement Royalties Multiples On Actual Award Received", "documentation": "Collaborative arrangement royalties multiples on actual award received." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r408" ] }, "fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentMultiples": { "xbrltype": "pureItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CollaborativeArrangementsFutureSalesBasedMilestonePaymentMultiples", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future sales-based milestone payments multiples", "label": "Collaborative Arrangements Future Sales Based Milestone Payment Multiples", "documentation": "Collaborative arrangements future sales based milestone payment multiples." } } }, "auth_ref": [] }, "fdmt_CollaborativeArrangementsSpecialTerm": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CollaborativeArrangementsSpecialTerm", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangements special term", "label": "Collaborative Arrangements Special Term", "documentation": "Collaborative arrangements special term." } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r93", "r287", "r802", "r803", "r804", "r805" ] }, "fdmt_CommitmentAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CommitmentAndContingenciesLineItems", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment And Contingencies [Line Items]", "label": "Commitment And Contingencies [Line Items]", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "fdmt_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CommitmentAndContingenciesTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment And Contingencies [Table]", "label": "Commitment And Contingencies [Table]", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r66", "r109", "r559", "r637" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r92", "r281", "r282", "r714", "r952", "r954" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares reserved for issuance", "terseLabel": "Common stock reserved", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r70" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r798", "r799", "r800", "r802", "r803", "r804", "r805", "r920", "r921", "r923", "r1050", "r1108", "r1110" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r70" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r70", "r638" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "totalLabel": "Common Stock, Shares, Issued, Total", "terseLabel": "Common stock, shares, issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r70" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares, outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r70", "r638", "r656", "r1110", "r1111" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common

stock, $0.0001 par value, 300,000,000 shares authorized at June 30, 2024 and December 31, 2023; 51,914,275 and 43,075,218 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r70", "r561", "r779" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock voting rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r36" ] }, "fdmt_CommonStockWarrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CommonStockWarrantsTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrants" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Warrants", "label": "Common Stock Warrants [Text Block]", "documentation": "Common stock warrants." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r862" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r861" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r863" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r860" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r156", "r158", "r163", "r550", "r572", "r573" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer Equipment and Software", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r26", "r27", "r54", "r55", "r227", "r713" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r26", "r27", "r54", "r55", "r227", "r594", "r713" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r26", "r27", "r54", "r55", "r227", "r713", "r899" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r58", "r125" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r713" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r26", "r27", "r54", "r55", "r227" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r25", "r26", "r27", "r28", "r54", "r106", "r713" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r26", "r27", "r54", "r55", "r227", "r713" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in Progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "fdmt_ContingentPaymentsDevelopmentMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ContingentPaymentsDevelopmentMilestones", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent payments development milestones.", "label": "Contingent payments development milestones", "terseLabel": "Contingent payments development milestones" } } }, "auth_ref": [] }, "fdmt_ContingentPaymentsDevelopmentMilestonesForInitialTarget": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ContingentPaymentsDevelopmentMilestonesForInitialTarget", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent payments development milestones for initial target.", "label": "Contingent Payments Development Milestones for Initial Target", "terseLabel": "Contingent payments development milestones initial target" } } }, "auth_ref": [] }, "fdmt_ContingentPaymentsEliminated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ContingentPaymentsEliminated", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments eliminated", "label": "Contingent Payments Eliminated", "documentation": "Contingent payments eliminated." } } }, "auth_ref": [] }, "fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct": { "xbrltype": "durationItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuous period where the Company ceases to develop or commercialize any product", "label": "Continuous Period Where Company Ceases To Develop Or Commercialize Any Product", "documentation": "Continuous period where the Company ceases to develop or commercialize any product." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Liability, Total", "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "verboseLabel": "Total deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r319", "r320", "r324" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r319", "r320", "r324" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, net of current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r319", "r320", "r324" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue included in deferred revenue at the beginning of the current year", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Receivable, after Allowance for Credit Loss, Total", "terseLabel": "Accounts receivable", "label": "Contract with Customer, Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r319", "r321", "r324", "r712" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number shares issued upon conversion of redeemable convertible preferred shares", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r15", "r36", "r69", "r97", "r311" ] },
"fdmt_CorporateBondMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CorporateBondMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Corporate bond.", "label": "Corporate Bond [Member]", "terseLabel": "Corporate Bonds" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Bonds", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r756", "r758", "r767", "r780", "r796", "r1105" ] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r173", "r174", "r297", "r303", "r480", "r499", "r554", "r730",
"r732" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label":
"Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CreditConcentrationRiskMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
], "lang": { "en-us": { "role": { "terseLabel": "Credit Concentration Risk", "label": "Credit Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement." } } }, "auth_ref": [ "r106" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype":
"gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] },
"fdmt_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CustomerAMember", "presentation":
[ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
], "lang": { "en-us": { "role": { "terseLabel": "Customer A", "label": "Customer A [Member]", "documentation": "Customer A." } } }, "auth_ref": [] }, "fdmt_CustomerBMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CustomerBMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
], "lang": { "en-us": { "role": { "terseLabel": "Customer B", "label": "Customer B [Member]", "documentation": "Customer B." } } }, "auth_ref": [] }, "fdmt_CustomerCMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CustomerCMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Customer C", "label": "Customer C [Member]", "documentation": "Customer C" } } }, "auth_ref": [] }, "us-
gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember",
"presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r87", "r227" ] }, "fdmt_CustomerMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "CustomerMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" ],
"lang": { "en-us": { "role": { "label": "Customer Member", "documentation": "Customer.", "terseLabel": "Customer" } } }, "auth_ref": [] },
"fdmt_CysticFibrosisFoundationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"CysticFibrosisFoundationAgreementMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CFF Agreement", "label": "Cystic Fibrosis Foundation Agreement [Member]", "documentation": "Cystic Fibrosis Foundation Agreement." } } },
"auth_ref": [] }, "fdmt_CysticFibrosisFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"CysticFibrosisFoundationMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Cystic Fibrosis Foundation", "label": "Cystic Fibrosis Foundation [Member]", "documentation": "Cystic Fibrosis Foundation [Member]" } } },
"auth_ref": [] }, "fdmt_DMolecularTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"DMolecularTherapeuticsMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "4D Molecular Therapeutics.", "label": "4D Molecular Therapeutics [Member]", "terseLabel": "4DMT" } } }, "auth_ref": [] }, "us-
gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Allowance for credit loss", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r234", "r270", "r275", "r276" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAggregateFairValuesOfMarketableSecuritiesWithUnrealizedLoss
], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate fair value of marketable securities in a continuous loss position for more than twelve months", "terseLabel":
"Individual securities held in an unrealized loss position for 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r119", "r272", "r745" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr":
"debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAggregateFairValuesOfMarketableSecuritiesWithUnrealizedLoss
], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of securities held in a continuous unrealized loss position for less than twelve months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r119", "r272", "r745" ] }, "us-
gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gains or losses on marketable securities", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "totalLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r946" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Available for Sale Securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTerm", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity period of marketable securities", "label": "Debt Securities, Available-for-Sale, Term", "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1054", "r1055", "r1056" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Aggregate Fair Values of Marketable Securities with Unrealized Losses and Gains", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r118", "r745", "r951" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Total", "terseLabel": "Deferred revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r910" ] }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Deferred Revenue", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r326", "r328", "r335", "r756", "r757", "r758", "r759" ] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan Disclosure [Line Items]", "label": "Defined Contribution Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r337" ] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan [Table]", "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r337" ] }, "us-gaap_DefinedContributionPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlan" ], "lang": { "en-us": { "role": { "terseLabel": "401(K) Plan", "label": "Defined Contribution Plan [Text Block]", "documentation": "The entire disclosure for defined contribution plan." } } }, "auth_ref": [ "r336", "r337" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r32" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset, or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r32" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value of derivative liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r13", "r76", "r104", "r105", "r151", "r732" ] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail
], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability", "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [ "r444" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiability" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r103", "r416", "r423" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability", "label": "Derivative Liability, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r152" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r423" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r10", "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r52", "r53", "r423" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation Of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r323", "r749", "r750", "r751", "r752", "r753", "r754", "r755" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation Of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r323", "r749", "r750", "r751", "r752", "r753", "r754", "r755" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Collaboration and License Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r960" ] }, "us-

gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r347", "r351", "r379", "r380", "r381", "r761" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Dividends, Common Stock, Total", "terseLabel": "Common stock dividend", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r3", "r99" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] },
"dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentQuarterlyReport", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r812" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r844" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r855" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r164", "r180", "r181", "r182", "r183", "r184", "r185", "r190", "r193", "r197", "r198", "r199", "r203", "r404", "r407", "r426", "r427", "r551", "r574", "r734" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r164",
"r180", "r181", "r182", "r183", "r184", "r185", "r193", "r197", "r198", "r199", "r203", "r404", "r407", "r426", "r427", "r551", "r574", "r734" ] }, "us-
gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EarningsPerShareReconciliationAbstract", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share, Basic and Diluted", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r189", "r200",
"r201", "r202" ] }, "fdmt_EmployeeOptionsIssuedAndOutstandingAndFutureVestingOfRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.4dmoleculartherapeutics.com/20240630", "localname": "EmployeeOptionsIssuedAndOutstandingAndFutureVestingOfRestrictedStockUnitsMember",
"presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" ], "lang": {
"en-us": { "role": { "documentation": "Exercise of options issued and outstanding and future vesting of restricted stock units.", "label": "Employee Options Issued and Outstanding and Future Vesting of Restricted Stock Units [Member]", "terseLabel": "Exercise of Options Issued and Outstanding and Future Vesting of Restricted Stock Units"
} } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r62" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl
], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
"verboseLabel": "Options Issued and Outstanding", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r810" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity

Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r810" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r895" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r810" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r894" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r810" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r810" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r810" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r810" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r849" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r890" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r890" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [
"r890" ] }, "fdmt_EquipmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "EquipmentCosts", "crdr": "debit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Equipment costs.", "label": "Equipment Costs", "terseLabel": "Equipment costs" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r137", "r159", "r160", "r161", "r175", "r176", "r177", "r179", "r184", "r186", "r188", "r205", "r263", "r264", "r277", "r318", "r394", "r395", "r401", "r402", "r403", "r405", "r406", "r407", "r417", "r418", "r419", "r420", "r421", "r422", "r425", "r454", "r455", "r456", "r457", "r458", "r459", "r461", "r462", "r474", "r570", "r587", "r588", "r589", "r608", "r681" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r859" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r817", "r827", "r837", "r869" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r814", "r824", "r834", "r866" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r865" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r429", "r430", "r443", "r767" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [
"r429", "r430", "r443", "r767" ] }, "fdmt_FairValueAssetsLevelOneAndLevelTwoTransfersAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FairValueAssetsLevelOneAndLevelTwoTransfersAmount", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets, Level 1 and Level 2 transfers", "label": "Fair Value Assets Level One And Level Two Transfers Amount", "documentation": "Fair value assets level one and level two transfers amount." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r444", "r768" ] }, "fdmt_FairValueAssumptionsChangeOfControlPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FairValueAssumptionsChangeOfControlPayment", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change of control payment", "label": "Fair Value Assumptions Change Of Control Payment", "documentation": "Fair value assumptions change of control payment." } } }, "auth_ref": [] }, "fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FairValueAssumptionsProbabilityOfChangeInControlDiscountRate", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in control discount rate", "label": "Fair Value Assumptions Probability Of Change In Control Discount Rate", "documentation": "Fair value assumptions probability of change in control discount rate." } } }, "auth_ref": [] }, "fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FairValueAssumptionsProbabilityOfChangeInControlEventPercentage", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in control event percentage", "label": "Fair Value Assumptions Probability Of Change In Control Event Percentage", "documentation": "Fair value assumptions probability of change in control event percentage." } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r434", "r435",

"r436", "r437", "r438", "r439", "r444", "r768" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r298", "r328", "r329", "r330", "r331", "r332", "r333", "r428", "r430", "r431", "r432", "r433", "r442", "r443", "r445", "r486", "r487", "r488", "r746", "r747", "r756", "r757", "r758", "r767", "r770" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail
], "lang": { "en-us": { "role": { "terseLabel": "Liability Class", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r444" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r429", "r430", "r431", "r433", "r767", "r1055", "r1058" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r438", "r440", "r441", "r442", "r445", "r446", "r447", "r448", "r449", "r548", "r767", "r771" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r298", "r328", "r333", "r430", "r443", "r486", "r756", "r757", "r758", "r767" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r298", "r328", "r333", "r430", "r431", "r443", "r487", "r746", "r747", "r756", "r757", "r758", "r767" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r298", "r328", "r329", "r330", "r331", "r332", "r333", "r430", "r431", "r432", "r433", "r443", "r488", "r746", "r747", "r756", "r757", "r758", "r767", "r770" ] }, "fdmt_FairValueLiabilitiesLevelOneAndLevelTwoTransfersAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FairValueLiabilitiesLevelOneAndLevelTwoTransfersAmount", "crdr": "debit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Level 1 and Level 2 transfers", "label": "Fair Value Liabilities Level One And Level Two Transfers Amount", "documentation": "Fair value liabilities level one and level two transfers amount." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r444" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r444" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Fair Value of Level 3 Financial Instruments", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r434", "r439", "r444" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r429", "r430", "r431", "r433", "r767", "r1055", "r1058" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail
], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value included in other income (expense), net", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r435", "r444" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail
], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r434", "r444" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r298", "r328", "r329", "r330", "r331", "r332", "r333", "r428", "r430", "r431", "r432", "r433", "r442", "r443", "r445", "r486", "r487", "r488", "r746", "r747", "r756", "r757", "r758", "r767", "r770" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value on Recurring Basis", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r767", "r1052", "r1053", "r1054", "r1055", "r1056", "r1058" ] }, "fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight", "crdr": "debit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of non monetary consideration of intellectual property right", "label": "Fair Value Of Non Monetary Consideration Of Intellectual Property Right", "documentation": "Fair value of non monetary consideration of intellectual property right." } } }, "auth_ref": [] }, "fdmt_FairValueOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FairValueOfOptions", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of options", "label": "Fair Value Of Options", "documentation": "Fair value of options." } } }, "auth_ref": [] }, "us-

gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": [ "r435", "r444" ] }, "fdmt_FebruaryAndMarchTwoThousandAndTwentyFourPublicOfferingSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FebruaryAndMarchTwoThousandAndTwentyFourPublicOfferingSaleMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "February and March two thousand and twenty four public offering sale.", "label": "Februray And March Two Thousand And Twenty Four Public Offering Sale [Member]", "terseLabel": "February / March 2024 Public Offering Sale" } } }, "auth_ref": [] }, "fdmt_FebruayTwoThousandAndTwentyFourPublicOfferingSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FebruayTwoThousandAndTwentyFourPublicOfferingSaleMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "February two thousand and twenty four public offering sale.", "label": "Februray Two Thousand and Twenty Four Public Offering Sale [Member]", "terseLabel": "Februray 2024 Public Offering Sale" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r265", "r266", "r267", "r268", "r269", "r271", "r273", "r274", "r299", "r314", "r423", "r450", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r571", "r745", "r767", "r768", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r780", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r946", "r947", "r948", "r949", "r1051", "r1054", "r1055", "r1056", "r1057", "r1058" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "totalLabel": "Financial Liabilities Fair Value Disclosure, Total", "terseLabel": "Liabilities", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [ "r1052", "r1053", "r1057" ] }, "fdmt_FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5858 Horton Street Building Lease and Expansion", "label": "Five Eight Five Eight Horton Street Building Lease and Expansion [Member]", "documentation": "Five eight five eight horton street building lease and expansion." } } }, "auth_ref": [] }, "fdmt_FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5858 Horton Street Building Lease and 2019 Expansion", "label": "Five Eight Five Eight Horton Street Building Lease and Two Thousand Nineteen Expansion [Member]", "documentation": "Five eight five eight horton street building lease and two thousand nineteen expansion." } } }, "auth_ref": [] }, "fdmt_FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5858 Horton Street Building Lease and 2024 Expansion", "label": "Five Eight Five Eight Horton Street Building Lease and Two Thousand Twenty-Four Expansion [Member]", "documentation": "Five eight five eight horton street building lease and two thousand twenty-four expansion." } } }, "auth_ref": [] }, "fdmt_FiveNineEightZeroHortonStreetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FiveNineEightZeroHortonStreetMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5980 Horton Street Building Lease", "label": "Five Nine Eight Zero Horton Street [Member]", "documentation": "5980 Horton Street." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r821", "r831", "r841", "r873" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r821", "r831", "r841", "r873" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r821", "r831", "r841", "r873" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r821", "r831", "r841", "r873" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r821", "r831", "r841", "r873" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r854" ] }, "fdmt_FundingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FundingAgreementMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funding Agreement", "label": "Funding Agreement [Member]", "documentation": "Funding agreement." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and Fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "fdmt_FutureSalesBasedMilestonePaymentExpectedPaymentsMultiplesOfActualAwardReceived": { "xbrltype": "pureItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "FutureSalesBasedMilestonePaymentExpectedPaymentsMultiplesOfActualAwardReceived", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected payments multiples to equal actual award received", "label": "Future Sales Based Milestone Payment Expected Payments Multiples of Actual Award Received", "documentation": "Future sales based milestone payment expected payments multiples of actual award received." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r79", "r661" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r79" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Public Offering", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r278", "r279", "r280", "r435", "r439", "r444", "r584", "r586", "r666", "r726", "r769", "r1078" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r279", "r280", "r435", "r439", "r444", "r584", "r586", "r666", "r726", "r769", "r1078" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r172", "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r396", "r398", "r399", "r400", "r603", "r764" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":

"Provision for income tax", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r120", "r133", "r187", "r188", "r204", "r212", "r222", "r387", "r388", "r397", "r575", "r764" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "terseLabel": "Accrued and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r516", "r916" ] }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDerivativeLiabilities", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of derivative liability", "label": "Increase (Decrease) in Derivative Liabilities", "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [ "r916" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r901", "r916" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "terseLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r916" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "fdmt_IncreaseInSharesAvailableForIssuancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "IncreaseInSharesAvailableForIssuancePercentage", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in shares available for issuance percentage", "label": "Increase in Shares Available for Issuance Percentage", "documentation": "Increase in shares available for issuance percentage." } } }, "auth_ref": [] }, "fdmt_IncurredExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "IncurredExpenses", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Incurred expenses", "label": "Incurred Expenses", "terseLabel": "Incurred expenses" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r821", "r831", "r841", "r865", "r873", "r877", "r885" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r883" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r813", "r889" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r813", "r889" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r813", "r889" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r204", "r211", "r222", "r740", "r915" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r620", "r622", "r623", "r625", "r627", "r689", "r691", "r693", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r800" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r620", "r622", "r623", "r625", "r627", "r689", "r691", "r693", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r800" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r113", "r136", "r229", "r230", "r451", "r452", "r1074" ] }, "fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of stock options and warrants.", "label": "Issuance of Common Stock upon Exercise of Stock Options and Warrants" } } }, "auth_ref": [] }, "fdmt_LeaseCommencementDate": { "xbrltype": "dateItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "LeaseCommencementDate", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r473", "r900" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r473", "r900" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "terseLabel": "Total", "totalLabel": "Total", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r466", "r778" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Components of Lease Expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1062" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease extended term date", "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r91", "r472" ] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Weighted-average discount rate", "verboseLabel": "Operating lease, discount rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r777" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [
"http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role":

{ "terseLabel": "Lease existence of option to renew term", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r465" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Maturities of Lease Liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1063" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments", "terseLabel": "Future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r471" ] }, "fdmt_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining six months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1063" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Amount representing interest", "negatedLabel": "Less: Amount representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease option to renew term description", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r465" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lesae term extended period", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r473", "r1060" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1061" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease initial term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1061" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r61", "r62", "r63", "r64", "r65", "r66", "r67", "r171", "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r411", "r414", "r415", "r453", "r636", "r735", "r808", "r957", "r1065", "r1066" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r75", "r110", "r564", "r779", "r919", "r950", "r1059" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r63", "r140", "r171", "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r411", "r414", "r415", "r453", "r779", "r957", "r1065", "r1066" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "fdmt_LicenseAgreementWithUniversityOfPennsylvaniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "LicenseAgreementWithUniversityOfPennsylvaniaMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement with university of Pennsylvania.", "label": "License Agreement With University Of Pennsylvania [Member]", "terseLabel": "License Agreement for sCFH with University of Pennsylvania" } } }, "auth_ref": [] }, "fdmt_LicenseArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "LicenseArrangementsAbstract", "lang": { "en-us": { "role": { "label": "License Arrangements [Abstract]", "documentation": "License arrangements." } } }, "auth_ref": [] }, "fdmt_LicenseArrangementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "LicenseArrangementsTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "License Arrangements", "label": "License Arrangements [Text Block]", "documentation": "License arrangements." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "fdmt_LongTermMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "LongTermMarketableSecuritiesMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Long-term marketable securities.", "label": "Long-term Marketable Securities [Member]", "terseLabel": "Long-term Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and Equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParentheti ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Axis]" } } }, "auth_ref": [ "r227", "r751", "r790", "r794", "r960", "r1077", "r1079", "r1080", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1106", "r1107" ] }, "fdmt_MarchTwoThousandAndTwentyFourAdditiionalPublicOfferingSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "MarchTwoThousandAndTwentyFourAdditiionalPublicOfferingSaleMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {

```
"documentation": "March two thousand and twenty four additiional public offering sale.", "label": "March Two Thousand and Twenty Four Additiional Public Offering Sale [Member]", "terseLabel": "March 2024 Additiional Public Offering Sale" } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAggregateFairValuesOfMarketableSecuritiesWithUnrealizedLoss
], "lang": { "en-us": { "role": { "label": "Marketable Securities", "totalLabel": "Total marketable securities", "documentation": "Amount of investment in marketable security." }
} }, "auth_ref": [ "r111", "r909" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MarketableSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Marketable Securities, Current, Total", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r909" ] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Marketable Securities, Noncurrent, Total", "label": "Marketable Securities, Noncurrent", "terseLabel": "Marketable securities, long-term", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r909" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "MaximumMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r341", "r383", "r433", "r515", "r583", "r585", "r593", "r628", "r629", "r690",
"r692", "r694", "r695", "r699", "r724", "r725", "r744", "r748", "r760", "r770", "r771", "r775", "r776", "r791", "r959", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072" ] },
"fdmt_MaximumUnrealizedLossAtIndividualInstrumentLevel": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"MaximumUnrealizedLossAtIndividualInstrumentLevel", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Maximum unrealized loss at individual instrument level", "label": "Maximum Unrealized Loss at Individual Instrument Level", "documentation": "Maximum unrealized loss at individual instrument level." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r857" ] },
"ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r857" ] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
], "lang": { "en-us": { "role": { "verboseLabel": "Minimum", "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r283", "r284", "r285",
"r286", "r341", "r383", "r433", "r515", "r583", "r585", "r593", "r628", "r629", "r690", "r692", "r694", "r695", "r699", "r724", "r725", "r744", "r748", "r760", "r770", "r771",
"r775", "r791", "r959", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r876" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu
], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r983" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r884" ] }, "country_NL": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "NL", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Netherlands", "label": "NETHERLANDS" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Domain]" } } }, "auth_ref": [ "r227", "r751", "r790", "r794", "r960", "r1077", "r1079", "r1080",
"r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100",
"r1101", "r1102", "r1103", "r1104", "r1106", "r1107" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r858" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } }
}, "auth_ref": [ "r83", "r84", "r85" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss",
"verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r78",
"r85", "r112", "r138", "r155", "r157", "r161", "r171", "r178", "r180", "r181", "r182", "r183", "r184", "r187", "r188", "r195", "r262", "r288", "r289", "r290", "r291", "r292",
"r293", "r294", "r295", "r296", "r404", "r407", "r427", "r453", "r569", "r658", "r679", "r680", "r806", "r957" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" ],
"lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total", "terseLabel": "Net loss", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r165", "r180", "r181", "r182", "r183", "r190", "r191", "r196", "r199", "r407" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label":
"New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description
```

[Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r857" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r821", "r831", "r841", "r865", "r873" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r848" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r847" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r865" ] }, "fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "NonRefundableLicenseFeePayableEveryYearAfterExecution", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties", "label": "Non Refundable License Fee Payable Every Year After Execution", "documentation": "Non-refundable license fee payable every year after execution until sales of a licensed product are made and royalties paid." } } }, "auth_ref": [] }, "fdmt_NonRefundableLicenseFeePayableUponExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "NonRefundableLicenseFeePayableUponExecution", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable license fee payable upon execution", "label": "Non Refundable License Fee Payable Upon Execution", "documentation": "Non-refundable license fee payable upon execution." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r884" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r884" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r80" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "fdmt_NumberOfCapsids": { "xbrltype": "integerItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "NumberOfCapsids", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of capsids.", "label": "Number of Capsids", "terseLabel": "Number of capsids" } } }, "auth_ref": [] }, "fdmt_NumberOfInstallmentsToPayActualAward": { "xbrltype": "integerItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "NumberOfInstallmentsToPayActualAward", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of installments to pay actual award", "label": "Number Of Installments To Pay Actual Award", "documentation": "Number of installments to pay actual award." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r741", "r927" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r737", "r743", "r927" ] }, "fdmt_NumberOfWarrantSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "NumberOfWarrantSharesIssued", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrant shares issued", "label": "Number Of Warrant Shares Issued", "documentation": "Number of warrant shares issued." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office Equipment", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party expenses", "label": "Operating Costs and Expenses", "totalLabel": "Operating Costs and Expenses, Total", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r116", "r736", "r926", "r928", "r929", "r930", "r931" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost", "verboseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r467", "r778" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Present value of future minimum lease payments", "verboseLabel": "Operating lease liability", "totalLabel": "Present value of future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r464" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current portion", "label": "Operating Lease, Liability, Current", "verboseLabel": "Less: Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r464" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, long-term portion", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Long-term portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r464" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, right-of-use assets", "label": "Operating Lease Right-of-Use Assets, net", "verboseLabel": "Operating lease right-of-use (\"ROU\") assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r463" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Amortization of right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r917" ] }, "fdmt_OperatingLeaseTermExtendedExpirationPeriod": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OperatingLeaseTermExtendedExpirationPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease extended term period", "label": "Operating Lease Term Extended Expiration Period", "documentation": "Operating lease term extended expiration period." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation":

"Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r470", "r778" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r469", "r778" ] }, "fdmt_OptionExerciseFeesPayableToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OptionExerciseFeesPayableToRelatedParty", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option exercise fees payable to related party.", "label": "Option Exercise Fees Payable to Related Party", "terseLabel": "Option exercise fee" } } }, "auth_ref": [] }, "fdmt_OptionExerciseFeesPayableToReletedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OptionExerciseFeesPayableToReletedParty", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option exercise fees payable to releted party.", "label": "Option Exercise Fees Payable to Related Party", "terseLabel": "Option exercise fee" } } }, "auth_ref": [] }, "fdmt_OptionExerciseFeesPerSelectedCapsidPayableToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OptionExerciseFeesPerSelectedCapsidPayableToRelatedParty", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option exercise fees per selected capsid payable to related party.", "label": "Option Exercise Fees Per Selected Capsid Payable To Related Party", "terseLabel": "Option exercise fees per selected capsid" } } }, "auth_ref": [] }, "fdmt_OptionsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OptionsToPurchaseOrdinaryShares", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase ordinary shares", "label": "Options To Purchase Ordinary Shares", "documentation": "Options to purchase ordinary shares." } } }, "auth_ref": [] }, "fdmt_OrganizationAndNatureOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OrganizationAndNatureOfBusinessLineItems", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization And Nature Of Business [Line Items]", "label": "Organization And Nature Of Business [Line Items]", "documentation": "Organization and nature of business." } } }, "auth_ref": [] }, "fdmt_OrganizationAndNatureOfBusinessTable": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OrganizationAndNatureOfBusinessTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization And Nature Of Business [Table]", "label": "Organization And Nature Of Business [Table]", "documentation": "Organization and nature of business." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompany" ], "lang": { "en-us": { "role": { "terseLabel": "The Company", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r59", "r102", "r595", "r596" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r62" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Noncurrent, Total", "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r144" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfComprehensiveLossUnaudited", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain (loss) on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r153", "r154", "r261" ] }, "fdmt_OtherImpairmentChargeRelatedToMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OtherImpairmentChargeRelatedToMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other impairment charges related to marketable securities", "label": "Other Impairment Charge Related To Marketable Securities", "documentation": "Other impairment charge related to marketable securities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount due to related party", "label": "Other Liabilities", "totalLabel": "Other Liabilities, Total", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r108", "r557", "r632", "r633", "r808", "r1076", "r1109" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other liabilities, noncurrent", "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r81" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r857" ] }, "fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "OtherRisksAndUncertaintiesPolicyPolicyTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other Risks and Uncertainties", "label": "Other Risks And Uncertainties Policy Policy [Text Block]", "documentation": "Other risks and uncertainties." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r819", "r829", "r839", "r871" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r822", "r832", "r842", "r874" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r822", "r832", "r842", "r874" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "verboseLabel": "Exercise of Overallotment Option", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r846" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments Of Stock Issuance Costs", "negatedTerseLabel": "Payment of ATM costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "totalLabel": "Payments to Acquire Marketable Securities, Total", "terseLabel": "Purchase of marketable securities", "negatedLabel": "Purchase of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r934" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Acquisition of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r82" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r856" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r856" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r848" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r865" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r858" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r847" ] }, "fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption": { "xbrltype": "percentItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of equity interest upon closing of first qualified financing at option.", "label": "Percentage of equity interest upon closing of first qualified financing at option", "terseLabel": "Percentage of equity interest upon closing of first qualified financing at option of UC Regents" } } }, "auth_ref": [] }, "fdmt_PercentageOfEquityInterestsIssuedAsCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "PercentageOfEquityInterestsIssuedAsCommonStock", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of equity interests issued as common stock", "label": "Percentage Of Equity Interests Issued As Common Stock", "documentation": "Percentage of equity interests issued as common stock." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r849" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r893" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r848" ] }, "fdmt_PotentialCashPaymentUponAchievementOfCertainLateStageDevelopmentRegulatoryAndSalesMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "PotentialCashPaymentUponAchievementOfCertainLateStageDevelopmentRegulatoryAndSalesMilestones", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones.", "label": "Potential Cash Payment Upon Achievement Of Certain Late Stage Development Regulatory And Sales Milestones", "terseLabel": "Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones" } } }, "auth_ref": [] }, "fdmt_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants.", "label": "Pre-funded Warrants [Member]", "terseLabel": "Pre-funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r69", "r301" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r69", "r638" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r69", "r301" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r69", "r638", "r656", "r1110", "r1111" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r69", "r560", "r779" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r911" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails", "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs", "label": "Proceeds from Issuance of Common Stock", "negatedLabel": "Issuance of common stock upon public offering, net of issuance costs", "terseLabel": "Issuance of common stock for the offering program, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "fdmt_ProceedsFromIssuanceOfEmployeeStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "ProceedsFromIssuanceOfEmployeeStockPlans", "crdr": "debit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock - 2020 ESPP", "label": "Proceeds From Issuance of Employee Stock Plans", "documentation": "Proceeds from issuance of employee stock plans." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Issuance of pre-funded warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "fdmt_ProceedsFromTenantImprovementAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecculartherapeutics.com/20240630", "localname": "ProceedsFromTenantImprovementAllowance", "crdr": "debit", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant improvement allowance", "label": "Proceeds From Tenant Improvement Allowance", "documentation": "Proceeds from tenant improvement allowance." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r224", "r517", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r727", "r749", "r789", "r791", "r792", "r795", "r797", "r955", "r956", "r960", "r1077", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1106", "r1107" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.4dmolecculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r224", "r517", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r727", "r749", "r789", "r791", "r792", "r795", "r797", "r955", "r956", "r960", "r1077", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104",

```
"r1106", "r1107" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "negatedLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income
(Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion
attributable to the noncontrolling interest." } } }, "auth_ref": [ "r138", "r155", "r157", "r166", "r171", "r178", "r184", "r187", "r188", "r262", "r288", "r289", "r290", "r291",
"r292", "r293", "r294", "r295", "r296", "r404", "r407", "r409", "r412", "r413", "r427", "r453", "r552", "r568", "r607", "r658", "r679", "r680", "r765", "r766", "r807", "r914",
"r957" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived,
physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r472" ] }, "us-
gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and
Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal
conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [
"r90", "r126", "r131", "r132" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-
us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
"totalLabel": "Property, Plant and Equipment, Gross, Total", "terseLabel": "Total property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation":
"Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples
include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r91", "r142", "r567" ] }, "us-
gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } }, "auth_ref": [ "r472" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel":
"Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "totalLabel": "Property and equipment,
net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and
amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to,
land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r472", "r553", "r567", "r779" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule
of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal
conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including
composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used
in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of
furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r91", "r472" ] },
"fdmt_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "PublicOfferingMember",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"documentation": "Public Offering.", "label": "Public Offering [Member]", "verboseLabel": "Public offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r846" ] }, "ecd_PvpTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r846" ] }, "srt_RangeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParentheti
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r327", "r341", "r374", "r375", "r376", "r383", "r433",
"r489", "r498", "r515", "r583", "r585", "r593", "r628", "r629", "r690", "r692", "r694", "r695", "r699", "r724", "r725", "r744", "r748", "r760", "r770", "r771", "r775", "r776",
"r791", "r800", "r953", "r959", "r1055", "r1068", "r1069", "r1070", "r1071", "r1072" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParentheti
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r327", "r341", "r374", "r375", "r376", "r383",
"r433", "r489", "r498", "r515", "r583", "r585", "r593", "r628", "r629", "r690", "r692", "r694", "r695", "r699", "r724", "r725", "r744", "r748", "r760", "r770", "r771", "r775",
"r776", "r791", "r800", "r953", "r959", "r1055", "r1068", "r1069", "r1070", "r1071", "r1072" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded
Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r814", "r824", "r834", "r866" ] },
"fdmt_ReigniteAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"ReigniteAgreementMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Reignite agreement.", "label": "Reignite Agreement [Member]", "terseLabel": "Reignite Agreement" } } }, "auth_ref": [] },
"fdmt_ReigniteTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"ReigniteTherapeuticsIncMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Reignite", "label": "Reignite Therapeutics Inc. [Member]", "documentation": "Reignite Therapeutics Inc. [Member]" } } }, "auth_ref": [] }, "us-
gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited
to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate
family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r228",
"r334", "r478", "r479", "r558", "r565", "r631", "r632", "r633", "r634", "r635", "r655", "r657", "r688" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [
"r478", "r479", "r1064" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionDomain", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-
gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r228", "r662", "r663", "r666" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-
```

gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r228", "r334", "r478", "r479", "r558", "r565", "r631", "r632", "r633", "r634", "r635", "r655", "r657", "r688", "r1064" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r475", "r476", "r477", "r479", "r481", "r604", "r605", "r606", "r664", "r665", "r666", "r685", "r687" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r173", "r174", "r297", "r303", "r480", "r499", "r554", "r731", "r732" ] }, "fdmt_ResearchAndCollaborationArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ResearchAndCollaborationArrangementsAbstract", "lang": { "en-us": { "role": { "label": "Research And Collaboration Arrangements [Abstract]", "documentation": "Research and Collaboration Arrangements." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r385", "r1048" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r385", "r1048" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r385", "r1048" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "terseLabel": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r384", "r726", "r740", "r1073" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1047" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r815", "r825", "r835", "r867" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r816", "r826", "r836", "r868" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r823", "r833", "r843", "r875" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSU)", "verboseLabel": "Restricted Stock Units Subject to Future Vesting", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r72", "r99", "r563", "r590", "r592", "r602", "r639", "r779" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r137", "r175", "r176", "r177", "r179", "r184", "r186", "r188", "r263", "r264", "r277", "r394", "r395", "r401", "r402", "r403", "r405", "r406", "r407", "r417", "r419", "r420", "r422", "r425", "r461", "r462", "r587", "r589", "r608", "r1110" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name", "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r760", "r897", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name", "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r760", "r897", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "terseLabel": "Collaboration and license revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r114", "r115", "r204", "r209", "r210", "r220", "r222", "r224", "r225", "r227", "r322", "r323", "r517" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues by Geographic Region", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r88" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "verboseLabel": "Aggregate amount of transaction price allocated to remaining performance obligation", "terseLabel": "Remaining performance obligations", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r129" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, estimated performance period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "verboseLabel": "Deferred revenue expected to be recognized over period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r130" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r130" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "label": "Revenues", "terseLabel": "Total revenue", "verboseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r114", "r115", "r162", "r171", "r204", "r209", "r210", "r220", "r222", "r224", "r225", "r227", "r262", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r453", "r552", "r740", "r957" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r884" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r884" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in redeemable convertible preferred stock financing", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock offering price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetic
], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r227", "r898" ] },
"fdmt_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accrued and Other Current Liabilities", "label": "Schedule Of Accrued And Other Current Liabilities [Table Text Block]", "documentation": "Schedule of accrued and other current liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa
], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAggregateFairValuesOfMarketableSecuritiesWithUnrealizedLoss
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r408" ] }, "fdmt_ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ScheduleOfCommonSharesReservedForFutureIssuanceTableTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of common shares reserved for future issuance [Table Text Block]", "label": "Schedule Of Common Shares Reserved For Future Issuance [Table Text Block]", "terseLabel": "Schedule of Common Shares Reserved for Future Issuance" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables" ], "lang": { "en-us": { "role": { "terseLabel": "Computation of Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r925" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseForEmployeesAndNonempl
], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense for Employees and

Nonemployees by Function", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1052", "r1053" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r472" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r56", "r57", "r662", "r663", "r666" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]", "label": "Research and Development, Contract to Perform for Others [Table]", "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding." } } }, "auth_ref": [ "r385", "r1048" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r348", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Units (RSU)", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r100" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Options Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r100" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r34", "r35", "r36", "r37", "r38", "r39", "r94", "r96", "r98", "r99", "r146", "r147", "r148", "r206", "r301", "r302", "r303", "r305", "r308", "r314", "r316", "r598", "r599", "r600", "r601", "r748", "r896", "r918" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Concentration of Risk", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r25", "r26", "r27", "r28", "r54", "r106" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r809" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r811" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r225", "r226", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r621", "r624", "r626", "r691", "r693", "r697", "r700", "r711", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r728", "r750", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r793", "r800", "r960", "r1077", "r1079", "r1080", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1106", "r1107" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r223", "r225", "r738", "r739", "r742" ] }, "fdmt_SeriesCRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "SeriesCRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series C Redeemable Convertible Preferred Stock.", "label": "Series C Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series C Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r761" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Canceled/Forfeited", "negatedLabel": "Canceled/Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r368" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Issued", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r366" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",

"periodStartLabel": "Number of Shares, Unvested Beginning Balance", "periodEndLabel": "Number of Shares, Unvested Ending Balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r363", "r364" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r375" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r348", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of maximum contributions of employee's eligible compensation", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r41" ] }, "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares available for grant", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Available For Grant", "documentation": "Share based compensation arrangement by share based payment award number of additional shares available for grant." } } }, "auth_ref": [] }, "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDurationPurchasePeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDurationPurchasePeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of duration purchase period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Duration Purchase Period", "terseLabel": "Number of duration purchase period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares authorized", "terseLabel": "Number of shares authorized and reserved for issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r763" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares Available for Grant, Balances at December 31, 2022", "terseLabel": "Number of shares available for grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Number of Shares Available for Grant, Balances at June 30, 2023", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Options, Options exercisable at June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r357" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "terseLabel": "Number of Shares Underlying Outstanding Options, expired", "negatedLabel": "Number of Shares Underlying Outstanding Options, expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r362" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares Underlying Outstanding Options, forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r361" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Options, granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares Underlying Outstanding Options, Balances at June 30, 2024", "terseLabel": "Number of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodStartLabel": "Number of Shares Underlying Outstanding Options, Balances at December 31, 2023", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r355", "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Underlying Outstanding Options, Options vested and expected to vest at June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r371" ] }, "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance": { "xbrltype": "percentItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock outstanding increased annually for future issuance", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Increased Annually For Future Issuance", "documentation": "Share based compensation arrangement by share based payment award percentage of outstanding stock increased annually for future issuance." } } }, "auth_ref": [] }, "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock overlapping offering period", "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Overlapping Offering Period", "documentation": "Share based compensation arrangement by share based payment award stock overlapping offering period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsRsuDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r762" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedInBlackscholesValuationModelToEstimateI ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r373" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Employee purchase price of common stock as percentage of fair market value", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "fdmt_SharedProductDesignatedByJsc": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "SharedProductDesignatedByJsc", "crdr": "credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Shared product designated by JSC.", "label": "Shared Product Designated by JSC", "terseLabel": "Shared product designated by JSC" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares priced under public offering", "label": "Shares, Issued", "periodStartLabel": "Shares, Issued, Beginning Balance", "periodEndLabel": "Shares, Issued, Ending Balance", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r9" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock sold and issued price per share", "label": "Shares Issued, Price Per Share", "verboseLabel": "Stock issued price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodStartLabel": "Stockholders' Equity, beginning balances (in shares)", "periodEndLabel": "Stockholders' Equity, ending balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "fdmt_ShortTermMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "ShortTermMarketableSecuritiesMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Short-term marketable securities.", "label": "Short-term Marketable Securities [Member]", "terseLabel": "Short-term Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r86", "r169" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r135", "r146", "r147", "r148", "r171", "r193", "r194", "r197", "r199", "r206", "r207", "r262", "r288", "r290", "r291", "r292", "r295", "r296", "r301", "r302", "r305", "r308", "r316", "r453", "r598", "r599", "r600", "r601", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r638", "r659", "r681", "r705", "r706", "r707", "r708", "r709", "r896", "r918", "r924" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r70", "r73", "r74", "r137", "r159", "r160", "r161", "r175", "r176", "r177", "r179", "r184", "r186", "r188", "r205", "r263", "r264", "r277", "r318", "r394", "r395", "r401", "r402", "r403", "r405", "r406", "r407", "r417", "r418", "r419", "r420", "r421", "r422", "r425", "r454", "r455", "r456", "r457", "r458", "r459", "r461", "r462", "r474", "r570", "r587", "r588", "r589", "r608", "r681" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r225", "r226", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r621", "r624", "r626", "r691", "r693", "r697", "r700", "r711", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r728", "r750", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r793", "r800", "r960", "r1077", "r1079", "r1080", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1106", "r1107" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r175", "r176", "r177", "r205", "r462", "r517", "r597", "r619", "r630", "r631", "r632", "r633", "r634", "r635", "r638", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r652", "r653", "r654", "r655", "r657", "r660", "r661", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r681", "r801" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r175", "r176", "r177", "r205", "r228", "r462", "r517", "r597", "r619", "r630", "r631", "r632", "r633", "r634", "r635", "r638", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r652", "r653", "r654", "r655", "r657", "r660", "r661", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r681", "r801" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock":

{ "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r818", "r828", "r838", "r870" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock - 2020 ESPP (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r9", "r69", "r70", "r99" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for the ATM offering program, net of issuance costs (in shares)", "verboseLabel": "Number of shares sold and issued", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r69", "r70", "r99", "r598", "r681", "r706" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares Underlying Outstanding Options, exercised", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r69", "r70", "r99", "r360" ] },
"fdmt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfRestrictedStockUnits", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and vesting of restricted stock units.", "label": "Stock Issued During Period Shares Stock Options Exercised And Vesting of Restricted Stock Units", "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock - 2020 ESPP", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r9", "r69", "r70", "r99" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r69", "r70", "r99", "r608", "r681", "r706", "r807" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r70", "r73", "r74", "r99" ] },
"fdmt_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStockUnits", "crdr": "credit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and vesting of restricted stock units.", "label": "Stock Issued During Period Value Stock Options Exercised And Vesting of Restricted Stock Units", "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSUs" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "periodStartLabel": "Stockholders' Equity, beginning balances", "periodEndLabel": "Stockholders' Equity, ending balances", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r70", "r73", "r74", "r89", "r640", "r656", "r682", "r683", "r779", "r808", "r919", "r950", "r1059", "r1110" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStock" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r95", "r170", "r300", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r315", "r318", "r424", "r684", "r686", "r710" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r460", "r482" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r460", "r482" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r460", "r482" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"fdmt_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies line items." } } }, "auth_ref": [] }, "fdmt_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "fdmt_SummaryOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "SummaryOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Supplemental Information Related to Operating Leases", "label": "Summary Of Supplemental Information Related to Operating Leases [Table Text Block]", "documentation": "Summary of supplemental information related to operating leases" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r864" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding", "verboseLabel": "Outstanding shares of redeemable convertible preferred stock", "periodStartLabel": "Redeemable Convertible Preferred Stock, beginning balances (in shares)", "periodEndLabel": "Redeemable Convertible Preferred Stock, ending balances (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r68" ] }, "fdmt_TotalAmountOfAwardUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmolecularthera peutics.com/20240630", "localname": "TotalAmountOfAwardUnderAgreement", "crdr": "credit", "presentation": [
"http://www.4dmolecularthera peutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Total amount of award under agreement.", "label": "Total Amount Of Award Under Agreement", "terseLabel": "Collaborative arrangement total amount of award" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r856" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r863" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r883" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r885" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r299", "r314", "r423", "r450", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r571", "r767", "r768", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r780", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r946", "r947", "r948", "r949", "r1051", "r1054", "r1055", "r1056", "r1057", "r1058" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r886" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r887" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date", "verboseLabel": "Expiration Date" } } }, "auth_ref": [ "r887" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r885" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r885" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r888" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date", "verboseLabel": "Termination Date" } } }, "auth_ref": [ "r886" ] }, "fdmt_TwoThousandAndTwentyFourExpansionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandAndTwentyFourExpansionMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024 Expansion", "label": "Two Thousand and Twenty Four Expansion [Member]", "documentation": "2024 Expansion" } } }, "auth_ref": [] }, "fdmt_TwoThousandFifteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandFifteenEquityIncentivePlanMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015 Equity Incentive Plan", "label": "Two Thousand Fifteen Equity Incentive Plan [Member]", "documentation": "Two thousand fifteen equity incentive plan." } } }, "auth_ref": [] }, "fdmt_TwoThousandFourteenPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandFourteenPlanMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Fourteen Plan [Member]", "documentation": "Two thousand fourteen plan.", "terseLabel": "2014 401(k) Plan" } } }, "auth_ref": [] }, "fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2020 Employee Stock Purchase Plan", "terseLabel": "2020 ESPP", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "documentation": "Two thousand twenty employee stock purchase plan." } } }, "auth_ref": [] }, "fdmt_TwoThousandTwentyEquityIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandTwentyEquityIncentiveAwardPlanMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Equity Incentive Award Plan", "label": "Two Thousand Twenty Equity Incentive Award Plan [Member]", "documentation": "Two thousand twenty equity incentive award plan." } } }, "auth_ref": [] }, "fdmt_TwoThousandTwentyFourFollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandTwentyFourFollowOnPublicOfferingMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty four follow on public offering.", "label": "Two Thousand Twenty Four Follow On Public Offering [Member]", "terseLabel": "2024 Follow On Public Offering" } } }, "auth_ref": [] }, "fdmt_TwoThousandTwentyOneFollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandTwentyOneFollowOnPublicOfferingMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Follow On Public Offering", "label": "Two thousand Twenty One Follow On Public Offering [Member]", "documentation": "Two thousand twenty one follow on public offering" } } }, "auth_ref": [] }, "fdmt_TwoThousandTwentyThreeFollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "TwoThousandTwentyThreeFollowOnPublicOfferingMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Follow On Public Offering", "label": "Two Thousand Twenty Three Follow On Public Offering [Member]", "documentation": "Two thousand twenty three follow on public offering." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r408" ] }, "fdmt_UCAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "UCAgreementsMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UC Agreements", "label": "U C Agreements [Member]", "documentation": "UC Agreements." } } }, "auth_ref": [] }, "fdmt_UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UC Regents and the Trustees of the University of Pennsylvania", "label": "U C Regents and the Trustees of the University of Pennsylvania [Member]", "documentation": "U C Regents and the Trustees of the University of Pennsylvania [Member]" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "US", "verboseLabel": "United States" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Sponsored Agencies", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r733", "r756", "r1075" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasu ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasuries", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r733", "r756", "r758", "r767", "r1075" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r882" ] }, "fdmt_UniQureAgreementMember": {

```
"xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "UniQureAgreementMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1" ], "lang": { "en-
us": { "role": { "terseLabel": "uniQure Agreement", "label": "Uni Qure Agreement [Member]", "documentation": "uniQure Agreement." } } }, "auth_ref": [] },
"fdmt_UniQureBiopharmaBVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"UniQureBiopharmaBVMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetail
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "uniQure", "label": "Uni Qure Biopharma B V [Member]", "documentation": "uniQure biopharma B.V." } } }, "auth_ref": [] },
"fdmt_UnpaidOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "UnpaidOfferingCosts", "crdr":
"credit", "presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": {
"role": { "documentation": "Unpaid offering costs.", "label": "Unpaid Offering Costs", "terseLabel": "Unpaid offering costs" } } }, "auth_ref": [] },
"fdmt_UpfrontConsiderationPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"UpfrontConsiderationPayment", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Upfront consideration payment.", "label": "Upfront Consideration Payment", "terseLabel": "Upfront consideration payment" } } }, "auth_ref": [] }, "us-
gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Use of Estimates and Judgements", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of
estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r29", "r30", "r31", "r122", "r124",
"r127", "r128" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit",
"presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" ], "lang": { "en-
us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable Lease, Cost", "verboseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost,
excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r468", "r778" ] },
"fdmt_VestingOfCommonStockWarrantInReturnForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname":
"VestingOfCommonStockWarrantInReturnForServices", "crdr": "debit", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Vesting of common stock warrant in return for services", "label": "Vesting Of Common Stock Warrant In Return For Services", "documentation": "Vesting of common stock
warrant in return for services." } } }, "auth_ref": [] }, "fdmt_VestingPeriodOfShareAwards": { "xbrltype": "durationItemType", "nsuri":
"http://www.4dmoleculartherapeutics.com/20240630", "localname": "VestingPeriodOfShareAwards", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Ordinary shares vesting period", "label": "Vesting Period Of Share Awards", "documentation": "Vesting period of share awards." } } }, "auth_ref": [] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date
Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } }
}, "auth_ref": [ "r852" ] }, "fdmt_WarehouseLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630",
"localname": "WarehouseLeaseAgreementMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Warehouse lease agreement.", "label": "Warehouse Lease Agreement [Member]", "terseLabel": "Warehouse Lease Agreement" } } }, "auth_ref": [] },
"fdmt_WarrantExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "WarrantExpense", "crdr": "debit",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "documentation": "Warrant expense.", "label": "Warrant Expense", "terseLabel": "Warrant expense" } } }, "auth_ref": [] }, "fdmt_WarrantExpiresYear": { "xbrltype":
"gYearItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "WarrantExpiresYear", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Warrant expiration year", "label": "Warrant Expires Year", "documentation": "Warrant expires year." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputa
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Common Stock Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of
stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r798", "r799", "r802", "r803", "r804", "r805" ] },
"fdmt_WarrantVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.4dmoleculartherapeutics.com/20240630", "localname": "WarrantVestingPeriod",
"presentation": [ "http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Warrant vesting period", "label": "Warrant Vesting Period", "documentation": "Warrant vesting period." } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Weighted-average shares outstanding used in computing net loss per share, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel":
"Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in
calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r192", "r199" ] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails",
"http://www.4dmoleculartherapeutics.com/20240630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Weighted-average shares outstanding used in computing net loss per share, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel":
"Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or
units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period." } } }, "auth_ref": [ "r190", "r199" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and
Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r850" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230",
"Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic":
"942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-
50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)",
"SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r11": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic":
"718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" },
"r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic":
"210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" },
"r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
```

3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph":

"(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":

"41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715-70/tableOfContent" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",

"Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":

"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r896": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1069": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 92 0000950170-24-094010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-094010-xbrl.zip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{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

**M<#A#^$N%%XM#_&P)O6&:$4,O>S\#]XL.B'^(4P(=L[-\2^/V/A%Z@^^6/8CP M=H/AP0&4(0(;JJA<7K>[69QW%L3)G0Y1.73W^Z0QS<7G_>%LC7B",4*=#N1/**
**M/HQA.ML?'@Y&PX/AO*NUG'U/[9\Z"3>\#CM2'RX2"/4WI-:H2NXQ#.?0YHN MXO2H>Y5E)='+"0(RH7X8G&VG,_C;\7K\0$]R'IB=7G\QCHLR)/,&"5%@?-XP**
**MZ:9J=47MGRWNN,NVJ5VWK#+!!8%,VLK=8]T,.S1@-M_IRY7A^V6/1*+T.V#C M28&3[^!ST>&3MQ_!1U:&TZ6%2E5)BX/QCV4X.QS%H\=T]&*+7?[0#)>/D6(:)8IW#]'$,-UIV&**
**<)=EIT(\M$%]H:C3BX<(8;YP@GLHN%FQ MZI. 1XKY'^^F$T2#[)@sEXU&;Q=*]?NU%'.U>OP7$/MU;6X&XS2F^W/)>\2KLR?*4%>X7XY)HY,/JANFT6S&>W_]7D**
**MH7CEMK'N__>FS:WD21IPG\E33N]6V6&8,=]2--CIM;1H]XJ22-5]=C[21:G MF%,@P$(".O;7OQ&)@Q3! P03%^%CTRH0FCK-/Y-/",;??IPFUU\T(6"KJQ7GB(-M?**
**M9[^6EQ+8[Z]2#>8XE?+%QIOR_<:Z\73K6/B]$M]L!N9!\ 1)Z:$R8 1'9G M%>QZ 188L?!N?W*VGQDQ?FI.8]P]0/Q].IKJ8SN:6;3BGY-!K!B>!2M*B:Z7 MT<P9R7LV?? >7%Y?-4O>7P**
**/-L#'@%Z#*V#/QK!G%>$,?@7 MF&%HT ZX?,Z+E6[K2KT+&&J3HDZ'_?S$9I,_5+WZ'?7?5.!\KBJUV5<"ZP!A-DO8R+8;A%F,!S'YB+ M'-%ZW#E+'M@HLZD [J!YF[P68U'4OO,_TMMKB9M9R92-**
**=;@A=OQ7APXK"KT-J M/P."H=/-(7>ZV8.V,!_?OVI+M+]}}}NKZL.K?SS_\/+-VW]4K]}}^._\$?WR M[MW_+7]__.WY;Z]^??7VMX^/OVW,8DKM4.I2*6#\5)PHQOYR]4U=S'*&:=O$**
**MD+9)Y]-[ 2&>#T?C:CBH7@]'9Q7!Z+_:.HNVGM:Z_&JSB=(?#O^N MIYVVYP5:\CT^C@;EV^%D5+E)DUV7RRE%U4]V[C\16.\"WKERJE>\L5/S_N MW"LE?+^6?**
**L>EE&]^6!8-@_*DMB5@_646X8_?SO.?EZIP7G[O&}\]J9X/OE^9 M4IEV#%5I[]KV%RP=#4>Q!:/9_%"<)B_B>#@]^FI5,JN:ZLQ^KURL2F6OTM^\ MM#&\9?E.JC=YLX=GL?**
***VB7FNWX>3_+&TRY7W+N]OH+/>0:3 MTI:QJ>YTSZ]^^WEH^U>_JPM]+[TJ[\K5KQ94 M=?5"H;JE[T8QU,L#.!\69JJ71W$^G#9ACTLC:6+\8^F[T^N69YSA(BZ]\FO=**
**M7WK;U_+S^7>%MH>M_[>I,PS846&8/;$V+4\L2'DVH_;+3,>9C>IY=_(I*29R ME7>^4%G+1=-OQJ.\M(4AIU68!O'S]++#PM/EX$UMR;,KEZ0#:MN6CM@'7)4({**
**M*=USF]NX8MZKMI?9^H+QVM:?+4_U+M]KR^GDIP_NMWI/]*QN5H2+=P_U,RZ@ MV&_'V+XJP\^3^%Y MH8ZJ=_S^TJ:;]**
**I7^CS>5IXTXTF89[4MOAR75^<;IQPRE[I7+K=2D;]$1.!> M^U\EVO\J,OT[+WO[7S;[FU#1OJ5\))=4H1\-"R!Q(/%+)#[M+YZA./^^I9X0 MBWMW3N%%BA85:HERRZU?**
**BQ0:Q<^3K$,,1]\K.QF?#F=)G$6!&I6LTR)PAEGY M*[I8_K94GRCTGNEL-/R2!_?(R/0A<32@T>MI} )TWPR^%-WRUIY1;^FFF3[UY"W*F3?U#;5NV=7 M@2B!*%+_V]*C7/3-L-**
**=F/AQ,0M#'6RI8Y@!<>G^ M9]4CHSV0VYLAOY$=-/TIBJBX094Q;RY>0'T!?1U)WT5X6E=I[Q M]TNV:B&CL_RA_>.RE3LCK0NQ>U6QFUK'11'L;C76TLCP]W43]N;ND OHAM_**
**MS43]U;,!EU86%W+O6Q?[M1=YH,6K_CW#RY"+A=]DK. M[QK$8N#84?N$F==S%GX[.XNC$IDK_J/KV0&(%(AT%1$_*E&KJ0OR$4@%^WQ&L=C$?IY-OZT^AH7 MZNX\( .T"**
**{1[^W._(BVB.EI^L;7>GR:8;$>92,E3Z&>>K?S+P;33.\Y*8 M KWBO@3%$4AQ+2D^CUU_'@V_9C);Y'/-4IF"-K<$HOY07ML[[N@T^*YG)KT M5TRD)HZ^9- ]'3:+5P#) LG>1;+Q6}**
**{[UE4^=2HMLEPO.9DN918M?$^_#]K$ MN;:YV2RA;SB*)5G##R>#K!0 8@+YK8:8TT333^GRF#3P?Y=]5?Z^'ETVG7O5FX$]ZU?-F M'/.3F^H?^;4EDS1/Z=+-ER:#^KZ)AN'IX?**
**FI'9[;Z^\F_3EJ:?_$]+[VO7M=N M-"P]MUZ7@[BSQ(\7KU__?"U2VW&>40'\Q72&H]DP+W%:[P&R M>M. B0>8F(J?*(0SRK?6^NF5Y.?O[A]%U&X<\C>]8LW +S,^:/[9-'**
**M$.RF]=&Y%VFJ"K1&^A^QS7_.TJ(\])?-_;H]\9^IN=5,R^GL:=6"IL3"(+H* M5+<23%KO)YG6OL^5S'E%A6*2?[:C%A"++W+0EIOP]KP>MZ<^V@.79XL3_X/2 M/*/U)!4M979H,E9,8_**
**9B!&(<14(0+,Z2ENB N@'Z.=N^OFAU,\%?K7J8):, MPU"%Z=FA14[2GY.\(>E[J8.3AJDJA.7Z++[?%B09*_:VJ'M8_[Y[N\J^=^**
**M?'(#0:Y7!XKH]0W;G92"NJ,>2PDZ%+X(I3[45&LI%PH%$?6LJ;+(&17'QN7] MZEV(GEX;;_:VF0F7K%G_3Y5SGFG+M_Q8PFGARL%:?):C(I;^%+269MN'N?N**
**MNZLC:4L6I5EJ7"EJ=\X1)9\7DOD\L2.,YS\YM(S5+2;I<'FIXI4#'H!P_^S+L M?XG5'X/AU^D)C\E@^KETU6M*X-"4=\L%IVHIC5P9OWV+C(_Z\L%G_)XOP]G MYD7KM!SV3ZKG^?>S)?**
**$TSWE0E96*'K'+ M>-X,N_/-QUQN=?,25,4BJ8K/S\?6M+YZVR(71S7RV]KS\-?1PP7%7WL MV, $GMJUR6,=?,KK-TV$*5?@?PR7>,&91KW$]N<+L\/YEWL(7JY%/M-_%H*
**M=]VV"B?5^X5!6;?% >[9_3J6\EV+S^>Z7.AU CKVZ^]M-G+8UOC*'%_-L]$\K810ICDG[ZCQ.*_U*6*TUT#;=7"]I"2;4K9ME(IJG@N M!QG?+O4^F&4W-Q?IS?.$E"G/G53_WW!2S8I?**
**5:?#K_DYHUX[BOR@]K[9DK=V M4^&S,H\0&S^JW>)AHW8IVDNE.%8YS1>GE)CAIXV3MO]=Y!%^?/6B:EUS]UW?**
**M@ROM^BCKU<*D5IX4Y5W[UZ&X\.../G_;5B)^\,;UNP^_/O_MS;NW#ZGLV,GHKI9Z MW####+^R_=LOJMG?WI2V[4,-VN6-OVB[I)}6+8;&(BV'X^\!.0IMF_'KA]/DX**
**M'^NVJW/>U;3ST1'-'A01YR^K7X?]Z">EY.PT+S=.QK6?I>8>XHX\6"EL6=C/ M>>>23L_WB7_C4G,:X6_Z]X-N_V_[.MZ9UNGQL%Z7Z:0$D/^];GG>_;-EEJ'67M*J"N866U'7>N**
**M"SC8R7CX,*:KEA$4U;74[,ZWHVQTE)K4J?X6P[.%,_T$_V7^@_8TP7D3GS:Q M%,@>>+X(-TPY'[,.?7.TE]J5NZFE(^>G\]\^6NX%-7R?EB3'L+S-M_)H;R(FD MMUV^[1H]T?**
**K69^_\O=>U8MM,\[4KW:JFE'L=W>Z3#V(]=K0=#?U\]\KPZV+ MV6:**5?^]H0^@9V'^=7\@T0_F/?^,<]_UMZFY90<\C672,,R-,Y2NC]- E7 M6JE_3@:Q8KBW20C:[/KL'6-T-**
**5W@BQWRQ! Z'!BD\R)N M.X^O%^_EL%^':HX*^\"#F\4IBBE?CVYN6;TIV*V%^NW=ZQU!/(=.*OE+ :< MU;5VT,JE9?7**
**YT5)OE/U("_8+F3C9HGR>=/$<0.*PMKFR@4G;'(MVJ#:'@FR MHU\ H/VCW?I'O@#WE[4,,,7W7-:NEJ T.T1D6Q'[%' &< 9P!F@?.!]HOV-[ M=EF<7C[J3:L'KTOE MI[;E3OC;D]>?**
***#;62TR1H5>B6,,#=]R8B]B>Y)6PL@C_5#3'1[\N*3 MISZ%$!QBE.3?$$&1E<0CK@.QK" HWA2#>Q9GL*D09^M/7]:F/7Y()3_O+K@ MU.?C%W8T^EX//O_+]B?Q2:F7/GW+**
**[Y]^__@R2]:\,_DI[$D5HJ_/;+_YVQ.4 M_YJ>$_O;D_K;^.E@<1KP,#->L1 6U]U2WYM^TI-CR]%/QG5I3 12*F#EE[[ M5$J.1C@%,:TS7""+F4'<.8.LUQXF1OK(021<*^@5_?**
**ERPY\SKW9%(8H+V MM!8@D@##P8+L!\&X"/&*-LI1D?5I$ASA6 IFD%8H:&\U+94'}#_%MD%+=2:F[LV4/E(W7)(A[90_ M)R1UE@OE(XX M2MR%);$]?-4]}B3**
**Z[[[_:GNP.AH'W+X1L=OP]+0!^P+\(*!%^P>LBMAS'", M&OG$->*!V:SG.XE*H-IBQ[,PZL3MOPDI)03M2<; \040!]L-$'<3Q'D2J K4**
**M(${4R#G!7+.)20H5MHKRH+H).UF$Q!'C>P)#>>DU6_?MKZ-5'Z+:&VZ3'_J M#TOGBC@Z_D"\@7DRQUIG33Q0 **SF85FFN.C/0164&##*TE%P9;50XXZBY-,+ 6^J=R9**
**MSB&/X)X1D#ZS=4_VL:C8[T>E>>_X^{1=ZY^3NFVOVZL&<0RB!D0-B)K;@ZLF M.]1:"42%Y8CKP++.F;"V2&%-&(I62LFZ25Z9<^KYO!^/G@_!JSJAO8V>"1O<4 M'!<%P(/M!L"**
**[Q5WM$O%=Z19O\L$;,?UX'/5C[:)5L!82J/&$[!X][I*4LP!#8KM^@)+]E=\=#NSJFPTQ/FPWF M$CYJ2(5VA9MJ#?Q+;5W=;\]IM.GN'\=#_\=I?D8<-?_[?^EL9C^K2J+9^#NT**
**M=X/V;M#>#6@?:!]HOV/WW*.4QRLM\Q]?>YU4=-]6Y_5ZJ&8"?]Z#3L_?!A[L?4+4%_ZSVUE(;,B3A_\GE".3I$+1 M>*6YT):F)?_L6B&O&8^G{)HQRUZ>IS!R6^**
**O(/=;H"\+4*>MYQ3RP1R5BO$ M?10H(YU%,FENI$H8D]1)2&JSD">@D-SV,]%'!;]1!1]-8KBF%]D]G&4@I!X] M@X)LNJ-A@#""'>YDU<4L8XD8I9)@@2$?O V<^"=Y-**
**!MJ47R\%E#MN(49[2D%M M$D [V&Y NYN3PYR-(:6$@B4&\6@5LCA89*)4V##K).FDM=<6T X3J'$*#O$] MT<9?QA0S?8=J%+_$P00 5WQ,] M_&H%U4N^\-**
**['07X^'4J!?$%=4J@3LG&11[5- 7)!,K/,XAK88KX8LAD%=X) M3;U9[B;_\$E)U9]V%$<,-)('0P"0%9!UY\C*I'%,&(42HQYO,G2Q"1D>;!&**
**M!>%Y6JIQ_?"*KYM#5K[!BJ^/&%FWZO2GN@-CHWW(X1L;T^)1D'8#CC!PA-V[ M/X/W3I/$?8QRR[&,Q))GTT#P[570BI)EAQAZU@%FXM FQ['X/D"F(/M!IB[ M$>:4MH;**
**[Q)!6UB!N/$/&<<((L=99()J4.2T'.=53TS<&<{AD!)WV@ .N6$F?: M_F;5,(&S'F0-R)I[R1J+8S2&9$$1&48\1(NLU5G#)EAJ8DQRN),,"[?&EKOO M9M]C!'J? ?**
**3!=@/TW:QF)Z21HHA%AR5*N#$_.;3:CJ'/J,H M !^T0-N4XCVJO]AQ_>4B2>,.&J8@:1X]?X&DN2-K'1MJI'$H\P/Q\D5OW5 M(4E"+/>&X-"%DGW!GI=<.YU+&*9!P@#@P78#X-VER?**
**HT04HDC+BT#IFL M4R,7\X^(PR3IR!1QMD#\B>U62/MX[+ M(! +-"*>?$*.9V&2O(D.FV"R6KW!U/"N?=FXQ^4&&P@?%QL ZAW5=A\-ZFEO ML@(M,8J49(W;)XJ<-**
**AAIY8TQCA'CV0;3NKM'/=(3%/P,X,G>E-K=5C^$]&LX M?@3'C[9:U5=)}DW(@HD:C7AD6>80D9!@(FO]-.H7H)BN) M/>*#1X"I@*F J9UB:@P\Z^L\(!RY0%Q;@S1G'%$CL= B>LJ[T?**
**TWCJE\@TE[ MCQA3P1G?Z>%,L I @H$$VZKWBFEK.:>^>S1)\E%:%9J/DMF.#W9V M%1LF/:442"VP! !' 4=WCJ-::I>L0Y(A7CD"AF+)2(,2V^L#RGJCD^.=H6C MM(?**
**E!OW]CQA'.XX)7$N&^]HX?'G]KMR-FNA1_0V=UIFF!T]??\]FLL)4*41# M:2M& D$V:9GU#6:<8]8EI^]\2.(Z>"\D\IH5W2-RV(RTI4M9XC2%:!A;PU"Y**
**ML:/Y\.RL'I_%TCRUM&XJ5^K!YSCPF0&KG]X.QI$R/R]HXJK_0/?G<^C^#-V? M@?9AZX]U 3IV$QZ4HM"IF_#C>.C_.!WVLT;9M#T^]220B11E'7$:/"$D***
**M28=Y=)%S)DP788W%A%O%Y+T=O1M]'-MQ#/^R_4E\'T#OM].VIF=U!X[I2\?7V'^^Z&QC5:2,(M1Y85-PDW#+GH#<*8 M4E,JV7G52:WW<3/GV22N:**
**[BW0W^S(W1_A2.SNVH^E+FWJMV1/J:6LV<=[INO/)$=S+NUW^MS>$.YU&91>3K.RX^N=D M$"N&>Q7%E+<.T)?1QS,71O4C!;?LV:[HW+%('3>EB%",B#MID:/&(B$DULK9**
**M8&DG#0FO(X4W33.Y-QD47W8AA:)3-'%P(_]:JKD+% 7%=89N4HZ2Z/P/%]$$ MIYPF2Z?HNB+Q33<3/. MY%L//F]HTT*,+!F,L%49=$7B&9>X0Q1[S%-I_*"7BOEUM6D=3FXP7**
**6/]@NQ MZI9F6W :7]S$BN@%V1%POA'.-]XJ9S/]:F$Q0593D56N#'(&FYBA+;@H \$L MT.YQN[4?H,_OGA$]8-Q1;??18)R6+#G)/=(X0Q7761^S#BN4?$P^8,:=VX#. M#1BW9]E9T-**
**6W$_6)$T-![MV 0<6&+8T(*EDUD&$4\B%;))9P76D.&<++_E_26 M18H,E]GNF'\W&NJ5Q*44C\S&=G)Y(B+/RU#CM0T6TRBZ*2Z_T\F\W_>]{$N, M>8$S?$9$9<8(R#=#63E-(?6.%-**
**SQT2_)<^O5,03Z3B*GAG$%65(QZBS&2*E M)"%*3SHQ0S8Y,X;![_OPDK[<"IW_EZW0]! /EB+-?41!6)*8+D]-D)XAO$>5 MV!OR+K2[LP"%IA23O*4TZ^H\BD*HA629Y29C;5 D;02+-**
**TJH>4*1:D50PJ7( MGRSAB60Y(HG(I+2*RG2M5G5/])SUL!(}>FVKFL/U9O>J_(CSZ$M9WCZT!P"_ M#_A];H=HP61B/(M,BK7/4C<;3!G:!/*66F=3<%AWK4L\P.FS+&_!YP/X!ML-**
**M^'9S;5+1".81L>BR54%H0K84*?(V&FVP,RHM57=XH++6);YML,];a1(\9#;O MR*?]\(2Z4*#M5^>V#GDRF8G.Z[M@Q@",01BZ'8QA!,4gLADIVG$\;&5X^**
**M6>MU5(I:U4FKVPLF?9]Y],W@Q91#+TFGSKK<8D5Z#$-W&D ^V&Y OAN1+WF7 M))$!15N:?"MED6,B(]8H(DP1\Q2TO,Z"OC6D$1]UB-, NY!LLF>*,;>3\XF M_9)V4 W:U@)^>);?**
**F6^]G6@^]G_K!I?@9Y!?+]D.55IWSSTXZBHHKQ M&&(6;$ZUMH!)R!J=4=']+Y*S%6>9UTB3L$BZTU;-?7$:%-X,,$O&7# IOX_A= M^LU^6UT\-GE_\J>["FH;]JADY(ITL#]9**
**>@"Z!XTZ&[CA(W3,ZG44=*197A3 MJM0T3$A1R4S4(HGEOHEK&0F;@L3;?25@+( 7?P^-A1!3[>LQR">HCWWL];$? MA6'A&$E1U)?=TQA\WS[2Y++(/- 9@.F'L,F"Z35%**
**(QAZ3!#G$E!7+$ MZ(SI(1*&RZFF3LJ[[ #3B>@Q>GSM:SK%=.B^UFGWM6;MXLH@4$&@/G>[:NHTC MZR++)VP<\B[%<@A0(E,,)A@G V7,L10[*9%VN8KZJY;!NSJ0H'6/\>L.MSYN**
**MJ0:94X"G^T(0@*<7+B&)&:%"H6Q'E)H!S" M#$5<"NN'WTDJ^I2^!'G@[ QN2_8%>(Y=,D'8 M@"V"[P0I4V&'!L$1*$88XCQP93P/2C,40F,I(O-1<**
***MYH&JGC<)MHR9GCY:*R\,K"=FQGYOS9[/YX/S Z?3?-IWI 7#<]I0NT6,>& MN1C+\A2G-Y3G/2W*H6I_LY%SAB*BOKRI$1_,A>*BX-AN-BZ8SRUYGO\VV?1^W9 M!]&X&J9J?!J;F-**
***G/3D(i.%F8/<1!DS^E>F'OF[#*78B')YON']^ V%>A1,5'B:ASTY&SP+=7/> MM]^?EJO/SFTH5.HNN1'J03N2F;V-3U3YYG\]FS;A.W^>O:7^+XB!D@/A6IID? M\72!%=]6!**
***(0EXMX+PKMI&WYL.)%7>?9OV9+3A9NBW9&H|\&F/,*GMO_5?F^> M/?GK8N\6=TY7ON6_&Y;[(:N[59BZN11+KUL=G.=KNK^P]76Z1RX+|/7)B;^L M?AWVHY_T[:C*$):?'B=9**
***G>]ZLW/PAV.AG?5=39QG:T2MH%]GX:GN=E*=+5 M?/KA9,"G MSNV,.H(B[/*R^THJRG#R:QEPK/IJPC&)-OQ.X4G_|O(E/FYVUN\R*1YFW M!N;TV4^NAA*^U$W=6F??GK]Y_?**
***UV,H'T=)R=[:&@N[VAH M?]^8_WP>URR6WD\!OEJ8\G048U:'!^/3IGJ55:NP^)F\'CVM$AO?AV7=.Y8S MP'#'P' ?ZV_ ,AU2(*@->X1AASS=!8U10+$[UI)T4P# VBIO=35=X*QIYZPI**
***M^VL#9X'F#9P%,FOO.0MDUK%P%LBLSLU7<_^SV%V.KYN4C)LER0_O2OQ.XE/0 M$^Z^9JMFHW:U%-]^T)9G!%?#KFK_!#$%?;(VNB18RQ@**
***M1CD7=ND$)F%>!8$UXI8XQ!DFR# ND8[*)^9MO^;++)OEMD^_#\ OP"_#; M'?OJKPC3€]%D%$.<)HE,5 X1G:*FTG!'TM((^$ DS]>0B)PC;F@Y )_R/UHI M%ZSE*=+]@5_*]K+H%@ P**
***#_ "P'X8FZPF2EDK$?;#($B(132IBFP$X.'D5 M@#%U%+,,P%00FO5?:C+V>H:T3)QP+)4C2E9"&{(SMPBA^GR6'.SC]1S MR"-.*@F-/*$%<4\MEAML!7A4W**
***+0>$2;?:302**Q0CF%M"Q! M%9D,LEIY)((SG@MA3=3=9!?MA&AHIZPG- 1H!&F&S 1I7@49/M3$I(>62+AJ@ M08])@()0WH7$L;.VFWR?74.C,#U%-]CXI;BX!:#QB#;**
***J2*&14DL%-111[C+, M!9J0IEHA)3#.F!>B8+Z;5)Q=0R.7/8PI0,,F,VI`;SBAOPC#F)IB%.\P3;D MN^IF7#)TOL"YV,>=E[J#"0?]J# E&*&>*HF'4]'92EN)=5<8!9@%F**
***68#9/8)9PI5E1":$ MK96(6TV1YE8AAQW.Z)4$9[@+O_F6? :RI]0&PX;/%V.WF4Y-N_"TT?A/_]M M.+;];KATK\4D(4A"D(3;=>LPZYRC'%E$.9;22,=8T34).%X)$FET(7W?'&& M?**
***2;ZFJBPK3')?ARP,0 8 5@W2=@I5A:BP-&)GJ%N-(1.8\SQ.9$933"2]>Z M\)=Q"E@9[3$%A7@(!6 %8 5CW"5%Q@UG6@KN"H;K\ YID23"S!(LJ;=*+.4\ MKN,BWQ2P:MR3%( 5@!6 %8!UGX"5&X-#-!))@;/&RDU %A..4HPA6$ZI3$N% MS==QBF*6"7M*065R_S@ ES8<.#K@ TVK MLL:R]Y2DB8F.67#@8Y2Q-BVL= F5-8=E*19"'SW@S\ M\"P6I%A=ZC5Y?**
***_*G%3SA0CZF$U+K5@'_&4#W@'<=0/>Q@ZZAR5KI-"H.!E M9090S#?RCG ?(I:T4V=XYL#749[A 'H N@"Z +H[C7H*F>P9\PB+5A#7%&_ M?+ 2$W#B,XD3I=**
***]T%N\!V!KL8J81Y5+0 70!= -W':[I!14%81EDC1'&/ MBX L)0GIQ+DEB7A*NW6I;PYT)>U1OL%$NP,'W6XSR:'WT:+WT?@TCJJZ)>OJ MIUFB^_ 0_PB:**
***MOGXX][_D#X1[KQOSY_(/PCW?ACGS\0_I%N_.:>/Q2\W$EF MTYM"2+$9SPPQ\#H>L-OCZ+V.6_<"AE*($FN#)$&\7(>S'!FD>"">4!F"%VFI M8?**
***HZ249O!E\RCY;*S%,WX)QK.\]O53W!-UC,YZ@'K 6#OB#;]2&$;6QIMLEGO MAH953H/DA -O*$"(Y,.V9D(DNE!=9)\DPI<&>((\]V RP!{ 'L+>YVF)916,T M**
***Y>/4B&NL4(9U0)*CEN%N4K:=\'(^=<.P1UB/&@:X!{@'FPVXM\KQ4 M-8C0>1J{QQY?81'GSS*&<-$96EH@L2(!X&1PRH@:H2QWFMNXE+RZ%IG4PO***
***MO!T.AC\FD=Z]1O&*QU2/KO0-)/<#Q@/&'X81$Q2)(66DU<&49G)*(J.)0!:8 MC+B2TAAD)T=3.\+,!XP_CJ.3ZY4|\()2:8.U3MEN%>.WF71R!!B_S4QQ:.VTV(M9:Z=+@0L( M5X**
***4!BF\?:DHL P1BXBX=EG"'4K*?XLS15-1C$3J9(K\YWPP:;I6*HG\ :S MD/93%((G" !U/\@#\/6FVCX""\;)0<(&CG@P+L DR_9'MAR2X#QBUTEZ^Z;Q ME?8$Q8"O@*^^**
***KX"O>X2O1$AJ?598,U*1C)6<(A=8<=],P91T5,FE4Y/K>.XW MC:\ED9Y!*!8 %@ 6 ':? -8S[2T5'1%9%%A1? , TF_V,!ZNR^D]=7PJ-KN,V MWS3**
***LJ[AX"#8PZS^(VG[]#:.]_ZP@59/CUN$K1N=^K4@2]Z7NWFLYU^-X@\U+>, ^(HY.]JH MM-PEHY"6-.-[X!C9TCP%RTA")!ML3@7X#O@.^ [X M?HCX;G:{W!.D%,M8[;Q**
***5EB)L-4>BXI4:R3X,(F\5VJ'A,<|!WP'?=\!WP M_?(Y?LQ|"C(AY;A'/.O?R/B,U2PPQIS%D=C826QCD_@N=(^:HXL<']0I@",+ M<53G,2_CJ1W%7N5I4_O*#D(5ZOY0'**
***/(UPUQ)CVAA37#<.+Z$23LG2L#,G8[ MJ8(;(46B&FA$>99$9E,(2^14!-@0PI-8RA|0)P.RRHX&]>!S\SZ./A;H^7L! MGA[E;?X8P\>Q>9<%X. -WTI;MJ?+"0QOBRJZ;]"^(88$(O&ZL#R**
***M,O.L+SCID6,*(XJUY#@;D0*33%RC:CF9RA"C3BX1E407L:=]E8U.""RHJ?D^)\O!T8!L2 PYBWW(AF!T>`EW ML(OYIT(VDA-J0#;":, 39"+(19.,JY2JY4YJY,"WY,#I"9|>Q\4LYVECIO**
***M$"4^>HUFD\OQ:!29K2L6S"@>0TA(QG)@346/#%$4N:0EP<$IU4TUN#ER(\|\" MQ]O)F8NC=ZF5E\V[^_A85CBF$'-9DN+U7,]2*)8$1YCSD&<:2@/B;&ACIR/)**
***M]K).>LGUW.%,9YK$TH0?.%E33GKHVU.?85(8=0@<)-(0ZZ@Q) M%EF2LF&6H11982PR%MOHHXG2V"Z"@+N7.4&8(#5+R!B>A4@V5)%F^+\G,14I M#UPQO<&9;DCF,-**
***UC+,L= BY'B/(') Y(/VAB! YMPH2LB(A@P8*12O#022'% MW>(GI2D9QU?25 YJQ? M6#+_U^;YM!\W"0/W$R?3=]-[90D-YWM-ZG%_F**
***M,^[E=!HKZTM\SPZ^MP&^X3B//[-7E8=4Y]L^CVR_,K>C<35,U?@T-C%SHIV$ M$C@O,!!*F===0I7I@!SZ_/,_#CN-9?GQSLL7%7(<^KB[>TNON0RFA_E+YOFTR**
***M&\UG/$.#88CSW^1QE\,G9X%FHF_,^_?ZT7'UV;D,! MO4OGMNO1<&:,|;GRBRC?_VG&=?H^?TW16Q0'(2//MS+'_(BG"Q#ZMJ*D7F*,.MO2#IF_;"_P!,>95G_9H5.5WD!**
***I0[,HWZVY1'^-3VQ|KOS;,G?UWLW>+.Z"Z^?C6J.?W@RRZ!Y.FJQ+-S\#A=X-G*50RD-UQU8Q MGK]Q-L2V#:B=C(=SXZ",H0B2/.AR,\HJP"'2)7G[+89GTU<1C$_P7^8_\"4[**
***M;R)3Y\N8M;),\?/9MX;R]-E/KN;'?:F;VM7]>OS]Z?SWUV6^M;_C] 3KO\Q$ MXS77R8FX[>IMU_")N?7)\-:MO?66++$1]_RS*;_EIF5RS6'H_Y?)*;_G;Z2C&K#X.QJ=-]2HK+]'Z**
***MYV00*X9IZ!3*O6]F\%9!XJE#C?. OQWCI?\6'\#=NN0 D%MV"...3'I+E", M HK=N9844PZ M57>ZFJZP%G5ED,. LT;^ LD%D'SUD@LXZ%LT!F;.D=+M2* MAK'XT&ZE??**
***_J2P/M5AYAV2++#/&&)<10"58A'I9!U4B$2<'!9<"CCELZB0#O< MQ]=N!? =\!WP_?'ANS98\0S*2#@O,V ;BK1D!B6])&,,4P#M,,%? =\!WP'M?#] ?%JLN';O"<'0#A?P'? =\!WP_0#Q?7?**
***@A!8. M61EQJ4|%D(U"(JHBTP)3BTTG996A'>|>\/$6RB-WG;&W#R&.|.)N{\:G<53] MT5P5O4'72W%M=)@AZ'8Y_$/Z1;ORQSQ\(_T@W_MCG#X1_**
***MI!O_N>_Z5RR=F)U*6XQGOI&UDDNNUQVH'WG\?B9]MAQ\YSSR:#0'#]/.Q0 M?:,UHN/JI&&(_5\-!E4?V1VP57HA^,JK'=80TM(A M?23>?A"/MW=RJB%D@PIAR7B$6$@%7]<8**
***MY5%+!=#=03R >#@0W5TE(;S12'(LBN\D%%>+02Q_]")P%|)2F^%U$LUV#]>W M>UAZ@I-CP^F=Q$UN35 !VC/XOPW'MG]-/AI(Q$?>(&S_LK[WN5/8HF]>>F.5"**
***M&1T1$Z4#4"*P@P'S ?.M,/1.S(_<>]:P0D9QE3&?%"N$3[.(^=3T.-Z,/068#Y@/ MF ^8?T"8'R(53A&&DBPAE)NK1H78#Y@-M/F ^8/X!8;YO&?03S8!M?4**
***\N8@TLQ31X!QQ*MA$.@FU;!'SA>PI_;Z=AV'^ M(31?[I2Y]OIV9SW -NS0J7RCNWI3'@OH5+X%M-ANIW* Q%7JJVRPR_H6%^-J M5_1I##&>%?GI*0^[U4;*YIP6*0YVN70W=43?**
***>=_OCSL?P7CH_SC-3XBCY0J4 MK_Z#K%4WZBY,J=RF_O M8L[H)IY{RS5U0OF67VE.]-H=XN&5M!{2K+:7MZ0BJFW5RENNE7%+VZ7N.KX> M2$NS1]B=EN-NC=-**
***'9LML/AB>'8V'&2=->MHNVYO!GQVB'QVCWLCY:+GH=L MRM3#@>W_NQO]|3_>VSJ@-X,'UV\"7@%>>>7R\XOWD;-*WQ84^+>_[0R_F :8 M!ICF%J8!!@$&**
***0:Y]F!>JWQ]O.1N_M__2U.B'EY(\S&R#+AA )SV )S #=,& MZ4K\Y\Y3Q." 0X##EM3@CVYCJ\!AP&' 81L*)=CSDG )+ 8L!BRV&1;[9852 M,\!?P%_**
***7^OQU\N8:E^#@=@L!BRV(1.;,YO\"4VW+,WO/_D+&'^_MW?;MP)?S7^/J9?3QS,5IQ4BOHHBRC9\!/V@$O.8EMYX6W<4*,"#=YSZ^AS; MOKK0RPO2^4%J%:F)-**
***K$7(B(Y:0X]8CKZPD)AJ/FU)]H&15P,[@_!OC$1;MZSO.2W/6 MPTKT*-E@5_0CXP* O=V+S-6GWF5IBZ/%OTA"M*&T1^,N("Y9UL"BETA9; 75**

*MT22%.\&_2QD/4_6ZH\VK;&^QF!N@'Z ?H]YC1SPL;J&81"HQNL&;C(7'CYFOP @[OY\X_/AS>B2GNJ$Q$9K-.,L19_J2U#(@)[0]1+93E M>JES!?&&.2&*O9XRDNK2N2)$E%1BVB1N R5;4T.95CU--]B@15!UT6X/<2VG M [13J$MEN_&4+=;)#[A<6ZM]R.6GXB6M8l?I RMMR9NFF91T@5+BST]KJ#?%.M^JO)>?*

X8O\61KYOVZO3KX7DAV*;R@U!]B,>!08Z>0$TEG#URX);J.Z*M*'IL$/PA AQ;/BB$*&AI2E M8K*:*L^B6C3F2.%L/)5GA=-CN-S3=IOT%Y\-V7K5S-^#\|\'X5]3fGZ7/N0/ MHJ/8VAO_3T+PN;!OF4R9X6X)4!Q(0-WRAB=K< #_+4&A+(AF(*)C3$_vI.. M6M,M6A-VE#'E*=*'$\3S_Y6,I(B4"\D2@R/E]IK69+QU7':.!E @#!\;QO<(:-% MUI^.)>1QA]VA-_[+.]27RXTO0 )T(OZWV@. %HPH:#X@2*$V ;#A@ & M8 !L.!A/*^66<*>95-D0(B8;0BD;3\I&1(A,-&BN&?9+QI-*/@3AD+28(JZE M0)[(B!@U@DKI+,8!C*?#Y.%-'\>&^.M:\=?*

SB>O7/E]+L?!0KQK$MH5G/?^5 M'S;CID+5Z^A&$SOZ7OVU^M6, &D\[.VK]].?OYO]O/J8&09$)HA,$)GW]3=& MAA7#'"EO->}!6*0UQHC): )61!*\E'B4DL+$9.&*N6>(YSN1-BH@@SWU$BNK MBIB]O'HID!M7K'VTL.#KZJGN>@0 N# ;248\<]75)A=1.,LQ0(+[@IQ9(8U=*"@G#6$S!Z.N+8FP)!QF1-M/<*A5A"(@6PXO)4@K@08 !L.& 8 !@ &PY6T4K'F;B-#-M2)= QE/\@2+,H M$0F<'$}4]'RI4(S6B482.8HQ09$N*,H ^T= 2)H++"-/$;ZM(CBT"X=V]R5H MW%(_\$EXL$FI*V1R&,68A!2N+!DPM[G;.G_F?2C,-R4)K?AL]#

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

4!]0_V!]*\%*'8*)B'A#$;>2(<>Y1$HD0FC6Q'%8*L&/293> M1(88CQCQ9"VRBA"$C69*6;^B7TJ8V9AO16+<$W)KV3+[!+U=H U4B]A1M8C2 M7;*DT2PUZ)ZGA>R;BH["-67B]

[>'S[^#@4GH(S3@9=Q MVD50P205?(8E6. LALAHB84/12,NQBXIXL!148)MR0;&WP;')PK$(1)BQ1 MX()BJUBV/M((O6=;]3?M(W.Y,-(TA::]^&[*U]!F_!Z>#\'B&-?AQU4^"$ , YKX!YC&?##TRD@ ,.+(-/U]E22"5= $ MQ>A2Z5(>D/54(<8L2=H3Q@V[]C3EM<>QEZ??[;K_E"BH5]>M4@CLMM]?PG?MB,(> * A $X'T%('788)\T MDDR14D=-

(2LX1]X20X72B=BE$[-!LL!#L$@'F86F=PEI13$B*F&M(PE6IVLS MC6Z*N>85:R\]/(XJM.@9ML&4SR/C"P#"([MP\ 8 2>S!= $##@ #'ITR) 6W M.GJ/DK,&<<<6:F0D3HAP)X6.6@MW M?=KU#0Z!ZW6A!YOR%STJ-WC$_Y]>(+U >MU3>@/GM%"E-M^2$BXH!%6D4@F(E&8/N1 Z4KQS5=5N_FJ_WA)SA-IGD_&?E3V\3W?3OH MX."HZ4FQP<)F1\8G

{Q'MN%@V@-)[,%T 0,. ,>G7(D=4A!68RBR?]PI372 M#AN$B:51>&<\7U*.[G-P=!73_D;=]"-37\$%VA$@(VPX:$>@'0$&P(8#!@ & M -

AH.%M$KP,V1%&'/()281%Y@A@UTV>03GVB=G->4/.1*%M*>,@H< ]U1 M)+2E#1B3Y@+B)$CGJ?&G':PWS24>!NPCX/0 _,VG&9WDHS6_#YR'490RV M_]{6XOZ+2VK^A_CGI&

[R1#_&?3:QZD=_ "ZX>=!^Y36 M).ZJ2TF/*PZV+\ H;#BH4]!* 0:.A@,& 8 !L"&@SFU@CE%A&:XM.GD5>)L M3@F"M/44&:.)}Y.%;KY>ZE:T3'01SZI"Y"@Y5[BB4^*^+AIP_G*G\:D(&TI

113!G:DGH>_8,/4:YB#"^ZI[39A/\]U?>GZ;6OAZ.9+=Q5,2%*P>8% MJ(0-!W4)U"'7 -APP_# , V' PF58PR:R3/GBO4= A(FZU0+984$DD+!)Q MV:(*#VY "2;3 7

.G#C<49CP.1QGJLY+U\\##U5_V#15YL\\I# BV+I^K)KH M)Z/,-! >!!D'>B[HN8 !L,& 8 !@ &PX8 !@ & ;#AA^CO6A4";G6)W;1F M/\V7:\<>-A5Q8L0RY*)PB&-

/D*:4(8#CBI0Y\Q24H(>41,<$=0U!\AQ M@5$BB?/(!9%T*4G_W?@TCDKN_2B>QD*]2P3?XEO!GYX%G]?N!,^<&78-.\&'Q=^A3SW)E^Z7/OK;1R_2[_9;ZN[W)]\T?G37;V/]"/+T?^18E8G MT)\!P ' 08D#)0XP #8W\ M060US2S!['-@("[ &L :P!K &L :P!K &L..Q$!9@#6 -8 U@#6 -8,U!8PU$ M4AX<2;'<<&:%1$X+A;C@&!EN/9+)*]JQMSK$JY$4Y:G

1AI$M$IY-\$AQR-! MT43H(M,J' UDO(VC]>ADQ(EZ3K\P7C/"\+,Y",B^XC]DN@# \ #P-\&\%$P MR8R.B!LE$(],(>N=1"P;Q9.SCG+11:@< 'I? 7[3)XK7B7KO6UC[ZW0!W+ ?

M]K'J2Q8TAH;C6A+&)KKTH^:G'"D1%$F<@BDSN#K(H9$;TT M*ODL-)E>:M9=2NTW[R;G9FP')1GL!^G7M%X$Z1G">U2);8F\ M*Z0#WBH V:T"V74UH7\#M-

U2\Q.G*)$LHFB#1)PRBZQ@#E')*;?^^H"!%@+6 M8"U(@0%@+2/.>^TB1Y!?WB)NM$(N$HM$M$E'E9352I[!C6$MZ6%%>@P, MP%S 7,!^I3 M",$A1DG&;2)HUKJ)1UAQ'(QA

<=.,?AV/|;6/<;Q,4)O%V@SSY+) RW%WMN/ MFZ3[""Y;#4POWOZ V>YF4O?2X>XYQ1?Y4STH[;LS)P_R2*IS^5F>['S.L)$W M3%Z0WG>T)OI/8W3OJWTUA9[X=G>03?2P/WP7!

<N,VOFVSR/;S_L] M&I?>[N/3V,0,I782\KA"@>H0!TU[%X/L#GE^=YV"%L&Z!$35,XIW5CJ]'W^FO:W*`Y"1MIO90WS(YXN0/?;BH*8T"O+ MOA>[?M,>RQ^@.*_RI-

^R);>+\)W2+8#;E+$ZU: ,.V>_/LR5\?>[>X<[KR M+?"?L.P/6=TM:<[7+^722U%87C*H-B M?$G(<9/VLZ55O!GW[WHFZKB_%B@>H?%UA>T/^R6OU_]EB?7WT^UP;.'Q?9<)(7[>?K?

%|;'62U\SW9 C;-.D=-WW>Y MUIN=C(=SDZJ.H(BC/.1R.\]*Q'"2!8'Z6PS/I]B&)-@O\Q_D/>I;\^;^+2) M62W)?#"?>VM-3Y_]Y&K,.Y>ZJ5W=SXSQ=/[fZ[+YV[=1?J+E7V8"]HKK9-UK

M^(3133SWEFOJA/(MO]*<: VOW,@KS6I[V>VAEVN!8IEW]JP/.]<"-^HAN2_6 M=>BF/1:O=*.9C$\.QL.ICK:>B2TRD&]_5A) MX+--

\|FI@_V@^\WRT47'?O_W8W^^A^E;2]Z,UB/5/9CO7;(*\>P , ]E[G'!M>\G9I&^+:[@M[U[]4-\=]A$#C#-+4P## (, @RR%*,$@F! MQ> MS96AJG2I*QTR^GCFXJABI*TL3>&P>

(>'Q0_UK;J:&WZT9[N]Y\HRF:%(4\L*MGNZT5^1Z6D,_5?HG!*29.HC+X$R*20N]?+.[\XK0 MC/8DE?E.;G/GNH^,"P#V=B\R5Y]ZE_4OCA;_A J<:LM1)%24BG(6V6@B$E(;

MHHD03G>#?YNj;,'!,G* ?H!^@'Z/&?V44\&%#'=!*(NXPQ$Y,20*BVF"NHK",S CMSHAS#U%W-NL9SJ]LH**E<3"Q^"64)%+QZR,$C'];-9-B4&. M8H /\5L<^;HKTZ,'IX7@KTS

MAQ3DV!$P+8BO^XGD8K+&3 $DX@KGD611SKK-03$BQ10>DEA[8F.V!NBJ"3 M&G&E)#*&(*SC"\+S+Y)6ZEKQ51@!AI>3Q4A>TJ

*(E%CS$7[A\ELU7[_^HU_NNZLDHWOK2OYWF'MSELX@R>X](^\R70&$^\;^!BT&@Y[W_@Q^!%-5ZP>_(,V@U+Y,:.A=K@MQU9MJ_M\VH!'XYM9W[6K?VW)S?5S=CO^PVNS6<:;?1C$L6]!{<_]^TPFTY27A\-$U*^7 M$SJ.GT@:-;G3]^_@L>=GD^_3J#T?^XOOZK??G_M44WI6]@2,)MV3+'QA>F+J M)_^ICN7 "!]'Z:?ZFO");Y;)=I\NB,@; CW40C>;=-@KT (C/+B M9YV2TU4(H9N1/B[@"SSA=W\!T5^TWW_SE]7CND^@*NS^1U<_/=*^=MMHDJ1,CDCX.?I^_KNS53RM[\6YE MKXYN@M;-T9>NN>+DO\S/3-);X.74[0> M;%*=X@\\|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|U MZ#P= ;-J%AN:^B%9!:RM#?IY PK3P(5A.)OI_'WORI0P[=I<{>38VW*AYTT MS*#'3>8#K<]G%10;IWI!QGX)7- -X,_A[VIJW:6>TAK5K9[YMJ07\W>KXP TGJ1;]@IQY]4!L0\YPY7%NCY M-9(5G1= 7/<;PD?Y:E9!1?_)=-.85].E+#O6[V#_DR3SWK[6\6[T6/.\?@+Z MY 7G:\0T7AH)\,/N2;=A:.J0CK[!+"KE9]>EE&:=T2DFY!%B;3!K,YT_]#PKQ_L"Q]= M/G5W^<Z;^QP1&&$8+,M#.FXY@5$XT7%9IJH,VNS*ZB\=HKSSELQ'J$,A//+W\ M>_ 1*&"]@__@1^/N_>MSY^:LK(6#G^_\&*]Z MR'(^UPG6]1,QW!S,V%=\]D:EJ?XV[1#2=Z6@NX6=Z;5RX>6P4K M9/#-U]\I=D=W\NJ!+.,+[5?;E4]T>G!<+0LL)NR[XRZ)==?$HGE9:VLUDF+>U M!A7,,/AGOYQT-0KPERMU^M:J=FZAW%|42N:ZWS4;,XGD??\!0R(S+!;*$]O< M6/*0;U:#>8B,_N#;45W"OBJ?%_W/ MKY/11YYDV8U,%<;URIRXT>8@,<,KU=?O&A-8(UCP%,>^Z8LSUFLUJ;,"W>I> MG\O1YR^T@|]V1KGZU"\ZˆPW?K -0.X*[G .I&GRIR-;|_>3=R>"O+UZ\765]M+]C;ID]F/%[RJR>]K/*SC3PM^>/6N!|.B+G#\]TI]-Y8KE"]S4R.0,!1]U"!)UFO=[8X!]65S*VN&K^OP8,^;I(S&-2EQ^.0@O<]//C<0[*>UD5V.9ZS M4_MNVEK1Y\&9W"9TW8QOM>"L7!(-\A@IU8BU7M>7X.12|\^K%L$-G1'T?=;, M0E. ^)&TKYVIZ_M!:M.84@M.P]$#!;EE7!V&6M3)ISH?W;G72O[!8X"B#AI, M/1YTV7\?+#EA_N+6MI4SUFR#WDP/BA\U7;I\;%&_]&[!O.W%C?YLL.WE>+N M-K'D:@T PPV1C";BBRDD4O@GE,RDW2B0|! F_7N;WY17 "[506Z?(V/^O:^Z MN1]#3KS_:Y[>7VD<*Q@OP?5'M^[G)C/@G%OWZM%|!&3:ROC%9BZQ-(*>V?^ MCPRRMC[D_UP.>;_^Y_OX3*^OU8S7B.%9GV,)S^3;-EMH.EQ%$[NNJ8LD MR^^[OR[YU.*%*N>LS|)?9Q$E75UJ ;#UYFLK>[>LX;VKP;7+=UE:@N[D7*-J M<-9R*=.*MDI_V14=W-Z]0E7?\YYIVLT7F MTI6PIRK6>Y7+Q>5C+E>L[@@Q_/T;VT[=PDPL TV4=N3\/EP7$SB_-1_^:.MS>A##[&C20O0T4US9WHF75!NYC^! <8\]XZT#7.GE;-[9R!Z+ ^V!=&M6$Q>7Z MZK1=DY$CJ=7QE%7_Q_DJZ/O15^,Z^/\/IB9)##L%\]BK^WU@)!"8WSX)5O M*S<;M7V2\' @]3-B@62DU,,7>A5RM#8#L@^;UU3.!Y\392A3!W9A,_(=1,[_T M4U^^^?OK'PES*^<1AB+ELU%PM_Z.EPD7UR.[IE?-LCH M,' ":M=-&CQK!&;>2<#:8L*Z5U-C:*%/$+|"GST3+#!DTV9AJ,)BLBN.55&[ M-K3M1.U7Y=#MB#C1?3O!B8QP>M+%<"8\4'53'LG/2\)SW2IW;]\N00(: M'4?&IO>*Q:(U*;2 ]B91B"W&$];!DD MWY!P>N@.U&;UHOWNN%521!N_XA42=KGM\W242!VW$^>+8 ZPL-S4 -RTVNN. M+77'7%ZP#E7'IJJ_V70.XBA_;&\)95:W:=FPJC!Y.I#8^6GSYGS:!GY3;,^OXI:/UXV&?R,^MMSI+)7 MAJ.B=3\<@SH>R&GWSFE_6K.TR\C@PG$^G]9C1MW2=COO$NJN;\NIYOC:=,9^ M.AN8SOHEV.=NM]2M6T6&M^T3]?0Z+C,M\[FT]9!,Ns>]*#"!T]S7,Y]IG%|A M$#"LLWD2$UT5#FZYF2L #+LIM?.;Z5_;W=)TW/^1VT9OS#<]:NO33FXH' M]"=TGJ^1^S&#]@=Q_/T:VT[=PDPL TV4=N3\/EP7$SB_-1_^:.MS>A##[&C20O0T4US9WHF75!NYC^!

*C=4*64H9B$85%0I3HD{@2B*&-M!TEH8%J90AMV@VH,(P"BK(/DB$)+9Q6@R?.061+")F--H3,81'+:RB-"ZJF2-M%10K*%90?#S_HJ/4)B\@&I5!A%RX%+4"'TU0SKG$%-T#*.XU)_WR.B 5)"M( MOE:0?!&9:!8EBX)+.,!1_"*(=^J8^@Q+1X#!>9:/7R<+AFHBL@-MOWI WD>=&6$T"I$AABA :&G!&H6NJQ62,<)99&(7<++GC!+051U;4$+Y62P!V-M 3T!GQ8RM\9/)_%1Q ?5;+T:],Q&ZWZC95UF/@@%,5(/@OO"0)HC6BY'T'@)-MRE+OA.4HH@PY.*"^.R-#!O N9DA,JLBRSIS8@>2?],)'PM9ROXJ*%14K*CZ^ M:H(_'E*.5D#.GZ,K34;,)& ^>>652E+V7/D=H.)>$|"45)%E1\H6@Y(O( M0!-ND^$A &*G14R-!FRR :C464F9"&'[$!WFH%^&:>WUA1T1>17C\A[P$NC MI(U6:. \V+)WA( )@8/2RA.FK$FR5SBQ#;S<<0JZ1/',U!QT+8(>: {ZG\=_M'#}6J_5UZEF/;*Y'-M^7L9%"<$HX9&XI")L8.*TD&)V49]$8 MEGM'O+DD> Z$0C0^XCV>@F4N >-!'RL'_I-FTB)-A ME+VK:%S1N*+Q0 3CN:#QBTC+4^%SUI&#M RQFW.+>$ 1]TZ*$$M*D3@[)-[O M@W .IWOFKBON%|Q WEXX48H':U(H!*"JXA)@Z'$@1?99]&BRDGO I5WG?PO MJ8\=UZ8,%'V?=8TZ.UM8'^>@OS7!SY.YVI2WY$8YKX>|5f)=@2RL85S"N8+R"!';-D+N/*D8GT JRS!JSA@K/ \)]+*>:#,,P'BO)?A1QR5.%9PK.%=P?NG@_'*6&#C1 MGBBA(81$0%B#4.Y)H,#}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}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{!39X MEXC62OL^1!DGW M (K!S4CO^B$UZ/0&]7@(B4A@J#9@?33 K)'6'45-1%=\?O5XO>TM"SZD%2&;"3'4%XZ\(P0X%H+[QGEHG]B-MS#;00 >EIR M/6@_.1%@"5;@-9$4_\,@) TDK<3L7>H0A&Q=ZK>FY/E#310PR! M@E'"@RI;7J@SK.1SF K]TUZVC[V(S)YW[+[P/VDV+>)D&&7O*AI7-*YH//#! M>"YH_'"R]#88R1,QD,N>1%=V>>8! A=LDC*1<;VX6OO]WB75PGW-9-?<;_B M_O/PPK,71DB>@3(M09@<2XE? "_323'BO[]WYWP,]+SCU0!V9.Q>C]8:#/@^ MZX+U>GS\S>/CVP=8,ZO)K,>AU>/0#F<_99*FU!^:!)& (*]#<4F";M%]STC_MMG=IH8DT>]RL*\,#B _=:C![@0M(O$!>'<*MSB|=G%_$ H/G6@IM,F>N=0AG<+@D&!BE.)>*"],KZA:U[A/=;-DZ\!!?UQB] M':AVX!DZZ9E[+5/VH*AG4,HOP7$2( CJ@]*49K>3A,FNSX^W1Y351,G@-BF\ M[C.W?I:3NJ16_5HB7JT1#UBI>I!U8.]!U4/JAY4/:AZ4/7@V16'U=WD]GM#- D!-,ZUFFK'"SBO#RV'H2T50"N `@! O=_^& ,."P302"X MZ3UD(KUQOFII>@>]I!-MU"/M'>"BX]@%4$K@@Y"):,H%'+S*4/8&/6(0E MB(:,@Y8L6D6"Y7V"_6T@Z(YKA922%24K3^E0,\OUG*Q*R5$I.0Z8DW:<61\D MN)0\"!4HV,PTH.6*(F4MC.I9/9Z%#XD*L$X72@XT>$9:-MP2)7.@EB0UD)PT M)4=,ZLK-45/7%7P'(A@5?"_!ER>,-[1U8&@0"+XD(NYZ 40+1%@8$)K9'L!W MKUEOON,SZ3H:5S2N:%S1^ E;>]G(>G/E2E($8+*Q.X)C/8%(@QTI"K=6'1.,G MF$*O:%S1N*)Q1>,G\.N8%+E@%"A"17&.;!1*TA,"!.3=='W&)RW@<:[/CF, M'#%C*^@^MWKP2A9ZDRQT?/|VVVHR*_5%I;XXX'QOTNEHHX.,IA($30]\9PPB M#<%) [HUP\:,]%%+&:!W&/51GO$=R,$IP<#[&Z P10H7A)/8M-94"HX8O%8LK M%@\F?$[P.+]YOGW>B)"!><*SA6< M*S@_Q5$V(FN:!&1O+ @F)$)N.,'>>D*=UMSY=$AP? OYI_PK.%9PK.%=P?@(A M.R&YO'0!_+[/WU_60 M_F-QEF:C@'_'T:>-.+IXFW^6QYOR[763@_YO1SD?YXO%0?/7Z;QF<8?3RL4:_M3^GS_'X]M6&YC2-8^:/9IJ;_UQ.4L/)4<, {$\VIBQT^%!U;N'+[?"T/7CM. M;=O,3[U=_+(W!?.2]A:R=N:=ECIG!/G8(DE0)0UX+A/D#C)S$;7F.BC%HZ6 MIX1!\%F R)Z -S$!T2Q8[G(4E-U$K1LNY T, ^YAF9]=P"'''\WL,%K"QYM6FR MQWF;?YXV%\G-KE:%;JI?_!WV9[CYN-IFB44CD^I\2D]XO>]PO. M[QMIH1)]](W>E:DC?0E#:W'7"'(X901*N"CY,$2 MS0GV%&%OUHRQNP4 )W>@*?8543$UY_B :6P;;$U; ,QXO/=>;,!HX'-T]8P7 M$0T]VO4FC%V+DW/N3A),I@B6[_O>+:!]>[ $X?8$XF]N'MYB;Q=GDW=QU)Z/ MW<7:\NV[_/G:M*WGI/-1!IB0:QGW/479MP|R[W6/IX#[@[TIZT_T M6# ^$LDE!XFI@(:')# \)V!&1B),.6:9[[[P7$]Z_39M1T5C?W2CV;_<>)$^ MEDL_8@/^-IZ&? /]I$!L9>Y\7=G2W2FU?A_!ZFG=#RFD,Y]F#:?= M|SY?C1!@S1=M/AU^2>WPXMZ=AS;K_N;WD|M.H'?G1 M>#2_>+M^QAVU=.O7:GL\N/BN0/W=%|%CP!ZZY"'O\3W]FQ]RD'8\4- UH]GDJ M29\"9&W!=FE?;W=J*M7V,*BV!Y$ LU,!>*PA~KQ4%#\=QZ\8K;41V@H3|\'& M.>)!*L]TN5QTVL(YLNF553YZZ/Z%,\"&!TVNQX%^UL^R%XE>)+)Y\N/X_9536$ M,1RDFKT2'Z:]6:=EO&K9\]CA^)0-C0SFO8*GGL&SQ0\RUEE,*XP MCULFP+,@@5HM$I%>$]FK&7,T6.ZE!!5-*9$VKNQ%3)!UYL9FX2*CSP(\&3D2 MMAZDEY.C\O$@S!"E,K[ $P0 MH=_(:B)[S(W[CQ_6IN_7V<_3R4F;/9.JG*]/;RI'*?/XTN<[7M3;36S*+AA^9LFY?>8EKM%&1>!'"'49'XB@9&"H1@ MZ0#AE8/(+H,@YHUGS+1#B0:QGW/479MP|RIW6/IX#[@[TIZT_T M6# ^$LDE!XFI@(:')# \)V!&1B),.6:9[[[P7$]Z_39M1T5C?W2CV;_<>)$^ MEDL_8@/^-IZ&? /]I$!L9>Y\7=G2W2FU?A_!ZFG=#RFD,Y]F#:?= M|SY?C1!@S1=M/AU^2>WPXMZ=AS;K_N;WD|M.H'?G1 M>#2_>+M^QAVU=.O7:GL\N/BN0/W=%|%CP!ZZY"'O\3W]FQ]RD'8\4- UH]GDJ M29\"9&W!=FE?;W=J*M7V,*BV!Y$ LU,!>*PA~KQ4%#\=QZ\8K;41V@H3|\'& M.>)!*L]TN5QTVL(YLNF553YZZ/Z%,\"&!TVNQX%^UL^R%XE>)+)Y\N/X_9536$ M,1RDFKT2'Z:]6:=EO&K9\]CA^)0-C0SFO8*GGL&SQ0\RUEE,*XP MCULFP+,@@5HM$I%>$]FK&7,T6.ZE!!5-*9$VKNQ%3)!UYL9FX2*CSP(\&3D2 MMAZDEY.C\O$@S!"E,K[ $P0 MH=_(:B)[S(W[CQ_6IN_7V<_3R4F;/9.JG*]/;RI'*?/XTN<[7M3;36S*+AA^9LFY?>8EKM%&1>!'"'49'XB@9&"H1@ MZ0#AE8/(+H,@YHUGS+1#B0:QGW/479MP|R[W6/IX#[@[TIZT_T M6# ^$LDE!XFI@(:')# \)V!&1B),.6:9[[[P7$]Z_39M1T5C?W2CV;_<>)$^ MEDL_8@/^-IZ&? /]I$!L9>Y\7=G2W2FU?A_!ZFG=#RFD,Y]F#:?= M|SY?C1!@S1=M/AU^2>WPXMZ=AS;K_N;WD|M.H'?G1 M>#2_>+M^QAVU=.O7:GL\N/BN0/W=%|%CP!ZZY"'O\3W]FQ]RD'8\4- UH]GDJ M29\"9&W!=FE?;W=J*M7V,*BV!Y$ LU,!>*PA~KQ4%#\=QZ\8K;41V@H3|\'& M.>)!*L]TN5QTVL(YLNF553YZZ/Z%,\"&!TVNQX%^UL^R%XE>)+)Y\N/X_9536$ M,1RDFKT2'Z:]6:=EO&K9\]CA^)0-C0SFO8*GGL&SQ0\RUEE,*XP MCULFP+,@@5HM$I%>$]FK&7,T6.ZE!!5-*9$VKNQ%3)!UYL9FX2*CSP(\&3D2 MMAZDEY.C\O$@S!"E,K[ $P0 MH=_(:B)[S(W[CQ_6IN_7V<_3R4F;/9.JG*]/;RI'*?/XTN<[7M3;36S*+AA^9LFY?>8EKM%&1>!'"'49'XB@9&"H1@ MZ0#AE8/(1H@:QGW/479MP|RIW6/IX#[@[TIZT_T M6## ^$LDE!XFI@(:')## \)V!&1B),.6:9[[[P7$]Z_39M1T5C?W2CV;_<>)$^ MEDL_8@/^-IZ&? /]I$!L9>Y\7=G2W2FU?A_!ZFG=#RFD,Y]F#:?= M|SY?C1!@S1=M/AU^2>WPXMZ=AS;K_N;WD|M.H'?G1 M>#2_>+M^QAVU=.O7:GL\N/BN0/W=%|%CP!ZZY"'O\3WJFQ]RD'8\4- UH]GDJ M29\"9&W!=FE?;W=J*M7V,*BV!Y$ LU,!>*PA~KQ4%#\=QZ\8K;41V@H3|\'& M.>)!*L]TN5QTVL(YLNF553YZZ/Z%,\"&!TVNQX%^UL^R%XE>)+)Y\N/X_9536$ M,1RDFKT2'Z:]6:=EO&K9\]CA^)0-C0SFO8*GGL&SQ0\RUEE,*XP MCULFP+,@@5HM$I%>$]FK&7,T6.ZE!!5-*9$VKNQ%3)!UYL9FX2*CSP(\&3D2 MMAZDEY.C\O$@S!"E,K[ $P0 MH=_(:B)[S(W[CQ_6IN_7V<_3R4F;/9.JG*]/;RI'*?/XTN<[7M3;36S*+AA^9LFY?>8EKM%&1>!'"'49'XB@9&"H1@ MZ0#AE8/(+H,@YHUGS+1#B0:QGW/479MP|R[W6/IX#[@[TIZT_T M6# ^$LDE!XFI@(:')# \)V!&1B),.6:9[[[P7$]Z_39M1T5C?W2CV;_<>)$^ MEDL_8@/^-IZ&? /]I$!L9>Y\7=G2W2FU?A_!ZFG=#RFD,Y]F#:?= M|SY?C1!@S1=M/AU^2>WPXMZ=AS;K_N;WD|M.H'?G1 M>#2_>+M^QAVU=.O7:GL\N/BN0/W=%|%CP!ZZY"'O\3W]FQ]RD'8\4- UH]GDJ M29\"9&W!=FE?;W=J*M7V,*BV!Y$ LU,!>*PA~KQ4%#\=QZ\8K;41V@H3|\'& M.>)!*L]TN5QTVL(YLNF553YZZ/Z%,\"&!TVNQX%^UL^R%XE>)+)Y\N/X_9536$ M,1RDFKT2'Z:]6:=EO&K9\]CA^)0-C0SFO8*GGL&SQ0\RUEE,*XP MCULFP+,@@5HM$I%>$]FK&7,T6.ZE!!5-*9$VKNQ%3)!UYL9FX2*CSP(\&3D2 MMAZDEY.C\O$@S!"E,K[ $P0 MH=_(:B)[S(W[CQ_6IN_7V<_3R4F;/9.JG*]/;RI'*?/XTN<[7M3;36S*+AA^9LFY?>8EKM%&1>!'"'49'XB@9&"H1@ MZ0#AE8/(1H@:QGW/479MP|RIW6/IX#[@[TIZT_T M6## ^$LDE!XFI@(:')## \)V!&1B),.6:9[[[P7$]Z_39M1T5C?W2CV;_<>)$^ MEDL_8@/^-IZ&? /]I$!L9>Y\7=G2W2FU?A_!ZFG=#RFD,Y]F#:?= M|SY?C1!@S1=M/AU^2>WPXMZ=AS;K_N;WD|M.H'?G1 M>#2_>+M^QAVU=.O7:GL\N/BN0/W=%|%CP!ZZY"'O\3WJFQ]RD'8\4- UH]GDJ M29\"9&W!=FE?;W=J*M7V,*BV!Y$ LU,!>*PA~KQ4%#\=QZ\8K;41V@H3|\'& M.>)!*L]TN5QTVL(YLNF553YZZ/Z%,\"&!TVNQX%^UL^R%XE>)+)Y\N/X_9536$ M,1RDFKT2'Z:]6:=EO&K9\]CA^)0-C0SFO8*GGL&SQ0\RUEE,*XP MCULFP+,@@5HM$I%>$]FK&7,T6.ZE!!5-*9$VKNQ%3)!UYL9FX2*CSP(\&3D2 MMAZDEY.C\O$@S!"E,K[ $P0 MH=_(:B)[S(W[CQ_6IN_7V<_3R4F;/9.JG*]/;RI'*?/XTN<[7M3;36S*+AA^9LFY?>8EKM%&1>!'"'49'XB@9&"H1@ MZ0#AE8/(1H@:QGW/479MP|R[W6/IX#[@[TIZT_T M6## ^$LDE!XFI@(:')## \)V!&1B),.6:9[[[P7$]Z_39M1T5C?W2CV;_<>)$^ MEDL_8@/^-IZ&? /]I$!L9>Y\7=G2W2FU?A_!ZFG=#RFD,Y]F#:?= M|SY?C1!@S1=M/AU^2>WPXMZ=AS;K_N;WD|M.H'?G1 M>#2_>+M^QAVU=.O7:GL\N/BN0/W=%|%CP!ZZY"'O\3WJFQ]RD'8\4- UH]GDJ M29\"9&W!=FE?;W=J*M7V,*BV!Y$ LU,!>*PA~KQ4%#\=QZ\8K;41V@H3|\'& M.>)!*L]TN5QTVL(YLNF553YZZ/Z%,\"&!TVNQX%^UL^R%XE>)+)Y\N/X_9536$ M,1RDFKT2'Z:]6:=EO&K9\]CA^)0-C0SFO8*GGL&SQ0\RUEE,*XP MCULFP+,@@5HM$I%>$]FK&7,T6.ZE!!5-*9$VKNQ%3)!UYL9FX2*CSP(\&3D2 MMAZDEY.C\O$@S!"E,K[ $P0 MH=_(:B)[S(W[CQ_6IN_7V<_3R4F;/9.JG*]/;RI'*?/XTN<[7M3;36S*+AA^9LFY?>8EKM%&1>!'"'49'XB@9&"H1@ MZ0#AE8/(1H@:QGW/479MP|RIW

*I_!PAV6ESECNBU,;S[<&D,;Y>]__S!/T0F$E\8?5"<8OAE;?FVQ0 MX]5.8.G2^9U:;)\[ 3]4$>^T)H:)%*4*W"MS#$+(QWPS M0>D9;?YW>@[+]'DCE/S8*+8%+L+9J#^7N5WXK_W?*
3D3<71&%RD22D9E(&S)Q MQ4E2.%=2"6N9.@JGH.P ML!;\+U=@4.J9::H[C> ^$AR/[>-\YOIA0C<;JYS+29.M?= I.N0H.FF%*XQX M2U%!,HS9F"54Q1BBY4ZY7I?/0QS%+7'XQPRI?
7Y#[V7QA&9^!O;\(SBGFQU8 M>SK70XNG%8GGS8&_"(+(UUNG]8U6:N%B^U1!U#6&ET^+LI&X5 >P%G1 HX *MVG1/A)F?
8S%X4R2&@PS?!KUU=B+N')Q9(;P2)"E,HL7LB(L0_+6L1$QWN<)O1 MSO2/W8IM>Y^]N:S\U'99,.=9(2+8N%U8IM:.@I]*H|\&IJC[N6CE,O)V,1)
M+*#;9'&N*SOQ;S$2SPCI6Y\!\Q&7,WF7]6 MG3507C_Y35_&.7U0'A]\^WNWI7;7^PCY VI5)E)]0G3!4Q'@C^L=)YXF2!4
MUHER]EE5ZPJ/^"Y>Y+2;Y+>EU;0UA/PM8\M73F]F\S>U%^KG!?9,QCPP7#\]T M1U5S_/-V7: .%YB<@O^_P)M@,SMJ>[\8@_>#;:1M-]JXW0+,\3<$VXOO3\-; M?;IZ]L"[?1?
>;:W//9ZX6WBN;?!ZY^K\CNWZ5; MD2LZ;_:8)VR_F_)D8W(O:@* 0I =_^S^^X=_<_/;W&@"_04;LHXK(@VSMB=UK/ MSJS^;YC_2R65?
[@PW64H^A06]"3/W+%>>3AR)W-DMOW6[MB)X=@-0B 6GA%C0 M!:"]>LQZ5@Q@+=CI]&E^P51CSR1_SZ-4?F"_[=>^G XC! # W ,S=N7)A93#1 MBTRH$(9(9RBQO$3"F+64,9=,<-?
33Y(&+255) 6!AD2RY5;F("2-^KI*S(]ZXK(E1A9%9 :%&I(@*^#>G4;- M'13B ,1Y8O[\Y=5D]BGGID<;P3OB!8*3#0[]8+T&ZW4_ZG6*U"\Y' KYX(5)[
M1US)DO@D.2\X2T9[\XW&!L8S5IYS[=F&(,#1* E7.IJHC$VEU[OS# Z]$6?" MJ,%Z#0IQ4(B#0KRK0A19>)&I)\9K<,VE<<26[(ED(HD@#,N\-YBG3&3@SFO"
MN!"@1&,FCD$AWS!O'Z4H M1E"]>6^^F/+BA*29Y"(+Q 5<+\#)R;0;)QAQFEQ$BJS-I[PW6#F=C2-H_ MLI>_D[3_P_G2'N!P"BR!{IU5>V:SS[,_64]3O)<$V5U5B;V:SS[,_64]3O)<$V5U5B;V:SS[,_64]3O)<$V5U5B;

*7,}6)^\|P$_|>Y9B;>AICI6:9K()164PO12M(Q'PM8F<{3 MY=!Z-]5?2,="39K:FOA#9PU@4@_OP6)Q_D*)_'8,ZX^EH].R>S|\E5M90_1Z M/(6Z5^.9LA{@&DQU)K 8YV/|Y12+@5ID)3XMJW&N&T+ZMJL\|'\1(<02@-2_3C &J6+XYYAM6_>%"9MAC;FV6,)2_F03N^L$9+=!*MD@K|)88CEH"X]-MCN\O8/18AAV^6LY&=>$+G *>@AOI*S#OZKTKN|GL_N*8X$T*_P_O+]43+P8;-MX?6[@6R*.0X9MUS*%&_7!%8I79HCX.UB6I=;77@K/);'4YZ.E006:5^/'UNX M,>$%G1ZDJVHW#SVDXAB!P /?2=N8I-(QHQ$- +)5I-LN9Z(1{(D<3=1^M@H7I.Z[;N_G:OM.2UP[3@+1*!;"t.]25+U1,0POL_%OL6L3-M[M+ CFS?=QQYT[GBX8GMV ;<2\XAM?>D2&T7BE)8K+'4:%3:A0BC O]8=PI1@HLXZ2[H%WW=NIZY7'E6VK$+C7-M@2$S"60>.0$CGDO#R/-E'%.^/->$*>5QGQ,F!,7"*9C8'6&G+.XG-8^"4+FG-MG:L3#E_0(/)H) !W9+CT(-6;NJ:ZCY 6(A^40(VNL%Q' ^K^6&DPH*W%C= & M&<#"' S45]9K[ZY_ @T&5"]QEZ[E$P2'LCRB18RH(%ATQ#LD@&BL)SRZ;S$ M-8)\|[ZQ\K6^R2-8JT!XU",!] [#BONBH|B=DQ%)%D4>|YAY-$O\4&.M:K M\'E ?2|"_><(/K>U3ZH)^'CN;CR2%)>.+$A (8P"+$H+6%!Q%DU@! M)QBNRZ$_.3ML*>';5DXR+;5/P-*V_S.M48_%2E'@L3CP A+#_N-1Z C0$?B) M4Y%X7 !,KO9$?8D'A\$)?'4_E'+D7*1F$D4*1)$X5(X\C8"9?.IX;2\57M"[Z3O>&;/0HE=$ MJJD1NBCT&S5>$'DBE+2 M+K-TA|_%^0W72L5C^4N75F/- &JOUC>$4>F'*QK$/9IC+B&V#4<9\"1 $@T$ M=<*93:D?ARN:G8"+4LJ8N%JSB.M[DI\<;17%\#\/+9^YH6X6|,Q6V8;>V"L^Z R@A "Q<@<.;6G+P9WZ? %K/2@KO*5):=CK[-.DXRH'E|*XPH@RVRJB|B]]M);6&ENL=@LQ;U-MNRQUGV-*$ZPSO&**4JPS[L8VZWX%/Z){SL4ZH%<%U_*Q L(DTX?<>H0-1(?C M; <%'W6E603J/.4/""GNBNUO(NDI8@#IR&V]'"%,QZ*&!CW]H ML*.H]BFE*WX8&0&?3>.0:(.E(L=(07)W3!?OS8K,1!7(B- M&IN|H+$)YU?QI=/K9'"VLY+7Y{$747K;P+ Q T\"M+/G8^BP.8>*O*.ATF9 MB22A(R7ZEET91USZMGS-SC<:W)>)(A0^OM6;_VXL/U8Y#)OIX(5AI.$ZS\") M%/44P>FQ0MAE.,H:O0H@X(PP%[*(O8)G;8#H-0 G8|U*%"1:WL248@Q*VFXL 5*8 #$,5*2E7C$&P^3B- MF /8H0!^0K =0U\FZ$/ADHDH##A?()&]%<_'>@4^@<#%O&V5*2SD7='-+_P1 MLX1_R[M6X]Y@I@? RIH$9W9>ZGG[C)}0LZIUHE|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|ZN-_$NFTN#A=VICIPV>W+7%MC16U)5 MS>$)#/$MSQ[X8WGSY@_+4==FZ?7YTPWK_IKE/<|SK7L-4#,W9-0.7!(*#^5[ MP%!5'1RXL2GKO!=M)BN=O)U@1S5W3F4QKK.,TO&1^?+"K|FNI&API)!\<+ M26_$9V8|/_S^HX5[>\9&:6D(5>)K/4K!T:9WY59]MK<^:HANK^T)X6?Y0=MX'$E@'$G%24_Y- M:Y3O)SJ?X@.YI:UYWW:<8SIMVEO6.T<*V%0!2'3SRB&,'SY:WT01:2YL,?A-E.A M%EVZ(R[5TF?JrZQ=!CU/^-R$8\V'=((%D#OG2)5<>%=KB?7(&6QLF21%Q(J MX@"/X\4DJK&SD:323\ (H"5;+?=#$LV-T57C2A6NMU$4__GYO+E9U[/U>0B[C%^FQ7R0T?I&C^D4. M.<76+M58!U;,_9/^$YZ!S=.FUC_Q^-^LQ))$_VS*RPOS.8:G8:-9"V.TZ-#Z MN1VD;C8:W)36AW:L6GR\:\K@;#@/?1IA?VJ+)@&H5_5M]"|_U4E">HQUSAQ M?0\\)TM5YW;SF/B|=)AL|\/ZGWQFE7?Y+$-+G-=\U7+T#NA:#8ODQCODEL^* M3IDLL:#CQ7S'W;K6E^JW0P06?)+SZ/I\[=FPSOYNTY7&,:=)<1^9:5Z MN*N"5M4QNO^:\6**);^TK!0%>:%@YH^LAR;_!=F[L/==Y!5 MP|LP27T00 \8U19E>VRO>HG6AM'"% PK( R\DR?+|=URSSE1BCLE)LPF\6#:Y9]>M\Z6"!M0XT M%]HZ#YF.[_,,R|&EY>_PH=FX=C9A7&JY8M3 *F<8"""^[PR|4+4Q(9Y#/L$07 MDDIULQ[TP,KC?U5Z#&:#=T8_P,50@I? U>"=%_J!*(2F'UA=X%ZA@.QAR0Q_-M5D_349VOWB9_U:,6FC)EFB2P#ID_R*)1+JHEI7NCL9J2T*@P*IT?/&+P.2'8>YRJK6<'IQE\MCG5 0MN M?:K>4]-8M<$K)^N1T' 3 O720:L7T/URC[Y$)7-AZ'|F_O)_]*H$HI4!U".%MBRP=ZPJ\)=:%L.(TG|QOP!*LRJ.)%DD.T @4#K0^&V/8IZTM-\.$WEQ# W-/-M,-(M&'5XNF>D)/#C6!\L*? +9[1W"P*1(U907CX"#):R+H5XKS2G5(.[2E7"-MPM25&36; ;2D"?3vPA6#235MC*5[6<_2]X:D\5#;H'L:R_MZZ]:'YO#1P.<:UR/5\&4'N;']?Z- UQ:OQ0P7%C/\5A/7HFI,>S1[>/ JNPM MU3G*.*B$&Y_ D+|IT^\ 5OD8E[8R^LO';,P9! _+NW=_K%%>B#X+#:TKU[YD" MN-.N]&HBW0736**Q?;YXN%2P0X@L"-8/=SG"8_XPKN!T376Y|R:2DP"?D[U MV:.A!02A!1) (B|\5[#:1J"X06I_BJ;P/=QO"TQP/<%[HV:.M/[],&V1&4RU<.L+ZH-61^7;+X*(C^)WP/*&EE R9NGOZ'4LIZU\7D?%/O[Y]"0/<@3R0X$D"ZM?CC# ML?3REB[U+"O"'G1SS0;U2;#Q# 5/E76CQK>X-KBF)4Y(X>&^%&Z>KZ@6W>)M"WO<(3"@5%'.UW.Z3R_X25Z-9&&;_.*8N61K6-.=|*?>>S>Z^8>JHGGO+,V0V"12$NME.@<-M#KOBS>]^_M >DM59ERF/]\6IGU12@=AI'OGP\|?V:&R]WCB?63[]8G M/_$8I$Q]*ZPA*,KYZ#$'GKA[U$\ZU%O_Y\36.+?]4',J2[D"SN4WN+5O)Q/ M_;]_^O67'?'5VZY"F(#S5^^=#Z/&XKRPY05&#"S==1'NXX\$*[Z1UD MTCL?U)@&2@$Q-%*K1X|&DUAGLK6!*/"\OV*HO>[/'+;Y:'VC_RPSX?9ZZ_[?A-MUR'8NW59Y@_% [-9Z)^QM)S6C C4TOD>@CW]-'-'OKWB.5Z9YK4Z(L06.&>>*V:[M<\!*+ MA@=NEE=K)K, 7Z9/".(+Y"?[&XY*E @.@\W(+UZE9 &M_4G$Q0RNF8N\'I0VQ MK-;!*P?$ ^P /'K&L/"P>XD2FN/W1(5.@;J[,[2<44,EIQP^ B&J=M[6Y<, M_.K,?_V!EQKVT:H @R%_J,O#UI_[H!V&!+.S>.)L11A 1W5ZSQ)XH3^P'<^J MFL\T1H98Z(V.7(2H0GU^/%\=D"L%2E^1Z,AJ"7ZI"""^9X .G0>%AD"IDRH%^UOn:@O%<^,G2GS,&X M=42U7LJOQ*TRJT!;1>&S-^9^G+^7G:A:VLUN<[&C!#.H\KZN 3[_^*>+RI)9/& MA5OE;E>ETT:C5/LZN_[-=J[S S#H*LC*W+K%1:QE1_M>553&\OR =[O"5:J9 M,_"H-V! 6)U*]_,E7UANU#WS\;CVJ+5DV8S)2(H3U^0SEPVCUU+W54J01MZWQWG0[8 --,2EO*E7866Y M[ETQCSU4/HZ,>C"_2;M8X'V%5N(Z[\L>*^_=8 8I.N\UDDSO$/P'.CB2C]MS M(EU_Q1K;<^XEG)LC>C/7V":#ROL'B I&(UC CY6G[9YG@5K@@!U\:^LG5]I&(F[]I3I-))6T?+L1L-*O[&T^R\;3YX?!WZ*I7H.>W5%; >&_%? MMD]{V1+G2+OPP=JM{DV]Q_;#G":HAH- A]"|_ZXU!'J:MEU:L6\A5OS1O2,1 MMJ,<*G,5\3645\Z$4&69S);TK#4J5AT%A,LSG? &SI$!IZAWKD-@H+U1#S.N" M\AVES)AW1Z),O??U$3/8]B<\BK@U]$@F[*10$/E;%+E4FGOB%,F-4+-01.I M:[FJ4M9M\SI]?3;M/9;4G*99E76DRTGQ(P+OF)-MUVK9S J:C)16PAJ4:\CD M=6:46O9VKO@X6[\FIE>AXT?=8A2[BL27=^FD^X7Y#=IA52>E#N;%/-<(I7<21J[[5-8, MAF()822&|;SG:;,O?KA3.%PK[?HM-,.K8E2B) 7@T+=@U=9J,.CTRK(5*"DX M%HI8(I%*#.*WI(X^8_A1-QZLJM;.8\D/.5S561.W61[##PI(*1]A"=@F7[", M[X2I<%80OUX^?/Q GLK#8K8*Y M5;<_ <$1HZV^_%]BT<8#))>)6[ XL.EU6K$9ULEF1S1{BFB =8\:U&8.LV#0@ MTPY%W?L1+A.Q6J?1U'2YL,?CA:W%O>YL+7QK6M-M96=6&1-2@64W@-F-4HWZ MV&X4'ZIZ%^@JNPN)#';>KPO]:6- _612H!#/FRCF5SQD1HY3EK,EL@ \##TK< M6:0I[7)L0*H:8('Y#/ #AA30T*D^!1]MU0@?(&!?\02]0NP\88,UQ._ZA(0I9#),G87"/^.SRFCS4T(IA#RA MDU.J+=">AZD84KZBA"UHH>MY7U;7KR0O$$W*@/(RK--NU&>/]31D|_VW9/E^\ M/A/>|^+V3RAVOA]5WR/59JW##$]6A]KU>BRL8"WC,8..]%B M_>!L O^IF_&,,!-OJI- ,FI;I*6FLY56TI M-'07C'R<.NBL^5-.I^%M8/V .S0W.DDJ;]6==WLMX/[\5!/9O+&3#0R]^_-O M5I4I_Z"J3O%-W@+[4">]=1)P<=0QI0.ZS'(NR_59*CJ- MR336_BA=K*(ZW5)BEE7%),UK:G6DPS/E/%Q:C:PZ,/ R6;TF;8($ M!O9KAFJ;>^MHL]WQZ=7M(52WE;QN\UQS4+9MK20C1L*7[3:J/#=[!:^ MBT5;(KWFN@=#35%\D? 1FX_2_4+&K0C$+K4%*#"HALHYAIEL YL(+A[ ^:7N* MJ.KO56NXFDRP*#:07YT=OT!H&R+C>A*-0HM#:C]U/[$MCW- M/*UA\94XH85WXAA!K? W.&SH+OM^VED&G_5]5):)TZ+$AS71A%^J4\UL^;n9 M>)YN7/ZJ=D/>!XHV&Z_61-_93%B)*WI_/R$SGS\S_(&#JG5YN9=R(V/,VB M6U$E?\ZIWYZG-!G9W\JO#\ 1!=,+!^[;IXWR\OX+N.E*XS3]:- MJGOB_%Q}GQ@UAK?'G=({$S0^#Z645.MRN_]E%T;?17Z,J]]DZF+<9'UJ.*)L< M[WGSF2>]L6UNPXJ_M56)XL,M15<2[;*3[,H.ANU>Z9Q%3#_13G0\$E(-8*Y5#JQ;&/.X&322.'YC MK$_$U#A9SM|\^I"*B>]J?)*KOVB:JW[?:$)?G9FF,"UE-5Z%S\KCT*>?? <5]H=:2LSD[IYG5MJF1CU3>I?8]-0N&S M28E/13NK ZOM0}{((.@A,)XZ*-7F[,7'Z=H^.TTE ITU6UV5)"( WC:/N<.G M2QU,T4>EV[2/T=]_:]@~^V11?@-]TW7C=*93F"

*MC^LSMI5#^J^IC6&OMN(U='/\U[>\!P5O"8$/7N0D%PW^O6<6S=O1J2MWY#M)>>6Z!&\J(<$H^!7VLK>QIW*%K>H 9+4R*;O(=0C4^CWAC MG%8(T"@1+4&%8T.{19OEJ:!@[%*B_;5H5PFLF/^0T).F=Q5TQ- 2;0'9'.];T-GW$7EHDGXJ@735I(/H:O>E)B1$@B;C25K M;8VOLB(IE@Q! TT;%R&;=5:E1UC,.SXG_37$NVU+O';<)+\UBH:7$3WO3$#" MOFS/C?L!A@SEW+-,C!5{T2R35APHC*MHR6+*MHZJK'YO00E+4^$}RBA=S]CP MI?YZ&G7A6&3X-%WM;I1[#P"$"M5%B_J!*P_0EK:P5;9-GNRTWBU_MJ5NNQX+@QT+R1$[?&E(#&YZ_PI%ZS%<0^.+ M48"1NG+XE=-AD_,DR_F!V)N\=.:LAJ:4%@>9"EHE]!F;]A1B).9}YHKJ:O2 M2U^%[-.^0CX_%,"460DJ^-90"{[ZL0M#NWZ_[75SF[#N\@C?%&HP;"Q MC:O%MP@/GUC[B+.S^SRH^2SY*N\']A^!SYRIFV9+O,P2?627&MZH=7 AM*^Z M(0>]&VV7\9>#4<,11#5?"O_H5HK"1+/YS>9WF?E1&)5(Q0M&QVP:>N02%V7U MGE$8" (FE<%!0,D+NT7^_L1$4DRXQ4H.Z_MKT#LJ%?U=!&(\H9\.=#?(Q'GT7=,<_H'[.1S49VF9'5QG#N4)DS-&-+A&;;$ VQ$6Q\ M;;,N*RVJS\WMXO/2F]KX&VR>5KA!0'+Q;&I2:X@##0"K;BJ$M<*UW:(:_ MPN7:.F*9KA.H74!KU+-MSK9Y*67A$BT4W7GQFET=ZQSF-'7\IQ2CI8#0{3R ME*C(#9'-6>YL=P?8W2;AK9@^2=ZQ+$P<5>4NR0%4L)F%SNV)?(4@8.'Z@A*S M;0=V@ ;T^R%7S6R2LTE>9I*R>S+F!9S%[A^N.@V6B,(Q2[=MFX*VWZ6M_HT[ M1\ B5F6>E;,)SB9XZ6[<<) [+MK:6;1EV5ADUQN@LJULE9ETEN:9[>HS^KMN MDV62LIHL3-#)2O_F(5RS=/AS]J2S)U4K2)Y1(A!S8; M3'SP[,XY1] 52VKTM#WRPUOZ(6T[&H,H*VCI(ZC1=M$10G;W61BF+'EAL^* M5>[YA?VP0<9D%63[E10=34+'HLN1,C>=B:I/'43ZM;6*D)N[V:=P5FB M.#-/;USEV*SHU{$EZ- 1)IU8= (+>=UXRP98=WK/C1@L3V5&ED5&XB&=GZW:S ME^RK>-H O&7Z+O7U0EBBHZ^+,LVSS]$},_L>=`6{)X)/T_'WOA4B'9C+4S MYS$- ;OZNT5>TG2A36_9>$P76KDW!5T._.9$+3;@P"#=?K%W2&W)6, M=^&!:I@BK&1U*X_9Z:KI].#N.'IKQ(/72CW69 UX,Y03XTU6OX[^$E]N*3%6 M"A#1IZC# <[U1.9RM;A>TZ4K18VQ>Z%;.(-(J3$NV(GFY.*> KJO!HX,Z0,5\ M85[= LL-U(W+)65E9*PZ7&M7Y8B)K]J*0U*='_6C*DI'CJ"47'USP&!JW.WL M}$=,PXG2 (^F%]^?(AP;C7$3Q2,C-ORGD-?RPC31ZP7#-39%GL4<"EWP*@^MSKK,4^M)/2RM =TM0(Y)/ MJ)WTXK]O4 C''#Z!:QGJ7604FN4CLP^H9UN63C*3L^]XZ19<5FV$Y_3ŶH M3/4984AD>]7KW{D@THD.D8\P6I+"[ZM,2+X!T2X2=T0.4_L^K$G>DXLB=X\I M;49S\P"VQKC"2%#U&MX#%N@CO=?!T\$ >BQ7C3]3B(1=#'2K_DIC5?;@'8+Y M^LI*6I^X}4M'I\@7U"]J<#/=FSO)R@8]'T$/8!2H>LI*G?:P4V5-O/_%)P4L5<5&X^)D\O MH#3IZ1U=-$PA4(E?#)(ZH9N\2.!)HE_>TS/ACGQ6ZQH.\C%-UC1UFX/G*Z$& M70UG]D:W8"_+59"O\GP!OQF?@%_H6)>-,_R^A72:N5-@%?8?WWXZ/B^/3YH0?TZ(X4U$<9]=MW=1FIF4SW7'G0MT M,Z R.1),_[ -F:(6%AYF>@&QSU_O^IO!- U(#/;W,\QXFFY)]\#Q3,5\/53,#V@8K[9^_0G*4J${@4D+\X;YES?X>#QJ%P= M@0S1,D^5JQ7[@&;B7^\=GSAG!,<:'N]OR7)9&7OD+7C)VLW?6/>X+9@H4'A7 M9+3?,8N1@_U(#^T<<$(N,/# MC;5/8C<6/#]&-^[$}Q(^#VZ!UQM#0(R7*A\ M^FZPQ;E:&'V:,G*,9*GU[W*IPL%F=8F">^#+?3AZ(/G.\('SE3X>_0}>=HN' MX$X9/B,]7WB;X9?!+%V!J4\):6XE->''\#EW CL[*,BY]U%!SH/'WL(."7). M@C#B4X.<8"WO"W*>!/'4H3'.R4?'.(\&3_=S7=6=8*G="%<5!J8]ES.]D&/< MR(./=W&3W^JO?.\'GRFB|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{'GOQ#!;4|&?R@AA\5'N!_J+.ZBPIM C&@BKZ@2X?>^=3P?5W"-"/ MHW^8PE1)#A$8^G/=$>2PCX-]OJF88AX.@MUR439TO;%G+)EA%;C<^V2-J494 @.(*2 M;2@84EN&^J T;?+.:7*Q1MF5:$QU=F]9M2:,[G@S+.C 2X'B3 HQD),",! MOG"HBN(>%-%.I2_#4V90Z!,_.U;NE)(7D&8Y+_;J[HN=6NW$.7*\K!'2C#R\VXRI1$57)XWZ]=NB 5 M'*Q5R74#);5 ^!.=R+YRI^K^B^P6MJ4@4*133?1=;2B(EFY>UFVEN,"+UJ:^ MUW1T8]=N) (;0VX7)62ZSM]3X1# M2J?;12%Q)@= <-Q34:6/TE;>E!6OZ4'GC\/Y(CI/Z/P0"Q5Y115(MIN5]G•W M8=^MTN1 X&03THS M%#)UWHZ,*]K@[VNM\[>UU'IUC=BZ*Z,"G10%++>R,!- "VSG[ &3NX< M_2]7_61%.KGD9V9I-@NRM7LG6ON\,4G=C32>+Q(BO!'1Q3#*JG;M8&R06BP&9 7<&J+(D',*1%ZF.$O.-*,H6+?[:*O ML.9WV!'0Q&9I.$7*%SA<;'- C!9C/VCQQ'2[\>WSI_/"^_J6_=^O?GR+Z'A> M8M>QQ/XM^16=C!8)+NPL.JO*'V[<;.@:=O\(LOEO2D5H/Z.-"FG_C]HI20C9>M- >VVQMO${KI[Y^1N]!V^\'__7X_OWKWS@WW5_,^3'[X_ICS>)G/V;_'$A2 J MYJ0)XL%1DJ(=39\IZ+F6$ D^S^INT0!Y89I4D,ZDW(G^5K>+FG)_!%X*?S<% MI9P6%!9>1{1CY"*G3J&VD12[1#'<'96RO7PG7;?L'(FSNTY.A]E'F=RP/#<4 MM:$7'G$?+3\WZF1HQS"<5)5@Y:^XWX=T+N@.VDV#1]LJM.%(ZW[E$'^A0CP\6@[%PJ M-#=(]? @;=U-LN9792-MSRLAUY?+J3H]\0|=K%7V7?3}(=![,$&OZ/3Z:)W5# MKW-G_0#GQW0>.TY@!,8;I.N27M-IZJ$VE I:KB;U@:=>@VAAL2QTED-/ M@V61HM.;.E\VL.XSQT@,%T=S}.XXM:"?U)/V?/0;"FNBD[N+II[M!M>SY!RE MB)/54[+ >;E<(L22:Q*TK2^ E8I(/!$##8K)27!.J2+%I7P++#ED@HG@X@%:B?5V'$T N>G+SUC;YM9(8I*&= M;SJ'RI^[ &@K**=W7'+?&8N7G;RG:U>5#EJ[=)K-49[5S1&M -PXGXK>B]-5 M4X_%$LWJ_SJMW<#[/:2K&FWAWSWX9/_M^NH>/?X_IT'J^X\? OS@{L/')_Y0Y@8YU1ZJ(GDBG@6)X]^D.)}6]=N:K!(\AWZ"'0Z?QI7C->CN1:$XBPHI_S! M6W:W43Y;^&SA/0L?S11,/U&0;1?;!CC@7B@FC&(1V1*;)++!)*2MR7XHV=%XJ MZ+4I7 Q=KKJVF9 47&B=%&+<3572]9R;,_3WN]B6+K1-?%+U-JD6'6WQ1Z\^ MY)0:N%SP3C<7"[,9H7S6+1G7RN&[@4 \0<V+B1M!S=%49OQ2KFK0>ZTPK:O5S#A MU&J%6;=3XY>Y%0=ZZ&,BM/>T:AN$=:BV+4P D./KWGV547[>K M?2.=R%?BB'B!V-#4]${@?-\;WAC.,^4&>Z_B<3F,NDN{JR.-P M.Q0,V.LY6IB$FT6;LC [^]!6;8& (8?)T,5>AI6O%6UF25=IHDS !#^3^V1>$T M"!X$/JY-G2@WYR;'Q?UR_/9X\(C^65[0WZLXI/FKU]A ,>Q@TJS='&&"LT?) MPVV^@Q\<;C+*-C@<%M3)G?_2BQV^-+TU9,OAB\ M_^G$3M.6:OTW13^EA]D4((@9GU8%%9=5^%LR=^#U@R2:>IF%$@)^\##W^7 MC>\:*#:BUL5-]@I7D0WH%>;2V#SEKW>?!#]34X1A.9GN.Y!/$U85M?K)"IDY/G:?8 M)1? W)/5TDVVCE;21@R^:"LRPK6"=VC!_)9U\G50;94^W MUT7?=#SM,E_>M0''@<'O'}7QLN J&X@PS7%TFLHUHG8P<43;7A%.^.2"A\!7 M7+VP?U)}QO'S7H=/$:6T= (V8L;9+71:7QR#:P#$!".I2@(5A[']3O26K7H:GZ:Z#R0\=:1HCP*U" K[7/_BG MO__!.V=''1G8)VRK#ZWFQZMX'+8S^3<0AH0)_;9100|\5+)SG&$G=2;L&)85.#Z({UI3M ;N7- \&0Y'&:LYI8M\%O>4?F @.P>+C&PO=U2P4>4IV:W3R4O#LM>[Z[?TD277N"WL0U,=&(;/@]SZ[J M4?;$_F9 %S/1D_O=_+DO&VZYI:$ !UWYX@B;3"@FW5@>K7=?.WVSHYJ[3"7 M?-8\L^VE1.@^/JP36,JYZ3\=A\V4AT,78B,.Y^B_%$7'_>,'=Q}?U5 6G>S> MH_^ZK"KZM2:R[A\_>D QU>.'}Y_YL;Q&B&B8V#UK>$0H6}(FSX 6RW+.N[!J1SLO)0U/0V&+N"^~ NIV MN;1 /E<2\)U?!U]H4GQ>#] .:>G XZPK8HTKH"AN>?# Z)P 1K0];W0U%&D!@ M^^3ZVR{GD_^JH_'&CE@;P\UWL=79*F>K/(Q'3XD+V@7&5GDB)_$)YS+9(N*!M(4K69$+=**@. (/_QF:?2BU4)\CX&?-@C4*96D.F:5+OJ9:$*'_(=J*3Q!(_ MOHK M#W UV9?0>6)D]HIY$FR)P&*K*5D"A:9=HFIC$;1, 1"7Q1F77!,1^2WE_O# M2-7W17G!$U&.(XC#TS;-!.M'YF!:? C=EFN2]H;+9"@53@US1$O9(5C&N@:8LZ{J:8?<:(%"RI3(KGA?K&VE/%RC MG73({FAVVXO%FT@GH&4ZBJX'XXW1%V_WU$+FA3$OC+V[H\YQ*J4&O775;A"R M%; <7U;N*7*YT=O9MC4SQ;YQLG M>H HR36>5,GB/$\6:.2'C=K9VF=KGU+LMA%9@X\**?T*))Z",#O$ MU-DR#C#X&:=\A3CEDQFG? *4XY=FQSX[=HB[W9*Z>F/FG9Z=Q)/SEJ76G5IH0$ MU5EZ,9V#M,VZM%.H%5"=Q5FSWL4^H8TE,P>$]*4K.XN57F>8>'+H6V@:CW-T MRG"YB$++R9YP&BU!"C]V"U7P? W5VT3+@(JWO"/].X+*4#DNET>^UW@_W.8V3F M>&I>=I?$4X;RYW)G##,NI69K&#HADU72]1:>)C+YA)607>FW&_H#-T,VJQE! M$-1++*X\.BY\1K8F0'++J358#'@3[M@DQ4HX*M6^ S4 ;ELF564!>41:<\F=> MSSI,+K^>*YVS'1Y@AQ72@UH26JV9])\'LZ\?8C%?62%@1B6FX_Z? M'LD*FB.LRK.EJ-:? 54FA![MC:$*=LC:/!=*@$:[>XVDF\P:4O.4O*A3,%= M1:Z\(NBI@7&;=;MJ89EFW]>B2DVO:4Q&2)9C'.G]C^')Z*3"-?VF;ZI6#[OQ3 MH#OQ)$[\J7:'WP2[X4!FTVHL+CH-9Y,"@G- _=.G%7@ #+D\7C,4X\W7H0[/WZ+ [!4AG?8E@}'[> M.9!"(.$MS5+[#/J5].]\EB7O_)PU.+L?^S[6.H>Q=+7|^;#0$5Y/6.@(.K)I MYUTM\;*4'5TI*AX20BV" (O/@%BNTHYW.$X/2TI\K#!Q,*LDUPF=33, MA$!Q8GG'@KMP&:>CO=I)%.->CK^:02F?]^<]/ADV8M<3KP7O{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{2] SWR"V-GQ:PYSU8Y M6^5^>=VE<(BQSOB10O9'47;38RGA&,IL<+/!{34X1A_2Y\@=EF#*%KI=DC<[ MGSELDYTPX:>M49%9!15J3R5D?K/#@$1+8JTW 4:6CS%;XVR-^_5D>+N,G6XS M#W$GA<@6\T1>,'RT9SH/7/NK,L_*V>)FB]N_X3.806;.ES9:V/VPS MQDI%^VE/!4[2TTAKD7?@;- :2QNE0R@^S:& M/EQNV*+L@'GL>&6KK!;AKU6>N-ED"QU,1=(9LE055^EF6YQM<8\MIF9E -H[ MHXBL;CH3A[D;A"-#R3:>.C7*DXNZS9K!]FHK=#^P226T.NE,U7]^FU2?)F M'9')55;7U8_LQEQ?-A\23/C&JKZ*.85E695%OOKUQ;.CDR>J M9_2]-]WW5XW3/IY.;[<"P_^*K29#34RP^%S%8%2_<5J(^B#N0]"_ M\$(4=H/&N!#S%(EELO;=NLQ3(QI6)X]^<-`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}? ZB@C1MLP$C[3B@G:-O?V0D[VVX[XA>1.9LN49!GC/Z_M)*6M JY;'KSE.?1/%YJ462>%=RE.4\X,$G/KZ8.TGKB8Q$2/ MKJ8$"A5R%U)/&JD6Q .R3=>5.H#- *;JL7#5:G$KRICSC1L,/^/SHP/^4UZ5OZ00[6(%3T'_0+W0JB#PN_V]S$0+^:(048&$B1!1,(CW MT 2',P].B5*4_+S^*AK)7BW%+\MA0#YH!M#,NF+\UT%G>QNK,O_VLE^#195TTQ,!38G%2+N)JUY2R4$2@6.FGO?:55_# MPCJY2,41E-QT/H?A.!F_7*V8W)V--S6+QF8-]*O8)A/IMLJP% M=@C+"=@-3X1KV=Z%,E)>GC"}6PEH&+$Z72H3^R3)X'39-XT)V7G2Y;O) HS80- MPBNPZ*$*%)[V{(YTGU,FTM09%*CX4 T3PQ-)CU\O-K;LY%8W1#*[\TS(X/NW MI/FOVJ)KVO- E",PTUMV4-W/5E8GMU5"N:!CTP,(T92T-)5MK[%[DLXQBG>T M+X?;,7GV'O?,22Q3\2.@IAB;.7(CL+84D"V3P,9N^+WH(.CTZ3UY>8N 4M7V M01C0<*X]$TIW<=9BN8MEY,@7Z,?,,9+A)WA[]V=]}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{)-[4PIA"O"<@?O5XV(ED?DH6'R4C'B>KP.N6J7>?3 MA\AICY?O}/IEK68LSO5@<>[/6)SKP>+6QX7'&? &DORI4Q6+!K,*,4<@/K:,@XY.9SD+X7WOL\O5=O/.V) (@!:B"/LJLO'8RYC8ZPLE^9QY11QZ*PIGWZ1^TTY^%8H MFW)K+!S^@L$RBL-Q9&[#4XYW9LO;?"#=? !IC4<@5XR'[EDEB6&*E92 M0'#*A1+H:-MFO$@VD1J&#=$@')5(3,;F'Qs6G8O^.UOK;*V'6BM7:Y{8.18)KXQ2UE' MBS;+I27>2C(9SMR$F_$Y<.-#*CI.\-&[@7L9R-<+DZ')U$^ UOQ(/P_\TP]'+T,VDQ'B'5WLTC(O'X.73_>(@EW;BJP=0B?=+99M%4MN(-MF6=+UP:UW75E2 -| M)@ %&QJZ}JGL!.^Q:DV"^HBJ91*=<%XH- _J=,;&/11WCXJEG@9+9$#[^:;'U++)DZ< G8E+_L^KI!S-QK M&9*OGHM8LRE>;HIV*&O)9/[.0BA*=*\EM"QMS\!QQ8.?U9V?Z8=G2YLM{1*G M)Y0A4A:US.N;9%F5;B9. ((F>>AT,'IQF'T*]?KL'GG*290W6A,93U+HQH$5 MGLWL5?0"Z,D^, ^0\!O3HI[YTPF[E)=)%H0?M-N5R;X^B?Y87AZ0/^MP3ATEOA M:9E+F1$EGF]K9?Q0$_*MV39RVL'V0K:+T8&O<%_W_'V=_N,=@QDH M@=Z@8H\+DDNK@W%0P2XH7%5);,@SYF0+/1"$##XK1"'Q,WOEP0"-'O25U2XJ M.PDXA'LP(OT/*'9DP$?RDU#3A".B&Y, ^@G.B&$OX&,OY5L=>_ V .*GC%TC_<*?B\3HN%',EESRZ@GQB&1*F%4^_E'(K_B!SO6[F1#*< ML5ZT)25PWQC]M,Y43Z'H)AB]]X_5R0M5F%Q(P9GOCJ.WO)%U ';VD_(}@4GA M_3@R+T9,;XP5AS4@6B&7(7CA397A+O=6R<$5/ 5_UF8ICZ9TGJ'FU#QK.>.CK MP4_,F/'0,Q[ZTW"X4W?_)JO?U'$;KT0#]_C& 7&>8;8;1.*QY99V+>BG8W/= MP+.^UJ+P4U<4OC*T\3PIO0=@?9KG^]BUL9=;AMY$15M.3W\=%K%<>70G07]O MX-=/*WNH3(B*#'1K&D<"\P5?#G#+'HTP(9QLA(.H#QWKC/WMI>UVV4FLRG6# M3SB6? $1FH1&GJ1-=^E!8SR\<+/27>Y]D.Q'>5F.RV,Y1OBJ ,U4J MB3V^R?$"H*5I9\)S4Z9)WF66OD&&-YBGNA4)Q$RQ "MJ M"ZL(YOQ{0[U,/2W&VAD*ADWS&/_$:X73(I:USC%KFR5;Y9%0CNZ%GB$N3(9;?EXHK0H5,09..?1L MTZHG8:D$2%SL6*:%F< MRK(B,R33TB*%^V@=M;7*#4E]QJ@4QA *ANQGQ#=*=R',;;@ K./(LOR+6)FNDC"<"_^Z,7OU;7Y06;* ]3 MP[&QT=*9\(=- JU/6(JA6"'^2"HY5QA9$]0R1C8&1Q4\XNZ&^T;WSWE^>__:5[ M[\E_,\F6$&N)')8W?G?6Q8X)F?K>.Q=6)&U%\=S(-!A$'"9]7LB\R>4N&XM= M=XGC5H0H;_P;Z6Q99TCY.$R^9 $9IKI+W4A?R _?G4Z2C?\XZC0Y{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

*7QX+L%,YO(;@2;)>"Z]_!'".HH{F2WSTJ8&F2/ERPB,N%Y6+2W7W6B?+P B<7M[8((]LY.U<%;I M8@@HWQU?Y A@T4^OVSGU)%?1HZ%PY8U$]}W&/>O=X-5W_4SXRD-_LX?3\R/, MH-M4CSOZA*KNP'(^8OVJ\54L766G%:V[O;!#WVD*OG%Z^BL$][1?HO&9+BO? M&74]+(N%@LKAY()>UO4.<{)M74 *PUOVQV1634#Q:YX*@8-[_HJEM)2 M6^9)ME&'/3@K\|2CXAO3?PW%2TLQS&RSH66;XRXRFYE)3M(6J^2|%(S9<&%8 MH 8E^E8BYC(Y&,!$_4-PU7O95=YA [7K.U=2)_08_YEW_7(H?.DHW\XP=H< M:\2@;G|RZ(=PW0J/X4=P(H?2:/;%LU:F#^F$=&LWN;>]E.5H]!JZSG8+I[G> MD[%*D"8LC*\YG3Q2'H3P1=MD[%*D"8LC*\Y63Q2'H3P1=MD!LF:.!*H1; M,'ZKTPV)DY$FA(K2V[D&LIELE9G M!2K!3H A9TRPT53833H,KSH)GIOZRKH3A/6)"7Q:+A!-C3W5L7'?70V E/@V9ZBOQG=PK^0""L@ZD^7.*AJ. MO:*2*HZ3*"-C91)JI=>3,D_>Z& [E/7PH/&A+]_*9D8TQEKJH/O5O>T,&TV[C=G'9W%X?^GS0XMD>.?Z>*=EV5Q&Z)):1)9WTX M"CNJ=ML$=7ZVUO&Z7=?])3+X$2JK4YQB\LCE=K80:PK53QR+^,J#'I8*X\!Q MCVN/B694P_6@&A[-J(;K035\R|\fXF1^6*\J `2OXS_NS$"[EK RD2L. ^JFS0 M F0.JW:4E1;<1L(OT:]WFN9H4FW(R2%ND[@^JW1P-2U!B'4!+G\>7C^F#*N# M*#3C4UF? =F*RKBFWGBY$4,B&J//@!,]](]K0-#4V!4?2YX% LSOC92RQH[GFZNP,-GOK=D=1_\255\F2G+7J_&!G_W#\Z+,8 1^ M!%K)7(F7LK/$=S<5L5+)FY7+X9=XQ-S^]D"J'9HA]\V>CC4? >??CR:"%) M1.#!'S,1PB=OW.%NF,;!V@&UE[!C@I M,UMSA6^IV]QQ>3M7='T96^JHF#^TYAVVP'F,OQJD:#YSRQVIG52TCZ,WXP&[ MLIHA\M#(?@BVQYD9"V2[_]T."^+\(@B^M: {911W) 6HCE=0#WJ:M9N$_/$I- M[D-3!''.C0Z_OOO'TIH'4GWGNLXE)4H1>L^^NZ M+V#.],1Z7P4XO$^MR(H]>=L+"NI"O=KX'-.SG Y-.8N5SN3,-X*< M>:+XPE59<6JVN*=,8HXE%P')0\\UQ2)";=X++NSWMEA*81RM1H""V4U9^26C M.#BW/<^LJ,:Y?]JYVB A0$>=6&Y4A15*_<_]91W.6I0?3*IC6^X[TE!E9+Z= MS,H-,}//P"DM0^!+! 2OA;D&T$>0!]5<,*]KAOXG/0I=;H]KS,&C LHPYZ_4 M?E9/FA5,K-SK+NEJ^V%>+?-JV;-.QA'(RK4".[I(=IU'3(8,BXY&]L(S+1RO M2]4I6%8CZ587):^=W]F;S_,Y*?;)9G9^E#T5I![GJ? LS?.7 M,_TPN+27)22WT{")(IGX^PS@AS!EGKDQJXH9;FU0T\D@5KU8)2P8Q5HN]-GG*U6;ER6 LF&T!^KV6)<=F YL-,)^!B?3-MI5972UG42!7 MW6ZEL-- BY[O0M@.!3 "\lvB_%{5Q$J6ZVP!QB3M&2N4F'5=2@$KJC(<"M#.VJ7W9 M!,%YEXO>Z,ZO@,=+$>,?9Y4NQY?8{IZ<{2#)S)N#-)\U-G<_ML* IAOF08EUO7I)DQT JO(M-0^,C"5VN1054? S&H<*#81 M@MVQX&^VP-D"#[3 #A]F![%(O3*Y(AHK_/TMYJ*SPK[^9#_I36""M99?^ MHT6WDV%NTWA>(-C0DJ,KF$!+=^JQ &HXL1>&@3/^=K;VV=HO*>H'|LEE><>7 MH@2M]$N>95$NMU%DA53W-_1/L=#"H/>%+'W:C&,!^JK%YB\CWP4TF3'&"E%] MH"/_1P"):+ M,ZMUF0^PS+:)PO0$ 8):@,N=F431MJG,>4;/NXL$(,M+9=CIZ;O3WF\!0 %%@ MQ/R+C9O\";$"X>=_X'Z_10GP;8&!5CD_5IF%YB?:[#]" $94%/AYLO<\5N7K(',YQK M[EDXV(<#[@2X?S#A8%DR#PV&52Q_PT[L7Z">R;J+(8&AU^:"A#"1=DV;HGT M*7:"$RRJ,DGSW0]^CLZ>*-E_*]PEA9E(\&<+/#),8V?MV4-!BSJCFZ+= MU&[PC6,KF-BO&T$W<:YG;D23@;,QDDFZ0%*]#V&]@<:}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{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}$KS.+%U/8#=]5&_*>:GK*.\L]8*YZ7++=CF3&_UX/Y/9DQOU>*^;W9)/>?M8D),ZJ5"O7'H:U-#&US=B'*@+0{(0%0KNMC^AP!^$5R**V2]BNTCC-)Z7HR M/CIRP63I_I(GR_<"+-3)?2>T%2AF#1WS"%I=Q4T_DA\)9! X,*1?ID;4E4>@#'].!VR.TZ(1._A1IRXU<2%])*./=VA>6?'S<_M(2OC++#DH_(,*?)N](@J-!SB % ,E=N19!7IY5!US[0WE(@EKBOJ*)ZIKZJHD2 M)TP*H?"""24O6(V!:5[)5HS3+,+9W-<*#E/{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fT>/8 CE.25(K4M-?(K=& V?$>]I"M[?!ZOU,V3V%D-F M)URM#/;0[MBKY?B",YL #,RWI,'L?"]<>*> {"\,CCVL17DEMLQFL4A!LM>'"J M@!)EV+D(L)%C^2PJ4)RK9:@TT5.'>3-YX#A#ALW/9RN>K?A2#QI"D&#!%MT? MY*.UY1M@ .V$VZ5$L12]9W0-T,IH>'"& M[9#F<[_&0[1$MJF)7(#;=#4'! UNYZ6U@&".#R694>H9R[4\A}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|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}^7 [>ZFJ"LF*'YXHOUZ2? Y@2DU%ZN_^OU-_IS%_;GVKA]E0I(C M T?>M9?6[D%(K>#1?EC7^+ >+<+3=@0EIP.6F.&O6NUA1OQ}4HGQK"AY6&.-= M'>FF^!KQE.1+B8F$X;RFB+QPG8U%6!IZ6Z8)8%M! (?:R8;RJ@V?RJ@&ZM%\5K"GQ=VAL[( 0T*#?I.P)(9[=R62DVN 79SP;W8 >*1F84^Z\% M0! +$&&("6+HMG9*(II)PI[EA>ZEB14]!]D2 MMZQX"6$L0F68=YJQBBX8H^]UL*%AA#PC?+]Y8EMHCN,1OSAB9^*54S_5.QZ1 M%=6 1N!Q0;-SE&QY==UF,T."K@<2=\^&!,V0H*_)^"[C@CQO<.YB[_=\8SM MD8{HQ="YJ7_'( Z>K-&<\=*5-PI(.O:0]US#PIOVSZPA(;9]V% 9*%P% MH/4J5X3.K@22VNPI.*2E4BK09(5JUY#AN@&NDH1#HN 8[5,H @%HH*'[,!##"BY?_MRUGZ0<%:4&$4SNVV[NV-0^|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|F&A3%&0#+E3PX.- MJ:2L] =7M'PG7WGC:^C?,6WDG1^>OGO#/YW\|+WK,-%GDY9VV/MT6U$VB\_YT4+> F]TYB.N;=NQ06K9&]7':X M@.F"5KX-!J*G[TX5X^()6VSG0? #7C%;C>$_5N(=54]1LZX@'V=F9<6M#NS5; MP\Z\2/3E:I/<6HZ.JQ0(3)S:HVG6P-[ $^"*].W2<\;.)(STP#'AE56*[+2= M:#,3(G?SZ/*4?4-.'#U2FMP,B#V8[N% ("IJ=V@5.G4#$D7PFD!5EI>/>[XT_ M6G"2\6,K:!L&,OBTZ]M7]YM"L M^E["Z.%W1NN#-9UB@2[#BH.,HS?B?4R,"Y$*C5C MJ5!J,.8(S0\RP:2H9?@*>5>I7[#Q4:DK,LQ[@(.9RF? $KUJQ'#DQPUDAPMW[ MCA?AZ1'@P+5Y5_%=]CTX?$H6!.\{)LK]%!]^B9NCKW^7T9%L/6UP(-Q9[Y?W M7#?/NR7[VF#=XGQMVSB\ UT&E[A*5(1TGEB=9&GPB98"DQ_40\H45RQ\UA# MOI97+U9+_XU\%PK$\DB+/&H4LGF9W]NWQCN/G82$O.U16OIJX20.J4",I?' MR\J^X\Y2HCMI/4UK2/N+]#5;&BM@7P6PP*=O7M4Q6ZZ"B'J$MK6R?;L-]>8$ M;#80!_U/%+)E$&L7L%HRT$00:(&_;(F$@EE MJQR)//)6KY6;%)U4185U@KE:Z;B\Z PRN!V#P M888S "#SU,IU$B1VZF,)9=,Q&[P0F>.RILDL77=;K;:%@`\:^/ZP4F^="68 M@;NK^0RVS"<^56F_G1.]\#SNW$Q2LCZ>S^0)$[K.@%]6)DYR),)8DD>5?YGS M)&<0( )JWMZC4S_- !!7*B0W$^G ,:U%1&6TPL9;+[]+-]H%ZJF9OWNMNGHN+9K M]P?)/GKN4!8AJ,ZJ(@J4=+)K#:6>IU/C =A.E@?,6+?3X_'$[*W1.2X<'PIE,T MQG8+T-$B:A66^\#S(,7CGPT-FM? ((ZS${[!G\F+=5 M)LT;?!\|$\FLO!:'HO?;@N[[E!]?YPGY\^&"FL"!XR+1,MGPZ*D0P)A-#Z^V MV/5NK5_RUZC+UN2[-AM'.O08#)-W;G/B'8W:2W?<6N5+)MUH+UCL!(J9]O@U MG..)T/WK.A3HH0<8O%=I$OE56]%+@B8"+W+/'#\"71X/AN PCC,.XET8]OP, M%/FSX7YNY",PE2]$'R%[%?+_@9J*$77;,&O$GL<(FR-IU5BAK Y%;G N.PS& MJ^3">#AM"#W"""@>8$(1"'-\&1])L>T16Q1J8PWBO\3UZG-Z_6:2"R^6] M!T_VJ9%^16M"OG?OR3Z=U.LRY#^=E_F6H\)7'HTJRWG$>5J^F[2=4{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{1VSJM&WH)"? WE9\K_Z>[I MIU=;NKZ$_MLV>5F^CZ/7*S+OZO'W\NNHR+R=:=`5[_=T/XI>,?+@@&M^3FH\(E.$+U?U@$B-ITQ{J27^F,DO?1RPJK41-"W,WH(W*=_I-"W>5\[.S M_05VG^%.EI.214!I:B6)G$BAJXD-G7BZ)9(/^_[DSVV#A3$&'8>A4IH.(\HSH ME9NEB(QUTE@QN^N^(%T=?RL;Z-CA_/8QIJ%(8%(:O!19\H@@ @,EDY{(M'47T:V#%LX. M0&? B'V_+7=N4[ASC,30SUA^BJ5*4QTH8=M,I<[]{@&S;.Z?N%:FS'H>;#$ M<0^#:TY;F.G"'06A05>C$=,&ZGW!:M?\3^46F75?G0Y4\X5)CV0]I7;E# M3BNP%&I2S5H*@KA4B,*W\F+&5\/DW.}(D"3-G7;E5*6JJ':>N5O#V_C6B/W M$J)`\.8%]4J">XMI"LI,$9/&S*^I2G[2>9FF!0VHL6*N^WHFX,ADX@3U;, MGKQ2\B!25[(S7;]"T\WTISD\(%?QP'$VCU-Y._N73IB\&&I0_?FKBZ\??_^[J.C2\^#VS]POXZ0??Q-.;.81 MR2=Y]/#A*B?FA"^J,RT1W#64=PRR*!P:.X59F3Y: M\N^8>+%XN_.(R9U*BSN=GG16+X_C9F"W_LA&G':!EZ,>3'F&XU90W83PZ31 M^&W,:T%^?$+DQ[<+\N.3(C\6-[JX47"X /IGM#HY;8L=)S,4RJ>RF8#6 3% M#-*

*)*RPDW.Q$[F*_2#QO7;IIBS;&S@'M'W8]E{U^,}OV,-BV(D-2* TDN"#KJ M5>4NZPY#ZB.\-%5EJ"M\$O,>1;0Q1A5)$ZJGKA4+M9CJ8JKO8:IP@<1_:JJW M$+?.H<-3;%@K"5}AP!:UI!^J62_O1P0+ $<;U5B75Q@7F[4\O9UML<['-L[;I M-^/.FUK'1570;6S3AA#1#OD@(!3&)L">X?L#HT:[XY(=[:P6V&*BBXG>Z#Y5 M8"R%(%E#6U-'C%7,0**=1+ 6KGSL.S!3=UP;T+;$VD*4H>^$A;^'CVDB"2E'A.Q;=6; L@W)APD9!?W MR1+MBHD13M/_OI@SPL^BE<-3[1.(<_ON[+B\/='6'\+7;I+:.S4T!D U!8GNT M:X5./T9FEC9'OZ=3\/4UJ/WS2GJ'UXZQ P$EM%7DT#P$G<[.D)CN' M''7KOEG;;"YN!(\C 2ZK1YR.#OIDK/44T)]f_*INHF15F#6+ M'*]+}{HZ M9' A,(K)=8DT"(,.0?9@=3K]XZD[%M.(R-44U.V#:D+L\>S"$*&5Q#>A*5*> ME$1!P#IV5O=L4]M.SP?$NND?@BS,@I1USGIPSV0EQ!=Q*TS8&=R(UF&TJZU, M"[&GG=(Q_$:HV,+>]8%@.%5A!$#;0&*(H[WA0F(? );ML 1{\G.^O-^$OI7[\ZC MO-DW=-9L@$,%R)@H_8U0NDB#N^,-<47S,N2<-V+A(O635 F1_#, MDLJJ,#JQ,G+R3H>Z:F5HC83O"Q\YCJ779:9&!\/HB\XU#UAKQ? _A5^\1J0>Q ME+UW[2HWJ+EF5[VBSQ!"L6=Y\'VEI1 _B?(7C=$*?C\,4F-J4, MH[$W"QK[XV.!YV[Y.2$F:6V>URZ0P$#$MM_P+VQ}'PB?J!A:L/#R M8G.+S9VU.9-SV40*@]/4T1F.S"P&M1C4S5G#0 '9(-D:A^Q8RJ2\$RECZ)+7 M+W:VV-E9.PO$$CHC1XQ4)(93MSH>EV_]CR.#QY("+$;W.SBW4,B8IOV4CN5@ MT-.HSU,E\SPYAS#D+M:X6.-YPL8P?;RFEW%I-;>*JG5-EVK+"Y9L;'SL&=$__M)HR%?U>SVDB1:9&*XR">-U)FF+N.JX(61=Y4D&*F3_V'7.L+L]#TA!]]^X-9 M'7HSB_4OUG\K""9;6K7:U}>)\RU: [#<+N:TF-.-6[LP<<5V8$&0&? +,L5+ M6M2[_3$WILW++$?6F5IPZ4?U88APE[ MEAQ\,;-,;]0^K'/59;>/6[?6?%)X,>..E_&"Q:QNAR-HW%5>AI(BF$T%P6!6Y&T JF6[&Q=@<@S3%U&O%T

*G,5C=G@OJEVI^#W5;X[^[C%4 M-EZ\?II-.3Z%T]6/$$=]_52!$.W . P3HG2?B'3Q4G09>82A3T/N@D+T1M-'FX7["(*TFP\F4_^?('1564^49T M*^7XH8-QZ?<(DIRA@8?*
0A69]9>:CE,^$31T?CQ[0UU\B"-=PYWN_2?L8_PR MKGN@)SN0][::[_T9$9UUE>X0Z8& >YOB%4:Z1,PH/+ZR?Y.MVS%PX Z!, M&D{@EZ^-_%M(,V*>)<"!*J7L9QWX2I*UQQ U-
VQQ($:L%8BW0R*4A)..">><:'-MM [@HS9FA (L%P=Z[$;,+3FI6>\XB5_T/!R40&M$_CNFQ,$C\MDBJ:S&;5MW M$,79.9 ]S8C8 2AV'.28^)ZY=D5'OUFPTDAIR MCDQY&%Q0CQ[E0!
<"#2;R-WCF%W&EOIA';0}'(L.'94@NMX;HQLFAV[@'T=A/: MTMZ@U4.!D(+09YH?12@KHP^[]WCF%ZM+2@;K#U-MI$,(Z52UWXB(`VGC@H/F016):B&;D"LA8EA -^! [- T/L2DU?
TAF-$&4P*-ILB'*D'PH B0#8/Z'=[T.%J#)W0!-OE^ )@LKTV]F M<&0UOR@-[59IOQFQFH[*1M\3LMBH0V8V[S1%L-IS&?-3H-_GWOG3MCPM2F#*M3GO:2}?
@P]X\3HG1E9:YZ'[{0<GAE>4PHKE)PGKJ]\2.51,XL<2>81 M%=/)D7Q"=`"Q^EL_K E&;!<2#^\4+G,X6<1ANX}%=NVIJ>.[H?Q98&E. MY46 KSFE< S QK2T-7C$S,OF_0%=SH&V-
/]4JU2I,JFY@^R+!&13]#]VU*A@. M6PP?]'-$!=#YA/[815U\IH9;"ZLR=PA,N!?!*N3ZQF9D'+UY6+,7&1$ZC)Z2 M9C@Z/*%12<<-
S7V!'%PVWD&:EZRHH"R"8^ER_X?:S40=\W2WRXLF#IC\3^2+ M,Q!DY914YKS0,\%I3.NTXZ32NQ?]\0KQ7\A^F=9]:G,)L8?)V<,5F]A+S^9? M(4.0@%]$697V2
IG,$)6T<.5.<:\%O[A&D1FUXPEZ,:%V\26KF5 MC_V?FTNA?.#"T"O#C<#RE]9+$.+7@\PQ^ACQ$9BBBYP3;7^D0J#.^,>1 2@S M?+2)5>9,_R 8,6\-4B"UT2;+4V0G]9]L\KX-
6_C>1S4*4"94(4'5\K:M-XSW MP_-C,Z"P%*@Q*9<@?FE$MS.]@@E_*06),?^Q^O6AZ]-"/M+C4HE;#YE%U!AW M#$<+,|+LZ-YI_7R6".S7(^,P*S-""S(MZ.AB/X#[WG+$ZY9H \NP+P?
+IN M<+O8Z,/>541QL:*Z2 %X)_>'<+_S98]=;1XYBH1MH Z'B*]K*;#7+X=N@Q;G>CMIMVH1EZ )B!\'H8T>=*QA?D\B MMF23(S!N3B5EW(]*B5#TS'(A-05R?<-
TRUR>3NEX#*$\;=@:*'I&,Y6 +&2 M5HGB_#'@0&U..L]20?E$1>?&ANP;'OE)M41#SF/U2J,N4Q/E2_O)I!&T++Y8?D!BC\3@CLTDB6CA!:XK.Q
M#DR03BD@,L)@71\F(3]4NSY2CKP#]1{T0X!P1[NT@VIZ9]=**Y77MAMPQBH7 MB8$T#F25J$S*#S70Q7){EG,-XC ?_806@.,'!&-&OH/&,E6\0O:E>0U7,JY<
M$Z\W)/7R99#7^A#:7R3*)VE6T(36*?H.0ZKGE4D8 ] >FW['WT*[B #18+'EP(H&PY$M'.>1ML\D['Z$*+.HPS M[X*I*:+]PB_H9**2CRO'U.F@]6FR&@-
KXPFW(@<GO$>Z9]{0@VGZ'E3 (> M!/*_%U @97YM6P:U/Y@MQLP-4H-3H!V7+OI#*'!#\?0/*_0+D0]#<8>V4A=8EB9GV:< M[9O&%V!$#%I6;7^D0J#.^,>1 2@S M?+2)5>9,_R 8,6\-4B"UT2;+4V0G]9]L\:B)%KP%I(L
#\FL!E;\,HG%/]3++//AB,V"TYED$PM YPC8:8QN6*IC\(#H@J3)/W@K6IX(?BMLLH.* M\[\1>OY>;GY,:US]2/Z-ZG,A:#NXO-):\OA7&K[9 M]&,DA^=3N9'@H2 IIO0.-
]@%) 0.V3L0^Y8F=?Z0Y"\AT/M1\>P#D2[ 1?CM[_MX]Q,8:@;Q;A!Z'$Xj#P.Z;-8P ]7CRA/%,8T-@H(D/>6;[1>:NTTBT66 %MDXI2?Y&%4FLG8 UE=C>0+,>6^QQ.+7]O"A8 M=-
LE0KR+.(7ZE]'KSDNLAIFW"?1!S8SRFPB*COLU_V*3']D@X$QYUI:2&A3K M&N'L,-CFN?[.4&XX"24"_RFY*=,J1Z,NX+)T)0M^:PD4[TF@F-A;XGY3D.2D M"9H@<[;K-
[")2=8+1>4-[.TF#CMGR[%.@$;9AYA]+7TBVACN?VENBBS,M+LDDB8E9O.&],36T1]@.*S/D6TQY.{5(80QV'B]U3B.VJ*-.C ATI9[1<\- M,IZ[PEFZ#G^3>5P5&::BF?M73Y%K
\[L2$?@CF :7VR=],N53\0VSKJB(A"TFN M@C0G+Q%_7Y>.'H#'O9'E4L.7\+#;R0-V+C_XU(4J@A-,WHS2"&5FM6L);$I=
MJZ;+/WR)B;UQA)\S/C=%:5D['#!;1)33/WDY;O9UW@%_N"K@*2\P-KEM&[{*5*Q@-5OND\U*@'\U=1U$+"..!N0 -"/%A# @+X M329$D;KQ0F.'J3._W"4L"]>KU[WM3V?
2B{'3AC9M4(CRHMH=+&WW;-(;0E MR_(# &+3P8^],#I6&D_9(PB)E6SVXH*G&'*NFT5*VYZ,[&\E39PEIS\;A+#G^R[B;+Q7'"DY(E3F-@H55;7 MH#]&8T+%)
<7PWK;Z9%NQ."6_])XB+2Q)#9[.#T=B$(NR3.0BYDM8_3TO%9DE0-M0W\^Y<@,>07UNN$G#_JA)D&+Q0PK\T^M?TQ8C+X6PHTZJ-V:1OR27RAO9GW)7P]_WY MKG>
(1;5H42U2;JF$)OEIU14/_D^Q>;O.-V]1^>MCJ5%J M/%QC-D"J,,E{ :"(N[5M08OG]52+&'&C*'OE*6 MJR_BDJ7/WLI%@R]^[5#8UNX;@ZV^S*1LP.!3JNSP?V4@T9<_,^3?J()N\G8O
MD?O;@:(6&ZZ9Z[=QEWG#9?0<1+OHRN>?M$B V:A_8TUW,C)K>II.B?#I+:. M2 [Q?[AFBY,@D*ZV6D7A49I+L,GE\@T6OYB _:)""9CKG9G!4P;= -<%AYEN7 M.;:NEJ$'2'G3-
9("#C]'V"U@M/'0(%ZMS@UB1A/6$(S!-.=U.HEQ%1X7K(/"J+K*NBR=\/T^X M\%3 7XV\.U%&/OZR'OY'\.L9^LI M=6 DK&?^#%>A)K - 0S_VG^G[4JW9@2F7QL?*Y"X?
=S^OWVQZO+#[{N2627) MT'Q*]J;IKJJ+K08[Q=67-HIJXU#4V]5KTO*2X3X MEP,\:.&<;GAX%ZM7:8\H52]AY<$CQ\EB'+RA&\Y!X#/PE@G(O#@0EKT X8FS MS9F&C S-
0]WNZ*@^5'E0YFN'-M6AUN9&I&MAA"B,3DC#XV9<=& OIWV0 QU_ MM19>.D !=:G<%E#[K=_C56*#'X %T@32\L#]R5+@P_+8CMO%;A(!1E(^J
M"_,FQ#:O,QUR>/9=0X^W;,G+EGSCEJQ&^?12WKT_???!+Z*O[]X]3105NB^H8I#89./^WI9Y'$\:I?FQ).Q.$JEIV.27DLJYR_J'$1-L?;>ZJ- 2NDU+O9RFQX>&;C6VDS<5&U
MG:5Y(ZSU4WY{)B7-?VN&8;Z-G[VF%:PA3,B6,Z2BBQ^[Y/YO1__^NSI+R,;,FB M.VY$V%L8; +,1Q,;&"06[9#.L1!,3@A@]54)62ICT>,\# M.?EBXXN-W]+&E5!H]4IG@-
_TU%.J8.D,&*2I (T5!IR_62 )%,%-+46/A#?% M-XL7GG/2(N%E5*-TYA4]MU0G,Q*XA?KRLWU1;AM7!67A<4"M2:S=&F@<_,"M60!KGQ"P]G@!K'U2P-JR,7S8QD#
<@YP_WE?,+>N>O^MXK[N$>X= >O8R6.' M"]PZ>57UR)OGTC%MZ "_H$#\D "6QL.SE.$+$AX1"2;.]D5KO*2N>4-L]T7 M.8F&
[C"QNCYINOIE%@X:IRC"KZ2&29=!1S8]T_@5E:]F>*WJF6G9_"B+XYW\M*?:&G%9"R^=FI#Q_F%>NJ9?1\:?R7RWVM%-R)M19!C\^%-
MK4E[_DNM]P/+,49.M3_!*/RCQ$&30H&K]UT^8*HCN\ M=A'J:7]88L0E1CS7>*IR;\PT5H](470&)_!,I@'X9_D:3?T^4*0"([ML&\/B M^U#J/Q[9HR3
4].6B,N9F."I]!4(ENK,4@LEPU=38!4::N5A M!2\RL 1"FA'&;"!7#,84)9+ ^P3Y&F=OGX?)/Q%!DYAV,[0)$D7Y7":I#S.OO MA$K$?B?
3+ZK*G"7/H:2D141#5&GPM9WW8^M"7EWD7":EF^X#*&G1=H#$GQ#O! MJP%:63S.P5 M$!W7JZW(1+07L[^-E^)W>\'3^("&7D,1]I MX/[
G2Y96]M566\@:7"MQ$K:?"=EYL"D/AY$XQ7A[YX{B)B6EX,ON\&R&Y$9 M#51O=XAM+522UYC_8&K6'':N?!QL6<\7X6 MV&H9+@3)W0!G'X<[U&OSSFN[_'#J/J\\[.Z:?
!CMWJE6V]L,'[[+:+2G'"IZ MA,,X50D4!X][60Q*G=[PZI-3^O+A%ZCEA2+2G"'U4?(5+5D,=-W(K M],>#__[1-=&0F-
H*5PG)A"05T>%O@T>H,0:+R#Q>.;E7+A&GA!EC9/G4$;\I MO:'K\(O7UF!Z^!MJN_#V+7?$'"E3C^5.=(:5_6*^>Q8X95;B/Z"Z// MS+3?
2IKZ*)8EO^SS9H4SA\$*OD#=/[IHT,257&_^0:M6[M.K&AUW"/ M:.#^R/[B.<6B003&;(-$8(R&\B);!QZO2,SV30A@DAY93R[@N9{\EY@>'Q0 P#0K/)C#?$TP!*_-
JG0X"LX1}:7A&J"_O\=%J& M5C^_!JF#0"[6Y%[D.S>G&+<#/L?3)2:I.3.W$B@_;QQ;>,;$;C),PN*_NJZT@ M_ST_S]J KX92 W@0=<@MQLC4!!=;U55#$BIH_AN 8RBU&B3F.O!SPV-
U^9+3RL@2_OPI=[(2D+++UYIDGVP2F1F]R<8 MN9>1Q\=C'--9RC#=KF }\SZ3V

*'*9D9JJL#WS85;>J6)^/F[O,Z;R,O M?1L"A7U_((+7HFU[VB@(A&%6 ,"7V !#M92 I=1?(\9D?UX.5XC\0V/Z!^9# M'9>86S<1@'[HPQQ_:^#&!I.ZDA]@T0*(!G"]T-
<6"RCY$\5I$20X/O01UA2 MYQYEO-.Q8T %0TEC*2#OL3M.GB4(/C'-*II\UYAN2>*2=%8,/_GN.\Y}3(@:X M)P;YOL6)C9"1!$=:IJ:K8 ZK>(%*=[!Q;GO7.] "?KD;\,N3!?RRL#7]9GP?
M.J3,(D&:+4JRGF@U26IU?3=O_;8F#<18P8"_YMJIC)^$:!DU(RJP,K!5T75C M\LE(VRILP?'+$^Q-S"@!^B:6S0QTH#[3:>B@YO<*WLN9R$F&/[)MBMN[2S!_ M%R'OLT'.G!1X,+05"?
C).HU8)>VYQ8%V=AK^9/8!B28WRF@E,YFQ0@#.>L!R M+#]9&^4/'B6O=:24''9Q#WQ.#_[M_44MN#=0KFC3(!:4SK$]O2?4:2YX,:6 M:7DEZ0C$XO<]=.F=K%ZIEZ(
W]_LC!/EX.YGSC\"XL*:942/&H%RIC%,E3"2^8YO!2U!LK.@)?^T,K OK1+[J,Q52A?).V3O; M4P[\B-RLPK.!DF?K?]G)'K"AS8)>FW:/'#??KA%A2Y6',&I'7GT5!_NJC10Z
M!$G]3>N&P[3.8ABH)D8/-#8E9GK(41/.OYU0OS]@C(02?N;4=5;E&[U]>I+\)84%=R:OAP7\ZLMZP7& MO:8G4[DFDEF1M,$L@&8.ETC>+BJ$VDU8; ^Z3/7O_D_^O9RV\L.'^; M=
[F0QDN_T:!MAM\C$I&VCA8? C67V](=_DKGSPIA_XBDD'JX 0.E65E3*R86 MA87K3;?.B=64GH=-G,N"@4I^O,A48UF#&2"'6(Q"C]1_;.F4=WVY(W@$_]*V M,4W
H<&$<@NXR+^[/GOY'7HKV8J#2Q]J\L1(!NB&)\>/"%NVW M,]DXZN[VK^>N"/AZ%9;662:(R2\'W53_O,L%7XOUZ/4CR(5G&8TC."FM@ > MUO"N.A$G%UP3.[AP +<-OP4,R,^P A+
(!/>FM8CGR(@\[Z"U489#<=/%;X$) MF@1^].YVZ'A0C8037%P-VP\INU5R0D$0$A&LM.H 20WB8"&S R7Z)51HI@(2 MRD@I51T^#&D6C5PERH@6@0.C]>F4](0(/8XW02 .2=
((HK!K\@-L+VK/;6OO MRP%GB+*"@O<9)3&&/R?AS@MHCDCVPLHNW+:67&XZC?L<7=2+2Z2U.$'$I53\[ MP'?73GQ@VYY=#TJ)CC4@.*@Q95R_T_YB[!)F4,YR48YP?@(^"V
#P=U;Q,, MRYB "#DS]DA1#U59OT2+)FA<:M]P0HJ(+&L%$F#L\^=UM^ V^TP D-?ND$1 M047JEVW[4P70\)SCY"Z Z],4+\$@$/)@H+$AHU"!6V&GA:*IF%,R-RR$(*TD M.IK^E.,
5S!VX6Q4=K)2I3$@CX'%E+D/!:,3$.D4][CL:G2(216+K:/Q._"! M,5@_H"1^3_V_S]>LO_O 3NPGIU#]IPLKB.KT!!FAS-+(F?[WWU^1+#"#F!U5 M+,BFT30XC0HA-DBF[BG
(C^Z==/3V.7CAX^2(\9 2F\\O%D#'JVSQM"\;PF M-KG5/U@%K :R]XL_)^ZN5.*@7VO[}%V5%OG%X%Y"&(K[% )0 MG46EP?.V]R<-->3^2
#.V"0YS[T:.N$(Y2#\>;T[0D4.LV4(E0\3D\D=/@(OG2 M[GIE+Q":NX'0?+5 .!8(S6\R(?9I89Z 2Y%2!VCWY!D9/P.7 ZKF5L3&BTW\ M@((W&HHW8TT83DP'CD;,C0]0?
D4Y\=R^HQ&*BQ)@!]$1H&"$!BEE!{>]Q2F M_@-XH[V+@+T0X1=6=^I?E>T&. .?IO1WL): MJ?9>%F]=.77]. +28&'(Z*BHB6*O2/W _.R _%%L]LENT%/]L1/$^J=$;]
MG28"%2#5TG1'$(8XR*H:7!2&,IG6#;Y_5EE MSM_QLW2;C//6K8Z,T*#V65F"3E^Z$1B=7N3Y%G*A>T$NE#IY:(* @M'6]"1'W1).M!-/9\+J!.D#&W)(5MA!G+Y,Z'I8:
MT&X8D:$2I#3[=-@EX4$S=@PL(Y0KBP=]RW#< V3&AT)14V%7F[&)S#M&9J3 .:/)^HY*89\2]6<5VLRV/3H$OJ))-7L:S99;)9M:=F>'E*#\-XJUVT*&3'$YJ'U052^H;89!;.#^N M!
(TC6"+3CLQ:B>F+FVI?/O%M!?3?M]8Q ?I%&8XE8N:"K,Y&4!W M(ZV]!FM,0GD3P*,79B){":@7.UWL]'TC@K7KKIVKQ"-,,^;!XR0BEFZ.C(,T M85S%B/%.MV[F0(#SV>_@M$Q#-
TAB\V9==+:0O:7N?M?:..2*B=JK"H@GUHV6I M+$OE/5WZUA%)%"($*JQ0(.QNUY^<[U!15TK*/8XV"3U#F*C#*$_EW\.-*RIP ML9$),5 @ 0/KY$5&A9N*.*N\7Q6:UJS<|>)9?
Y47)Y%>]Z'/2 MC(0#>)D/%T'_<"L],JJT1,C)1HKN70G-* N5,,I7E%(^^R4I>5^MXK-4&H MZWBQ!/6@&@)_NA/>50PNDW4/?@/8_7'T9RR$M5_'&%$:+6R,9KFLJ,IM'1'-MUX-US?
2I,;Y!==W>T"R/C\TS9X-)TV6%+"OD/5:(4BPQ4{$'NTD-K&8EV@11( M4I- 92G4..2NW8Q8 Q]@)L(K=A,1YUJ&2G'P1,KS7D&OOUZ@UY\4>KWX[D6Z M<^3&1;;ERG *$\;6^+
4J=>)7) !E<7J/50DA-;=])^VRK-%7(U1HQF'=?[\ M]4'8& TR#:$-]M% N$7!R4\/-UJBG27:N2G:01!BQE+M!"W4,;D^2^V"'"]DV MK'XB8M'N *V<@C#M(84PH*3:(-@G3Z>41TL[=
[%K#^N?E=014,0[J9LQ2";,M,?OQ3=%L^@/-I)^1,L\'=(J+(2AYR#(QAPXRF5-B2_*1$K:WM3E8J6+E;YG M->:,-869-]I.,[!EEK)G>9OW2!3%-Q;O@JYG73,"J8F$B-?NS:*:2]FNYCM
M>YKMVD>^!R/$HMLJURY%[A,P.T!=SCN MMIJO.LUM('P^"UPAY[\-!AA,G_9XAXXD <6LTL_M_A@T8[+5VZJ^?K"OK{DH.0FM'-<@YZ#9.D^]!.W++NGFO=?/6G8P>WN3T(X)Z
MEU^Y5->O@H;C%=5T2+QN+/$GULA?(;::6'!/3K#8Z&*CM_3M&$>TLH[L@D5A MC.@Q1(6-"O<^> "9&:D"] UD6%G0C'A\C#+TMBA[4:*$0"ZI.$%MC;DQ6,Z,
MN<<'=HTBSFNYCO^YKOVIG8EJP) D3Q3YD8N:++"MF$\:-07W&A4JX?\X5TRNIV->, MF7XNG"CTM'IYQ@WD..6/)P.SJA$A;>,!)U-D?UO6A==PGKAHDF!*?
7+R[K/T7M6:!3$V8_@:* MT_$LD4DC[R#.T2ITM,U+G0@.?27#RX[\ MUNBEV9B,0=Q4)T(A]<;%;HFX."JC44H/#&Z$R&JF-V9,I*QC0@Q-3,3I.# =HZS:A ,S.SP:Z&V M=P?F]
6W52*$/:"M39+ UH'8%*0)S>%VQ&A_9)M1= M&TM\JL@#%E6+_?V@"3/@P/,!0.C;J7>JJ01?D-PF_1 =NO^#1C7B%@4=J M>I)/(V]R5_2[4,X;,%G3A3H?0Y/_D6D\KH<#?
FB>@H3]U.QI"M#$XVP(W2N;$ M%FP==1BQ,QH+]P/G/H!?]CEH"ES8/GCI = QFV!3DS2G,Z^83(A MVAIHWST>F&7V#R,.$?6<4/R6?[,J/.VU0) M=TA++X1N_G(]!4L\V8?
X,00TT!_TKZK:Z/;85[PMG).0 [7YR SP%%(5NT,> M=`>$*BF12AR+V@0%/U(*4"[S;&;$8^O.35.L.98"R['H5Y+^VNI'GHH0(4LJ MC_.RF6:50M]H/>#1SWFP6.^TGAN"\@VMGW$HM\
M83>N5{)Q+4*1]X%GEEZ/U'G8'Z=)-N'-YZZ3&%\?3LE2_$7>)D3&?" $?P(Z/XFB$(;0N$R+PXN4EDE MQ^^KTI_DTJ23WPRN8Q6^GV@R1K]+O#5>VNL
C4C9H4KYJ7%K{=\\I:)N087 M=H'>B-.9A4J$\B!B%*B$IYX)LQ'Y*FR2%XP22X>!E:1L_L*D-[5V ,+RQ2D1 M@?RG?HKYU?^)0WN$* $ M/0P7QQ>_7+RYT"-5M?_AHT?9HR??
9%]_6U&_[F MR5?9-]\@K4^>IA]_]UWV=>/OO]2$E*:M'\}(#QE9\G1S2=RN_^\|$WWV9? M?_^-=/].WV5???)-[_OYAEO[]N__\ZONOLN^^>\)7X#_Z]O,__\O,^5FIDD<
M\LHPGRB("'T<[RSD>ZER>Z9(<,&))XCP3^J1F[W?*1\DR/$G7Z_HEIY=K\X_M?))%7&VNS'5[KIO6URR+$2\G6QDEQL //CHMTSGE JODJI'6=[BD/!6B4!T6
M$ACH6[*8(ATA4VRDO0ZB\B8K2^L4Q=\0/"A,PNM*=A'6D%'9SGKF@BC@76F'H.>\[WT0 M)'4FF!P3/*S^OOJB??;CW[_T%W,J:2N,M_'HVXEKAQ_W?HFJA?1=40.8CB^&
MNWQ!MBF&Y72!"BPP,%[F &+^L?BO @3D'U52]CPE,8&&$0V5IVBFAXMPE]"__M:%9OG3L*8WJ$(T( T9LV'H385FAILK2,X>48,-MYW\#3XUJDYN-+I9RY9>Q V"C{ZQ?@"6Q%V
I7LN6;^+Y; #9PNX*N&0BB9 MON Y6@9UTH#O^FV-+4,VX@^TQ7ZS^7E^[*]E")YH>3*EM+Z^.'GYP@2(-3P86 M%_<'7W)A6KY[O-USN;1#FSIO:^YU$",4-
AV_':6*NZ0"*NL1B:2/2B>M1B\ M)$CF(9BH#ID$]>8ZJY1DN_AW7H7]+-.;SR$"3D(M@S@P!?^]JVDR!9%<[>?D M18R7V^9B<^?2"VZXF:Z6R!
(GFB1B[VFYOA[E',E0M@3%V+QFN8AOOU[6IR@Y M+!JNR1J;,$#MVI\011FT148A&26,!L]P+,AC(;!,^O9/E[^_V9*E4$IUC]
MA/QPJ87TW'YY\^KGGZ39QFF0A99XJB[#+0ZX=9G10(:Z,NZ1+?Z.!=R5C9Z6C MV##98Q=0]K)DSR[9J6]AE?&D"DPFZB[+>:UF-!L@OW#8MJ+_M:9\Q;<;^A")0%K!+U_OZH
A5*]A['?+4)M7&JJ0VQ66PX0%0*K20=+\D7-N1 MP*7A8;5I1Q8%%:7DS]6.TE_ 5E,04WOG'(I5) \%DG5_G3M*N7A2D5'1A0#T M!BW!0_[69:AXT1VTU#=$EA2S^
^:Q5TP2[!0H_3M@E'ZI!BE90=9=A#L(QU M2E,U^.E17Y@V&FZ^1SX&PC/82I,-L!3P4=-)9*X!YE4S.(9=T7)\<85%%. MU>_:T*Z1^P<-
OY+_3O<4RM]]TBL$R[N2E&XCV>SX%-G*%7@F:\$Z!+FZ M_.W0]?MZZT^!&TUVZ]]7?%_8@*-@L^I)[*MS?:E&;W 2Y8D9EFG9}>I*)K
M3;@^!F"2R'6'OLMUQ7")4%8.LQ!BAN[8T"KI4<:1^DWEZ,A4.U99=4$ !5A, MLM+E.^:";M(R:$7>%OMF/:0&C1@[C]2]QI(!6HLKA!]"OH/#= (H],6IVD!#3!DE,&@4U(TK0S6
ME,ZLV*0_]?O!!)=%M"RB&$:4F43 R'B[K3'2=4IH/+\9I(;)}TJ;?0/+_D MJ)?0Y4\2D?3]3701HG]4_D +#\P9#4(F=!LC\Y5O3GP.0YO\[Z05VTHJ=-M6(R?$A$!
(I9J076BS%'016^!//8HV^RU>.'CYXL:VE92S?U'!L74)6F5.8/ M32@!MQ)@.AJ3!I:I8ZP-TS/X#2CI-Z[K;>%$SX\P9\FT_QB4[]\]*0.W7%*F MI*W#O\<;XH[IE#*/WU%)\! 3)EKV-
K3+H,ZDBY-.W* ]:O*IB_]^2KHN\P9N MX{INRNTUG7#O\K(C*!CA!DCM=2&A6=;0C20T&I1QD(:Z]-AR0_(OYE_FU^V* MA@Y6N_RJ;A2/QI\ZK6\SP+_[EV)?07KD-
'A&4.41=8)/7\+[]Q)!"&#X@L M#1JCYLPJ9%G"("'$#5:8; S,_9Q);GY.H S$_39$96$HHO5BYRDR R+H- 12")2T.4C3'39S R/#!=Y0%W3_0 MP1R.97URE-YLZN;(;#@#(@'=S%H
+6F#'7[CV>N?<("*R0C|>^H)@^YOL^&_ M$Y(@6X2?5;U,(ED5@]+6)451ZGCXZ^6+CL[')!LVX)W%A^D+RZS, M&%+HW=&OKC[2)OHO!?
B9YA9::/W>]=PN_.7VFYS9O'NJAGZ,+B9*%_S?OB M(GP2<(*ZO j$'._\UG69,[7]3@"C_]N34E^8BMOG!'<1T5W-E/Q%';C: MC,1M4:'^[2_UY!>>WVA>>@.L =G6 3H
Q2ST2TCP*4XK>W:XS.&)SBZE:7YA M{8MCQE%GM@(6HN ,,* ;8*J1Z4,*D>!]89A%' (,;=^UYN'>YBAUG9#O= QXS:MQ5X:[E!_ P@!'R'ZN^+)$Y*,G7UC7%5>2^
MXK>,6T/7@7W,>/)-QP;M*\T?MBX+&M^3\A:7M1#]L&4T?-^9(@\93H@26#I[ M!X1A3DB6&O;(>Z=,,<{^D3(0ND,'?!B]8,^%MZ2/DY%=BFDT+UC,Q0#VWDW
MNZT/=NB?M^*T{L!8L"IOFOIZ@-BA[R/D2[ X& 3PFUD9C]=TZ?@*IUM#3TR$ M.VQY;(4TT'(Y[*I#*TA> !T>&^LF@A!F"N$9U^LURR/ J"4"2=[I],>%ZN_ MX2V#%>1 474H9
I>=1N*_ F)C2B$RIQ7(+1AZZ1C$+W/9$E2%HE!J<,(K" 2 M)@)}8%)6J/$%,2< M8'[?"5AKKKMQZ\@:_BN\>&:]]EIH3;?M)$Y\U6G;&6>2:3]V,EGKO0/) M0PEN$* !0C+GUS]5NZK.J0.
E-IVMS1NW-@MB<1GG3KUL6MO:=V-PO8CAA9I MO[+0V4+V(=/U@_N6:^G17H0M6_D2YP".?5+BT/M_KA_E=@_N8]NRL,Q+M9 MR?
2]_(/P<;\2X48LS2L\AFQAZ*0FODP'+UW&)]%EG.XYQ6AL_P*%4U;2 M/$L,5DCWQZ;D==>*6]16]'^_9@R(B.?6W3C%]/^N49]@8#L/-$=+}7"SU<:
MD]IB=8O5/6!RI$_$@CJ$,>K)Q]F\@CL4W"%M,:%72"6I=G7Q6">+TQ9EULY0 M4"R+C*R'8_JXM+ RS& -""WHJQ C2O6L<.GXQ],70+QJZX3F<56?"&;E8R)G, M%8I$GA*JTT0G(*
(0Q0"."%0QDC%I7#9>;:DL-KS8\'TV_(#1!';6@A9 \U\H M@Y-G!01FY%,!M[H0=P^=[!7=V:O9\=$M;_~>TM>;&GCN/<*:.W:ZSK^9:U8 M_=LP_JL/6'KMV9^\QBFR@QIP
MZRQ%UK*O+^9\CSEGLZM6HXIHU'L\K G">U(X:RQ+B_.FK;6[+*U1UPF?:3?+ MR)*<"RVN]CN?77F08\;(^0HS09ISK "Q2H&=1:C6XSN7@KE.+%ANED!+Y(9
ML,8D1G62WE"V)O.P6-EB96_#76G9,WU %<{/#! Z%7B9AM&QX3L,X8_TV:= M+T.N1,6QH;>.)S.2R=1%3:?F,24G5Y;.ZG3#,ZB7A; "XG1G87!M9]U"E8=U&[=(S&ZG&3H[
MPSNZGf8;,[22=LLEU]*!''3FUX0W9-\&QGXG7Q_)5>J{$D#Q_DN;5D9*'1HY M5;6$%,%/)CO<-<:;C%9Y:S M%Y3;M'"-@?6(IZ)'K#^\V@HI_< QYZ#@1+(GY}]%[]_'B^
!XN^P7BH%4[U\Y^9+Y47C-=W/-7\R"(;=AKMJ%_#:Y,,7E(H4DT3=9G*KYFV2(RJNXR_S)D\/(4*3!@W=A) 48;4OG;Z8$C#Y*D"HY4UU=6(.WN!^Q*Z5N'G_C4
MT,;)WD[4LE6FDNE(HRG=)K+K7:/>7^8&?4D]4X4[RL_& Q['Q&!JF?/&B)M2 M%&$DQ!0'&=%7N;FIPFVDSN8TR=$^,2_7&S#F(L+U$N.#4S43+]E>$]"'R>(>\@'T'*)

*M+W2B[QVS KW>IQ^VO>. Z!?N77<2=JS;>GO_+=W3S'^3$Z; M<':.+HK(%Y1_[C**M2@=[.=I:8,PS]< M])?/8MQKY,%%M#AQJ/)%,\^<#!-L8Q6)!L_8SKR"=;X?E/:04.J+//'S1&MZ MRD@K@U,KWS@>+F^(7/#=>@'Q,:!4E&G'P*'3|8VC5D.O#-MM3F=U4[D79B>A MVQLV,G\?]<0>>L:|%$#_4IZT*.7I;YN#ZYO=N,WFO+.WJ7M'6Q]LP46V32?* M@7POIXM,-O!'V,/$(§!QU40&9GWQ4FW-&69-4J:#M=.'X?M{PLH?_BAT, M##F=C-I^2DTX>KTI<1T:I>?>KMXT[=VSF_:N\#6 3 T[>H=1%AF[#^SR*)GL/I1,PB'U^J,DD>=6IH16GMYF]MD+ZR?O'6W#V\9F M$P[\M XWIUZ27E\XP6]X6^SX^=CE7*V^>I§"ODJ*]0(A:<++$G]A"OC5NRB (: M7)J/U_6$BAEO&D2YVZ%&4H@626HY7.)UQCY]AM;YPK/PAC%C\>>>9RK6O0I_^ M<>!L/1+?[:P.)A<6^E&PA;]-'N=44-@.? ^+2W8O.U_9,Q[=4O@"]E6/,57Z MIHNY_? U");.)9NH)MX5Y(§%P!="M52]N8V*8]FK%Q(Z7[BVH<,SL28]L93<^ M)3]. ^4W,O3/K@-)#U.K97B]E":A4:&S&"& I_[!]R=EOZ40&8Y!*/8_>^FGI MDE**#W/%W)=K^,3B.=UCD\@^F2]>%L6\D1TR6]"&<%S*:ES.=|7>)=YB:G M,=M\?&:3)5&)8WUV=7V5HOS+]T_Z@?>@=@BV9>Z4*1N?FTGGH M?2:"=C;'L3O+'A%!!YT??!3)!62:)7- )D/%P8/_04A%]E[8<33H+S)'?P M=SZJ13(KKR]H.GE96;%])B>Q4W[;(^--2?2&S)%#'.YM02 MS(:F]N5C &=I8\MSAVP[.\5F$EXP(@H^%%I#OY4)TY9;*[3O\0%!6U%MY'>Z MZ:18*.UUC48).'=DN!Q9MHS.XT7_#&NE'.16IP'K%LV3 M,E_,A]<]A\[6#%A*M/AVD)/ %K&3.T4Y"UK.P;K M(T302N!_IO#6(Q+OE§Y^'RA<;@ MIA? =&9U7G@&*Z@#CD/2]YXXJ!U5\]UZLGB4A$D<47^R0F"D%6 ;P.[5;,!)9E MWI>;*HY5W7,KDNWJ+?/*=/\X@2SJ1?ANBGI^,7HA>;=&TJ2P%Q;JHLYG/18 M,=,KBA1!J22@Y7W0GB4EVtm;QYEQ0'433'T=#N;,+#_QZ.3_21W M_G<5DU[J4RIPV8H)%?N;I;9C1\3]0.?|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|+6EK5VF:",SCQ8.%+"I-?A>!> ;D!H2+)5,=]%NWL0IVC2B7P["':B55[IC4QZXXR;R=RBB[80#[D%K M#\[6IQ!#\D&6X+)=%EB;QE&!=+9]Y[OQ^Z1<;FDCVZ>'XG&]"]HR09K\T690:&8 M+WWE5L,)>/W'^4[%\5-SC//"VYJ61G+RGAXN2DR.]'HCA\K3UE[6JK_[.I MN7U'.0(/(+.798.&/7V8CEM+#X!)<,2(-P%$4^>A61]_RWC!C"\[P DSN7\)6=T,'1S\M)'/Y)IR2 MIKI&.SNO7):08T@=CI DEJ9&2SN+Q$N2^G)-C7_2<_U(<4VU8[EF=X)YBKN, MZK;*FGD9PX]VQ7\91>V"1?QU93HM#U'F%4UPFB!P=G?U/BD5L-W4JQZ[,<8O*0]CEN<-]JG0 ;K M-A)L1UEO(RH40? 4TM!Y^@MH!(@B"1! .)/!|AY+:G.,Y;+F3Q@:_EM>2/*<>Z,'|Z+ MSG5P=U=NV YTZ.PK2B1/%'KS8.0KMO*V:ZJRD,H.\W1:M;+]&<>5D,.\ E1;70'7ER M I#@1D65>36.EA^OU;*I8@K\U}\;)I542XU#=<:QK4!T'599Z94M<%=7[-WQM MSNNOH*!^%/I/U;$X#EW#B?H*C*VL_+86G^$1L2"#&Z_^&]:6N[3@TWEGE-U0 MUCTR2R&(4<-/H@OKT/;&[TMY1T?+;46>/YAP73L<>V8K=;2R3'V+AG[+6U_? M1])C*2A+KY]= ZW-93FJ%QK#%AO)QFF81#\L+Q8$]+[VQ.A/LGRT&HJ0I*RY M70;P8-FSS7/2QGTI!#$RWVE@E1;%<'.!K?H"\^(*A"X7D&:U?6D@).6CXL) MWCP($,N"&:!G5 Z\TAEM1'OZK(#7=?)3+D2*P7$[QU.K6XIJE=$O*I2*12_M..1\U] Y&@DU]X$R5=EO!I-3#IBMMNPLFH28.);J/$3$TMLEX^WQ!^M.6SOZ, M,APXE* R'H2P4,=(#,4VOG+PY!A/V M@D53(;H7^)7CZ,)7*9);*5AMJJYD/!AS^ 1H^N!M/A$[fDNE:76$- M(7!2QRD8RL##&EEO@.M?FBB&3"C1-?@VF\^38D1(/] @7_98(H_I1 N8?E:VFMB8ID(HC\EG2@@@#NP MJFRR<+)4#$RIOKUUM9V2[#*)M/0\GD3/0_0I=B? 4GC0XQ[\YM;B6QEWAJE"(-M<%R)*BVUN*]7#O1B!ENX4@F@]RH__[ZRY=D MH[<5/5!TRWIA;_'0)?[86="$*;*)(&T"QEIL;UA")W5FDO,RZ^-VD6R&8ED+ MRUJXN!8HVBV,*')Yt41QX#A--R%=>*!U@A+)}>>7:E.-F[!E2?]%+V8QP8>[-M8W*P72C!'. ,T5E25VD]D^Z.9UT,.:*8%TD*,ZU4G0("UL,,#EDW1P=>'TK>8LHZ>Q\@B- 22<[#H(95!ZWB-ML%J%Z%+&Q6;:M? Z+12IDS8HLTTXW"[#\D7(N#S1^WVVY6-F/&\ +VC!G*]+ M"GB:,|< "O45W&J9E:E5L MEVR61H_N]E&S&A!WZ+17I/E#3? >1(J;1(WM,-9!5)E7ZW4T+:N$#1T6H%$B MI'9CK!+_G*N8W""^WVF4H7(J>@Z@^HUQ*#Y$VMPH4A@U*8[RR#2(ORK_2?4PM M%M]^'%5[9P7RIBL;,<1P%+3\=H124_UH* [UR;94)K:=(S+,9.7SVM,7^;2@'D MB39A1'-VC^7AG M>K3T|&U]+X;SIN$--D>VR,N<,/@1M^ML -'P=N^%Q=,)D&ESNXLR]D9.V M#>\.-Q6F IB[Q74CZ<-Y8DM!W7#HA5PEN3QU@>82WO+'!L!#R6!)4TP42$|^ M7W,!F5/P!D@F31?)@4L4Q3,Y=V 1YD;EYKEOKEO:[O[=-7^0+((1R<@<[9=C9"PH>XH]T_H&-CQ[SZ_FJUY?F63N>L5+F-MFYJ3"VR[B+7B !R/D[4]Q,?RGUD=N@^L\Z:S\"SG31<=KV[.WC6,1_.%>T;2 ML:O6-44Y6*<_J1M S4 IM"*#EI:F0'VYJ^,H\.9N>W[_+A9YNO'H=IR;@/= M! #]TDOR\+K51_&;"F0Q*EA:K+ZO;&W1P?-,51!.JS^7S9N/+RSRW>Z]0NI? MUW**,TWIY_9_XI'-$#'EZO; MDMD@D$#R#A=2B=+6DA:"+_ *@AI*!. <3V1=P6ZN=Y45#Y>[CETL?!D*-G5 M)N;Q5RGC7+W5-A$BH&Y$!P:W M1M61@1]1=,$XGH+(]_4#3\\!$:Y:/*?<^^$#I^PRV%.41C*RH=VIW2MR5V@2 MR!.*@L|)8'_Q;43FCDC9O'H9B<%1$[MNI09P#S(MEC?HO2'&L,-NJ@,*J'5M M:!Q3?+G@]C" 'A\K.ZGH^.MJ;P#|\2XTC7<6P-P3BU8EX0K--=>2V'4D^DDQ M\%- B7NS.QCRX+C>RG K?.W#1EE+.^4QO-5$];R\'LUN:I$^KR9X2&,U-.7SZZ<#3.WT:A_^^?0[+.+29U MK\X/JNR#T07QIK8^ABTF>]ONS%^&-9B6/<.%E=01&6JXT(R5M4'BA@E()0D MY6X\);MQIPY[C8//Q? 6P[M.P.+TGFD'IQEW#,!Y?T4Y3P.HAE6%[9^+M$" MVVS(B*Z@I63:Y'\"AX]KC@BLMCR8LOW.E&@YGK'HYD@=I%=*B'F(FM:A):< M(12H&O+ F!=%O@9>06" 49YM'10]+?:f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

*{4=M!;6CH=/0T5T@UC/ZIAT7+1Q@HF>]3$-4X#?G)M(U_1%+K4I]7:O M8M)UE91?Z=B,?F++{CINO,$QL;9%84TD1$ZR3{1DC7;+3EL]/>))CLE- M0+$/W6VUB0JJ;3L^AK, ^^4XA'2RRVU,4!W-6E(+4.-D=@^PK5LPX&3.3K0 M%"V36&JL(;8.IU8)Y55M1&IE/,#"F5{85B)N:B!8B.#9Q\S],+-Z)*B_.*L0<7 Z ;1R)%7FI;VF M2T%QYV!4/TH-T%WU$RA9!%S0W<\Q<<3C2YU2N.U MQR,Y6"'!<)+Y%6Q4DCLO2TW!=E$Q%5<1/4=?*<;!C(-;.+?-;HH?C-;M;N=Y2<]M'J?Z'KFKFS MV 1%,)COJRC* M%RT9@S& (>^)=''0^.^=*V6/AJ[ §28](=CAMESF=Z'S+9!11F#&{B11F9U%8RAC7;2LO(6PAN7C*+G)NI[_V:)!]\H2K:LVW% M@7S/&!0^'ID-F1 P/>O0!);U@L ?;=D6:{!91A-EN?^;OY\69(+-,GJKP.% MD)\ ^+Q@\\]E(-DU:A7GP9IWY$AGQ=9"ZJD4/YKO<2]%+2'@.<E1*_=98 MMLW/+L9(:1/@TZH,T4Z4 #26.V#O.F:KMVIL]7I.3=YJ@8JM@-UY.)OJV0P> MP\E1(@;=M*C!26;,MW!-NWA[=[SQF"[&G<+ ^[+/]GLP[&-9%%^#DT[D0HH ,MN'^T!?%UW?;H(= GA>$22,91Y6CO30RVUB,;71[58C;C_^OK/WW, )D(B4Y?S6+[AZ/NVA'RLUX"E M+7"OS3* \7@,NAUZ9V&9U=H1[2V#I$&ZA(.03,@W5(9Y^]E=U&R|/GGO5SRJ2GGX)^ M4U%C!+ fDQ:C{6DD0X!24]W'2%QJ-IZ/UR?A9B[/(+Y&W3=F'FK99 M5[+QTYNK>N;G06VY+-Z&$\87 MH9";:-&E7?A05^HMDN.$]J[7"B=V7C]J-&GYVI@&H50NDV6TMM@7 XXW;[- M^+ S]YO8&W^1EGK ^(L=:]';L=U:=2T>PJGFPEQ83E\N(&22RZ+EO:+F-@ZZ[FQ;W=FEE2,5#OB+4 M4SM5E)E_XH@VT?$^L];'3]VR*+Z//?L9N0LRV(C^CG?1RWTIA<(9KX&P>UMQ M1$Y/[ND$3K_Q[6=4 :UV*4J0!('>XG8:9(RCB[56>.^"@W*4*,/S@6B,@0U MZ'2:AYVA'"4YG6'>&0,4%'M_^S"$]FF++>F2C'@QF:&,&41[NI/*C:7]TGEY M\4=W0?? 5=U29L&3S6!8X&57X5)>3;SOL"2142<2W"$,@W5(9Y>"249N!{XA^-M05;1 H[F+2TKW@@OIFTX*E0%BN9^&OW%FU99"-1W7/6:Z5QB^U?=MZA;\"J^-NNPE-MM"VM)K;XF>L*Q?KVC-F^"A6+4 T]-]K4)'(I5LR(."0"*9X\%Z1%$]B M 2.,#1&1)NF!0(FJQ1KA,WQ#//B* MB'R"\QD'|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|&?<'2982^Z0L(7"S.6U:Y^B%KRL[LB&D8H[ .>_\UDZ+@E=.Q\W MX-.;3]EJ:H\Q3*@^6P1N=NT)-2^S&=(S,.56]^NYU+R@A76/R/=R/'8\,J8K< ME%6G&=S3F/I8>MV/T^O^9.EU+[WN=UUC_C8OQ.B>8$PN2K%Y%)5 ;NAR,?:H M4YE63;1M8O9;ZU-=WHE3_9+RQ#N.M^E_.O; 32N,C^(94=XI4<0E6Y*[F/N2:F\E4G3[<[UO/_TA**,A?+_ Z;\3YEH MR?BH32GY[/G"MV9]E$%P51_H"5Z6I/L:? VDX)KM.GCYS_\?)"O5I))(W&!^O M9=USG$]V1>$;SOL"2142<2W"$,@W5(9Y>"249N!{XA^-M05;1 H[F+2TKW@@OIFTX*E0%BN9^&OW%FU99"-1W7/6:Z5QB^U?=MZA;\"J^-NNPE-MM"VM)K;XF>L*Q?KVC-F^"A6+4 T]-]K4)'(I5LR(."0"*9X\%Z1%$]B M 2.,#1&1)NF!0(FJQ1KA,WQ#//B* MB'R"\QD'|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|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|&?<'2982^Z0L(7"S.6U:Y^B%KRL[LB&D8H[ .>_\UDZ+@E=.Q\W MX-.;3]EJ:H\Q3*@^6P1N=NT)-2^S&=(S,.56]^NYU+R@A76/R/=R/'8\,J8K< ME%6G&=S3F/I8>MV/T^O^9.EU+[WN=UUC_C8OQ.B>8$PN2K%Y%)5 ;NAR,?:H M4YE63;1M8O9;ZU-=WHE3_9+RQ#N.M^E_.O; 32N,C^(94=XI4<0E6Y*[F/N2:F\E4G3[<[UO/_TA**,A?+_ Z;\3YEH MR?BH32GY[/G"MV9]E$%P51_H"5Z6I/L:? VDX)KM.GCYS_\?)"O5I))(W&!^O M9=USG$]V1>$;SOL"2142<2W"$,@W5(9Y>"249N!{

*(X(N%!Q"89,U*ZQWAK5ZM_9CO7C*Z< M5F:MCS@6%)_6-V=)[*W"\NJ=?[BNU#+?!R0,*5O^1]XDJI@+;,EK+/#TR%.S"WL M#,DSTR R6\DI|4>$N*CY?^U=:7/;2)+|O/LK$)KHC>X)?NA47)|(M0^ICW3 MA\=R1\\W1Q$HBEB3 >'*.ZOW\JL P40I"2*%D$R>R-V:),$*JNRLK)>9KI4 M@!*X1@_GKZ0YFS22EAF@-]];%A>2#=\;&YZK'2(<%&CPFPQ^S-=SGD96?UL M'0:(W+[4B8"@XK?F]:CTT3%E3YYY.MH&_MYMY\#D^M<{0G".C);D,*O!R-KDY_HZ!W38SPGS9E$^[E8B>S2F/;, MLLELK M;G4R9N+S'&_5Z9_1 HQP7A6\CI'K)WTHR, Q=JENWA)IM8C1*A+],0I7!QM=OT?HVCA:0>@NG/N2:TS2%>](:\7-6?70RN^Y]CVNRE%>&8CQ@N]GM13[""Y M;'PWL_C^+;IHS!! \XX>K[\-K75QLM1Q1*9WB:2, MSWO)MCB24:Y;FLVEB M;5++\|U>9MS:W$HAP52#O.L#$[YE0V6KA]EL!,&SL?)/$PBT*4X^\1,6!CIE M&T[2>18GF8R@0D*B3A2VEDE/^]-'IV<(;Y,::!9>E>%\4@\54>-4#RVD]BP+Z M$!9FD%ER)V%W114F?6O8QA#O3"8EXE'M=:L\YN&6.QZ;LS67TGR8**,Y]S-]*

*MV#/KBK6+VP1=1UGBCBOB%IG4>ER6%=5_SH"8#JX%(=:!%%<-'C^,-# Y MEQL1$@tl=(J.5-K?9R/(S]B38:E4(=S-C M>/OX5$€=1TO CJ2Z06/5V%1G';RFS;D7C(&P&/+-QC&@!YAS@*T(\VV**%MJJ MQ5'U(F.+6%1W0(P6KDHX^,.!XC69QUIl.'V S ;)E]@38, MJ]7DJ5VI:S&DJ,0/&^H3X63A]_,E!D J!VVGP$6B9( M2'AM6T7Q+QL[*YI!K08EEC4+B^8,1-(T5"49K=**Z87(,-V$GXY:!CH2;1^@!J !6UQ@**151A!09'3 E$ M;C!4!- LA.HBH@"U3<627\-HT9R(FW_>V4 NG# -BRC^B@!69K>>QV3-M9:P*

*MPI0Q:VCBX1C<2.5T%^J45\U:R63E<9IU2T:04KMF+M2K9,XXLZG+1& M0KO_9K%YG3H$9+<0[\#.RJ,M*W#)T*LL*9DW:W$B8,U,+-&[3?T/8@4>*:=_M$9K,X8?L_"8SWW*L3NS5<180*SK@6O2#GT_'2OR"OE5B78]&@M=AU6RW,V M1 X6(3NNK>$K47](>?=W:)]T\ UEY#&XTOX=:*.NDT585K6Y:MU[:.QFDSV4*

*MVH;PH,Z;LAZYX2/,KT.CM5#)=F;S6C9D0YID6Q#@_PO1S;_^G6E>)F%?@9^F(*;LQB&8R3-4\E_P,<_MJP3T#6D!X"PQI0)&;7+7019ZBO7$,BO-E0J_5]RH^NWH/,JN*=*H%0@!\T"WM 1+*WT'C+9Jf:,&7S<#4>3H[T'X'3MQB(NY!^K!<>9!^$0YG;3#B0"&A,F8F M8R;.HZRV_79HGD_'37Z/Q7\JSN;S9 Z,%)*I0K^^H.:%K)?E\BQ?IQA\->%4J.*A934Q+8?+TL=2$*FZ[E`MI203TCUN"CO+)5C&L5Z_V4LWI.J MWBX#"QC'YB,>=#P@(]WA+_QL:AG5>%;IGI?BOJL?:G6GX M2ZLX$_*X"+'E?;_T \VVF12FT9Z/S7.95UE(TDX,&R6RS(CEK+R&'X)-.Y5 M#&\8*1AQ0ZRIJ,G,E58I8H6(0-&OZCA4P\)^2D(V*LZ@5-Q998&<+%$_%6M. MQ +T\*KIJ/D=!W&2.N)?.,M.LDS$HDE*6(B18$T,?E%'!@Q5,*L0V4@,(,%T MJD.:&ALILXK*BCKA-,DO)MD(.*67$>_M3)FY9"007I,C,#B'?91><15,!SJZALKZ(YK7<'B #F;(A)P+#3%N MNG95X6:%3 2,6XI+/0\-CZ111^T#8"C0?ID)85\FF4IPKQ8@$*X-XN^7/*9) M'"KJ^)AU#!5N>`8[5O?L2*7VS9Z%XBA<7FI2V1+Z+7]5W.D>:YP5H%9 M46D"T#Q+1PJP^L93-E &$JT"TNB.N8!+A?3EB0&FE3&*/^*7':N;@& "R7'MF$WG+P\C$++I ]@MG2Z$(5:[2FJD+ 52VV^CPOEM'I+L["J+QG@&2ZX?5:(S M5D3-T,,HY\$6KS MBT']>V3:)-FW8A4_V*Y>RMHZ$RK6'LOJSQ=FQ"[ZM35 M*

*[%^LY%R^,Y4J833$|#<.<%;H:.B5,*$_$ OUXRX3S-2"L66D^0F#$FLY M],*$W#*5BY;GM.3)!)8O:/'AR*Q12 ,P B$1[5CW'M*=N8">Q@0<\T;K^<-] M2\|';.'887%*

*JV.8B8UCG\ZJ'PM<[%.HX9-I"2Q=HR"?-0&.7H2E(>$S"7:5 MU1]J_STN.I*&I)3V%?(1+0K&@D**ZS-JCHD0M$[1Z")Q#[*L2D@A4;U?E^OM M"|Z55CVW<<%=W;1@=A;O?45%KI8FNS BB$"G\Q040,PAE1O!*;9-&I<5Q:+I MK S^:"$V]"Z*M%TA/_]5HF1K[*VB,9G-LVD2F6:>LD'-(M%T(2@@*]S.G)E8 M:)FSD%-F529CY_;_=-A(U]9:!*O-BED'DT]:*

*(+S*T11YQU&MJWGH*?)3ZY]U-MHB{6\7W0Z?)F& WS+IO61&=(82<>L1]#+G2NY7R?)?2C:<(K:QK^_#HY$ZH MRI,W*8ACRG_>M[M. ^1)[RI?H4;X$Y4L\KZ= FDIW4;4QZ.-(5IE"F$U+& : M.6=IX6ABJ>26%5\?<:O9&E.&$]%I,53X]\0+I\N2(U1"3_('8H^\1%+=%7HJ-M0W^>C8Z!,RQ*2LRY_I)*IIM"U$]!B$LTH\ M-6=*ZU&7]A/S9/Q%>D8%-*

*B_BHM8QODAD5K13!:B MPFUSQ:3$E;JB6K\?@A\Y=]JG4S2D2;]€9,F"!"AM0XVX8IB8.KP$V?+3AO#9 M00P[,3O^.-9PVUN6BEWL%2\1*LRZ]P=S_>VETL7!;LD9K<,1G/0C/'P3<,MT>B-(IFHL2Q%JHBFK8180NCJ<1!^-HTJ8=6UNFE?29.>&(K>\FK;,?\JO15W MLG7Z;@7ZK0S^7 ]EROY'S)8./+FM>(BO'E.-9RQN)@MH&\NE(H(<97*#&NA):.MRR??5I*

*.OQ.%]HT7FB6)A4H,E<`%E@-NVKT[AQ^C0'IG(3BRA5$-J]4_$, MOE-I"--@S#%IO-"WL7+ >/S+(@C99@%&#E"&=5><2YT MXYU2U7-I1\L@K\ZJ6.:D>?!%G-RJD.!J.*PXP4^:=?0?9&$UGEM7&FK3^:%T M6)A0/*15 %E=BF2?V@^)E+L1H41G,-+FNYCF."QIUHAS18H@UFTMT%C+(@^:). M^3R5?)@ZT62Z5*DF4H.%4LXERZ\GKAW_)*

*]8"U#W#IGEW\W=H-I%"RH.R:K(+ MF8X!Z,IL1:63!"D_Y-2Y<+;F1:.- E:K>GY@!.Y^"=>>`"%-3=K1*!1K25X( M"2G*SO)J#=3SQ%'TE4/'9?QGY G0N29(V.!)DBRQ<*[((14R0= IQT<,Y M'HEH/72VH5AODV&H(DB:O$UQE(FK(V9)3*/HJ[3HT(P+#UX.F6:JI7;HBTNI M[&*MZ>XQ^BA,88+>1$.==EJ14--X&@=>4KR0%GQ_E5(Y=>X$LB)HA!+OOV!! MQ41A4!NP|@*72|"?HNVIA%CE%YJI4!4("05%E8!H]U!79IE^?,2/I,=.SV M3=#GI:$W4Y;J3MNEW@>1:I4&W\);M.61@=\UW/BXT5DBCRQ-N8ZGD+8"JIF?`M[*

*I\#_1U(G^2^>9&4XKZ8Y9K[T?L'BX] MOT4AIW#&MU?!@[$"QZWIJ873[0M@RH;_WA>?CYFX0HK-0RB^$O>:'3OQVP/`M:D=P<,X?GU\IWG%_% MT,1).|ZJA1-SX[S-Y^:1\,6QZ6N]#-[@BS!R%K/LWA5VT')^1P!Q[^KZP>+; MW?M@3M(I>)N'Q\)?";K"[\Y\,.J.AK!A8?OZ1"^.N\W++KMHGGOL@@^[ MPX[/NF>8UBQ6Y!,?OSY(\\7M>1?^H#-LJDI.O9[`:/(+;]SSV'C$*9D3BOX^N.>?R7.RD.9E+N=T<"IGN-K/YJGW_9;=GCE1U813NJ[\]P7 MHYXF?.UH!WP\"QOV+IH=X9 T^X/+<.9=NYWFY;CQG?>?ZSN:+<8ZHLE M5LKAF"U9F***O[_P72ZJ-I[.JJ;7'W>|?K?;9(-+L=+A^CS5'?3YL7O0ZC'['+Q?XM] M1(\;[$LMO29QJ*]NRM[@LCB€@;U1X\S3G&JZ1>U\RBS:TRP6AEA2^ /|2U\ M?C-3V28LP509/!DLMDI,!1$' ]fER*4NZ[3%*&2-"@)0L*8,+&K3_=[!0>>[ MJN MI/M97T"V?LQZC&.F2GH:FN&D>,)(']PS_)f|@&\QI=[.3?.?9>^/PBA[ M"[,,*

*(QR3&$4*65^QSG_PN^Q8GK_U_'SEO KY5B>?O7;Z!)O%JXR(BXS,=7[-MU/!@*%R!_MA.X_(<*_L&&WT1R"KL*WSR^FQP MMD%NX_-H[W2>.DDT#?R|S,C6CL C@423!XQ@9+F*;GM\M"7M?/F_&6,_W5Z M1ZA3&\W%RA4)_@_?4]FNYCF."QIUHAS18H@UFTMT%C+(@^:). M^3R5?)@ZT62Z5*DF4H.%4LXERZ\GKAW_)*

*]8"U#W#IGEW\W=H-I%"RH.R:K(+ MF8X!Z,IL1:63!"D_Y-2Y<+;F1:.- E:K>GY@!.Y^"=>>`"%-3=K1*!1K25X( M"2G*SO)J#=3SQ%'TE4/'9?QGY G0N29(V.!)DBRQ<*[((14R0= IQT<,Y M'HEH/72VH5AODV&H(DB:O$UQE(FK(V9)3*/HJ[3HT(P+#UX.F6:JI7;HBTNI M[&*MZ>XQ^BA,88+>1$.==EJ14--X&@=>4KR0%GQ_E5(Y=>X$LB)HA!+OOV!! MQ41A4!NP|@*72|"?HNVIA%CE%YJI4!4("05%E8!H]U!79IE^?,2/I,=.SV M3=#GI:$W4Y;J3MNEW@>1:I4&W\);M.61@=\UW/BXT5DBCRQ-N8ZGD+8"JIF?`M[*

*I\#_1U(G^2^>9&4XKZ8Y9K[T?L'BX] MOT4AIW#&MU?!@[$"QZWIJ873[0M@RH;_WA>?CYFX0HK-0RB^$O>:'3OQVP/`M:D=P<,X?GU\IWG%_% MT,1).|ZJA1-SX[S-Y^:1\,6QZ6N]#-[@BS!R%K/LWA5VT')^1P!Q[^KZP>+; MW?M@3M(I>)N'Q\)?";K"[\Y\,.J.AK!A8?OZ1"^.N\W++KMHGGOL@@^[ MPX[/NF>8UBQ6Y!,?OSY(\\7M>1?^H#-LJDI.O9[`:/(+;]SSV'C$*9D3BOX^N.>?R7.RD.9E+N=T<"IGN-K/YJGW_9;=GCE1U813NJ[\]P7 MHYXF?.UH!WP\"QOV+IH=X9 T^X/+<.9=NYWFY;CQG?>?ZSN:+<8ZHLE M5LKAF"U9F***O[_P72ZJ-I[.JJ;7'W>|?K?;9(-+L=+A^CS5'?3YL7O0ZC'[''

*}B,9DK(J;K%7]++;8O;86NU|"%L14Q9LNL)K!G M<'?3TOBN+@EI0,|]P|S+1A^43[#BM9*Z_5'WSWLDX@XI!RL<@%$YN0RO<1Q$`M90>&S9%,&Q4J>83U:8278?Y80>Z@?*QJ$0MC:<[(`JTTT5-O$U!MM2,L9 "|`M5V%6ZQ-/9VJ8^:B>,6PW-)[4!R'+*K&;&**L*U%$7:UG("2IZ!9NZ&NX6PF; M!LN^@3/T&,+EPJ_.TRA)>QK!38ZU?^^<'@DKB_O 2;Z@FO=EF&)Z+%*(*[H*_M0@@L,OWX#1U^1J_%=8PW7N#++F1O/`XMXO1R|BL_)?]ZAW|]\[`#>=- MC9Z=,8C2OO 8G.$D> S!+GNR_8]DV2@$-[6?\M1%,ZS2N;H%DMK64^2"L%DL M8KJ@S9]+NR0[X]D=I5X*:`.=QGAU5,$ZJ^U@ M6H8_!+]D2XS!.H)Y4E7Q>'IL+6.[!V}Y%5M;179FCN87G@<@<@W#H/<*2,9N]`M?.^$H'6'0VG3*l6<7/<#_G&9)2A^/ M6,70]"0U*;0V;\D0(D[C ZZ\OT>QG%32$!U0TVBZ'1'3])SS5]MH5R_3YB . MYG-*6T+A(2IL4BET*?YUFV;^EFDVM5:?GEV-9YV#D+Q842&9Y;TTS*ZNV81Q M!&G (=%Z99TW-L >A'2R5?T7[Y4;4]#$MZN=^D5X HNUA*SL3AW1>B4AM-2W]9:I%,;%O3G!A_<3B2,YPBH(+WZF+*F M5K.R&W!WQUW$*B8V"2,],DX7]U=ROI;<_LMEMLY8#-BGF-5VTI?>)W@3O0!+ MU10-;(2VZ1@@_!!GL:?5XFZ,]=";Z^R!GGNs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}JE3U$,P/N63;CY.{[*^^HST7/%Y,_"10/`M%^H*?8#.O>63.,V^J$PV)#+0U)#[=ZB4Z50&[%C#5VT9:28>^K|BB!?_C&] M +W'0L,<"(5MY;_O06;Z.D/Y>],5 -?;O3080+6*NU:T7?GJZS!MOEWGEK/'MEO8+_LK^,C!#K]1WEJP9P~=IH3.=:[fT"-M[Q&;5TF#KFA"<_9CPPOL6KT=A\ M2IL47*U)GJS998*J;^XXX\,2ZUJB/-F?)UO3^]M/$7VY0O9P/^)P24_L `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m> M+QR8D-B0CRA5-:J?,L:^&T2I!2E3_AZ#'V M-D_!TB,-58.:V]Y&H2ZIE#GJ*$LA*X;KG^!5%,/F<"\SM*>#FK*C6R!,M 7XDD\&O/?KG)7.RD)]N=ZAT/16)<$BV;!!J?JN[V4Z+]@5%7 M> 2"Y+ <\;Z@Q..MR3I1\VQ|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{J5E.0C|^N9% %LOWI8>CJO:YZ5ZW_D+ M>]>#'.FQK+5V-0\B!^&ZE&L>I=$CH;,]@RTY:[$2*FBK(06WFL/#U?U&37K) M21O=+0$\,1S6JOE"]VT!O4ZQO0SDK\C/ 7TWJ42Yf6>IZT5C.OV8*0<=V2F%.M-G-+LJR!'6K@8P !-P #PMHW&%Z@V,!1A:V$V^$@HB%A#AY5Z4JHQ%<928,- MJ8\&,T!U;I5J>/F":OPE#OOGR^1_4^A?&-K57)30\S*NG3^$B0I:D@^(1K< M12QEJ$G,'4;#J=AX0;^[6 ")E??!E;SL[=WJ$[=_1Q=IL?+IX!>XOEM-^C2 MK.D]G>5!POJ&E-R(!+Y\KJ!I%0?!-#Q"5:GFRDV0]_^0,C[,=&=?EGF-CI?'T M^,6X#OVNZ?SKCZN=A\:%D;S;9 (E\|%V 4IV%-7U?0H9E|<4 ?-^,?))8/I MM18NKS-OL2U(\-R'OJB^B?WSER5MV@K\L1NM MFP#5;P"/'H>A%=-.:V%!9:%\+H(&ZUAAO\&, 3':8-(92US4P+V5N[(2XO@HWG]FRH399!L>,31AMH^8P!RH/IV%9=_M65CK.6UF\[\DQO\^,0!BRR]ZA5CFGK,7W,7U[?JV4GFEJ;1J2* M4H"(] @+!&N!O!U0,%-X7CA-XRL&./].'XA:RAK488ZKT0F9 %&\A6!0 M'JOC68Q0E\\GO<4>A-F3SI.E3%Z&++HZ(BP@.<^M[HI7WX7D9(?W$PZI^$P@ MU<-?!R$S=(##3O@&?GTGS_^<2I/VXFI0P\Q"W!')&C$()%=9H:.DPND!4Q7IKBZ/IV MGS);#KQ38(0&S/X>^+++'6;PG=9KAWJ-.1'RM\IV>)5 M+2*

*M&X>)8F(DEF\&+B!W|E-'JR -UUI82F.=Y,**N(L^*3N4;WC9&2U,9M?20WIQ M:$'\4!:U*519$0,X\H,99Y0,X''OF"LDDWA;^CO"#]ID4A;\<_?!"M98B9,[ M^H G$/4:A#A4[;FOO#ZA\I#E5Q];PE+9L[36^GW%R2_T6^-_N\%_2]BV(C(I$L_MQ71:^@L8ZQ7P6Q*.DD9>#^#C86G$?$37L;FR:BV5"J^8(CI1/65X=Z^X;CK/ MRLJN%DC;TN7""*N%*=C)CV=7;]G5_E5J+H,]X+U8H\E]+W,!$,&&#FG"(1I]%(;>8#SN+I,.CV%>"1{6L?Z M,<,,;E;AD9T$=[$'(AK/Q#==.E,+7 MUJ9:U?X=M:#S0F)B BSAVTE]GX%N&B#&2OPW]/'#T8^Y MST6099KJOG(G3D'|_BG&J&?4S55HD>/2>W:GF\17@6/,.0\4YQLZG/T0&VM> MLR\1^\]QJW6!NY[^2C7?V1>_L|WTW47Q(#V>CX" <(ZK.?-F;ZWIJB^8&=A?" MJX\IISYP>T&\QU&V!$D( :793IFXG&TN7BUCR-DXP_R_&KA<$75T9WF)TT7O MY C?@MQ40EQU!P!@C=^"K51QQ_-A2!X?9AVTD)X;,YB7+7P=(*(4)D? (E\99 M)64NJVC [L NC7-7S)O]7-XM7HUXLG.KJG.!1F7(2I%7 BO!YCC$H37(U81% MSG)S+P!A@^6856K4(,#&2AR:01F&X*9D-L@!*N*!N<7]M\6Y+]+VYJVYQ&]> M_08GSX:2/PS"PR4?#/_XJCI&6O?2JCG@DK\1OO!ICTVED>2L1Z$;F7PN>/)) MG^_#I N1MJZ66ZFE'CC".9)C'"'S'PC>R>#10'05^(Y!TZ-HWQ$QC#685\+F) M+1:ATQ# \\)<8TMP I[BK"=9}/L>-* 0@Q9?06E&VB4#'-4C?Y MER=04]_11Y5GW5J/)[_(.:,Q>]XR+DX$&!VNIIE# H])>DC2%'R:4[&]*+7RNX:W@BX=>YQ+]64.I@[(" M_Y&%&'W_X8!E#KSZ%;1W|\&<7#G")&@&9++C9TPB%HDNO@83T5_"}8,EK><# M[""%,I)TC>8-8-\T:3"M-] M#&2U%PR0^KE;WP4X0C=P]XZ_F0"4+$C28.D1!:4NFNG,2>NDW:#T+N)'+PS^_MR=_9T/_BI73XQ>HD2X(0)\EH) 6=/LO]XB, L((MGL61S+;#*_M(:0\YJU3*?!##6_^P B3AV".4PV-_'81!DG)$+P,I58(TXZQ(7_H"CC0)TSQ@>DK\1OO:#Z,3HU<9OF=,D;Y[YJ0BBI04/_WRU)+|FA#MA:OC629J?8:9I719TOU9J/Z>@K M,\LCZ$WRZH5N+?]@$]+1 LU E'<;#0R2YTYP2X*X>3LFS,>Y#-Q9"F]R.(P M@*?\&&*U?^ G_$@BJHH87R,P5G#,7AX#9_1HGF1 M+HW7$1I4*!,Y[ML3\B;+/K"A7 MQER9W'W!O9WC<&AD$311DU1 ) =.(.3,\43* {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}$K_@7M@X9P:CX)*F3Q63"IOM)VW+:GH2GS)62 SD{G4UGA%2UBBM=N(K6$E MQS4=BD'M:5O#OYQ^7XO=@@%-ZDARN\'+P", MV_.1J8M78(2/@('3,*]X[%+ -MUT]0((]N]I&]TK?0MD6T]@K!F^H8K6[V@U2.M".#*[YQ76ZM_[&YRD<;!,A7A_'P9IPE[Y MXR6=<" J]8\NKU;GE\KO*_!\RVD( 0DF< ?/O-2ST < *>+-, ((*-MVC9MFB4S* M#:.^Y+!W1GW.PZ_^ Z{((:R!_0CE2>A'EU"5.SE>0Y3-J.L.NHXHX^.F!F? M__P1!7*L5\"XV&'-BZX>)SBF S(T!/XO5IM&#HKXJ*]@(..GJKXQ!!*@3+D=M]) M^/EX/HC.@I9P>^9@_F9B(4%5C;6F##5RMH(LT.CQH5 MLT-1$%VLOD3A%94*4ZJ^GM(#$/@X%I874)(PY(#HP*(\-?]\&1 M'!S=O+*%,=9CQIP6O\I@X\)G5HETU.6%"6OF&"ND-;M(1#(V==)C.UP*F895G/E/O20&@P&, MOF>QO@1S_SA2.;,^$PZO5B./@I-[9O>9E@.'W9FN+H+0"R$H0"M?K%F*QWOM M-?N6LS*REMFK6N[4,'HQ\(.",V .*'EC=? @N5#F7GE@K?#;X5XL9*,R9%2Q9 M^}ZCF)0ZF!GU-5T!|K0IGWPC8)69C>-T -F'!10A'Y0//L:)0 M4# B^+5*-2WDS=29DNB M5%"VJ,3#1Q#ZJZ7>]1K 9*$\)N5^9!5>20&@Z+ fJQ|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€ @ T:(7M@($'8T6&J0GJ-V*3XQ:KES2[$G>G&.F.' MOZXWPREKX*D. _,"+MR"LB)R(7=`T"]9ZC^2V!;WA@-1,WA$,R!>.<0O]2=1Q1 M(1$]0>ERO:E#ZE&H '%,;Y!G+NB:P*"!5*D5B;XF:!5':RKART(3GAIG_SD6 MV_D% O& 83D4!"*^$UZC;Y$:$.4CNL*[TSRQX(-_0XA@L>T'94?2C0=Y(['!VB)!2!_ZR)!E$04,,/T__\Y[&9>!Q 5]]E++ 7FZG!P2 M="0Q*)*C(CJLL^0D^PM20/]7,.K"CRG0SZ5.] KX):/WWF$:-2^A#@G^U<+]M)A.JBP75.7V""=4W. UXLBH\U5\\RMQ(-2FGR 4TH+D?7)\F!AQI3'S[Z4'/ M<:IWCC(KFEC$P.*DI;\E)KD@Y>Ex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

*MTK1MQ?D@&0*=*&(ZTM)] 71SG&EO'Y3>1]N; GTP*%N'BXSR16]1)E:,RG#[^$$:T!5]HG6W8S'ASP:?8NCJ<-MWQ:.)P+Y-!6,>LB8U3J1@$?9&&(E=U?*Y !!#[T3%+_=$TY*#O-&=AR]7*KPS*!",ZIFW28?J A? ?XYN.A6[WG^_2 M0=YMWZTI41# =1=[@"APNUT_1&14L35,'"%*LYTR<3G;'$*A'+@XWAZ9U 1E M8B=!F>.Y$9O .U-1(.59SDS622- T[;FP@HI]GHUI'4J?Y+TCR]Z#]1C[PNI'V-MZQ(;XBVO"EK&>/$50%VQU5A4\60+,%=C43H C/GP,W.NW=$9.DV*U?2=0IY( M!TN6P3MXF8887V2ACWV)@VQ$&J14#U>,K'PW,19%-7T%#^U$)C?$ M1M%46N"%2;.1YM_[$H5+4RX^[M8CND?58)X,E343G=;F$P8VVN@BQB=/7X M&F=0N7D-#1Y#]E? Z^6,P>'OA]A0BXY*[Z P_8Q)M%C$H[5!T@57;. ZWUSR+ M=QRTD*KA(6RQ7V$&B%Y#2$P#+=D\8--]/A,PRB_UN2!H)G**7]URD%[XXWN""6[]MH>YW/?^'X;JC4CB,)$=8=G/G1 M1)+'"& 1H+"JQ?_W-DPN0 #(3 +%DDE2$W461N9V3V!FS/(=\YRPBAPT (-U+ M0W#P&\R'(^52#TE? M>X@$E.^OG(2 >]*Y3+VG3DR1#WC0&E)&S.QMC 5L%P@#@=BV& MX, 8P(K"1N$(!I>*I84,93HSBSF>5?-H"[S#]ZQ\&X+O/-#9\EX]U:LL8J5 MAO)N$A.-8>95]I"&72?CS'0'[M5F&T0[Q"-0%"%F01 M69#H8YY!B0]%<,DF M?2.D&P-\F/L:=21GDP=CX.&A[!1W)H3QM8:'I9L]VVS<>)?'@;#0GU*X{W<% MA 7'ATZCLN^C$.5?O.SPXSR<)$PD]U*[PV)61A&S 3*^YJ:6E/V^RDYM-;^U MFY"&&M^$/*ZXUQ/W%98CG'5"3E6?=0%?4T4H?,$0*U5]W[TM]_GTUGT"YUZ5S(\P"_.HMTPN1Y(]W/.:+812>&F,?#_V M&[E@C*8C)]U8/.!2HM4RG\ <;=1*G11Z(KRA:Q^]VU5^Z05^3]HC600P^](-MHCP(56?,BJOF$N^_C^AOO\;X "BQ@*8

BNZA,9X?"T%PAW"*WK+?QS?3XY@'Q Z)"-MH7JL7N(!F?].!7DJ,.JOM8T(&+#D_\W2GZ(UB"¥Y+),'GZO#FT\0&(K!N/._MTSS%2VP1NR%E/86W'00OIFB4@>8> B75}^1D1)14C2_X-
>Z!21""%"77;*AQ! MSG=%$;;;J$,M"PPFN5(@(T*,"ON S_]5RSI[8=SZ,X1AU3"2'W9.6(Y{GA, M:lH.7-1L.2R$3K4I@NB0?X'*"S6T/:TMHV9MM$.T0?D)S+FTYETH6)CX.G'IQ27SY].7?
1M\,RU?D9>!CWI,_HQ_+BXT%7B*#^9=,\|@\V MRT2V860\PWLD9IG5PY-SX080C$;? ]/P)D<+$>(C[_"FR6+DS?'M#(8#S )B M&WD.HY<$Q6\PL)L0LPG_'(5+7*N?
=EA<9@*^BH@!R8?DS.&&9X.B%AM'')9# MQN64!S:IBMD&A@957I[)F1G5F'EF"3>)LN$\\P./":*#Q#CR%]DE95RGH@%& MS^8Q'5S-I3W@_H5Q>W]9__]M=/SL]8,"?
B9(RP,%2F:@+++!@AE%-O@T4_^ M>8$W@)_"IYZ9N8IFBZ6P< M4MB\2 3OZHT^7;*QXE$^ !BMH)ZP?N!!?4#E,4I>59/$T&P]> ^CD+FDT?R'_8P2-'>
M.TF2QZ$)DGGR'3XY;*T]TG=0 HL^G&GRJ'YP114L_8(>80|<$&T!63^V0.3WW)XTEHCKBW<0YD"9IH8<\\ MCQB$W 4T#O@!S^!&GN9MY-
"RX>G+Y8"'"#_8T&+PR1R+H8#YC78CXB M9V2Y0.%;^$O53.0 O&.+CS(W7PTH"Y0,fT?#!./9(;"M[0712FK_L'*V"N9Y>>A-4X)?=E0<[__>=2{IKXBKK8;N
M]K:V%TV3V.YRQ.X4CKX#TQ8<)UD545,@CR"UGU\7>DK MG;9X)K6S)_)H!88>0VJ5008?Z.=A7 S0=,/1,;$LM{!=/6U#58S/Q5T>C@_. MP]#PN
^PH0@IVQ&!CAQQF+5[&$24'A/HC89!T%$H)Z$:5Z]/,/P^0!&+-:4 M(_1 2MF(ZR,EQ" RLH"V/G_83=[V.P0K,+.UO*,R&04\LMTV=M#TCKDQK.AZ8PD!(7&2*NC.I3P?
RA[-(LRI+G$%]-Q'D!U+,/$8WQ F72XM4- M/W_IKR2:,68@&JA#H0HAYKBPH[RB@&C17?:@AX'ALXV/C*K=MVQLSBJ*'7S@ M)?
A>=4.(G);HL9T&>=2Q2(J.);0Z%$0K#6H57PG,$*'X,P1(4TIFAXOOUQ.P1G]>9CGD\|_ M4R=W.]ZW26\1Q+?+9C/-P.QT!ME'.$ @607!J)(RH(D7VX\C4R)+3<4B$
M!NW+H\FA1*G3F?/ETY<_T42V:$G4A,Y/G\FW-M/_T?Y\^?S_[V^:4]G7_[R9U+B3S^=??K+G\^^?)YK!9^/Y%HOGJ!MVS\#M/(M-M-E\0%.QL9W\M$W/I#
<-B1,W@W0Y#6BE!MXZXR8^3WCM'3 ;OH^P@SH&@D9#Q-M*0CP-Q$XH[R5,P.%'AA8%3\3F!F7>&L/$PU3&D8%#7PCY[3X-
S6>$RU"N=*T03"058""Z8(_VDV(%P^9N^H"MX<\V^#!. ^T MQ4.AI.0{2-O2D [T9H\Q@<P>>>6*0Q%>>6*0$,$)=6%>+;2Q%CM]#_N ;+J;C"UB_C1HX8
M"!W2X%3.#=IG;G%;@-,NY0;I]RB84<9N;[<^1O:-DQ_<< @5/*_UXA(RI M.5;*#!+R+0I&X^:5,[X+IMR_>?!\|P="1R6W))@["(@/*DIAY=*&@4;0U:,
MM<14%HY^/H&]!!P',UTBS]U5TZ77QA/[?!)RQL5<,Q!?4ICUIB$RV#5P8K'.M.R%*1D+W=.%V.7C:^8Z!E,'ZNH[1OS(4+G>S]ST2_HB(.D6;3MIH =(4:,AQ M_AM:G
3(19&W;HPL=0=$CCR,)ZE'A#C?W4U0\N[4N20CJ/2ET2]$WX)@]>W?)<.6>.1T=WX+)RFOQ M6#=.D;=0EK3X\BAH%^6) 1@PD3Y;G\MBX/NU(8O'8=+*EGESAI+I1*=';+,"Z M\?
(5'^>7Z T%$8'19]@F%'67Q)@3<'_O)GR(HR5*$G!,V3M-$VN1V0KS/CD@ MD_-=WBU/*D#.0=8S\8D9_2Z8D"TE!8_(&Z_H>'3G*+H*$Z]' +'V']7{)EI4 M4T>R=IVBX3/F_ZZQTEl,&D
Y*,WE=&:4|CAO^)1("0:803.[5%"[D21?[C)= M1 \HAER**$E(3%W)^62!>^C{4E*>926D.3X*,%>P<1^6T9'@98Y';#(;A$87HFQL AD^?%4.QJ6/:F .(/0=&3,#14"!HL*:=Q02D*:_E
M:SE0SJLY4*@^AQV<[& 6D3PE2!C4_F)SAN68)_AISKP0Y8)G3$ MTG\E9_R#!T8&!S-&L>'!UH"O:WY7\IH+E#WS^J3L_^2+TD7-MOAZI/RZXL. MV19(E$F0<
Z56%$F)4*E647];&2*&4),$$ALH-?^&[H"/4,^@68TH D-2AD3 MZ(D 2]JVN'Q.(!M9>C*(7TYPL?V#)BD&K&!2SE0, MV(0M1,?FK(JKY1#">702RGY"\]_Z2!&-XTK=(TU)>,0((F7*(SP\3
%L9R5Q\M8/C:Z@F:31H0D+?("GC1L$YUGB MAZA?Y!M#!2#M.,Q!R\|0H:HN!?3EFP=<*XHH=5M':,XE@^" MKV7/HZG8^_RTB(G/P6X@#.OG)X>W."5R]?#TB
OH^<>G'SE98T,CD<5*TWK, M5^3%3[0PLS66^/>)?UT1*^E>=<&G;(#P(?Z4&73AN+R/<7W3AZ8P$'U8I*W%%8^D=9Bs!!GD&/&&RT1W M!~Q+R*>
GX>X^[=F.KN^^5B8D:+-"HROT>L=>;<=DBD!66]%I'#VW5XPTRC M<$A42:/MM',VNKYKMES&B-B2A%1(X%N74+>#6>@!Q&CC9YNDB*G<&X^'=^9|
MJW.W/5SP>8I$XNX/VJ>0%:82KY);4QPO0\PGA@!\KG#?XY!D MDI"C9"&L&@@+^R"WI"8.H!!O1+45^CS\+E0TGGD&,!CGP7@MR5)^G.-#^=P M.7BZ))++9Q5$WQ)G%4<;9\6[F3
1TO@4!\61ITE>E'=H)GF1$ 9#4AE#IHBKBG\%CF\'X=VI)W%.9[M M8Q-?501C)J2<"3EE N),("!NQ5-KBSI=^[TO2D;@D'GUGJ(07WE7[UN?6E5I M@MW^]V(M4Q<6AT*-
'-@O.6/_[+ "UTXO -^G2(3E*#Y08FLZ@?)CA\QF/K>H M)K.L.CZ@5R,9,!O]/Q-@8:>%0.=#3B=#'S)44-?*&IH MXGSGAXQAHR=NCL.' @VV+1<0728F6)#?+5?A%A-
^"P%7/_4 A4D[SD\'-'IN M,82,)1PWE30*23,(.9.=N64!KN(.^XC@?A:EN\'^#@DO$O'U1](,%"=K[\=?C MV+3+Y?4SI^8-G/0R+,.0]@W'+]Q#HV=/HCT15NV3)^@Z##FEL.&O2 M5-
QW/XJ"!F(.@PIW#H#69TD<^4PZ39I*Q8/6)%ISNXOG\;'HEZ"DRVZ1/3?FQ_< M#3+D<5/I/N!=PCG.VW>^XSU\#W MK!-'Z&6B@WT4@LL'9)PGPR"XZ4'1"\"$2
M%W2=R!9$SN)EB2PW7O(AX0\-HV(E_K@$)(3,=G*5%NXW7>2#*7

*{;6K8?*8K=TRK;HCC=-4PT057$-M\B#)MG6/U)M)4\6PP-)P8=]QX14(-/JQ-U2RC9C&;=YE-"=!.#U6M;)YE-+&:MA\$LSKQBZIX>)$^-3>-M]E':F173PDDP2VV/|;/E-+=@RJ1T:MSJ?!&VMF6=!">[-M\]YJ*#L1)NUW);9?IB?!QN;+LLFN>4)L:G$+M#*<'C50U'ZW9SO+[*DQKO-%MVF@'/@D.=N-9&V/S2;"M^2[0F[!/B$EMW@/2,W_8V+X(KU:,F-/MS&\RSA\U-M4N-0IWf+AX"3X&"\{ZKS\%)\+#Y\&]P7AB##2[6()CLV;HNS3:,&&C:$V>(K-MH/MYIG'/,&HXU/T.LC:,("?!MA9GE]RIY"2X,Y""%BHP9N'H)[+33XQPE@:,?#QKG#]-6K?H#P>LX(:R2O" M[:EYH]_#0"XXVB#:LF\0GJ%%Y3 :L9OOH XH)\"M^>P,+5&U2E81PA0E"M=" M^^P,+5&U2E81PA0E=[M:F,S=L>NF:$ N_-$_:7E0GX8PX#!/K>_LD?%*&9!X_44[^A#LDXV3X[L=M M*-J7>ZUDC)-0R [-0>61=YSXKX-SKG+>';=Z;3"NR0Z["91K-FJ&\F^2^8H9-MQJ/P4/$L'!$;"C/4A$%6*V8P!)Z,Y!HO,TP M,)*7""FG35G<&_%?48@Y&^!U-/,V?DARFX(C...P@HZF6F8!093K175BZ"N9 M/_D*I*F,T\H:7[8_ !N>U!;>#)U/9$,DH#2QF52+F-LJ-S5C#_@S]W$7R]&_M+"]KS= O_2!+E4IU56ECP_\5@?!M\F9O>/&N61J8^:KV3M/-2+9F4WT#T>0R=A?FAX+TF8>&I8&8U/LC*\>CQ^3H"=K=!%(EO5 M+*X>3X%/F'3<]%(EZK-++N?CKB,MS7 690YI;#$6QB[OZN=2*3 M14>;T]C#+9QVIH8RLPK0Y0%/%);!V,*9I[0/VWG'G,C9-I1#37X-2UU73NN\ MZX%>=;1[=TSOH%J AL29YB16X/[../GV[>,$<-QKN->;3GM+G0:ZWP@HT\<. M'SGTNTIA.S4H-^T5=H9YR(USE9W$$3"0!-_=9^XDN#ND+-_=6>\D6-P+N_%H MH6G"%N[W\K\|B?783^+OX//Y$MSL)>\K>7X2Z*U#"ZLU%IV3X.(P0F]7N3AE MMO95'FNZU=P4]Y.7>]^+7^YR>R@-O=^E-IN(\"&!WA<]\F MUH\@,=3\X$\">7L8H:&+__U)K,]AA(8N'O\GP=:I1 9M%,(IGPM=+(+MHR5. M@J,32 N=W.K'P.FW-/_;Z!'X\U&&T?-E670YYP8!HNF8?2^3,-VX Q:O"!S7W7!G M[GC<"QT@7KLADQ?PFS)/@_C>K<'8>CS%,L"(<\13QG0 TY3-OF@=U!/Z#%]8 M&7B.SP,U^MK@W=@A<@VZL$K:B,&G9;H8$^N.K:=LLW'CW7SUY*]#?^4OP1N" MNN^ [S|F[5+ R3B,(ZT^_B988G4%<^#"NOEH.E):5K;CH&B>KI*;;DN^G/"> MOG;]F.3 NT,N_&WXT;;/ZL])**AJVL3:*L.VL6Q43;M77\>.3=MF@L1MV\"' M4]]M!0=T,-&'L4\%7>(E>N%^E.E.R'+8E&:H=0,&\9_R,8+O(AEE,76U\8;> M!8I3UP_Y6YK$ZK5_#X56G1TG1_NWQHI0^33DW8<4"TGLA*)%0'5IW27A:2,5=3)EH.!7=!0<@GV M|(%L>!H=!(<\HW6PSM#0E#;W\3=VG!f*;> M>UI+OA1=&';"V_S67O*$3LMVM618NDVL*S[PS2KI2GN7:LM;L-%:<#]_.O6T MG_N L@#GZH%R(%%K (H/#$;E8:0]DE1. [5A\$IM,QOZD9H:&+5DI9,Z1!/C[&@5XH25T3/=1BMIOR?;U[=B? M\LDI(IVUYL@I79Q5SS#@DC*[^6%LU((:@HJ64_&( HA0(7 I'CZ!>CDH"H- M&[MGH^92^[4=] [DX[];CH6^K=AP:PRR4$H1?VZ?\-%3!XH_ %^2@=%!H2:3 M\%"K)M.4WV.3]F_v%A2?TG8]=M(([HF'+'E#,SQI_2<*<@PP?0@>\Y[=PX], -U M3DS3]E(5-W8!5T? 4=+6JRUNR'QLF1+P.-;2?TLZL7'1U(,0#BQXK"+@)\>1G M7"7Y,_+6>4'+[_)DCQ8-9LWN/.A&N;I/DW:<#P.LCC(H6!\FG_IPYX<#[B! MG9"ZY=)8S5CAX9J9.W/B"XMV'$DMU$<=]WXM,);_._?:K\G^#^ M>EC;6M2-$,BFU(\KCD+-YN[6+1B4$%9^B(BI-O9?,A@KS%6S%-!0S8YMO<TX_GGH%'QO(5>1GF/?CU".?H? 6'Q/D._GN- M1QC%C4^./5HR]*U^O>@+0]A@\O^XT*'T!J?BB1 MW9;625Q+8S*TXQ(^I;NI'=+F(=Y1DZ#M3?*#EW'ZK#8FB?]H-4!4?,@-[- MN)K%B0!0= [[5.)_LW9LEN[H"ZV8-QI[2W]P#A-+#'3QJ*$|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}A'=\;&?^EAZ?N!:,.+)2Q-WJO"47("Z8^)%23,)'2P9Q) $^%WE<=3E, M+K--1HQZD 9DZ.L3.356M$NU=9_!CI'28Z['O7"#

*'GG.R[\"L8*==\'@=6K5! M1=;J.E,5MT.3WZAZ+4%KZY2<8Q@^_HML\NU5HR++!-WC25B&6BDR2[E3Y>K"*

*MDV"6E5J5Q^O2^/;FD$*+2>P1*)I/&I6=-9NEFRO^MUXU(R3ZE+Y"BHMKF.] MN?;2I);73SN]Z1@=M,##RKU\36N)="'W:AJ/=?!\MX'G2E5!F?!*<&53H7*5Y;.MW1TGP>#]1'B-POO(0Y[WDCT]^X8+#J.R[5DA#B)\(-N^V]/6\E11Q#T>PVH MY9>39UKKK5K1^1TUXX;=G*_7SM5H:<=@VE'K,D'OMWHY+^.09J-W.S2;R.?AGT6[NS<&|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

*OLO7W7447_NA&RY\?!LF"2+YB_)O:GWWO0_\M%%"K!EOEN:-S,-'/,0XQE?%N9OXR4$^;'-]MWN/:-MR>>[^@*ZQ0>1] W=L,)YXO3[1!MPTZT-\Z2>[_@:W%T$;B(+96E7QSPI M^LU$=[&S+TD*';V@9MPFZ7XYP@?;X%/SJ0]8>UF>K1^C;'T)GQ#24H2UNE] M\R4%+1GT!7[BK?%%_SMAL-9IN$5%)XN[N,V;U&;:*M$)H7??WAN%5.^.P 8?N MSA@#[Z(0[> [<^)HO2]78%D+O2?,,W^)9V"^RH7+FQ^O MSXSCQYNDR=PP;|_F#%AD)+K566_418W-]OU M/:43^2<ES2_6\)WPO+J.T;\R%'YW]+XNRIKFR9(-K?-KLUK3%/%FB&-5NCBKE MS9,@ON;SDF? M@+G-$H;^COFE)D@'7SK+$U^.DR'1%[>_,MO6-D;>\|,B)OMYUW*U:2I8M=1^ MZKS4?C)-QO/3U^C_M?=E38[K5H_9:+?W>[KK>V.Z8E0+BIG=U4IG:FL&^Z7 M&TP1DMBF2%TN627_^CG@(G'!4A(@ )(1,^Y;*0 $/AP0 -QY MVX$/"'!:4J-KV7]T;FIE\%D"K,+/7\T"(UNE98#N:F[D6 MZM75ICZOK>@2IT%@X"3;_;P@E&GVK^5BTHWE\^[&6/.@ !BJ M6B\9-+!]#!4-*;O.19H MJ!?3F&ZQ66"L1$GXW3PA5*4D"#L+%[@E7G5-J6\696!4LUR68W@6 "OAM[^?`MX0J& #)'33U"D?J#[UH!,(LWM!3>X'1#&H]"E"91,1CB04D[WR\[!\?LAT_ML!P9NMB0/\VPA1!P%BYKI>Q^BG8A|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|V^$L,-8<^"8U#L@$^5!K"2223?D)N))^ MQ15),19Q4FIH+E4CV+?&6 MTG=#<>]O@5P*Y,DID#?44[H4TE-VZ=:\N$NY/ 7FWT\E(@3U$10D$/^%(] MS_;J>;2G#*,8W+\,4'S,GNV?T>[E)Y9_FV#FD]!?^0_#.XG6?(UEGR-F>=K MZ"`0964%L6GD"'!%S4R+9IU%-!0O,K,N8,W8#=PE-G.)S5P"#.U"?0DPG)45 M<"E,UBNG8@EHDQW0MB"ZU&2;|~,8&MEFG-NF>#"U!N%DZJ_=:)\9%!EU:63 M=1L6IWP=1AN,J:`Y<_`-%IX>L_\[H(%3J9A1\,82WFXI3S<7,O#F>@>36\7X MU5$G_H0"M,VN'0_%3\&.[C/F]+ "1\V'N1#Q?6O?7HPTN<>%L1%F ;!$IY MBG6T<2-Y/C@I0TO>QN<0)*O$<_Q\)SX6D;TXIK?(&Y*Q(4FT# <|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`0]TE*LI*2.WH-YI//P!..Z M+>:.1F],1IK879=)E^[L? 14%OC8IZ_>8&WM-#>F\W0?%'#-0+3"0"OK4.HW6: MX"|!0 V_Y6)EK.^S[P34D$%*(E>T-8K0[EH]A3@2F1P0ZR^.Y&+IT")>DZ MA#Y_Z31"JR<4!%G2-F/FM29+-&GWJ?^#D-DLPXWR"&>^=LYH9CT MNGC7^EIEIPT921"M8M2DPUF 8G*3Q&8%C5-"-<1CU\>#GUXEU1_"IKG$W\O3+QF,,,'CBHNGMV[>T3A(+&+2E\QW*[ MVW>_?DWQQ L"YA?0D?^=.7N?;=6R^H);HQY6XLC"H1$'J M^/Z%)UUHG_M+>&\"4BRFKR\OC'#V=A] MJ-+"_W\SWN.;COI

*M_U:X>_)%_"3[^B%|PCZ@"BOB5=5-W^-=Y&4WZXN34"U@]CYG'X!KQXNR&A\K-MN^!.N4B"'P;!(F^9/*X"2>'OFN§+7]*'53C0A=UG!@:M&1A^M80>5T"AN,;*.M8E -]!0\H"!6(ZUB-&D8E/G7N %[T\93CC..$L(]=(=FL0/BT@G?E3B/*%PE MDHD"=^;\ L?EL>3&M3<+PE:5N3#MD'.Y{$"O-WP6&S:I' &3RL$IE8W)^3Z3 M+8YJMI#1=N(M21T2DCH$@PW&S-*8*CN1<;X6FA_&B.3$H,RB6*AAUP$|S&46 M-4E-$OD|!-K,HA"]@KWI&MRCHG3JQ'$»((JHVJ8_+|LR$FOBA345&_*794-& MOBMH456EE7>B>H59LA6<6IE"0MYI#FAF@|IYUXZ\H$^TLR*ML'$MSTZ M0:'??PVS20]R:)!?/WEZQZ<[/]+4&D?!EWQ_M G3 |-FD<[++$?"_T3|-,I89QFGL$EN!EH] V[%RT]5\E@;6YYO88M$^&?H^] MT', 5[=]'MR4@[?:)=X'X&.E3W7QALRZ\)]VR.IZVZ4AO49%YA'&5N3S^0-'.B^GU];L/9'VMW+(_E/D5&5^R%K9"Z 5NK!HV MTI>LA4T;,__EC_:"5G 9,%-2"EK[.]9"EMMD0+D]PQJW(?[36.0G_'DS-"L% M3@'Y?&)&?B_S]H,H4<["':]@+WJ{J.Q*9M^"$3Q>";F3?-V@RAU2S6]+;LQ M3,A6D]U.-W§N^\'6§V:1GV!>5MH%.EMNOW!G#SJZZ1%Y6\M+-&.O;0?&?W MCWAWA&%BG+F6M?\'2NLC?AH|OXIU@HZ!9.75/@14>A"4K2^8I*:Q)KV@*3LS'M*-1\<'F2-OGEBQ>PGZ2M_;X\2;LDSRT^6(.>(_D6P]{)"T06G"M>'%,9UT|W M"5 =1CYBK,}&.#Q.)CU^6D MO+Q.U3)4*(Q@5*0633HGBOP)@VD++.+.#1N!PR+F^^A M4DXZT*#?PWC3A&+6*9CF[8*U?*-4XV;Q]HX%V\0T9BQ//AB\28V3M+P(80C# M(U9I'>&%" N""&K9A*Y?,8!!C)\9*&L2QZO_1H&J/SGW66=!CO M)#XW]C/O[^)90#?:M2;!3,S"H-^9L@7%L?' TV]^:E2TNK]-MBOBS$V5)TK=70Y^"?1B='&M-2?>^$|>;?;&P3?3B'8X)PQI";Z]-H2!.B6D) M8?70%YCG^&56$ZX4N-EO87*QL^/:=00ZZK-3/6^8"MWM=|/(AV4197301SSI M>^RYGA-=*M3 ,,;T|AHK>Q5W5EYt$>_R89 I'8QE,/OM+;\0>2V^@]*ML;)C'MQV,\UHO9;3>|BI*XNOREEH&6V3Y4W97.WQ>?RFB5Y M+9/&_+C-)<_L.4+K%(M+1!Q&)%%F4\DSVGX/M\|-!K3,F_[C676TDOB?P4- Y0B M#\'7WCN\C|^[2G'D?$#J,.H*XFNT5Z-S9T>~<+]?7FD@)D 5!6T@?%?T<,|<01 M6JF91^V!:L9,ZNVT;>IS%,X0"ZB&D;"VGDV1@ZP!S\G!*]9V8\CX*O L ,,,%&N<7,!V MG 5J JZ(*XU1C1FS0*J;0-77UC(++EV]'J8LM=4S]X4'QBV"@R6LA/3$D:V0W M[2P^2,37Q>:H E>#"[I(,//K4"A:6KIC-0C2.C/VK59A[QGS0+/0E=4.:,URP+OOP2S,+(&#Q.)DWZ|+\@*(DL1)&>A0E&!WU6;&<.;,8^U8\ET^73)=MYY#INN3W"#12;4B&^73))ETQ2VY,SEWPUR4S!_@QYW9X9\|)RIYG(;HJ?V)AT M,), "2$<-7)ZVI4Y%X/)TZ6|)%ENRQ>R.0IXLS5F1++&428%U\-&/G+IJ$TY)/-MIBL394F 6A*@-%0\D.J],Y!LC,K0:.%ECY.NXOA\#A.8C >BV"7|T?M -PGM M\WS,M M1'"IU-@*<+B0!V!8.U5^<.;VW^$V^&OM^('I(_9@F92/N'IH>&XK:S(&5OGTU$)".8XT [? F^:E\0OKV^1Z,8?53'5=1NK>94 R|/XZF[ M;86\A+4WV!Y0Y\D|!)|HQWS\2U:AOLW. M3(FCI*(;PK|N.B\'XY<7)SB0WSIN_BI7:^,5 2M*?T1)U8_7=|:\9?MEN"M 6RV&A7);L)%NKZ;P8@R#,4DEI*M@:M'2_ZYO@I6L5Q>LHX67Q_Q"#AQXF# M!#A"0(QR0[4H;@()3'#X 11+T=OBX.Q.<\A@ZI>868'+"Y-M_:(D4I97&\^ |W6=_V9/$!JXAXG37:\L21$-*F M!Z+,40-A5O& #/GF]JEV$3MF'|EIO*:6]OK9.Y]1!Y#'GNA@T"jL1@54SS^G, MP.G&H3}KPN2,L3:>5@H.3!V%[5G;*||03X0COL, UPJ^3VQX4,+3B%&Q!7R MK$G<;CIC1A D'<(O 2M#A"TKSI<8^TIHM|M@IS?PINL9F"$!K @W;2\'M9MJ"NM\,>@E!L*] MMR Z&CDM!),Q/MJGI&*]%#^*8N1RE M(4L0&VO47?#Z[U*8"8.1(E\YEF\W,L/"(ZNR-L%266CQI MD[X4?;H.IKAV.FED>SE+I@E%)Q7U:L ^FZHN3QDJOD]ND>AIT!?=*(FS%<|)T MTE5K)2>'=6+V<\;3EIK(86ESAHQAD*8AN,#&$549MI!9^,,%5BZG[*J09!Z7 MJ|%GMA,5N)XSP+/SF0G M;$0OX/O#_[(@V53$6EZ2 JH_SS 4 MJ__]M-_XVH\4PK}3+PH,SKC=7%+]U*;JZLIAQ]821 *A O($3IHC$QIXL4, M2B$VUIB(N0?.X&91]-Y]BBD83^QV%J,HY6**3R ]D7>H0#^(P.^.ET0NHN2 M!]1:?^+]=;]>AVUG^4T3N#/)>0[5K*$_2%;YPE^7+E_\7NQ\#T.Y!HG"\]^.G&@-?V'=3|V66B::8R4V MU6K;D2?]MQ3$%Q3YEQ=T#]FB8;5Q|[Y#P2,QRD8$G7BE.:CLZL\=(_)|XHF MHTYMZ_QX<@$0;^_M,B,#9YZT|]-,>N6ZO(%Q\7^P%>FKLQJ[6.BF=EF$SU'X8<7[.@B(*6YCBD_A\'*_/_QSO>ARYUPO?%8$A;^ M?H0?^RR^I04W9/8 MC##%FV.$Z';Z.7+P]-SD/[^O!G_^2!)E*+,;T.0'XDCWYFP_[/?XG1H?HT M0]-K=77N>$'R6]<[79U6(.+7?56BQ@OLIV((#1A^J-ZH_%L+E;WCWRH#"B_[ M"'-'N_0=_0;^BD .:#P,A&*BN.H.[P60G7"!:JM\'#HMI9<;_QNWMJI&=@?/K50E A)4ED!0^#U48'U]IB-[7I]6?&N>5='Q:+,EX.F MX|_P$5FZ]JZ;W7 _]5CU[\Q:-<6]6+UOS=W]2VWF8KU_!+]=>\<2H0^*,Y M"+1|$BR,E05IGG\E*!@K%%:#"92LW%B!D![KH,0D9*!$R(A^4_*!_ML2(A(:9'''0#&BH6T6 TE*!@K'Y+++/Y1@8*!X6(\14;)] T7"=MB*D14;*Q!R MHF*4@&&@1-B.I%&R<@.EP$8 CY)E&R@"DD,$Q%9?Y%/7\Z4U9U/?7/XA#!T MR->_E,[@8^C#=L2XE&QR>0N%.@H.>=ZE9PV^SV*@'V"R'R(/*#GNRV M^DDYWW%L$ ,1"-B%2 X^L8^V!31FPR03M)^QY|K.=&E MPG58=$|M/T4>]9>(ED|':RRVJD|[ZW*SDWHZ8&9Y+SWT*|#VS MES@^!W2R^^B589[B.$7N0YK=GIG/ZIOCIRC[+?1$')>5B)MIG/W'D4Q);_0>-MI9%SJ10/7-7N!CLP\@N(EBG(*Q(Z=36>RQ\%+D#U2S-:B)G98{Q)1:A(PYF M_D#8!G$B+[=[?],H-6=1$DB5-9 B6@6B^@*Z]U$FS?8>4V=E80=7=7MTH@"F M1*ZLQ&DL>8,Z QQ]E!!C.0N-5#OF(;'\|({]BOZGOU"UV|%^]]VM'R;>]ZMV=FTQ678 M%U5N<[;SG,(1=6*$*VOVV$?Z6*8M/=\;ZGO[;31C-(W]RO^F<9*9]KD71A[=#^?; H%UX MR)T0&>D/ 6O(9V7;707F>[V]'YR"KL4D!GF(0),P#(A<3 M.TX*M^X,.S*&*$*0&8REY2'?YCQ_\4A>D9>F";5Q@ >0&O*(Y3 M2"V ,NH4#&+#]V&0629^]H+C?1HGX0E%)6.EE7[N.HJ^DA8E$,Y,L_GB'8]) M9@^L)].@}>U<+50UMMY&-,8-<$B-=BD91(1US>H.,G2^NLL?1FA[%]H4-=F MG[$3K,D!:WF.T,E+3W%^AV;R-7XR!%"NJ \3<"&&K08L7Z6 S:6N4(X MLM!R/"5=B"<&I[A4]U-VGG"%7+(95]CW)B5"U':RR&UST8UG)@ MY:@174)J+2^*]VI10O+M1RGL4YLWRC@650R'N[(L;>:WPO\SR^W)6V/",>O M.,'E5A3S*=B'T2FCF ="U?-2!+N*SF+BO-=4O4^\7[ZLJ=\)XXW^\)'MHFRJYU1\XK>WJPE,.ORL7I, M8OG7MJZ6HHDR/%_7TO"\6DFG_KK^<*.M535IU46(?,4MA/IK26 *YK.[#W"ZC MDWR$<WD3CF.DLITX5^WJ<(_?6Q\1GCB!)N_ZC[H3X/IY22RS:UZ\Q,<)1 MJO|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|[#J.0- MG^&(XT<0#J !X1G00\T$>^H.QX())?G\7KSX'W>7.Q3LCD!8K'AH;C>#%E3. MBYV?Q>LVM07I3S!HS7+'^NYIDH/?G6&$_^-M"ERC2D MU"|=I53+,&&=;&J L<2AN)7*FO:=9AR1_4ZM@2-C6)83SCL(!*QF,!>,GFV ML-H4<$V&|(^02O%(-DH<4TOW-N=F2)12"""9!DY'1=9)NI,GI\I 0)=#/ #FLR MPQ, .C7^5[>5K|RO/Q?!X< *O DTV(BN4T-F?R2Y#E&$&6G BM:S&53R@\ M &\XPN'V*0%P]+;F|(&EX9/%&=HQ@)+3:PFAM"&$TJQ0!1FQB"M^,,)*!XD6 M1H4J]Z+N/KVM?5/6'[-F8"1AC';_>@@_?IM)L=$E7T7QC|L'BC_\|O;:F&?E M!ZVE5D%1_4!!BK54YEU!,KOD"_!XV1V?E|VIG<s}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|-$>DYS M6=<+!!M3:F$U S"I6FN#%Y?FJMBLN,)ML@Q30.1-&'K?E?-6PBM*L@FHS2$_[2U|]I3W2RMQ'*?2# ^6+$_! MF2I\;(BZC^6>Y D7_*9*C552-A4PM++*/>;]42$HN)9]B|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i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i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i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i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iX^3!BA^#!(O\7'APP*E M=1@].KMC$;CF%A$E74ZJK$_*+I-^SK6E\+D0*S>1ZX&6<7D%=DBIB<[H(GF& MWP -@+S@\H]@+WU_41G\V^0(0T*(KZ30>X\6CZ\&. M'WWO!!N2T-@##H]TZC$!W_0)TG@"=X$Q+ST4Y@]KLGP(LIZ%=DCI^F;OYXAV. MQ,,U<$05A;Y177\R]M-AC3/,^10VLWQ%R7T;18A5<8[>17?.R O"^G+,-#+K M9+!#FW??.V341%F16%_)QRGC9N5-\(!BI'V=VKO+?\4]TF%AMM<(.^DF?/QO MQO<<%6Y6G\7+O'B919UA/0VS31=K2\ U&I;%^,X\6D(X"TRI8ZU>4]=#8R\V MTWC017D4,\T,:S(H2Y5)A-.,"(9S2P-/9$D]"".]I>C8%" WL80>CMA@,H(: MN5=W]X^EZ5'R^58WAY.EL V4Q]C>++),Q,82KC?!&X8B';RPN)N:O*^'3BO1%$Q/ Q@E+ MQH+%#]2S+=;]#YO]*_PUWN?,(;=!_439 6G#VPO0*RC^R0.(MPQ"E?R1)41Y M"5%>0I27$.4E>M?42(JE=MH2TVJHX5)(V#,Y_X0*M40P#BQ8"E5(OAB'BW-MHP_%6R>+E72QDEIB)5W,=%:8Z18+]4R+O"U64K.LI(OA;Y:&O\7"M5A!%\/? M8OB;E$%@,?PMAC_SJ52*X6\BUJ?[!7IYCV$Q/$W!\#0WXP?M41D!:XAHU\4R M.!7+X/)BPR2->?:\V##&8Y)#YK<-$\)=?G?!9A.W!J;IO(]=\O5), ^3V&:F M^6IW!$"!<&\!H2)%N MFU=E=A^H.O_\>,0=Y>]F*@5WUB,CE4"3]#?]###?AVD E_H9 M+HC+5^=$(V%BLW$S)] YA7L(%)D5W+39Z6!.BDH?XGVGMR151^_M\/X&\L&= M%YZ/3G1R[K[1R9[:5ML55YPXVCU^_5DVW[C$('^MO?/5V^ TXZ1U<@:Y2)4=$NC(:"NY18,E=UU0( )63M7RSDV@MM3%-NS0\01[DT$QZ.B1[P%+ MW7'#**]IBLW3H_" ]BB*D+NX$!87PB1=\"(O[58K]=9)&ROLP2"(@3?Q[Y7T:_M)^$)1=??$*GL@1'7'0G/F8DYZ]'Z+Z]RD2Z1,*T#8353P4/P4[? F03I8>95]#"+HXK_1\"7-'M -MCUFH/8LCS3AE8J7X_<#N,"4C(3_N"-R/&')W?%+*9I0D;MS=V5[.6MUZ[*H MGUT8M%X0@.(\E>3PO0PGXG:<.0C\i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i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iX^3!BA^#!(O\7'APP*E M=1@].KMC$;CF%A$E74ZJK$_*+I-^SK6E\+D0*S>1ZX&6<7D%=DBIB<[H(GF& MWP -@+S@\H]@+WU_41G\V^0(0T*(KZ30>X\6CZ\&. M'WWO!!N2T-@##H]TZC$!W_0)TG@"=X$Q+ST4Y@]KLGP(LIZ%=DCI^F;OYXAV. MQ,,U<$05A;Y177\R]M-AC3/,^10VLWQ%R7T;18A5<8[>17?.R O"^G+,-#+K M9+!#FW??.V341%F16%_)QRGC9N5-\(!BI'V=VKO+?\4]TF%AMM<(.^DF?/QO MQO<<%6Y6G\7+O'B919UA/0VS31=K2\ U&I;%^,X\6D(X"TRI8ZU>4]=#8R\V MTWC017D4,

"Q:89&+9$%ACE'ELB" M>3A)3\ &-}\LH0@+"${VIW,W2\5W3Z/)5+!,"*:4J3"-%RIBP-^$@[XP4&1 M-CL*-FD2)R"U8I=A"--(/+AG+MF/W@>Z73^//W9^"G/$;C5\L:=)412A&*?Q M%=VNAA4LQ!5?Q*,3!8# =?H\IX2TX0TH+#=P+6(5Y:1\1%^5+^+LVV^T"E%) MI9L^.W!9^N3V-AS3J$IO;]B>'%/4W84\ ,,>]?*+AL$XF+0-J,PW;+=6IS"] M&1OE4D(QMLZZ? JSGHXE+9O=1!6&Ll9_G--H=`1!B?8?,M?J-H6T["C&5"7^] MC;4F=]EB&,FPH!R)QG(;@BACKUDCZ6*,T6B(O2FO7F"HE7(CXF\)I*RZ@H9A M.IG2A"KYI"3!R&2$>Q1=IL,R\;9;+4\ M]S[GYITH@S2&T;W1_RUS?X>=$XXW.631R1+1H?>$WPOO0.DSU'X7O!0"9# MZ"DH$'K\ `Q`JMK[ W%.0$?4U0$U_E0)H2+6\N=M.V=UM -.DQ+M>J#-2ZS$S6WV;Q^+"PDDJ10T9Z7G=Y:UFJ_L(YKIW%!4M- /H? M]!W1SM%WSSO),Y9;/E1@5)>(+#=\=+[G>?+29,P@+\C'3^P\PP"72BRPF8^) M4";+,XQPNQD02$;;A[M+ [1>A>+\$N8YGY/B{ICH+11^-21/!F!$=U&&"QD(UE M.U%%%LS0,'8?R4;2%^0=X.9!JT.$,@V,'A!$;SHA\Z/4_1;>9#4[^_"E% NV M%;& OKW,]D8 6CD,W1FI.70AA0_HCP\=0.KZ) f\Y(_PV8'#G]$6:(0&4A M16^OB!\7S^\3L.-S97(R;/#>;E9O7!0):I.HX6B-KJW^4<0%)-)M(GD$> MU%>F@:T1BI^=*Y;BMR'0.2KIG#0ST:[J9XRD5_@@C@'}41JR!+&Q1MT%[_\N M.(;L0M0PB%87^GP31]8ND-BE]"&3&@H(_0R3 9F8R&,0+G)#)N M!*YDC@7/\C"3+B>`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f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l5 /^$UB7R0OH-YV="$O&@ ,89ON4]*^&QG7H9 MNL$O")=:36AW'/5G(R^Yk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`Z4M2I"60M3ZW$IAG%30FAI#&I>##,9"0N>2,@/S42# M-I$\:2V-? 8AC+P_7T8)+9\U$!';4#(7U?'P.,77]ZYO:<;75/[ 6/|L'"'2[' M67&S\R,-TS2OMRWSE52Z^:,;J_K7NMG.2K].1V(@+,L\;F[^ MCS;:'C[L2?\;FYYT-4^JO?]YQ_/33Q_\|H)=?F17O?.+T_.KSB?6 M_=P|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|8UGB_K^"D1^?3,]K-9.6B8'=IXUTGZI MPE#@Y:[9

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{GJ7%KA2A/N81\&,_^5VX MS\N(V4G,AIV>]C0P'RCOYLC\@H&MD&<*XT9&T\ M\2V#@!+N+[UJV<'L(M2XA580?.!V?H2O^VQ1CO-%"IF+>*SD&"@\(C_DP_XB4 MSH,%B!*I9H!/)R.5A0=\A440]8^3ONR,&CQ:5Z?=@#=Z4:Z5O)1&"M [;J@O MB7OH1'I%YQ- 3'"%IS!M"%L;H"])GAAHFJQX.T>;>\4KZ]N],8<2^&T*B5G MC-HLVN="*!6L^O,1CH5S=6"#.P0:WWI^O"* ?^C;^FR<_ D:Z UPW_C2=#*\] MNK%!S3$%MIB9YHN+GO&\7@N\[WN &R:T-/6EF+H)!<7;KF30"T#$MKO<=M4T M*]$W62<=XK,,WE788?6P\7/XT*/,PX?9/%_]86,P=H^)G;^4G4W*_E&"RM%G M%G[Z*<[ ?& ,EMY7>J60+IG_)9KZR$1=8N2U,,XK,O51,7(Z$A"R[A3\E IB MV656CR\!\]I*]Z!69^JB V;W*/B_&Y3IJ]KX&&_Q-993G6%%;J^NM#7?/8F_"-MA^#%*H"BSW !GQ\M"",G(XX3/C+AJ0%^5!?Z7]H'!DJW_ U!+ P04 " #X M@0A9O3$XT\IGSAH) A2P #P &9D;70M97@$,5]R+FAT;>U<;5/;2!+ ^OK]B MCM1M095E;&Q(L+YIV4<7#@;KUC/@? S3!0.@#MX2T#7'MYN;867#IK)B*PHT8HK.?C>8AI MZE_?58]S=8^C?C8VD_P/WK%>>=<&J;)KWN1V)@; LBZBY^3_.:KGSK\]/.SW6 M_Z/#KCHGU[UNOXO79N5R84Q7CVOUTMOR4/N*M4\O+ON=4[8NO(LOGSO_F;GLH%)Y3G9_P'[]PKE]DT7;1L!#+GBWQ*YC@!OV M)XPT+S$?M!7AE-D1MXU7?R4I(?4E- ^:W'5P[)0PU@,)$1"@<+D$\)YIGNN1 MIHU:N5;K_I>)-/FV$$FY7W?#>2U) ?9PHX"<]8KFW3&>S1>]8QX :DB&'- M-0LS\]6>-49]Y7K],7'UN%H_K%,.:L? O%Z:*F/3UG,5?,1+)MCQS]E+.GTU? MK53N3OBL<]&? Q,PUC ! *,=6'87RFJ#5I.60^HA&$J9F=*1ZQ.\?YB*F3U M4_:GDN"GDFO6'P&J *D5OBFQ:NR7%Z%%^?SS9/4%:%X;; Y>+&@^H=,# D4T M93>QFD@(AE#*L*,SQ 0* 5=6EM$H+F+&XRE+8ZM30 VY=1%"4.(LPB-:CH7< MQX\T4Q'6AE9E"Z2W;,_"Q 97!)24D0K4$"OM!^&]%8 MC,-1DP T0Z_X(V92^K$8/P$-^21D0"2,!$X-"C81=H0&F@1\IR#-BP$N5(!F MCG%8P;)393<41% 0P>.)H/:S0&P4,0(-4+M EHE9 $4Q]-ZZ;R(0!Q:N14X MCXA[F08X(\))W"4B6,TX? GYL1"Z6:F!E7:!AB^&J."W'Z,-,M2PM0=[,E%G3MD!@?K'H[[^ M8E'?7X'(K^]N#RK5XZ,)@9U7C;1?JC 4>+AK]AR NKO6<%!%Z(F:!((4 S1X M@($SHA$D%F&Z0"D#",.1OE0FQ7&TOE8RPVRBE0\!?ES8+D(T ,1\AL/,K3_B M\1!8&_?H7BI\PO79#G V.Q7RD)[E6]< &-J+(S+ % *8C@;H8)47 K5-T8$0@N!9D@;AJ$)<1 MQ313;]@NF%]2CL0B(;A1,:L!]S MU=1O(!KA.IA!&DE&\(&0PDZIXMBT+!&<0\#=19-*Z)+_0]71-WF!B6I3!8 MC*N0?%_ID"G@.A=#B+']PD<@O> 82(BX226.; <0@2G$@PCVFR@D8*&GDTC?@O MED8Z8RY3MW$3QB ,P;=BC.@P&UH B_IFBTPD.IS<%G"T@0.QBS!9\V&@4GN_ M"MOD2GPN#=19",_=DF2#6<_&,2%DKD!]FC1Y ?P"^(&? O!B@7^;06H=FG1W M(B_GW9G-!/ =:0-5&,KW4TT(7$KG-TT;*6/Q!#WR@9,9'V?Z.[L#R7;O&Q,B MF>"6?D<\U]W'V'+W5NBV2YS.-=O+]!IQ,Z]^*!EPY .!RY*<2_(,9LJDN &9 MWVBY(U]ZO)<*QBEZI4_3*SU\L8SS\%ZI>RXAF!%6:;%O4QJO3!F++9PP_QU% MT5J/8Z$>3P-AE3;S0L1]@'-&D; 6X&MITD!AK4,"@4 -W2R[R"P8WH:R'OQ- M_989(<+?J4 #'/>EL>]NR^P53=$&VQ H>'2D0\W05@&&K^(0H7D- M,6I.3H#24%05?2N+"']/>;&*Q+3IA/*%GG#5YDK7QEF'1!!P?>Z^;2$X .W MHR-\W<-%,;>_4JF!N]!8<*Z-GJU$O.&+4Q&Y\+H52P&L^'N!;Z:M\&]PC4 MOW7^:$4 _]\WI9F(+=X MXB;AOOIT0>,@;&NYI@26ZQ\XN+D?&R7M=[Z/MY M&QQ:F/1.3- V$@ME;J&30*T#$MKO<=MTT:J$W6#L=XK,,/I380>6@_G/$T)/Z MX=-T7J_^L#48>X!CYR]+9TXI'R:H'#VT\-.]/-/QOME??F/IC6*ZH/[7:.J3 MPJ4 R1N*G#=DZI."Y&0D(&1G\W*8.E>? 4B/UA]0;,O5)T;.[-MF3T_AL!9A5!]8A9#]KZ$(?U.3Y27VFI;Z?!FO+/; 5G/ A>+:$*8#9FQZ6' MZ;]6$3XWCX]@^?<'5QU]:.^ZKL?X/4$I.#!!0 ( /B!"%D%6#M@E04 M &4N / 9F1M="UE>#,R7S$N:'1M[5KK<]HX$/_>OT*7SG62&0PF)&FQ M:68H<>:X:R%%&@*W5OK2_]:ID M5J@C?OJ.M$*@ 7Z3EF::PZGWP6H<5NNM6GZ)!+4E16LN'C/A1DQ8(:!I MJ)TZ7H!CN:78OX;#.)8!2 OO()64K"8Q$(:$G#]=J+=7(VYH"T9Y;<:]LU#-F:.Y+&U,O^A#?\,:WNW M83=6!*%-\E$NR. ^ZF!UO,_J>=SOM4;??&Y+ ^.,D8='N=[D7[+?$^>)W'+4?=/ M#'V\CB3<@[=[9OOAYM?$G_AK.?ZT?'=Q.1A>MGK&XX(\@

fdmt:CustomerBMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001650648 country:US 2023-01-01 2023-06-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMember us-gaap:SubsequentEventMember 2024-07-31 0001650648 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001650648 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001650648 us-gaap:CommonStockMember 2023-03-31 0001650648 2024-01-01 2024-03-31 0001650648 country:US 2023-04-01 2023-06-30 0001650648 us-gaap:CommonStockMember fdmt:TwoThousandTwentyFourFollowOnPublicOfferingMember 2024-02-01 2024-02-29 0001650648 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 country:NL 2024-01-01 2024-06-30 0001650648 fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember 2024-01-01 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember fdmt:AtmOfferingProgramMember 2024-04-01 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001650648 fdmt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001650648 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001650648 fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-12-31 0001650648 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001650648 2023-12-31 0001650648 fdmt:WarehouseLeaseAgreementMember 2024-01-01 2024-01-01 0001650648 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001650648 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001650648 fdmt:TwoThousandFifteenEquityIncentivePlanMember 2024-06-30 0001650648 2023-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CysticFibrosisFoundationAgreementMember 2023-01-01 2023-12-31 0001650648 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001650648 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember 2024-04-01 2024-06-30 0001650648 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001650648 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001650648 us-gaap:CommonStockMember 2022-12-31 0001650648 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001650648 srt:MaximumMember fdmt:LicenseAgreementWithUniversityOfPennsylvaniaMember 2023-04-21 0001650648 srt:MinimumMember 2024-01-01 2024-06-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember 2018-10-31 0001650648 us-gaap:CommonStockMember 2024-03-31 0001650648 2023-04-01 2023-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001650648 fdmt:ArborBiotechnologiesIncMember fdmt:ArborAgreementMember 2024-01-01 2024-06-30 0001650648 us-gaap:RetainedEarningsMember 2024-03-31 0001650648 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001650648 us-gaap:USTreasurySecuritiesMember fdmt:ShortTermMarketableSecuritiesMember 2024-06-30 0001650648 2020-12-31 0001650648 fdmt:TwoThousandFourteenPlanMember 2024-01-01 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:SeriesCRedeemableConvertiblePreferredStockMember fdmt:FundingAgreementMember 2020-04-01 2020-04-30 0001650648 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001650648 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember srt:MaximumMember fdmt:CysticFibrosisFoundationAgreementMember 2016-09-01 2016-09-30 0001650648 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001650648 fdmt:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001650648 fdmt:AtmOfferingProgramMember 2024-04-01 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CollaborationAndLicenseRevenueMember 2023-04-01 2023-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CollaborationAndLicenseRevenueMember 2024-01-01 2024-06-30 0001650648 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001650648 fdmt:FiveNineEightZeroHortonStreetMember 2016-01-01 2016-01-31 0001650648 fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember 2023-01-01 2023-06-30 0001650648 fdmt:AtmOfferingProgramMember 2024-01-01 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:UniQureAgreementMember 2019-08-31 0001650648 srt:MaximumMember 2023-04-01 2023-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001650648 srt:MaximumMember fdmt:ReigniteAgreementMember 2024-03-31 0001650648 2024-06-30 0001650648 fdmt:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001650648 us-gaap:CommonStockMember us-gaap:IPOMember 2020-12-31 0001650648 srt:MaximumMember fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember 2021-07-01 2021-07-31 0001650648 srt:MaximumMember fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember 2024-06-30 0001650648 fdmt:TwoThousandFourteenPlanMember 2023-01-01 2023-03-31 0001650648 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-06-30 0001650648 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001650648 fdmt:AevitasTherapeuticsIncAgreementMember 2024-06-30 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001650648 fdmt:EmployeeOptionsIssuedAndOutstandingAndFutureVestingOfRestrictedStockUnitsMember 2024-06-30 0001650648 fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember 2023-12-31 0001650648 fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001650648 us-gaap:CommercialPaperMember fdmt:LongTermMarketableSecuritiesMember 2023-12-31 0001650648 us-gaap:OfficeEquipmentMember 2024-06-30 0001650648 fdmt:AstellasGeneTherapiesIncMember 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember fdmt:PublicOfferingMember 2023-04-01 2023-06-30 0001650648 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001650648 fdmt:UniQureBiopharmaBVMember srt:MaximumMember fdmt:AmendedUniQureAgreementMember 2019-08-31 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember 2023-01-01 2023-12-31 0001650648 fdmt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001650648 fdmt:CorporateBondMember fdmt:ShortTermMarketableSecuritiesMember 2024-06-30 0001650648 fdmt:TwoThousandFourteenPlanMember 2023-01-01 2023-06-30 0001650648 us-gaap:CommonStockMember fdmt:AtmOfferingProgramMember 2024-04-01 2024-06-30 0001650648 fdmt:WarehouseLeaseAgreementMember 2024-06-30 0001650648 fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2024-02-29 0001650648 us-gaap:RetainedEarningsMember 2024-06-30 0001650648 us-gaap:CommonStockMember fdmt:TwoThousandTwentyThreeFollowOnPublicOfferingMember 2023-05-01 2023-05-31 0001650648 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001650648 srt:MinimumMember 2023-01-01 2023-06-30 0001650648 srt:MaximumMember fdmt:ReigniteAgreementMember 2024-03-01 2024-03-31 0001650648 fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember 2020-12-31 0001650648 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001650648 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001650648 2020-12-01 2020-12-31 0001650648 fdmt:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001650648 fdmt:FiveNineEightZeroHortonStreetMember 2018-10-01 2018-10-31 0001650648 fdmt:UCAgreementsMember 2016-01-01 2016-01-31 0001650648 fdmt:TwoThousandFifteenEquityIncentivePlanMember 2024-01-01 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember 2024-01-01 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CysticFibrosisFoundationAgreementMember 2023-08-01 2023-08-31 0001650648 fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember 2021-07-31 0001650648 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001650648 srt:MaximumMember fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember 2024-01-01 2024-06-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember 2024-06-30 0001650648 fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember 2023-12-31 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001650648 fdmt:FiveNineEightZeroHortonStreetMember 2015-05-31 0001650648 fdmt:CollaborationAndLicenseRevenueMember 2024-01-01 2024-06-30 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001650648 us-gaap:CommonStockMember fdmt:TwoThousandTwentyOneFollowOnPublicOfferingMember 2021-11-01 2021-11-30 0001650648 srt:MaximumMember 2024-04-01 2024-06-30 0001650648 2023-01-01 2023-03-31 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:UniQureAgreementMember 2014-01-31 0001650648 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001650648 us-gaap:OfficeEquipmentMember 2023-12-31 0001650648 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 2023-03-31 0001650648 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001650648 srt:MaximumMember 2023-01-01 2023-12-31 0001650648 fdmt:FiveNineEightZeroHortonStreetMember 2024-06-30 0001650648 fdmt:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001650648 us-gaap:CommonStockMember fdmt:TwoThousandTwentyThreeFollowOnPublicOfferingMember 2023-05-31 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-06-30 0001650648 us-gaap:CommonStockMember fdmt:TwoThousandTwentyOneFollowOnPublicOfferingMember 2021-11-30 0001650648 2021-01-01 0001650648 fdmt:UCAgreementsMember 2018-12-31 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CysticFibrosisFoundationAgreementMember 2023-12-31 0001650648 us-gaap:CommonStockMember 2023-12-31 0001650648 fdmt:CollaborationAndLicenseRevenueMember 2023-01-01 2023-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:CollaborationAndLicenseRevenueMember 2024-01-01 2024-06-30 0001650648 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001650648 fdmt:UniQureBiopharmaBVMember 2023-12-31 0001650648 us-gaap:CommonStockMember fdmt:FebruaryAndMarchTwoThousandAndTwentyFourPublicOfferingSaleMember 2024-01-01 2024-03-31 0001650648 fdmt:ReigniteAgreementMember 2024-01-01 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CysticFibrosisFoundationAgreementMember 2024-06-30 0001650648 fdmt:LongTermMarketableSecuritiesMember 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:CollaborationAndLicenseRevenueMember 2024-04-01 2024-06-30 0001650648 2024-03-31 0001650648 srt:MaximumMember fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2024-06-30 0001650648 2024-01-01 2024-06-30 0001650648 fdmt:EmployeeOptionsIssuedAndOutstandingAndFutureVestingOfRestrictedStockUnitsMember 2023-12-31 0001650648 fdmt:UniQureBiopharmaBVMember 2024-07-01 fdmt:UniQureAgreementMember 2014-01-31 0001650648 country:NL 2023-04-01 2023-06-30 0001650648 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001650648 fdmt:UCAgreementsMember 2019-01-31 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMember 2024-06-30 0001650648 us-gaap:USGovernmentAgenciesDebtSecuritiesMember fdmt:ShortTermMarketableSecuritiesMember 2023-12-31 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001650648 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001650648 srt:MinimumMember fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember 2021-07-01 2021-07-31 0001650648 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001650648 fdmt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001650648 fdmt:FiveNineEightZeroHortonStreetMember 2018-11-01 2018-11-30 0001650648 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-12-31 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandTwentyFourExpansionMember us-gaap:SubsequentEventMember 2024-07-01 2024-07-31 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CollaborationAndLicenseRevenueMember 2024-04-01 2024-06-30 0001650648 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 2018-05-01 2018-05-31 0001650648 fdmt:WarehouseLeaseAgreementMember 2024-01-01 0001650648 fdmt:CollaborationAndLicenseAgreementMember 2024-06-30 0001650648 country:NL 2024-04-01 2024-06-30 0001650648 fdmt:AstellasGeneTherapiesIncMember srt:MaximumMember 2023-07-05 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember 2024-01-01 2024-06-30 0001650648 2024-04-01 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember 2023-01-01 2023-06-30 0001650648 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001650648 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2024-03-01 2024-03-31 0001650648 fdmt:AstellasGeneTherapiesIncMember 2023-07-05 2023-07-05 0001650648 us-gaap:CertificatesOfDepositMember fdmt:ShortTermMarketableSecuritiesMember 2024-06-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember 2018-10-01 2018-10-31 0001650648 us-gaap:CommonStockMember 2023-06-30 0001650648 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001650648 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001650648 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001650648 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001650648 us-gaap:CommonStockMember fdmt:PublicOfferingMember 2023-04-01 2023-06-30 0001650648 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001650648 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 us-gaap:CommonStockMember 2024-08-02 0001650648 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0001650648 srt:MaximumMember fdmt:UCAgreementsMember 2019-01-01 2019-01-31 0001650648 fdmt:PublicOfferingMember 2023-01-01 2023-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CysticFibrosisFoundationAgreementMember 2016-09-01 2016-09-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember 2023-12-31 0001650648 us-gaap:CommonStockMember 2024-06-30

0001650648 fdmt:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001650648 country:NL 2023-01-01 2023-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:FundingAgreementMember 2021-10-31 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001650648 srt:MinimumMember 2023-01-01 2023-12-31 0001650648 us-gaap:CommercialPaperMember fdmt:LongTermMarketableSecuritiesMember 2024-06-30 0001650648 srt:MaximumMember us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2024-02-01 2024-02-29 0001650648 fdmt:TwoThousandFourteenPlanMember 2024-01-01 2024-03-31 0001650648 fdmt:CollaborationAndLicenseRevenueMember 2023-04-01 2023-06-30 0001650648 us-gaap:CommercialPaperMember fdmt:ShortTermMarketableSecuritiesMember 2023-12-31 0001650648 srt:MinimumMember fdmt:UCAgreementsMember 2019-01-01 2019-01-31 0001650648 fdmt:PublicOfferingMember 2023-04-01 2023-06-30 0001650648 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001650648 fdmt:PreFundedWarrantsMember us-gaap:CommonStockMember fdmt:TwoThousandTwentyFourFollowOnPublicOfferingMember 2024-01-01 2024-06-30 0001650648 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember 2024-06-30 0001650648 fdmt:FiveNineEightZeroHortonStreetMember 2016-01-31 0001650648 fdmt:AtmOfferingProgramMember 2023-04-01 2023-06-30 0001650648 fdmt:CorporateBondMember fdmt:LongTermMarketableSecuritiesMember 2024-06-30 0001650648 us-gaap:RetainedEarningsMember 2023-12-31 0001650648 fdmt:CorporateBondMember fdmt:LongTermMarketableSecuritiesMember 2023-12-31 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:FundingAgreementMember 2020-04-30 0001650648 srt:MaximumMember 2024-06-30 0001650648 fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember 2024-06-30 0001650648 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-06-30 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001650648 srt:MaximumMember 2024-07-01 fdmt:CysticFibrosisFoundationMember 2024-06-30 0001650648 fdmt:UCRegentsAndTheTrusteesOfTheUniversityOfPennsylvaniaMember 2023-04-01 2023-06-30 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001650648 fdmt:PreFundedWarrantsMember us-gaap:CommonStockMember fdmt:TwoThousandTwentyFourFollowOnPublicOfferingMember 2024-02-29 0001650648 fdmt:ArborBiotechnologiesIncMember fdmt:ArborAgreementMember 2024-04-01 2024-06-30 0001650648 fdmt:LongTermMarketableSecuritiesMember 2023-12-31 0001650648 srt:MaximumMember 2023-01-01 2023-06-30 0001650648 srt:MinimumMember 2023-04-01 2023-06-30 0001650648 us-gaap:CommonStockMember us-gaap:IPOMember 2020-12-01 2020-12-31 0001650648 2022-12-31 0001650648 fdmt:CollaborationAndLicenseRevenueMember 2024-04-01 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember srt:MaximumMember fdmt:UniQureAgreementMember 2014-01-31 0001650648 fdmt:CysticFibrosisFoundationMember 2024-06-30 0001650648 us-gaap:MachineryAndEquipmentMember 2024-06-30 0001650648 country:US 2024-01-01 2024-06-30 0001650648 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndExpansionMember 2019-12-01 2019-12-31 0001650648 srt:MinimumMember 2024-07-01 fdmt:CysticFibrosisFoundationMember 2024-06-30 0001650648 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 us-gaap:RetainedEarningsMember 2023-06-30 0001650648 fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001650648 fdmt:ReigniteAgreementMember 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember fdmt:FebrurayAndMarchTwoThousandAndTwentyFourPublicOfferingSaleMember 2024-01-01 2024-03-31 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001650648 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-06-30 0001650648 fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2023-12-31 0001650648 fdmt:ReigniteAgreementMember 2024-04-01 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:CollaborationAndLicenseRevenueMember 2023-01-01 2023-06-30 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001650648 us-gaap:CommonStockMember fdmt:AtmOfferingProgramMember 2023-01-01 2023-03-31 0001650648 2023-01-01 2023-12-31 0001650648 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001650648 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-06-30 0001650648 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-01-01 2023-06-30 0001650648 fdmt:CollaborationAndLicenseAgreementMember 2023-12-31 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:CollaborationAndLicenseRevenueMember 2023-04-01 2023-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CollaborationAndLicenseRevenueMember 2023-01-01 2023-06-30 0001650648 us-gaap:CommercialPaperMember fdmt:ShortTermMarketableSecuritiesMember 2024-06-30 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-06-30 0001650648 us-gaap:WarrantMember 2024-06-30 0001650648 us-gaap:ComputerEquipmentMember 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember fdmt:AtmOfferingProgramMember 2023-01-01 2023-03-31 0001650648 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001650648 fdmt:CysticFibrosisFoundationMember fdmt:CysticFibrosisFoundationAgreementMember 2024-01-01 2024-06-30 0001650648 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember us-gaap:SubsequentEventMember 2024-07-01 2024-07-31 0001650648 srt:MaximumMember fdmt:AevitasTherapeuticsIncAgreementMember 2023-04-21 0001650648 us-gaap:RestrictedStockUnitsRSUMember fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember 2024-01-01 2024-06-30 0001650648 fdmt:FiveEightFiveEightHortonStreetBuildingLeaseAndTwoThousandNineteenExpansionMember 2021-02-01 2021-02-28 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember 2023-12-31 0001650648 2018-05-31 0001650648 srt:MinimumMember 2024-04-01 2024-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:AmendedUniqureAgreementAndSecondUniqureAgreementMember 2024-04-01 2024-06-30 0001650648 us-gaap:ComputerEquipmentMember 2023-12-31 0001650648 fdmt:AtmOfferingProgramMember 2023-01-01 2023-03-31 0001650648 fdmt:ShortTermMarketableSecuritiesMember 2024-06-30 0001650648 2023-01-01 2023-06-30 0001650648 us-gaap:RetainedEarningsMember 2022-12-31 0001650648 fdmt:PreFundedWarrantsMember 2024-08-02 0001650648 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 fdmt:ReigniteAgreementMember 2024-03-01 2024-03-31 0001650648 us-gaap:ConstructionInProgressMember 2023-12-31 0001650648 fdmt:TwoThousandTwentyEquityIncentiveAwardPlanMember 2024-02-29 0001650648 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001650648 us-gaap:RetainedEarningsMember 2023-03-31 0001650648 fdmt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001650648 fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember 2024-06-30 0001650648 us-gaap:AdditionalPaidInCapitalMember fdmt:AtmOfferingProgramMember 2023-04-01 2023-06-30 0001650648 fdmt:AtmOfferingProgramMember 2023-01-01 2023-06-30 0001650648 fdmt:UniQureBiopharmaBVMember fdmt:UniQureAgreementMember 2014-01-01 2014-01-31 0001650648 fdmt:ArborBiotechnologiesIncMember fdmt:ArborAgreementMember 2024-06-30 0001650648 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001650648 fdmt:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001650648 us-gaap:ConstructionInProgressMember 2024-06-30 pure fdmt:Period utr:sqft shares fdmt:Segment fdmt:Installment iso4217:USD fdmt:Product iso4217:USD shares false 0001650648 Q2 --12-31 http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense P1Y 10-Q true 2024-06-30 2024 false 001-39782 4D Molecular Therapeutics, Inc. DE 47-3506994 5858 Horton Street #455 Emeryville CA 94608 (510) 505-2680 Common Stock, par value $0.0001 per share FDMT NASDAQ Yes Yes Non-accelerated Filer true true false false 51969590 3583476 189061000 249108000 352885000 39124000 10687000 8356000 552633000 296588000 35715000 10954000 18761000 20126000 10688000 11539000 2320000 684000 620117000 339891000 3431000 3515000 12776000 12014000 0 273000 3196000 3149000 19403000 18951000 1318000 972000 382000 369000 10460000 11522000 214000 248000 31777000 32062000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 300000000 300000000 51914275 51914275 43075218 43075218 5000 4000 1071309000 723136000 -293000 16000 -482681000 -415327000 588340000 307829000 620117000 339891000 5000 239000 33000 538000 31860000 23584000 59727000 46002000 10601000 8791000 20898000 16777000 42461000 32375000 80625000 62779000 -42456000 -32136000 -80592000 -62241000 7548000 2512000 13293000 3955000 -45000 8000 -55000 -12000 7503000 2520000 13238000 3943000 -34953000 -29616000 -67354000 -58298000 -0.63 -0.63 -0.77 -0.77 -1.29 -1.29 -1.63 -1.63 55282754 55282754 38335219 38335219 52277369 52277369 35661995 35661995 -34953000 -29616000 -67354000 -58298000 -184000 615000 -309000 1541000 -35137000 -29001000 -67663000 -56757000 43075218 4000 723136000 16000 -415327000 307829000 236856 3113000 3113000 7845314 1000 316148000 316149000 5974000 5974000 22000 22000 -125000 -125000 -32401000 -32401000 51157388 5000 1048393000 -109000 -447728000 600561000 81290 850000 850000 585938 15263000 15263000 89659 707000 707000 6074000 6074000 22000 22000 -184000 -184000 -34953000 -34953000 51914275 5000 1071309000 -293000 -482681000 588340000 32626627 3000 547020000 -1196000 -314490000 231337000 122207 1135000 1135000 487934 9647000 9647000 4221000 4221000 22000 22000 926000 926000 -28682000 -28682000 33236768 3000 562045000 -270000 -343172000 218606000 72217 894000 894000 8625000 1000 129207000 129208000 82637 658000 658000 212000 212000 4969000 4969000 22000 22000 615000 615000 -29616000 -29616000 42016622 4000 697583000 345000 -372788000 325144000 -67354000 -58298000 12048000 9190000 44000 44000 13000 0 2367000 2108000 851000 732000 3092000 615000 2330000 475000 1636000 0 -83000 614000 785000 -2239000 72000 -538000 -1016000 -494000 -59331000 -49971000 374084000 20156000 38346000 114391000 1059000 1817000 -336797000 92418000 3963000 2029000 316148000 129720000 15263000 9647000 707000 658000 0 329000 0 212000 336081000 141513000 -60047000 183960000 249108000 52351000 189061000 236311000 0 183000 177000 312000 1. The Company 4D Molecular Therapeutics, Inc. (the “Company”) was formed as a limited liability company in September 2013 under the name 4D Molecular Therapeutics, LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware in March 2015. The Company is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. Initial Public Offering In December 2020, the Company sold and issued 9,660,000 shares of common stock at a price to the public of $23.00 per share, which included shares sold upon the underwriters’ exercise of their overallotment option to purchase 1,260,000 additional shares. The Company received an aggregate of $204.7 million in net proceeds, after deducting underwriting discounts and commissions and offering costs. Upon the closing of the Company’s initial public offering in December 2020 (the "IPO"), all outstanding shares of redeemable convertible preferred stock automatically converted into 11,575,984 shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding. 2021 Follow On Public Offering In November 2021, the Company completed an underwritten public offering ("2021 Offering") in which 4,750,000 shares of the Company’s common stock were sold at an offering price of $25.00 per share pursuant to an effective Registration Statement on Form S-1. The net proceeds from the 2021 Offering were $111.1 million, after deducting underwriting discounts and commissions and offering expenses.<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-

width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">2023 Follow On Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In May 2023, the Company completed its third underwritten public offering (the "2023 Offering") in which </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,625,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock were sold at an offering price of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> per share pursuant to an effective Registration Statement on Form S-3. The net proceeds from the 2023 Offering were $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">129.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">2024 Follow On Public Offering</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2024, the Company completed an underwritten public offering (the "2024 Offering") in which </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,586,015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock were sold at an offering price of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">29.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> per share, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,583,476</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock at an offering price of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">29.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> per underlying share pursuant to an effective Registration Statement on Form S-3. The net proceeds from the 2024 Offering were $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">281.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses. The Company also granted the underwriters the option to purchase up to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,525,423</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> additional shares of common stock in connection with the offering.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In March 2024, the underwriters exercised their option to purchase </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,259,299</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> additional shares of common stock resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, after deducting commissions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Liquidity</span></p><p style="text-indent:5.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">482.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> as of June 30, 2024. The Company believes that its cash and cash equivalents and marketable securities as of June 30, 2024 are sufficient for the Company to fund planned operations for at least one year from the issuance date of these unaudited condensed financial statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Company has historically financed its operations primarily through the sale of equity securities, and to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">lesser extent, from cash received pursuant to its collaboration and license agreements. To date, none of the Company's product candidates have been approved for sale, and therefore, the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows from operations to continue for the foreseeable future. The Company plans to raise additional funding as required based on the status of its clinical trials and projected cash flows. There can be no assurance that, in the event the Company requires additional financing, such financing will be available on terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company's ability to achieve its business objectives.</span></p> 9660000 23 1260000 204700000 11575984 0 4750000 25 111100000 8625000 16 129200000 6586015 29.5 3583476 29.4999 281200000 1525423 1259299 34900000 -482700000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The accompanying unaudited condensed financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP") and the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim reporting.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The accompanying financial information for the three and six months ended June 30, 2024 and 2023 is unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's financial position as of June 30, 2024 and December 31, 2023 and its results of operations and cash flows for the six months ended June 30, 2024 and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2023. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Use of Estimates and Judgments</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and the derivative instrument and income tax uncertainties. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Due to the war in Ukraine, conflicts in the Middle East, rising interest rates and inflation, and the lingering impacts of the coronavirus ("COVID-19") pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2024. While there was not a material impact to the Company's unaudited condensed financial statements as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, these estimates may change, as new events occur and additional information is obtained, as well as other factors that could result in material impacts to the unaudited condensed financial statements in future reporting periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> reportable and operating segment. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Company's cash is held at two financial institutions in the United States of America. The Company's cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, U.S. government sponsored agencies, commercial paper, corporate bonds and certificates of deposit. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company's partners in collaboration and license agreements who represent 10% or more of the Company's total revenue are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.435%;"></td> <td style="width:1.479%;"></td> <td style="width:12.792%;"></td> <td style="width:1.479%;"></td> <td style="width:12.792%;"></td> <td style="width:1.479%;"></td> <td style="width:13.532%;"></td> <td style="width:1.479%;"></td> <td style="width:13.532%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;">  </td>  <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;"> Customer A </td>  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;text-align:left;"> 0% </td>  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;text-align:left;"> 96% </td>  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;text-align:left;"> 0% </td>  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;text-align:left;"> 98% </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;">  Customer B </td>  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 100% </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> * </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">  <td style="text-indent:14pt;vertical-align:top;"> Total </td>  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 100% </td>  <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 96% </td>  <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 100% </td>  <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 98% </td>  </tr></table>  * Less than 10%  The Company did not have accounts receivable from its partners in collaboration and license agreements as of June 30, 2024 and December 31, 2023.    The Company's total revenue by geographic region, based on the location of the customer, are as follows (in thousands):    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:41.452%;"></td>  <td style="width:1.48%;"></td>  <td style="width:1%;"></td>  <td style="width:10.798%;"></td>  <td style="width:1%;"></td>  <td style="width:1.48%;"></td>  <td style="width:1%;"></td>  <td style="width:10.798%;"></td>  <td style="width:1%;"></td>  <td style="width:1.48%;"></td>  <td style="width:1%;"></td>  <td style="width:11.517999999999999%;"></td>  <td style="width:1%;"></td>  <td style="width:1.48%;"></td>  <td style="width:1%;"></td>  <td style="width:11.517999999999999%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;text-align:left;">  </td>  <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended June 30, </td>  <td style="vertical-align:bottom;text-align:left;">  </td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;text-align:left;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-

align:bottom;text-align:left;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Netherlands </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 525 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> United States </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 13 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total revenue </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 239 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 538 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td></tr></table> Other Risks and Uncertainties  The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (“CMOs”) and contract research organizations (“CROs”), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting.  There can be no assurance that the Company’s

*research and development will be successfully completed, that adequate protection for the Company's intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing).*

*Recently Issued Accounting Pronouncements Not Yet Adopted*

*On December 14, 2023, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2023-09, Improvements to Income Tax Disclosures. The final guidance adds clarifications related to the presentation of rate reconciliation for public business entities and definitions of specific categories in rate reconciliation. These amendments are effective for public business entities for annual periods beginning after December 15, 2024. For other entities, amendments are effective for annual periods beginning after December 15, 2025. The Company is not early adopting ASU 2023-09.*

*The Company expects to make additional disclosures for income taxes upon adoption of this ASU.*

*Basis of Presentation*

*The accompanying unaudited condensed financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP") and the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim reporting.*

*Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC.*

*The accompanying financial information for the three and six months ended June 30, 2024 and 2023 is unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's financial position as of June 30, 2024 and December 31, 2023 and its results of operations and cash flows for the six months ended June 30, 2024 and 2023. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods.*

*Use of Estimates and Judgments*

*The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and the derivative instrument and income tax uncertainties. Actual results could differ from those estimates.*

*Due to the war in Ukraine, conflicts in the Middle East, rising interest rates and inflation, and the lingering impacts of the coronavirus ("COVID-19") pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2024. While there was not a material impact to the Company's unaudited condensed financial statements as of June 30, 2024*, these estimates may change, as new events occur and additional information is obtained, as well as other factors that could result in material impacts to the unaudited condensed financial statements in future reporting periods.*

*Segment Information*

*The Company operates and manages its business as one reportable and operating segment. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance.*

1 1

*Concentration of Credit Risk*

*Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Company's cash is held at two financial institutions in the United States of America. The Company's cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, U.S. government sponsored agencies, commercial paper, corporate bonds and certificates of deposit. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits.*

*The Company's partners in collaboration and license agreements who represent 10% or more of the Company's total revenue are as follows:*

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|---|---|---|---|---|
| | 2024 | 2023 | 2024 | 2023 |
| Customer A | 0% | 96% | 0% | 98% |
| Customer B | 100% | 4% | 100% | 2% |

style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 100% </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> * </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 100% </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> * </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:14pt;vertical-align:top;"> Total </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 100% </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 96% </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 100% </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 98% </td> </tr> </table> * Less than 10%
The Company did not have accounts receivable from its partners in collaboration and license agreements as of June 30, 2024 and December 31, 2023.  The Company’s total revenue by geographic region, based on the location of the customer, are as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.452%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:11.517999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:11.517999999999999%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Netherlands </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 525 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> United States </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:right;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 538 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company's partners in collaboration and license agreements who represent 10% or more of the Company's total revenue are as follows:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.435%;"></td> <td style="width:1.479%;"></td> <td style="width:12.792%;"></td> <td style="width:1.479%;"></td> <td style="width:12.792%;"></td> <td style="width:1.479%;"></td> <td style="width:13.532%;"></td> <td style="width:1.479%;"></td> <td style="width:13.532%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Customer A </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 96% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 98% </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Customer B </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 100<span style="color:#000000;white-space:pre-

wrap;font-family:Arial;min-width:fit-content;">% </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> * </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 100% </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> * </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:14pt;vertical-align:top;"> Total </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 100% </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 96% </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 100% </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"> 98% </td> </tr> </table> * Less than 10% The Company did not have accounts receivable from its partners in collaboration and license agreements as of June 30, 2024 and December 31, 2023.  0 0.96 0 0.98 1 1 1 0.96 1 0.98 0.10 0 0 The Company's total revenue by geographic region, based on the location of the customer, are as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.452%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:11.517999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.48%;"></td> <td style="width:1%;"></td> <td style="width:11.517999999999999%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="white-space:pre-wrap;vertical-align:top;"> Netherlands </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 525 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> United States </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 538 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 0 230000 0 525000 5000 9000 33000 13000 5000 239000 33000 538000 Other Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (“CMOs”) and contract research organizations (“CROs”), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing).  Recently Issued Accounting Pronouncements Not Yet Adopted On December 14, 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2023-09, Improvements to Income Tax Disclosures. The final guidance adds clarifications related to the presentation of rate reconciliation for public business entities and definitions of specific categories in rate reconciliation. These amendments are effective for public business entities for annual periods beginning after December 15, 2024. For other entities, amendments are effective for annual periods beginning after December 15, 2025. The Company is not early adopting ASU 2023-09. The Company expects to make additional disclosures for income taxes upon adoption of this ASU. 3. Fair Value Measurements The following tables represent the Company’s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.543%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:15.794%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Basis for Fair Value Measurements </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Fair Value as of </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-

align:bottom;border-bottom:0.5pt solid #000000;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">146,308</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96,220 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96,220 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

*style="font-family:Arial;min-width:fit-content;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 203,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 203,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">146,308</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 388,600 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 534,908 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Liabilities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Derivative liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times*

*New Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">382</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">382</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table>  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.543%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:15.794%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Basis for Fair Value Measurements </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Fair Value as of </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;font-family:Arial;min-width:fit-*

content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">217,644</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 217,644 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,243 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,243 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,939 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government sponsored agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">217,644</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,078 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 267,722 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:top;"> Liabilities </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td>  <td style="vertical-align:bottom;text-align:center;">  </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Derivative liability </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 369 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">369</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">369</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 369 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  </tr>  </table> Level 3 Inputs  The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability was determined using a present value analysis with multiple scenarios. In determining the fair value of the derivative liability, the inputs impacting fair value include the change of control payment to Cystic Fibrosis Foundation (CFF), the probability of a change of control event, the product status at time of a

change of control event and the discount rate. See Note 15 for further discussion on the embedded derivative. There were no transfers between Level 1, 2 and 3 during the periods presented. The following tables set forth a summary of the changes in the fair value of the Company's Level 3 financial instrument during the six months ended June 30, 2024 and 2023 (in thousands):  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.736%;"></td> <td style="width:3.081%;"></td> <td style="width:1%;"></td> <td style="width:15.183%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Derivative<br/>Liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_cf84c1bd-4d0b-4fb5-8d6b-ef0fb860d636;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value included</span></span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> in other income (expense), net</span></p></td> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Balance as of June 30, 2024</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Derivative<br/>Liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2022 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_71d8a36f-a987-4ff4-a26a-a9e075fd3cca;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value included</span></span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> in other income (expense), net</span></p></td> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Balance as of June 30, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 212 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following tables represent the Company's fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands):  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.543%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:15.794%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Basis for Fair Value Measurements </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Fair Value as of </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Level 1 </td> <td style="vertical-

align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">146,308</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 146,308 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96,220 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96,220 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 203,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 203,733 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">146,308</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 388,600 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 534,908 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Liabilities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Derivative liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">382</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">382</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">382</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">382</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.543%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:8.917%;"></td> <td style="width:1%;"></td> <td style="width:1.479%;"></td> <td style="width:1%;"></td> <td style="width:15.794%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Basis for Fair Value Measurements </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Fair Value as of </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> 

</td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">217,644</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 217,644 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,243 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,243 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,939 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,939 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government sponsored agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> </tr> <tr

*style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">217,644</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,078 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 267,722 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Liabilities </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Derivative liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">369</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 369 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 369 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 369 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> </table> 146308000 146308000 69677000 69677000 96220000 96220000 203733000 203733000 18970000 18970000 146308000 388600000 534908000 382000 382000 382000 382000 217644000 217644000 18243000 18243000 28939000 28939000 2896000 2896000 217644000 50078000 267722000 369000 369000 369000 369000 0 0 0 0 The following tables set forth a summary of the changes in the fair value*

of the Company's Level 3 financial instrument during the six months ended June 30, 2024 and 2023 (in thousands):      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:79.736%;"></td>  <td style="width:3.081%;"></td>  <td style="width:1%;"></td>  <td style="width:15.183%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Derivative<br/>Liability </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td>  <td style="white-space:pre-wrap;vertical-align:top;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">369</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_cf84c1bd-4d0b-4fb5-8d6b-ef0fb860d636;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value included</span></span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> in other income (expense), net</span></p></td>  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Balance as of June 30, 2024</span></p></td>  <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 382 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  </tr>  </table>    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:80.236%;"></td>  <td style="width:1.94%;"></td>  <td style="width:1%;"></td>  <td style="width:15.823%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Derivative<br/>Liability </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2022 </td>  <td style="white-space:pre-wrap;vertical-align:top;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_71d8a36f-a987-4ff4-a26a-a9e075fd3cca;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value included</span></span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> in other income (expense), net</span></p></td>  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Balance as of June 30, 2023</span></p></td>  <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 212 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  </tr>  </table>  369000 13000 382000 212000 0 212000  4. Marketable Securities Marketable securities, which are classified as available-for-sale, consisted of the following as of June 30, 2024 and December 31, 2023 (in thousands):    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:42.629%;"></td>  <td style="width:1.54%;"></td>  <td style="width:1%;"></td>  <td style="width:9.422%;"></td>  <td style="width:1%;"></td>  <td style="width:1.54%;"></td>  <td style="width:1%;"></td>  <td style="width:9.422%;"></td>  <td style="width:1%;"></td>  <td style="width:1.54%;"></td>  <td style="width:1%;"></td>  <td style="width:9.422%;"></td>  <td style="width:1%;"></td>  <td style="width:1.54%;"></td>  <td style="width:1%;"></td>  <td style="width:14.943%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Amortized Cost Basis </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Gains </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Losses </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Fair Value as of June 30, 2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-

width:fit-content;">Short-term marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">69,674</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;color:#000000;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 95,009 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (68 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,949 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169,491 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (212 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169,289 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,977 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">353,151</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 39 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">305</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 352,885 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Long-term marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,275</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,271 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 34,466 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (42 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 34,444 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total long-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,741</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,715 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.629%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:9.422%;"></td> <td style="width:1%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:9.422%;"></td> <td style="width:1%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:9.422%;"></td> <td style="width:1%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:14.943%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Amortized Cost Basis </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Fair Value as of December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Short-term marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,603</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

*style="color:#000000;font-family:Arial;min-width:fit-content;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,578</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,641</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,650</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government sponsored agencies</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,900</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,896</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term marketable securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 39,144 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (33 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 39,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Long-term marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td*

style="vertical-align:bottom;text-align:center;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">661</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 665 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,257 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 32 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,289 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total long-term marketable securities </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,918</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 36 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,954 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">  </td>  </tr>  </table>  All marketable securities held as of June 30, 2024 had contractual maturities of less than two years. There have been no material realized gains or losses on marketable securities for the periods presented.  Aggregate fair values of marketable securities with unrealized losses and gains were as follows as of June 30, 2024 and December 31, 2023 (in thousands):    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:71.034%;"></td>  <td style="width:1.42%;"></td>  <td style="width:1%;"></td>  <td style="width:11.062%;"></td>  <td style="width:1%;"></td>  <td style="width:1.42%;"></td>  <td style="width:1%;"></td>  <td style="width:11.062%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:left;"> June 30, </td>  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td>

<td style="vertical-align:bottom;text-align:left;">  </td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Aggregate fair value of marketable securities in a continuous loss position for less than twelve months </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">304,777</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,494 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Aggregate fair value of marketable securities in a continuous loss position for more than twelve months </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,986 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,">  <td style="white-space:pre-wrap;vertical-align:top;"> Aggregate fair value of marketable securities in unrealized gain position </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 83,823 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 24,598 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word,">  <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">388,600</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,078 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  </tr>  </table> The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for any period presented. The Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company further considered the maximum unrealized loss amounts both at the individual instrument level, $13 thousand, as well as in aggregate, $350 thousand, as of June 30, 2024, as immaterial. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses.  The Company anticipates that it will recover the entire amortized cost basis of such securities, and therefore, no credit loss existed as of June 30, 2024.  Marketable securities, which are classified as available-for-sale, consisted of the following as of June 30, 2024 and December 31, 2023 (in thousands):    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:42.629%;"></td>  <td style="width:1.54%;"></td>  <td style="width:1%;"></td>  <td style="width:9.422%;"></td>  <td style="width:1%;"></td>  <td style="width:1.54%;"></td>  <td style="width:1%;"></td>  <td style="width:9.422%;"></td>  <td style="width:1%;"></td>  <td style="width:1.54%;"></td>  <td style="width:1%;"></td>  <td style="width:14.943%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">  <td style="vertical-align:bottom;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Amortized Cost Basis </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Gains </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:center;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Fair Value as of June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Short-term marketable securities: </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">69,674</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,677 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,009 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (68 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,949 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169,491 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (212 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169,289 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-

align:top;"> U.S. Treasuries </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,977 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total short-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">353,151</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 39 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">305</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 352,885 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Long-term marketable securities: </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,275</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:center;"> 1,271 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <span style="font-family:Arial;min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 34,466 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (42) </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 34,444 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Total long-term marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,741</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,715 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.629%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:9.422%;"></td> <td style="width:1%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:9.422%;"></td> <td style="width:1%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:14.943%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Amortized Cost Basis </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Fair Value as of December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Short-term marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,603 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 

</td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,578</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,641</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">12</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,650</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">U.S. government sponsored agencies</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,900</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,896</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total short-term marketable securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 39,144 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Long-term marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-

wrap;font-family:Arial;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">661</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">665</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,257</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,289</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total long-term marketable securities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,918 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,954 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 69674000 21000 18000 69677000 95009000 8000 68000 94949000 169491000 10000 212000 169289000 18977000 0 7000 18970000 353151000 39000 305000 352885000 1275000 0 4000 1271000 34466000 20000 42000 34444000 35741000 20000 46000 35715000 17603000 1000 26000 17578000 18641000 12000 3000 18650000 2900000 0 4000 2896000 39144000 13000 33000 39124000 661000 4000 0 665000 10257000 32000 0 10289000 10918000 36000 0 10954000 P2Y 0 0 Aggregate fair values of marketable securities with unrealized losses and gains were as follows as of June 30, 2024 and December 31, 2023 (in thousands):  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:71.034%;"></td> <td style="width:1.42%;"></td> <td style="width:1%;"></td> <td style="width:11.062%;"></td> <td style="width:1%;"></td> <td style="width:1.42%;"></td> <td style="width:1%;"></td> <td style="width:11.062%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> <span

style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">June 30, </td> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;">  </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Aggregate fair value of marketable securities in a continuous loss position for less than twelve months </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">304,777</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,494 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Aggregate fair value of marketable securities in a continuous loss position for more than twelve months </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,986 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Aggregate fair value of marketable securities in unrealized gain position </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 83,823 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 24,598 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">388,600</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,078 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> </table> 304777000 20494000 0 4986000 83823000 24598000 388600000 50078000 0 0 0 0 13000 350000 0 5. Property and Equipment, Net  Property and equipment, net, consisted of the following (in thousands):    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.86%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.04%;"></td> <td style="width:1%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.059999999999999%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Machinery and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,766 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,996 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,325 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,902 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 566 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 566 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Office equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 866 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 805 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Construction in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 299 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,061 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32,058 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Less: Accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (14,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (11,932 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> ) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,761</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,126 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> All property and equipment are maintained in the United States. Depreciation expense was $1.2 million and $1.1 million for the three months ended June 30, 2024 and 2023, respectively, and $2.4 million and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million for the six months ended June 30, 2024 and 2023, respectively.</span></p> <p style="text-indent:5.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.86%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.04%;"></td> <td style="width:1%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.059999999999999%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">June 30,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Machinery and equipment</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,766 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,996 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,325 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,902 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 566 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 566 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Office equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 866 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 805 </td> <td

style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Construction in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 299 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,061 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32,058 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Less: Accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (14,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (11,932 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> ) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,761</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,126 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 13766000 12996000 17325000 16902000 566000 566000 239000 239000 866000 805000 299000 550000 33061000 32058000 14300000 11932000 18761000 20126000 1200000 1100000 2400000 2100000 6. Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.873%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.043%;"></td> <td style="width:1%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.043%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Payroll and related expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,494</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,149 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued clinical and preclinical study costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,180 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Consulting and professional </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,021 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,581 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 96 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"> Total accrued and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,776</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,014 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accrued and other current liabilities consisted of the following (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.873%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.043%;"></td> <td style="width:1%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:13.043%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Payroll and related expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,494</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,149 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued clinical and preclinical study costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,180 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Consulting and professional </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,021 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,581 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Other accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 96 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"> Total accrued and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,776</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,014 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> </table> 5494000 8149000 5165000 2180000 2021000 1581000 96000 104000 12776000 12014000 7.  Research and Collaboration Arrangements  Collaboration and license revenue for each period was as follows (in thousands):     <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:50.38%;"></td>  <td style="width:1.22%;"></td> <td style="width:1%;"></td>  <td style="width:9.184%;"></td>  <td style="width:1%;"></td>  <td style="width:1.22%;"></td>  <td style="width:1%;"></td>  <td style="width:9.184%;"></td>  <td style="width:1%;"></td>  <td style="width:1.22%;"></td>  <td style="width:1%;"></td>  <td style="width:9.184%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  </tr>  <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> uniQure </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>  <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 525 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> CFF </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span style="font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 538 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Deferred revenue is summarized as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> CFF </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,318</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,245 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"> Total deferred revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,318</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,245 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The total amount of revenue in the six months ended June 30, 2024 which was included in deferred revenue at January 1, 2024 was zero. The total amount of revenue in the six months ended June 30, 2023 which was included in deferred revenue at January 1, 2023 was $0.5 million. uniQure <p style="text-indent:5.733%;font-

size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In January 2014, the Company and uniQure biopharma B.V. ("uniQure") entered into a Collaboration and License Agreement (the "uniQure Agreement") to collaborate on the discovery and non-clinical research activities related to the Company's Therapeutic Vector Evolution platform in order to generate and validate vectors for gene delivery to treat diseases within the central nervous system and liver (together, the "uniQure Field"). The uniQure Agreement provided uniQure with a research license as well as an exclusive development and commercialization license for each project variant selected for further development. The initial research term is three years with an option for uniQure to extend the research term one time for an additional year. Once the Company's research plan has concluded, uniQure is solely responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. In October 2016, uniQure exercised its option to extend the research term for an additional year to January 2018. The Company was also required to work exclusively with uniQure in the uniQure Field (the "uniQure Exclusivity Clause"). Pursuant to the uniQure Agreement, the Company received upfront payments of $0.2 million, and was entitled to receive (i) contingent payments for the achievement of research and development milestones of up to $5.0 million for each licensed product selected under the arrangement, and (ii) royalties in the single digit range on future sales of the potential product candidates and sublicense consideration in the low teens to low thirties range on any future sublicensing arrangements. The Company also received capped research and development service fees based on contractual full-time employee rates per year. In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of 609,744 of uniQure ordinary shares that vested over the initial three-year term of the agreement. The upfront payment of $0.2 million was recorded as deferred revenue and was recognized on a ratable basis over the estimated performance period of four years. Payments and reimbursements for research costs were recognized on an as-incurred basis. The options to purchase uniQure shares were deemed to be a noncash component of the arrangement consideration, as the vesting of options is linked to the uniQure Agreement and there is a requirement for the holders of the options to provide services under the agreement. The fair value of the uniQure options, which was estimated to be $10.6 million, was recognized ratably as revenue over the estimated performance period of four years and the associated compensation expense related to the stock options was recorded as research and development expense. In August 2019, the Company and uniQure entered into an Amended and Restated Collaboration and License Agreement (the "Amended uniQure Agreement"), which amended and restated the uniQure Agreement, and a separate Collaboration and License Agreement (the "Second uniQure Agreement"). Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the uniQure Exclusivity Clause and transferring other rights back to the Company. Under the Amended uniQure Agreement, uniQure continues to have an exclusive license to select AAV capsid variants (the "Selected Variants") in the uniQure Field. uniQure continues to be solely responsible, at its cost, to develop and commercialize the compounds and products containing the Selected Variants. The amended uniQure Agreement eliminated the uniQure Exclusivity Clause in the uniQure Agreement. Furthermore, the contingent payments that the Company was entitled to from uniQure for the achievement of research and development milestones of up to $5.0 million for each licensed product selected under the uniQure Agreement were eliminated and sublicense consideration on any future sublicensing arrangements was reduced from the low teens to low thirties percentages to mid-single digit to mid-twenties percentages. Under the Second uniQure Agreement, the parties agreed to research and develop new AAV capsid variants (the "New Variants") that are not Selected Variants that affect certain targets selected by uniQure (the "uniQure Targets") in the uniQure Field. The Company is solely responsible, at its cost, for the research of the New Variants. The Company granted uniQure an exclusive license to a certain number of the New Variants (the "uniQure New Variants") that affect the uniQure Targets. uniQure is solely responsible, at its cost, to develop and commercialize the compounds and products containing the uniQure New Variants that affect the uniQure Targets (the "Licensed Products"). The Company retains all rights to New Variants in the uniQure Field that affect targets other than the uniQure Targets. Under both the Amended uniQure Agreement and the Second uniQure Agreement, uniQure will be required to pay the Company royalties on worldwide annual net sales of Licensed Products at a mid-single digit percentage rate, subject to certain specified reductions. uniQure will also be required to pay the Company sublicensing consideration for sublicensing the Company's intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties at a rate between the mid-single digit to mid-twenties. The Company has reciprocal obligations, at the same percentage rates as uniQure, to pay uniQure royalties and sublicensing consideration for sublicensing certain intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties. The Company concluded that the Amended uniQure Agreement and the Second uniQure Agreement should be accounted for as one combined contract that should be accounted for as a separate contract from the uniQure Agreement given that the incremental licensed intellectual property rights and research and development services are distinct from the rights and services previously transferred to uniQure under the uniQure Agreement and the transaction price increased by an amount that equals the standalone selling price of the incremental rights and services to be transferred to uniQure under the Amended uniQure Agreement and Second uniQure Agreement. Neither party was required to pay monetary consideration in connection with the execution of the Amended uniQure Agreement or the Second uniQure Agreement or for subsequent performance by the parties under those agreements, notwithstanding the potential future royalty and sublicense consideration described above. The fair value of the non-monetary consideration given by uniQure to the Company, for the intellectual property right is $5.1 million. This intellectual property right is considered to be an in-process research and development asset with no alternative future use and, accordingly, was written off as acquired in-process research and development expense in the year ended December 31, 2019. The incremental transaction price described in the paragraph above was recorded as deferred revenue given that the Company identified one single combined performance obligation under ASC 606, which includes the licenses to the New Variants, research services and participation in the joint steering committee ("JSC"). Revenue is being recognized using the input method based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligation. The Company completed its performance obligation during the third quarter of 2023 and the deferred revenue was recognized as revenue in the same period. The Company determined the transaction price using the risk adjusted net present value analysis ("rNPV") methodology to value the elimination of the uniQure exclusivity clause and other material rights received by the Company, including the potential royalties the Company would receive from uniQure. The rNPVs incorporate estimates and assumptions including the number of products the Company and uniQure would develop, the risk-adjusted probability of successfully developing a biopharmaceutical product, the probability that uniQure will develop a product, the research and development costs, the potential worldwide sales and associated commercialization costs, corporate tax rate, and discount rate. During each of the three and six months ended June 30, 2024, the Company recognized no revenue under both of the Amended uniQure Agreement and the Second uniQure Agreement. The Company recognized $0.2 million and $0.5 million during the three and six months ended June 30, 2023, respectively, under both of the Amended uniQure Agreement and the Second uniQure Agreement. There were no amounts due from uniQure under the uniQure Agreement, Amended uniQure Agreement or Second uniQure Agreement as of June 30, 2024 and December 31, 2023. As of June 30, 2024 and December 31, 2023, deferred revenue relating to uniQure was zero and the aggregate amount of the transaction price allocated to the remaining performance obligation was zero. Cystic Fibrosis Foundation (CFF) In September 2016, the Company entered into an award agreement for the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program with CFF, a non-profit organization dedicated to finding a

*cure for cystic fibrosis, an inherited disorder that causes disease in the pulmonary airways leading to morbidity and mortality. Under this agreement, CFF contributes funding to help advance the Company's CF research program. The September 2016 grant award agreement was incorporated into a new grant award agreement with the CFF in September 2017 with the same objectives, which was subsequently amended in August 2018 and February 2021. In August 2023, the Company executed a third amendment to the agreement (the "August 2023 Amendment"), which modified the research plan, increased the aggregate milestone payments from $3.5 million to $6.3 million and extended the estimated project completion date. The aforementioned September 2017 agreement and three amendments are collectively referred to as the "CFF Agreement". The August 2023 Amendment represents a contract modification to an existing contract under Topic 606, given the amendment did not include any additional goods or services, and the remaining research activities are not distinct from those previously provided. The August 2023 Amendment did not impact the transaction price, given the increased award amount relates to variable consideration for future milestones that are fully constrained. Accordingly, the contract modification did not result in a revenue adjustment. As of June 30, 2024 and December 31, 2023, the Company had achieved milestones totaling $1.8 million and $1.7 million, respectively, under the CFF Agreement. The remaining award amount will be paid by CFF based on achievement of certain development milestones by the Company. The Company expects to make payments to CFF equal to six times the actual award received by the Company in three installments within the first four years of the first commercial sale of a product developed under this agreement. The Company also has agreed to make future sales-based milestone payments to CFF of up to three times the actual award received upon achieving specified commercialization milestones with respect to the first of any product developed utilizing any compound covered under the CFF Agreement. The CFF Agreement also requires the Company to pay to CFF royalties of a mid-single digit percentage, up to six times the actual award received, on any amounts received by the Company from the sale, license or transfer to a third-party of rights in the technology developed as a result of this collaboration. Any such royalty payments shall be credited against the payments owed by the Company upon first commercial sale. In the event of a change of control of the Company, CFF will receive certain payments, depending on the timing of the change of control and the size of the transaction. To date, the Company has not developed a commercial product in connection with the CFF Agreement, and it has not licensed, sold or otherwise transferred to another party the product developed under the CFF Agreement or the underlying technology. If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of 180 consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Company's interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license.  The Company identified one performance obligation within the CFF grant agreement for research activities. The Company's contract with CFF does not include a significant financing component. The Company concluded that the transaction price should not include the variable consideration related to future research milestones as they were considered to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company re-evaluates the transaction price and estimated period of performance at each reporting period.    Revenue recognized during each of the three and six months ended June 30, 2024 and 2023 was immaterial. As of June 30, 2024 and December 31, 2023, deferred revenue relating to the CFF Agreement was $1.3 million and $1.2 million, respectively. There were no accounts receivable from CFF under the CFF Agreement as of June 30, 2024 and December 31, 2023. As of June 30, 2024 and December 31, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligation was $1.3 million and $1.2 million, respectively. Based on current timelines, the deferred revenue is expected to be recognized as revenue over the next one to three years as the Company performs research services through the completion of IND-enabling studies. The obligation to make payments to CFF upon a change of control meets the definition of an embedded derivative that is required to be bifurcated and separately accounted for as a derivative liability. See Note 15 for further discussion of the embedded derivative. Arbor Biotechnologies, Inc. On December 20, 2023 (the "Effective Date"), the Company entered into a co-development and co-commercialization agreement (the "Arbor Agreement") with Arbor Biotechnologies, Inc. ("Arbor"), pursuant to which the Company and Arbor agreed to co-develop and co-commercialize on a fifty-fifty cost-and-profit-sharing basis up to six genetic medicine products to treat central nervous system ("CNS") indications, based on combining the Company's CNS-targeting vectors and Arbor's Cas enzymes and Guide RNAs. The first product candidate under the Arbor Agreement will address a molecular target implicated in amyotrophic lateral sclerosis (ALS). The Company will account for its costs related to the co-development and co-commercialization of product candidates under the Arbor Agreement as research and development expenses in the periods in which they are incurred. As of June 30, 2024, no Shared Product has been designated by the JSC (each as defined in the Arbor Agreement) under the Arbor Agreement, and no research and development expenses were incurred related to the Arbor Agreement during the three and six months ended June 30, 2024. Collaboration and license revenue for each period was as follows (in thousands):  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184%;"></td><td style="width:1%;"></td><td style="width:1.22%;"></td><td style="width:1%;"></td><td style="width:9.184%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New*

Roman;margin-bottom:0;text-align:center;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> uniQure </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">525</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">CFF</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">239</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 538 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>  0 230000 0 525000 5000 9000 33000 13000 5000 239000 33000 538000 Deferred revenue is summarized as follows (in thousands): <p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> CFF </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,318</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,245 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"> Total deferred revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,318</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,245 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1318000 1245000 1318000 1245000 0 500000 P3Y 200000 5000000 609744 P3Y 200000 P4Y 10600000 P4Y 5000000 5100000 0 0 200000 500000 0 0 0 0 0 0 3500000 6300000 1800000 1700000 6 3 P4Y 3 6 If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of 180 consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Company's interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license. P180D 1300000 1200000 0 0 1300000 1200000 P3Y 0 0 0 8. License Arrangements Astellas Gene Therapies, Inc. On July 5, 2023, the Company entered into a licensing agreement (the "License Agreement") with Astellas Gene Therapies, Inc. ("AGT"), pursuant to which the Company granted to AGT a license to utilize its intravitreal R100 vector ("4D Vector") to develop and commercialize licensed compounds and licensed products for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees. Under the terms of the License Agreement, the Company has provided its 4D vector technology to AGT to deliver AGT's genetic payloads for the treatment of rare monogenic diseases. AGT will conduct all subsequent research, development, manufacturing, and commercialization activities. As partial consideration for the rights and licenses granted to AGT by the Company under this Agreement, AGT paid the Company an upfront amount of $20 million, which was received in July 2023. The Company may receive potential future option fees and milestones of up to $942.5 million. In addition, the Company is entitled to receive mid-single digit to double-digit, sub-teen royalties on net sales of all licensed products. Under the License Agreement, the Company's performance obligation is to grant and make available to AGT the Licensed IP and Licensed Know-How (each as defined in the License Agreement) with respect to the 4D Vector. In connection with the grant of the license, in July 2023, the Company delivered to AGT the Transferred Material (as defined in the License Agreement). As of June 30, 2024, there was no deferred revenue and no accounts receivable relating to the License Agreement. Aevitas Therapeutics, Inc. and The Trustees of the University of Pennsylvania On April 21, 2023, the Company entered into an agreement (the "Agreement") with Aevitas Therapeutics, Inc. ("Aevitas"), pursuant to which the Company acquired all of Aevitas' worldwide rights to short-form human complement factor H ("sCFH"), which the Company plans to use for its 4D-175 product candidate research program. The asset purchase was accounted for as an asset acquisition. As consideration for the Agreement, the Company shall pay Aevitas up to approximately $144 million in cash upon certain late-stage development, regulatory and sales milestones being achieved plus royalties in the low single digits range on sales of 4D-175. In addition, as part of the Agreement, the Company was assigned a License Agreement for sCFH with the Trustees of the University of Pennsylvania, under which the Company shall pay the University of Pennsylvania up to approximately $42 million in cash upon certain late-stage development, regulatory and sales milestones being achieved plus royalties in the low single digits range on sales of 4D-175. No upfront consideration was paid under the Agreement. As of June 30, 2024, the Company has not recorded a liability related to contingent consideration for future milestone and royalty payments to either Aevitas or the University of Pennsylvania, as the achievement of such milestones has not occurred and was not deemed probable and product sales have not commenced. Regents of the University of California The Company has exclusive, worldwide license agreements (the "UC Agreements") with the Regents of the University of California (the "UC Regents") relating to the use of certain patents and intellectual property surrounding its core technologies, including Therapeutic Vector Evolution. Pursuant to each of the UC Agreements executed prior to January 2019, the Company was obligated to pay a (i) non-refundable license fee of $5,000 upon execution, (ii) a non-refundable license fee of $5,000 each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents, (iii) reimbursement of domestic and foreign patent filing, prosecution and maintenance fees, and (iv) either $50,000<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-

family:Arial;min-width:fit-content;"> or issuance of a 3% equity interest in the Company upon the closing of the first qualified financing at the option of the UC Regents. The Company's first qualified financing occurred in 2015 and at the election of the UC Regents, the Company issued the UC Regents in January 2016 an amount of common stock equal to 6% of the equity interests in the Company pursuant to the applicable clause in each of the UC Agreements. Pursuant to an agreement with the UC Regents executed in January 2019 the Company paid a non-refundable license fee of $50,000 to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license fee of $5,000 on the one-year anniversary of the contract effective date and each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $3.1 million, (ii) low single digit royalties on the net sales of its developed products that consists of a minimum annual royalty of up to $0.1 million per year for the term of the agreement beginning in the first calendar year after the year in which net sales first occurred, and (iii) sublicense consideration in the mid-teens to the mid-twenties-range on any future sublicensing arrangements the Company may enter into with third-party licensees. Regents of the University of California and The Trustees of the University of Pennsylvania In July 2021, the Company entered into an exclusive license agreement with the UC Regents and the Trustees of the University Pennsylvania to license intellectual property related to certain vectors. In July 2021, the Company paid a non-refundable license fee of $100,000 to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license maintenance fee of $10,000 on the one-year anniversary of the contract effective date and each year thereafter, except years for which the Company has paid royalties on the net sales of a licensed product. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $3.9 million, (ii) low single digit percentage rate royalties on the net sales of its licensed products that consists of a minimum annual royalty of up to $0.1 million per year for the term of the agreement beginning in the first calendar year after the year in which net sales first occurred and (iii) sublicense consideration in the mid-single digits to the low twenties percentage rate range on any future sublicensing arrangements the Company may enter into with third-party licensees. On February 22, 2023, the Company provided 90 days written notice to the UC Regents and the Trustees of the University Pennsylvania to terminate said agreement in its entirety at-will. Accordingly, the effective termination date of this agreement is May 23, 2023. The Company did not incur any expense under the provisions of the outstanding license agreements during each of the three and six months ended June 30, 2024 and 2023. 20000000 942500000 0 0 144000000 42000000 0 0 5000 5000 50000 0.03 0.06 50000 5000 3100000 100000 100000 10000 3900000 100000 0 0 0 0 9. Commitments and Contingencies Operating Lease Commitments 5980 Horton Street Building Lease In May 2015, the Company executed a lease agreement for office and laboratory space in Emeryville, California. In January 2016, the Company executed the first amendment to the lease agreement for additional rentable office and laboratory space which extended the lease term to March 31, 2023 and updated the option to renew the lease at market rent from the prior additional term of three years to five years. In October 2018, the Company executed a second amendment to extend the lease to September 2026. Additionally, the second amendment provided a tenant improvement allowance of $0.2 million, which was paid to the Company in November 2018. The 5980 Horton Street Building Lease is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of June 30, 2024, the operating lease right-of-use asset and operating lease liability were $1.0 million and $1.2 million, respectively. As of December 31, 2023, the operating lease right-of-use asset and operating lease liability were $1.2 million and $1.4 million, respectively. The discount rate used to determine the lease liability was 7.5%. 5858 Horton Street Building Lease and Expansion In October 2018, the Company executed a second lease agreement for additional office and laboratory space in Emeryville, California. The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years at market rent. The Company did not have to pay rent until October 2019. This lease agreement also provided for a tenant improvement allowance of $0.4 million, which was paid to the Company in December 2019. The Company amortizes the tenant improvement allowance on a straight-line basis over the remaining term of the lease as a reduction of rent expense.  In May 2019, the Company amended the second lease agreement executed in October 2018 to add additional office, manufacturing and laboratory space (the "2019 Expansion"). The amendment extended the term of the lease to December 31, 2029. The Company did not have to pay rent until December 2019. The lease agreement also included a tenant improvement allowance, which was increased to $2.3 million in February 2021 pursuant to a second amendment to the second lease agreement. The Company fully received the $2.3 million tenant improvement allowance in 2023. The tenant improvement allowance funds improvements to the additional office, manufacturing and laboratory space, which the Company has determined to be lessee owned. The allowance is treated as a reduction of lease payments used to measure the lease liability.  The 5858 Horton Street Building Lease and 2019 Expansion are considered operating leases under ASC 842 as they do not meet the criteria of a finance lease. As of June 30, 2024, the operating lease right-of-use asset and operating lease liability was $9.7 million and $12.5 million, respectively. As of December 31, 2023, the operating lease right-of-use asset and operating lease liability was $10.3 million and $13.2 million, respectively. The discount rate

used to determine the lease liability was 7.8%. In July 2024, the lease term for the 5858 Horton Street Building Lease and 2019 Expansion was  extended for a period of 12 months and will expire on December 31, 2030. Neither of the leases include a general option for the Company to terminate the leases. In July 2024, the Company entered into a lease for additional office and laboratory space in Emeryville, California (the "2024 Expansion") with a projected lease commencement date of September 1, 2024. The lease consists of approximately 32,038 square feet of office and laboratory space and has a lease term through December 31, 2030. Future minimum lease payments under the 2024 Expansion from its projected commencement date through lease expiration are approximately $13.2 million. As of June 30, 2024, the Company has not recorded a right-of-use asset or lease liability on its condensed balance sheets as the Company has not yet obtained control of the additional office and laboratory space. Emeryville, California Warehouse Lease In January 2024, the Company entered into a new lease for warehouse space in Emeryville, California (the "Warehouse Lease Agreement"), with a projected lease commencement date of August 31, 2024. The lease consists of approximately 7,800 square feet of warehouse space and has a lease term of five years and four months. Future minimum lease payments under the Warehouse Lease Agreement from its projected commencement date through lease expiration in the fourth quarter of 2029 are approximately $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of June 30, 2024, the Company has </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t recorded a right-of-use asset or lease liability on its condensed balance sheets as the Company has not yet obtained control of the warehouse space.</span></p><div style="font-size:11pt;font-family:Arial;"><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes the components of lease expense for the three and six months ended June 30, 2024 and 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">which are included in operating expenses in the Company's condensed statements of operations (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.88%;"></td><td style="width:1.24%;"></td><td style="width:1%;"></td><td style="width:9.299999999999999%;"></td><td style="width:1%;"></td><td style="width:1.24%;"></td><td style="width:1%;"></td><td style="width:9.299999999999999%;"></td><td style="width:1%;"></td><td style="width:1.24%;"></td><td style="width:1%;"></td><td style="width:8.78%;"></td><td style="width:1%;"></td><td style="width:1.24%;"></td><td style="width:1%;"></td><td style="width:8.78%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Three Months Ended June 30,</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Six Months Ended June 30,</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease cost</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 698 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,397 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> <span

style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Variable lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 354 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 311 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 707 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 622 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,052</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,009 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,104</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,019 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Variable lease payments include amounts relating to common area maintenance and are recognized in the condensed statements of operations as incurred. The following table summarizes supplemental information related to operating leases:  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.233%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:13.102%;"></td> <td style="width:1%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:13.102%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, <br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, <br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining lease term (in years): </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> The following table summarizes the maturities of lease liabilities as of June 30, 2024 (in thousands): <span style="white-

space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remaining six months) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,588</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,244</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2026</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,135</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2027</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,810</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2028</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Thereafter</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,982</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total future minimum lease payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,653</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Amount representing interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,997</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Present value of future minimum lease payments</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,656</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: Current portion of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,196</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Long-term portion of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,460 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Indemnification Agreements In the ordinary course of business, the Company enters into agreements that may include indemnification provisions, such as with vendors and other parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently maintains directors' and officers' liability insurance that would generally enable it to recover a portion of any future amounts paid. The Company believes the estimated fair value of its indemnification agreements in excess of applicable insurance coverage is not material. Legal Proceedings From time to time, the Company may become

*involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. There are no material legal proceedings outstanding at June 30, 2024.   2023-03-31 P3Y P5Y 2026-09 200000 1000000 1200000 1200000 1400000 0.075 The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years at market rent. P87M true P5Y 400000 2300000 2300000 9700000 12500000 10300000 13200000 0.078 P12M 2030-12-31 2024-09-01 32038 2030-12-31 13200000 0 0 2024-08-31 7800 P5Y4M 1500000 0 0 The following table summarizes the components of lease expense for the three and six months ended June 30, 2024 and 2023, which are included in operating expenses in the Company's condensed statements of operations (in thousands):     <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.88%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.299999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.299999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.78%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.78%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">698</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 698 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,397</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,397 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 354 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 311 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 707 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 622 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span*

style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,052 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,009</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,104 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,019</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> </tr> </table> 698000 698000 1397000 1397000 354000 311000 707000 622000 1052000 1009000 2104000 2019000 <p style="text-indent:5.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes supplemental information related to operating leases:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:67.233%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:13.102%;"></td> <td style="width:1%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:13.102%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">June 30,<br/>2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted-average remaining lease term (in years):</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted-average discount rate:</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p> P5Y2M12D P5Y8M12D 0.078 0.078 <p style="text-indent:5.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes the maturities of lease liabilities as of June 30, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td>  <td style="width:15.823%;"></td> <td style="width:1%;"></td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024 (remaining six months)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,588 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,244 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,135 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,810 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,894 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  </tr>  <tr style="height:10pt;background-color:#fffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,982 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"> Total future minimum lease payments </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,653 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Less: Amount representing interest </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,997 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"> Present value of future minimum lease payments </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,656 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  </tr>  <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Less: Current portion of operating lease liabilities </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,196 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Long-term portion of operating lease liabilities </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td>  <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,460 </td>  <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td>  </tr>  </table>  1588000 3244000 3135000 2810000 2894000 2982000 16653000 2997000 13656000 3196000 10460000  10. Income Taxes  For the three and six months ended June 30, 2024 and 2023, the Company did not record a federal or state income tax provision due to its recurring net losses. In addition, the Company has taken a full valuation allowance against its net deferred tax assets as the Company believes it is not more likely than not that the benefit will be realized.  0 0 0 0  11. Common Stock  As of June 30, 2024 and December 31, 2023, the Company's certificate of incorporation authorized the Company to issue 300,000,000 shares of common stock, at the par value of $0.0001 per share. The holder of each share of common stock is entitled to one vote per share.  Common stockholders are entitled to dividends, if and when declared by the board of directors. To date, no dividends on common stock have been declared by the board of directors.  As of June 30, 2024 and December 31, 2023, the Company has reserved common stock, on an as-converted basis, for future issuance as follows:    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">  <tr style="visibility:collapse;">  <td style="width:66.967%;"></td>  <td style="width:1.22%;"></td>  <td style="width:1%;"></td>  <td style="width:13.297%;"></td>  <td style="width:1.22%;"></td>  <td style="width:1%;"></td>  <td style="width:13.297%;"></td>  <td style="width:1%;"></td>  </tr>  <tr style="height:8pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;">  <td style="vertical-align:bottom;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,<br/>2024 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  <td style="vertical-align:bottom;">  </td>  <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,<br/>2023 </td>  <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td>  </tr>  <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">  <td style="white-space:pre-wrap;vertical-align:top;"> Issuance of common stock under the 2020 Equity Incentive Award Plan </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,332,657 </td>  <td style="white-space:nowrap;vertical-align:bottom;">  </td>  <td style="white-space:pre-wrap;vertical-align:bottom;">  </td>  <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 524,078 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Issuance of common stock under the 2020 Employee Stock Purchase Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273,375 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313,034 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercise of options issued and outstanding and future vesting of restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,450,290 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,423,481 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercise of common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,637,145 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 53,669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total common stock reserved for future issuance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,693,467 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,314,262 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Funding Agreement with CFF — In April 2020, CFF made a $10.0 million investment in the Company's Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of Series C redeemable convertible preferred stock, and the Company and CFF entered into a Funding Agreement (the "Funding Agreement"). Pursuant to the terms of the Funding Agreement, except in the event of a technical failure, the $10.0 million received from CFF will be used to advance the development program for 4D-710, the Company's lead product in cystic fibrosis, or any other therapeutic approved by the Program Advisory Group ("PAG") to alleviate pulmonary complications of cystic fibrosis (the "Funding Agreement Product"). CFF committed to provide an additional $4.0 million of funding upon acceptance of an Investigational New Drug ("IND") application or its equivalent to allow for human testing of the Funding Agreement Product ("Acceptance").   In October 2021, the IND was cleared by the U.S. Food and Drug Administration and CFF made the additional investment of $4.0 million in cash for the issuance of 125,715 shares of the Company's common stock to CFF.  The Company was committed to providing an amount equal to the funding provided by CFF to be used solely to advance the Funding Agreement Product. As of June 30, 2024, the funding commitment has been fulfilled. Under the terms of the Funding Agreement, neither the $10.0 million investment in the Series C redeemable convertible preferred stock, which converted to common stock as of December 31, 2020, nor the $4.0 million of funding upon Acceptance are restricted as to withdrawal or usage.  300000000 300000000 0.0001 0.0001 one vote per share 0 0 As of June 30, 2024 and December 31, 2023, the Company has reserved common stock, on an as-converted basis, for future issuance as follows:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:13.297%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:13.297%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-

wrap;font-family:Arial;min-width:fit-content;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Issuance of common stock under the 2020 Equity Incentive Award Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,332,657 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 524,078 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Issuance of common stock under the 2020 Employee Stock Purchase Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273,375 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313,034 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercise of options issued and outstanding and future vesting of restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,423,481 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercise of common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,637,145 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 53,669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total common stock reserved for future issuance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,693,467 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,314,262 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2332657 524078 273375 313034 8450290 8423481 3637145 53669 14693467 9314262 10000000 10000000 4000000 4000000 125715 10000000 4000000 12. Stock-based Compensation 2020 Equity Incentive Award Plan In December 2020, the Company adopted the 2020 Incentive Award Plan (“2020 Plan”), which became effective on December 10, 2020. The 2020 Plan initially reserved 2,606,546 shares of common stock for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance bonus awards, performance stock units, dividend equivalents or other stock or cash based award granted to employees, directors and consultants of the Company. The number of shares reserved for future issuance under the 2020 Plan will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) 5% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than 18,000,000 shares of the Company's common stock may be issued upon the exercise of incentive stock options. On February 29, 2024, an additional 2,153,533 shares of common stock became available for issuance under the 2020 Plan, as a result of the operation of the automatic annual increase provision. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options were issued. As of June 30, 2024 there were 1,997,052 shares available for grant under the 2020 Plan. Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the “2015 Plan”). However, the 2015 Plan continues to govern the terms of options that remain outstanding under the 2015 Plan. As of June 30, 2024, there were 335,605 shares available for grant under the 2015 Plan. 2015 Equity Incentive Plan The 2015 Plan provided for grants of stock options, stock appreciation rights, restricted stock and restricted stock unit awards to employees, directors and consultants of the Company. As of June 30, 2024, options to purchase 1,545,023<span style="color:#000000;white-

space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock were outstanding under the 2015 Plan. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options were issued and are granted at prices not less than the estimated fair market value of the Company's common stock on the grant date as determined by the board of directors. No additional grants will be made under the 2015 Plan, and all outstanding grants under the 2015 Plan that are repurchased, forfeited, expire or are cancelled are returned to the 2015 Plan and are not available for grant under the 2020 Plan. Employee Stock Purchase Plan In December 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the "2020 ESPP"). Under the 2020 ESPP, 252,337 shares of the Company's common stock were initially reserved for employee purchases of the Company's common stock under terms and provisions established by the Company's board of directors and approved by the Company's stockholders. The number of shares reserved for future issuance under the 2020 ESPP will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) 1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than 15,000,000 shares the Company's common stock may be issued under the 2020 ESPP. On February 29, 2024, an additional 50,000 shares of common stock became available for future issuance under the 2020 ESPP, as a result of the operation of this automatic annual increase provision. Under the 2020 ESPP the Company's employees may purchase common stock through payroll deductions at a price equal to 85% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2020 ESPP provides for a series of overlapping 24-month offering periods comprising four six-month purchase periods. The initial offering period under the 2020 ESPP is longer than 24 months, commencing February 15, 2021 and ending on May 14, 2023. Contributions under the 2020 ESPP are limited to a maximum of 15% of an employee's eligible compensation. Restricted Stock Units The Company has granted restricted stock unit (RSU) awards under the 2020 Equity Incentive Award Plan that vest over a period of four years. The following table summarizes the RSU activity for the six months ended June 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.22%;"></td><td style="width:1.54%;"></td><td style="width:1%;"></td><td style="width:16.24%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of<br/>Shares </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested balance at December 31, 2023 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 181,181 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Issued </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 129,650 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Vested </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (21,963 </td><td style="white-space:nowrap;vertical-align:bottom;"> ) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Canceled/Forfeited </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (30,751 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested balance at June 30, 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 258,117 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> Stock Options The following table summarizes the stock options activity for the six months ended June 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.22%;"></td><td style="width:1.54%;"></td><td style="width:1%;"></td><td style="width:16.24%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-

family:Arial;min-width:fit-content;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balances at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,240,154 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 434,500 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (296,183 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,837 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (177,461 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balances at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,192,173 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options exercisable at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,726,662 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options vested and expected to vest at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,192,173 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="visibility:collapse;"> <td style="width:50.86%;"></td> <td style="width:1.24%;"></td> <td style="width:11.295%;"></td> <td style="width:1.24%;"></td> <td style="width:11.295%;"></td> <td style="width:1.24%;"></td> <td style="width:10.796%;"></td> <td style="width:1.24%;"></td> <td style="width:10.796%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Expected term </td> <td style="vertical-align:bottom;">  </td> <td style="vertical-align:bottom;text-align:left;"> 6.0<span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-

width:fit-content;"> - 6.1 years </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 6.0 - 6.1 years </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 6.0 - 6.1 years </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 6.0 - 6.1 years </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 6.0 - 6.1 years </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> 84.9% - 85.4% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 81.1% - 82.2% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 81.4% - 85.4% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 80.9% - 84.4% </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.4% - 4.5% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.5% - 4.0% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.9% - 4.5% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.5% - 4.0% </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected dividend yield </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> </tr> </table> Expected Term. The expected term for employee options is calculated using the simplified method as the Company does not have sufficient historical information to provide a basis for this estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee options is the contractual term of the options. Expected Volatility. The expected volatility is based on a mix of the Company's historical volatility and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. For each grant, the Company measured historical volatility over a period equivalent to the expected term. Risk-free Interest Rate. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues whose term is similar in duration to the expected term of the respective stock option. Expected Dividend Yield. The Company has not paid and does not anticipate paying any dividends on its common stock in the future. Accordingly, the Company has estimated the dividend yield to be zero. Stock-Based Compensation Expense The following table is a summary of stock-based compensation expense incurred for employees and nonemployees by function (in thousands):  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.88%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.299999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.78%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.78%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended<br/>June 30, </td> <td

style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended<br/>June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,196</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,678 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,877 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,817 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,042 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,073</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,969</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,048 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="font-

family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,190 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2606546 0.05 18000000 2153533 P10Y 1997052 335605 1545023 P10Y 0 252337 0.01 15000000 50000 0.85 P24M 4 0.15
The Company has granted restricted stock unit (RSU) awards under the 2020 Equity Incentive Award Plan that vest over a period of four years. The following table summarizes the RSU activity for the six months ended June 30, 2024:  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:16.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of<br/>Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 181,181 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Issued </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 129,650 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (21,963 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Canceled/Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (30,751 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Unvested balance at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 258,117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>  P4Y 181181 129650 21963 30751 258117
The following table summarizes the stock options activity for the six months ended June 30, 2024:
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;"></td> <td style="width:1.54%;"></td> <td style="width:1%;"></td> <td style="width:16.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balances at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,240,154 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 434,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (296,183 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,837 </td> <td style="white-space:nowrap;vertical-align:bottom;"> ) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options

forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (177,461 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balances at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,192,173 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options exercisable at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,726,662 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options vested and expected to vest at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,192,173 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> </table> 8240154 434500 296183 8837 177461 8192173 3726662 8192173 The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Company's stock options was estimated using the following assumptions for the three and six months ended June 30, 2024 and 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.86%;"></td> <td style="width:1.24%;"></td> <td style="width:11.295%;"></td> <td style="width:1.24%;"></td> <td style="width:11.295%;"></td> <td style="width:1.24%;"></td> <td style="width:10.796%;"></td> <td style="width:1.24%;"></td> <td style="width:10.796%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;">  </td> <td style="vertical-align:bottom;">  </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Expected term </td> <td style="vertical-align:bottom;">  </td> <td style="vertical-align:bottom;text-align:left;"> 6.0  -  6.1  years </td> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;text-align:left;"> 6.0  -  6.1  years </td> <td style="vertical-align:bottom;">  </td> <td style="vertical-align:bottom;text-align:left;"> 6.0  -  6.1  years </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:top;">  </td> <td style="vertical-align:bottom;text-align:left;"> 84.9%  -  85.4% </td> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;text-align:left;"> 81.1%  -  82.2% </td> <td style="vertical-align:bottom;">  </td> <td style="vertical-align:bottom;text-align:left;"> 81.4%  -  85.4% </td> <td style="vertical-align:bottom;text-align:left;">  </td> <td style="vertical-align:bottom;text-align:left;"> 80.9%  -  84.4<span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-

content;">% </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.4% - 4.5% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.5% - 4.0% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.9% - 4.5% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.5% - 4.0% </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Expected dividend yield </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> —% </td> </tr> </table> P6Y P6Y1M6D P6Y P6Y1M6D P6Y P6Y1M6D P6Y P6Y1M6D 0.849 0.854 0.811 0.822 0.814 0.854 0.809 0.844 0.044 0.045 0.035 0.04 0.039 0.045 0.035 0.04 0 The following table is a summary of stock-based compensation expense incurred for employees and nonemployees by function (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.88%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.299999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.299999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.78%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.78%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended<br/>June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended<br/>June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,196</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,678 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,231</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,877 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,291 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,817 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,042 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,073</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,969 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,048</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,190 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 3196000 2678000 6231000 5148000 2877000 2291000 5817000 4042000 6073000 4969000 12048000 9190000 13. Common Stock Warrants In May 2018, the Company issued a warrant for 23,669 shares of the Company's common stock to a service provider with an exercise price of $3.19 per share. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model, expires in 2025 and upon issuance was fully vested. In December 2020, the Company issued a warrant for 30,000 shares of the Company's common stock to a service provider with an exercise price of $18.00 per share. This warrant vests over a period of four years and expires in 2027. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model.  In February 2024, the Company completed an underwritten public follow-on offering which included the sale of pre-funded warrants (the "Pre-funded Warrants") to purchase 3,583,476 shares of the Company's common stock at an offering price of $29.4999. The exercise price of each Pre-funded Warrant is $0.0001 per share, and each Pre-funded Warrant is exercisable from the date of issuance. The Pre-funded Warrants are classified as a component of stockholders' equity within additional paid-in-capital. The Company valued the Pre-funded Warrants at issuance and recorded net proceeds of $99.4 million after deducting underwriters fees during the six months ended June 30, 2024 related to the sale of the Pre-funded Warrants. There was no material expense related to the above warrant shares during each of the three and six months ended June 30, 2024 and 2023.  23669 3.19 2025 30000 18 P4Y 2027 3583476 29.4999 0.0001 99400000 0 0 0 0 14. Net Loss Per Share, Basic and Diluted The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.88%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.3%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.3%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.780000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.780000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-

align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Numerator </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,953</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (29,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">67,354</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (58,298 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> ) </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Denominator </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average shares outstanding used in computing net loss per share, basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 55,282,754 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38,335,219

</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 52,277,369 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,661,995 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share, basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.63</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (0.77 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.29</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1.63 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> ) </td> </tr> </table> In February 2024, the Company issued and sold Pre-funded Warrants to purchase 3,583,476 shares of common stock at a nominal exercise price of $0.0001 (see Note 13). The shares of common stock into which the Pre-funded Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and the Pre-funded Warrants are immediately exercisable upon their issuance date. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:13.297%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:13.297%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,192,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,422,876 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units subject to future vesting </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 258,117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2020 ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 244,622 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 269,102 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 53,669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 53,669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,748,581 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,745,647 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.88%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.3%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:9.3%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.780000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.24%;"></td> <td style="width:1%;"></td> <td style="width:8.780000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Numerator </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-

space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">34,953</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (29,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">67,354</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (58,298 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> ) </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Denominator </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">  </td> <td style="vertical-align:bottom;text-align:center;">  </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average shares outstanding used in computing net loss per share, basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 55,282,754 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,335,219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 52,277,369 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,661,995 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">  </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share, basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.63</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.77 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">  </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.29</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1.63 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> ) </td> </tr> </table> -34953000 -29616000 -67354000 -58298000 55282754 55282754 38335219 38335219 52277369 52277369 35661995 35661995 -0.63 -0.63 -0.77 -0.77 -1.29 -1.29 -1.63 -1.63 3583476 0.0001 The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:13.297%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:13.297%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,192,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,422,876 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units subject to future vesting </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 258,117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2020 ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 244,622 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 269,102 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 53,669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 53,669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,748,581 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,745,647 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 8192173 6422876 258117 0 244622 269102 53669 53669 8748581 6745647 15. Derivative Liability The Company identified an embedded derivative resulting from the change of control provision in the CFF Agreement. Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as separate financial instruments. At the inception of the derivative in 2017, the Company recognized this

*derivative as a liability and revenue was reduced by the initial fair value of the derivative liability. The Company remeasures the derivative liability to fair value at each reporting period and records the change in fair value of the derivative liability as other income (expense), net. The Company uses a present value analysis with multiple scenarios, which incorporates assumptions and estimates to value the derivative instrument. The Company assesses these assumptions and estimates on a periodic basis as additional information impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the change of control payment to CFF (range of zero to $18.9 million at June 30, 2024 and December 31, 2023), the probability of a change of control event, the probability of the product achieving development or commercial status at time of change of control (range of 4.8% to 17.2% at June 30, 2024 and December 31, 2023) and the discount rate (15% at June 30, 2024 and December 31, 2023). The Company determined the estimated fair value of this liability as of the inception date of the CFF Agreement and concluded that the amount was immaterial. The Company determined the fair value of this derivative liability was $0.4 million as of June 30, 2024 and December 31, 2023. 0 0 18900000 18900000 0.048 0.048 0.172 0.172 0.15 0.15 400000 400000 16. Related Party Transactions In March 2024, the Company entered into a research and option agreement (the "Reignite Agreement") with Reignite Therapeutics Inc. ("Reignite"), which was founded by David Kirn, M.D., Chief Executive Officer of the Company. Reignite has the expertise to develop high-capacity, helper-dependent adenovirus capsids which the Company plans to utilize as they expand their therapeutic capsid evolution platform. Reignite and the Company plan to collaborate on a one-to-two year program to develop these high capacity, helper-dependent adenovirus capsids. Under the Reignite Agreement, the Company shall have the final authority to amend and make updates to the plan and budget of the program. Further, the Company is responsible for the funding of the related research which includes the budgeted full-time employees and CRO costs, equipment costs not to exceed $60 thousand and all other costs, in total not to exceed $1.5 million in any year of the program. The Company will have an option to acquire up to three capsids resulting from the program. The Company shall pay to Reignite an option exercise fee of $1.0 million per selected capsid for which the Company has exercised its option. The maximum total amount payable is $3.0 million. During the three and six months ended June 30, 2024, the Company paid Reignite $0.4 million for research and development expenses. No option exercise fees were incurred during the three and six months ended June 30, 2024. As of June 30, 2024, no other amounts were due to Reignite under the Reignite Agreement. 60000 1500000 3 1000000 3000000 400000 400000 0 0 0 17. 401(k) Plan In 2014, the Company adopted a 401(k) plan for all employees who have met certain eligibility requirements. The 401(k) plan allows employees to make pre-tax and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company made contributions to the 401(k) plan for all eligible participants and recorded contribution expenses of $0.4 million and $0.2 million for the three months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and 2023, the Company recorded contribution expenses of $0.8 million and $0.7 million, respectively. 400000 200000 800000 700000 false false false false*